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Production of Universal Red Blood Cells via Enzymatic Conversion
Abstract
Red blood cell (RBC) transfusion units are considered one of the most essential healthcare components in
the world. In the United States alone, approximately 21 million transfusion units are required every year.
Despite this high demand, RBC units are becoming increasingly scarce since only a fraction of eligible donors
provide RBCs to for medical use. Additionally, RBC transfusions are limited to immune compatibility in
patients, making it difficult to serve all patients with such a limited supply. This proposed design provides a
method in which RBCs of any blood group can be converted into the universal blood type, O, to eliminate any
concerns regarding blood type compatibility between donor and patient. This conversion process uses
bacterial glycosidades to cleave the sugar groups on the surface of RBCs that defines our blood type. This
process will help increase hospitals’ supply of readily usable RBCs for any situation while also providing a
solution to hospitals’ struggle to use their blood bags before they expire.
This proposal seeks to design a start-up scale plant that will both prepare the glysocidases needed for the
treatment process and execute the conversion. This project design expects a production capacity of 200,000
tranfusion units of successfully converted RBCs per year and will be located in Medford, MA. With an initial
investment of $25.6 million, the designs yields a a twelve-year net present value of $8,461,700 and has an
investor’s rate of return of 21.73%. A limited twelve-year lifespan was chosen in an attempt to more accurately
represent the lifespan of a start-up and to more strictly analyze its financial feasibility. The proposed project is
forecasted to breakeven in early 2028, at the beginning of its eighth year of its operation, with a return on
investment of 17.17%. With initial evidence of profitability, this project design is recommended. Furthermore,
the financial analysis performed in this report limits the scope of this project to satisfying the blood demands
of one major hospital in a metropolitan area. In reality, however, it is expected that the start-up will expand to
other major hospitals or blood collecting organizations within the first several years of operation, further
increasing its potential value. It should be noted, however, that investors exercise caution as the blood market
has been in constant flux for the past seven years, making it difficult to predict how valuable RBC transfusion
units will be compared to other blood components. The process should be executed only if an acceptable
pricing can be established to sustain the large costs associated with guaranteeing endotoxin and
contamination free products.
Disciplines
Biochemical and Biomolecular Engineering | Chemical Engineering | Engineering
This working paper is available at ScholarlyCommons: https://repository.upenn.edu/cbe_sdr/105
Universal RBCs | Catella, Coler, Hayes 
 
April 18, 2017 
University of Pennsylvania 
School of Engineering and Applied Science  
Department of Chemical and Biomolecular Engineering  
220 S. 33rd Street 
Philadelphia, PA 19104 
 
Dear Professors Vrana and Wattenbarger: 
 
Enclosed is a process design to produce universal type O red blood cells (RBCs) via enzymatic 
conversion on a startup scale. Type O RBCs, as the type of red blood cells most used in blood 
transfusions, are in increasingly high demand and increasingly short supply. Successful FDA 
approval is assumed for eventual market launch; it is hoped that our product will advance 
movement towards a universal blood supply. 
 
The design of the universal enzymatically converted (ECO) RBC involves two processes: growth 
of the ECO-enzymes in E. coli and subsequent purification, and enzymatic conversion treatment 
of the RBCs themselves. Upstream operations in the first process include an inoculum bioreactor 
followed by a growth bioreactor and two production fermenters wherein E. coli grows in high 
density in high-salt media supplemented with glucose, kanamycin, and chloramphenicol. 
Downstream operations for the first process include disk stage centrifugation, high-pressure 
homogenization to release cytoplasmic ECO-zymes, cobalt affinity, HIC, and endotoxin affinity 
chromatography to ensure nearly complete removal of cell debris and endotoxins. 
Ultrafiltration/diafiltration and bulk microfiltration follow to resuspend and sterilize the isolated 
ECO-zymes. The RBC conversion process involves centrifugation of unconverted RBCs, 
incubation of RBCs and ECO-zymes in a WAVE bioreactor to effect conversion, centrifugation, 
diafiltration, and cryogel affinity chromatography to separate enzyme from converted ECO RBCs. 
 
The process in theory yields 22.91 kg ECO-A-zyme, 0.376 kg ECO-B-zyme, and 200,000 units of 
ECO RBCs produced annually. Internal rate of return (IRR) is 21.73%, net present value (NPV) 
is $8.46 million in 2019, and return on investment (ROI) is 17.17%. Our process requires $27.3 
million working capital for a 12-year facility life span.  
 
All calculations within stem from suggestions from Dr. Jeffrey Cohen, Dr. Robert Luo, Dr. Daniel 
Green, Mr. Gary Sawyer, and other industrial consultants or from the literature. Please do not 
hesitate to reach out should any questions or the need for supplemental information arise. 
 
Sincerely, 
 
 
 
______________________          ______________________          ______________________ 
         Carly Catella           Rachel Coler            Brandon Hayes 
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1. Abstract 
 Red blood cell (RBC) transfusion units are considered one of the most essential healthcare 
components in the world. In the United States alone, approximately 21 million transfusion units 
are required every year. Despite this high demand, RBC units are becoming increasingly scarce 
since only a fraction of eligible donors provide RBCs to for medical use. Additionally, RBC 
transfusions are limited to immune compatibility in patients, making it difficult to serve all patients 
with such a limited supply. This proposed design provides a method in which RBCs of any blood 
group can be converted into the universal blood type, O, to eliminate any concerns regarding blood 
type compatibility between donor and patient. This conversion process uses bacterial glycosidades 
to cleave the sugar groups on the surface of RBCs that defines our blood type. This process will 
help increase hospitals’ supply of readily usable RBCs for any situation while also providing a 
solution to hospitals’ struggle to use their blood bags before they expire. 
This proposal seeks to design a start-up scale plant that will both prepare the glysocidases 
needed for the treatment process and execute the conversion. This project design expects a 
production capacity of 200,000 tranfusion units of successfully converted RBCs per year and will 
be located in Medford, MA. With an initial investment of $25.6 million, the designs yields a a 
twelve-year net present value of  $8,461,700 and has an investor’s rate of return of 21.73%. A 
limited twelve-year lifespan was chosen in an attempt to more accurately represent the lifespan of 
a start-up and to more strictly analyze its financial feasibility. The proposed project is forecasted 
to breakeven in early 2028, at the beginning of its eighth year of its operation, with a return on 
investment of 17.17%. With initial evidence of profitability, this project design is recommended. 
Furthermore, the financial analysis performed in this report limits the scope of this project to 
satisfying the blood demands of one major hospital in a metropolitan area. In reality, however, it 
is expected that the start-up will expand  to other major hospitals or blood collecting organizations 
within the first several years of operation, further increasing its potential value. It should be noted, 
however, that investors exercise caution as the blood market has been in constant flux for the past 
seven years, making it difficult to predict how valuable RBC transfusion units will be compared 
to other blood components. The process should be executed only if an acceptable pricing can be 
established to sustain the large costs associated with guaranteeing endotoxin and contamination 
free products. 
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2. Introduction 
2.1. Project Background 
 Blood  is  an  essential  part  of  healthcare,  listed  on  the  World  Health  Organization’s  
List  of  Essential Medicines1. Its components are always in high demand, of which red blood cells 
(RBCs) are the most used in transfusions. Globally, around 85 million units of packed RBCs are 
used annually, of which approximately 21 million are used in the United States alone2,3. Despite 
the importance of RBC transfusions, the compatibility of donated blood, based on the ABO group 
system, with patients’ immune systems often hinders treatment efficiency4. Plasma of blood group 
A individuals contains naturally occurring antibodies to the B antigen present on group B RBCs, 
marking them for destruction. Similarly, plasma of blood group B contains antibodies against A 
antigen. This means that individuals with blood of group A cannot receive transfusions from group 
B blood and vice-versa. Otherwise, patients will become anemic and suffer immune responses4.  
 Type-O RBCs, however, do not contain A or B antigens and can be safely transfused into 
patients of any blood type, as shown in Figure 2.1. For this reason, type-O blood is considered the 
“universal” blood type and is in high demand by blood banks and hospitals4.   
 
Figure 2.1. Blood type compatibility chart. Note that type-O donors are able to donate to any other 
RBC type when not considering the Rh factor. 
                                                          
1 World Health Organization. WHO Model List of Essential Medicines, 19th List [Internet]. 2015 [cited 2018 Apr 15]. Available from:  
http://www.who.int/medicines/publications/essentialmedicines/en/ 
2 American Red Cross. Blood Facts and Statistics [Internet]. 2018 [cited 2018 Apr 15]. Available from: https://www.redcrossblood.org/learn-
about-blood/blood-facts-and-statistics 
3 Carson JL et al. Red blood cell transfusion:  a clinical practice guideline from the AABB.  Annals of Internal Medicine 2007; 157: 49–58. 
4 Liu QP et al. Bacterial glycosidases for the production of universal red blood cells. Nature Biotechnology 2007; 25(4): 454-464. 
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Donations from type-O donors are highly sought after, but a significant amount of type-A, 
B and AB are also collected to be used with compatible recipients. However, a disproportionate 
amount of type-O blood is used in trauma or situations with significant incompatibility risks, which 
leads to a surplus of type-A, B and AB transfusion units5. RBCs are only stable and efficacious for 
42 days when refrigerated at 4ºC, limiting their long-term viability and monetary value6. Improper 
blood management strategies leads to a significant number of unused packed RBC units, which 
tends to range from 20 to 30% of a hospital’s entire blood supply7. 
 
Figure 2.2. Blood type distribution in the United States.  
 
Although 49% of the population of the United States has type-O RBCs, as shown in Figure 
2.2, only an estimated ten percent of the eligible U.S. population (38% of the total population) 
donates blood2. In addition, the already limited number of willing donors has been affected by 
changes in blood transfusion policies in the country in recent years. After a 15-year steady increase 
in blood transfusions, the number of transfusions performed has been decreasing since 2011 due 
to more strigent requirements for patients to receive tranfusions8. Hospitals have begun limiting 
transfusions to patients only when their hemoglobin levels drop below 10 grams per deciliter, 
nearly a two-fold change compared to the time prior to this policy’s implementation. This was 
done to minimize hospital stays; to prevent the risk of infection, allergic reaction, or 
                                                          
5 Strobel E. Hemolytic transfusion reactions. Transfus. Med. Hemother. 2008; 35(5): 346-353. 
6 Miraflor E et al. Emergency uncrossmatched transfusion effect on blood type alloantibodies. J. Trauma Acute Care Surg. 2012; 72(1): 48-52 
7 Kurup R et al. A study on blood product usage and wastage at the public hospital, Guyana. BMC Res. Notes 2016 Jun; 9: 307. 
8 Mohebbi Far R et al. Determination of rate and causes of wastage of blood and blood products in Iranian hospitals. Turk. J. Haematol. 2014 Jun; 
31(2): 161-167 
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contamination; and lessen treatment and operating costs imposed on hospitals for performing 
unnecessary transfusions. As a result of this policy change, hospitals began to use significantly 
fewer RBC transfusion units, leaving them with a surplus of transfusion units that only have a shelf 
life of 42 days8. This eventually affected the blood collection industry, as sales began to drop since 
hospitals now required fewer transfusion units. It also began to affect public awareness on the 
issue, and both blood banks and the Red Cross began to receive fewer active donors.  
The policy change has constrained current blood supplies significantly without properly 
considering new health and medical treatment challenges in the present and upcoming years. 
According to the World Health Organization, blood-intensive procedures are expected to grow, 
such as solid organ transplants, hematopoietic stem cell transplants, and aggressive chemotherapy 
against cancer, all of which will require increased blood supplies. The prevalence of cancer in the 
American population, which is expected to surpass heart disease as the main cause of death in the 
United States by as early as 2030, is specifically considered an area where RBC transfusion units 
are predicted to be needed in a greater supply than what is currently available. According to the 
American Cancer Society, more than 1.69 million people were diagnosed with cancer in 2017. 
Many of them will need blood, sometimes daily, during their chemotherapy treatment. Lastly, the 
continually growing population over 65 years of age is also expected to increase demand for blood 
to combat anemia, aggressive immunogenic responses, and other health complications9,10. 
Surgery cancellation at hospitals has become increasingly more common across the United 
States and is often reported in mainstream media. Blood supply scarcity announcements from 
hospitals are also becoming more frequent. An example of the poor blood supply occurred in 
Puerto Rico in February 2016. Due to the growing prevalence of the Zika virus and FDA concerns 
of it being possibly transmitted via transfusion, blood collections in Puerto Rico ceased until 
nucleic acid testing could be implemented under investigational new drug protocols11. This forced 
the territory to eventually import blood and packed RBCs. 
The global blood collection market size was valued at $7.6 billion in 2015, to which RBC 
transfusions contributed $1.8 billion12. Economic analyses predict that this market is projected to 
                                                          
9 Schulson M. Blood transfusions decline 2011-14, study finds [Internet]. Cornell Chronicle 2018. Web. 
http://news.cornell.edu/stories/2018/02/blood-transfusions-decline-2011-14-new-study-finds 
10 Olson ML, Clausen L. Modifying the red cell surface: towards an ABO-universal blood supply. British Journal of Haematology 2007;140,3-12. 
11 Sullivan L. Blood Industry Gets A Transfusion From An Aging Population. BCC Research 2017 [cited 2018 Apr 15]. Available from: 
http://blog.bccresearch.com/blood-industry-gets-a-transfusion-from-an-aging-population 
12 Ellingson KD et al. Continued decline in blood collection and transfusion in the United States-2015. Transfusion 2017 Jun; 57(2); 1588-1598 
Universal RBCs | Catella, Coler, Hayes 
18 
 
grow by 6.1% by the 2021-2022 period due to the increasing prevalence of infectious disease and 
non-communicable disease, cancer, accidents, and trauma cases. This validates that there is a need 
for improve the currently available supply. This proposal seeks to develop a platform in which 
universal, type-O RBCs can be prepared from any other blood cell type, taking advantage of the 
surplus of transfusion units that large hospitals usually have. These enzymatically converted type-
O (ECO) RBCs will be usable in all patients, will function exactly the same as type-O cells, and 
not generate adverse reactions in patients.  
2.2. Basis for Project and its Biochemistry 
The ABO blood group system, which determines all transfusion compatibility, categorizes 
blood based on the presence or absence of the A and B blood group antigens on the surfaces of 
RBCs. The carbohydrate structures that make RBCs type-A, B, or O are designated A, B, and H 
and are present at oligosaccharide chain termini of glycolipids and glycoproteins on RBC 
surfaces4. A antigen structure and specificity are determined by a terminal α-1,3-linked N-
acetylgalactosamine (GalNAc); B antigen specificity is derived from an α-1,3-linked galactose 
(Gal). O RBCs are capped with the H antigen containing a terminal α-1,2-linked fucose (Fuc)4. 
Enzymatic removal of the immunodominant monosaccharides from type-A and B RBCs 
respectively, will uncover the H antigen and yield universal type-O RBCs. This biochemical 
reaction is shown in Figure 2.3. 
 
Figure 2.3. Biochemical reaction showing the terminal sugar groups that create human blood 
group A and B antigens on RBCs. Note that R in the above image is shorthand for RBC. 
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In  the  1980s,  a  procedure  was  established  to  convert  group  B  RBCs  into  group  O  
by  using  an  α-galactosidase derived from green-roasted coffee beans (Coffea canephora). This 
coffee bean-derived enzyme completed phase I and phase II clinical trials, and the treated RBCs 
were shown to be safe and functional. Unfortunately, the amount of enzyme needed to treat a single 
unit of group B RBCs was too high to create a cost-effective process (1 to 2 grams/unit packed 
RBCs)  with which these universal blood cells could be manufactured. Additionally, the coffee 
bean-derived α-galactosidase could only treat group B RBCs, not group A, limiting its usability4.    
In 2007, however, another research group identified two prokaryotic glycosidase gene 
families that could be  used  to  potentially  convert  any  RBC type into  the  universal  type:  one  
containing  α-N-acetylgalactosaminidase (GH109), which has high activity with group A antigens, 
and another containing α-galactosidase (GH110), which targets group B antigens4. Additional 
progress in the field was made in 2015 when the family 98 glycoside hydrolase from Streptococcus 
pneumoniae SP3-BS71 was found to cleave the entire terminal trisaccharide antigenic 
determinants of both A and B antigens on the RBC surface13.  
 
Figure 2.4. Illustration of the specific cleavages of A and B antigens and the uncovering of H 
antigen via ECO-A and ECO-B enzymes, respectively. Color code for monosaccharides (hexagon 
symbols): fucose (black), galactose (grey), N-acetylgalactosamine (hatched) and precursor chain 
constituents (white). 
 
The α-N-acetylgalactosaminidase and α-galactosidase genes will be used to enzymatically 
convert groups A and B RBCs into ECO RBCs. These genes will be inserted into E. coli to produce 
                                                          
13 Kwan DH et al. Toward efficient enzymes for the generation of universal blood through structure-guided directed evolution. J. Am. Chem. Soc. 
2015; 137(7): 5965-5705 
Universal RBCs | Catella, Coler, Hayes 
20 
 
ECO-A and ECO-B enzymes for downstream treatment of RBCs. The cleavage process is detailed 
in Figure 2.4, which highlights the targets that the ECO-zymes use to cleave the A and B antigens 
to form the blunt H sugar group found on type-O RBCs.  The resulting ECO RBCs will have the 
terminal H antigen that is universal to all patients.  
 The conversion process that transforms group A and B RBCs to ECO RBCs is quick and 
efficient.  The incubation step is an hour at room temperature, and the buffers for both ECO-zymes 
are the same.  Approximately 60 mg of A ECO-zyme is needed to treat a liter of group A RBCs, 
and 2 mg of B ECO-zyme is needed to treat a liter of group B RBCs.  
 
 
Figure 2.4. General schematic of process for converting type-A, B, or AB red blood cells 
to universal RBCs. 
 
2.3 Introduction to Project Process Synthesis 
The enzymatic treatment process of RBCs can be separated into upstream production of 
the ECO-zymes, and the downstream conversion of the RBCs.  In the upstream phase, the ECO-
zymes are produced through E. coli growth in a three-stage bioreactor system.  The cells are lysed 
using a microfluidizer to release the ECO-zymes, the broth is centrifuged. and the debris is 
discarded.  The ECO-zymes are then separated and purified through three chromatography stages.  
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The first stage is an affinity chromatography column, which uses His6-tag technology to bind to 
and separate the ECO-zymes from the other extracellular proteins. The last two columns, a 
hydrophobic interaction chromatography column and an affinity column, are used to remove 
endotoxins.  The ECO-zyme product will be tested for endotoxins with the Lonza Endotoxin kit. 
The downstream treatment of the RBCs uses the ECO-zymes produced upstream to 
enzymatically convert type-A and B RBCs into non-immunogenic type-O RBCs.  After the RBC 
units are emptied and the packaging buffer is removed the RBCs are sent to a wave bioreactor for 
conversion. The conversion process takes one hour at room temperature, with ECO-zymes and a 
neutral buffer.  Centrifugation and filtration are used to separate and remove the ECO-zymes from 
the RBCs.  Cryogel based affinity chromatography is used to capture and remove unconverted 
RBCs, which could cause an immune response if left in the product.  Finally, the RBCs are 
resuspended in packaging buffer and filled into blood bags for distribution.  Quality control 
measures are in place to test and confirm the conversion of the RBC units prior to distribution.  
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2.4. Project Charter 
 
Project Name Production of Universal Red Blood Cells via Enzymatic Conversion 
Leaders Carly Catella, Rachel Coler, Brandon Hayes 
Project Scope 
In Scope: 
 Manufacturing process for annual production of 205 g of α-N-
acetylgalactosaminidase and 189 g of α-galactosidase, beginning with inoculum 
preparation and concluding with large-scale fermentation 
 Post-manufacturing purification and separation of product enzymes using 
multiple chromatography and filtration steps 
 Testing to verify enzyme product, determine purity, and quantify endotoxin 
concentration to guarantee patient safety when using treated RBCs 
 Production of 200,000 RBC transfusion units/year with selected enzymes 
 Establishment of sterile unpacking/packaging mechanism of RBCs to be 
processed to minimize human error and risk of contamination 
 Adherence to current health and safety regulations for blood products 
 Observance of process integrity and compliance by adhering to current good 
manufacturing practices (cGMP) 
Out of Scope: 
 Removal of Rh factor to account for positive/negative typing of RBCs 
 Research and development (performed in laboratory): 
- General characterization and kinetics of α-galactosidase and α-N-
acetylgalactosaminidase 
- Specific design of hyperbaric chamber for blood bag emptying 
- General characterization of cryogel polymer matrix used in cryogel-based 
affinity chromatography 
 Long-term storage of RBCs at customers’ facilities 
 FDA approval for a Biological License Application (BLA) for conversion 
process and blood product 
 Establishment, funding, and success of clinical trials 
 Pilot plant study to analyze cell growth rates and optimal conditions 
Deliverables 
Business Opportunity Assessment 
 What are the current and projected markets for type-O RBCs? 
 What added value does our process provide over traditional RBC sources? 
Technical Feasibility Assessment 
 Is it feasible to produce enough enzyme for 200,000 ECO RBC units/year? 
 Is it feasible to convert 200,000 units of RBCs/year with minimal RBC lysis and 
build a sustainable business model? 
Manufacturing Capability Assessment 
 Will the process require significant capital investment to produce enzymatically 
converted RBCs? 
 Will the process meet FDA requirements for blood products? 
Timeline Facility, process design, economic analysis will be completed in four months.  
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3. Innovation Map 
 Figure 3.1 shows the innovation map for enzymatically converted RBC units. Customers 
value the non-immunogenic nature of type-O RBCs because they can be used in situations where 
the blood type of the patient is not known4. Traditional RBC units come in a variety of blood types, 
and only limited supplies of the non-immunogenic type-O are available10. Potential customers are 
currently limited to the fluctuating supplies of type-A, B, AB, and O red blood cells available, 
which have become more limited in the past decade due to transfusion medicine policy changes9.  
Enzymatically converted universal RBCs utilize the traditional RBC supply chain but add 
value by removing the immunogenic antigens from the surface of the RBCs with bacterial 
glycosidases. The antigen-cleaving glycosidases, α-galactosidase and α-N-
acetylgalactosaminidase, function with high affinity and low consumption, making them suitable 
choices for large-scale RBC treatment processes1. Enzymatically converted universal RBCs are 
poised to enter the market to fill the need for a greater and steadier supply of non-immunogenic 
units. In regards to potential competition, recent academic researchers presenting at stem cell 
research conferences have claimed that they engineered an immortalized hematopoietic stem cell 
line that can continuously produce red blood cells14. However, the production rates of this stem 
cell line are still unknown, making it uncertain that they can produce RBCs at a fast enough rate 
to satisfy global demand. Additionally, these RBCs have not yet undergone pre-clinical or clinical 
trials yet, indicating that their potential use in human patients is still several decades away. The 
RBC treatment process described here has already undergone several trials, in which certain of its 
weaknesses were addressed and have since been occurred1,2. Prior data on the efficacy, 
performance, and immunogenicity of ECO RBCs should allow the process and product to move 
through Phase I-III clinical trials and the FDA approval process more smoothly. Thus, it can be 
concluded that there are currently no other RBC products on the market that can offer non-
immunogenic properties in large quantities, so there would be no competition in this market 
segment. 
 
 
 
                                                          
14 Shah S, Huang X, and Cheng L. Concise review: stem cell-based approaches to red blood cell production for transfusion. Stem Cells Transl. 
Med. 2014 Mar; 3(3): 346-355. 
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Figure 3.1. Innovation map for ECO RBC transfusion units.  Enzymatically converted RBCs will be prepared as ready-to-administer 
so they can directly enter the market due to their ability to meet market needs and differentiation from traditional RBC units. 
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4.  Concept Stage 
4.1. Market Analysis 
 The global blood collection market size was valued at $7.6 billion in 2015, to which RBC 
transfusions contribute $1.8 billion15. This market is projected to grow at 6.1% by the 2021-2022 
period. RBC demand is also expected to increase due to the increasing prevalence of infectious 
disease and non-communicable disease, cancer, accidents, and trauma cases10. The number of 
blood-intensive procedures performed, such as solid organ transplants, hematopoietic  stem  cell 
transplants, and aggressive chemotherapy against cancer,  is also expected to grow; all of these 
treatments require increased blood supplies10. Lastly, the continually growing population over 65 
years of age is also expected to increase demand for blood10.   
Despite the need for packed RBCs in transfusion medicine, supply has decreased 
significantly, especially in the last decade. Although an estimated 38% of the US population is 
eligible to donate blood at any given moment, less than 10% of that eligible population donates2. 
Another problem for transfusion medicine is how quickly packed RBCs expire. Typically, any 
given unit of RBCs is only usable for 42 days. Due to their short life span, packed RBC units are 
constantly being discarded, forcing hospitals to replenish their stock. It has become increasingly 
difficult to maintain inventories, because demand is expected to grow while supply is being 
hindered by stricter donation regulations and fewer donors.   
The current industry standard for RBC unit production is whole blood donation, separation, 
purification, and repackaging.  Supply is dependent on the donors’ blood types, willingness to 
donate, and limited shelf life of the packaged RBC unit.  Certain hospital wards, such as trauma 
wings and emergency rooms, will transfuse O negative RBCs until properly cross matched blood 
is available when there is no time to type a patient’s blood16.  This leads to a disproportionate use 
of O RBC units, which contributes to the wastage of the lesser used blood types, A, B, and AB.  
Approximately 78% of wasted RBC units are thrown out due to time expiry17.   
                                                          
15 Ellingson KD et al. Continued decline in blood collection and transfusion in the United States-2015. Transfusion 2017 Jun; 57(2); 1588-1598. 
16 Miraflor E et al. Emergency uncrossmatched transfusion effect on blood type alloantibodies. J. Trauma Acute Care Surg. 2012; 72(1): 48-52. 
17 Miraflor E et al. Emergency uncrossmatched transfusion effect on blood type alloantibodies. J. Trauma Acute Care Surg. 2012; 72(1): 48-52. 
Strobel E. Hemolytic transfusion reactions. Transfus. Med. Hemother. 2008; 35(5): 346-353. 
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Additional concerns for RBC unit transfusions are the liabilities associated with transfusion 
incompatibilities, which can lead to adverse events, such as acute hemolysis.  Reactions can range 
from mild to fatal, with rates of fatal reactions estimated to be between 1:70000 and 1:100000 
units transfused5.  Each transfusion incompatibility event can cost hospitals and their respective 
insurance companies upwards of $500,00018.  The most common cause of transfusion 
incompatibility events is mismatched blood types from the donor and patient, which can be caused 
by systemic problems and/or human error5.  The former may be addressed by implementing more 
rigorous quality assurance practices, while the latter is harder to control for, and will likely 
continue to be a problem in the current system.  
A universal RBC supply could solve both the wastage and liability concerns associated 
with the standard RBC transfusion practices.  Currently, there is no universal option for blood 
products.  Work has been done to produce RBCs ex vivo using differentiated stem cells.  However, 
these RBCs lack adult hemoglobin, their production relies on animal serum, and scale up has not 
been successful thus far14.  Enzymatically converted universal RBCs would be the first universal 
blood product to go to market in this sector and would be highly desirable in situations where 
blood typing is performed on a limited scale or there are incompatibility risks.   
4.2. Customer Requirements 
 Hospital systems are the primary users of RBC units and typically source them from 
regional suppliers, the Red Cross, and internal blood drives.19  The enzymatically converted RBC 
units will directly replace RBC units sourced from these three suppliers while providing additional 
benefits, such as reduced liability and higher usage efficiency.  In addition, these units must meet 
the same safety guidelines set by the Food and Drug Administration (FDA) that traditional RBC 
units meet. 
In general, RBC units must be processed in a way that reduces activity loss and prevents 
contamination.  Thus, strict control of temperature and application of mechanical stress are 
necessary. Cell lysis due to mechanical stress will be avoided by the use of carefully selected 
reactors, pumps, and separation columns. Temperature control is the most important consideration 
                                                          
18 Ah-Moye D et al. Clinical Biochemistry: Metabolic and Clinical Aspects. London: Churchill Livingstone; c2014.  Chapter 26, Introduction to 
haematology and transfusion science; p. 497–514. 
19 Siegel DL. Re: Costing of ECO-RBC units [Internet]. Message to: Carly Catella. 2018 Apr 3, 10:00 pm [cited 2019 Apr 15]. [about 6 paragraphs]. 
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for the handling of RBC units in this process.  Hospitals typically adhere to the “thirty-minute” 
and “four-hour” rules stipulating that RBC units should not be reissued after thirty minutes of room 
temperature exposure, and that transfusions should be completed within four hours.  The risks 
associated with exposure to temperatures above 4ºC include bacteria proliferation and loss of 
activity.20  However, studies have shown that bacteria proliferation is insignificant for times less 
than two hours, and loss of activity is negligible.21  The enzymatic treatment process must maintain 
proper temperature control throughout, and have a total time below two hours at a temperature 
above 4ºC.  Sterilization processes will be implemented to reduce the risk of contamination and 
quality control testing will be performed prior to the distribution of the treated RBC units to ensure 
that there is no measurable loss in activity or bacterial contamination. 
 Customers also require consistent packaging and delivery for efficient use in 
hospitals.  The most important considerations in this area are meeting FDA packaging guidelines, 
salient labeling, and compatibility with existing storage options.  The FDA requires that blood 
storage bags be sterile and clear to allow for observation of hemolysis or change in color.  They 
must also be clearly labeled with antigen type and may be color coded.22  Delivery must be prompt 
to maximize the usable shelf life of the RBC unit, which is capped at 42 days in most situations10.  
Measures will be put in place to ensure a quick turnaround time for the treatment process to allow 
the customer to have relatively fresh RBC units.  
4.3. Regulatory Requirements 
The use of enzymatically converted RBC units in the place of traditional RBCs will require 
approval from the FDA.  Due to the extensively processed nature of this product and its 
differentiation from traditional RBC products, it will need to undergo comprehensive clinical 
testing. A Biologic License Application (BLA) for ECO-RBCs will need to be approved.13  The 
FDA will look for good manufacturing practices associated with the large scale production and 
proper quality control of the enzymatically converted RBCs in their approval process.  Additional 
concerns arise from the novel nature of the enzymatically converted RBCs, which include potential 
                                                          
20 Ramirez-Arcos S et al. Evaluating the 4-hour and 30-minute rules: effects of room temperature exposure on red blood cell quality and bacterial 
growth. Transfusion 2013; 53(4); 851-859. 
21 Vosta J. FDA Evaluation of Red Cell Products. Laboratory of Cellular Hematology, U.S. Food and Drug Administration, 2016. 
22 Diamond SL. Re: Cost of FDA Approval of ECO-RBCs [Internet].  Message to: Carly Catella. 2018 Apr 2, 11:08 am [cited 2018 Apr 15]. [about 
44 paragraphs]. 
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toxicity and efficacy issues.  Studies will need to be performed to confirm that “immunogenicity, 
reduced cell flexibility, increased fragility, low oxygen delivery capacity, and unanticipated 
toxicities” are not properties of the enzymatically conveted RBCs.4  In vitro studies will need to 
be performed to study the morphology, biochemistry, and the hemolysis of the enzymatically 
converted RBCs.   Phase I and II clinical trials must be performed to assess kinetics, and Phase III 
clinical trials need to be performed to assess safety and efficacy of the enzymatically converted 
RBCs.   
The design and performance of clinical trials for FDA approval are out of the scope of this 
project; however, it is important to consider what these trials would encompass.  Clinical trials for 
the enzymatic conversion using ECO-B have already shown the feasibility of the process, but more 
rigorous studies inclusive of enzymatic conversion with ECO-A need to be performed14.  These 
studies would primarily look for safety and efficacy markers that match or surpass those of RBC 
units collected via apheresis.  Safety studies would address the immunogenicity of the 
enzymatically converted RBCs by looking for antibody formation.  The efficacy markers would 
include markers for hemolysis, hemoglobin concentration, and oxygen dissociation.  Phase III 
studies would address both safety and efficacy concerns, and additional Phase IV post market 
safety studies would likely be necessary.4 Safety concerns would be addressed by testing for 
mismatched immune response and the safety of the potentially augmented clearance 
pathway.  Phase III and IV studies would compare the efficacy of ECO-RBCs to that of wild-type 
RBCs.  They would also compare and contrast the circulatory half-life, hemoglobin clearance, and 
storage stability of both wild-type and enzymatically converted RBCs.   
While Phase I clinical trials can be performed in healthy patients to test for safety and dose 
escalation, Phase II and III clinical trials must be done in patients with measurable indications of 
need.  These indications can range from bleeding from elective surgery to traumatic bleeding.  
However, indications of need like traumatic bleeding are difficult criteria under which to enroll 
patients because obtaining informed consent is challenging and the transfusion of the RBCs is 
difficult to control12.  Indications like anemia and bleeding from elective surgery are easier 
indications as researchers have time to obtain informed consent prior to transfusion, and the 
response to wild-type RBCs is well characterized, as both of these indications routinely utilize 
RBC transfusions.  Clinical trials can be performed for either or both of these indications; for the 
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purposes of this report, the specific design of the clinical trials is not considered.  The expected 
cost to complete these trials is projected to be $100-200 million.22  
4.4. Summarized Project Description 
The design described in the project consists of two separate processes: (1) the production 
of the necessary bacterial glycosidases for the RBC conversion and (2) the RBC treatment process. 
The production of bacterial glycosidases was determined to be done in-house rather than 
purchasing the enzymes in bulk to reduce costs. Additionally, the implementation of this portion 
of the design gives greater control over the E. coli strains which are used for upstream processing. 
By establishing the upstream process design, if further research finds more suitable bacterial 
glycosidases or enzymes that can perform the same function, the entire plant design will have 
already been established. The only change required is the substitution of the cell line used for 
enzyme production. 
The upstream processing consists of three growth phases: (1) inoculum grow up, (2) 
microbial fermentation in a seed reactor, and (3) production fermentation in two large stainless 
steel fermenters. This production train was chosen to prevent overdiluting the cell samples and 
accidentally inducing cell death. Additionally, this setup allows for high-cell density microbial 
cultures, which is required since the enzyme product yield is still relatively low.  
The downstream purification of the enzyme products involves numerous chromatography 
and filtration steps to reduce endotoxin levels below the limitations established by the FDA. Since 
the enzyme is cytoplasmic, cell membrane disruption is done using microfluidization to harvest 
the internalized enzyme. Then the product solution undergoes three chromatography steps: (1) 
cobalt ion affinity chromatography to remove cell debris and purify the enzymes, (2) hydrophobic 
interaction chromatography to separate endotoxins, and (3) endotoxin affinity chromatography to 
further separate endotoxins that may have unexpected hydrophobicity values. The product solution 
will then undergo ultrafiltration/diafiltration using a tangential flow filtration system to remove 
buffer components. Lastly, the product solution will undergo two bulk microfiltration passes to 
further eliminate endotoxins and concentrate each enzyme. 
 The RBC treatment process is simple, requiring that the donor RBCs be charged into a 
WAVE bioreactor to which ECO-zyme will be added. The RBCs will be agitated with the enzyme 
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for one hour at 25ºC and at a pH of 7.4-7.6. Afterwards they will undergo 
microfiltration/diafiltration to eliminate the enzyme from the treated RBC suspension, as the 
presence of enzyme in unpurified samples has been found to show adverse reactions in pre-clinical 
animal models. Lastly, to guarantee that the treated RBCs will not provoke an immunogenic 
response in patients, a specialized, cryogel-based affinity chromatography step will be used to 
separate purely converted RBCs from unconverted ones. This chromatography system uses a soft, 
polymer gel matrix, instead of traditional resin, that is coated with a protein A and antigen-
targeting IgG antibody complex that will bind cells that still have A or B antigens. The soft cryogel 
was chosen rather than traditional affinity chromatography resin because it is proven to have 
minimal cell lysis (less than five percent), to release bound cells by applying mechanical stress, 
and allowing multiple uses of the affinity binding IgG antibody. 
 The overall process flow diagram in Figure 4.4.1 illustrates the designed production 
process macroscopically. All final RBC units will undergo numerous quality control tests (flow 
cytometric analysis and thin layer chromatography (TLC) quantification of surface antigens) to 
confirm that negligible amounts of non-converted RBCs remain in the transfusions units that will 
be given to patients. 
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Figure 4.4.1. Process flow diagram for the creation of universal RBC units via enzymatic 
conversion.  
 
4.5. Facility Location and Requirements 
 An important decision that determines the feasibility is choosing the location in which the 
plant design should be executed. Given that the production goal that this project seeks to fulfill 
depends on hospitals requiring substantial blood supplies, establishing the facility in a metropolitan 
area with a strong hospital system was deemed a necessity. Furthermore, given the biotechnology 
nature of the project and the possibility for research collaborations to optimize the RBC treatment 
process and perhaps explore alternative enzymatic treatments, it was decided that the facility 
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should be established in a biotechnology hub. The Boston metropolitan area fits all of these 
considerations, with significantly cheaper utilities pricing and space rental costs compared to the 
biotechnology hub in California. It also has one of the largest and most well-funded hospital in the 
United States, Massachusetts General Hospital, which allows for both service partnerships and 
research opportunities. Additionally, developing this RBC treatment platform in the Boston 
metropolitan area also allows expansion in additional metropolitan markets easier. There are other 
major numerous hospital systems along the East Coast relatively close in proximity: New York 
City, Philadelphia, Newark, among others.  
 Although many of the customers are expected to be directly in Boston, the new facility for 
RBC treatment will be built in Medford, MA, which is located less than five miles away from 
Cambridge, MA. This allows it to be in close proximity to Massachusetts General Hospital and 
major universities such as Harvard University, Massachussetts Institute of Technology, Tufs 
University,  and more. The rental pricing per square foot of land is also significantly  cheaper than 
in Boston: $30 versus $60 per square foot, according to realtor Cummings Properties.  
 The rental space will come equipped with biosafety cabinet hoods for conducting sterile 
cell culture and RBC management (if necessary). It also contains clean room spaces that can be 
used for RBC handling and other sterile procedures. Lastly, the facility comes equipped with an 
autoclave room to sterilize equipment, which will be fundamental in both research and the actual 
upstream E. coli cell culture process, which uses an autoclavable glass bioreactor vessel. The use 
of this autoclave is included in the facility’s rent. The property also features a construction-ready 
zone with HVAC (heating, ventilation, and air conditioning) which will be used for sterile air.  
Additionally, a vacuum system will be establishing for better biowaste management and to 
eliminate exposing bloodborne pathogens to the environment. Additionally, Cummings Properties 
has in-hous design and construction teams that can be employed to make necessary modifications 
before beginning production. This helps outsource plant design while reducing costs. In particular, 
the design of three 900 ft2 cold rooms (subject to change depending on factors such as equipment 
size constrants and personnel maneuverability) will be organized with Cummings Properties and 
possible third party contractors.
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5.  Critical-to-Quality (CTQ) Variables  
 
5.1. Endotoxin Concentrations 
Endotoxins are the single most important class of pyrogens, substances that cause fevers 
when injected into humans and animals. Although fevers induced by endotoxins are not life 
threatening, endotoxin presence in blood transfusion units can have numerous adverse effects, 
even potentially fatal consequences. Endotoxins are continuously shed from the outer membrane 
of viable gram-negative bacteria, such as E. coli, and are also released when the bacterial cell dies. 
In E. coli, endotoxins come in the form of complex aggregates of lipopolysaccharides (LPS). The 
LPS consists of an innermost region composed of hydrophobic fatty acid groups, or lipid A, and a 
central and outermost region composed of hydrophilic polysaccharides. They may cause 
uncontrolled activation of mammalian immune systems, releasing a storm of pro-inflammatory 
agents, such as cytokines and interleukins, which may lead to septic shock in patients. 
Additionally, this inflammatory reaction may cause either damage to the endothelial layer of blood 
vessels or vasodilation, both of which eventually lead to leakage from the vessel walls. The 
substrates required to form a blood clot in the case of injury may be diminished or depleted. Given 
that blood transfusion units are often used in scenarios in which hemorrhage will occur, patient 
safety is at risk if the presence of endotoxins prevents proper clotting. Other common 
consequences of endotoxin contamination are, but not limited to, cardiac malfunction, internal 
organ failure (usually of the kidneys, adrenal glands, and the lungs), gangrene in the limbs, and 
hemorrhage-induced Waterhouse-Friderichsen syndrome.23  
Due to the serious risks associated with endotoxin contamination, the FDA has set limits 
on concentration of endotoxin for medical devices, parenteral drugs, and any type of ingestible 
substance for medical treatment. The endotoxin limits currently accepted by the FDA are 
summarized in Table 5.1. For most medically injected and transfused substances, the limit is set at 
<0.25 EU/mL, where EU is endotoxin units. One EU equals approximately 0.1 to 0.2 ng 
endotoxin/mL of solution.24 
 
                                                          
23 Raetz CRH and Whitfield C. Lipopolysaccharide endotoxins. Annual Review of Biochemistry 2002 Jul; 71:635-700. 
24 Bacterial Endotoxins/Pyrogens, Inspection Technical Guides. U.S. Food and Drug Administration (2015). 
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Table 5.1. Endotoxin limits for various products, as established by the FDA. 
 
Given that bacterial glycosidases are going to be used to cleave the A and B antigens from 
the red blood cell surface to convert them to type-O, it is important to minimize the endotoxin 
concentration in the enzyme solution that is going to be used to treat the RBCs. Any endotoxins 
remaining in the enzyme solution could also end up in the transfusion units produced. For this 
reason, three chromatography columns are used to maximize elimination of endotoxins from the 
final enzyme product. Additionally, thorough quality control tests will be performed on all 
converted RBC units, using Limulus Amebocyte  Lysate (LAL) assays. The LAL kinetic 
turbidimetric assay25 will be used to detect endotoxin concentration down to 0.01 EU/mL. These 
precautionary measures will help prevent adverse effects on patients and eliminate endotoxins 
prior to treating RBCs. Literature has reported that minimal quantities of endotoxin in the blood 
can alter RBC morphology and functionality and may even induce hemolysis. 
The endotoxin concentration was a heavily considered variable in this process design. We 
assume that for our product to receive FDA approval, it must satisfy the threshold values 
established for water-for-injection (WFI), given that the RBCs will be resuspended in preservation 
solution made from WFI. Even though this project is conceptualized as a start-up and funding is 
highly dependent on available funding from investors and government subsidies, minimizing 
endotoxin concentration was deemed a primary concern. While the costs associated with the 
presence of two chromatography columns dedicated to endotoxin removal are high, they help 
guarantee that the produced ECO RBCs will have endotoxin values well below FDA standards.  
 
 
                                                          
25 Lonza. Traditional Kinetic Limulus Amebocyte Lysate (LAL) Assay User Quick Guide. Walkersville, MD: Lonza Walkersville; 2014 [cited 
2018 Apr 16]. Available from: https://www.lonza.com/products-services/pharma-biotech/endotoxin-detection/endotoxin-detection-assays/kinetic-
turbidimetric-lal-assays.aspx 
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5.2. Final Universal RBC Product Purity 
 This project assumes that the bacterial glycosidases, α-galactosidase and α-N-
acetylgalactosaminidase, needed to convert type-A and type-B RBCs to type-O manage to convert 
>90% of the treated RBC population. However, this assumption implies that there are still cells 
with antigens that could cause immunogenic responses if transfused into incompatible patients. 
Given that this project seeks to provide a product and service that can eliminate the concern of 
blood transfusion incompatibility, a specialized chromatography column was designed for the sole 
purpose of separating non-converted RBCs from successfully converted ones. From an ethical 
standpoint, this imperfect conversion could not be ignored as it could lead to health problems and 
potentially have fatal consequences in patients. Even though this additional chromatography 
column adds significant additional operation and installation costs, its inclusion helps guarantee 
patient safety, comply with ethical concerns, and provides a proper business model that future 
venture capital investors may appreciate. 
 
5.3. Production Capacity 
 The most important variable in this project was the production capacity of this small-scale 
RBC treatment plant. Given the limited size and finances of the project, the production goal for 
enzymatically converted RBCs is used to determine all other key parameters in this process: annual 
enzyme mass required, number of donor transfusion units that need to be treated to satisfy 
production goal, physical and financial constraints to place on process design, sizing parameters, 
among others. As a result, a realistic production goal of 200,000 transfusion units of enzymatically 
converted RBCs was established. This production goal would satisfy approximately 25% of the 
annual RBC transfusion unit demand required by a major metropolitan hospital. In a broader 
perspective, this would satisfy nearly 1% of the annual blood demand in the United States. 
 Even though the production goal is realistic for the start-up scale of this project, it still 
requires a relatively high cell density bacterial culture to produce sufficient enzyme to satisfy 
production. The genetically engineered E. coli BL21(DE3) cells that produce the α-galactosidase 
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and α-N-acetylgalactosaminidase enzymes have relatively low protein yield coefficients.26 To 
minimize costs of purchasing more equipment and maximize return on investment, the cell density 
was increased from a common 16 grams of biomass per liter of culture to 29 grams per liter. This 
operating condition was then used as the second most important variable used in sizing all reactors 
for upstream and downstream processes. 
 
5.4. RBC Storage Temperature 
 The optimal storage temperature value for RBCs outside of physiological conditions is 4ºC. 
These storage conditions allows them to remain viable for the entirety of their 42-day shelf life. If 
cells are kept at higher temperatures, they begin to degrade over time. Transfusion policies have 
only recently become more stringent in the United States and have not established how long an 
RBC transfusion unit may remain at room temperature. A common practice established by the 
Medicines and Healthcare Products Regulatory Agency in the United Kingdom, however, states 
that RBC transfusion units that have been exposed to an ambient temperature of 25ºC for four or 
more hours should be discarded immediately27. Their decision to implement this policy comes 
from medical reports that found that the oxygen-transfer capability of RBCs is drastically reduced 
if the cells are not stored at 4ºC for more than four hours.  
 This project assumes that the methodology applied in the United Kingdom should be a 
standard in transfusion medicine. Thus, the entire RBC treatment process, with the exception of 
the enzymatic conversion to type-O, is performed at 4ºC. As a result, the design schematic 
presented in this report includes calculations for numerous, large-sized cold rooms to satisfy the 
strict temperature requirements needed to maintain RBC viability.  
 
 
 
 
                                                          
26 Sivashanmugam A et al. Practical protocols for production of very high yields of recombinant proteins using Escherichia coli. Protein Science 
2009; 18: 936-948. 
27 Brunskill S et al. What is the maximum time that a unit of red blood cells can be safely left out of controlled temperature storage? Transfus. 
Med. Rev. 2012; 26(3): 209-223. 
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6. Product Concepts 
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7. Superior Product Concepts 
 
Not applicable. 
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8. Competitive/Patent Analysis 
Not applicable. 
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9. Preliminary Process Synthesis 
 
9.1. Initial Considerations 
 Prior to upstream production, Esherichia coli strains that produce α-N-
acetylgalactosaminidase or α-galactosidase need to be genetically engineered. These two enzymes 
were originally discovered in Elizabethkingia meningosepticum and Streptomyces avermitilis, 
respectively.4 For the purposes of this design, it was decided that the best approach for ensuring 
high protein yielding bacterial cells are used in the fermentation process is to contract the 
preparation of the E. coli cell lines to a contract research organization. Many of these organizations 
have well-established gene editing platforms that can engineer a specific cell line in four to six 
weeks. This will allow plant setup to occur simultaneous with cell line preparation. Additionally, 
it eliminates expenses required to initially perfect and optimize an internal gene editing platform 
to prepare the desired E. coli strains. Given the limited funds allotted to this project due its start-
up nature, it was determined that expediting the production stage should be prioritized over the 
development of an internal gene editing system. Future sales funds can be allocated to research 
once the project is established and is able to deliver functional universal blood cells.  
The preparation of these bacterial cell lines will be contracted to GenScript, a contract 
research organization that specializes in genetic engineering using the CRISPR-gene editing 
system. The product of each cell line will cost $5,400. GenScript was chosen for their λ Red-
CRISPR/Cas9 gene editing platform, which uses a two vector system that enables editing accuracy 
down to a single base pair. It is a seamless platform with high efficiency (>95%) and easy 
precision. 
The entire coding region of Elizabethkingia meningosepticum α-N-
acetylgalactosaminidase, shown in Figure 9.1.1, will amplified by polymerase chain reaction 
(PCR) from genomic DNA with the following primers4:  
1. FLAV28: 5’-GCGGGATCCAATGGGTGCTTTAATTCCCTCGAGC-3’  
2. FLAV13: 5’-CGGCGGCCGCTTAGTAGTCGTCATTTATTGCAAATG-3’.  
The product will be ligated into the pCR4-Topo TA vector to give a full length 
FLAV28/13US construct. A truncated construct lacking the N-terminal signal peptide will then be 
amplified by PCR from the FLAV28/13US construct using the following primers/restriction sites: 
FLAV34US, 5’-GCGGGATCCGAATTCTAAAAAGGTAAGAATAGCTTTTATAGC-
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3’/EcoRI; FLAV13, 5’-CGGCGGCCGCTTAGTAGTCGTCATTTATTGCAAATG-3’/NotI. The 
PCR product will be inserted into EcoRI/NotI digested pET28 expression vector to create a N-
terminal truncated construct with a histidine-6 (His6) tag at the N-terminus to be used for future 
separations.4 
 
 
Figure 9.1.1. The original gene sequence that encodes α-N-acetylgalactosaminidase (GH109), 
which cleaves A antigens on the surface of RBCs.. This enzyme was originally discovered in 
Elizabethkingia meningoseptica. This sequence will be engineered into a plasmid vector that also 
encodes genes for kanamycin and chloramphenicol antibiotic resistance. The engineered plasmid 
will knocked-in to E. coli using  λ Red-CRISPR/Cas9 gene editing to develop a bacterial platform 
that can be selected using antibiotic resistance to mass produce this enzyme. 
 
 The engineering of the α-galactosidase-producing strain of E. coli, originally from 
Streptomyces avermitilis, will undergo a near identical gene editing process to also insert His6 tags 
as previously described. The original gene sequence for α-galactosidase is shown in Figure 9.1.2. 
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Figure 9.1.2. The gene sequence that encodes α-galactosidase (GH110), the enzyme that is 
responsible for cleaving B antigens. This enzyme was originally discovered in Streptomyces 
avermitilis. This sequence will also be engineered into a plasmid vector that also encodes genes 
for kanamycin and chloramphenicol antibiotic resistance.  
 
9.2. Upstream E. coli Cell Culture Process 
 
9.2.1. Reactor and Cell Density Considerations 
 The final iteration in determining the adequate equipment for culturing E. coli cells 
required analyzing oxygen mass transfer limitations in the design setup. Originally, the system was 
designed exclusively using single-use, disposable bioreactor systems (Figure 9.2.1), which are 
becoming increasingly used in the biotechnology industry. However, single-use bioreactor systems 
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have difficulty at operating above a volumetric oxygen transfer coefficient 𝑘𝐿𝑎 of 40 hr
-1. This low 
value also has the tendency to fall below 20 hr-1 during operation. Jeffrey Cohen, Ph.D., from 
Johnson & Johnson expressed concerns that this system would not be able to supply sufficient 
oxygen to the cell culture and could result in massive cell death. 
 
 
Figure 9.2.1. The original schematic used in the initial conceptualization of the project. The 
original design consisted of using three single-use bioreactors, with working volumes of 0.110 L, 
5.44 L, and 200 L, respectively. The production bioreactor was set to achieve a maximum cell 
density of 100 grams per liter, as certain high microbial density protocols fermentation protocols 
claim. The concept of using a single-use production bioreactor because it has limited oxygen 
transfer capabilities and is unable to satisfactorily support high-density microbial cultures. 
 
Many aggressive microbial cultures, however, require systems that can produce a 
volumetric oxygen transfer coefficient greater than 360 hr-1 to satisfy the oxygen demand of fairly 
high density bacterial cultures.28 Another complication associated with using single-use systems 
is that these high volumetric oxygen transfer coefficients often require gas flows of two vessel 
volumes per minute. Satisfying this gas flow demands is made difficulty since single-use systems 
have constrained gas flow rates due to pressure safety limits of the single-use flexible container. 
The required low operating backpressure decreases the gas flow capacity of exhaust filters. For 
                                                          
28 Sartorius Stedim Biotech GmbH. High-cell-density Cultivation of Escherichia coli in a BIOSTAT® D-DCU 10-3 Stainless Steel Bioreactor 
[Internet]. High-cell-density Cultivation of Escherichia coli in a BIOSTAT® D-DCU 10-3 Stainless Steel Bioreactor. Goettingen, 
Germany: Sartorius Stedim Biotech GmbH; 2013 [cited 2018 Apr 17]. Available from: 
https://www.sartorius.com/mediafile/Appl_BIOSTAT_D-DCU_High-cell-density-Cultivation_E_Coli_SBT1015-e.pdf 
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these reasons, the use of single-use bioreactors were discarded for the purposes of our microbial 
fermentation. 
 Recent progress has been made in developing single-use fermenters that vastly outperform 
single-use bioreactors, potentially providing a solution to the lack of single-use technology for 
bacterial growth. During equipment selection, however, it was noticed that there are major 
discrepancies among different sources on the actual volumetric mass transfer coefficient. Some 
reports stated that the single-use fermenters could operate achieve a 𝑘𝐿𝑎 of 80 hr
-1, while others 
stated that it could be well above 400. Additionally, the experiments from which this data was 
obtained often reported that there was difficulty in controlling cooling capacity and foaming levels, 
both of which could cause enzyme denaturation upon protein expression. These considerations led 
us to conclude that a stainless steel fermenter, which has well-studied volumetric oxygen transfer 
coefficients and agitation configurations, would be a safer choice for conducting all cell growth. 
Additionally, stainless steel reactors can be seen as permanent investments with no further major 
operating costs (with the exception of maintenance, CIP, and SIP procedures). Using single-use 
technology for microbial fermentation though will require continuous purchases of storage bags 
and containers for the cell harvest, which quickly add on to operating costs.  
 The final unit chosen to serve as the production bioreactor was the BIOSTAT® D-DCU 
from Sartorius28, which has a volumetric oxygen transfer coefficient of 308 hr-1. Additionally, due 
to sizing limitations of available stainless steel fermenters, two fermenters are required per batch 
to achieve the desired production goal. Please refer to Section 11 to see the final upstream process 
configuration. Once this reactor unit was chosen, the maximum allowable cell density for the 
fermentation process was calculated (see Appendix F) to be approximately 29 grams of cell per 
liter of culture. These renewed calculations after taking into account the oxygen mass transfer 
limitations of the reactor also helped resolve the concern on the high density at which the reactors 
originally planned to reach (100 g cells/L). Many were considered that this cell density would be 
too viscous and prevent the culture from being well mixed, which would have further hindered 
oxygen availability to the cells.  
 
9.2.2. Batch Timing   
The original process setup applied cell growth parameters that are significantly different 
from those more commonly seen in industrial fermentation. The growth rate of E. coli cells that 
Universal RBCs | Catella, Coler, Hayes 
52 
 
was originally used for the mathematical modeling of cell growth was 0.60 hr-1. This value was 
obtained from several online literature sources and from several pilot plant studies that used E. coli 
to produce protein. The maximum cell density established for each culture was 100 grams cells/L, 
which is considered the highest possible density that can be attained in microbial fermentations. 
With these two parameters, the calculated batch times were 13.25 hours for the inoculum growth 
reactor, 5.53 hours for the growth bioreactor, and 8.8 hours for the production bioreactor. 
Numerous industrial consultants, however, revealed that these values are several fold lower than 
what is usually observed in practice. Under ideal conditions in which E. coli are grown almost 
exclusively on glucose, a growth rate between 0.60 and 0.70 hr-1 can be observed. In reality, 
however, the substrate in the culture media changes over time. E. coli excrete acetate upon growth 
on fermentable sugars. The addition of the acetate substrate causes the growth rate to drop to values 
between 0.22 and 0.28 hr-1.  
Under their recommendation, it was decided that the final process design would use a 
growth rate of 0.25 hr-1, the average of the range in the presence of excreted acetate. Readjusting 
the growth model with this new parameter, the batch times increased to 16.08, 23.86, and 28.49 
hours for the inoculation growth, seed growth, and production units, respectively. Industrial 
consultants confirmed that these values coincide with typically observed batch times in small-scale 
biotechnology and pharmaceutical fermentation processes. Additional adjustments were later 
made to the model (as explained in Section 10.2.1 once reactor limitations were considered), 
changing the batch times to change to 17.86, 24.05, and 26.08 hours for the inoculation growth, 
seed growth, and production units, respectively. These values are still in line with industrial 
processes, confirming that the material balances for the E. coli growth  
 
9.3. Downstream Enzyme Purification 
 As discussed in Section 5.1, the presence of endotoxins in the enzyme product could have 
numerous adverse effects. Not only have endotoxins found to affect RBC functionality and 
viability, but their presence in the enzyme product that is used to treat RBCs may also cause 
endotoxins to end up in the final packaged RBCs. To minimize the endotoxin concentration in the 
packaged universal RBCs, the downstream purification process underwent several iterations to 
explore different chromatography column uses.  
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 Patents recommended a hypothetical separation model that used a cation exchange, anion 
exchange, and hydrophobic interaction chromatography train to purify α-galactosidase and α-N-
acetylgalactosaminidase from endotoxins4,10. The original process flow diagram for the above 
configuration is shown in Figure 9.3.1. However, a review of the biochemical properties, 
specifically the electrical charge of both enzymes and endotoxins, revealed that all of these proteins 
have a high net negative surface charge. Based on this finding, the notion of using any form of ion 
exchange was discarded since the charge differences among the endotoxins and enzymes was too 
little to exploit for a separation process. Another consideration was the possible use of size-
exclusion chromatography, but this idea was quickly discarded as the molecular weights of α-
galactosidase, α-N-acetylgalactosaminidase, and endotoxins are roughly 45, 75, and 10-100 kDa, 
respectively.4 After consulting with professional engineers, it was deemed that the size differences 
were too small (less than ten-fold) to be useful for size-based separations.   
 
Figure 9.3.1. Proposed process flow diagram from patents that explored the hypothetical 
feasibility of scaling up enzymatic treatment of RBCs to create a universal blood supply.  
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The last option explored was using an affinity chromatography column that would 
specifically bind endotoxins using porous cellulose beads coated with poly(ε-lysine) as the resin. 
Poly(ε-lysine) strongly binds endotoxins with relatively high specificity. Given that this resin does 
not have the issues associated with surface charge and size that renders the other chromatography 
techniques inapplicable for this particular separation, an endotoxin affinity chromatography 
column was incorporated into the process design. The hydrophobic interaction chromatography 
column was also kept in the design as an additional method to further eliminate endotoxins. Jeffrey 
Cohen (Johnson & Johnson), Daniel Green (GlaxoKlineSmith), and Robert Luo 
(GlaxoKlineSmith) all recommended that both chromatography columns be included to ensure 
that endotoxins were eliminated from the final product as much as possible. Given that the overall 
goal is to produce universal RBCs that will be transfused into patients, safety and risk minimization 
should be prioritized. This setup is shown in Figure 9.3.2. 
In addition to the chromatography columns meant for separating the α-galactosidase and 
α-N-acetylgalactosaminidase enzyme products, it was further recommended that an additional 
chromatography column be incorporated into the design process prior to the other two to eliminate 
organelles and cytoplasmic material from the bacterial lysis. Thus, an additional affinity 
chromatography unit was added at the beginning of the separations process to bind all His6-tagged 
enzyme. 
The final iteration of the downstream purification design for α-galactosidase and α-N-
acetylgalactosaminidase took into account in which order the endotoxin affinity and hydrophobic 
interaction chromatography columns should be placed. This decision was made by performing a 
financial analysis on the resin required for different setup configurations. It should be noted that 
although there are endotoxins losses are associated with transport losses, we assume that no 
endotoxin is lost for the design of the chromatography columns. This allows us to have a stricter 
design that can treat more endotoxin than what may actually be present in the final enzyme product 
solution. The first step in the separations process involves treating 11.5 grams of LPS endotoxin. 
Assuming a conservative 90% elimination of endotoxins, the second step must process 1.15 grams 
of LPS. Table 9.3.1 shows an initial general assessment of reagent costs if the endotoxin affinity 
column is placed before the hydrophobic interaction column. 
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Figure 9.3.1. Second major iteration of the downstream purification process of ECO-zymes. In this setup, endotoxin affinity 
chromatography and hydrophobic interaction (HIC) chromatography are used to eliminate endotoxins from the final enzyme product. 
The elimination of endotoxins is necessary to ensure endotoxin concentrations are low enough so that transfused ECO RBCs do not 
cause adverse immune responses.
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Table 9.3.1. Preliminary reagent costing for a process design in which a separations train consists 
of an endotoxin affinity chromatography column followed by a hydrophobic interaction 
chromatography column for the removal of endotoxins. The resins in questions are highlighted in 
light red. 
 
 
 The costs for the endotoxin affinity resin alone in this configuration reached approximately 
$13 million annually (600 L of resin are required annually at a price of $20,200 per liter). These 
high costs motivated looking into a new configuration in which the hydrophobic interaction 
column was placed before the endotoxin affinity column. The general reagent costs of this setup 
are shown in Table 9.3.2. Altogether the costs of the required volumes of resin between these two 
columns together only slightly exceeds $4 million, a three-fold reduction in costs compared to the 
previous setup. This configuration was thus chosen for the final design. 
 
 
Raw Material
Annual Amount 
Required  
Cost of Raw 
Material   
Cost per 
RBC Unit Annual Cost
AGE 2.2 L 173.00$                 $/L 0.0019$        381.81$                    
Ammonium sulfate 5017.6 g 51.76$                   $/kg 0.0013$        259.71$                    
APS 285.6 g 78.60$                   $/kg 0.0001$        22.45$                      
Detergent 431856.3 g 62.60$                   $/kg 0.1352$        27,034.21$               
DMAAm 16.4 L 93.00$                   $/L 0.0076$        1,521.26$                 
Ethanol 4154.3 L 4.18$                     $/L 0.0868$        17,359.76$               
Ethylenediamine 78175.7 g 73.50$                   $/L 0.0320$        6,391.45$                 
Glutaraldehyde 129.8 L 99.50$                   $/L 0.0646$        12,917.37$               
Guanadine HCl 48563.2 L 246.75$                 $/L 6.9758$        1,395,162.01$          
HEPES 66823.8 g 223.00$                 $/kg 0.0745$        14,901.70$               
IgG 1298.2 mg 790.00$                 $/mg 5.1280$        1,025,600.36$          
Imidazole 312256.0 g 265.00$                 $/kg 0.4137$        82,747.84$               
MBAAm 5712.2 g 1,044.00$              $/kg 0.0298$        5,963.54$                 
MES 105392.0 g 1,003.00$              $/kg 0.5285$        105,708.18$             
Na2CO3 55044.9 g 137.00$                 $/kg 0.0377$        7,541.15$                 
NaBH4 9822.4 g 118.18$                 $/kg 0.0058$        1,160.76$                 
NaCl 2838618.0 g 10.38$                   $/kg 0.1473$        29,464.85$               
NaOH 1113125.4 g 36.00$                   $/kg 0.2004$        40,072.52$               
Protein A 4154.3 g 366.00$                 $/g 7.6024$        1,520,484.99$          
Sodium phosphate 579760.4 g 42.00$                   $/kg 0.1217$        24,349.93$               
TEMED 246.7 mL 168.00$                 $/L 0.0002$        41.44$                      
Urea 2146439.7 g 67.40$                   $/kg 0.7234$        144,670.03$             
HisPur® Cobalt Resin 50.0 L 4,980.00$              $/L 1.2450$        249,000.00$             
Pierce Endotoxin Removal Resin 660.0 L 20,200.00$            $/L 66.6600$      13,332,000.00$        
POROS Benzyl HIC Resin 70.0 L 3,800.00$              $/L 1.3300$        266,000.00$             
Total 91.55$          18,310,757.32$        
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Table 9.3.2. Preliminary reagent costing for a process design in which a separations train consists 
of a hydrophobic interaction chromatography column followed by an endotoxin affinity 
chromatography column for the removal of endotoxins. The resins in questions are highlighted in 
light red. 
 
 
 
9.4. Universal RBC Purity and Separations 
The final major consideration in the process design was the establishment of a unit 
operation that could separate successfully prepared ECO RBCs from non-converted cells. 
Originally it was assumed that the enzymes would accomplish a 100% conversion. Upon 
recommendations from Daniel Green, Ph.D from GlaxoKlineSmith, however, it was decided that 
this assumption could have potentially severe consequences. Although the kinetics of the bacterial 
glycosidases have been studied at the bench-scale and shown near complete conversion, there may 
still be concerns that the scale-up of this procedure may affect the enzymes’ contact area with the 
Raw Material
Annual Amount 
Required  
Cost of Raw 
Material   
Cost per 
RBC Unit Annual Cost
AGE 2.2 L 173.00$                 $/L 0.0019$        381.81$                    
Ammonium sulfate 5017.6 g 51.76$                   $/kg 0.0013$        259.71$                    
APS 285.6 g 78.60$                   $/kg 0.0001$        22.45$                      
Detergent 431856.3 g 62.60$                   $/kg 0.1352$        27,034.21$               
DMAAm 16.4 L 93.00$                   $/L 0.0076$        1,521.26$                 
Ethanol 4154.3 L 4.18$                     $/L 0.0868$        17,359.76$               
Ethylenediamine 78175.7 g 73.50$                   $/L 0.0320$        6,391.45$                 
Glutaraldehyde 129.8 L 99.50$                   $/L 0.0646$        12,917.37$               
Guanadine HCl 48563.2 L 246.75$                 $/L 6.9758$        1,395,162.01$          
HEPES 66823.8 g 223.00$                 $/kg 0.0745$        14,901.70$               
IgG 1298.2 mg 790.00$                 $/mg 5.1280$        1,025,600.36$          
Imidazole 312256.0 g 265.00$                 $/kg 0.4137$        82,747.84$               
MBAAm 5712.2 g 1,044.00$              $/kg 0.0298$        5,963.54$                 
MES 105392.0 g 1,003.00$              $/kg 0.5285$        105,708.18$             
Na2CO3 55044.9 g 137.00$                 $/kg 0.0377$        7,541.15$                 
NaBH4 9822.4 g 118.18$                 $/kg 0.0058$        1,160.76$                 
NaCl 2838618.0 g 10.38$                   $/kg 0.1473$        29,464.85$               
NaOH 1113125.4 g 36.00$                   $/kg 0.2004$        40,072.52$               
Protein A 4154.3 g 366.00$                 $/g 7.6024$        1,520,484.99$          
Sodium phosphate 579760.4 g 42.00$                   $/kg 0.1217$        24,349.93$               
TEMED 246.7 mL 168.00$                 $/L 0.0002$        41.44$                      
Urea 2146439.7 g 67.40$                   $/kg 0.7234$        144,670.03$             
HisPur® Cobalt Resin 50.0 L 4,980.00$              $/L 1.2450$        249,000.00$             
Pierce Endotoxin Removal Resin 80.0 L 20,200.00$            $/L 8.0800$        1,616,000.00$          
POROS Benzyl HIC Resin 650.0 L 3,800.00$              $/L 12.3500$      2,470,000.00$          
Total 43.99$          8,798,757.32$          
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RBC, potentially lowering its conversion efficiency. If for any reason that the efficiency is low 
enough for there to be a substantial presence of non-converted RBCs, then using unseparated RBCs 
in transfusion units may introduce a high concentration of ABO-incompatible RBCs into the 
patient. Not only would this be detrimental to one of the main selling points of this service and 
product, but it could also cause severe health complications in treated patients, raising ethical 
concerns.  
Originally, the process design sought to explore using magnetic-activated cell sorting 
(MACS) to separate non-converted RBCs, which still possess the A or B antigen, from 
successfully converted cells (Figure 9.4.1). By using MACS cell depletion separation, non-
converted RBCs would be labeled with human blood group antigen-targeting IgG antibodies 
attached to cellulosic magnetic microbeads. By passing the RBC suspension through a magnetic 
field, ECO RBCs, which should not be labeled, will pass through while cells with attached 
microbeads would be magnetically attracted and retained. However, there were two major 
limitations associated with the use of this technology. First, the microbeads can only label 107 to 
109 cells. The number of RBCs that each batch will process is on the order of 1015. The second 
limitation is that the microbeads are only usable once, which would require new antibody and new 
microbeads for each batch of RBC treatment. The amount of microbeads required, combined with 
the fact that they are only single-use, would lead to exorbitant costs. For these reasons, this option 
was discarded after numerous consultations with industrial engineers. 
The next iteration of the purification and separation of RBCs replaced the MACS unit 
operation with a cryogel-based affinity chromatography column. Instead of using a traditional 
affinity chromatography column, in which its resin is coated in protein A from Staphylococcus 
aureus. Protein A has a strong affinity to the fragment crystallizable (Fc) region of antibodies. In 
the traditional setup, cells can be labeled with antigen-specific antibodies and passed through the 
column. Labeled cells will bind to the resin while unlabeled ones will pass through for collection 
or discarding. These basic principles are illustrated in Figure 9.4.2. A major disadvantage of this 
setup is the amount of IgG antibody required for annual production, as new labeling antibody will 
be required for each treatment. Often, the elution buffer used compromises the binding efficiency 
of the antibody, which can affect later purification attempts. Another major disadvantage is that 
traditional resins often show significant cell lysis. This last issue could potentially be a significant 
hindrance in this process design, given that a significant number of RBCs are already lost in each 
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unit operation. Given that we assume a total 35% loss of RBCs across the entire process, 307,693 
RBC transfusion units already have to be requested to provide only 200,000 ECO RBC units in 
return. Even though a significant number of those original blood bags would be discarded due to 
no usage before expiration, this process should still attempt to minimize the number of units 
required for production goals to incentivate hospitals to engage in our service. If lysis is higher 
though, the 35% assumption may not be valid and more units may be needed, which may push 
hospitals away.
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Figure 9.4.1. Simplified process flow diagram of the RBC conversion process in its initial conceptualization stages.  While the basic 
setup  from the process flow diagram is used in the final iteration, note that  the technique implemented  to separate non-converted RBCs 
is magnetic-activated cell sorting (MACS).  It operates by labeling the antigens of non-converted cells with human blood group targeting 
antibodies. The antibodies are also linked to magnetic microbeads, which can then be attracted to a magnetic field while non-labeled, 
successfully converted RBCs can pass through to the next unit operation.
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Figure 9.4.2. Representation of the fundamental principles behind the cryogel-based affinity chromatography column. A protein A-
coupled cryogen complex will be packed into a chromatography column. RBCs that were not converted still possess their A or B 
antigens, so they can be labeled with antigen targeting antibodies. This labeled cell population is then introduced into the column and 
allow to pass. Labeled cells will bind to the protein A coat on the cryogel due to IgG antibodies’ high affinity to protein A, while all 
universal RBCs will pass through and be collected. The remaining cells can then be released using mechanical stimulation while the 
antibodies stay bound for another treatment process.
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The cryogel-based method addresses both of these disadvantages and provides unique 
solutions to each. The binding of protein A and IgG antibodies is typically is very strong, requiring 
harsh buffers to release bound antibodies and cells in a traditional setting. However, the cryogel 
takes advantage of this strong binding to only release bound cells while keeping the antibodies 
attached to the protein A. The application of mechanical stress, recommended using a piston, and 
compressing the cryogel is reported to detach all cells with antibodies remaining bound to the 
cryogel-protein A complex for subsequent uses. This helps reduce costs associate with purchasing 
labeling antibodies  More specifics details on the composition of the cryogel and the operation of 
the column are described in Section 14. 
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10. Assembly of Database 
 
10.1. RBC Conversion Treatment Parameters 
The literature that serves as the basis for this project, which describes the methodology and 
biochemistry of converting any RBC type into the universal type-O, reports that 60 mg of α-N-
acetylgalactosaminidase and 2 mg of α-galactosidase for every 300 mL of blood are needed to 
convert type-A and type-B cells, respectively.29 The average RBC count is 5x106 RBCs/µL of 
blood. Although additional glycosidases have been used to accomplish the same conversion, the 
mass of enzyme required to treat type-A and type-B cells is 30-fold and 1,000-fold less than the 
next best alternative, respectively.  
 
10.2. E. coli BL21(DE3) Growth and Protein Yield Parameters 
A literature review was performed to determine what protein yield parameters are common 
in industrial E. coli fermentation processes. Emphasis was placed on growth parameters reported 
in high cell density cultures, which tend to vary from the values presented in cultures with densities 
of 16 grams of cells per liter. Recent protocols have been published detailing how to obtain high-
density E. coli cells with yields of 15 to 25 mg of recombinant protein in 50-mL of culture at an 
OD600 of 20.
30 (They report that an OD of 1 is approximately 1.0x1010 cells/mL.) We assume that 
our protein yield will be closer to the lower bound. Assuming that we can obtain 15 mg of enzyme 
per 50-mL of culture, this value corresponds to a protein production rate of approximately 0.30 g 
protein/L of culture. This corresponds to a yield of 1.88x10-2 g of enzyme per gram of cell mass. 
Lastly, an additional literature review, both from academic and industrial sources, was 
performed to determine key operating parameters for modeling the cellular growth of E. coli cell 
cultures. Nearly all literature sources2 reported E. coli growth rates ranging between 0.25 and 0.30 
hr-1. To have a conservative approach, a growth rate of 0.25 hr-1 was assumed for this process. The 
specific oxygen uptake rate for E. coli is reported to be 12 mmole O2/g cells-hr. These numbers 
were screened and approved by Jeffrey Cohen, Ph.D., from Johnson & Johnson, for further 
verification that these values align with common industrial assumptions and yields. 
                                                          
29 Liu QP et al. Bacterial glycosidases for the production of universal red blood cells. Nature Biotechnology 2007; 25(4): 454-464. 
30 Sivashanmugam A et al. Practical protocols for production of very high yields of recombinant proteins using Escherichia coli. Protein Science 
2009; 18: 936-948. 
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11. Process Flow Diagrams and Material Balances 
11.1. E. coli Upstream and Downstream Processing  
Figure 11.1.1 represents the process flow diagram for the upstream processing of the E. 
coli cell lines. Upstream processing refers to the microbial fermentation process in which the E. 
coli cells are grown up to a high enough cell density to express the desired mass of recombinant 
enzyme. The overall  material balances for each reactor are shown in Table 11.1.1. The calculations 
to determine batch times are found in Appendix A. A summary of all batch culture data for the 
production of both α-galactosidase and α-N-acetylgalactosaminidase is included in Appendix D. 
Table 11.1.1. Overall material balance for each bioreactor or fermenter in the upstream processing. 
 
 Figure 11.1.2 shows the downstream purification process of the ECO-zymes expressed in 
the  E. coli cells.  The overall material balance of the downstream purification process is shown in 
Table 11.1.2. 
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Table 11.1.2. Overall material balance for the downstream purification of ECO-zymes. 
 
 Figure 11.1.3 shows a Gantt chart showing the time period in which two batches of enzyme 
production can be completed.  
 
Figure 11.1.3. Gantt chart for E. coli processing scheduling. Two batches can be achieved in 
approximately a week. The bottlenecks of the setup are the production fermenters. The color black 
represents CIP/SIP times. Orange is the first batch, blue is the second batch. 
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Based on the equipment processing times, it was decided that 112 batches would be done for the 
production of α-N-acetylgalactosaminidase and two batches for the production of α-galactosidase. 
Additionally, in consultation with several industrial consultants, it was decided that the facility 
would be operational throughout the entire year, seven days aweek. Although the Gantt chart 
shows that only two batches can be prepared in roughly a week, six days a week is not sufficient 
to accomplish the entire production goals. There would need to be weeks in which all seven days 
required labor. For simplicity purposes, it was then decided that the facility should operate seven 
days a week to meet production goals and to compensate for any delays. 
 
11.2. RBC Treatment Processing  
The final process flow diagram in Figure 11.2.1 (at the end of the section) represents the RBC 
treatment process and its respective downstream purification. The overall material balance is 
shown in Table 11.2.1. 
Table 11.2.1. Overall material balance for the key components of the RBC treatment process. 
 
 
A Gantt chart for the RBC treatment process is shown in Figure 11.2.2. Only one batch is 
shown though, given that we are limiting ourselves to only three batches per week. There are 
therefore very little time constraints to satisfy RBC production goals. Since it was decided that the 
facility would operate seven days a week to fulfill enzyme production goals, then  there will still 
be sufficient time for three batches of RBC treatment to be carried out since they can be done in 
parallel to the bacterial growth.  Additionally, each batch takes approximately one day, meaning 
Input (kg/batch) Output (kg/batch)
For type-A
RBC suspension 0.559 0.386
GalNAc-ase 0.118 0
Waste 0 0.291
For type-B
RBC suspension 0.551 0.381
α-galactosidase 3.95×10
-3 0
Waste 0 0.174
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that conversion batches do not be need to occur back to back. However, this available free time 
between each treatment process indicates that there is additional time that can used later on to 
increase the number of batches per week if expansion occurs. 
 
 
Figure 11.2.2. Gantt chart for a single batch for RBC conversion. Three batches can easily be 
achieved in approximately a week, which is what production capacity will limit itself to for the 
early years of the facility. The color black represents CIP/SIP times, while red represents an RBC 
conversion process unit operation.. 
Universal RBCs | Catella, Coler, Hayes 
70 
 
 
 
Figure 11.1.1. The finalized process flow diagram for upstream cell culture processing of the engineered E. coli BL21(DE3) strains 
expressing either α-galactosidase or α-N-acetylgalactosaminidase. Blue represents bulk media preparation and sterilization to charge 
into fermeneters. For the smaller bioreactors, media will be pre-made and stored in sterile conditions. 
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Figure 11.1.2. The finalized process flow diagram downstream purification of either α-galactosidase or α-N-acetylgalactosaminidase 
that is harvested from the E. coli BL21(DE3) culture. 
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Figure 11.2.1. The finalized process flow diagram for the RBC treatment conversion process. 
 
73 
 
 
 
 
 
 
Section 12: 
Process Description 
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12.A. ECO-enzyme Production Process Description 
 The bioreactors and fermenters chosen for this process were designed by finding the 
production volume required to satisfy production. It is assumed that for all vessels, the culture will 
only occupy at most 80% of the vessel’s volume. It should also be noted that all bioreactors and 
fermenters purchased in this step come equipped with sampling ports to measure cell density at 
different sampling times throught the growth period. All cell density measurements will be done 
using a Tecan Spark Microplate Reader, with all measurements being done in replicates to ensure 
goal cell density has been achieved. It is assumed that any loss of microbial culture due to sampling 
is negligible.  
 
12.A.1. E. coli Cell Growth Model for Batch Bioreactor  
To analyze cell growth, it was assumed that Escherichia coli (E. coli) follows Monod 
growth kinetics, a commonly accepted approach for industrial fermentation. The cell growth times 
were selected based on a literature review of common experimental values for E. coli. The selected 
growth rate, 𝑢𝑔, was 0.25 hr
-1. For simplicity of calculations, it was assumed that the first-order 
death rate, 𝑘𝑑 is negligible. Therefore, the net growth specific rate was determined as follows: 
𝜇𝑛𝑒𝑡 = 𝑢𝑔 − 𝑘𝑑                                                              (12.1) 
The mathematical model used to quantify the batch time for cell growth was:   
𝜇𝑛𝑒𝑡 =
1
𝑋
𝑑𝑋
𝑑𝑡
                                                                (12.2) 
Rearranging the above expression to have the cell concentration and time variables isolated on 
the left and right-hand sides of the equations, respectively: 
𝑑𝑋
𝑑𝑡
= 𝜇𝑛𝑒𝑡𝑡                                                                (12.3) 
Given that the E. coli cells are thawed from a frozen stock with a specific concentration, the initial 
concentration, 𝑋𝑜, is known. Thus, to solve for the final cell concentration, 𝑋, the integral was 
taken from t = 0 to t with their respective cell concentrations.  
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∫
𝑑𝑋
𝑋
𝑋
𝑋𝑜
= ∫ 𝜇𝑛𝑒𝑡
𝑡
0
𝑑𝑡 
Solving the integral: 
𝑙𝑛
𝑋
𝑋𝑜
= 𝜇𝑛𝑒𝑡𝑡 
Isolating the batch time required to grow an inoculum of cells at a concentration of 𝑋𝑜 to a final 
concentration, 𝑋, the resulting equation used was: 
𝑡 =
1
𝜇𝑛𝑒𝑡
 𝑙𝑛
𝑋
𝑋𝑜
                                                               (12.4) 
 
12.A.2. Cell Culture Media Preparation 
 Literature on high-density microbial cell cultures recommends using high-mineral salt 
culture media to sustain large cell concentrations.31 The composition of the culture is included in 
Appendix Q. All mineral salts will be purchased in dry powder form, dissolved in ultrapure water, 
and mixed at 300 rpm in a 500 L HyPerforma Single-Use Mixer from Thermo Fisher. The prepared 
solution will be supplemented with 0.04% vol/vol glycerol and 0.01% vol/vol β-lactose. All 
samples will then be passed through a 0.2 µm filter to sterilize and eliminate any foreign particles, 
bacteria, or large viruses. All culture media will also be supplemented with 2 grams of glucose per 
culture of media, as recommended by Jeffrey Cohen, Ph.D (Johnson & Johnson), prior to insertion 
the microbial bioreactors and fermenters. The total time for this mixing step, including charging 
all the high-salt powders and water, mixing and heating to 37ºC, and sterilization, will take roughly 
five hours. 
For the inoculum grow up and additional grow up in a seed reactor, antibiotics will also be 
included to eliminate any E. coli cells that do not express the genes that code for either α-
galactosidase and α-N-acetylgalactosaminidase. Successfully engineered E. coli strains that 
express the genetic sequence to produce the enzymes of interest also include an attached antibiotic 
resistance gene. If for any reason any of the E. coli cells do not have the genes for enzyme 
                                                          
31 Sivashanmugam A et al. Practical protocols for production of very high yields of recombinant proteins using Escherichia coli. Protein Science 
2009; 18: 936-948. 
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expression, they will not express the antibiotic resistance gene either. The use of antibiotics will 
allow only enzyme-producing E. coli cells to be selected for the microbial cultures. The working 
concentrations for kanamycin and chloramphenicol established in the literature are 50 and 34 
µg/mL, respectively.31 It is assumed that after the first culturing steps, the microbial culture will 
consist exclusively of enzyme-expressing bacterial cells. Therefore, the antibiotics are removed 
from the production fermentation step to reduce costs. 
12.A.3. Inoculum Preparation 
The inoculum for the growth bioreactor and production fermenter will initially be grown 
up in a 0.250 L single-use, disposable stirred tank bioreactor operated in batch using the ambr® 
250 modular system (Sartorius).32 The process will be carried out with a working volume of 0.11 
L incoluated with 1.0 mL of a frozen stock of E. coli BL21(DE3) cells at a concentration of 
7.95×106 cells/mL. It is assumed that only 80% of the cells in the frozen vial will survive the 
freeze-thaw process. After insertion of the inoculum into the culture media and accounting for cell 
death, the initial concentration of the cell population will be 5.09×106 cells/mL. The culture will 
grow for 17.86 hours, regardless of the enzyme product, up until a final cell concentration of 
4.42×108 cells/mL is obtained. The reactor will operate at 300 rpm with a dual 20 mm Rushton 
impeller and at 37ºC achieved via electrical heating. Media in the bioreactor will contain 33.9 g 
Na2HPO4·7H2O, 15.0 g KH2PO4, 5.0 g NH4Cl, 2.5 g NaCl, 7.1 g Na2SOL, 6.0 g MgSO4, 2 g 
glucose, 34 mg chloramphenicol, and 50 mg kanamycin per liter of solution. During the 
inoculation growth, it should be noted the cells will produce small amounts of endotoxin, 
approximately 3.2 grams. Additionally, roughly 5 milliliters of water in the culture media will be 
lost due to evaporation. 
After the near 18-hour growth period, the inoculum culture will be transferred to a a seed 
bioreactor via peristaltic pump for further grow up prior to insertion into the production fermenters. 
All the contents of the unit will be transferred into the new growth bioreactor. If for any reason the 
seed bioreactor is not available for immediate use, the inoculum culture will be transferred to a 
                                                          
32 Sartorius Stedim Biotech GmbH. Data sheet: ambr 250 modular bioreactor [Internet]. Data sheet: ambr 250 modular bioreactor. Goettingen, 
Germany: Sartorius Stedim Biotech GmbH; 2015 [cited 2018 Apr 16]. Available from: 
https://www.sartorius.com/_ui/images/h0c/h06/8870706315294.pdf 
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single-use disposable bag and refrigerated at 4ºC to inhibit further cell growth until inoculation for 
the growth bioreactor. 
12.A.4. Growth Bioreactor 
The growth bioreactor will be inoculated from the E. coli culture grown in the single-use 
bioreactor. The culture will be grown up in an autoclavable glass stirred tank bioreactor operated 
in batch using a BIOSTAT® B control tower (Sartorius).33 The process will be carried out with a 
working volume of 5.44 L in a 10 L UniVessel autoclavable glass vessels34, also purchased from 
Sartorius. Prior to inoculation, 5.33 L of prepared and sterilized high-salt medium will be 
transferred into the 10 L using a peristaltic pump. Immediately after, the remaining 0.11 L of 
culture from the inoculum growth step will be charged into the reactor via peristaltic pump. 
Assuming that approximately 95% of the active microbial population is transferred into the seed 
bioreactor, after dilution with fresh media the initial cell concentration is 8.50×106 cells/mL. The 
remaining five percent that is lost is due to either cell death or transfer losses. Growth will continue 
for 24.03 hours and 23.69 hours for α-N-acetylgalactosaminidase and α-galactosidase, 
respectively. A maximum cell concentration of 3.45×109 and 3.17×109 cells/mL will be obtained 
in each culture. Media in the seed bioreactor will contain 33.9 g Na2HPO4·7H2O, 15.0 g KH2PO4, 
5.0 g NH4Cl, 2.5 g NaCl, 7.1 g Na2SOL, 6.0 g MgSO4, 2 g glucose, 34 mg chloramphenicol, and 
50 mg kanamycin per liter of solution. In addition to microbial growth, this setup will also increase 
the final endotoxin yield thus far to approximately 0.16 grams. It is expected that after the near 24-
hour growth period elapses, approximately 23 milliliters of water will have evaporated. 
The culture will be stirred continuously at 800 rpm with a 6-blade disk (Rushton turbine) 
impeller to keep the culture well mixed and allow for an optimal volumetric oxygen transfer, as 
indicated by the manufacturer’s protocol. The final biomass density in the cultures are 3.45 g/L 
for α-N-acetylgalactosaminidase and 3.17 g/L for α-galactosidase, both of which are fairly low 
density microbial fermentations. The manufacturer’s protocol indicates that the BIOSTAT® B 
                                                          
33 Sartorius Stedim Biotech GmbH. BIOSTAT® B: The Multi-Talented Bioreactor for Research and Development [Internet]. BIOSTAT® B: The 
Multi-Talented Bioreactor for Research and Development. Goettingen, Germany: Sartorius Stedim Biotech GmbH; 2014 [cited 2018 Apr 16]. 
Available from: https://www.sartorius.com/mediafile/Broch_BIOSTAT-B_SBI1513-e.pdf 
34 Sartorius Stedim Biotech GmbH. UniVessel® Glass: Reliability and Continuity [Internet]. UniVessel® Glass: Reliability and Continuity. 
Goettingen, Germany: Sartorius Stedim Biotech GmbH; 2017 [cited 2018 Apr 16]. Available from: http://www.emdmillipore.com/Web-US-
Site/en_CA/-/USD/ShowDocument-File?ProductSKU=MM_NF-
C173675&DocumentId=201504.204.ProNet&DocumentUID=17731154&DocumentType=DS&Language=EN&Country=NF&Origin=PDP 
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system is capable of a volumetric oxygen transfer coefficient greater than 40 hr-1. Based off the 
higher cell density, the oxygen transfer rate is 45.6 mmole O2/g cell-hr while the oxygen uptake 
rate of the cells under these conditions is 41.4 mmole O2/g cell-hr. This calculation additionally 
ensures that the oxygen transfer rates for this bioreactor setting is greater the oxygen uptake rate 
of the E. coli cells, which maximize cell growth and promotes a healthy microbial population for 
production fermentation. The pH of the culture will be maintained at 7.0; the temperature, at 37ºC 
with electric heating. Sterile oxygen will be sparged to maintain a dissolved oxygen concentration 
(pO2) of 40% throughout the whole growth period. All conditions will be stabilized using PID 
feedback controllers. 
If for any reason the production fermenters are not available for immediate use, the seed 
bioreactor culture will be transferred to a single-use disposable bag and refrigerated at 4ºC to 
inhibit further cell growth until inoculation for the growth bioreactor. 
12.A.5. Production Fermenter Preparation 
 The production fermenters will be inoculated with the E. coli culture from the growth 
bioreactor in the previous step. The culture will be grown in two separate stainless steel 
BIOSTAT® D-DCU fermenters (Sartorius).35 First, 391 L of high-salt culture media will be 
prepared, sterilized, and then transferred into the two stainless steel fermenters in equal volumetric 
quantities via peristaltic pump. Immediately after the fermenters have been charged with media, 
the 5.44 L of culture from the growth bioreactor will be separated into two volumetrically equal 
streams, both of which will be transferred into the fermenters through a peristaltic pump. It is once 
again assumed that nearly five percent of the microbial population grown in the seed bioreactor 
will be lost to cell death of transport losses. The culture will be stirred continuously at 800 rpm 
with a 6-blade disk (Rushton turbine) impeller with an optimal oxygen transfer coefficient of 308 
hr-1, allowing a maximum cell biomass density of 29 grams per liter to be supported (see Appendix 
F). These operating conditions were chosen following the manufacturer’s protocol and published 
data, which report optimal E. coli BL21(DE3) cell growth and viability when operating at high 
impeller velocities.  
                                                          
35 Sartorius Stedim Biotech GmbH. BIOSTAT® D-DCU: Your “Fast Lane” to Production [Internet]. BIOSTAT® D-DCU: Your “Fast Lane” to 
Production. Goettingen, Germany: Sartorius Stedim Biotech GmbH; 2015 [cited  2018 Apr 16]. Available from: 
https://www.sartorius.com/mediafile/Broch_Biostat_D-DCU_SBI1512-e.pdf 
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The pH of the culture will be maintained at 7.0; the temperature, at 37ºC with the 
fermenters’ integrated heat jackets. Sterile oxygen will be sparged to maintain a dissolved oxygen 
concentration (pO2) of 40% throughout the whole growth period. All conditions will be stabilized 
using PID feedback controllers.36 The culture will be grown for 25.89 hours to reach a final cell 
concentration of 2.91×1010 cells/mL. This corresponds to a cell mass of approximately 11.5 kg. 
Media in the all bioreactors will contain 33.9 g Na2HPO4·7H2O, 15.0 g KH2PO4, 5.0 g NH4Cl, 2.5 
g NaCl, 7.1 g Na2SOL, 6.0 g MgSO4, and 2 g glucose per liter of culture media broth. Note that in 
this unit operation, the kanamycin and chloramphenicol antibiotics are no longer included. After 
the seed growth, it is assumed that any cells that do not contain the plasmid coding for the gene of 
interest and antibiotic resistance are eliminated. If for any reason any of these cells do remain, they 
are found in a exorbitantly small proportion compared to the engineered E. coli strain, meaning 
that their growth in culture will be minimal. The exclusion of these expensive antibiotics in the 
product fermentation step also reduces costs. 
 When the desired optical density measurements (OD600) value is obtained, isopropyl β-D-
1-thiogalactopyrranoside (IPTG) will be added to the culture to induce protein production. IPTG 
will be transferred in the fermenters until a final concentration of 1.0 mM for the working volume 
is achieved. Protein production will occur for five hours with the culture conditions at a 
temperature of 25ºC, pH of 7.0, and a pO2 of 40%.  The culture will continue to be mixed at 800 
rpm. Assuming that the cell concentration remains approximately constant throughout the protein 
production period, with a cell productivity of 85.4 ng of α-N-acetylgalactosaminidasper cell per 
day, 216 grams of α-N-acetylgalactosaminidasenzyme can be produced. Under the same 
assumption with a cell productivity of 85.6 ng of α-galactosidase per cell per day, one batch can 
produce 199 grams of α-galactosidase. In addition to enzyme production, the microbial 
fermentation produces 11.5 grams of lipopolysaccharide endotoxins. 
After the five hour protein production period, the full cell culture will be transferred via 
peristaltic pump to a 500 L HyPerforma Single-Use Mixer and cooled to 4ºC via the mixer’s heated 
jacket. However, given the transport losses when passing the microbial culture to downstream 
purification and processing, another five percent of the microbial population will lost. Therefore, 
                                                          
36Temperature/PID Controllers [Internet]. Omega. Omega; 2018 [cited 2018Apr17]. Available from: 
https://www.omega.com/guides/tempcontrol.html 
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the mass of enzyme available to harvest once the microbial culture is charged into the holding tank 
is 205 grams of N-acetylgalactosaminidase or 189 grams of α-galactosidase. Once the fermenters’ 
contents are transferred out completely, CIP/SIP procedures will begin immediately afterwards. 
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12.B. ECO-zyme Purification Process Description 
 It should be noted that for all chromatography column designs, a conservative assumption 
made regarding the mass of enzyme that the column will treat. The amount of enzyme lost in the 
previous downstream steps is neglected, leaving us to calculate required resin and column volumes 
using the enzyme mass that originally entered the downstream process. This is done to calculate 
the maximum volume of resin and column that would be required to accomplish the desired 
separation. This serves as the upper bound for costing calculations, which will be usefully in 
providing more constraints to gauge the financial feasibility of the project. Additionally, this 
approach will help ensure that there is a surplus of resin if ever required.  
 Another important note for this section is that the values reported for resin and 
chromatography column volumes correspond to the calculations done for α-N-
acetylgalactosaminidase purification. Since a single batch of α-N-acetylgalactosaminidase has a 
higher mass yield than a batch of α-galactosidase (205 grams versus 189 grams), it can be expected 
that all designs parameters for α-N-acetylgalactosaminidase purification will be greater than the 
minimum volume needed for α-galactosidase purification. Therefore a single chromatography 
column can be used for the purification of both enzymes. 
 The last major calculation done in this section assumes that the hydrophobic interaction 
chromatography column used to eliminate endotoxins from the enzyme product will process the 
original endotoxin mass yield from the microbial fermentation. Similarly to how the resin volumes 
were calculated, this assumption provides the upper bound on how much resin will be required for 
the separation step. Additionally, this assumption allows for a more stringent purification process 
to make sure that the process design’s enzymatic product complies with FDA endotoxin standards. 
12.B.1. Holding Vessel 
 Upon completion of upstream enzyme production, the entire spent media and culture with 
the product from both stainless steel fermenters (396 L for α-N-acetylgalactosaminidase or 364 L 
for α-galactosidase) will be transferred via peristaltic pump to a 500 L HyPerforma Single-Use 
Mixer. This unit was chosen for its single-use technology, which consists of harvesting cells in 
single-use disposable bags to reduce CIP times, and its heated jacket for temperature control. The 
culture will be mixed at 300 rpm on a WAVE bioreactor rocker table to prevent settling of the cells 
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and to minimize loss during transfer out of the holding tank via peristaltic pump to centrifugation. 
The culture will also be lowered to 5ºC, the lower limit of the operating temperature for the vessel, 
to completely inhibit further cell growth. The vessel will also operate at a pressure of 0.03 atm.37 
12.B.2. Centrifugation 
 The content held in the holding tank will be transferred into a Culturefuge100 disk stack 
centrifuge, purchased from Alfa Laval. The unit will separate the solid parts of the culture, 
including cell mass and debris, from the spent liquid media. The spent culture media will then be 
directed into a waste tank, while the solid biomass will remain in a sludge that is 60% by mass 
water and 40% by mass solids.38 The cell biomass will be directed to a disposable 3D bioprocess 
container (Thermo Fisher Scientific)39 and kept at 4ºC until it undergoes homogenization via 
microfluidization. The centrifuge will operate with a flowrate of 100 L/hr at a temperature of 25ºC. 
It is assumed that 5% of the ECO-zyme will be lost in the liquid waste stream, leading to a product 
yield of 95%. Centrifugation will last for approximately one hour, while CIP and SIP procedures 
will require 5.8 hours as recommended by the manufacturer’s protocol. 
 It is assumed that approximately 4.5% of the biomass will be lost from the centrifugation 
process. Thus, after centrifugation, roughly 10.9 kg of biomass will be available for harvesting, 
meaning that the mass of enzyme that can be harvested lowers to 195 grams of α-N-
acetylgalactosaminidase or 180 grams of α-galactosidase. It is also assumed that the same amount 
of endotoxin is lost, leaving 10.9 grams of endotoxin. After the centrifugation process, the 
expected mass of the cell sludge output is approximately 12.7 kg. 
12.B.3. High-Pressure Homogenization 
 The cell sludge from the centrifugation step will be sent through a high-pressure 
microfluidizer processor (Microfluidics)40 to lyse the E. coli cells and release the internalized, 
                                                          
37 Thermo Scientific. Data Sheet: HyPerforma 500 L Single-Use Mixer [Internet]. Data Sheet: HyPerforma 500 L Single-Use Mixer. Waltham, 
MA: Thermo Scientific; 2017 [cited 2018 Apr 16]. Available from: https://www.thermofisher.com/order/catalog/product/SUM0500.9002 
38 Alfa Laval AB. Culturefuge 100 Solid Ejecting Centrifuge [Internet]. Culturefuge 100 Solid Ejecting Centrifuge. Lund, Sweden: Alfa Laval 
AB; 2018 [cited 2018 Apr 16]. Available from: https://www.alfalaval.com/globalassets/documents/products/separation/centrifugal-
separators/disc-stack-separators/culturefuge-100.pdf 
39 Thermo Scientific. Single-Use BioProcess Containers [Internet]. Single-Use BioProcess Containers. Waltham, MA: Thermo Scientific; 2017 
[cited 2018 Apr 16]. Available from: https://www.thermofisher.com/search/results?query=3D bioprocess 
containers&sort=relevancy&persona=DocSupport&focusarea=Search All 
40 Microfluidics. M-7125, M-7250 Enhanced BioPharmaceutical Microfluidizer® Processor [Internet]. M-7125, M-7250 Enhanced 
BioPharmaceutical Microfluidizer® Processor. Westwood, MA: Microfluidics International Corporation; 2010 [cited 2018Apr16]. Available from: 
https://www.microfluidicscorp.com/sites/default/files/700bp-enhanced.pdf 
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cytoplasmic α-galactosidase or α-N-acetylgalactosaminidase. 326 L of bacterial protein extraction 
agent (B-PER) and DNAse solution will be added to the disposable bioprocess container in which 
the cell sludge from centrifugation is stored. (It is assumed that the BPER and DNAse solution has 
the same density as water.) This membrane disrupting solution is added prior to entering the 
microfluidizer to further weaken the cell membrane and promote cell lysis. The microfluidizer will 
pump the cell sludge through a pressure differential of up to 20,000 psi in fixed-geometry 
microchannels to generate high velocity and shear stress. The impact against the microchannels’ 
with the high shear conditions will cause cells membranes to break, releasing the internalized 
protein. The microfluidizer will operate at 25ºC to prevent denaturing of the enzyme. The 
temperature will be controlled and maintained using a digital PID controller. This process will 
require three passes to create a uniform emulsion. The total homogenization process, including 
SIP and CIP procedures, will require approximately 3.8 hours. CIP/SIP procedures are 
recommended to last for two hours. It is once again assumed that the recovery of the product in 
the unit operation is roughly 95%.  
12.B.4. Microfluidization Product Resuspension Tank and Container 
 The lysed cell mass and released enzyme product will be emptied into a new disposable 
500 L 3D bioprocess container fitted into a 500 L HyPerforma Single-Use Mixer (Thermo Fisher 
Scientific). The biomass suspension will be resuspended in 396 L of equilibration buffer to 
maintain its pH at 7.4. It is once more assumed that product recoveyr in this step is 95.5%, meaning 
that 185 grams of α-N-acetylgalactosaminidase  or 171 grams of α-galactosidase will be collected. 
To prevent the lysed biomass and product enzymes from settling, which could result in lower 
product yield, the production suspension is gently agitated at 300 rpm on a WAVE bioreactor 
rocker table. This agitation speed is reduced enough to not generate shear stress that could 
otherwise compromise the biological functionality of the enzyme proteins. The operation time, 
including CIP and SIP sterilization, will be approximately one hour. If the cobalt affinity 
chromatography is not immediately available due to unexpected bottleneck constraints, 
mechanical malfunctions, or other issues, the holding bag and its content will be kept in a cold 
room at 4ºC. 
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12.B.5. Cobalt Affinity Chromatography  
 As previously mentioned, the gene sequence encoded into the E. coli BL21(DE3) cell 
creates an N-terminal truncated construct of the enzymes with a His6 tag at the N-terminus that 
can be used for separation procedures. After complete cell lysis and resuspension of both cell 
debris and product in equilibration buffer, cobalt ion affinity chromatography will be performed 
to separate α-galactosidase and α-N-acetylgalactosaminidase from the cell debris, BPER-DNAse 
mixture, and other buffers. The His6 tags at the N-terminus of the enzymes will bind to the resin 
in the chromatography column, while all non- His6 tagged particles, debris, and organelles will 
pass through the column. 
 As previously mentioned, for the purpose of designing the chromatography, we assume 
that the mass of enzyme that will be processed is equal to the mass of the enzyme at the beginning 
of the downstream purification. This solves for the upper bound of resin and column volume that 
would be needed for purification and separations. The total required chromatography column size 
to treat one batch, which yields 205 grams of enzyme, is 14.6 L. Resolute® chromatography 
columns will be used for this unit procedure and will be purchased from Pall Corporation. The 
column will be packed with HisPur Cobalt Resin41, a tetradentate chelating agarose resin charged 
with divalent cobalt (Co2+) for obtaining high-purity His6-tagged proteins, from Thermo Fisher 
Scientific. The volume of resin required per batch is 10.25 L. Assuming product recovery  of 
95.5%, the mass collected is 176 grams of α-N-acetylgalactosaminidase or 162 grams of α-
galactosidase. It is assumed that all cell debris and antibiotic mass is eliminated in this unit 
operation. Lastly, the affinity chromatography column will operate a linear velocity of 150 cm/hr 
and at a temperature of 25ºC. The chromatography separation, including resin set up, will require 
5.27 hours. CIP and regeneration will take an additional 3.14 hours. 
 For operating, the column must first be run with ten column volumes of equilibration 
buffer. The resuspended solution of cell debris and product in equilibration buffer will then be 
added to the column to allow for protein binding to the resin. The resin has an expected binding 
capacity of 20 grams of enzyme per liter of resin for both α-galactosidase and α-N-
acetylgalactosaminidase. After binding, the column will then be washed with ten volumes of wash 
                                                          
41 Pall Life Sciences. Resolute® Manual Chromatography Columns [Internet]. Resolute® Manual Chromatography Columns. Port Washington, 
NY: Pall Corporation; 2017 [cited 2018 Apr 16]. Available from: https://shop.pall.com/us/en/biotech/chromatography/columns-pilot-and-
process-scale/resolute-manual-chromatography-columns-zidgri78lcv 
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buffer to eliminate any cell debris that may have bound to the resin. Lastly, ten column volumes 
of elution buffer will be added to the column to release and collect all bound enzyme.  
 Regeneration of the resin will be done by washing the column and resin with ten column 
volumes of regeneration buffer. According to the manufacturer’s protocol, the resin can be 
regenerated a maximum of 25 times without decreasing the purity of the product below 90%.  
12.B.6. Hydrophobic Interaction Chromatography 
 The removal of endotoxins, the pyrogenic components of the outer cell wall of Gram-
negative bacteria such as E. coli, is necessary to prevent inducing immunogenic responses in 
patients. Since α-galactosidase and α-N-acetylgalactosaminidase will be used to treat RBCs and 
could possibly remain in solution with them after the conversion, transfusion of these units could 
theoretically cause significant levels of endotoxin contamination. Although endotoxin removal is 
reported when cell solutions are run through a cobalt affinity chromatography column, this process 
operates under the assumption that the endotoxin removal is negligible. This assumption is made 
given that the cobalt-chelate coordination core is reported to have off-target binding to endotoxins 
and other protein host contaminants.  
This column will be packed with POROS Benzyl HIC Resin42, which consists of cross‐
linked poly(styrene-divinylbenzene) POROS base beads with aromatic hydrophobic benzyl ligand, 
suited for both bind/elute and flow-through purifications. The benzyl resin system was chosen over 
other available resins because binding affinity can easily be controlled even with relatively small 
differences in hydrophobicity. Assuming that no endotoxin has been removed since the beginning 
of the downstream purification to be stricter on design calculations, each batch of E. coli 
BL21(DE3) culture produces 11.5 grams of endotoxin to be processed. Therefore, the volume of 
resin required for each batch HIC chromatography operation is 57.5 L. The total required 
chromatography column size to treat one batch is 96 L. Resolute® chromatography columns will 
also be used for this unit procedure. Lastly, the endotoxin affinity chromatography column will 
also operate a linear velocity of 150 cm/hr and at a temperature of 25ºC. The chromatography 
separation, including resin set up, will require 3.79 hours. CIP and regeneration will take 
                                                          
42 Thermo Scientific. Instructions: HisPur™ Cobalt Resin [Internet]. Instructions: HisPur™ Cobalt Resin. Rockford, IL: Pierce Biotechnology; 
2012 [cited 2018 Apr 16]. Available from: https://www.thermofisher.com/order/catalog/product/89964 
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approximately one hour. Although the manufacturer’s protocol for this resin reports a 99% 
removal of endotoxins, other sources report that only a 90% removal was often obtained. For this 
reason, it is assumed that the hydrophobic interaction column will only remove 90% of the 
endotoxins from the enzyme product. After processing, 1.15 grams of endotoxin will remain. 
Assuming approximately 95% enzyme product recovery, either 167 grams of α-N-
acetylgalactosaminidase or 162 grams of α-galactosidase will be collected. 
 For operating, the column must first be run with five column volumes of equilibration 
buffer. The collected product solution from the previous chromatography step will then be added 
to the column to allow for endotoxin binding to the resin. After binding, the column will then be 
washed with five volumes of wash buffer to eliminate any cell debris that may have bound to the 
resin. Lastly, two column volumes of elution buffer will be added to the column to release and 
collect all bound enzyme. CIP procedures include adding two column volumes of 6M guanidine 
HCl43 and another two column volumes of 1% mass/volume Brij35 nonionic detergent. 44 
 Regeneration of the resin will be done by washing the column and resin with five column 
volumes of regeneration buffer. According to the manufacturer’s protocol, the resin can be 
regenerated a maximum of ten times without any loss in performance.  
12.B.7. Endoxotin Affinity Chromatography 
 The hydrophobic interaction chromatography (HIC) unit operation alone by itself cannot 
sufficiently reduce the endotoxin concentration in the product suspension to the FDA standard of 
0.1 EU/mL. Therefore, an endotoxin affinity chromatography operation was added to the process 
to further remove endotoxins from the product.  
 The last column will be packed with Pierce High Capacity Endotoxin Removal Resin 
(Thermo Fisher Scientific)45, which combines porous cellulose beads with poly(ε-lysine) as an 
affinity ligand to selectively bind endotoxins. The binding affinity is also reported to be 2×106 
EU/mL, where EU is shorthand for endotoxin units. After the HIC separation step, 1.15 grams of 
                                                          
43 Thermo Scientific. User Guide: POROS™ HIC Resins: Ethyl, Benzyl, and Benzyl Ultra [Internet]. User Guide: POROS™ HIC Resins: Ethyl, 
Benzyl, and Benzyl Ultra. Waltham, MA: Thermo Scientific; 2017 [cited 2018 Apr 16]. Available from: 
https://www.thermofisher.com/order/catalog/product/88272?SID=srch-srp-88272 
44 Brij 35 for Synthesis; MSDS No. 801962 [Online]; EMD Millipore: Saint Louis, MO, Sep 16, 2014.  http://www.emdmillipore.com/Web-US-
Site/en_CA/-/USD/ProcessMSDS-Start?PlainSKU=MDA_CHEM-801962&Origin=PDP (accessed Apr 10, 2018). 
45 Thermo Scientific. Instructions: Pierce High-Capacity Endotoxin Removal Resin [Internet]. Instructions: Pierce High-Capacity Endotoxin 
Removal Resin. Rockford, IL: Pierce Biotechnology; 2016 [cited 2018 Apr 16]. Available from: 
https://www.thermofisher.com/order/catalog/product/88272?SID=srch-srp-88272 
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endotoxin will need to be treated. Therefore, the volume of resin required per batch is 5.75 L. The 
total required chromatography column size to treat one batch is 9.6 L. Resolute® chromatography 
columns will be used for this unit procedure and will be purchased from Pall Corporation. Lastly, 
the endotoxin affinity chromatography column will also operate a linear velocity of 150 cm/hr and 
at a temperature of 25ºC. The chromatography separation, including set up, will require 3.01 hours, 
while CIP and regeneration will last slightly over an hour. It is assumed that there is a 99% removal 
of endotoxins in this unit operation, as indicated in the manufacturer’s protocol. After passing the 
enzyme product solution from the previous unit, either 159 grams of α-N-acetylgalactosaminidase 
or 146 grams of α-galactosidase will be collected. 
 For operating, the column must first be run with five column volumes of equilibration 
buffer. The collected product solution from the previous chromatography step will then be added 
to the column to allow for endotoxin binding to the resin. After binding, the column will then be 
washed with five volumes of wash buffer to eliminate any cell debris that may have bound to the 
resin. Lastly, two column volumes of elution buffer will be added to the column to release and 
collect all bound enzyme. CIP procedures include adding two column volumes of 6M guanidine 
HCl and another two column volumes of 1% mass/volume Brij35 nonionic detergent.  
 Regeneration of the resin will be done by washing the column and resin with two column 
volumes of regeneration buffer. According to the manufacturer’s protocol, the resin can be 
regenerated a maximum of five times without any loss in performance.  
12.B.8. Ultrafiltration/Diafiltration 
 After separating α-galactosidase and α-N-acetylgalactosaminidase from endotoxins via 
several chromatography steps, the next major unit operation is separating these enzymes from any 
remaining cellular debris and the buffer components from the endotoxin affinity chromatography 
step. An ultrafiltration/diafiltration setup will be prepared using a Cogent Process-Scale Tangential 
Flow Filtration System (EMD Millipore)46 loaded with Pellicon 3 Cassettes with Ultracel 
Membrane.47 The membrane will have a 30 kD nomical molecular weight limit with C-screen. The 
                                                          
46 EMD Millipore. Data Sheet: Cogent® Process-Scale Tangential Flow Filtration System [Internet]. Data Sheet: Cogent® Process-Scale 
Tangential Flow Filtration System. Darmstadt, Germany: EMD Millipore; 2015 [cited 2018 Apr 16]. Available from: 
http://www.emdmillipore.com/US/en/product/Cogent-Process-Scale-Tangential-Flow-Filtration-System,MM_NF-C173675#documentation 
47 Millipore Sigma. Pellicon® 3 Cassettes with Ultracel® Membrane [Internet]. Pellicon® 3 Cassettes with Ultracel® Membrane . Burlington, 
MA: Millipore Sigma; 2018 [cited 2018 Apr 16]. Available from: http://www.emdmillipore.com/US/en/product/Pellicon-3-Cassettes,MM_NF-
C9947?CatalogCategoryID=#documentation 
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Ultracel membranes have a surface area of 1.14 m2 and can be run with a flow rate of 4 L/min. As 
the process is carried out, the feed tank will be continuously replenished with equilibration buffer. 
It is assumed that roughly 95% percent of the product will be recovered, while the remaining five 
percent will be lost to the permeate. This means that either 151 grams of α-N-
acetylgalactosaminidase or 139 grams of α-galactosidase will be collected. The 
ultrafiltration/diafiltration step will require approximately two hours. The operation time of the 
ultrafiltraton/diafiltration unit will be roughly two hours, with an equivalent amount of time used 
for CIP/SIP procedures. 
12.B.9. Sterile, Bulk Microfiltration 
 Sterile filtration is used as the final purification step to remove endotoxins and any 
remaining microscopic cell debris and organelles from the final product solution. This step is taken 
to ensure that the final concentration of endotoxins in the ECO-zyme solution meets FDA 
standards. The filters will be hydrophobic Durapore PVDF membranes with a 0.22 µm pore 
diameter size.48 The PVDF filters and their respective holders are disposable, and one of each will 
be used per batch. The filters have a 100 cm2 surface area and will run at a flowrate of 11 L/min. 
Recovery of ECO-zyme product in this step is 95%. This unit procedure will be run twice as 
additional precaution to ensure that FDA requirements for endotoxin removal are satisfied. It is 
assumed that 99% of endotoxins are removed after each filtration pass. After this unit operation, 
1.04×10-6 grams of endotoxin will remain. 136 grams of α-N-acetylgalactosaminidase or 125 
grams of α-galactosidase will be collected. The final concentration of the enzyme product solution 
after passing through bulk microfiltration will be 1 mg/mL and will be stored in 200 mM glycine 
solution to prevent the protein from aggregating in solution. Several filters will be run in parallel 
to allow this unit operation to last approximately 30 minutes. All filters are disposable, but 
preparation of new units is estimated to last approximately two hours. 
 
 
                                                          
48 EMD Millipore. Data Sheet: Millidisk® Cartridges and Millipak® Disposable Capsules [Internet]. Data Sheet: Millidisk® Cartridges and 
Millipak® Disposable Capsules. Westwood, MA: EMD Millipore; 2015 [cited 2018 Apr 16]. Available from: 
http://www.emdmillipore.com/US/en/product/Durapore-Membrane-Filters,MM_NF-C7631?CatalogCategoryID=#documentation 
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12.C. Red Blood Cell Conversion Process Description 
 To enzymatically convert type-A and type-B RBCs, α-N-acetylgalactosaminidase and α-
galactosidase, respectively, will be added to pooled transfusion units. The RBC units will be 
acquired in variable sized transfusion bags from suppliers such as hospitals, regional blood banks, 
or the Red Cross, with an average size of 300 mL per transfusion unit. The production goal is 
200,000 enzymatically converted RBC transfusion units. Across the entire treatment process, 
however, there is an assumed 35% loss of RBCs due to lysis and transfer losses. Thus, additional 
transfusion units will be required to account for the losses to be able to satisfy production goals. 
Therefore, the process system is designed to operate with an annual working volume associated 
with approximately 308,000 transfusion units.  
 One important aspect of this process is that all steps, with the exception of the actual 
conversion step, are done at 4ºC to preserve the biological activity of the RBCs. This decision was 
made following the most stringent medical standards for transfusion medicine, which are found in 
the United Kingdom. There, transfusion units that have been outside of a controlled temperature 
of 4ºC for longer than four hours are to be eliminated. This is done in precaution of adversely 
altering the biological activity and functionality of the RBCs.   
12.C.1. Hyperbaric Chamber for Blood Bag Emptying 
The first step in the RBC conversion process is the collection of the RBC units for future 
treatment steps. Each batch of enzymatically converted RBCs uses 1,973 units, all of which need 
to be pooled in a storage vessel prior to downstream treatment. Currently available methods for 
emptying RBC units, however, are only meant for single bags. These include gravity aided 
emptying, blood pressure cuffs, pressure infusers, or manual emptying. Given the scale of this 
process, however, there is a high risk of human error and a requirement for a significant workforce 
to accomplish this goal.  
 The proposed solution to efficiently empty many RBC units in parallel uses the same 
mechanism as commercially available pressure infusers, which empty blood bags using a pressure 
differential. They operate by surrounding a single RBC unit and increasing the pressure by 300 
mmHg, achieve flow rates of 257±54 mL/min. Using this technology as a base, a hyperbaric 
chamber will be developed to generate a pressure differential of 1.0 atm and generate pressure-
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driven flow from the blood bags to the storage vessel. RBC units will be stored on carts that will 
carry a total of 1,973 units per batch and will be rolled into the hyperbaric chamber. This is 
approximately the same regardless of which blood type that is being treated. The chamber will be 
similar to commercially available units but will be designed to contain a storage cart, an exit for 
the tube bundle to which the blood bags will be connected, and reach an operating pressure of 1.5 
atm and temperature of 4ºC. Eight rounds of pressurization will need to be performed per batch. 
Each run will take approximately ten minutes. The entire RBC unit emptying step will take roughly 
2.5 hours. Three hours will be allotted to proper CIP/SIP procedures to eliminate any bloodborne 
biological waste that may remain in the system. This time also includes disposal of the original 
blood bags. The chamber will be designed and constructed by a third party vendor, with an initial 
estimated cost of $100,000 after consultation with numerous industrial consultants. 8.00% of sales 
will also be allocated to research expenses, which will place a heavy emphasis on the optimization 
of this process to enhance the speed with which the blood units are emptied. 
12.C.2. Centrifugation 
The contents of the RBC storage vessel will be transferred into a Culturefuge 100 disk 
stack centrifuge via a Quattroflow quaternary diaphragm pump. The centrifuge will separate the 
solid RBC components from the additive solution waste in which they were suspended. The spent 
additive solution will be directed to a waste tank for safe disposal. The RBC pellet will be 
transferred to a new single-use, disposable holding bag and resuspended to its original volume in 
a 0.9% NaCl solution with 140 mL of CPDA-1 anticoagulant for every liter of blood treated. The 
stored contents will be kept at 4ºC until the next major unit step. The centrifuge will operate with 
a minimal flowrate of 100L/hr to minimize RBC lysis at a temperature of 4ºC. It is assumed that 
5% of the RBCs that pass through this unit operation will lyse, leading to a product yield of 95%. 
Centrifugation will last for two hours to handle the entire blood volume but at lower velocities to 
prevent shearing. CIP/SIP procedures will require 2.8 hours. 
12.C.3. Conversion WAVE Bioreactors 
The RBCs from the disposable holding bag will be transferred into six 100 L WAVE 
bioreactors via a Quattroflow quaternary diaphragm pump.49 The initial temperature of the reactor 
                                                          
49 Holland Applied Technologies. Spec Sheet QF1200S-CV [Internet]. Spec Sheet QF1200S-CV. Chicago, IL: Holland Applied Technologies; 
2015 [cited 2018 Apr 16]. Available from: http://www.hollandapt.com/Documents/Ctrl_Hyperlink/doccopy11285_uid192018402382.pdf 
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will be set at 4ºC. As soon as the RBC contents have been emptied into the WAVE bioreactors, 
the temperature will be programmed to increase in increments of 0.5ºC every 45 seconds until a 
final temperature of 25ºC has been reached. This temperature increase interval is the common 
standard employed in blood warmers to prevent RBCs from lysing due to drastic temperature 
changes. When the temperature of the contents in the WAVE bioreactors has reached 25ºC, pre-
warmed α-N-acetylgalactosaminidase for type-A RBCs, or α-galactosidase for type-B cells, will 
be added to the WAVE bioreactors. 60 mg of α-N-acetylgalactosaminidase will be required for 
every 0.3 L of type-A RBC solution treated (the equivalent of one transfusion unit), while only 2 
mg of α-galactosidase will be needed to treat the same volume of type-B RBC solution. The 
conversion reaction will take place for one hour. The WAVE bioreactors will operate at 25 rpm at 
an angle of 8º to minimize foaming. The pH will be maintained between 7.4 and 7.6. Once the 
reaction has been completed, the temperature of the WAVE bioreactor and its content will be 
decreased to 4ºC in decreasing intervals of 0.5ºC every 45 seconds. For scheduling purposes, an 
additional 30 minutes to the hour reaction time is allotted for charging all red blood cells into the 
devices. 
12.C.4. Centrifugation 
One hour after the enzymatic conversion has elapsed and as soon as the treated RBCs have 
been cooled to 4ºC, the contents of the WAVE bioreactor will be transferred to a Culturefuge 100 
disk stack centrifuge via a Quattroflow quaternary diaphragm pump to separate the treated RBCs 
from the enzyme in solution. The centrifuge will operate at 100 L/hr and at 4ºC. The spent 
anticoagulant-saline solution with the conversion enzyme will be charged to a waste tank for safe 
disposal. The remaining solid RBC mass, expected to be 60% by mass saline-anticoagulant 
solution and 40% by mass solids, will be transferred into a single-use, disposable HyPerforma 
Smartainer 3D Bioprocess Container (BPC) and resuspended to its original volume again with in 
a 0.9% NaCl solution with 140 mL of CPDA-1 anticoagulant for every liter of blood treated. 
Centrifugation will last for two hours to handle the entire blood volume but at lower velocities to 
prevent shearing. CIP/SIP procedures will require 2.8 hours. 
12.C.5. Diafiltration 
To remove any remaining enzyme from the resuspended RBCs, diafiltration will be used. 
Pellicon 2 Durapore PVDF microfiltration filters will be used with a 500 kD nominal molecular 
 
92 
 
weight limit (NMWL) and will be run in tangential flow in a Cogent Process-Scale Tangential 
Flow Filtration System. This filter size will allow RBCs to remain in the retentate while remaining 
enzyme is eliminated through the permeate. The resuspended RBCs from the previous 
centrifugation step will be transferred into the diafiltration system by a Quattroflow quaternary 
diaphragm pump. The enzyme-free retentate will flow back into the original storage system feed 
tank, and the permeate containing the enzymes will be discarded. While this process occurs, new 
saline-anticoagulant solution will be continuously added into the system feed tank to maintain the 
osmolality of the RBC solution equivalent to what is found in biological systems to prevent 
hemolysis and RBC aggregation. As the diafiltration process is performed, the spent saline-
coagulant solution that may contain traces of enzyme will be removed and will be replenished by 
enzyme-free solution. It is assumed that 5% of the RBCs will be lost due to lysis during the 
diafiltration step, leading to a 95% recovery of the converted RBCs. The diafiltration step will 
require approximately 2.5 hours to complete and will be run at 4ºC. Cleaning time will be set at 
two hours. 
12.C.6. Cryogel-based Affinity Chromatography 
To separate RBCs successfully converted to type-O from those that did not undergo a 
successful conversion, cryogel-based affinity chromatography will be used. This technique is used 
instead of using the typical affinity chromatography approach of having protein A-coated resins to 
which antibody-selected cells would bind. Traditional affinity chromatography for cell separations 
has been proven to be harsh on RBCs and induce significant lysis. To minimize lysis and costs 
associated with having to work with even more RBC transfusion units, the cryogel-based technique 
was chosen given its success in separating blood cells with less than five percent lysis (shown in 
Figure 12.C.6.1).50 Supermacroporous cryogel monoliths can have a pore diameter of up to 100 
μm, which enables its application for chromatography of cells of varying size (between 1 and 
15 μm) without being mechanically entrapped in the column. Convectively transported cells 
also do not experience large shear forces because of laminar flow of liquid in the interconnected 
pores in the monolithic cryogel, which helps prevent mechanically-induced cell lysis. 
                                                          
50 Kumar A, Srivastava A. Cell separation using cryogel-based affinity chromatography. Nature Protocols. 2010Oct7;5(11):1737–47. 
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Figure 12.C.6.1. Blood passage through a cryogel-based affinity chromatography done in 
academic research to quantify shearing and lysis. The literature reports less than five percent 
hemolysis of the total RBC population that was introduced into the column. 
The cryogel matrix for the column will be produced from different hydrophilic gel -
forming polymers either by polymerization of the appropriate monomers, polyacrylamide and 
poly(dimethylacrylamide). A cryogel affinity matrix will then be developed by covalent 
coupling of protein A on the surface of the pore wall, which can capture immunoglobulin (IgG) 
antibodies or IgG-labeled specific cells. Protein A, which consists of a 40- to 60-kD protein 
present in the cell wall of Staphylococcus aureus, has affinity to the Fc portion of the IgG from 
a wide range of species. Protein A will be covalently coupled to epoxy-activated cryogel 
monolith by two-step derivatization using functionalization of epoxy-activated cryogel with 
ethylenediamine and then crosslinking of protein A using glutaraldehyde.  
The protein A-bound monolithic cryogel will be used as a generic affinity adsorbent for 
specific IgG antibodies against A or B antigens and loaded into the chromatography column. 
The system will operate at a pressure of 1 atm, a temperature of 4ºC, and a linear velocity of 
2,000 cm/hr. RBCs that have undergone the enzymatic treatment will then be loaded into the 
cryogel-protein A column. Cells that still have their A or B antigens will bind to the IgG 
antibodies bound on the cryogel-protein A matrix. The RBCs that were successfully converted, 
which have no antigens, will not bind to the antibodies and pass through the column. These 
cells will be collected into a disposable bioprocess container, in which the RBCs will be 
resuspended to a working volume of 100 L with anticoagulant-saline solution, until the next 
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centrifugation step. The RBCs will be placed on a WAVE bioreactor rocker table for gentle 
agitation to prevent them from settling and aggregating.  
Mechanical stress will then be applied to the cryogel to release cells that were bound to 
the column. This system has the advantage though that the mechanical stress only releases 
bound cells and not the antibodies bound to the protein A, allowing it to be re-used several 
times before the antibodies begin to lose their binding affinity. This circumvents another issue 
with using traditional resin: the costly replenishment of antibodies used for binding.  
This column will operate for 4.51 hours at a linear velocity of 300 cm/hr. Cleansing and 
regeneration of the resin will take 1.62 hours.  
12.C.7. Microfiltration/Diafiltration 
An additional ultrafiltration/diafiltration step will be implemented after the cryogel-based 
affinity chromatography step to remove the column buffer components from the final treated RBC 
product suspension. Pellicone 3 Durapore PVDF microfiltration filters will be used with a 500 kD 
nominal molecular weight limit (NMWL) and will be run in tangential flow in a Cogent Process-
Scale Tangential Flow Filtration System. This filter size will allow RBCs to remain in the retentate 
while all buffer components are eliminated through the permeate. The resuspended RBCs from the 
previous centrifugation step will be transferred into the diafiltration system by a Quattroflow 
quaternary diaphragm pump. The buffer-free retentate will flow back into the original storage 
system feed tank, and the permeate containing buffer will be discarded. While this process occurs, 
new saline-anticoagulant solution will be replenished to maintain physiological osmolality for the 
RBCs. It is assumed that 5% of the RBCs will be lost due to lysis during the diafiltration step, 
leading to a 95% recovery of the converted RBCs. The diafiltration step will require approximately 
2.5 hours to complete and will be run at 4ºC. CIP/SIP will take two hours. 
12.C.8. Centrifugation 
After the converted RBCs have been separated from non-converted RBCs, the collected 
contents from the previous microfiltration/diafiltration step will be transferred to a Culturefuge 
100 disk stack centrifuge via a Quattroflow quaternary diaphragm pump. The centrifuge will 
operate at 100 L/hr and at 4ºC. The spent anticoagulant-saline solution will be charged to a waste 
tank for safe disposal. The remaining solid RBC mass will be resuspended in 191 L of Adsol-1 
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additive solution and transferred into a disposable bioprocess container. Centrifugation will last 
for two hours to handle the entire blood volume but at lower velocities to prevent shearing. CIP/SIP 
procedures will require 2.8 hours. 
12.C.9. Holding Tank 
Upon completion of centrifugation of the contents that were processed in the 
microfiltration/diafiltration step, the remaining solid RBC mass will be transferred into a 500 L 
HyPerforma Smartainer 3D bioprocess container and resuspended in 191 L of Adsol-1 additive 
solution. It is assumed that the the RBC sludge from the centrifugation process will make up 
approximately 50% of the resuspended solution that will be packaged. The final RBC suspension 
will have a 50% hematocrit (volumetric ratio of RBCs to total volume). The stored RBC solution 
will be kept at 4ºC and placed on a gentle rocker at 25 rpm to prevent RBCs from settling until 
final packaging.  
12.C.10. Preparation of Converted Red Blood Cell Transfusion Units 
The hyperbaric chamber will be operated in reverse to create pressure driven flow from the 
storage vessel to dry, empty blood bags connected to the central tubing line. The final output of 
the RBC treatment process will be prepared as a ready-to-administer product. The converted RBCs 
stored in the Adsol-1 additive solution will be packaged into TERUFLEX dry blood bags with a 
working volume of 300 mL at a final concentration of 50% hematocrit. Each batch of the treatment 
process will produce 1,283 transfusion units of ECO RBCs. The bags will be filled after five 
pressurization runs, taking a total 1.62 hours to complete packaging. A maximum of 2.5 hours, 
however, has been scheduled to account for the time needed to fit empty blood bags to the central 
lines through the RBC suspension will travel. All filled transfusions units of enzymatically 
converted RBCs will be stored at 4ºC at all times and have a maximum shelf-life of 42 days. Note 
that there will be some variability in the shelf-life depending on the age of the donor RBCs. 
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13. Energy Balances and Utilities Requirements 
Energy balances not applicable. 
 
For utilities requirements, please see section 18. 
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14. Equipment List and Unit Descriptions 
 
14.1. Common Units 
 
14.1.1. Peristaltic Pumps 
 Peristaltic pumps will be used to transfer all fluids that contain E. coli cell mass or enzyme 
product. These pumps are best for transferring viscous fluids such as cell suspensions and can 
show better performances for fluid transport than centrifugal pumps under these operating 
conditions. The peristaltic pumps will also handle all buffer transfers in the chromatography 
column steps. Thirty-nine Masterflex (Model 77924-80) 600-rpm pumps will be purchased from 
Cole-Parmer for $3,635 per pump. This value includes spares as well. The construction material 
for each pump is stainless steel AISI 304. Each pump comes equipped with graphical LCD that 
show four operating modes: continuous run, timed dispense, copy dispense, volume dispense. The 
flow rate through each pump can vary between 0.001 and 3,400 mL/min with L/S tubing. The 
sterile L/S tubing will also be provided by Cole-Parmer. Each pump will operate at room 
temperature and at a pressure drop of 3.5 atm. The power requirement is 253 W. The CIP and SIP 
processes can operate at a maximum temperature of 90 and 130ºC degrees, respectively. 
 For large volumes of chromatography buffer, primarily in the steps in which ten column 
volumes must be passed through the unit, Watson Marlow 840 Series Hygienic Peristaltic Pumps 
will be used. One unit was purchased for each chromatography column required in the facility. 
Each one of these pumps will operate at room temperature and at a pressure drop of 3.5 atm. 
GORE® STA-PURE® PFL tubing will be used here to ensure that the tubing can handle all 
organic solvents and materials  found in the buffers. These pumps are mounted on a steel frame 
with fixed speed motor gearboxes that require a power input of 0.2 W for operation. 
 
14.1.2. Quattroflow Quaternary Diaphragm Pumps 
 For the treatment of RBCs, nine Quattroflow quaternary diaphragm pumps (Model 
QF1200S-CV) will be purchased for $10,772 per pump from PSG Dover. The Quattroflow pumps 
are made of stainless steel AISI 304. These pumps were chosen due to their ability to mechanically 
imitate the pumping of the heart. Each stroke of the 4-piston diaphragm is generated by an 
eccentric shaft connected to an electric motor. The method of operation of the Quattroflow pumps 
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allows them to transfer shear-sensitive biological molecules and cells with minimal impact, which 
helps prevent additional cell lysis that could affect the RBC production goal. The flow rate through 
each pump can vary between 10 and 1,200 L/hr with a 5º eccentric shaft. Each Quattroflow pump 
will be operated at 800 rpm to achieve a flow rate of 350 L/hr and at a pressure drop of 6 atm. For 
sterile sealing, all valves and O-rings are sealed with ethylene propylene diene monomer rubber. 
The power requirement for each Quattroflow pump is 370 W. The CIP and SIP processes can 
operate at a maximum temperature of 90 and 130ºC degrees, respectively. 
 
14.1.3. Media Sterilization Filters 
0.2 µm pore-sized Millipore Express® SHF filters will be used to purify bacterial culture 
media by removing any impurities and toxins before introduction in the stainless steel fermenters. 
Each filter has a nominal length of 30 inches, a diameter of 6.9 cm, and a filtration area of 1.62 
m2. The devices uses polyethersulfone (PES) for the filtration chemistry. The device material is 
polypropylene/polysulfone. The seal material is code 7 silicone. All filtration cartridges were 
sterilized by 25 forward or 22 forward and 3 reverse SIP cycles of 30 min at 135 °C. Sterilization 
can also be done using 25 autoclave cycles of 60 min at 126 °C. The maximum forward inlet 
pressure is 7 bar and the maximum reverse inlet pressure is 2.07 bar, both at at 25ºC. The maximum 
forward pressure differential is 6.9 bar and the maximum reverse pressure differential is 2.1, both 
at 25ºC. Each filter costs $650/unit. The filters require a type of housing for security, which will 
be contracted to Millipore for a one-time cost of $2,000. The filters are disposable and replaced 
after every batch. Since they are disposable, no CIP or SIP will be required for the filter. SIP, 
however, is required for the housing unit. 
 
14.1.4. Digital Control Units 
Digital control units will be purchased to conduct proportional integral derivative (PID) 
feedback control. The PID controllers, purchased from Omega, will be used to control the agitation 
speed and maintain temperature at 37ºC, pH between 7.0 and 7.2, constant percent oxygen at 40%, 
and a constant liquid level to avoid excessive foaming for all bioreactor systems in the E. coli 
BL21(DE3) upstream culture process. A total of 30 units will be purchased, including back-ups. 
Each unit will be purchased at a price of $300/unit. 
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14.2. Upstream Process for E. coli Growth 
 
14.2.1. Inoculum Growth Bioreactor 
 The ambr 250 modular bioreactor system will be purchased from Sartorius at $45,799 for 
the control tower and system. Each individual vessel will be purchased for $155. The bioreactor 
tower and control system is made of stainless steel, while the bioreactor vessel is sterile plastic. 
Each batch will begin with a new, sterile ambr 250®  bioreactor with a freshly thawed vial of E. 
coli BL221(DE3) cells. All bioreactor vessels are single-use and disposable. Agitation will occur 
at 300 rpm using a dual 20 mm Rushton impeller. The ratio of the impeller diameter to the 
bioreactor inner diameter is 0.5. The geometric ratio of height to inner diameter of the reactor 
vessel is 1.8. The bioreactor vessel has a maximum working volume of 0.250 L; the chosen 
working volume for this unit operation is 0.110 L. Temperature control will be done using 
electrical heating. The vessel design incorporates disposables sensors to simplify system 
preparation. The bioreactor package includes DO sensors to measure pO2, disposable pH 
electrodes, integrated gas and liquid inlet filters, and an integrated condenser for output to exhaust 
gas analysis. The bioreactor will operate at a temperature of 37ºC, a pressure of 1.0 atm, a pH of 
7.0-7.2, and 40% pO2. Each vessel will be in operation, preferably overnight, for 17.68 hours, 
regardless of the enzyme product. It is assumed that 5% of the bacterial population will die during 
culture, due to shear-induced lysis or health complications, leading to a percent yield of 95%. 
 
14.2.2. Growth Bioreactor 
 The cell suspension from the inoculum growth reactor will be transferred into a larger 
bioreactor to continue cell growth in a larger culture volume to prepare for inoculation of the final 
production fermenters. The growth bioreactor system will consist of a stainless steel AISI 316L 
BIOSTAT® B control tower and an autoclavable borosilicate glass vessel. It also allows for four 
peristaltic pumps integrated into the control unit, two external peristaltic pumps, and two balances 
connections. The complete bioreactor system will be purchased for $100,000. The bioreactor 
vessel has a maximum working volume capacity of 10 L; the chosen working volume for this 
process is 5.44 L. The dimensions of the entire system are 330mm x 860mm x 420 mm. Agitation 
will be performed at 800 rpm with a 6-blade disk Rushton turbine impeller to allow for an 
volumetric oxygen transfer coefficient greater than 40 hr-1. Temperature control will be done using 
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a single-wall heated jacket. The bioreactor will operate at a temperature of 37ºC, a pressure of 1.0 
atm, a pH of 7.0-7.2, and 40% pO2. Each vessel will be in operation for 24.03 hours for α-N-
acetylgalactosaminidase or for 23.69 hours for α-galactosidase. Standard CIP procedures will be 
used for sterilization of control tower when necessary. The borosilicate glass vessel will be 
autoclaved at 121ºC for one hour. It is assumed that 5% of the bacterial population will die during 
culture, due to shear-induced lysis or health complications, leading to a percent yield of 95.5%. 
 
14.2.3.  Production Bioreactors 
          The cell suspension from the growth bioreactor will be split between two stainless steel 
(AISI 304) fermenters. The BIOSTAT® D-DCU, which includes the control tower and the two 
fermenters, will be purchased from Sartorius for a total of $300,000. The bioreactor vessel has a 
maximum working volume capacity of 200 L; the chosen working volume for this process is 198 
L for each reactor. The dimensions of the entire system are 3.1m x 3.05m x 1.8m. Agitation will 
be performed at 800 rpm with a 6-blade disk Rushton turbine impeller to allow for an volumetric 
oxygen transfer coefficient of 308 hr-1. The ratio of the impeller diameter to the bioreactor inner 
diameter is 0.5. The geometric ratio of height to inner diameter of the reactor vessel is 3.0. The 
high performance servo drive motor assembly combines low shear, gentle agitation for cell 
cultures and high speed mixing for microbial high cell density cultivation, ensuring high oxygen 
transfer rates. Temperature control will be done using an integrated closed loop system with a 
recirculation pump and heat exchanger. The bioreactors will operate at a temperature of 37ºC (for 
growth) and 25ºC (for protein expression), a pressure of 1.0 atm, a pH of 7.0, and 40% pO2. Each 
vessel will be in operation for 25.89 hours for cell growth and then an additional five hours for 
enzyme protein expression. Standard CIP and SIP procedures will be used for sterilization. It is 
assumed that 5% of the bacterial population will die during culture, due to shear-induced lysis or 
cell viability complications, leading to a percent yield of 95.5%. 
 
14.2.4.  Cell Culture Storage Vessel 
The cell suspension from the production fermenters will be stored in a Thermo Fisher 500L 
HyPerform Single-Use Mixer, which has a purchase cost of $165,000. Each disposable bag is 
appraised at $300. The mixer is made of stainless steel AISI 304, while the single-use disposable 
biocontainers will be made of CX5-14 multi-layer plastic. The dimensions of the unit are 122cm 
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x 129cm x 198cm. The unit will be operated at a pressure of 0.03 atm and a temperature of 5ºC. 
The liquid chill-down time for the mixer is 3.7 hours. 
 
14.3. Downstream Purification Section 
 
14.3.1. Disk stack centrifuge 
 The purpose of the centrifuge is to separate the solid biomass (E. coli cells with desired 
enzyme product in their cytoplasm) from the spent liquid media. All spent culture media will be 
directed to a waste holding tank while the solid E. coli cell pellet will be moved downstream to 
harvest the α-galactosidase or α-N-acetylgalactosaminidase enzyme product. A Culturefuge 100 
disk stack centrifuge will be purchased from Alfa Laval for $46,500 per unit. The solid biomass 
product will be in the form of a cell sludge that is 40% by mass solids and 60% by mass  water. 
The centrifuge unit will consist of a molybdenum-bearing austenitic stainless steel bowl and a cast 
iron grey bottom frame. The centrifuge has a maximum operating capacity of 2,000 L/hr, 12,220 
g for G-force, and 9,550 rpm bowl speed. The volumetric flow rate that the Culturefuge 100 will 
operate at is 100 L/hr. The unit will operate at a temperature of 25ºC and a pressure of 1.0 atm. 
The process time, including CIP and SIP procedures, will take approximately 6.8 hours. It is 
assumed that appromximately five percent of product enzyme will be lost in this unit operation. 
 
14.3.2. High Pressure Homogenization 
 The cell sludge from the centrifugation step will be sent through a M175 Aseptic 
Microfluidizer, purchased from Microfluidics, to disrupt the cell membrane of the E. coli bacterial 
cells and release the internalized enzyme product. The device can operate at a maximum pressure 
of 30,000 psi with a volumetric flow rate of 7.56 L/min. The hydraulic capacity of the fluidizer is 
13 L/hr. The hold-up volume is less than one liter. The microfluidizer comes equipped with a heat 
exchanger for product temperature control, using a pharma grade, double tubesheet style. For 
cooling purposes, a chilled water loop will be used. The unit also comes equipped with a feed 
pump for air and requires a flow rate of 0.65 m3/min at 6.2 atm. For product pathing cooling and 
dry down, a sterile compressed air stream of 0.085 m3/min at 1 atm is required. The overall power 
requirement for this device is 18.6 kW. The cell membrane disruption process via 
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microfluidization will require approximately four hours. CIP and SIP procedures will last two 
hours. Steam-in-place requirements are 22.6 kg/hr at 2.4 atm.  
The microfluidizer will pump the sludge through a pressure differential of 20,000 psi, and 
the cells will pass through fixed-geometry microchannels to induce high linear velocities. The high 
velocities at which the cells travel generate impact and shear-inducing conditions to lyse the cells. 
The shearing conditions are not sufficient to denature proteins, providing an effective method to 
collect cytoplasmic protein product. It is assumed that product recovery is approximately 95%. 
 
14.3.3. Microfluidization Product Resuspension Container 
After centrifugation and homogenization, the resulting cell sludge with product will be 
resuspended in equilibration buffer to a volume equal to the volume of culture media in which the 
cells were originally suspended. This amount is added to ensure that the pH of the resulting 
suspension is that the same as that of the equilibration buffer, a pH of 7.4. The cell sludge will be 
resuspended in a HyPerforma Single-Use Mixer lined with a 500 L 3D bioprocess container, both 
purchased from Thermo Fisher Scientific. The mixer unit is made of stainless steel AISI 304. The 
disposable containers are sterile single-use CX5-14 multi-layer plastic. A volume equal to that of 
the cell sludge will be first added to the mixer, after which the cell cludge will be pumped into the 
device via peristaltic pump. Equilibration buffer will then be added until the pH and volumetric 
conditions are satisfied. The HyPerforma Single-Use Mixer will be purchased at $150,000 per unit, 
while each 3D bioprocess container will be purchased for $300/ per bag. A PID feedback controller 
will be incorporated into this step to maintain the agitation speed of the mixer at 300 rpm, the 
temperature at 25ºC, and the pressure at 0.003 atm. The process time, including CIP and SIP 
procedures, will take approximately 3.6 hours. It is assumed that 5% of product enzyme will be 
lost in this unit operation. 
 
14.3.4. Cobalt Affinity Chromatography Column 
 A cobalt affinity chromatography system will be used as a first purification pass to separate 
the enzyme product from cell debris and intracellular materials. A Resolute 280 chromatography 
column, from Pall Corporation, will be purchased at $110,000 per unit. The column is comprised 
of electropolished stainless steel and has a diameter of 280 mm. It will be packed with HisPur 
Cobalt Resin, which contains a cobalt-chelate coordination core to bind His6-tagged proteins, and 
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is applicable for treatment of both enzymes. The resin has a void fraction of 0.3. Each column is 
designed to separate either 205 grams of α-N-acetylgalactosaminidase or 189 grams of α-
galactosidase. 10.25 L of resin will be required to purify α-N-acetylgalactosaminidase, and 9.45 L 
will be needed for purification of α-galactosidase. The required height for the column is 237 mm. 
The column volume required to satisfy both resin volume requirements is 14.6 L. The resin allows 
for an operating linear velocity of 150 cm/hr and has a binding capacity of 20 grams of proteins 
per liter of resin. The resin can be used 25 times before losing efficiency and requiring replacement. 
The column will be located in a cold room section of the work space so that operating conditions 
are 4ºC and 1.0 atm. The entire column operating time, including regeneration and sterilization 
procedures, is 7.46 hours. A product recovery of 95% is assumed. 
 
14.3.5. Cobalt Affinity Chromatography Collection Container  
 All column flow-through will be directed to a waste tank for heat inactivation to eliminate 
any remaining active bacterial cells. The eluted product from the column will be collected in a 
separate single-use 200 L 3D Productainer bioprocess bag purchased from Thermo Fisher 
Scientific at $250/bag. These disposable containers are sterile single-use CX5-14 multi-layer 
plastic. The working volume of each container will be 147 L for α-galactosidase elute and 94.5 L 
for α-N-acetylgalactosaminidase elute. The containers will be stored at 4ºC if the following 
chromatography column is not immediately available for use. 
 
14.3.6. Hydrophobic Interaction Chromatography Column 
 A hydrophobic interaction chromatography step will be used to separate endotoxins from 
the α-galactosidase and α-N-acetylgalactosaminidase products to comply with FDA standards. A 
Resolute 800 chromatography column, from Pall Corporation, will be purchased for $250,000. 
The column is comprised of electropolished stainless steel and has a diameter of 800 mm. It will 
be packed with POROS Benzyl HIC Resin, which contains beads with aromatic hydrophobic 
benzyl ligand that strongly bind the highly hydrophobic endotoxins. The resin has a void fraction 
of 0.4. Each batch will separate either 11.5 grams of endotoxin from the α-N-
acetylgalactosaminidase culture or 10.6 grams from the α-galactosidase culture. 57.5 L of resin 
will be required to purify α-N-acetylgalactosaminidase, and 52.9 L will be needed for purification 
of α-galactosidase. The required height for the column is 191 mm. The column volume required 
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to satisfy both resin volume requirements is 95.9 L. The resin allows for an operating linear 
velocity of 150 cm/hr and has a binding capacity of 2×106 endotoxin units/mL resin. The resin can 
be used ten times before losing efficiency and requiring replacement. The product purity, 
according to the manufacturer’s protocol, is ≥ 90%. The column will be located in a cold room 
section of the work space so that operating conditions are 4ºC and 1.0 atm. The entire column 
operating time, including regeneration and sterilization procedures, is 4.68 hours. A product 
recovery of 95% and an endotoxin removal of 90% are assumed. 
 
14.3.7. Hydrophobic Interaction Chromatography Collection Container 
 All column flow-through will be directed to a waste tank for heat inactivation to eliminate 
any possible remaining active bacterial cells. The eluted product will be collected in a separate 
single-use 1500 L 3D Labtainer bioprocess container purchased from Thermo Fisher Scientific at 
$500/bag. These disposable containers are sterile single-use CX5-14 multi-layer plastic. The 
container will be stored at 4ºC if the following chromatography step is not immediately available 
for use. 
 
14.3.8. Endotoxin Affinity Chromatography Column 
 An endotoxin affinity chromatography system will be used to separate endotoxins from the 
α-galactosidase and α-N-acetylgalactosaminidase enzyme products. A Resolute 280 
chromatography column, from Pall Corporation, will be purchased at $110,000 per unit. It is 
comprised of electropolished stainless steel and has a diameter of 280 mm. This column will be 
packed with Pierce High-Capacity Endotoxin Removal Resin, which contains poly(ε-lysine) 
coated beads that bind endotoxins. The resin has a void fraction of 0.4. Each batch will separate 
either 1.15 grams of endotoxin from the α-N-acetylgalactosaminidase culture or 1.06 grams from 
the α-galactosidase culture. 5.75 L of resin will be required to purify α-galactosidase, and 5.29 L 
will be needed for purification of α-N-acetylgalactosaminidase. The required height for the column 
is 156 mm. The column volume required to satisfy both resin volume requirements is 9.59 L. The 
resin allows for an operating linear velocity of 150 cm/hr and has a binding capacity of 2×106 
endotoxin units/mL resin. The resin can be used five times before losing efficiency and requiring 
replacement. The product purity, according to the manufacturer’s protocol, is ≥ 90%. The column 
will be located in a cold room section of the work space so that operating conditions are 4ºC and 
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1.0 atm. The entire column operating time, including regeneration and sterilization procedures, is 
3.01 hours. A product recovery of 95% and an endotoxin removal of 99% are assumed. 
 
14.3.9. Endotoxin Affinity Chromatography Collection Container 
 All additional column flow-through will be directed to a waste tank for heat inactivation to 
eliminate any possible remaining active bacterial cells. The eluted product from the α-
galactosidase separation will be collected and stored in a single-use 50 L 2D Productainer 
bioprocess bag purchased from Thermo Fisher Scientific at $37.54/bag. These disposable 
containers are sterile single-use CX5-14 multi-layer plastic. The containers will be stored at 4ºC if 
the following chromatography column is not immediately available for use.  
 
14.3.10. Ultrafiltration/Diafiltration Unit 
 An ultrafiltration/diafiltration process will be implemented using a Cogent M1 Process 
Scale Tangential Flow Filtration System. It is manufactured by EMD Millipore and has a purchase 
cost of $47,999, The system will be equipped with Pellicon 3 Ultracel filter cassettes made of 
regenerated cellulose and polyethylene. The filtration area of the casettes is 1.14m2 and will handle 
a flow rate of 4 L/min. The system can operate with a maximum pressure drop of 2 atm. The 
stainless steel cassette holder will be purchased at $995. A pack of 100 Ultracell membranes will 
also be purchased for $479.08. The system will be operated in a cold room at 4ºC and 1 atm.  
 
14.3.11. Bulk Microfiltration Unit 
A bulk microfiltration pack will be purchased from EMD Millipore for $503 for a pack of 
three filters. The filters will be hydrophobic Durapore PVDF membranes with a 0.22 µm pore 
diameter size. Given that there is two-fold difference in hydrophobicity between endotoxins and 
the ECO-zymes, the use of bulk microfiltration allows endotoxins to be retained in the filter while 
enzyme product is filtered. The enzyme product will go thorugh two passes of bulk microfiltration 
to guarantee compliance of FDA standards regarding endotoxin concentration. It is assumed that 
these filters remove 99% of endotoxins, as stated in the manufacturer’s protocol. The diameter and 
thickness of the filter are 142 mm and 125 µm, respectively. The PVDF filters and their respective 
holders are disposable, and one of each will be used per batch. The filters have a 100 cm2 surface 
area and will run at a flowrate of 16.5 L/min. The porosity of the filters is 75%. Protein binding at 
 
108 
 
the membrane is 150 µg/cm². Recovery of ECO-zyme product in this step is 95% for each pass. 
All microfiltration units are single-use and disposable once the batch process has completed. 
 
14.3.12. Final Product Holding Container  
 The final concentrated product from the bulk microfiltration step will be concentrated to 1 
mg enzyme/mL and stored in a five 50 L 2D Labtainer bioprocess bags purchased from Thermo 
Scientific for $37.54/bag. The bioprocess container is a made of sterile single-use CX5-14 multi-
layer plastic. Containers will be stored at 4ºC in a cold room if needed in the immediate future for 
RBC conversion treatment. Otherwise, bags will kept at -20ºC for long-term storage. 
 
14.4. RBC Conversion Treatment Process 
 
14.4.1. Hyperbaric Chamber 
 A hyperbaric chamber will be used to empty 264 blood bags for every pressuration run into 
a storage container. The chamber will be designed to sustain preferential differentials up to 1.5 
atm. A total of 1,973 blood bags are expected to be processed, on average, for every batch. Each 
batch treatment will take approximately 2.5 hours. The process will be carried out in a cold room 
at 4ºC. 
 
14.4.2. Hyperbaric Chamber Collection Container 
 The RBCs collected from donor transfusion units will be emptied by the hyperbaric 
chamber into three 200 L 3D Productainer bioprocess bags, purchased from Thermo Fisher 
Scientific at $250/bag, all of which are sterile single-use CX5-14 multi-layer plastic containers. 
The RBCs will be kept at 4ºC until proceeding to the centrifugation step. They will also be kept 
on a rocker to prevent the cells from settling and to maximize the RBC content drained from the 
containers. 
 
14.4.3. Disk Stack Centrifuge 
 Another Culturefuge 100 disk stack centrifuge, purchased from Alfa Laval for $46,500 per 
unit, will be used to separate RBCs from their spent additive preservation solution. Upon 
centrifugation, the solid RBCs will settle to the bottom of the centrifuge bowl. All spent 
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preservation fluid will be directed to a biowaste holding tank for heat inactivation while the RBC 
pellet will be directed to a WAVE bioreactor. The centrifuge unit will consist of a molybdenum-
bearing austenitic stainless steel bowl and a cast iron grey bottom frame. The centrifuge has a 
maximum operating capacity of 2,000 L/hr, 12,220 g for G-force, and 9,550 rpm bowl speed. The 
volumetric flow rate that the Culturefuge 100 will operate at is 100 L/hr. The unit will operate at 
a temperature of 4ºC and a pressure of 1.0 atm. The process time, including CIP and SIP 
procedures, will take approximately 4.8 hours. It is assumed that 5% of product enzyme will be 
lost in this unit operation. 
 
14.4.4. WAVE Bioreactor 
 The RBCs to be converted will be transferred from the disposable holding bag into five 
WAVE bioreactors. The chosen model is the BIOSTAT® RM bioreactor system, which includes 
the control tower and the disposable bag rocker. Each system will cost $20,000. Additionally, the 
disposable bag necessary is the FLEXSAFE® RM. The control tower is made of stainless steel 
AISI 304; the rocker, stainless steel ABS; and the disposable bags, polyethylene multilayer plastic. 
The area dimensions of each individual system is 740 mm x 720mm. The temperature control 
consists of an integrated open thermostat system with a ciruclation pump and an automatic cooling 
water valve. Temperature can be increased and decreased in intervals of 0.5ºC every 45 seconds. 
The power requirements are 1.20 kW per unit.  Each WAVE bioreactor will operate at a 
temperature of 25ºC, a pressure of 1.0 atm, a pH of 7.2 to 7.4, and 40% pO2. Each bag has a total 
volume of 200 L but only has a working capacity of 100 L, which is what approximately used in 
each. The rocking base will perform 15 rocks/min at an angle of 10º.  
 
14.4.5. Disk Stack Centrifuge 
 Another Culturefuge 100 disk stack centrifuge, purchased from Alfa Laval for $46,500 per 
unit, will be used to separate the converted RBCs from the enzyme in solution. Upon 
centrifugation, the solid RBCs will settle to the bottom of the centrifuge bowl while the α-
galactosidase or α-N-acetylgalactosaminidase enzyme will remain in solution. All spent fluid with 
enzyme will be directed to a waste holding tank while the RBC pellet will be collected into a 
bioprocess container until sent transferred into the diafiltration unit. The centrifuge unit will 
consist of a molybdenum-bearing austenitic stainless steel bowl and a cast iron grey bottom frame. 
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The centrifuge has a maximum operating capacity of 2,000 L/hr, 12,220 g for G-force, and 9,550 
rpm bowl speed. The volumetric flow rate that the Culturefuge 100 will operate at is 100 L/hr. The 
unit will operate at a temperature of 4ºC and a pressure of 1.0 atm. The process time, including 
CIP and SIP procedures, will take approximately 4.8 hours. It is assumed that 5% of product 
enzyme will be lost in this unit operation. 
 
14.4.6. Diafiltration Unit 
  A diafiltration unit operation will be implemented to remove ECO-zyme from the RBC 
suspension. The unit operation will be done using a Cogent Process Scale Tangential Flow 
Filtration System from EMD Millipore, with a purchase cost of $47,999. The system will 
implement Pellicone 3 Durapore PVDF Ultracel microfiltration filters will be used with a 500 kD 
NMWL, which is large enough for all enzymes to pass through but retain all RBCs. Each pack of 
filters has a purchase cost of $479.08, while the sterile stainless steel cassette holder will cost $995. 
The filters will be made of regenerated cellulose with a polyethylene frame. The filtration rea of 
each filter is 1.14 m2 and will be operated at 4 L/min. It is assumed that 95% the treated RBCs will 
be recovered in this step, with a 5% loss associated with filtration through the cassette membrane 
or lysis. This entire process will be done at 4ºC in a cold room and at a pressure of 1 atm. 
 
14.4.7. Cryogel-based Affinity Chromatography Column 
 A cryogel-based affinity chromatography column will be used to separate non-converted 
RBCs from the successfully converted universal RBCs. A Resolute 280 chromatography column, 
from Pall Corporation, will be purchased for $200,000. The column is comprised of 
electropolished stainless steel and has a diameter of 280 mm. It will be packed with a cryogel 
polymer made of polyacrylamide and poly(dimethylacrylamide) that is coated in protein A-IgG. 
The protein A binds IgG antibodies that will target blood group antigens on RBCs. The cryogel 
will be pre-loaded with 72.1 mg of blood group-specific IgG antibody per batch prior to running 
RBCs through the column. Each column run will process 1,237 L of processed blood. The resin 
has a void fraction of 0.4. For running the column, 14.42 L of cryogel will be needed for 
purification processes. The cryogel will be used five times before replenishing and antibody 
replacement. The required height for the column is 292 mm. The column volume required to satisfy 
the cryogel volume requirement is 18.0 L. The cryogel allows for an maximum linear velocity of 
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1,200 cm/hr but will operated at 300 cm/hr. The product purity is reported to be ≥ 95%. The column 
will be located in a cold room section of the work space so that operating conditions are 4ºC and 
1.0 atm. The entire column operating time, including regeneration and sterilization procedures, is 
4.51 hours. A product recovery of 95% is assumed. 
 
14.4.8. Disk Stack Centrifugation 
 A Culturefuge 100 disk stack centrifuge, purchased from Alfa Laval for $46,500 per unit, 
will separate the converted RBCs from any remaining buffer solution. It is assumed that the output 
of the centrifuge will be 60% by mass water and 40% by mass RBCs. All spent buffer and solution 
will be directed to a waste holding tank while the RBCs will be collected into a final product 
holding container. The centrifuge unit will consist of a molybdenum-bearing austenitic stainless 
steel bowl and a cast iron grey bottom frame. The centrifuge has a maximum operating capacity 
of 2,000 L/hr, 12,220 g for G-force, and 9,550 rpm bowl speed. The volumetric flow rate that the 
Culturefuge 100 will operate at is 100 L/hr. The unit will operate at a temperature of 4ºC and a 
pressure of 1.0 atm. The process time, including CIP and SIP procedures, will take approximately 
4.8 hours. It is assumed that 5% of product enzyme will be lost in this unit operation. 
 
14.4.9. Final Product Holding Container 
 After centrifugation, the converted RBCs will be transferred into a 500 L HyPerforma 
Smartainer 3D bioprocess container made of sterile single-use CX5-14 multi-layer plastic. The 
RBC mass will be resuspended to a volume of 191 L of Adsol-1 additive preservation solution. 
The RBCs will be kept at 4ºC from this point forward to preserve their biological activity. The 
container will be placed on a WAVE rocker set at an agitation speed of 25 rpm to prevent RBCs 
from settling until final packaging.  
 
 
 
 
 
 
 
112 
 
 
 
 
 
 
Section 15: 
Specification Sheets 
 
 
 
 
 
 
 
 
 
 
113 
 
15. Specification Sheets 
 
The following pages contain the specification sheets for all unit operations. Description 
and function, vendor, operation, characteristics, operating conditions, and purchase cost are all 
detailed. 
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15. 1. Inoculum Bioreactor (P-1, PFD#1) 
 
Description and Function Inoculum for the growth bioreactor will be prepared and grown 
in a 0.250 L single-use, stirred tank bioreactor, with a working 
volume of 110 mL. The purchased unit will also include a control 
tower to monitor aeration, pH, temperature, and rocking speed. 
The vessels are made of single layer injection molded plastic and 
are 15 kGy β-irradiated for sterilization. 
 
Vendor Sartorius Stedim Biotechnology Group 
 
Operation Batch 
 
  
Materials Handled  Input (kg/batch) Output (kg/batch) 
 Cells 5.60×10-7 4.87×10-5 
 Nutrients 
Water 
9.74×10-5 
0.110 
0 
0.105 
 Kanamycin 5.50×10-6 5.50×10-6 
 Chloramphenicol 
Endotoxin 
Waste 
3.40×10-6 
0 
0 
3.40×10-6 
3.20×10-3 
3.39×10-4 
  
    
Characteristics Model: 
Material construction: 
 
Heating method: 
Percent yield: 
Sterilization: 
Sparger: 
Agitation speed: 
Impeller configuration: 
Ratio d:Di 
Ratio H:Di 
Volume: 
ambr® 250 modular system  
Sterile plastic vessel, stainless steel 
control tower 
Electric heating 
95% 
Disposable stirred tank 
Microsparger 
300 rpm 
Dual 20 mm Rushton impeller 
0.5 
1.8 
0.2 L 
 
Operating Conditions Temperature:  
Pressure:  
pH: 
pO2: 
Growth time: 
37ºC 
1.0 atm 
7.0-7.2 
40% 
17.86 hours 
  
  
Purchase Cost Control tower: $45,799 
Bioreactor vessel: $155/vessel 
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15.2. Growth Bioreactor (P-2, PFD#1) 
Description and Function The growth bioreactor will consist of an autoclavable glass vessel 
operated by a control tower. It will be used to further increase the 
cell concentration before splitting the culture between two stainless 
steel fermenters. The total reactor volume is 10L and will operate 
with a working volume of 5.44 L. The PID controller, ez-Control 
from Applikon, will be purchased separately to monitor and control 
the pH, temperature, pO2, foam level, glucose and agitation rate. 
 
Vendor Sartorius Stedim Biotechnology Group 
 
Operation Batch 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
 Cells 4.62×10-5 1.88×10-2 
 Nutrients 
Water 
3.76×10-2 
5.44 
0 
5.21 
 Kanamycin 2.72×10-4 2.72×10-4 
 Chloramphenicol  
Endotoxin 
1.85×10-4 
3.20×10-3 
1.85×10-4 
0.158 
 Waste 0 0.584 
    
  
    
Characteristics Model: 
Material Construction: 
 
Dimensions: 
Heating method: 
Percent Yield: 
Sterilization: 
Agitation speed: 
Impeller configuration: 
Volume: 
BIOSTAT® B  
Borosilicate glass vessel, stainless 
steel AISI 316L control tower 
330mm x 860mm x 420mm 
Single-wall heated jacket 
95% 
CIP/SIP 
800 rpm 
Dual 20 mm Rushton impeller 
10 L 
  
Operating Conditions Temperature:  
Pressure:  
pH: 
pO2: 
Growth Time: 
 
 
37ºC  
1.0 atm 
7.0 
40% 
24.03 hr for α-galactosidase, 23.69 
hr for α-N-acetylgalactosaminidase 
 
Purchase Cost Bioreactor system: 
Controller: 
$100,000 
$500 
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15.3. Production Bioreactors (P-3, P-4; PFD#1) 
 
Description and Function The production bioreactor system will consist of two stainless steel 
bioreactors with a volume of 323 L and a maximum working volume 
of 200 L. Each reactor will handle a working volume of 198 L and 
will be used to grow up cells to a desired cell concentration and for 
induce protein production using induction by IPTG. The controller, 
ez-Control from Applikon, will be purchased separately to monitor 
and control the pH, temperature, pO2, foam level, glucose and 
agitation rate. 
 
Vendor Sartorius Stedim Biotechnology Group 
 
Operation Batch 
  
Materials Handled   Input (kg/batch) Output (kg/batch) 
 Cells 1.78×10-2 11.5 
(overall) Nutrients 23.1 0 
 Water 396 379 
 IPTG 9.44×10-2 9.44×10-2 
 GalNAc-ase  
OR α-galactosidase 
Endotoxin 
Waste 
0 
0 
0.158 
0 
0.216 
0.199 
11.5×10-3 
358 
    
    
Characteristics 
 
(for each reactor) 
Model: 
Material Construction: 
Dimensions: 
Heating method: 
 
 
Percent Yield: 
Sterilization: 
Agitation speed: 
Impeller configuration: 
Ratio d:Di 
Ratio H:Di 
Maximum working volume: 
Total volume: 
BIOSTAT® D-DCU  
Stainless steel AISI 304 
3.1m x 3.05m x 1.8m 
Closed loop system with 
recirculation pump and heat 
exchanger for heating and cooling 
95% 
CIP/SIP  
800 rpm 
6-blade disk Rushton turbine 
0.5 
3 
200 L 
323 L  
  
Operating Conditions Temperature:  
Pressure:  
pH: 
pO2: 
37ºC (growth), 25ºC (production) 
1.0 atm 
7.0 
40% 
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Growth Time: 
Protein Production Time: 
25.89 hours 
5 hours 
  
  
Purchase Cost Bioreactor: 
Controller: 
 
$150,000/reactor 
$500 
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15.4. Cell Culture Storage Tank (P-6, PFD#1) 
 
Description and Function Upon completion of fermentation and protein production, the cell 
suspension with internalized enzyme product from the production 
bioreactors will be quickly transferred into a 500 L HyPerforma 
Single-Use Mixer. This will enable CIP and SIP procedures to 
begin promptly. Additionally, the suspension will be gently 
agitated to prevent cells from settling. 
 
Vendor Thermo Fisher Scientific 
 
 
Operation Batch 
 
    
Characteristics Material construction: 
 
 
Dimensions: 
Volume: 
Sterilization: 
 
Liquid chill-down time: 
Agitation speed: 
Stainless steel AISI 304, sterile 
single-use CX5-14 multi-layer 
plastic 
122cm x 129cm x 198 cm  
500 L 
Disposable single-use bags, 
CIP/SIP for mixer when needed 
3.7 hours 
300 rpm 
 
  
Operating Conditions Temperature:  
Pressure:  
 
5ºC  
0.03 atm 
 
  
  
Purchase Cost $100,000/mixer 
$300/bag 
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15.5. Disk Stack Centrifuge (P-1, PFD#2) 
 
Description and Function The Culturefuge 100 disk stack centrifuge will be used to separate the 
cells (solid biomass) from the spent media (liquid). The resulting cell 
sludge will be 60% by mass water and 40% by mass solid. Five 
percent of the cell suspension from the production fermenters are lost 
due to transfer losses prior to centrifugation. 
 
 
Vendor Alfa Laval 
 
Operation Batch 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
Cells 11.5 10.9 
Media 379 12.7 
IPTG 9.44×10-2 8.97×10-2 
Kanamycin 2.72×10-4 2.59×10-4 
Chloramphenicol 
Endotoxin 
1.85×10-4 
11.5×10-3 
1.76×10-4 
10.9×10-3 
 Waste 0 368 
 GalNAc-ase  
OR α-galactosidase 
 
0.205 
0.189 
 
0.195 
0.180 
 
 
Characteristics Model: 
Centrifuge type: 
Material construction: 
 
 
Finish: 
Hydraulic capacity: 
G-force: 
Bowl speed: 
Percent Yield: 
Sterilization: 
Culturefuge 100 
Disk stack 
Mo-bearing austenitic steel 
for body and cover; cast grey 
iron bottom frame 
Electro-polished 
2,000 L/hr capacity 
12,220 g maximum 
9,550 rpm maximum 
95% 
CIP/SIP 
  
 
Operating Conditions Temperature:  
Pressure:  
Flowrate: 
25ºC 
1.0 atm 
200 L/hr 
  
  
Purchase Cost $46,500/unit  
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15.6. High Pressure Homogenizer/Microfluidizer (P-3, PFD#2) 
 
Description and Function The high-pressure M-7125 Microfluidizer is used to homogenize and 
lyse cells after centrifugation to release expressed α-galactosidase or 
α-N-acetylgalactosaminidase, along with cell debris and other excess 
proteins. The microfluidizer generates a pressure differential of 
20,000 psi, causing high-velocity pressure-driven flow of cells across 
fixed-geometry channels. The geometry of the channels combined 
with the high velocity generate high impact and shearing conditions 
that disrupt the cell membrane and cause the E. coli cells to lyse.  
 
Vendor Microfluidics 
 
Operation Batch 
 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
Cells 10.9 10.4 
B-PER 326 0 
Endotoxin 10.9×10-3 10.4×10-3 
 Water 12.7 12.1 
 IPTG 8.97×10-2 8.52×10-2 
 Kanamycin 2.78×10-4 2.64×10-4 
 Chloramphenicol 1.85×10-4 1.76×10-4 
 GalNAc-ase  
OR α-galactosidase 
Waste 
0.195 
0.180 
0 
0.185 
0.171 
328 
    
Characteristics Model: 
Material construction: 
Dimensions: 
Hydraulic capacity: 
Maximum pressure: 
Percent yield: 
Hold-up volume: 
Power requirement: 
M-7125 Series Microfluidizer 
Stainless steel 
272cm x 161cm x 211cm 
13 L/hr capacity 
2000 atm 
95% 
<1 L 
18.6 kW 
  
  
Operating Conditions Temperature:  
Pressure:  
Flow rate: 
25ºC 
1,316 atm 
13 L/hr 
  
  
  
  
Purchase Cost $38,740/unit  
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15.7. Cell Sludge Resuspension Container (P-4, PFD#2) 
 
Description and Function A 3D bioprocess container will be used to collect the lysed 
biomass and harvested enzyme product after the microfluidic 
cell membrane disruption. The biomass and product will be 
resuspended in equilibration buffer to prepare for binding in the 
cobalt affinity chromatography column. A control unit will be 
used to monitor the pH until the solution reaches a desired pH 
of 7.4. Buffer will be continuously added until the cell 
suspension achieves a volume of 396 L for α-galactosidase or 
374 L α-N-acetylgalactosaminidase. The total volume of the 
container will be 500 L and at least ten column volumes of 
equilibration buffer will be added.  
 
 
Vendor Thermo Fisher Scientific 
 
 
Operation Batch 
 
    
Characteristics Material construction: 
 
Volume: 
Sterilization: 
Sterile single-use CX5-14 
multi-layer plastic  
500 L 
Disposable 
  
 
Operating Conditions 
 
Temperature:  
Pressure:  
 
 
4ºC in cold room  
1.0 atm 
 
  
  
Purchase Cost $300/bag  
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15.8. Cobalt Affinity Chromatography Column (P-5, PFD#2) 
 
Description and Function The cobalt affinity chromatography column will be used to bind 
the His6-tagged α-galactosidase and α-N-acetylgalactosaminidase 
enzymes and separate them from most of the cell debris, buffers, 
and B-PER. HisPur Cobalt Superflow Agarose resin (Thermo 
Fisher Scientific) will be used. Assumes no endotoxin removal. 
 
Vendor Pall Corporation 
 
 
Operation Batch 
 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
Cells 10.4 0 
Buffers 1330 146 
Endotoxin 10.4×10-3 10.4×10-3 
Water 12.1 0 
GalNAc-ase  
OR α-galactosidase 
0.185 
0.171 
0.176 
0.162 
Kanamycin 2.64×10-4 0 
Chloramphenicol 1.76×10-4 0 
Waste 0 1140 
    
Characteristics Model: 
Material construction: 
Required volume: 
Diameter: 
Height: 
Max linear flowrate: 
Percent yield: 
Sterilization: 
Regeneration: 
Purity: 
Resin: 
Resin volume: 
Void fraction: 
Binding capacity: 
Resolute 280 Chromatography Column 
Stainless steel, electropolished 
14.6 L 
280 mm 
237 mm 
1200 cm/hr 
95% 
CIP/SIP 
25 times 
≥ 90% 
HisPur Cobalt Superflow Agarose 
10.25 L 
0.3 
20 g enzyme/L resin 
    
Operating Conditions Temperature: 
Pressure: 
Linear Flowrate: 
4ºC in cold room 
5.0 atm 
150 cm/hr 
  
Purchase Cost Column: $110,000 
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15.9. Affinity Chromatography Product Collection Container (P-6, PFD#2) 
 
Description and Function The product that is eluted from the cobalt affinity 
chromatography column will be directed to a single-use, 
disposable 3D bioprocess container. All other column flow-
through that came into contact with the cell culture materials 
will be directed to the waste tank for biowaste heat inactivation 
and neutralization. Buffers that did not come into contact with 
biological material will be directed to a waste tank for 
immediate neutralization. 
 
 
Vendor Thermo Fisher Scientific 
 
 
Operation Batch 
 
    
Characteristics Material construction: 
 
Volume: 
Sterilization: 
Sterile single-use CX5-14 
multi-layer plastic  
200 L 
Disposable 
  
 
Operating Conditions 
 
Temperature:  
Pressure:  
 
 
4ºC in cold room  
1.0 atm 
 
  
  
Purchase Cost $250/bag  
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15.10. Hydrophobic Interaction Chromatography Column (P-7, PFD#2) 
 
Description and Function The hydrophobic interaction chromatography column will be used 
to exploit the two-fold difference in hydropathy between 
endotoxins and the product enzymes and separate them based on 
hydrophobicity. It serves as an additional step to eliminate any 
remaining endotoxins in the product suspension and comply with 
FDA endotoxin standards. POROS Benzyl HIC Resin, cross‐
linked poly(styrene-divinylbenzene) POROS base beads with 
aromatic hydrophobic benzyl ligand, that bind highly hydrophobic 
particles. It is assumed that 90% of endotoxins will be removed. 
 
Vendor Pall Corporation 
 
 
Operation Batch 
 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
Buffers 3678 959 
Endotoxin 10.4×10-3 1.04×10-3 
 GalNAc-ase  
OR α-galactosidase 
Waste 
0.176 
0.162 
0 
0.167 
0.154 
2709 
    
Characteristics Model: 
Material construction: 
Required volume: 
Diameter: 
Height: 
Max linear flow rate: 
Percent yield: 
Sterilization: 
Regeneration: 
Purity: 
Resin: 
Resin volume: 
Void fraction: 
Binding capacity: 
Resolute 800 Chromatography Column 
Stainless steel, electropolished 
95.9 L 
800 mm 
191 mm 
1200 cm/hr 
95% 
CIP/SIP 
10 times 
≥ 90% 
POROS Benzyl HIC Resin  
57.5 L 
0.4 
2×106 EU/mL, 90% endotoxin removal 
    
Operating Conditions Temperature: 
Pressure: 
Linear Flowrate: 
4ºC in cold room 
3.0 atm 
150 cm/hr 
  
Purchase Cost $250,000 
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15.11. HIC Product Collection Containers (P-8, PFD#2) 
 
Description and Function The product that is eluted from the hydrophobic interaction 
chromatography column will be directed to two single-use, 
disposable 3D bioprocess containers. All other column flow-
through that came into contact with the cell culture materials 
will be directed to the waste tank for biowaste heat inactivation 
and neutralization. Buffers that did not come into contact with 
biological material will be directed to a waste tank for 
immediate neutralization. 
 
 
Vendor Thermo Fisher Scientific 
 
 
Operation Batch 
 
    
Characteristics Material Construction: 
 
Volume: 
Sterilization: 
Sterile single-use CX5-14 
multi-layer plastic  
500 L 
Disposable 
 
  
Operating Conditions Temperature:  
Pressure:  
 
4ºC in cold room  
1.0 atm 
 
  
  
Purchase Cost $300/bag  
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15.12. Endotoxin Affinity Chromatography Column (P-9, PFD#2) 
 
Description and Function The endotoxin affinity chromatography column will be used to 
bind endotoxins remaining in the product suspension and separate 
them from the α-galactosidase and α-N-acetylgalactosaminidase 
products. Pierce High-Capacity Endotoxin Removal Resin 
(Thermo Fisher Scientific), porous cellulose beads coated with 
poly(ε-lysine) to act as affinity ligands to endotoxins, will be used. 
It is assumed that 99% of endotoxins will be removed. 
 
Vendor Pall Corporation 
 
 
Operation Batch 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
Buffers 1240 19.2 
Endotoxin 1.04×10-3 1.04×10-5 
 GalNAc-ase  
OR α-galactosidase 
Waste 
0.167 
0.154 
0 
0.159 
0.146 
1220 
    
Characteristics Model: 
Material construction: 
Required volume: 
Diameter: 
Height: 
Max linear flow rate: 
Percent yield: 
Sterilization: 
Regeneration: 
Purity: 
Resin: 
 
Resin volume: 
Void fraction: 
Binding capacity: 
Resolute 280 Chromatography Column 
Stainless steel, electropolished 
9.60 L 
280 mm 
156 mm 
1200 cm/hr 
95% 
CIP/SIP 
10 times 
≥ 90% 
Pierce High-Capacity Endotoxin 
Removal Resin 
5.75 L 
0.4 
2×106 EU/mL, 99% endotoxin removal 
    
Operating Conditions Temperature: 
Pressure: 
Linear Flowrate: 
4ºC in cold room 
3.0 atm 
150 cm/hr 
  
Purchase Cost $110,000 
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15.13. Endotoxin Affinity Chromatography Product Collection Container (P-8, PFD#2) 
 
Description and Function The product that is eluted from the endotoxin affinity 
chromatography column will be directed to a single-use, 
disposable 2D bioprocess container. All other column flow-
through that came into contact with the cell culture materials 
will be directed to the waste tank for biowaste heat inactivation 
and neutralization. Buffers that did not come into contact with 
biological material will be directed to a waste tank for 
immediate neutralization. 
 
 
Vendor Thermo Fisher Scientific 
 
 
Operation Batch 
 
    
Characteristics Material Construction: 
 
Volume: 
Sterilization: 
Sterile single-use CX5-14 
multi-layer plastic  
50 L 
Disposable 
 
  
Operating Conditions Temperature:  
Pressure:  
 
4ºC in cold room  
1.0 atm 
 
  
  
Purchase Cost $37.54/bag  
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15.14. Ultrafiltration/Diafiltration (P-11, PFD#2) 
 
Description and Function Upon completion of the purification in the three chromatography 
steps, the enzyme product will undergo a ultrafiltration-diafiltration 
(UFDF) step using casette filters, stabilized with a cassette holder in 
a Cogent Process Scale Tangential Flow Filtration (TFF) System. 
The filter will have a 30 kD NMWL to allow for ECO-zymes to stay 
in the retentate and allowing smaller particles, such as the 
chromatography buffer components, to filter through. It is assumed 
that 95% of ECO-zyme will be recovered in this step, with a five 
percent loss associated with filtration through the cassette 
membrane. 
 
 
Vendor EMD Millipore 
 
 
Operation Batch 
 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
Buffer 31.0 30.5 
GalNAc-ase  
OR α-galactosidase 
0.159 
0.146 
0.151 
0.139 
Endotoxin 1.04×10-5 1.04×10-5 
Waste 0 4.71x10-1 
Characteristics Model: 
 
TFF System material: 
Membrane Filter Material: 
Filtration Area: 
Flow Rate: 
Maximum Pressure Drop: 
Sterilization: 
 
Percent Yield: 
 
Cogent Process ScaleTFF System, 
Pellicon 3 Ultracel filter cassettes 
Stainless steel AISI 304 
Regenerated cellulose, polyethylene 
1.14m2 
4 L/min 
2 atm 
Disposable cassettes, SIP for 
stainless steel holder 
95% 
 
Operating Conditions Temperature:  
Pressure:  
4 ºC in cold room 
1 atm 
  
 
Purchase Cost Cogent Process Scale TFF System: 
Stainless steel cassette holder:  
100 pack of Ultracel membranes:  
$47,999 
$995 
$479.08/pack 
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15.15. Bulk Filtration (Microfiltration) (P-12, PFD#2) 
 
Description and 
Function 
The final step in purification after ultrafiltration-diafiltration (UFDF) 
will be a microfiltration to dispose of any remaining endotoxins. 
Disposable Durapore PVDF filter membranes with a pore size of 
0.22 µm will be used. These filters are ideal for sterilization and 
clarification of protein solutions, allowing ECO-zyme to pass 
through the filter and be collected, while endotoxin remains bound 
to the filter membrane. The filters are housed in a disposable 
Millipak holder unit as well. Each batch will pass through the unit 
twice, removing 99% of endotoxins each time. 
 
 
Vendor EMD Millipore 
 
 
Operation Batch 
 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
Buffer 30.5 27.5 
GalNAc-ase  
OR α-galactosidase 
0.151 
0.139 
0.136 
0.125 
Endotoxin 1.04×10-5 1.04×10-9 
Waste 0 3.31 
 
 
  
Characteristics Model: 
Membrane filter material: 
Filtration area: 
Maximum pressure drop: 
Sterilization: 
Percent yield: 
Flow rate: 
Protein binding: 
Wettability: 
Millipak® Disposable Units, 0.22um 
Durapore PVDF 
100 cm2 
4.1 atm 
Disposable 
95% 
16.5 L/min 
150 µg/cm² 
Hydrophobic 
  
  
Operating Conditions Temperature:  4 ºC in cold room  
Pressure: 1 atm 
  
  
Purchase Cost Pack of 3 disposable  
membranes and holders: 
$503/pack 
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15.16 Product Storage Tank (P-13, PFD#2) 
 
Description and Function A final 500 L 3D disposable biocontainer will be used to collect 
the product solution from bulk microfiltration. The product will 
be resuspended in 205 or 189 L of water for α-N-
acetylgalactosaminidase and α-galactosidase, respectively. The 
resuspension solution will have a concentration of 200 mM 
glycine to prevent protein aggregation.  
 
 
Vendor Thermo Fisher Scientific 
 
 
Operation Batch 
 
    
Characteristics Material Construction: 
 
Volume: 
Sterilization: 
Sterile single-use CX5-14 
multi-layer plastic  
500 L 
Disposable 
 
  
Operating Conditions Temperature:  
Pressure:  
 
4ºC in cold room 
1 atm 
 
  
  
Purchase Cost $300/bag  
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15.4 Hyperbaric Chamber (not shown, PFD#3) 
 
Description and Function Donor packed RBCs that are designated for treatment will be 
emptied in bulk into a storage vessel using a hyperbaric champer 
to induce a pressure differential between 0.3 and 0.5 atm between 
the blood bags and the collection vessel. This will generate 
pressure-driven flow from the blood bags into the disposable 
storage container. This unit operation will minimize both the labor 
force required to empty the number of blood bags required in each 
batch and the risk of human error and contamination during 
emptying. Additionally, it allows blood to be emptied quickly and 
minimize the amount of time it could be exposed to room 
temperature. 
 
Vendor To be custom made by third party manufacturer after discussions 
with Cummings Properties. 
 
 
Operation Batch 
 
    
Characteristics Material construction: 
 
Sterilization: 
 
Pressure differential: 
Number of bags to empty: 
Blood bags emptying rate 
Run time: 
Stainless steel AISI 304, PVC 
tubing for blood bags 
Disposable dry blood bags and 
tubing, CIP/SIP when needed 
0.5-1.0 atm 
1973 bags max. 
264 bags/run 
2.5 hours/batch 
 
  
Operating Conditions Temperature:  
Pressure:  
 
4ºC  
0.5-1.5 atm 
 
  
  
Purchase Cost $100,000  
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15.5 Blood Collection Container (not shown, PFD#3) 
 
Description and Function The blood emptied from the blood bags by pressure-driven flow will 
be collected in a 500 L 3D bioprocess container. The container will 
be kept at 4ºC at all times to preserve the biological activity of the 
RBCs. 
 
 
Vendor Thermo Fisher Scientific 
 
 
Operation Batch 
 
 
    
Characteristics Material Construction: 
 
Volume: 
Sterilization: 
Sterile single-use CX5-14 
multi-layer plastic  
500 L 
Disposable 
  
  
Operating Conditions Temperature:  
Pressure:  
 
4ºC in cold room  
1 atm 
 
  
  
Purchase Cost $300/bag  
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15.4 Disk Stack Centrifuge (P-1, PFD#3) 
 
Description and Function The centrifuge will be used to separate the RBCs (solids) 
from the spent additive preservation solution (liquid). The 
output will be 60% by mass water and 40% by mass RBCs. 
 
 
Vendor Alfa Laval 
 
 
Operation Batch 
 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
For type-A 
RBC suspension 
 
0.595 
 
0.559 
For type-B 
RBC suspension 
 
0.586 
 
0.551 
   
    
Characteristics Model: 
Centrifuge type: 
Material construction: 
 
 
Finish: 
Hydraulic capacity: 
G-force: 
Bowl speed: 
Percent Yield: 
Sterilization 
Culturefuge 100 
Disk stack 
Mo-bearing austenitic steel 
for body and cover; cast grey 
iron bottom frame 
Electro-polished 
2,000 L/hr capacity 
12,220 g maximum 
9550 rpm maximum 
95% 
CIP/SIP 
  
  
Operating Conditions Temperature:  
Pressure:  
Flowrate: 
4ºC 
1 atm 
200 L/hr 
  
  
  
  
Purchase Cost $46,500/unit  
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15.5 WAVE Bioreactors (P-2, PFD#3) 
 
Description and Function The conversion process in which type-A and type-B RBCs will be 
converted to type-O cells via enzymatic conversion will take place 
in multiple WAVE bioreactors. The total working volume of 
approximately 413 L will be divided among five WAVE bioreactors 
that have a maximum working volume of 100 L. The reduced 
volume in each reactor will also allow for better mixing of the RBCs 
and conversion enzymes, hopefully increasing conversion efficacy.  
 
Vendor Sartorius Stedim Biotechnology Group 
 
Operation Batch 
  
Materials Handled   Input (kg/batch) Output (kg/batch) 
 For type-A 
RBC suspension  
 
0.559 
 
0.526 
 GalNAc-ase  
For type-B 
RBC suspension 
α-galactosidase 
 
0.118 
 
0.551 
3.95×10-3 
 
0.111 
 
0.518 
3.71×10-3 
 
    
Characteristics 
 
(for each reactor) 
Model: 
 
 
Material construction: 
 
 
Dimensions: 
Heating method: 
 
 
Heating capacity: 
Percent Yield: 
Sterilization: 
 
Rocking speed: 
Rocking angle: 
Maximum working volume: 
Total volume: 
BIOSTAT® RM bioreactor system 
linked to BIOSTAT® control tower, 
FLEXSAFE® RM disposable bag 
Stainless steel AISI 304 control 
tower, stainless steel ABS rocker, 
low-density polyethylene bags. 
740mm x 720mm 
Open thermostat system with 
circulation pump and automatic 
cooling water valve 
2 × 600 W 
95% 
Disposable, single-use bags: 
CIP/SIP for rocking base  
15 rocks/min 
10º 
100 L 
200 L  
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Operating Conditions Temperature:  
Pressure:  
pH: 
pO2: 
Reaction time: 
25ºC 
1.0 atm 
7.4-7.6 
40% 
1 hour 
 
Purchase Cost $20,000/unit 
$200/bag 
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15.4 Disk Stack Centrifuge (P-3, PFD#3) 
 
Description and Function The centrifuge will be used to separate the RBCs (solids) from 
the spent enzymatic solution (liquid). The output will be 60% by 
mass water and 40% by mass RBCs. This step is taken as a first 
purification step to separate enzymes from converted RBCs, 
given that remaining enzymes in solution have found to cause 
toxicity in pre-clinical and early clinical studies. 
 
 
Vendor Alfa Laval 
 
 
Operation Batch 
 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
For type-A 
RBC suspension 
GalNAc-ase  
 
0.525 
0.111 
 
0.494 
0.104 
For type-B 
RBC suspension 
α-galactosidase 
 
0.518 
3.71×10-3 
 
0.487 
3.49×10-3 
   
    
Characteristics Model: 
Centrifuge type: 
Material construction: 
 
 
Finish: 
Hydraulic capacity: 
G-force: 
Bowl speed: 
Percent Yield: 
Sterilization 
Culturefuge 100 
Disk stack 
Mo-bearing austenitic steel for body 
and cover; cast grey iron bottom 
frame 
Electro-polished 
2,000 L/hr capacity 
12,220 g maximum 
9550 rpm maximum 
95% 
CIP/SIP 
  
  
Operating Conditions Temperature:  
Pressure:  
Flowrate: 
4ºC 
1 atm 
200 L/hr 
  
  
  
  
Purchase Cost $46,500/unit  
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15.11 Diafiltration (P-4, PFD#3) 
 
Description and Function To remove any remaining enzyme from the converted RBCs to prevent 
immunogenic responses in patients, diafiltration will be performed using a 
Cogent Process-Scale Tangential Flow Filtration System with 500 kD 
nominal molecular weight limit (NMWL) microfiltration filters. The 
NMWL will allow RBCs to remain ni the retentate and return to the storage 
tank while enzymes are continuously removed from the system. Saline will 
continuously be added to the process to ensure the suspension buffer of the 
RBCs has an osmolality equivalent to biological conditions to prevent 
hemolysis. It is assumed that 95% the treated RBCs will be recovered in 
this step, with a 5% loss associated with filtration through the cassette 
membrane or lysis. We assume near complete removal of enzyme to the 
point that remaining presence is negligible. 
 
Vendor EMD Millipore 
 
Operation Batch 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
For type-A 
RBC suspension 
GalNAc-ase  
Waste 
 
0.494 
0.104 
0 
 
0.465 
0 
0.133 
For type-B 
RBC suspension 
α-galactosidase 
Waste 
 
0.503 
3.49×10-3 
0 
 
0.458 
0 
4.85×10-2 
 
 
  
Characteristics Model: 
 
TFF system material: 
Filter Material: 
Filtration Area: 
Flow Rate: 
Maximum Pressure Drop: 
Sterilization: 
 
Percent Yield: 
 
Cogent Process ScaleTFF System, Pellicon 3 
Ultracel filter cassettes 
Stainless steel AISI 304 
Regenerated cellulose, polyethylene 
1.14m2 
4 L/min 
2 atm 
Disposable cassettes, SIP for stainless steel 
holder 
95% 
 
Operating Conditions Temperature:  
Pressure:  
4 ºC in cold room 
1 atm 
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Purchase Cost Cogent Process Scale TFF System: 
Stainless steel cassette holder:  
100 pack of Ultracel membranes:  
$47,999 
$995 
$479.08/pack 
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15.9 Cryogel-based Affinity Chromatography Column (P-6, PFD#3) 
 
Description and Function The cryogel-based affinity chromatography column will be used to bind 
non-converted RBCs to separate them from successfully converted 
RBCs. This is done as a precautionary measure to ensure that the 
finalized product does not have antigen- incompatible RBCs that may 
cause a harmful immunogenic response in patients. Instead of traditional 
resin, the column will be packed with a polymer-based cryogel that is 
coated in a protein A-IgG antibody coat that bind the antigens of either 
type-A or type-B RBCs. It is assumed that there is a 95% recovery of 
converted RBCs. 
 
Vendor Pall Corporation 
 
 
Operation Batch 
 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
For type-A 
RBC suspension 
Buffers 
Waste 
 
0.465 
2125 
0 
 
0.437 
702 
1423 
For type-B 
RBC suspension 
Buffers 
Waste 
 
0.458 
2125 
0 
 
0.430 
702 
1423 
 
Characteristics Model: 
Material construction: 
Required volume: 
Diameter: 
Height: 
Max linear flow rate: 
Percent yield: 
Sterilization: 
Regeneration: 
Purity: 
Gel volume: 
Affinity IgG: 
 
 
Void fraction:  
 
Resolute 280 Chromatography Column 
Stainless steel, electropolished 
18.0 L 
280 mm 
292 mm 
1200 cm/hr 
95% 
CIP/SIP 
5 times 
≥ 90% 
14.42 L 
Mouse monoclonals: anti-blood Group A 
antigen Ab [clone 9A] & anti-blood Group B 
antigen Ab [HEB-29] 
0.4 
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Operating Conditions Temperature: 
Pressure: 
Linear Flowrate: 
4ºC in cold room 
5.0 atm 
100 cm/hr 
  
Purchase Cost $110,000 
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15.10 Cryogel-based Affinity Chromatography Product Collection Container (P-7, PFD#3) 
 
Description and Function The flow-through of the cryogel-based affinity chromatography 
column, which contains successfully converted RBCs, will be 
collected in four single-use, disposable 2D bioprocess container in 
equal volumetric amounts. All other column flow-through that came 
into contact with the biological substances will be directed to the 
waste tank for biowaste heat inactivation and neutralization. 
Unconverted RBCs bound to the column will be released via 
mechanical stress and also directed to the aforementioned waste tank. 
Buffers that did not come into contact with biological material will be 
directed to a waste tank for immediate neutralization. 
 
 
Vendor Thermo Fisher Scientific 
 
 
Operation Batch 
 
    
Characteristics Material Construction: 
 
Volume: 
Sterilization: 
Sterile single-use CX5-14 multi-layer 
plastic  
200 L/bag 
Disposable 
 
  
Operating Conditions Temperature:  
Pressure:  
 
4ºC in cold room  
1.0 atm 
 
  
  
Purchase Cost $250/bag  
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15.11 Diafiltration (P-8, PFD#3) 
Description and Function To remove any remaining enzyme from the converted RBCs to 
prevent immunogenic responses in patients, diafiltration will be 
performed using a Cogent Process-Scale Tangential Flow Filtration 
System with 500 kD nominal molecular weight limit (NMWL) 
microfiltration filters. The NMWL will allow RBCs to remain ni the 
retentate and return to the storage tank while enzymes are 
continuously removed from the system. Saline will continuously be 
added to the process to ensure the suspension buffer of the RBCs 
has an osmolality equivalent to biological conditions to prevent 
hemolysis. It is assumed that 95% the treated RBCs will be 
recovered in this step, with a 5% loss associated with filtration 
through the cassette membrane or lysis. Assuming complete 
removal of all buffer salts and components. 
 
Vendor EMD Millipore 
 
Operation Batch 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
For type-A 
RBC suspension 
Buffer salts 
Waste 
 
0.437 
702 
0 
 
0.410 
0 
1423 
For type-B 
RBC suspension 
Buffer salts 
Waste 
 
0.430 
702 
0 
 
0.404 
702 
1423 
Characteristics Model: 
Membrane Filter Material: 
Filtration Area: 
Flow Rate: 
Maximum Pressure Drop: 
Sterilization: 
 
Percent Yield: 
 
Pellicon 3 cassettes 
Regenerated cellulose, polyethylene 
1.14m2 
4 L/min 
2 atm 
Disposable cassettes, SIP for 
stainless steel holder 
95% 
 
 
Operating Conditions 
 
Temperature:  
Pressure:  
 
4 ºC in cold room 
1 atm 
  
Purchase Cost Cogent Process Scale TFF System: 
Stainless steel cassette holder:  
100 pack of Ultracel membranes:  
$47,999 
$995 
$479.08/pack 
 
 
143 
 
15.4 Disk Stack Centrifuge (P-9, PFD#3) 
 
Description and Function The centrifuge will be used to separate the RBCs (solids) 
from the spent enzymatic solution (liquid). The output will 
be 60% by mass water and 40% by mass RBCs. This step 
is taken to separate RBCs from any remaining buffer 
solution. It also allows greater control of the final volume 
in which the RBCs are suspended to facilitate final 
packaging. 
 
Vendor Alfa Laval 
 
 
Operation Batch 
 
 
Materials Handled  Input (kg/batch) Output (kg/batch) 
For type-A 
RBC suspension 
 
0.410 
 
0.386 
For type-B 
RBC suspension 
 
 
 
0.404 
 
 
 
0.381 
 
   
Characteristics Model: 
Centrifuge type: 
Material construction: 
 
 
Finish: 
Hydraulic capacity: 
G-force: 
Bowl speed: 
Percent Yield: 
Sterilization 
Culturefuge 100 
Disk stack 
Mo-bearing austenitic steel 
for body and cover; cast grey 
iron bottom frame 
Electro-polished 
2,000 L/hr capacity 
12,220 g maximum 
9550 rpm maximum 
95% 
CIP/SIP 
  
  
Operating Conditions Temperature:  
Pressure:  
Flowrate: 
4ºC 
1 atm 
200 L/hr 
  
  
Purchase Cost $46,500/unit  
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15.13 Product Storage Containers (P-10, PFD#3) 
 
Description and Function The centrifuged RBC mass will be directed and resuspended in 
Adsol-1 additive solution (previously prepared in a mixing 
tank) in four single-use, disposable 2D bioprocess container in 
equal volumetric amounts. The stored converted RBCs will be 
kept in a cold room on a rocker at gentle agitation to prevent 
settling until they can be packaged 
 
 
Vendor Thermo Fisher Scientific 
 
 
Operation Batch 
 
    
Characteristics Material Construction: 
Volume: 
Sterilization: 
Sterile plastic 
200 L/bag 
Disposable 
  
Operating Conditions Temperature:  
Pressure:  
 
4ºC in cold room 
1 atm 
 
  
  
Purchase Cost $250/bag  
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15.15 Small Peristaltic Pumps (All main pumps in PFDs) 
 
Description and Function Peristaltic pumps are used to transfer unit contents throughout 
the process. All peristaltic pumps are specifically designated 
for use in the E. coli upstream and downstream processes to the 
high viscosity of the cell suspensions. The consistent flow 
ensures accuracy in dispensing flow from unit to unit. A 
brushless motor allows for speed control of the pump. 
 
 
Vendor Cole Parmer 
 
 
Operation Batch 
 
    
Characteristics 
Model: 
Material construction: 
Flow rate range: 
Maximum Pressure Drop: 
Power requirement:  
 
Masterflex Model 77924-80 
Stainless Steel AISI 304 
0.001-3,400 mL/min 
2.07 atm 
253 W 
 
  
  
Operating Conditions Temperature:  
Pressure:  
 
4-37ºC 
1.0 atm 
 
  
  
Purchase Cost $3,635/pump  
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15.15 Large Peristaltic Pumps (Used for regeneration buffers) 
 
Description and Function Peristaltic pumps are used to transfer unit contents throughout 
the process. All peristaltic pumps are specifically designated 
for use in the E. coli upstream and downstream processes to the 
high viscosity of the cell suspensions. The consistent flow 
ensures accuracy in dispensing flow from unit to unit. A 
brushless motor allows for speed control of the pump. 
 
 
Vendor Watson Marlow 
 
 
Operation Batch 
 
    
Characteristics 
Model: 
Tubing: 
Material construction: 
Flow rate range: 
Maximum Pressure Drop: 
Power requirement:  
 
840 Series Hygienic Pump 
GORE® STA-PURE® PFL 
Stainless Steel 316 
120-8,000 L/hr 
3.5 atm 
0.2 W 
 
  
  
Operating Conditions Temperature:  
Pressure:  
 
4-37ºC 
1.0 atm 
 
  
  
Purchase Cost $25,000/pump  
  
 
147 
 
15.15 Quattroflow Quaternary Diaphragm Pumps (All pumps shown in PFD#3) 
 
Description and Function The Quattroflow quaternary diaphragm pumps mimic 
cardiovascular pumping in the human body to prevent shear-
induced hemolysis. All Quattroflow pumps are specifically 
designated for use in the RBC conversion treatment process. 
Each stroke of the 4-piston diaphragm is generated by an 
eccentric shaft connected to an electric motor. Each 
Quattroflow pump comes with an integrated PID controller for 
optimal flow rate adjustments. 
 
 
Vendor PSG Dover 
 
 
Operation Batch 
 
   
Characteristics 
Model: 
Material construction: 
Flow rate range: 
Maximum Pressure Drop: 
Power requirement:  
 
QF1200S-CV 
Stainless Steel AISI 304 
10-1,200 L/hr 
6 atm 
0.75 W 
 
  
  
Operating Conditions Temperature:  
Pressure:  
Flow rate: 
4ºC 
1.0 atm 
350 L/hr 
  
  
Purchase Cost $10,772/pump 
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16. Additional Equipment Description 
 There are a number of units that will be needed for the completion of this project but are 
not shown in the process flow diagrams. These pieces of equipment are required for sterile cell 
culture and storage, sterile buffer preparation, proper waste disposal, and product verification 
steps, thus allowing for good manufacturing practices. 
16.1. Biosafety Cabinet 
 Two class II biosafety cabinets will be required for sterile cell culture spaces. Each 
biosafety cabinet will come equipped with mounted motor driven blowers to draw directional mass 
airflow around a user and into the air grille to protect the operator. The airflow drawn into the air 
grille will then be HEPA-filtered and exhausted into the environment. Additionally, a column of 
HEPA filtered, sterile air is blown downward at the front of cabinet, over products and processes 
to prevent contamination. The first biosafety cabinet will be designated to handle E. coli 
BL21(DE3) cells exclusively and is provide a sterile environment to transfer the contents of 
thawed vials of cells for inoculating the ambr® 250 bioreactor. The second biosafety cabinet will 
be designated to handle any RBCs or other blood-derived materials/products for research purposes. 
The rented laboratory space will provide both biosafety cabinets, which is factored in the rental 
costs in annual expenses. 
16.2. Cell Bank 
 Engineered E. coli BL21(DE3) will kept frozen in a -80ºC freezer in 1.5-mL vials at a 
concentration of 7.95×106 cells/mL. 250 vials annually to allow for a year’s worth of production 
of α-galactosidase and α-N-acetylgalactosaminidase, with additional an additional stock in the 
event of complications with the cell line. The cell solution will also be 20% glycerol by volume. 
The addition of glycerol stabilizes the frozen bacteria, preventing damage to the cell membranes 
and keeping the cells alive. All vials will be prepared in a class II biosafety cabinet.  
16.3. Refrigeration 
 A -80ºC freezer will be necessary to maintain the frozen cell stock and certain reagents for 
long-term storage. A -20ºC freezer will also be purchased to maintain certain reagents at their 
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proper storage temperature. Both the ultra-low temperature freezer and the -20ºC freezers will be 
purchased from Thermo Fisher Scientific for $30,000 and $8,700, respectively.  
16.4. Biowaste and Neutralization Tanks 
 All waste streams that have been in contact with cell culture or debris will directed to 
10,000 L stainless steel tank, which will be purchased from Sharpsville Container for $2,500. The 
tank’s contents will undergo proper heat inactivation before disposal to ensure that there are no 
remaining proliferating E. coli cells that could cause environmental health hazards. This tank will 
be jacketed to be able to reach and sustain a temperature of 121ºC for approximately 11 minutes 
via a digital PID controller unit to complete a 25-log reduction of bacteria.  
 Cell-free waste streams will be directed to an additional 10,000 L stainless steel tank, also 
purchased from Sharpsville Container. This tank will mainly collect the different buffers used in 
the chromatography steps, which will undergo neutralization to adjust the waste to a pH of 7.0. 
After neutralization, this waste will be discarded by the laboratory facility into the sewer line.  
 The disposal of non-liquid waste, which primarily includes all single-use, disposable bags, 
containers, and reactor vessels, will be contracted to the biohazardous waste disposal unit of 
Stericycle. The costs of outsourcing this task will be added to the annual expenses.  
16.5.  Water-for-Injection Generator 
 A multiple effect still will be used to purify water for use in preparing media, preparing all 
buffers and additive solutions, and conducting SIP procedures. FDA standards require that 
pharmaceutical and biological products injected or transfused into patients do not touch any water 
other than water-for-injection (WFI) to ensure sterility and reduce contamination risks. The WFI 
will also ensure sterility of the process equipment and eliminate cross-contamination issues. The 
PyroPure Multiple Effect Still will be purchased from the Paul Mueller Company for $20,000. 
16.6. Water Treatment Package 
 Although WFI will be used for the water requirements in the process, U.S. Pharmacopeia 
(USP) grade water is needed for temperature control needs in the bioreactor processes. This water 
will not be in direct contact with the cell culture suspension. It will be inserted into the reactors’ 
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for heating and cooling procedures. The cost for the water treatment package is included in the 
operations costs of the annual expenses.   
16.7. Clean Steam Generator 
 Clean steam will be necessary to conduct SIP procedures for numerous process units. The 
generator for will produce clean steam from WFI, supplied by the WFI generator. The clean steam 
generator will be purchased from BMT USA for $60,000. 
16.8. Buffer Transfer Bags 
 Disposable bioprocess containers (Thermo Fisher Scientific) will be used to prepare the 
equilibration, wash, elution, and regeneration buffers for all chromatography columns. Each 
column will require five containers (with its respective holder): one for equilibration, wash, 
elution, regeneration, and CIP reagents.  
16.9. Filter Integrity 
 Although disposable filters are used throughout the process, they must be tested before 
each use to ensure they are not clogged, torn, or generally unusable. The filter integrity test will 
help minimize losses due to filter manufacturing error. The test will be purchased from and 
performed by EMD Millipore for $3,500 upon ordering the filters. 
16.10. Purified Air Generator  
 A purified, zero air generator for all space in the laboratory facilities will be purchased 
from Domnick Hunter for $2,500 per unit. This device will produce a continuous stream of organic 
impurity free air from an external dry compressed air source. The system will provide clean air to 
bioreactors and fermenters, clean rooms, and process equipment.  
16.11. Laboratory Information Management System  
Laboratory information management system (LIMS) will be implemented for workflow, 
data tracking support, and data exchange interfaces. It will be used to enforce standard operating 
procedures (SOPs) and to provide defined workflows to analysts. Its functions will include, but 
are not limited to: sample management (login, registration integrity, life cycle tracking), chain of 
custody, instrument integration for data collection automation, automatic results reduction & 
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flagging, integration with third party systems (ERP/HR/CDS), workflow management, work 
allocation & scheduling to reduce as of yet unidentified bottlenecks, electronic document 
management, lot & batch management, instrument management (maintenance, scheduling), data 
security & integrity, multivariate data analysis, and quality assurance and control.  
16.12. Portable Pump on Cart 
 In the event of pump malfunction in either the E. coli upstream/downstream processes or 
the RBC treatment, two extra peristaltic pumps and two extra Quattroflow quaternary diaphragm 
pumps will be stored as replacements. These pumps will be mounted onto carts for easy intra-
facility movement in the event of a pump’s mechanical malfunction.  
16.13. Quality Control Lab Equipment 
 Quality control analysis will be divided between the enzyme production and RBC 
conversion steps. These product verification steps must be passed for conversion enzymes to be 
used to treat RBCs and for successfully converted RBCs to proceed to final packaging. Less than 
10 µg of each enzyme per batch will be required for quality control analysis. 500 mL of both 
converted and non-converted blood will be aliquoted and kept for flow cytometry and thin layer 
chromatography (TLC) analysis to ensure that the final product contains minimal traces of non-
converted RBCs. 
16.13.1. Protein Gel Materials 
Protein gels will be run for each to confirm the identity of the isolated enzymes from the 
E. coli culture. Additionally, the protein gels will help identify possible protein variations that 
could be associated with genetic drift or mutations in the E. coli cell line. Thus, this control step 
has a secondary purpose of validating cell productivity. The materials needed include hydrochloric 
acid, 30% acrylamide solution, SDS ammonium persulfate, TEMED, glycine, EDTA, 50% 
glycerol solution, mercaptoethanol, bromophenol blue, and pre-stained molecular weight markers. 
These materials will be purchased from BioRad for $1,540 per batch. 
16.13.2. NanoDrop 
The NanoDrop 2000 UV-Vis Spectrophotometer will be used to determine the 
concentration of α-galactosidase and α-N-acetylgalactosaminidase in their respective final 
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solutions. Once known, the concentration will be used to determine the appropriate volumes of 
enzyme to use for treating RBCs. This unit will be purchased from Thermo Fisher Scientific for 
$9,100. 
16.13.3. Endotoxin Test Kit 
Endotoxin detection will be done using a Kinetic Turbidimetric Limulus Amebocyte 
Lysate (LAL) test. A test kit will be purchased annually to ensure that all batches of conversion 
enzyme have an endotoxin level below the FDA standard of 0.1 EU/mL. If a batch does not pass 
this test, it will be discarded. The kit will be purchased from Lonza at $1,000 per kit. Each kit can 
be used 192 times. 
16.13.4. Flow Cytometer 
Flow cytometry analysis will be performed on native and enzymatically converted RBCs 
using a BD LSR II flow cytometer (BD Biosciences) with mouse monoclonal antibody reagents 
specific to human A or B antigens on the RBC surface. The flow cytometer will come equipped 
with 488, 594, and 633 nm lasers. The final RBC population must have less than 1.0% non-
converted RBCs to be considered acceptable for transfusion. 
The principle of action is that if any remaining antigens are not cleaved on the red blood 
cell surface, then fluorophore-labeled primary antibodies specific to the antigens can be used to 
bind to them. The fluorophores will be Alexa Fluor 546 or 547 secondary antibodies and will bind 
specifically to the primary antibodies. The flow cytometer will perform a high-throughput analysis 
of the liquid blood sample, one cell at a time, by shining lasers of specific wavelengths on them. 
Successfully converted cells will emit no signal, while cells that still contain antigens will give off 
signal when they are excited by 594 or 633 nm wavelength lasers.  
16.13.5. TLC for Glycolipid Analysis 
The TLC of native and converted RBC glycolipids should show that converted cells no 
longer have glycolipid bands associated with the sugars that constitute the A and B antigens. RBC 
membranes will be extracted by homogenization in ten volumes of isopropanol/hexane/water 
(55:25:20 vol/vol/vol), filtered, evaporated and partitioned by Folch extraction method. The upper 
phase will be collected, evaporated, dialyzed and applied to a DEAE Sephadex column. The pass-
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through fraction will contain the total upper neutral lipids, and the monosialyl fraction will be 
eluted with 0.05 M ammonium acetate, evaporated and dialyzed against water to remove acetate. 
Total upper neutral and monosialyl glycolipid fractions will be analyzed by high-performance thin-
layer chromatography. TLC plates (Merck) will be developed using the solvent system 
chloroform/methanol/0.5 M CaCl2 in water (50:40:10, vol/vol/vol). Glycolipids will be stained by 
heating with 0.05% orcinol in 0.5 M H2SO4. 
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17.  Equipment Cost Summary 
17.1.  Major Unit Operation Costs 
 The total purchase cost for the major operation equipment is $1,948,914. Using a bare 
module factor of 3.21, the bare module cost is approximately $6.23 million. This bare module 
factor is determined assuming that the cost of installation materials is 71% of equipment purchase 
cost; the cost of installation labor is 54%; the cost for freight, insurances, and taxes is 9%; the cost 
of construction overhead is 57%; and the cost of contractor engineering expenses is 30%. A bare 
module factor of 3.21 yields a highly conservative estimate of the bare module cost for a process 
that relies heavily on off the shelf equipment as this process does. In reality, however, the cost of 
installation materials and contractor engineering expenses will be significantly less since most 
items are purchased already manufactured. The real bare module cost for this process is likely 
lower than the estimated $6,231,443. However, for the purpose of the profitability analysis the 
upper bound is used to provide a stricter analysis on the feasibility of this project. The breakdown 
of the major unit operations costs, including manufacturer, number of units required, purchase 
cost, and final bare module cost, is shown in Table 17.1.1.  
The most expensive pieces of equipment are the Resolute chromatography chromatography 
columns, followed by the production bioreactor and the WAVE bioreactor setup. It should be noted 
that although the Resolute 280 chromatography column is used for the cryogel-based affinity 
chromatography column, similar to the cobalt ion and endotoxin affinity chromatography steps, 
an additional cost of $90,000 is added to the original purchase cost of $110,000 for customization 
to add a piston to apply mechanical stress for releasing bound cells.  
The costs of genetically engineering the E. coli cell lines was included in the major unit 
operation costing given their similarity to purchasing equipment: it is a one-time investment. A 
bare module factor of 1.0 was applied for the costing of the gene editing since it does not require 
any of the previously aforementioned costs.  
It should be noted that the major unit operation costs include two Cogent M1 Tangential 
Flow Filtration systems that are not previously discussed in the process description. These two 
units are being purchased as backups in the event that the Cogent Process Scale Tangential Flow 
Filtration System suffers from a malfunction and cannot be used. The elimination of enzymes and 
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buffers in these products are important for marketability purposes. If they cannot be eliminated, 
the RBCs will have enzymatic content that could cause an immunogenic response in patients, 
defeating the purpose of this project. Thus, for equipment functionality concerns, these units were 
included in our calculations. The presence of these two units will also allow for more increasing 
processing capability in the event that expansion occurs or if donated whole blood, which requires 
a separate sets of ultrafiltration and diafiltration processes, becomes incorporated into the plant 
design. 
The unit operation costs associated with the E. coli process are significantly higher than 
the treatment of RBCs (approximately 2.6-fold higher), as shown in Figure 17.1.1. 
 
Figure 17.1.1. Contributions of both the E. coli culture/purification and the conversion treatment 
of RBCs to the total bare module costs of the major unit operation costs. Given the complexity of 
ensuring that endotoxins concentrations are lowered to a concentration considered acceptable by 
the FDA, the multiple incorporated chromatography column steps imposes significant costs on just 
the microbial fermentation.  
 
 The total purchase cost for the additional equipment is $1.17 million. The costing of other 
common units required in the processes is described in Table 17.1.2. Using a bare module factor 
of 3.21, the bare module cost is $3.74 million. Of these units, only the cold rooms and hyperbaric 
chamber will need to be designed and fabricated, which is accounted for in their total bare module 
72%
28%
E. coli culture and purification RBC treatment
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costs. Other equipment, such as pumps, freezers, and refrigerators, will be purchased as off the 
shelf units, which will likely result in a bare module cost lower than the predicted value. However, 
we again choose to analyze the economics from this standard of 3.21 to provide a clear upper 
bound on what equipment purchases costs will be for this project. 
 The most significant costs are associated with the construction of the several cold rooms 
required throughout the process ($1.7 million). The price for construction of the cold room was 
quoted at $170 per square foot (ANC Cold Storage Construction, Inc.). Each cold room was 
designed to be 900 ft2 in area, but this number will be subject to change after further consultation 
with Cummings Properties and process equipment vendors. For costing assessment, however, we 
believe that this area is sufficiently large for each to house RBC transfusion units, downstream 
purification equipment for the microbial culture, or the RBC treatment process equipment. This 
will thus give us an upper bound on the cost estimation of the cold rooms and allow for more 
stringent analysis of this process design. 
 The total breakdown of all equipment costs is shown in Figure 17.1.2. The total bare 
module cost of all units is $9,976,534. Thus, it is estimated that just on equipment purchases alone, 
an initial capital investment of $10 million would be required to just have the machinery with 
which the bacterial growth and RBC treatment processes can be performed. For plant operating, a 
complete, initial capital investment of $25.6 million will be required. This means that equipment 
costs account for roughly 37.5% of the initial investment. 
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Figure 17.1.2. Complete breakdown of all equipment that need to be purchased for plant operation. 
The total mare module cost is $9.98 million. We expect this number to be lower given that the bare 
module factor of 3.21 applied to nearly all units in this design was deemed too high by numerous 
industrial consultations. Since these units are purchased off-shelf, there are no major installation 
material costs will be lower.  
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Table 17.1.1. Major equipment purchases costs, including information on manufacturers, number of units, and the final, expected bare 
module cost associated with each unit. 
 
 
 
Equipment Description Vendor Type Units
Purchase Cost 
(per unit)
Total Purchase 
Cost
Total Bare 
Module Cost
Innoculum Bioreactor Sartorius Process Machinery 1 45,799$                45,799$             $         147,015 
Seed Bioreactor Eppendorf Process Machinery 1 100,000$              100,000$           $         321,000 
Bioreactor Thermofisher Process Machinery 2 150,000$              300,000$           $         963,000 
Cobalt Affinity 
Chromatography
Pall Process Machinery 1 110,000$              110,000$           $         353,100 
Endotoxin Affinity 
Chromatography
Pall Process Machinery 1 110,000$              110,000$           $         353,100 
Hydrophobic Interaction 
Chromatography
Pall Process Machinery 1 250,000$              250,000$           $         802,500 
Disk Stack Centrifuge Alfa-Laval Process Machinery 4 46,500$                186,000$           $         597,060 
High Pressure Homogenizer Microfluidics Process Machinery 1 38,740$                38,740$             $         124,355 
WAVE Bioreactor Sartorius Process Machinery 5 20,000$                100,000$           $         321,000 
Cryogel Affinity 
Chromatography
Pall Process Machinery 1 200,000$              200,000$           $         642,000 
Cogent Process Scale TFF 
System
EMD Millipore Process Machinery 3 47,999$                143,997$           $         462,230 
Cogent M1 TFF EMD Millipore Process Machinery 2 12,000$                24,000$             $           77,040 
HyPerforma Single-Use 
Mixer
Sartorius Process Machinery 2 165,000$              330,000$           $      1,059,300 
E. coli cell line engineering GenScript Biological Processing 2 5,400$                  10,800$             $           10,800 
Gene fabrication GenScript Biological Processing 2 159$                     318$                  $                318 
Total 1,949,654$       6,233,819$      
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Table 17.1.2. Additional, common equipment purchase costs, including information on manufacturers, number of units, and the final, 
expected bare module cost associated with each unit. 
 
Equipment Description Vendor Type Units
Purchase Cost 
(per unit)
Total Purchase 
Cost
Total Bare 
Module Cost
Masterflex 77924-80 L/S Cole-Palmer Process Machinery 39 3,635$                  141,765$          455,066$         
840 Series Hygienic Pump Watson Marlow Process Machinery 4 25,000$                100,000$          321,000$         
Quattroflow Quaternary 
Diaphragm Pump
PSG Dover Process Machinery 10 10,772$                107,720$           $         345,781 
Spark Multimode Microplate 
Reader
Tecan Process Machinery 1 2,450$                  2,450$              7,865$             
Nanodrop VIS 
Spectrophotometer
Thermo Scientific Process Machinery 1 9,140$                  9,140$              29,339$           
BD Biosciences LSRII Flow 
Cytometer
Biosciences Process Machinery 1 55,115$                55,115$            176,919$         
4ºC Refrigerator Thermo Scientific Storage 1 13,600$                13,600$            43,656$           
Freezer (-20ºC) Thermo Scientific Storage 4 8,700$                  34,800$            111,708$         
Freezer (-80ºC) Thermo Scientific Storage 1 30,000$                30,000$            96,300$           
Clean Steam Generator BMT USA Process Machinery 1 60,000$                60,000$            192,600$         
Clean Air Generator Domnick Hunter Process Machinery 1 2,500$                  2,500$              8,025$             
Water for Injection Supplier Paul Mueller Co. Process Machinery 1 20,000$                20,000$            64,200$           
Digitial PID controller units Omega
Computers, Software, 
Etc.
30 300$                     9,000$              28,890$           
Control software Omega
Computers, Software, 
Etc.
1 20,865$                20,865$            66,977$           
Cold room N/A Fabricated Equipment 1 459,000$              459,000$          1,473,390$      
Hyberbaric chamber N/A Fabricated Equipment 1 100,000$              100,000$          321,000$         
Total 1,165,955$       3,742,716$      
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18.  Fixed Capital Investment Summary 
 
A breakdown of the required investments costs, beginning with total bare module costs and ending 
with the required total capital investment for the project is shown in Table 18.2. $14 million will 
be requested to cover the minimum necessary costs to build the production facility.  
Table 18.2.  Summary of the investment for the entire plant, including both the E. coli processing 
and the RBC conversion process.  
 
Investment Summary
Total Bare Module Costs:
Fabricated Equipment 1,813,373$              
Process Machinery 7,815,631$              
Spares -$                         
Storage 251,664$                 
Other Equipment -$                         
Catalysts -$                         
Computers, Software, Etc. 95,867$                   
Total Bare Module Costs: 9,976,534$              
Direct Permanent Investment
Cost of Site Preparations: 498,827$                 
Cost of Service Facilities: 498,827$                 
Allocated Costs for utility plants and related facilities: -$                         
Direct Permanent Investment 10,974,188$            
Total Depreciable Capital
Cost of Contingencies & Contractor Fees 1,975,354$              
Total Depreciable Capital 12,949,541$            
Total Permanent Investment
Cost of Land: 258,991$                 
Cost of Royalties: -$                         
Cost of Plant Start-Up: 1,294,954$              
Total Permanent Investment - Unadjusted 14,503,486$            
Site Factor 1.00
Total Permanent Investment 14,503,486$            
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19.  Operating Costs  
19.1. Variable Costs 
 The purchase of raw materials per ECO RBC transfusion unit is approximately $43.75, 
which leads to an annual cost of $8.75 million. These values are shown in Table 19.1.1. 
Table 19.1.1. Estimated raw material pricing and their respective yearly costs. The following 
table includes all materials needed for both the E. coli processing and the RBC treatment. 
 
Raw Material
Annual 
Amount 
Required
 
Cost of Raw 
Material
  
Cost per 
RBC Unit
Annual Cost
AGE 2.21 L 173.00$                      $/L 0.0019$    381.81$                       
Ammonium sulfate 5.20 kg 51.76$                         $/kg 0.0013$    259.71$                       
APS 0.29 kg 78.60$                         $/kg 0.0001$    22.45$                         
Beta-Lactose 4.50 L 463.00$                      $/kg 0.0104$    2,082.28$                   
Chloramphenicol 0.02 kg 16,905.00$                $/kg 1.7892$    357,845.04$              
Detergent 432 kg 62.60$                         $/kg 0.1352$    27,034.21$                 
DMAAm 16.4 L 93.00$                         $/L 0.0076$    1,521.26$                   
Ethanol 4154 L 4.18$                           $/L 0.0868$    17,359.76$                 
Ethylenediamine 78.2 kg 73.50$                         $/L 0.0320$    6,391.45$                   
Glucose 310 kg 9.56$                           $/kg 0.0148$    2,968.04$                   
Glutaraldehyde 130 L 99.50$                         $/L 0.0646$    12,917.37$                 
Glycerol 180 L 87.50$                         $/L 0.0787$    15,740.76$                 
Guanadine HCl 2428 L 246.75$                      $/L 2.9957$    599,133.68$              
HEPES 668 kg 223.00$                      $/kg 0.0745$    14,901.70$                 
HisPur® Cobalt Resin 50.0 L 4,980.00$                   $/L 1.2450$    249,000.00$              
IgG 1.30 g 790.00$                      $/mg 5.1280$    1,025,600.36$           
Imidazole 312 kg 265.00$                      $/kg 0.4137$    82,747.84$                 
IPTG 2.64 kg 44,800.00$                $/kg 0.5919$    118,373.71$              
Kanamycin 0.03 kg 14,400.00$                $/kg 0.0022$    448.36$                       
KH2PO4 675 kg 137.00$                      $/kg 0.4621$    92,420.75$                 
MBAAm 5.71 kg 1,044.00$                   $/kg 0.0298$    5,963.54$                   
MES 105 kg 1,003.00$                   $/kg 0.5285$    105,708.18$              
Magnesium sulfate 270 kg 157.00$                      $/kg 0.2118$    42,365.13$                 
Sodium carbonate 55.0 kg 137.00$                      $/kg 0.0377$    7,541.15$                   
Sodium phosphate heptahydrate 1525 kg 56.88$                         $/kg 0.4336$    86,711.91$                 
Sodium sulfate 319 kg 27.92$                         $/kg 0.0446$    8,914.14$                   
Sodium borohydride 9.82 kg 118.18$                      $/kg 0.0058$    1,160.76$                   
Sodium chloride 2950 kg 10.38$                         $/kg 0.1532$    30,631.91$                 
Sodium hydroxide 1113 kg 36.00$                         $/kg 0.2004$    40,072.52$                 
Ammonium chloride 225 kg 79.00$                         $/kg 0.0888$    17,764.57$                 
Pierce Endotoxin Removal Resin 80.0 L 20,200.00$                $/L 8.0800$    1,616,000.00$           
POROS Benzyl HIC Resin 650 L 3,800.00$                   $/L 12.3500$  2,470,000.00$           
Protein A 4.15 kg 366.00$                      $/g 7.6024$    1,520,484.99$           
Sodium phosphate 58.0 kg 42.00$                         $/kg 0.1217$    24,349.93$                 
TEMED 0.25 L 168.00$                      $/L 0.0002$    41.44$                         
Urea 2146 kg 67.40$                         $/kg 0.7234$    144,670.03$              
Total 43.75$       8,749,530.74$           
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The total cost for raw materials for the process is $8.75 million. This cost estimate was 
determined from prices quotes provided by vendors. All reagents are United States Pharmacopoeia 
grade (USP), as required by the FDA. The resin for the endotoxin affinity chromatography column 
is the most expensive raw material needed to perform the process, followed by protein A, and 
guanidine HCl. Although relatively high, it should be noted that numerous steps in the purification 
processes require costly resin. Additionally, the cryogel-based affinity chromatography column 
requires expensive chemicals, polymers, and IgG antibodies that drastically increase this cost. 
Although for the purposes of this design the amount of materials and costs required for this column 
are reasonable, there are concerns that the possibility of expansion may cause financial strain if 
antibodies need to be purchased more often. 
In addition to the raw materials required for the process, there are a number of disposable 
products that will be used for each batch. These costs are summarized in Table 19.1.2.  
 
Table 19.1.2. Additional variables costs associated with the single-use, disposable technology that 
is used annually.  
 
 
 
 
 
 
 
 
 
 
 
Unit Disposable Unit Vendor Cost
Number 
per Batch
Cost per 
RBC Unit
Annual Cost
Media Sterilization Filter Filter Millipore  $       650.00 1  $      0.36  $     72,800.00 
Innoculum Growth Reactor ambr 250® Vessel Sartorius  $       155.00 1  $      0.09  $     17,360.00 
Microfluidization Product 
Resuspension Container
500L 3D Bioprocess 
Container
Thermo Fisher 
Scientific
 $       300.00 1  $      0.17  $     33,600.00 
Cobalt Affinity Chromatography 
Collection Container
500L 3D Bioprocess 
Container
Thermo Fisher 
Scientific
 $       300.00 1  $      0.17  $     33,600.00 
Endotoxin Affinity 
Chromatography Collection 
Container
500L 3D Bioprocess 
Container
Thermo Fisher 
Scientific
 $       300.00 1  $      0.17  $     33,600.00 
Endotoxin Affinity 
Chromatography Collection 
Container
200L 3D Bioprocess 
Container
Thermo Fisher 
Scientific
 $       250.00 1  $      0.14  $     28,000.00 
HIC Collection Container
50L 2D Labtainer 
Bioprocess Bag
Thermo Fisher 
Scientific
 $       150.00 1  $      0.08  $     16,800.00 
Final Product Holding Container 
(Enzyme)
5L 2D Labtainer 
Bioprocess Bag
Thermo Fisher 
Scientific
 $       150.00 10  $      0.84  $   168,000.00 
Hyperbaric Chamber Collection 
Container
200L 3D Bioprocess 
Container
Thermo Fisher 
Scientific
 $       250.00 3  $      0.42  $     84,000.00 
WAVE Bioreactor
200L Flexsafe® RM 
Bag
Sartorius  $       200.00 6  $      0.67  $   134,400.00 
Final Product Holding Container 
(RBC)
500L 3D Bioprocess 
Container
Thermo Fisher 
Scientific
 $       300.00 1  $      0.17  $     33,600.00 
Blood Bags for Distribution Terumo Blood Bags Terumo BCT  $            0.90 1786  $      0.90  $   180,028.80 
Total  $      4.18  $   835,788.80 
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These include disposable bags for reactors, storage containers, and filters. The total annual 
cost for these products is $835,789, which is an order of magnitude smaller than the total annual 
cost for the raw materials. This also amounts to $4.18 per RBC unit, of which the cost of the final 
distribution bag accounts for $0.90. All costs were obtained from vendors and requested quotes. 
This result was particularly satisfactory as it justifies the use of single-use technology for all short-
term storage. Originally, industrial consultants, particularly Jeffrey Cohen (Johnson & Johnson) 
and Daniel Green (GlaxoKlineSmith) were concerned that the cost of using single-use technology 
would outweigh the benefits of reduced CIP/SIP times. Upon performing this financial assessment 
of the annual costs required, though, single-use technology great increases the time with which 
batches can be processed and greatly reduces the demand for steam in this plant. 
 
19.2. Utilities 
The total annual cost of utilities is $580,547, which is shown in Table 19.2.1.  The cost per 
RBC unit is $2.90 and includes WFI, lighting, HVAC, electricity, refrigeration, and steam costs.   
 
Table 19.2.1. Annual utility cost estimates required with the respective costs per ECO RBC 
transfusion unit made. 
 
 
The WFI is produced by a WFI supplier, which treats tap water to later be used in the 
process for SIP. WFI is required for all production processes since the facility is built to be 
pharmaceutical grade. The water required for the WFI priced is based on estimates from the 
Medford, Massachusetts Department of Public Works, Water and Sewer Division.   
Utility
Annual Amount 
Required
 
Cost of 
Utility
  
Cost per 
RBC Unit
Annual Cost
Water for Injection 41400 L 0.0050 $/L 0.001$     207$                      
Lighting and HVAC 2120000 kWh 0.0516 $/kWh 0.547$     109,400$               
Electricity 2886000 kWh 0.1541 $/kWh 2.223$     444,600$               
Refrigeration 46200 kWh 0.0506 $/kWh 0.012$     2,340$                   
Steam 2334 kg 0.0130 $/kg 0.012$     2,400$                   
Total 2.79$       558,947$               
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Lighting and HVAC requirements were adapted from average values in established 
literature “Energy Benchmarking in the Pharmaceutical Industry,” assuming a plant size of 6,000 
square feet. 10.6 kWh of lighting/HVAC utility are required per unit RBCs. Electricity 
requirements for each process unit were obtained from manufacturer brochures; 4.81 kWh per unit 
of RBCs are required to power process equipment. The industrial cost of electricity in Medford, 
MA, $0.0514/kWh, was used to determine the cost of electricity for operating all unit operations, 
lighting, HVAC, and refrigeration. Lighting/HVAC and process electricity requirements are priced 
at $0.547/unit RBCs and $0.74/unit RBCs, respectively. 
Refrigeration is required to maintain the cold room, where blood bags for conversion will 
be organized and stored until they are processed. Each cold room will have dimensions of 30 ft x 
30 ft x 8 ft and is maintained at 4°C and 25% relative humidity. Thermal resistance values for wall, 
ceiling, and floor materials are standard values for cold room building materials provided by North 
Carolina State University. The service load, which accounts for lighting requirements, cold room 
control equipment, and storage carts, people, and humid air entering and exiting the cold room, 
are included in utilities analysis and assumed to be 10% of the heat conduction in the cold room. 
The total heat load, including heat conduction and service load, is 15,500 kWh per year with a 
requirement of 0.077 kWh/unit RBCs. The cost of refrigeration per unit product was determined 
to be $0.0039/unit RBCs.  
Lastly, low pressure steam is required in the process plant to sterilize the stainless steel 
fermenters and to kill any live mass remaining the bio-waste tank. All cultures or surfaces that 
were exposed to microbial cultures will be heated to 121ºC (see Appendix C) for approximately 
11 minutes and then cooled to 80ºC. The steam is priced at $0.013 per kilogram, and it is assumed 
that the process requires 2,334 kg annually (0.10 grams enzyme per mg enzyme). This leads to a 
cost of $0.012/unit RBCs.  
 
19.3. Fixed Operating Costs 
 The inputs for calculating fixed operating costs are shown in Table 19.3.1. To ensure 
successful plant operation, it assumed that five daily operating shifts are necessary, each lasting 
approximately 4.8 hours. It is assumed that there will be two operators for each shift, while there 
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will be an quality control specialist for three of the five shifts. Although the number of operators 
is quite high, they are necessary given that there are two separate processes being conducted in 
parallel.  
Table 19.3.1. Summary of the inputs for fixed cost analysis. 
 
  The complete fixed cost summary is shown in Table 19.3.2. The combination of fixed 
operating expenses, site maintenance costs, and general yearly expenses totals $15.2 million. It 
should be noted that this value is quite high and exceeds the fixed costs associated with certain 
industrial chemical processes. The reason behind these high costs is most likely associated with 
having a large number of operators present. Additionally, operating overhead, property taxes and 
Fixed Costs
Operations
Operators per Shift: 13 (assuming 5 shifts)
Direct Wages and Benefits: $40 /operator hour
Direct Salaries and Benefits: 15% of Direct Wages and Benefits
Operating Supplies and Services: 6% of Direct Wages and Benefits
Technical Assistance to Manufacturing: $60,000.00 per year, for each Operator per Shift
Control Laboratory: $65,000.00 per year, for each Operator per Shift
Maintenance
Wages and Benefits: 4.50% of Total Depreciable Capital
Salaries and Benefits: 25% of Maintenance Wages and Benefits
Materials and Services: 100% of Maintenance Wages and Benefits
Maintenance Overhead: 5% of Maintenance Wages and Benefits
Operating Overhead
General Plant Overhead: 7.10% of Maintenance and Operations Wages and Benefits
Mechanical Department Services: 2.40% of Maintenance and Operations Wages and Benefits
Employee Relations Department: 5.90% of Maintenance and Operations Wages and Benefits
Business Services: 7.40% of Maintenance and Operations Wages and Benefits
Property Taxes and Insurance
Property Taxes and Insurance: 2% of Total Depreciable Capital
Straight Line Depreciation
Direct Plant: 8.00% of Total Depreciable Capital, less 1.18 times the Allocated Costs 
for Utility Plants and Related Facilities
Allocated Plant: 6.00% of 1.18 times the Allocated Costs for Utility Plants and Related Facilities
Other Annual Expenses
Rental Fees (Office and Laboratory Space): $3,555,000
Licensing Fees: $0
Miscellaneous: $342,100
Depletion Allowance
Annual Depletion Allowance: $0
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insurance, and other annual expenses may actually be lower than the assumptions made for this 
project. However, it was assumed that all these values were useful in calculating an upper bound 
on what the fixed costs would be, allowing for a strict feasibility analysis. 
Table 19.3.2. Summary of all fixed costs, including operating expenses required per year for the 
execution of plant duties, site maintenance, and general expense estimates. 
 
Fixed Cost Summary
Operations
Direct Wages and Benefits 5,408,000$              
Direct Salaries and Benefits 811,200$                 
Operating Supplies and Services 324,480$                 
Technical Assistance to Manufacturing 780,000$                 
Control Laboratory 845,000$                 
Total Operations 8,168,680$              
Maintenance
Wages and Benefits 582,729$                 
Salaries and Benefits 145,682$                 
Materials and Services 582,729$                 
Maintenance Overhead 29,136$                   
Total Maintenance 1,340,278$              
Operating Overhead
General Plant Overhead: 493,280$                 
Mechanical Department Services: 166,743$                 
Employee Relations Department: 409,909$                 
Business Services: 514,123$                 
Total Operating Overhead 1,584,055$              
Property Taxes and Insurance
Property Taxes and Insurance: 258,991$                 
Other Annual Expenses
Rental Fees (Office and Laboratory Space): 3,555,000$              
Licensing Fees: -$                         
Miscellaneous: 342,100$                 
Total Other Annual Expenses 3,897,100$              
Total Fixed Costs 15,249,104$            
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20. Economic and Profitability Analysis 
20.1. Market Analysis Flux and Basic Approach 
The service fee applied to the enzymatic treatment of RBC units is based on the current 
cost for hospitals to collect and treat RBC units from donors. The average cost for RBC units to 
hospitals has risen over the last 20 years, from $155 in the early 1990s to $243.10 in 2016 [25,26]. 
The price charged to patients is higher, at $219 in the early 1990s and $423 in 2016 [25,26]. The 
enzymatic treatment of RBC units will be an additional service added to the collection and 
treatment of existing RBC units.  The price for this service will be a portion of the cost to collect 
and treat RBC units and will be charged to hospitals, but ultimately the patient or insurance agency 
will cover the fee.   
Approximately 21 million units of RBCs are needed yearly in the United States and the 
demand is steadily increasing as the population ages and more surgeries are required [2]. The 
enzymatic conversion operation aims to reach 200,000 RBC units annually, or almost 1.0% of the 
national market. This is enough to cover the demand for a large hospital system in the United 
States. With further development of the process and expansion, a larger proportion of the market 
could be reached. 
20.2. Clinical Trial Considerations 
 The process for the enzymatic conversion of RBCs for transfusion medicine shows the 
promise to be both lifesaving and somewhat profitable. No other blood product offers both non-
immunogenic properties and large scale production. The large scale production of universal RBCs 
is revolutionary and could replace traditional packaged RBCs for most applications.  
 The plant produces 200,000 units of universal RBCs annually and generates $34,293,532 
annual revenue in the third production year. The Return on Investment (ROI) for the plant at the 
current selling price of $187.50 is 17.17% and the Internal Rate of Return (IRR) is 21.73%. The 
Net Present Value (NPV) of this project in 2019 is $8,461,700.  
 The price of clinical trials for FDA approval was not included in the profitability analysis.  
As previously mentioned, the projected cost for Phase I-III clinical trials is approximately $100-
200 million, as advised by Scott Diamond, Ph.D., from the University of Pennsylvania. The scale 
of this plant is not sufficient to recoup the initial investment required to perform these trials. 
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However, this plant is large enough to produce the requisite materials necessary to perform the 
large scale Phase I-III trials and thus could initially operate as a pilot plant.  Initial safety studies 
and Phase I trials of the ECO-B enzyme have been successful, which paves the way for an 
accelerated Phase I trial [4]. Phase II and III trials will need to be more comprehensive, with larger 
patient populations [23].  These trials could take additional time, approximately 2-3 years and 
subsequent approval a year later. However, the design and performance of these trials is out of the 
scope of this project and will not be included in the profitability analysis.  
 Nonetheless, it is worth mentioning that the start-up nature of this project, if successful, 
could make it an enticing partner with large biotechnological and pharmaceutical companies 
present on the East Coast. Currently, GlaxoKlineSmith, Celgene Corporation, Kite 
Pharmaceuticals, and Merck have all been developing their blood biology departments to address 
numerous hematological diseases. If this project is deemed financially feasible, collaborations with 
these conglomerates could help provide adequate funding to execute clinical trials without 
imposing further costs. Additionally, it opens up the possibility of mergers with these companies 
that could help with the recovery of initial investments and lead to additional profitability. 
20.3. Pricing of ECO RBCs 
 Current blood transfusion unit prices tend to average around $309 in the Boston area. Using 
this as a basis, the service price for the enzymatic treatment of RBCs to convert them to universal 
type will be approximately 60% of the purchase cost hospitals pay for transfusion units. This 
decision was done after performing a sensitivity analysis on the profitability of this venture by 
varying the selling price of the transfusion unit. The service price for the enzymatically converted 
RBCs is approximately half of the collection and treatment cost to hospitals.  The selling price will 
$187.50 per transfusion unit, and it increases by 4.34% up until the year 2024, shown in Table 
18.3. Once 2024 begins, however, the price change will only happen in increments of 0.5% for the 
duration of the facility’s production life.  The increase in price is to account for the natural market 
growth in demand for RBC units. Additionally, since it is difficult to protect how other blood 
collecting organizations will evolve in the next decade, it may be a more realistic approach to 
stabilize prices after some time to be competitive with other transfusion unit sources. Overall, the 
price increases by $34.16 over the duration of the facility’s production life.  
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Table 20.3.1. The projected selling price and yearly increase for enzymatically converted RBC 
units. Up until the year 2024, the transfusion units will see a yearly increase of 4.34% in price, 
reflecting the most recent trends in the transfusion market. Beginning in 2024, it has been decided 
that the price will only increase by 0.5% annually.  
 
 
 
20.4. Profitability Analysis 
 An initial capital investment of $25.6 million will be required. Table 20.4.1 summarizes 
the working capital allotted to the project. It is assumed that one year will be needed for finalizing 
design and an additional year for construction. The plant will be active for 12 years, leading to a 
total duration of 14 years for the project.  A conservative approach was taken and it was assumed 
that the plant will operate at 90% of the desired production goal of 200,000 ECO RBC transfusion 
units, beginning from year one.  
 
 
 
 
Year Manual Input Price Percent Increase
2021 $187.50 --
2022 $195.64 4.34%
2023 $204.13 4.34%
2024 $212.99 4.34%
2025 $214.05 0.50%
2026 $215.12 0.50%
2027 $216.20 0.50%
2028 $217.28 0.50%
2029 $218.37 0.50%
2030 $219.46 0.50%
2031 $220.55 0.50%
2032 $221.66 0.50%
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Table 20.4.1. Summary of working capital requirements for the first year of production. 
 
 
 Table 20.4.2 provides an overview of multiple profitability metrics for the process in its 
third year of production. As previously mentioned, the plant will have an IRR of 21.73%, slightly 
above the nominal rate of 15%. The ROI is calculated to be 17.17%. The net present value of the 
project in 2019 is $8.46 million. The total capital investment involved in the project is $27.3 
million. It should be noted that this process will require a significant amount of research and 
specialized technology optimization, which will cause future cash flows to be reinvested with 
return rates even greater than the estimated IRR. 
 
Table 20.4.2. Summary of profitability metrics for the RBC conversion plant using a selling price 
of $187.50 per ECO RBC transfusion unit. 
 
 
 
 
 
 
Working Capital
2020 2021 2022
Accounts Receivable 8,321,918$              -$                         -$                           
Cash Reserves 870,676$                 -$                         -$                           
Accounts Payable (678,199)$                -$                         -$                           
ECO RBCs Inventory 3,624,658$              -$                         -$                           
Raw Materials 647,260$                 -$                         -$                           
Total 12,786,313$            -$                         -$                           
Present Value at 15% 11,118,533$            -$                        -$                           
Total Capital Investment 25,622,019$            
Profitability Measures
The Internal Rate of Return (IRR) for this project is 21.73%
The Net Present Value (NPV) of this project in 2019 is 8,461,700$       
ROI Analysis (Third Production Year)
Annual Sales 36,743,070       
Annual Costs (28,146,775)     
Depreciation (1,160,279)       
Income Tax (2,751,326)       
Net Earnings 4,684,690         
Total Capital Investment 27,289,799       
ROI 17.17%
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 This financial analysis provides some initial insight into the feasibility of the project. 
Assuming proper partnerships can be established with major hospitals and blood banks, this project 
is slightly profitable. The successful profit in this analysis is also assuming that the process plant 
continues to produce only 200,000 ECO RBC transfusions per year. Realistically, it is expected 
that the start-up will expand to cover the blood demands of other major hospitals in the state of 
Massachusetts and potentially other nearby metropolitan areas along the East Coast. This implies 
that after several years of operation, the actual production goal and capacity will increase. 
Although expansion will also imply increased equipment and operating costs, there will be 
additional compounded profits. Our equipment selection was also careful to incorporate smaller 
scale bioreactor towers that can actually handle the operation of more than one seed bioreactor, 
providing an initial area in which costs will already be lower than expected upon expansion. Once 
the process has been optimized, industrial consultant Arthur Etchells, Ph.D., states that the number 
of batches completed in a week. This will naturally increase production capacity without investing 
in further equipment costs. 
 The net present value of the studied base for the process over a production lifetime of 12 
years was approximately $8.46 million with a selling price as described in Section 20.3. A plot of 
the cumulative cash flow is shown in Figure 20.4.1. 
 
Figure 20.4.1. Cumulative discounted free cash flow for project over a twelve year production 
period. The base selling price of each ECO RBC unit is $187.50, which increases by 4.34% until 
2024 and then only by 0.50% for the rest of the plant’s lifetime. 
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20.5. Sensitivity Analysis 
The cost to produce a unit of enzymatically converted RBCs can be broken down into 
principal components to assess how changes would affect the overall cost.  The total capital 
investment is the largest component of the cost to produce the RBC units, at 46% of the cost.  The 
largest variable in the total capital investment is the bare module factor, which can change based 
on the nature of the process machinery required for the plant.  The next largest section are the raw 
materials, contributes 16% to the total cost of the RBC units.  The raw materials constitute a 
majority of the variable costs associated with the production of the RBC units.  This is followed 
by direct wages and other expenses as the leading contributors to the cost of RBC unit production.  
 
Figure 20.5.1:  Distribution of costs per unit of RBCs. 
 To examine how key factors contribute to the plant’s profitability, a sensitivity analysis 
was performed on the components that comprised the largest segments of the total cost of the RBC 
unit.  Variables, such as product price, variable costs, operator wages, and bare module cost were 
studied to determine which were most influential on the profitability of the plant.  The sensitivity 
analysis was used to guide the selection of the final values for these variables. 
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20.6.  Service Price and Variable Costs 
 The service price was studied in relation to the variable costs to determine its effect on the 
Internal Rate of Return (IRR).  The service price was varied between +/- 50% of the initial set 
service price, which corresponds to approximately half the price of a traditional RBC unit.  
Additionally, the variable costs were studied for +/- 50% of the set variable cost. 
The plant becomes unprofitable below a product price of $122.50 and has an IRR of 
48.54% at a service price of $262.50, 150% of the set price. The IRR varied from -0.80% to 31.57% 
as the variable cost ranged from +/- 50% of the set variable cost. While the variable cost does 
affect the profitability of the plant, the service price has a much larger effect on the profitability.  
For the set service price of $175 the plant can be profitable for variable costs ranging from below 
$7,165,373 to $20,063,045. For this reason variable costs were not considered as an important 
metric for further studies of plant profitability, which is detailed in Figure 5.10.3.3. 
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 The IRR sharply rises with small changes in the price of the RBC unit service, as shown in 
Figure 5.10.3.2.  The plant has a negative IRR when the service price is set below $150 per unit of 
RBCs.  The final service cost of $175 was chosen to maximize profitability and customer 
requirements.  At this value the plant has an internal rate of return of 16.22% and the customer 
pays a service fee that is approximately half of the original cost of the RBC unit, which was 
determined previously to be the upper limit for customer satisfaction.  
 
 Figure 20.6.1: Effect of service price per RBC unit on Internal Rate of Return (IRR) 
 The effect of variable costs on the IRR is much smaller than that of the service price, but 
as shown in Figure 5.10.3.3 the profitability of the plant does marginally increase as the variable 
costs decreases.  As the variable costs ranged from $7 million to $21.5 million, or +/- 50% of the 
original variable costs the IRR only increased 32.4%.  In order to see increases in profitability, 
dramatic reductions in the variable costs would have to be made.  Because the variable costs didn’t 
greatly influence the profitability as other factors did, optimization efforts were focused elsewhere. 
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Figure 20.6.2: Effect of variable costs on Internal Rate of Return (IRR). 
20.7.  Operator Wages 
 The operator wages account for $5,408,000 of the $28,145,384 annual costs, or 19.2% of 
the total costs.  This is the second largest cost, behind variable costs, excluding the capital 
investment. Because of this, it is important to determine the effect changes in operator wages have 
on the profitability of the plant.  
 As operator wages increased the IRR and ROI decreased linearly, suggesting a strong 
relationship between profitability and the operator wages.  The operator wage of $40/hour was 
selected for its acceptable profitability measures and industry competitiveness.  The technical 
nature of the work in this plant and high quality control measures in place raise the operator wage 
rate.  However, even at high wage rates, the plant can be profitable, only becoming unprofitable at 
wages higher than $60/hour. 
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Figure 20.7.1: Effect of operator wages on Internal Rate of Return (IRR) and Return on Investment 
(ROI). 
 
20.8.  Bare Module Factor 
 The bare module factor is used to predict the final purchase and installation cost for 
equipment.  It is highly dependent on the nature of the equipment purchased.  For instance, 
machinery that needs to be custom designed, fabricated, and installed incurs a larger bare module 
cost than equipment purchased off the shelf.  Much of the equipment needed for this process falls 
in the later category, and thus has a lower bare module cost.   
The default bare module factor used for most applications is 3.21, however that likely 
overestimates the bare module cost for this plant.  A sensitivity analysis was performed to see how 
the bare module factor affected the profitability of the plant.  This is especially important, because 
the equipment costs are a majority of the total capital investment.  
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Figure 20.8.1: Effect of Bare Module Factor on the Internal Rate of Return (IRR) and the Return 
on Investment (ROI). 
 The bare module factor had a modest effect on both profitability measures.  Large changes 
in the bare module factor showed only about a 20% change in the IRR and ROI values, but 
corresponds to significant changes in the bare module cost.  For the purpose of the profitability 
analysis a bare module factor of 3.21 was used as an upper bound as further effort to quantify the 
bare module factor would have a modest effect on the overall plant profitability. 
20.9. Facility Lifespan 
The plant has an operation life expectancy of about 12 years. The anticipated lifespan of 
the facility accounts for the manufacturers’ projected lifespans of the equipment and the projected 
market for RBCs in general. New methods for producing universal RBCs are being studied, but 
they will not be viable for large scale production for at least a decade until they begin to collect 
human clinical trial data [11]. Enzymatically converted RBCs will therefore be the only competitor 
in this market segment for the lifespan of the facility. If the plant were to shut down before the end 
of its projected 12-year lifespan, there could be some value in the salvage of the purchased 
equipment. It is recommended however to operate at full production capacity for its planned 12-
year occupancy.  
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21. Other Important Considerations 
21.1. Steam-in-Place (SIP) Requirements 
         Unless otherwise specified, process equipment will be steam-sterilized in place (SIP) after 
cleaning in place (CIP) to ensure neutralization of E. coli, unconverted A and B RBCs, used ECO-
A and ECO-B enzyme, and other biological process waste that could pose harm to the environment 
or persons if disposed of before neutralization. SIP requires equipment sterilization with saturated 
steam at 50 psi and 138°C to ensure that all equipment reaches 121°C for 11 minutes, complying 
with FDA sterilization regulations.51 Flow of room temperature air through equipment tubing will 
be used to cool the equipment post-SIP. Cooling times for equipment are according to 
manufacturer brochures and/or equipment size.     
21.2. Clean-in-Place (CIP) Requirements 
         Any and all equipment that processes cells, enzyme, or other biological material must be 
treated as biological waste or cleaned according to FDA clean-in-place (CIP) regulations. Non-
disposable equipment that contacts biological materials will be cleaned according to CIP protocol 
between batches; CIP is accounted for on all process scheduling Gantt charts. 
         CIP for reusable process equipment will consist of a rinse with water for injection (WFI), 
followed by two detergent flushes and an intermediate rinse with WFI. An acidic solution will be 
used to ensure neutralization of all bio-waste and clearance of all protein and cell residue. A rinse 
with WFI to rid the equipment of any remaining detergent and an air blow over the equipment to 
remove moisture complete CIP. The amounts of detergent and acid solution required annually for 
CIP and, correspondingly, the costs of these materials, are assumed negligible as compared to other 
raw material costs in the economic analysis for the process. 
21.3. Waste Treatment and Environmental Concerns 
         All live cells and cell cultures, particularly E. coli, may grow or accumulate in water supply 
or elsewhere and become a hazard to the surrounding environment. Thus, it is critical to inactivate 
E. coli cultures before disposal. For a 12-log reduction in E. coli population size, it was assumed 
                                                          
51 Effective Bactericidal Treatment , 21 C.F.R. Sect. 1240 (2017). 
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that E. coli must be treated at 121°C for 5 minutes.52 A D-value (thermal deactivation coefficient) 
of 0.4167 minutes, the time required for one decimal reduction of the population, was calculated 
based on this assumption. The number of cells to be inactivated was calculated from batch volumes 
and final cell concentrations for ECO-A enzyme and ECO-B enzyme production assuming first-
order deactivation kinetics. To more thoroughly ensure cell death, it is optimal to achieve a 25-log 
reduction in cell population; a thermal inactivation time of 10.4 minutes for both ECO-A and ECO-
B E. coli cells was calculated based on this criterion and final cell concentrations. Live cultures 
will thus be heated to 121°C for 10-11 minutes to ensure cell death (see Appendix D). Any process 
units that contact live cells or other biological materials will be autoclaved or otherwise thoroughly 
sterilized. Waste transport and disposal may be contracted to a nearby facility in Cambridge due 
to the costly nature of waste handling equipment for a startup venture. 
         In addition to CIP/SIP practices, hygienic conditions will be met for equipment and 
operating personnel with quality materials and ventilation. Quality assessment may be performed 
at various points in the process to assure batch uniformity; quality control in the form of limulus 
amebocyte lysate (LAL) assay, flow cytometry, or thin layer chromatography will be performed 
on the final product before packaging and shipping. Current good manufacturing practice (cGMP) 
protocols will be strictly followed at every step of the process. 
21.4. Water for Injection (WFI) Concerns 
         It is critical that all water for injection (WFI) generated for process operations be 
maintained at the proper pH, have no microbial colonies, and contain no particulate matter. Thus, 
the temperature of the WFI distribution at peak load will be maintained at 80°C. The WFI still will 
be monitored daily for microbes. WFI samples with sizes of 100-300 mL per test will be taken 
from various points in the supply loop for 20 working days. Tests for compliance with FDA 
specifications for WFI will be taken over the course of one year to monitor changes in the WFI 
chemical composition over time. Tests for residual chlorine, conductivity, and pH will be 
performed on the WFI year-round. All growth media must pass growth promotion testing. 
         In addition to the routine testing for microbial growth previously described, the presence 
of microbes in the WFI will be tested using a membrane filtration technique called total 
                                                          
52 Osaili T et al. Thermal inactivation studies of Escherichia coli O157:H7, Salmonella, and Listeria monocytogenes in ready-to- eat chicken-fried 
beef patties. Journal of Food Protection 2006: 69(5):1080–1086. 
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heterotrophic plate count. WFI will be plated using plate count agar to perform testing for presence 
of microbiological agents; any colonies present on the agar filter will be identified and further 
tested for potential safety concerns. For WFI to be considered safe according to FDA standards, 
plate counts must be less than 10 CFU/mL. 
         Finally, sanitary clamped piping, instruments, and valves will be used to transport WFI to 
distribution and storage systems. Piping and instruments will be labeled, properly sloped for 
optimal flow, and maintained to pass integrity testing. A backflow valve will be installed with the 
still to protect source water. 
21.5. Intellectual Property Concerns and FDA Approval 
         Consideration of intellectual property concerns prompts consideration of the possibility of 
licensing the process to a research institution that has conducted studies on enzymatic conversion 
of RBCs. In addition, a Biologic License Application (BLA) for production, distribution, and 
medical usage of ECO-RBCs would need to be filed with the FDA before plant startup. A BLA 
requires extensive pre-clinical tests and successful passage of Phase I-III clinical trials. Pre-clinical 
tests would study ECO-RBCs for their stability in storage, morphology, biochemistry, oxygen 
dissociation, and hemolytic properties as compared to those of natural type O RBCs. Clinical trials 
in human patients would examine the immunogenicity, circulatory half-life, hemoglobin 
clearance, and blood clearance rate of ECO-RBCs relative to those of wild type O RBCs. 
Indication selection of patients for clinical trial would need to be performed very carefully. While 
Phase I clinical trials may be conducted in healthy patients, Phase II and III clinical trials would 
need to be conducted with patients with measurable indications. Patients with indications such as 
traumatic bleeding would not be selected, as obtaining informed consent is difficult and transfusion 
challenging to control. Instead, patients with anemia or undergoing elective surgery would be 
chosen to participate in clinical trial as response to WT RBCs is well-established and obtainment 
of informed consent is easier. Consultation with Scott Diamond, Ph.D, of the Department of 
Chemical and Biomolecular Engineering at the University of Pennsylvania led to an estimated cost 
of $100-$200 million for FDA approval of ECO-RBCs. While this cost is considered out of scope 
for the purposes of this project, it is vital to consider if the plant were to be realized. 
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21.6. Alternative Applications 
         The primary alternative application of production of ECO-RBCs to use in hospitals and 
distribution to blood banks for use in clinical application is production of ECO-RBCs to provide 
a more universal blood supply to the US military. The high demand for blood products, particularly 
universal RBCs and plasma for transfusion, on the battlefield could lead to defense funding for 
ECO-RBC production if this application were to be pursued. 
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22. Conclusions and Recommendations 
The design of a start-up-scale plant that produces the glycosidases for RBC conversion and 
treats RBC units to create universal RBC units shows promise for profitability and expansion.  The 
plant requires an initial capital investment of $25.6 million and will operate over a 12 year lifespan.  
During this time the plant will be able to produce 200,000 converted RBC units, enough to satisfy 
the needs of a single hospital system near the plant’s location in Medford, MA.  The start-up-scale 
plant will have a 21.73% internal rate of return over its lifespan, and can maintain profitability 
over a variety of operating conditions.  The plant breaks even in its eighth year of operation, and 
opportunities for expansion could enhance the profitability of this process. 
The profitability of this plant does not account for the expected cost of clinical trials and 
FDA approval, which is estimated to be $100-200 million.  The high cost of the clinical trials 
makes the start-up-plant unprofitable, however, the scale of this plant was not designed to recover 
the initial costs of FDA approval.  Instead, the start-up-scale plant is designed to be a proof of 
concept and to produce enough converted RBC units to supply the Phase I-III clinical trials 
necessary for approval.  Once the blood product is approved for use in humans, the process could 
be expanded beyond the start-up-scale plant.  Large scale central production of the glycosidases 
could be optimized for distribution to local treatment facilities.  Under this expansion regime, the 
process could provide universal RBCs to east coast cities with relative logistical ease and could 
recover the initial capital investment required for approval.  
Due to the high profitability of the start-up-scale plant, projected FDA approval, and the 
potential for further expansion, it is recommended that this venture is pursued.  The enzymatic 
conversion of RBCs has the potential to alleviate many of the growing concerns in the blood 
market, including blood wastage and incompatibility reactions.  However, investors should be 
mindful of the risks associated with the blood market.  Shifts in the demand for different types of 
blood products and the growing efficiency of surgeries could affect the demand for RBC units, 
however, the scale of the process is not likely to ever exceed this demand. 
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Appendix A: Cell Growth Analysis 
 
Assumptions: 
1. Prepared media begins with a glucose concentration of 2 g/L in all fermenters and 
bioreactors. 
2. During the exponential growth phase, there is negligible cell death. Therefore, the specific 
growth rates is defined as: 𝜇𝑛𝑒𝑡 = 𝑢𝑔 = 0.25 ℎ𝑟
−1. 
3. All glucose consumption is due to metabolic consumption by the cells.  
4. The batch bioreactor is well mixed at all times. Therefore, the cell, nutrient, and oxygen 
concentrations are uniform throughout the bioreactors’ contents. 
5. Cell loss due to optical density testing of inoculum, growth, and production bioreactors is 
considered negligible. The only loss that is not negligible is accounted for in the mass 
balance during transfer out procedures. 
6. Oxygen level is held constant in the production bioreactor to ensure aerobic cellular 
respiration throughout the growth period. 
 
Cell Growth Mathematical Modeling: 
Equation (3) was used to determine all batch times required to achieve desired final cell 
concentrations at the end of each bioreactor/fermentation step. The mathematical manipulation of 
equation (3) is as follows: 
𝑑𝑋
𝑋
= 𝜇𝑛𝑒𝑡𝑑𝑡 
 
∫
𝑑𝑋
𝑋
𝑋
𝑋𝑜
= ∫ 𝜇𝑛𝑒𝑡
𝑡
0
𝑑𝑡 = 𝜇𝑛𝑒𝑡 ∫ 𝑑𝑡
𝑡
0
 
 
𝑡 =
1
𝜇𝑛𝑒𝑡
∫
𝑑𝑋
𝑋
𝑋
𝑋𝑜
 
 
205 
 
𝑡 =
1
𝜇𝑛𝑒𝑡
 𝑙𝑛
𝑋
𝑋𝑜
                                                               (𝐴. 1) 
Where: t = time (hours) 
X0 = initial cell concentration (cells/mL) 
X = cell concentration at time t  
µnet = specific growth rate for cell culture (hr
-1) 
 
Initial and final cell concentrations for the various steps taken in the process were obtained from 
literature on high-density microbial cultures. 
 
A. For inoculum culture: 
𝑡 =
1
0.25 ℎ𝑟−1
 𝑙𝑛
4.42 × 108
5.09 × 106
= 17.86 ℎ𝑟 
Recommended growth times for E. coli inoculum growth range between 12 to 16 hours, which 
validates this batch time calculation.  
 
B. For growth bioreactor: 
We assume that 5% of the cells cultured in the previous step are either lost or lysed, implying that 
95% of the previous culture inoculates the new bioreactor. 
For the culture to produce α-N-acetylgalactosaminidase: 
𝑡 =
1
0.25 ℎ𝑟−1
 𝑙𝑛
3.45 × 109
8.50 × 106
= 24.03 ℎ𝑟 
 
For the culture to produce α-galactosidase: 
𝑡 =
1
0.25 ℎ𝑟−1
 𝑙𝑛
3.17 × 109
8.50 × 106
= 23.69 ℎ𝑟 
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C. For production fermenters: 
We assume that 5% of the cells cultured in the previous step are either lost or lysed, implying that 
95% of the previous culture inoculates the new fermenters. 
It was recommended from the literature that the initial concentration of E. coli in the fermenter be 
adjusted to 4.50×107 cells/mL.  
𝑡 =
1
0.25 ℎ𝑟−1
 𝑙𝑛
2.91 × 1010
4.50 × 107
= 25.89 ℎ𝑟 
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Appendix B: Required Protein Yield to Satisfy Production Goals 
Assumptions: 
All suggestions to account for losses were provided by Robert Luo, Ph.D. from GlaxoKlineSmith. 
1. 200,000 universal RBC transfusion units will be prepared. Following the blood-type 
distribution in the United States, nearly two-thirds of these prepared units will come from 
type-A blood and the remaining one-third will from type-B. 
2. Type-AB conversions will not be considered for this process since they make up such a 
small percentage (<3%) of the donor population. 
3. During RBC conversion treatment/processing, 35% of the RBCs will be lost. To satisfy the 
RBC cell count in each blood bag, 307,693 RBC units are needed to account for losses and 
meet production goals.  
4. 40% of each enzyme product will be lost in downstream purifications steps. 
5. 10% of the enzyme product will not be functional due to protein misfolding, denaturation, 
or possible points mutations that altered amino acid sequence and affect functionality. 
6. One unit of packed RBCs is 300 mL. 
 
Required mass yield of α-galactosidase: 
307,693 𝑢𝑛𝑖𝑡𝑠 × 0.67
𝑡𝑦𝑝𝑒 − 𝐴 𝑢𝑛𝑖𝑡𝑠
𝑡𝑜𝑡𝑎𝑙 𝑢𝑛𝑖𝑡𝑠
× 60
𝑚𝑔
𝑡𝑦𝑝𝑒 − 𝐴 𝑢𝑛𝑖𝑡
 ×  
1 𝑔
1000 𝑚𝑔
×
1
1 − 0.4
×
1
0.9
 
 
= 22,906 𝑔 of α − galactosidase 
 
Required mass yield of for α-N-acetylgalactosaminidase: 
307,693 𝑢𝑛𝑖𝑡𝑠 × 0.33
𝑡𝑦𝑝𝑒 − 𝐴 𝑢𝑛𝑖𝑡𝑠
𝑡𝑜𝑡𝑎𝑙 𝑢𝑛𝑖𝑡𝑠
× 2
𝑚𝑔
𝑡𝑦𝑝𝑒 − 𝐴 𝑢𝑛𝑖𝑡
 ×  
1 𝑔
1000 𝑚𝑔
×
1
1 − 0.4
×
1
0.9
 
 
= 376.07 𝑔 of α − N − acetylgalactosaminidase 
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Appendix C: Biowaste System Design 
Assumptions: 
1. The final cell concentration in the production culture is 2.91×1010 cells/mL. Upon removal 
from the process, the E. coli bacteria will be inactivated in the waste vessel. 
2. Inactivation kinetics are first order. 
3. The thermal deactivation coefficient is D = 0.4167 minutes. A literature review was 
performed to determine what the decimal reduction time for E. coli at 121ºC was. 
Numerous sources reported different values. Therefore, an average value was taken for 
these inactivation times.  
 
Using the production of α-galactosidase as the base case with which to determine the time for 
thermal inactivation of E. coli since it requires a larger processing volume, the calculations the 
time to reach the thermal death point are as follows: 
 
2.91 × 1010
𝑐𝑒𝑙𝑙𝑠
𝑚𝐿
 × 396
𝐿
𝑏𝑎𝑡𝑐ℎ
 ×  1000
𝑚𝐿
𝐿
= 4.16 × 1016
𝑐𝑒𝑙𝑙𝑠 𝑡𝑜 𝑖𝑛𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑒
𝑏𝑎𝑡𝑐ℎ
 
  
First order inactivation kinetics: 
ln (
𝑁
𝑁0
) =  −𝑘𝑡                                                               (𝐶. 1) 
 
Where: N = microbial population at any time, t 
N0 = initial microbial population 
D = decimal reduction time; time required for a 1-log (or 10-fold) cycle reduction in the 
microbial population 
 
The thermal inactivation constant is defined as: 
𝑘 =
2.303
𝐷
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Manipulating equation (B.1), the following expression for thermal inactivation is obtained: 
 
log (
𝑁
𝑁0
) = −
𝑡
𝐷
                                                            (𝐶. 2) 
 
To determine heating time required for thermal inactivation: 
 
𝑡 = −𝐷 ∙ log (
25 − log  𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑠𝑖𝑧𝑒
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑡𝑜 𝑖𝑛𝑎𝑐𝑡𝑖𝑣𝑎𝑡𝑒
)                                 (𝐶. 3) 
 
𝑡 = −0.4167 𝑚𝑖𝑛 ∙ log (
4.16 × 10−9
4.16 × 1016
) 
 
𝑡 = 10.42 𝑚𝑖𝑛𝑢𝑡𝑒𝑠 
 
Therefore, bio-waste tank will be heated to 121C and maintained at this temperature for 
approximately 11 minute to inactivate bacteria. 
 
Conclusion: Thus, there is 4.16 × 10−9 chance that a single E. coli cell will be active after an 
eleven minute heat inactivation in each batch.  
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Appendix D: Batch Sizing 
Assumptions: 
1. The process to produce bacterial glycosidases is designed to run 114 batches per year: 112 
for the production of α-N-acetylgalactosaminidase and 2 for α-galactosidase. The plant will 
be operational for 24 hours, 7 days a week, 52 weeks per year. Six batches will be 
completed each week. Although this exceeds calculated operation times, it provides 
additional time to account for possible errors or malfunctions that may arise.  
2. Accounting for losses and possible inactive enzyme, the ultimate goal is to produce 22.9 
kg of α-N-acetylgalactosaminidase and 0.376 kg of α-galactosidase per year.  
3. The specific growth rate for BL21(DE3) recombinant E. coli cells is 0.25 hr-1.  
4. 20% of the inoculum died from both the freezing and thawing processes. 
5. 5% of the cell population in the growth and production bioreactors will be dead or inactive.  
6. Frozen stock of E. coli will be prepared at concentration of 7.95×106 cells/mL. 
7. Oxygen limitations will not be a concern for the growth periods and will be held constant 
using PID control at 40% dissolved O2.  
 
All values were validated by Jeffrey Cohen, Ph.D. from GlaxoKlineSmith to confirm similarity 
to commonly observed values in industrial fermentation. 
 
For the production of α-N-acetylgalactosaminidase 
Table D.1. Inoculum batch sizing details for α-N-acetylgalactosaminidase production. The 
parameters for the predicted growth model were obtained from literature review. All final cell 
concentrations were obtained from a report on high density microbial cultures. 
Inoculum Growth Bioreactor 
Working volume 0.110 L 
Initial cell concentration 5.09×106 cells/mL 
Specific growth time 0.25 hr-1 
Batch time 17.86 hr 
Target cell concentration 4.42×108 L 
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Table D.2. Growth bioreactor batch sizing details for α-N-acetylgalactosaminidase 
production. The parameters for the predicted growth model were obtained from literature review. 
All final cell concentrations were obtained from a report on high density microbial cultures. It was 
assumed that five percent of the inoculum culture was lost due to cell death or transfer 
inefficiencies when inoculating the seed bioreactor. 
Growth Bioreactor 
Working volume 5.44 L 
Initial cell concentration 8.50×106 cells/mL 
Specific growth time 0.25 hr-1 
Batch time 24.03 hr 
Target cell concentration 3.45×109 L 
 
 
Table D.3. Production fermentation batch sizing details for α-N-acetylgalactosaminidase 
production. The parameters for the predicted growth model were obtained from literature review. 
All final cell concentrations were obtained from a report on high density microbial cultures. Again, 
five percent of the seed bioreactor culture was assumed lost due to cell death or transfer 
efficiencies. In this step, the culture from the seed bioreactor was equally split between two 
stainless steel fermenters to achieved productions goals. During IPTG induction, the temperature 
of the reactor was lowered to 25ºC to inhibit cell growth. 
Production Fermenters 
Working volume 396 L 
Initial cell concentration 4.50×107 cells/mL 
Specific growth time 0.25 hr-1 
Batch time 25.89 hr 
Target cell concentration 2.91×1010 cells/mL 
Protein production rate 85.4 ng/cell-day 
Protein production time 5 hr 
Protein produced 0.205 kg 
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For the production of α-galactosidase  
Table D.4. Inoculum batch sizing details for α-galactosidase production. The parameters for 
the predicted growth model were obtained from literature review. All final cell concentrations were 
obtained from a report on high density microbial cultures. 
Inoculum Growth Bioreactor 
Working volume 0.110 L 
Initial cell concentration 5.09×106 cells/mL 
Specific growth time 0.25 hr-1 
Batch time 17.86 hr 
Target cell concentration 4.42×108 L 
 
 
Table D.5. Growth bioreactor batch sizing details for α-galactosidase production. The 
parameters for the predicted growth model were obtained from literature review. All final cell 
concentrations were obtained from a report on high density microbial cultures. It was assumed that 
five percent of the inoculum culture was lost due to cell death or transfer inefficiencies when 
inoculating the seed bioreactor. The final cell concentration in this seed bioreactor is slightly less 
for α-galactosidase production than for α-galactosidase production since the volume of culture is 
less to satisfy production goals.  
Growth Bioreactor 
Working volume 5.44 L 
Initial cell concentration 8.50×106 cells/mL 
Specific growth time 0.25 hr-1 
Batch time 23.69 hr 
Target cell concentration 3.17×109 L 
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Table D.6. Production fermentation batch sizing details for α-galactosidase production. The 
parameters for the predicted growth model were obtained from literature review. All final cell 
concentrations were obtained from a report on high density microbial cultures. Again, five percent 
of the seed bioreactor culture was assumed lost due to cell death or transfer efficiencies. In this 
step, the culture from the seed bioreactor was equally split between two stainless steel fermenters 
to achieved productions goals. During IPTG induction, the temperature of the reactor was lowered 
to 25ºC to inhibit cell growth. 
 
Production Fermenters 
Working volume 364 L 
Initial cell concentration 4.50×107 cells/mL 
Specific growth time 0.25 hr-1 
Batch time 25.89 hr 
Target cell concentration 2.91×1010 cells/mL 
Protein production rate 85.6 ng/cell-day 
Protein production time 5 hr 
Protein produced 0.189 kg 
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Appendix E: Culture Media Composition 
 
Table E.1. High-salt medium will be used for high-density microbial fermentation. This 
composition has been experimentally determined to promote optimal cell growth to OD600 values 
up to 45, which corresponds to a cell concentration of 3.6×1010 cells/mL.  
 
 
 
 
 
 
 
 
 
 
Component
Na₂HPO₄∙7H₂O 33.9 g/L
KH₂PO₄ 15.0 g/L
NH4Cl 5.0 g/L
NaCl 2.5 g/L
Na₂SO₄ 7.1 g/L
MgSO₄ 6.0 g/L
Glycerol 0.4 % v/v
ß-lactose 0.01 % v/v
High-Mineral Salt Microbial Culture Media
Concentration
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Appendix F: Oxygen Transfer Limitations for Reactor Design 
Assumptions: 
1. The final cell concentration in the production culture is 2.91×1010 cells/mL.  
2. Specific uptake rate of oxygen, 𝑞𝑂2, is 12.0 mmole O2/g cells-hr for Escherichia coli. 
3. The difference between the saturated oxygen solubility, 𝐶𝑂
∗ , and the actual concentration 
of dissolved oxygen in the culture broth, 𝐶𝑂
 , is 1.13 mmole O2/L.  
4. For the chosen bioreactor and impeller configurations, the volumetric oxygen transfer 
coefficient,𝑘𝐿𝑎, is 308 hr
-1. 
 
To find the maximum cell density at which the production bioreactor can provide enough oxygen 
to maintain cell growth and viability, the oxygen uptake rate (OUR) was set equal to the oxygen 
transfer rate (OTR). 
 
OTR calculation: 
𝑂𝑇𝑅 = 𝑘𝐿𝑎(𝐶𝑂
∗ − 𝐶𝑂
 )                                                          (𝐹. 1) 
 
𝑂𝑇𝑅 = 308 ℎ𝑟−1 (1.13
𝑚𝑚𝑜𝑙𝑒 𝑂2
𝐿
) 
 
𝑂𝑇𝑅 = 348.04
𝑚𝑚𝑜𝑙𝑒 𝑂2
𝐿 − ℎ𝑟
  
Maximum cell density: 
𝑂𝑈𝑅 = 𝑞𝑂2𝑋 = 𝑂𝑇𝑅                                                           (𝐹. 2) 
 
𝑋 =
𝑂𝑇𝑅
𝑞𝑂2
=
348.04
𝑚𝑚𝑜𝑙𝑒 𝑂2
𝐿 − ℎ𝑟
12.0
𝑚𝑚𝑜𝑙𝑒 𝑂2
𝑔 𝑐𝑒𝑙𝑙𝑠 − ℎ𝑟
 
 
𝑋 = 29.0
𝑔 𝑐𝑒𝑙𝑙𝑠
𝐿
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Appendix G: Endotoxin Yield Calculations 
Assumptions: 
1. There is 1.00×10-10 grams of endotoxin for every 105 E. coli cells in the final culture. 
2. The final cell concentration in the production fermenters is 2.91×1010 cells/mL. It is further 
assumed that all endotoxin production is accounted for in the final cell concentration.  
 
For α-N-acetylgalactosaminidase production: 
Batch volume: V = 396 L 
1.0 × 10−10𝑔 𝑒𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛
105𝑐𝑒𝑙𝑙𝑠
∙
2.91 × 1010 𝑐𝑒𝑙𝑙𝑠
𝑚𝐿
∙
1000 𝑚𝐿
1 𝐿
∙ 396 𝐿 = 11.5 g endotoxin 
 
For α-galactosidase production: 
Batch volume: V = 364 L 
1.0 × 10−10𝑔 𝑒𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛
105𝑐𝑒𝑙𝑙𝑠
∙
2.91 × 1010 𝑐𝑒𝑙𝑙𝑠
𝑚𝐿
∙
1000 𝑚𝐿
1 𝐿
∙ 364 𝐿 = 10.6 g endotoxin 
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Appendix H: Cobalt Affinity Chromatography Sizing and Timing 
The cobalt affinity chromatography column size and volumes of solution needed were 
calculated according to the manufacturer’s protocol for the HisPur® cobalt affinity resin. The 
given binding capacity of the resin (20 grams of protein per liter of resin) and the mass of either 
α-galactosidase or α-N-acetylgalactosaminidase entering the column were used to calculate the 
volume of resin required per batch. This calculation assumes that all enzyme that passes through 
the column will bind to the resin and disregards the 90% recovery from the unit. This assumption 
ensures that recovery is not limited by the binding capacity of the resin. The void fraction of the 
resin packaging is 0.30 according to the manufacturer’s protocol. The column volume was 
calculated as follows: 
𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒 =
𝐸𝑛𝑧𝑦𝑚𝑒 𝑚𝑎𝑠𝑠 𝑖𝑛𝑡𝑜 𝑡ℎ𝑒 𝑐𝑜𝑙𝑢𝑚𝑛 (𝑔)
𝑏𝑎𝑡𝑐ℎ
∙ 𝐵𝑖𝑛𝑑𝑖𝑛𝑔 𝐶𝑎𝑝𝑎𝑐𝑖𝑡𝑦                      (𝐻. 1) 
 
For α-N-acetylgalactosaminidase: 
205
𝑔
𝑏𝑎𝑡𝑐ℎ
∙
1 𝐿 𝑟𝑒𝑠𝑖𝑛
20 𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
=  10.25 
𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
 
 
𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =
𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
𝑏𝑎𝑡𝑐ℎ
∙
1
1 − 𝑉𝑜𝑖𝑑 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛
             (𝐻. 2) 
 
10.25 𝐿 𝑟𝑒𝑠𝑖𝑛 ∙
1
1 − 0.30
= 14.6 𝐿  
 
The data sheet for the resin allows for 25 regenerations before resin must be replaced. The amount 
of resin needed for processing α-N-acetylgalactosaminidase on an annual basis was calculated as 
follows: 
 
𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑
𝑦𝑒𝑎𝑟
=
𝑅𝑒𝑠𝑖𝑛 
 𝐵𝑎𝑡𝑐ℎ
∙
𝐵𝑎𝑡𝑐ℎ𝑒𝑠
𝑦𝑒𝑎𝑟
∙
1
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔
   (𝐻. 3) 
 
𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 = 10.25 
𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
∙ 112 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙
1
25 
=  45.92 𝐿 𝑟𝑒𝑠𝑖𝑛 
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For α-galactosidase: 
 
189
𝑔
𝑏𝑎𝑡𝑐ℎ
∙
1 𝐿 𝑟𝑒𝑠𝑖𝑛
20 𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
=  9.45 
𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
 
 
𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =
𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
𝑏𝑎𝑡𝑐ℎ
∙
1
1 − 𝑉𝑜𝑖𝑑 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛
 
 
9.45 𝐿 𝑟𝑒𝑠𝑖𝑛 ∙
1
1 − 0.30
= 13.5 𝐿 
 
Assuming that we use new resin when switching over to the production of α-galactosidase, the 
calculations for the total amount of resin needed on an annual basis for processing α-galactosidase.  
 
𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑
𝑦𝑒𝑎𝑟
=
𝑅𝑒𝑠𝑖𝑛 
 𝐵𝑎𝑡𝑐ℎ
∙
𝐵𝑎𝑡𝑐ℎ𝑒𝑠
𝑦𝑒𝑎𝑟
∙
1
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔
 
 
𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 = 9.45 
𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
∙ 2 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙
1
25 
=  0.756 𝐿 𝑟𝑒𝑠𝑖𝑛 
 
From these calculations, the total volume of resin required to treat both enzymes is approximately 
46.7 liters. An additional conclusion that can be made is that since the mass of α-N-
acetylgalactosaminidase that will be processed is greater than the mass of α-galactosidase, its 
minimal required will satisfy the volumetric requirements for both enzymes. 
A conservative approach was used in calculating the batch time and amount of buffer 
needed by using the maximum column volumes of buffer suggested in the protocol.  
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Table H.1. Calculated Material Requirements for Chromatography Buffers. Compositions 
and volumes required were obtained from the HisPur® Superflow Agarose resin vendor sheet. 
Masses required were calculated using the maximum protocol volumes listed.  
 
 
𝐶𝑜𝑙𝑢𝑚𝑛  𝑟𝑢𝑛 𝑡𝑖𝑚𝑒 = 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 ∙
1
𝑙𝑖𝑛𝑒𝑎𝑟 𝑓𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 ∙ 𝑐𝑜𝑙𝑢𝑚𝑛 𝑐𝑟𝑜𝑠𝑠 𝑠𝑒𝑐𝑡𝑖𝑜𝑛
          (𝐻. 4) 
 
𝐶𝑜𝑙𝑢𝑚𝑛 𝑟𝑢𝑛 𝑡𝑖𝑚𝑒 =
689,000 𝑚𝐿
150
𝑐𝑚
ℎ𝑟
∗ (14 𝑐𝑚)2 ∗ 𝜋
= 7.46 ℎ𝑟 
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Appendix I: Hydrophobic Interaction Chromatography Sizing and Timing 
The hydrophobic interaction chromatography column size and volumes of solution needed 
were calculated according to the protocol for the POROS Benzyl HIC Resin. Note that endotoxin 
here is denoted as LPS. The given binding capacity of the resin (2×106 endotoxin units per mL of 
resin) and the mass of endotoxin entering the column were used to calculate the volume of resin 
required per batch. This unit disregards any endotoxin loss that may have occurred in the past few 
steps.  Random packing was assumed with a void fraction of 0.40 as no other data could be found 
in the literature. The column volume was calculated as follows: 
𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒 =
𝐸𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 𝑚𝑎𝑠𝑠 𝑖𝑛𝑡𝑜 𝑡ℎ𝑒 𝑐𝑜𝑙𝑢𝑚𝑛 (𝑔)
𝑏𝑎𝑡𝑐ℎ
∙ 𝐵𝑖𝑛𝑑𝑖𝑛𝑔 𝐶𝑎𝑝𝑎𝑐𝑖𝑡𝑦                   (𝐼. 1) 
 
For α-N-acetylgalactosaminidase: 
 
11.5
𝑔 𝐿𝑃𝑆
𝑏𝑎𝑡𝑐ℎ
∙
1 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛
2 × 106𝐸𝑈
∙
1 𝐿 𝑟𝑒𝑠𝑖𝑛
1000 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛
∙
1 𝐸𝑈
1 × 10−10 𝑔 𝐿𝑃𝑆
=  57.5
𝐿
𝑏𝑎𝑡𝑐ℎ
 
 
𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =
𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
𝑏𝑎𝑡𝑐ℎ
∙
1
1 − 𝑉𝑜𝑖𝑑 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛
             (𝐼. 2) 
 
57.5 𝐿 ∙
1
1 − 0.40
= 95.8 𝐿 
 
The data sheet for the resin allows for 10 regenerations before resin must be replaced. The 
amount of resin needed on an annual basis was calculated as follows: 
 
𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑
𝑦𝑒𝑎𝑟
=
𝑅𝑒𝑠𝑖𝑛 
 𝐵𝑎𝑡𝑐ℎ
∙
𝐵𝑎𝑡𝑐ℎ𝑒𝑠
𝑦𝑒𝑎𝑟
∙
1
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔
    (𝐼. 3) 
 
𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 = 57.5 
𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
∙ 112 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙
1
10 
=  644 𝐿 𝑟𝑒𝑠𝑖𝑛 
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For α-galactosidase: 
 
10.6
𝑔 𝐿𝑃𝑆
𝑏𝑎𝑡𝑐ℎ
∙
1 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛
2 × 106𝐸𝑈
∙
1 𝐿 𝑟𝑒𝑠𝑖𝑛
1000 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛
∙
1 𝐸𝑈
1 × 10−10 𝑔 𝐿𝑃𝑆
=  52.9
𝐿
𝑏𝑎𝑡𝑐ℎ
 
 
𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =
𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
𝑏𝑎𝑡𝑐ℎ
∙
1
1 − 𝑉𝑜𝑖𝑑 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛
 
 
52.9 𝐿 𝑟𝑒𝑠𝑖𝑛 ∙
1
1 − 0.40
= 88.2 𝐿 
 
Assuming that we use new resin when switching over to the production of α-galactosidase the 
calculations for the total amount of resin needed on an annual basis for processing α-galactosidase.  
 
𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑
𝑦𝑒𝑎𝑟
=
𝑅𝑒𝑠𝑖𝑛 
 𝐵𝑎𝑡𝑐ℎ
∙
𝐵𝑎𝑡𝑐ℎ𝑒𝑠
𝑦𝑒𝑎𝑟
∙
1
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔
 
 
𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 = 52.9 
𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
∙ 2 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙
1
10 
=  10.6 𝐿 𝑟𝑒𝑠𝑖𝑛 
 
A conservative approach was used in calculating the batch time and amount of buffer 
needed, by using the maximum column volumes of buffer suggested in the protocol.  
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Table I.1. Calculated Material Requirements for Chromatography Buffers. Compositions 
and volumes required were obtained from the POROS Benzyl HIC Resin vendor sheet. Masses 
required were calculated using the maximum protocol volumes listed.  
 
𝐶𝑜𝑙𝑢𝑚𝑛  𝑟𝑢𝑛 𝑡𝑖𝑚𝑒 = 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 ∗
1
𝑙𝑖𝑛𝑒𝑎𝑟 𝑓𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 ∗ 𝑐𝑜𝑙𝑢𝑚𝑛 𝑐𝑟𝑜𝑠𝑠 𝑠𝑒𝑐𝑡𝑖𝑜𝑛
     (𝐼. 4) 
 
𝐶𝑜𝑙𝑢𝑚 𝑟𝑢𝑛 𝑡𝑖𝑚𝑒 =
3,532,200 𝑚𝐿
150
𝑐𝑚
ℎ𝑟
∗ (40 𝑐𝑚)2 ∗ 𝜋
= 4.68 ℎ𝑟 
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Appendix J: Endotoxin Affinity Chromatography Sizing and Timing 
The endotoxin affinity chromatography column size and volumes of solution needed were 
calculated according to the manufacturer’s protocol for the Pierce High Capacity Endotoxin 
Removal Resin. Note that endotoxin here is denoted as LPS. The given binding capacity of the 
resin (2×106 endotoxin units per mL of resin) and the mass of endotoxin entering the column were 
used to calculate the volume of resin required per batch. The void fraction of the resin packaging 
is 0.40 according to the manufacturer’s protocol. The column volume was calculated as follows: 
𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒 =
𝐸𝑛𝑑𝑜𝑡𝑜𝑥𝑖𝑛 𝑚𝑎𝑠𝑠 𝑖𝑛𝑡𝑜 𝑡ℎ𝑒 𝑐𝑜𝑙𝑢𝑚𝑛 (𝑔)
𝑏𝑎𝑡𝑐ℎ
∙ 𝐵𝑖𝑛𝑑𝑖𝑛𝑔 𝐶𝑎𝑝𝑎𝑐𝑖𝑡𝑦                       (𝐽. 1) 
 
For α-N-acetylgalactosaminidase: 
 
1.15
𝑔 𝐿𝑃𝑆
𝑏𝑎𝑡𝑐ℎ
∙
1 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛
2 × 106𝐸𝑈
∙
1 𝐿 𝑟𝑒𝑠𝑖𝑛
1000 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛
∙
1 𝐸𝑈
1 × 10−10 𝑔 𝐿𝑃𝑆
=  5.75
𝐿
𝑏𝑎𝑡𝑐ℎ
 
 
𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =
𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
𝑏𝑎𝑡𝑐ℎ
∙
1
1 − 𝑉𝑜𝑖𝑑 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛
            (𝐽. 2) 
 
5.75 𝐿 ∙
1
1 − 0.40
= 9.58 𝐿 
 
The data sheet for the resin allows for 10 regenerations before resin must be replaced. The 
amount of resin needed on an annual basis was calculated as follows: 
 
𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑
𝑦𝑒𝑎𝑟
=
𝑅𝑒𝑠𝑖𝑛 
 𝐵𝑎𝑡𝑐ℎ
∙
𝐵𝑎𝑡𝑐ℎ𝑒𝑠
𝑦𝑒𝑎𝑟
∙
1
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔
       (𝐽. 3) 
 
𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 = 5.75 
𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
∙ 112 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙
1
10 
=  64.4 𝐿 𝑟𝑒𝑠𝑖𝑛 
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For α-galactosidase: 
 
1.06
𝑔 𝐿𝑃𝑆
𝑏𝑎𝑡𝑐ℎ
∙
1 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛
2 × 106𝐸𝑈
∙
1 𝐿 𝑟𝑒𝑠𝑖𝑛
1000 𝑚𝐿 𝑟𝑒𝑠𝑖𝑛
∙
1 𝐸𝑈
1 × 10−10 𝑔 𝐿𝑃𝑆
=  5.29
𝐿
𝑏𝑎𝑡𝑐ℎ
 
 
𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =
𝑅𝑒𝑠𝑖𝑛 𝑉𝑜𝑙𝑢𝑚𝑒
𝑏𝑎𝑡𝑐ℎ
∙
1
1 − 𝑉𝑜𝑖𝑑 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛
 
 
5.29 𝐿 𝑟𝑒𝑠𝑖𝑛 ∙
1
1 − 0.40
= 8.82 𝐿 
 
Assuming that we use new resin when switching over to the production of α-galactosidase, the 
calculations for the total amount of resin needed on an annual basis for processing α-galactosidase.  
 
𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑟𝑒𝑠𝑖𝑛 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑
𝑦𝑒𝑎𝑟
=
𝑅𝑒𝑠𝑖𝑛 
 𝐵𝑎𝑡𝑐ℎ
∙
𝐵𝑎𝑡𝑐ℎ𝑒𝑠
𝑦𝑒𝑎𝑟
∙
1
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔
 
 
𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑛𝑒𝑒𝑑𝑒𝑑 = 5.29 
𝐿 𝑟𝑒𝑠𝑖𝑛
𝑏𝑎𝑡𝑐ℎ
∙ 2 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙
1
10 
=  1.06 𝐿 𝑟𝑒𝑠𝑖𝑛 
 
A conservative approach was used in calculating the batch time and amount of buffer 
needed, by using the maximum column volumes of buffer suggested in the protocol.  
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Table J.1. Calculated Material Requirements for Chromatography Buffers. Compositions 
and volumes required were obtained from the Pierce High Capacity Endotoxin Removal Resin 
vendor sheet. Masses required were calculated using the maximum protocol volumes listed.  
 
𝐶𝑜𝑙𝑢𝑚𝑛  𝑅𝑢𝑛 𝑡𝑖𝑚𝑒 = 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 ∗
1
𝑙𝑖𝑛𝑒𝑎𝑟 𝑓𝑙𝑜𝑤 𝑟𝑎𝑡𝑒 ∗ 𝑐𝑜𝑙𝑢𝑚𝑛 𝑐𝑟𝑜𝑠𝑠 𝑠𝑒𝑐𝑡𝑖𝑜𝑛
      (𝐽. 4) 
 
𝐶𝑜𝑙𝑢𝑚𝑛 𝑟𝑢𝑛 𝑡𝑖𝑚𝑒 =
499,090 𝑚𝐿 + 55,600 𝑚𝐿
150
𝑐𝑚
ℎ𝑟
∗ (20 𝑐𝑚)2 ∗ 𝜋
= 3.01 ℎ𝑟 
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Appendix K: Endotoxin Level Calculation 
 According to both manufacturer’s protocols, there is a 99% removal of endotoxin using the 
POROS Benzyl HIC Resin and the Pierce High Capacity Endotoxin Removal Resin. However, 
literature values report that the removal is actually closer to 90% in practice for the POROS Benzyl 
HIC Resin. Thus, we assume that after each pass, 90% of the endotoxins are removed through the 
hydrophobic interaction column and 99% through the endotoxin affinity chromatography column. 
To be more stringent on the purity of our final product, we also assume that the 
ultrafiltation/diafiltration step does not change the endotoxin concentration in the product solution. 
This assumption is valid given that the endotoxins and the enzymes are all similar in molecular 
weight and that there no filtration units that can provide decent separation. We also assume that 
the product solution will undergo two passes through a bulk filtration step to further remove any 
remaining endotoxins and impurities, each with an assumed 99% removal. Lastly, we for the 
design of the chromatography columns, we assume that none of the endotoxin that was produced 
in the original E. coli microbial culture that was introduced into downstream purification has been 
lost. This is done to ensure that the chromatography column is designed to handle the highest 
possible amount of endotoxin mass to treat. The final product solution will have a concentration 
of 1 mg/mL. 
A sample calculation for the production of α-N-acetylgalactosaminidase, which has a 
higher endotoxin mass yield from the E. coli culture, is shown. The mass yield of α-N-
acetylgalactosaminidase is 205 grams per batch. 
11.5
𝑔 𝐿𝑃𝑆
𝑏𝑎𝑡𝑐ℎ
∙ 0.10 ∙ 0.01 ∙ 0.01 ∙ 0.01 ∙
1 𝐸𝑈
10−10𝑔 𝐿𝑃𝑆
∙
1
205,000 𝑚𝐿
= 0.056
𝐸𝑈
𝑚𝐿
 
This final values complies with FDA limitations. 
 
227 
 
Appendix L: Cryogel-based Affinity Chromatography Sizing and Timing 
 
The material composition of the cryogel used in the column is outlined in Table L.1. The 
preparation of the affinity matrix by coupling of protein A to the cryogel packed into the 
chromatography is outlined in Table L.2. Lastly, Table L.3 gives the composition of the storage 
solution used to preserve the cryogel in the column. 
Table L.1. Materials required for the synthesis of the cryogel used in the affinity chromatography 
of RBCs. 
 
 
Table L.2. Materials required for the coupling of protein A to the cryogel. 
 
 
Material
Degassed water 100 mL
DMAAm 6.3 mL
AGE 0.85 mL
MBAAm 2.2 g
APS 110 mg
TEMED 95 uL
Total volume 107.245 mL
Cryogel Composition
Amount
Component
Water 86 L water/L gel
Ethanol 14 L EtOH/L gel
Na2CO3 2 moles/L gel
Ethylenediamine 5 moles/L gel
Sodium phosphate 1 moles/L gel
Glutaraldehyde 0.5 L glutaraldehyde/L water
Protein A 16 g protein A/L gel
Sodium borohydride 1 moles/L gel
Water 40 L water/L gel
Protein A Cryogel Coating Composition
Reagent:Gel ratio
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Table L.3. Composition of the storage solution used to preserve the cryogel. 
 
 Given that the cryogel-based affinity chromatography column was originally used to 
handle B lymphocytes from whole blood, a volumetric ratio was determined between B 
lymphocytes and RBCs to approximate what volume of RBCs the column could be treated via this 
cell separation technique. In this mathematical approach, lymphocytes are modeled as spheres and 
RBCS as cylinders. The radii are 7 µm and 4 µm, respectively. The height of an RBC is 
approximately 2 µm. This assumption is valid given that the blood that the RBC treatment process 
handles only contains RBCs whereas the blood sample in the literature that was used in the column 
only had B lymphocytes. Neither sample contains additional cell populations that may affect the 
volumetric ratio. 
B lymphocyte volume: 
𝑉𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒 =
4
3
𝜋𝑟3                                                         (𝐿. 1) 
𝑉𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒 =
4
3
𝜋(7𝜇𝑚)3 = 1,437 𝜇𝑚3  
RBC volume: 
𝑉𝑅𝐵𝐶 = 𝜋𝑟
2ℎ                                                                  (𝐿. 2) 
𝑉𝑅𝐵𝐶 = 𝜋(4𝜇𝑚)
2(2𝜇𝑚) = 100.5 𝜇𝑚3  
 
Component
Sodium phosphate 1 moles/L gel
Ethanol 2 L EtOH/L gel
Water 8 L water/L gel
Reagent:Gel ratio
Cryogel-Protein A Complex Storage Solution
 
229 
 
The fold-difference between the two is: 
𝑉𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒
𝑉𝑅𝐵𝐶
= 14.3 
The current plant design expects to produce three batches of universal RBCs per week, for a total 
of 156 batches throughout the year. To be conservative, it is assumed that no RBCs have been lost 
yet due to the previous unit operations. This maximizes the amount of cryogel that needs to be 
prepared, providing the upper bound on cost estimates. The amount of cryogel required to treat 
one batch of RBCs under this set up is: 
𝐶𝑟𝑦𝑜𝑔𝑒𝑙 𝑣𝑜𝑙𝑢𝑚𝑒
𝑏𝑎𝑡𝑐ℎ
=
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑅𝐵𝐶𝑠 𝑡𝑜 𝑏𝑒 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑝𝑒𝑟 𝑏𝑎𝑡𝑐ℎ 
# 𝑅𝐵𝐶𝑠 𝑝𝑟𝑜𝑐𝑒𝑠𝑠𝑒𝑑
𝑚𝐿 𝑔𝑒𝑙
                                 (𝐿. 3) 
 
𝐶𝑟𝑦𝑜𝑔𝑒𝑙 𝑣𝑜𝑙𝑢𝑚𝑒
𝑏𝑎𝑡𝑐ℎ
=
307,693 𝑅𝐵𝐶 𝑢𝑛𝑖𝑡𝑠 ∙ 0.3
𝐿 𝑏𝑙𝑜𝑜𝑑
𝑅𝐵𝐶 𝑢𝑛𝑖𝑡
∙
5 ∙ 1012 𝑅𝐵𝐶𝑠
1 𝐿 𝑏𝑙𝑜𝑜𝑑
∙
1
156 𝑏𝑎𝑡𝑐ℎ𝑒𝑠
3 ∙ 1010𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒𝑠
𝑚𝐿 𝑔𝑒𝑙
∙
𝑉𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒
1 𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒
∙
14.3 𝑉𝑅𝐵𝐶
𝑉 𝑙𝑦𝑚𝑝ℎ𝑜𝑐𝑦𝑡𝑒
∙
1 𝑅𝐵𝐶
 𝑉𝑅𝐵𝐶
 
 
𝐶𝑟𝑦𝑜𝑔𝑒𝑙 𝑣𝑜𝑙𝑢𝑚𝑒
𝑏𝑎𝑡𝑐ℎ
=
2.96 × 1015
𝑅𝐵𝐶𝑠
𝑏𝑎𝑡𝑐ℎ
4.29 × 1011
𝑅𝐵𝐶𝑠
𝑚𝐿 𝑔𝑒𝑙
 
 
𝐶𝑟𝑦𝑜𝑔𝑒𝑙 𝑣𝑜𝑙𝑢𝑚𝑒
𝑏𝑎𝑡𝑐ℎ
= 6,896 𝑚𝐿 ≈ 6.90 𝐿 
 
It is recommended that the cryogel occupy below 50% of the total column volume. Therefore: 
𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑐𝑜𝑙𝑢𝑚𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑜𝑛𝑒 𝑏𝑎𝑡𝑐ℎ =
𝐶𝑟𝑦𝑜𝑔𝑒𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑝𝑒𝑟 𝑏𝑎𝑡𝑐ℎ
1 − 0.5
                         (𝐿. 4) 
 
6.90 𝐿
1 − 0.50
= 13.8 𝐿 
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We assume that the cryogel complex can be used five times before requiring replacement. 
Therefore, the total volume of cryogel needed for the 156 planned batches of production is: 
 
𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑐𝑟𝑦𝑜𝑔𝑒𝑙 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑
𝑦𝑒𝑎𝑟
=
𝐶𝑟𝑦𝑜𝑔𝑒𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 
 𝐵𝑎𝑡𝑐ℎ
∙
𝐵𝑎𝑡𝑐ℎ𝑒𝑠
𝑦𝑒𝑎𝑟
∙
1
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑈𝑠𝑒𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝐷𝑖𝑠𝑐𝑎𝑟𝑑𝑖𝑛𝑔
  (𝐿. 5) 
 
𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑖𝑛 𝑐𝑟𝑦𝑜𝑔𝑒𝑙 𝑛𝑒𝑒𝑑𝑒𝑑 = 6.90 
𝐿 𝑐𝑟𝑦𝑜𝑔𝑒𝑙
𝑏𝑎𝑡𝑐ℎ
∙ 156 𝑏𝑎𝑡𝑐ℎ𝑒𝑠 ∙
1
5 
=  215 𝐿 𝑐𝑟𝑦𝑜𝑔𝑒𝑙 
 
A conservative approach was used in calculating the batch time and amount of buffer 
needed, by using the maximum column volumes of buffer suggested in the protocol.  
 
Table L.1. Calculated Material Requirements for Chromatography Buffers. Compositions 
and volumes required were obtained from the HisPur® Superflow Agarose resin vendor sheet. 
Masses required were calculated using the maximum protocol volumes listed.  
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Appendix M: Utility Requirements for the Refrigerated Room 
Assumptions: 
1. Conduction was assumed to obey Fourier’s law.  
2. Thermal resistance values (R-values) were adapted from values given in a paper titled 
“Design of Cooling Facilities: Structure and Energy Requirements”; the R-values used are 
for standard cold room construction materials. 
3. The heat load for the cold room was determined as the amount of heat that would travel 
through the walls, floor, and ceiling due to conduction. 
4. An outside temperature of 21°C (69.8°F) was assumed, as the cold room is located in the 
interior of the facility. 
5. Service load, or field heat, accounting for lighting requirements, equipment requirements, 
and transport of equipment, laborers, and humid air into and out of the cold room, was 
assumed to be 10% of the total heat conduction 
 
Three separate cold rooms are required for this process design: one for the downstream purification 
of the enzymes, another for the RBC treatment process, and a third to store pre-converted and 
converted RBC transfusion units. The three processes will be kept separate from each other to 
prevent any type of cross-contamination. For design purposes, it is assumed that all three cold 
rooms will have the same dimensions. The size of the cold room is estimated to be 900 ft2, with 
dimensions of 30 ft x 30 ft x 8 ft (W x D x H). Total energy requirement was calculated by summing 
heat conduction and service load. The energy requirement in kWh was calculated assuming 365 
days/year of cold room operation. Cold room refrigeration calculations are summarized in Table 
M.1. 
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Table M.1. All parameters required to calculate the utilities requirements for the designed cold 
rooms. . 
 
Room Width 30 ft
Room Depth 30 ft
Room Height 8 ft
Inside Temperature 39.2 ºF
Outside Temperature 69.8 ºF
Temperature Difference 30.6 ºF
Walls 16 sq. ft-ºF-hr/BTU
Ceiling 20 sq. ft-ºF-hr/BTU
Floor 11 sq. ft-ºF-hr/BTU
Walls 1836 BTU/hr
Ceiling 1377 BTU/hr
Floor 2504 BTU/hr
Total without service load 5717 BTU/hr
Total service load 572 BTU/hr
Total heat 6288 BTU/hr
Price of Electricity 0.0514 ($/kWh)
Total Heat 1.843 kW
Total Power Requirement 16145 kWh
Total Cost of Refrigeration 830 dollars
Price Calculations
Cold Room Dimensions
Temperature Conditions
R-Values
Total Heat Calculations
Heat Conduction
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Appendix N: Flow Cytometry Quality Control Analysis Representation 
Flow cytometry will be employed to determine cleavage of A and B antigens from ECO-A and 
ECO-B RBCs produced. It also counts the number of individual cells and register their respective 
signal intensities. This data will be analyzed using FloJo® FACS software. The information 
provided by flow cytometry should show that <1% of the treated RBC population have a signal 
corresponding to blood group antigens. If a sample fails this quality control test, the batch will 
either be re-treated or discarded. 
 
 
Figure N.1. Expected flow cytometry quality control data for (A) ECO-A and (B) ECO-B 
RBCs. Flow cytometry measures signal intensity given off by antibodies conjugated with 
fluorophores. Anti-blood Group A and anti-blood group B antibodies will be mixed with 
enzymatically converted RBC units for one hour at room temperature to allow for specific binding 
to blood group antigens. Successful conversion will be determined by signal similarities to pure 
type-O blood cells – only background noise should be registered. Graphically, this is represented 
as all the A- and B-ECO signals overlapping with the signal registered from type O-cells.  
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Sensitive FACS/flow cytometry analysis may be conducted with anti-A and anti-B 
antibodies. Analysis using FDA-licensed Anti-A blood group reagents should demonstrate total 
cleavage of A antigen from ECO-A RBCs; similarly, FDA-licensed anti-B reagents should not 
react or cleave antigen from ECO-B RBCs. Flow cytometry performed with anti-H antibody 
should show exposure of the H antigen on ECO-A and ECO-B RBCs at similar levels to WT O 
RBCs. ECO-A RBCs should then have characteristic peaks that align with those of native type-O 
RBCs, while any A and B control RBCs should have peaks characteristic of A and B RBCs.  
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Appendix O: TLC Quality Control Analysis Representation 
 
 
Figure O.1. Representative image of expected results of TLC/SDS-PAGE Western blot analysis 
of (a) ECO-A and (b) ECO-B RBC glycolipid extracts. 
 
Thin layer chromatography (TLC) and SDS-PAGE Western blot will be conducted as additional 
quality control tests on treated RBCs’ glycobiology (sugar groups). (A) Western blot analysis of 
glycoprotein extracts from enzymatically converted cells should demonstrate no presence of 
glycolipids active in A antigen (Aa, Ab , and Ac) and exposure of glycolipids common to native O 
RBCs (H1, H2 , and H3). (B) Similarly, ECO-B RBC glycolipid extracts should only show 
expression of O glycolipids, not B glycolipids (B1, B2, and B3).  
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Appendix P: Adsol-1 (AS-1) Composition 
 
Table P.1: Composition of Adsol-1 (AS-1) preservative solution that will be used to package 
and store RBCs. AS-1 consists of two major components: anticoagulant reagents that prevent 
agglutination and additional reagents that increase RBC shelf life. This preservative solution 
allows RBCs to be stored for 42 days at 4ºC. The full name of the preservative solution is CPDA-
1 Anticoagulant Citrate Phosphate Dextrose Adenine Solution USP. 
 
 
 
 
 
 
 
Components
Sodium Citrate (dihydrate) 26.3 g/L
Anticoagulant and Preservatives Dextrose (monohydrate) 25.5 g/L
Citric Acid (anhydrous) 3.27 g/L
Monobasic Sodium Phosphate (monohydrate) 2.22 g/L
Sodium Chloride 0.900 g/L
Mannitol 0.750 g/L
Adenine 0.275 g/L
Concentration
CPDA-1 Anticoagulant Solution USP
AS-1 additives
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Appendix S: Quattroflow Quaternary Diaphragm Blueprints 
 
 
 
 
 
 
 
Appendix: 
Literature Sources & Prompt 
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IntroDuctIon
Preparative cell separation is an important tool to provide a highly 
purified population of specific cell type for diagnostic, biotech-
nological and biomedical applications1. However, challenges 
remain associated in the development of effective methods for 
cell separation on a large scale. An effective cell separation tech-
nique should deliver high purity and yield while maintaining 
cell function. There are two basic approaches to separate cells. 
The first type is based on physicochemical properties such as size 
(centrifugal elutriation and density gradient centrifugation), density 
(density gradient centrifugation), light scattering properties (cell 
sorter), membrane potential, pH, electrical impedance and charge 
(aqueous two-phase system and free-flow electrophoresis)1–3. 
Methods of the first type are commonly used for prepurification 
and concentration, but have low specificity and are difficult to 
process on a large scale.
The second approach is more specific, is based on affinity inter-
actions, and uses cell-surface molecules. Methods that follow this 
approach include cell isolation on affinity matrices4,5. In flow 
cytometry, target cells are labeled with an immunofluorescent 
tag. The technique is accurate but can be time consuming and 
expensive6–8. Similarly, magnetic bead separation technology9–11 
has received attention within the fields of biomedical sciences. 
Automated magnetic cell sorters are available that can process 
up to 50 ml of sample volume, but the process is quite expensive 
and different affinity matrices are required for the separation 
of different cells. Other cell separation methods have also been 
developed, such as aqueous two-phase systems12,13 that are based 
on specific partition of cells in two immiscible aqueous polymer 
solutions. This technique can be used for cell separation on a pre-
parative scale, but it requires repetitive extractions of target product 
to achieve desirable selectivity.
Cell affinity chromatography provides an efficient method 
for preparative-scale cell separation. The main requirement for 
cell affinity chromatography is the design of a suitable matrix. 
Hence, chromatography columns can be either bead packed or 
monolithic.
Bead-packed chromatography column
The chromatography column is comprised of granular beads 
of similar or varying sizes. Fluidized bed chromatography, e.g., 
expanded bed affinity adsorption (EBA), has shown great promise 
for a preparative-scale cell separation technique, in which the sta-
tionary phase is in the form of a fluidized bed made up of spherical 
beads14,15. In one such example, an immunoaffinity EBA technique 
was used for the separation of monocytes from human peripheral 
blood15. The limitations associated with this technology have been 
high shear stress for cells, long equilibration time, requirements for 
large special columns, narrow range of flow velocity and detach-
ment of bound cells. Furthermore, conventional chromatographic 
adsorbents such as agarose16 or silica17, used in EBA, can cause 
nonspecific interactions. The technique also suffers from the 
inherent limitations of bead-packed chromatography, which 
include the relatively time-consuming column-packing process 
and the slow rate of diffusion of solutes within the pores of the 
bead matrix. Hence, there has been an essential need for designing 
suitable chromatographic matrix or adsorbents and an efficient 
approach for the preparative cell separation process.
Monolithic chromatography columns
These columns have a continuous matrix rather than beads with 
porous channels. The desired ways of designing such columns can 
be the development of macroporous chromatographic matrices 
with interconnected pores that are large enough (much bigger than 
the cell size), allowing unhindered movement of large particles such 
as mammalian cells. Moreover, chromatographic matrices should 
govern the convective mass transport of particles, which is possible 
if the columns are monolithic.
Therefore, new methods are desirable for the production 
of hydrophilic macroporous material with a sufficiently large 
pore size by displacing soluble polymeric chains from a porous 
network to the walls of pores so that there will be high local poly-
mer concentration in the pore walls (compared with hydrophilic 
non-macroporous gels). This high local polymer concentration 
Cell separation using cryogel-based affinity 
chromatography
Ashok Kumar & Akshay Srivastava
Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kanpur, India. Correspondence should be addressed to A.K.  
(ashokkum@iitk.ac.in).
Published online 7 October 2010; doi:10.1038/nprot.2010.135
In cell affinity chromatography, type-specific cell separation is based on the interaction between cell-surface receptors and 
an immobilized ligand on a stationary matrix. this protocol describes the preparation of monolithic polyacrylamide and 
polydimethylacrylamide cryogel affinity matrices that can be used as a generic type-specific cell separation approach. the 
supermacroporous monolithic cryogel has highly interconnected large pores (up to 100 µm) for convective migration of large 
particles such as mammalian cells. In this protocol, they are functionalized to immobilize a protein a ligand by a two-step 
derivatization of epoxy-containing cryogel monolith (reaction with ethylenediamine and glutaraldehyde). target cells were labeled 
with specific antibodies and then they were captured in the cryogel through affinity with protein a. these specifically captured 
cells were recovered in high yields while retaining their viability by mechanical squeezing of the spongy and elastic cryogel 
matrices. the suggested cell separation protocol takes  < 30 min for complete separation on a preprepared protein a–immobilized 
cryogel column.
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in the pore walls provides an increasing mechanical stability 
of the material. Such materials known as supermacroporous 
monolithic ‘cryogels’ have been developed by carrying out gela-
tion or polymerization at subzero temperature under frozen 
conditions.
Supermacroporous monolithic cryogels
The process of cryotropic polymerization or gelation18 has been 
established for the development of macroporous hydrophilic gels 
known as cryogels. Although the polymeric nature of cryogel-
type materials has been under study throughout the past decade, 
their potential for biotechnological applications has been explored 
only in recent years19. Here, cryogels are specially designed from 
hydrophilic polymers for technologically challenging separation 
processes such as cell separation.
Cryotropic gelation or polymerization is a process whereby 
under frozen conditions, most of the solvent is frozen, and the dis-
solved solutes (monomers or polymer precursors) get concentrated 
in small unfrozen regions called nonfrozen liquid microphase, in 
which the polymerization or gelation proceeds. After complete 
synthesis, the melting of solvent crystals (ice, in the case of aque-
ous media) that function as porogen leaves behind a system of 
large, continuously interconnected pores. These pores function as 
capillaries and provide channels for the flow of the mobile phase 
(Fig. 1). The initial concentration of precursors in solution, their 
physicochemical properties and the freezing conditions deter-
mine the pore size of the cryogel. In contrast to traditional hydro-
gels, cryogels have a system of interconnected macropores and, 
because of the structure of pore walls formed as a result of high 
polymer concentration in nonfrozen liquid microphase, provide 
relatively higher mechanical strength. High polymer density within 
pore walls retards solvent diffusion that causes poor swelling and 
ensures elasticity of cryogels, which allows the flow of liquid at high 
flow rates with minimal flow resistance. The physical strength of 
cryogels largely depends on the polymer type and concentration 
and temperature during cryogel formation. The concentration of 
polymer in gel phase is higher in cryogels than in conventional 
gels prepared by other preparation methods. It demonstrates the 
higher mechanical stability of cryogels in spite of their macro-
porous morphology.
Cryogels are suitable for the chromatography of bioparti-
cles and cells. Inert cryogel matrices have been produced from 
different hydrophilic gel-forming polymers either by poly-
merization of the appropriate monomers (e.g., polyacrylamide 
and poly(dimethylacrylamide)) or by physical gelation (e.g., 
agarose). For bioseparation applications, these matrices provide 
the convective flow of the solution through the pores wherein 
the mass transfer resistance is practically negligible. Cryogel 
matrices also provides sufficiently high flow-through charac-
teristics; the flow rate of water through the monoliths has been 
estimated in our laboratory at a hydrostatic pressure of 0.01 
MPa and has shown a linear flow rate of 2,000–2,500 cm h − 1. 
These gels have been designed and used by our group for a vari-
ety of challenging separation applications in a monolithic chro-
matographic mode, including cell separations. The application 
of these cryogels in the area of cell separation is discussed in the 
following section.
Cell separations using supermacroporous cryogels
The protocol describes the separation of mammalian cells using a 
supermacroporous monolithic cryogel column. Cryogel monoliths 
were prepared both in the column format20 and in 96-minicolumn 
plate format21 for their application in cell chromatography. The 
pore diameter of up to 100 µm (and even larger) enables its appli-
cation for chromatography of cells of varying size (between 1 and 
15 µm) without being mechanically entrapped in the column. It 
was shown that a pulse of blood can be convectively transported by 
liquid flow through the monolithic plain cryogel column without 
any physical entrapment of blood cells (Fig. 2). Convectively trans-
ported cells do not experience large shear forces because of laminar 
flow of liquid in the interconnected pores in the monolithic cryogel. 
Cells can bind to the monolithic cryogel column through specific 
interactions with some immobilized groups (charges, hydropho-
bic moieties or affinity ligands) introduced on the surface of their 
pore walls. For example, Escherichia coli cells were captured on 
an ion-exchange monolithic cryogel column at low ionic strength 
and were then eluted with 70–80% recovery at 0.4 M NaCl concen-
tration. The same cells can also bind to a Cu(II)-coupled cryogel 
column and have been recovered using either 100 mM imidazole or 
20 mM EDTA22. Moreover, different microbial cells having different 
cell-surface properties can be specifically separated from the mixed 
population. This was demonstrated on the mixtures of wild-type 
E. coli and recombinant His-tagged E. coli cells as well as wild-type 
Polymer or monomer
solution
Ice crystals
Nonfrozen liquid microphase
Freezing of mixture at subzero
temperature (polymerization/
gelation step)
Cryogel with interconnected pores
after thawing at room temperature.
Dark patches are pores and
white patches are pore wall
Figure 1 | Cryogelation process: polymer or monomer is mixed in aqueous 
solvent and then the whole system is incubated at subzero temperature 
for cryopolymerization and/or gelation, along with ice crystal formation 
(ice crystals function as a porogen). After complete gelation, and when 
incubated at room temperature and washed with water to remove unreacted 
monomers or polymeric precursors, the ice crystals melt and leave behind 
large interconnected pores. 
1
Passage of blood through cryogel column
2 3 4
Figure 2 | Human blood is passed through a cryogel column showing the 
convective movement of large particles such as mammalian cells.
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E. coli and Bacillus halodurans cells23. This 
approach was also used for the separation 
of yeast and E. coli cells on immobilized 
concanavalin A as ligand on the cryogel 
monolith24. The cryogel matrices were also 
applied for the separation of a variety of 
bioparticles, such as inclusion bodies25, 
mitochondria26 and viruses27.
Cell affinity chromatography using supermacroporous mono-
lithic cryogels proved to be an efficient approach for the sepa-
ration of specific cell types such as T and B lymphocytes20,28. 
Antibody-based affinity interactions are remarkable and highly 
efficient as ligands for cell separation because of their great 
diversity and specificity. The interaction of antibody with 
a specific cell-surface antigen is generally used for isolation 
of a particular cell type. The concept of affinity separation 
follows either negative selection or positive selection of cells. In 
negative selection, nonspecific cells attach to the affinity ligand 
on the support matrix and the target cells pass through the 
matrix unretained. In contrast, positive selection involves the 
specific binding of target cells to the affinity adsorbent; after 
washing, bound cells can be recovered from the matrix in a 
purified form.
However, the cell affinity chromatographic method using cryo-
gels has been used here in a more generic manner. A cryogel affi-
nity matrix has been developed by covalent coupling of protein 
A on the surface of the pore wall, which can capture IgG-labeled 
specific cells. This provides an advantage over the existing 
methods of cell separation such as magnetic affinity cell sort-
ing and flow cytometry. Protein A consists of a 40- to 60-kD 
protein present in the cell wall of Staphylococcus aureus that 
has affinity to the Fc portion of the IgG from a wide range of 
species. Protein A can be covalently coupled to epoxy-activated 
cryogel monolith by two-step derivatization using function-
alization of epoxy-activated cryogel with ethylenediamine and 
then crosslinking of protein A using glutaraldehyde. The pro-
tein A-bound monolithic cryogel can be used as a generic affin-
ity adsorbent for specific antibody (IgG type)-labeled cells and 
can thus separate them from nonspecific cells in the mixture. 
After treating cells with antibodies (IgG type) to the cell-surface 
receptors, the cell mixture was loaded onto the cryogel-protein A 
column. The antibody-labeled cells bound to protein A through 
the Fc region of the labeled antibody, whereas nonlabeled cells 
remained unbound and passed through the column (Fig. 3). 
The results were compared with control experiments in which 
lymphocytes and umbilical cord blood (UCB) without anti-
body labeling were passed through both protein A–coupled and 
protein A noncoupled cryogel columns. The protocol is detailed 
in the PROCEDURE. With this separation strategy, the generic 
protocol presented here describes the separation of mammalian 
cell types, with the particular examples of fractionation of T and 
B lymphocytes from human blood buffy coat (Step 16A(i–viii) 
of PROCEDURE) and hematopoietic stem cells (CD34 + ) from 
human UCB (Step 16B(i–ix) of PROCEDURE). The established 
cell separation approach using affinity cryogels can be integrated 
in many cell-based studies and for cell-based therapy in which a 
large purified cell population is required.
Experimental design: cell separation strategy
Affinity cryogel matrix. Cryogel matrices were developed in 
monolithic format to provide a suitable chromatography matrix 
for cell separation. Two different matrices were developed on 
the basis of acrylamide (AAm) derivatives such as AAm and/ 
or N,N-dimethyl acrylamide (DMAAm). Both of the cryogels 
developed can be used as cell separation matrix. The epoxy 
group was incorporated by copolymerization with allylglycidyl 
ether (AGE). The final optimum concentration of monomers 
can vary from 5% to 6% (wt/vol). Above this concentration of 
monomers, the optimum pore size for convective movement of 
cells in the cryogel decreases; below this concentration, the cryo-
gel formed does not have enough mechanical strength and does 
not retain its shape. The freezing temperature is very critical 
for cryogel synthesis. Here, the cryogel was prepared at  − 12 °C 
to provide a sufficiently large pore size. However, the cryogel 
can be prepared at a temperature range of  − 10 to  − 15 °C. 
Below  − 15 °C, the pore size of the cryogel decreases and 
above  − 10 °C the developed gels become loose with low poro-
sity. The cryogel matrix was covalently coupled with protein A 
(ligand) to capture different cell types labeled with a specific IgG 
antibody. Scanning electron microscopy images of the prepared 
cryogel should be taken to check the pore size of the synthe-
sized column. The pore size should be 50–100 µm. The water 
flow parameter should also be checked for its applicability 
to chromatography. The volumetric flow rate of the aqueous 
solvent should be around 5–8 ml min − 1. The synthesized cryo-
gel column should be properly packed in a syringe without any 
leakage (refer to TROUBLESHOOTING table).
Target cells attached to
protein A–coupled
cryogel matrix
Washing unbound cells
after 10 min incubation
Protein A–coupled
cryogel affinity column Elution of cells by
a) mechanical deformaton
of matrix
OR
b) immunoglobulin solution
Loading antibody-incubated
mixture on the top of affinity
cryogel column
Cell population
+
Target cells
Protein A
Antibody
Figure 3 | The cell separation strategy used for 
stem cell separation from umbilical cord blood. 
Monoclonal antibody was incubated with cell 
population to label a specific cell type. The cell 
population containing the labeled target cells 
was then passed through a protein A–coupled 
epoxy-activated cryogel column. After 10 min of 
incubation, the affinity column was washed with 
buffer to remove unbound cells. The target cells 
bound on the affinity cryogel column were then 
eluted by mechanical squeezing of the affinity 
cryogel matrix as shown in Figure 4.
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Cell binding. All the cell chromatography experiments were con-
ducted under sterile conditions and inside a cell culture biosafety 
laminar hood. Cells were incubated with a specific antibody, e.g., 
goat anti-human IgG and anti-human CD34 + . Labeled cells were 
then applied to a protein A–coupled cryogel column. Here, the 
cells were labeled before chromatography; this approach enhances 
the binding capacity of cells. Labeling the matrix with an anti-
body before chromatography can cause disorientation of the 
bound antibody, which does not provide an accessible antigen-
binding fragment (F
ab
) for efficient cell binding. The cell bind-
ing on the protein A–monolithic cryogel column was carried out 
as presented schematically in Figure 3. As a control experiment, 
lymphocytes and UCB without antibody labeling were passed 
through both protein A–coupled cryogel column and cryogel 
column without protein A. The detailed protocol is presented in 
the PROCEDURE.
Cell recovery. Target cells were recovered by two different 
approaches:
Treatment with immunoglobulin (Ig) solution: In this approach, 
cells can be specifically eluted. The fresh solution of second-
ary antibody was passed through the affinity cryogel matrix 
bound with targeted cells. This step causes desorption of bound 
cells because of its displacement with a higher-affinity secondary 
antibody.
Mechanical deformation of cryogel matrix: The recovery 
of captured cells was carried out by the compression of an 
affinity cryogel matrix to ~50% of its original length and the 
collection of squeezed liquid. Thereafter, the compression force 
was released and the compressed affinity matrix was reswollen 
with buffer to regain its original size and shape, followed by 
immediate flow of buffer (10 ml) at a flow rate of 2 ml min − 1 
(Fig. 4).
The developed protocol for cell separation will remain the same 
for all cell types. The step that might need optimization for some 
cell types is the one that involves preclarification of unwanted 
•
•
cells from the mixture to increase the binding and recovery of 
cells after binding (see Box 1). As proposed in the above-men-
tioned cell recovery process, cells can be recovered by 50% com-
pression of the cryogel column with a subsequent buffer wash. 
However, for the separation of other cell types, it is possible that 
compression percentages could be more (~80%) or a little less 
(~30%) than what is proposed in PROCEDURE Step 16A(viii) 
and B(ix).
An unlabeled sample mixture of cells is an appropriate control 
to run in parallel to the chromatography of cells. It should pass 
through the protein A–coupled cryogel column, and retention 
of these unlabeled cells should be compared with that of the 
labeled sample. The obvious result of the control experiment is 
that there should not be any nonspecific binding of cells in the 
cryogel column. In the present protocol, as a control experiment, 
lymphocytes without antibody labeling were passed through 
both a protein A–cryogel column and a cryogel column without 
protein A.
50% compression by
∆
I =
 50%
Piston
Affinity cryogel
monolith containing
specific cell type
Squeezed liquid
containing cells
Removal of external
force
Reswelling by addition
of buffer
Liquid flow
containing cells
Figure 4 | Mechanical squeezing of the cryogel matrix for the recovery 
of bound cells. Affinity-bound cells on cryogel matrix were removed by 
compressing the cryogel column to up to 50% of its original length by using 
an external piston that squeezes out the liquid that contains cells. In the 
next step, the buffer was added to reswell the affinity cryogel matrix and 
then the column was flushed with fresh cold buffer.
 Box 1 | PreParation and ConCentration of mononuClear Cells or  
lymPhoCytes 
1. Add Ficoll-Paque PLUS (3 ml) to the centrifuge tube.
2. Carefully add a layer of diluted blood sample (4 ml) over Ficoll-Paque PLUS.
3. Centrifuge at 400g for 30–40 min at 18–20 °C.
4. Pipet out the upper layer using a clean Pasteur pipette, leaving the lymphocyte layer undisturbed at the interface. Do not disturb 
the lymphocyte layer.
5. Now draw off the lymphocyte layer to a clean centrifuge tube by using a clean Pasteur pipette. It is critical to remove all the  
material at the interface but in a minimum volume.
! cautIon Removing excess Ficoll-Paque PLUS causes granulocyte contamination; removing excess supernatant results in platelet 
contamination.
6. Add at least three volumes (6 ml total) of balanced salt solution to the lymphocyte-concentrated sample in the test tube and  
gently suspend cells using a Pasteur pipette.
7. Centrifuge at 60–100g for 10 min at 18–20 °C.
8. Discard the supernatant.
9. Suspend cells in 6–8 ml of balanced salt solution by gently drawing them in and out using a Pasteur pipette.
10. Repeat Steps 7–8, and the lymphocyte-concentrated cell suspension should now be suspended in the medium appropriate to  
the application.
 crItIcal step To obtain a sufficiently pure preparation of lymphocytes, recentrifugation with Ficoll-Paque can be necessary to 
remove contaminating red blood cells. When layering the sample, do not mix the Ficoll-Paque PLUS and the diluted blood sample.
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MaterIals
REAGENTS
Acrylamide (AAm, ≥99% (wt/wt); Sigma-Aldrich, cat. no. A9099, CAS no. 
79-06-1) ! cautIon It is an irritant, and is very toxic if inhaled, if it comes 
in contact with skin, and if swallowed.
N,N′-Dimehtylacrylamide (DMAAm, 99%; Sigma-Aldrich, cat. no. 274135, 
CAS no. 2680—03-7) ! cautIon It is toxic if inhaled; use eyeshields, 
faceshields, full-face respirator, and gloves while handling.
N,N′-methylenebisacrylamide (MBAAm, ≥98%; Sigma-Aldrich, cat. no. 
M7279, CAS no. 110-26-9) ! cautIon It is an irritant, and is very toxic if 
inhaled, if it comes in contact with skin, and if swallowed.
Allylglycidyl ether (AGE,  > 99%; Sigma-Aldrich, cat. no. A32608, CAS no. 
106-92-3) ! cautIon It is an irritant and a moderate skin and severe eye 
irritant on contact. Use protective gloves, eye and face shields.
Ammonium persulfate (APS; Bio-Rad Labs, cat. no. 161-0700, CAS no. 
7727-54-0) ! cautIon It is an irritant and may cause fire on contact with 
flammable materials. Use protective gloves and glasses.
N,N,N′,N′-tetramethyleneethylenediamine (TEMED, Bio-Rad Labs, cat. no. 
161-0801, CAS no. 110-18-9) ! cautIon It is highly flammable and causes 
burns. Use protective gloves and glasses. Keep away from heat and open flame.
Glutaraldehyde solution (grade 1, 50% in water; Sigma-Aldrich, cat. no. 
G7651, CAS no. 111-30-8) ! cautIon It is highly flammable, and is toxic  
if inhaled, if it comes in contact with skin and if swallowed. Keep the  
container tightly closed and in a cool place.
Ethylenediamine (99%; Sigma-Aldrich, cat. no. E26266, CAS no. 107-15-3) 
! cautIon It is corrosive and flammable. It is harmful on contact with skin 
and if swallowed. It causes burns.
Ethylenediaminetetraacetic acid (EDTA, tetrasodium salt dihydrate  
 > 99.5%, 50 mM solution; Sigma, cat. no. E6511, CAS no. 10378-23-1)  
! cautIon While handling all these chemicals and reagents, use protective 
gloves and glasses and work in a fume hood.
Goat anti-human IgG (Zymed Laboratories)
Anti-human CD34 +  was produced in ascites by injecting HSCA hybridoma 
cells (Kaneka Chemical Industries) into mice, and purified using a protein 
G column (1 ml; PerSeptive Biosystems)
Protein A (Bangalore Genei, cat. no. 105254).  crItIcal Store below 0 °C.
Ficoll-Paque PLUS (GE Life Sciences)
Penicillin-streptomycin solution (Sigma-Aldrich, 10,000 units penicillin and 
10 mg ml–1 streptomycin, cat no. P4333)
Hydroxyethyl cellulose, high viscosity (HEC; LOBA Chemie, cat no. 4137, 
CAS no. 9004-62-0)
Sodium citrate (Merck, cat no. 567446, CAS no. 6132-04-3)
Citric acid, anhydrous (Merck, cat no. 61804105001730)
Dextrose or glucose (Merck, cat no. 346351, CAS no. 50-99-7)
Sodium borohydride (NaBH
4
; Merck, cat no. 1063710100, CAS no.  
16940-66-2)
Tris buffer (Merck, cat no. 61771401001730)
Hydrochloric acid, 35% pure (HCl; Merck, cat no. 61752690251730)
Sodium azide (Merck, cat no. 61824401001730)
Ethanol (Merck, cat no. 1085430250, CAS no. 64-17-5) ! cautIon Highly 
flammable liquid and vapor. Keep away from heat/sparks/open flames/hot 
surfaces.
Calcium chloride (CaCl
2
; Merck, cat no. 1023780500, CAS no. 10043-52-4) 
! cautIon Causes serious eye irritation. In case of contact with eyes, rinse 
with water for several minutes.
Magnesium chloride (MgCl
2
; Merck, cat no. 8147330100, CAS no.  
7786-30-3)
Potassium chloride (KCl; Merck, cat no. 61753325001730)
Sodium chloride (NaCl; Merck, cat no. 61751990201730)
Sodium phosphate monobasic (NaH
2
PO
4
; Merck, cat no. 567545,  
CAS no. 10049-21-5)
Sodium phosphate dibasic (Disodium hydrogen phosphate) (Na
2
HPO
4
; 
Merck, cat no. 567550, CAS no. 7558-79-4)
Distilled water
Nitrogen (N
2
) gas
Bovine serum albumin (BSA; Merck, cat no. 12657, CAS no. 9048-46-8)  
 crItIcal store at 2–8 °C.
Sodium chloride (NaCl; Merck, cat no. 567440, CAS no. 7647-14-5)
Potassium dihydrogen phosphate (KH
2
PO
4
; Merck, cat no. 
60487305001730)
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Hydrochloric acid (HCl; Merck, cat no. 60906005001730)
Sodium hydroxide (NaOH; Merck, cat no. 61757390511730)
Sodium carbonate (Na
2
CO
3
; Merck, cat no. 61784490511730)
Sodium bicarbonate (NaHCO
3
; Merck, cat no. 61752090501730)
Sodium acetate trihydrate (Merck, cat no. 61751890201730)
HEPES (Merck, cat no. 1152310025, CAS no. 75277-39-3)
Acetic acid, glacial (Merck, cat no. 61780790251730)
EQUIPMENT
Thermostatic bath/circulator (Proline 1840; Lauda-Wobser,  
cat no. LCK 1891)
Laminar hood
Florescent activated cell scanner (Cyflow; Partec, cat no. CY-S-3001)
Sterile tubes for blood collection (50 ml; Tarsons Products, cat no. 546040)
Conical flasks
Filter (0.2-µm pore size)
Vacuum pump (Rocker 300; Tarsons Products, Rocker 300, cat no. 7010)
Magnetic stirrer and stir bars (Tarsons Products, cat no. 4020)
Plastic syringes (any company with required size range of 2 ml to 20 ml)
Peristaltic pump (P1; GE Healthcare, cat no. 18-1110-91)
Centrifuge (Hermle Labortechnik Model Z323)
Pasteur pipette
Sterile vials (for collecting bound cells from compressed cryogel columns,  
2 ml) (Tarsons Products, cat no. 500020)
Polystyrene pipe (Tygon vacuum tubing; Tarsons Products, cat no. 740000)
REAGENT SETUP
Phosphate buffer (0.01 M), pH 7.4 Add 57 ml of 0.02 M sodium phosphate 
monobasic and 243 ml of 0.02 M sodium phosphate dibasic heptahydrate. 
Dilute the mixture with distilled water to bring the total volume up to  
600 ml.
Phosphate buffer (10 mM) containing 0.15 M NaCl (pH 7.4) Recipe is the 
same as that for the preparation of phosphate buffer (0.01 M) pH 7.4, with 
the exception of the addition of 0.15 M NaCl.
Phosphate-buffered saline (PBS; pH 7.2) supplemented with 0.5% bovine 
serum albumin (BSA) For 1 liter PBS, dissolve 8 g NaCl, 0.2 g KCl, 1.44 g 
Na
2
HPO
4
 and 0.24 g KH
2
PO
4
 in 800 ml distilled water. Then adjust the pH  
to 7.4 with HCl and NaOH and add distilled water to bring the volume to  
1 liter. Add 0.5 % (wt/vol) bovine serum albumin.
Sodium carbonate buffer (pH 9.2) Mix 10 ml of 0.1M Na
2
CO
3
 and 90 ml  
of 0.1M Na
2
HCO
3
HEPES buffer (pH 7.4)  Mix 20 mM HEPES in 100 ml distilled water and 
then add 0.2 M NaCl.
Acetate buffer (pH 2.5) Mix 10 ml of 0.2 M sodium acetate trihydrate and 
90 ml 0.2 M acetic acid.
Balanced salt solution Combine 0.145 M Tris-HCl (pH 7.6) containing 
0.1% glucose, 0.05 mM CaCl
2
, 0.98 mM MgCl
2
, 5.4 mM KCl and 14 mM 
NaCl.
Acid Citrate Dextrose (ACD) or sodium citrate (anticoagulant) This can  
be prepared by performing the following steps:
Dissolve 1.32 g of sodium citrate in 85 ml of distilled water
Dissolve 0.48 g of citric acid in the solution from step 1
Dissolve 1.47 g of dextrose in the solution from step 2
Add distilled water and make up to 100 ml
Filter-sterilize through a 0.2-µm-pore filter
Use 0.25 ml of solution for 1 ml of blood
Umbilical cord blood Under aseptic conditions inside a laminar hood,  
collect UCB into a sterile tube containing anticoagulant (ACD or sodium  
citrate) and store at 4 °C. It is better to carry out experiments with fresh 
blood (within 6 h after collection) to avoid contamination and to capture  
the CD34 +  cells. Delaying the process may lose CD34 +  expression.
Peripheral blood Under sterile conditions, collect whole blood in a sterile 
tube containing anticoagulant (heparin or ACD) and store at 4 °C. It is better 
to carry out the experiment with fresh blood (within 6 h after collection)  
to avoid contamination and to capture CD34 +  cells. Delaying the process  
may lose CD34 +  expression.  crItIcal Appropriate ethical approval 
should be taken before the collection of UCB and peripheral blood for stem 
cell isolation. Consent from parents should also be taken before the collection 
of UCB after childbirth.
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proceDure
preparation of supermacroporous monolithic cryogel–protein a affinity matrix
1| To degas distilled water, fill the distilled water to half the volume in a conical flask provided with a nozzle on its neck. 
Attach one end of a polystyrene pipe to the nozzle and the other end to a vacuum pump to create a vacuum in the conical 
flask. During vacuum, the water should be under constant magnetic stirring. Allow the degassing to continue for ~1 h.
2| Choose which polymer is the most appropriate for your experiment. Two different types of AAm-based cryogels can be 
prepared: (A) DMAAm-based cryogel and (B) AAm-based cryogel.
 crItIcal step Both AAm and DMAAm are suitable polymers for the preparation of cryogel-based chromatography matrix. 
Highly hydrophilic matrices are preferred for chromatography purposes to avoid nonspecific interactions during the separa-
tion process. Both the matrices are hydrophilic in nature and are appropriate for cryogel preparation. AAm is slightly more 
hydrophilic than DMAAm and is a preferred choice of polymer for cryogel preparation. In contrast, DMAAm can be stored 
more stably than AAm. However, the overall porosity, pore size and mechanical strength of the developed cryogel matrix are 
approximately similar and they have the same physical morphology.
(a) DMaam-based cryogel
 (i) In 100 ml of degassed water, mix monomers, 6.3 ml of DMAAm and 0.85 ml of AGE.
 (ii)  Dissolve 2.2 g of MBAAm as a crosslinker in the monomer solution. A total concentration of 5% monomeric precursors 
should be used for the cryogel formation.
(B) aam-based cryogel
 (i) Mix monomers, 4 g of AAm and 1 ml of AGE, in 100 ml of degassed water.
 (ii)  Dissolve 1 g of MBAAm as a crosslinking agent in monomer solution. A total concentration of 6% monomeric  
precursors should be used for the cryogel formation.
3| Next, keep the mixture under constant N2 purging for 5–10 min to remove dissolved oxygen.
4| Cool the mixture at 4 °C and then add 110 mg of APS, followed by 95 µl of TEMED as initiator/activator agent.
 crItIcal step Ensure that the water is properly degassed and purged with N2 before the addition of APS/TEMED to  
remove O2 (to inhibit free-radical polymerization).
 crItIcal step The mixture of monomers should be cooled to 1–4 °C before the addition of APS/TEMED to retard the  
free-radical reaction.
5| After addition of APS/TEMED, quickly pour 1 ml of the mixture into precooled plastic syringes (diameter 0.9 cm) and 
store at  − 12 °C in a refrigerated circulatory bath for 12 h.
 To process large sample volumes (up to 50 ml), we recommend an optimal column size of 20 ml (length 6.3 cm × diameter 
2 cm). The column can be prepared as per the sample volume and scaling up of chromatography. To prepare such a column, 
pour the desired volume of the monomer mixture into defined plastic syringes (e.g., 5 ml mixture into a 5 ml syringe, 10 ml 
mixture into a 10 ml syringe and so on). However, it is not recommended to increase the column size beyond 20 ml, as it may 
not be very uniform.
6| After a complete incubation period of 12 h, thaw the synthesized cryogel with ~20 ml of water at room temperature (25 °C), 
followed by washing with another portion of 20 ml of water and water/ethanol mixture to remove any unreacted monomers.
7| After complete washing, dry the cryogel monolith in a vacuum and store it for further use.
 pause poInt The cryogels in dried form can be stored from days to weeks or even for several months for further 
modification and use. However, in the wet form, the gel needs to be modified soon after the cryogel washing in Step 5.
? trouBlesHootInG
two-step derivatization of epoxy-containing cryogel monolith for the attachment of protein: reaction with 
ethylenediammine
8| Place 1-ml cryogel columns (dried or freshly prepared wet) in a 50-ml plastic tube closed with a lid. One to five gel 
columns can be placed in a single tube.
9| Wash cryogel columns with water (10 ml per gel) and then with 0.2 M Na2CO3 (pH  > 10; 10 ml per gel).
10| Incubate cryogel columns with ethylenediamine (0.5 M in 0.2 M Na2CO3; 10 ml per gel) for 4 h and wash with water until 
the pH is close to neutral.
 crItIcal step Reactions and water washes are carried out by gently shaking the gels in the tube on a pedal shaker as 
indicated or for a minimum of 5 min.
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reaction with glutaraldehyde
11| Wash the ethylenediamine-treated cryogel columns with 0.1 M sodium phosphate buffer (pH 7.2; 10 ml per gel).
12| Next, incubate the cryogel columns in glutaraldehyde solution (5% (vol/vol); 10 ml per gel) in 0.1 M sodium phosphate 
buffer (pH 7.2; for 5 h).
13| Wash the columns in distilled water (10 ml per gel, washing repeatedly three to five times).
14| Incubate the derivatized cryogel matrix with the solution of protein A (1.6 mg ml–1; 10 ml) in 0.1 M sodium phosphate 
buffer (pH 7.2) at 4 °C for 24 h. The unreacted protein A solution after this step can be reused if needed.
15| Finally, wash the protein A–coupled cryogel matrix with freshly prepared sodium borohydride (NaBH4) solution  
(0.1 M in sodium carbonate buffer (pH 9.2); 10 ml per gel) to reduce Schiff ’s base formed between the protein and the  
aldehyde-containing matrix.
 pause poInt The protein A–coupled column can be stored in phosphate buffer (0.1 M, pH 7.2) at 4 °C for several months 
in the presence of 0.02% (wt/vol) sodium azide or 20% (vol/vol) ethanol.
16| The column can now be used for cell separations. To illustrate how this is done, we have included procedures for two 
examples: (A) fractionation of lymphocytes and (B) separation of CD34 +  stem cells from UCB.
(a) Fractionation of lymphocytes
 (i)  Separate mononuclear cells (lymphocytes, buffy coat) from freshly collected human peripheral blood using  
Ficoll-Paque PLUS density gradient separation medium by centrifugation at 400g for 40 min at room temperature  
as per the manufacturer’s instructions. The detailed procedure as described in a handbook available from GE Life  
Sciences29 can be found in Box 1. As a control experiment, lymphocytes without antibody labeling were passed  
through both protein A–coupled cryogel column and cryogel column without protein A.
 (ii)  Place 2 ml of cryogel column into a sterile plastic syringe and wash thoroughly by passing 20 ml of 20 mM HEPES 
buffer (pH 7.4) containing 0.2 M NaCl through it at a flow rate of 2 ml min − 1 using a peristaltic pump. (This process 
can be scaled up. The column size can be increased to process a 50 ml sample. The optimum column size of 20 ml 
(length 6.3 cm × diameter 2 cm) can be used to process a 50 ml sample volume in recycle mode).
 ? trouBlesHootInG
 (iii) Next, add a small amount ( < 0.3 ml) of buffer above the top surface of the cryogel column.
 (iv)  Treat the lymphocytes (1 ml, 2.0–4.0 × 107 cells per ml) with 50 µl (0.1 µg µl − 1) of goat anti-human IgG and incubate 
at 4 °C for 5 min. This will bind to B lymphocytes having surface IgG molecules.
 (v) Centrifuge cells at 200g for 5 min and suspend the cells in 1 ml of balanced salt solution.
 (vi)  Add antibody-treated lymphocytes to the top of the column and collect 1.5 ml (about void volume of the column) 
flow-through. Close the column outlet and allow the cells to bind efficiently to the matrix for 10 min without any 
buffer flow, at room temperature.
 (vii)  After 10 min of incubation, run the cold HEPES buffer (20 ml) through the column at a flow rate of 1.5 ml min − 1 to 
wash out unbound or loosely bound cells.
 ? trouBlesHootInG
 (viii)  Bound cells can be recovered by either of two ways. One approach is to recover cells with Ig solution after complete washing. 
To do this, first incubate the column and the buffer at 37 °C for 10 min and then add 2 ml of IgG (30 mg ml − 1) through the 
column. Thereafter, incubate the column at room temperature without buffer flow for 5 min. Next, run 20 ml of buffer through 
the column at a flow rate of 1.5 ml min − 1 and collect a 4-ml aliquot containing a specific cell type. An alternative approach is to 
compress the cryogel column gently with a syringe piston to up to 50% of its original length and collect the squeezed liquid in a 
sterile vial. Thereafter, flow the buffer (10 ml) at a flow rate of 1.5 ml min − 1 to recover the remaining loosely bound cells on the 
cryogel column. The process described here is used for the mechanical squeezing of cryogel for the recovery of bound cells.
 ? trouBlesHootInG
(B) stem cell (cD34 + ) separation from ucB
 (i)  Sediment red blood cells (RBCs) from UCB by using hydroxyethyl cellulose (HEC) as the sedimenting agent. Add 6% 
(vol/vol) HEC into the blood at a 5:1 ratio of blood:HEC, and mix properly. Thereafter, allow RBCs to settle down for 
15–20 min, then remove the settled RBCs and store supernatants containing mononuclear cells. 
 crItIcal step To achieve high purification and high yield, preclarification is a desired step. The RBC and/or  
platelets can be removed from whole blood by using sedimenting agents, e.g., Ficoll-Paque PLUS and HEC,  
as discussed in step Box 1 and PROCEDURE Step 16B(i), respectively.
 ? trouBlesHootInG
 (ii) Incubate the RBC-sedimented UCB (1 ml) and whole UCB (1 ml) with human anti-CD34 (1 µg ml − 1) at 4 °C for 5 min.
 (iii) Centrifuge the cells at 200g for 5 min and suspend in 1 ml of PBS (pH 7.2, supplemented with 0.5% BSA).
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 (iv)  Sterilize the protein A–coupled cryogel column (1 ml; height × diameter: 1.0 cm × 0.9 cm) by passing 20 ml of  
2% (vol/vol) penicillin-streptomycin solution in buffer (0.1 M PBS, pH 7.4) at a flow rate of 1.5 ml min − 1.
 (v)  Thereafter, equilibrate the sterilized protein A–cryogel matrix by passing 50 ml of PBS (pH 7.2 supplemented with 
0.5% BSA) at a flow rate of 1.5 ml min − 1.
 (vi) Close the lower end of the cryogel column and leave  < 0.2 ml buffer above the top surface of the column.
 (vii)  Load 0.8 ml of antibody-treated, UCB and RBC-sedimented onto the top of the cryogel column. Thereafter, open the 
lower end of the cryogel column and collect 0.6 ml of flow-through. Close the column outlet and allow the cells to 
bind efficiently to the matrix for 10 min without any buffer flow at room temperature.
 (viii)  After 10 min of incubation time for cell binding, wash the column with 10 ml of buffer at a flow rate of 1.5 ml min − 1 
to remove unbound or loosely bound cells.
 (ix)  Bound cells can be recovered by either of two ways. One approach is to recover cells with Ig solution after complete 
washing. To do this, first, incubate the column and the buffer at 37 °C for 10 min and then add 1 ml of IgG  
(30 mg ml − 1) through the column. Thereafter, incubate the column at room temperature without buffer flow for 5 min. 
Now, run 10 ml of buffer through the column at a flow rate of 1.5 ml min − 1 and collect 3 ml of aliquot containing  
a specific cell type. An alternative approach is to compress the cryogel column gently with the syringe piston to up to 
50% of its original length and collect the squeezed liquid in a sterile vial. Thereafter, run the buffer (10 ml) at a flow 
rate of 1.5 ml min − 1 to recover the remaining loosely bound cells on the cryogel column. The process described here is 
used for the mechanical squeezing of cryogel for the recovery of bound cells. 
 crItIcal step If the recovery of cells by mechanical squeezing is  < 70% in the first step, we suggest repeating it.
   ? trouBlesHootInG
regeneration of the column
17| Used columns (1 or 2 ml) can be regenerated by passing 10 column volumes of 50 mM acetate buffer (pH 2.5) at a flow 
rate of 1 ml min − 1.
18| Equilibrate the column by passing 20 column volumes of 0.1 M PBS (pH 7.2).
? trouBlesHootInG
Troubleshooting advice can be found in table 1.
.
  taBle 1 | Troubleshooting table.
step problem solution
7 After synthesis, some of the  
cryogels are irregular in shape
Choose only those synthesized cryogels with proper shape as shown in Figure 5
16A(ii) Sample or liquid leaks from  
the sides of the cryogel  
matrix packed in the syringe
Use only those cryogels that are tightly packed in syringes. Incubate the packed cryogels 
with water for complete swelling. Check each cryogel’s packing by inverting the packed 
syringe to see whether the cryogel matrix moves or not. If the cryogel slides, the matrix 
is not properly packed. Either change the matrix or swell the matrix for additional time
16A(vii) The target cells are eluted  
out of the column during  
the washing procedure
Decrease the flow rate of washing buffer. Check the pH of washing buffer
Check for leakage of cells through the sides of the cryogel matrix in the syringe  
or appropriate mold (refer to TROUBLESHOOTING advice for Step 16A(ii))
16A(viii) Low recovery of bound cells Repeat the cell release process two or three times
16A(viii), 
16B(ix)
Bound cells do not release  
after mechanical squeezing  
of the cryogel
Compress the cryogel again with 70–80% compression followed by liquid flow at  
1.5 ml min − 1. If cells are not coming out even after this treatment, then the developed 
matrix does not have sufficient pore size. Please check the pore size of developed  
cryogel before chromatography
Released cells are not viable Carry out the viability test before and after the chromatography
Decrease the compression on cryogel, restrict the compression up to 25% of original 
length, change in length followed by buffer flow (1 ml min − 1)
Maintain the temperature during chromatography; it should be less than room tempera-
ture. Pass cold buffer through the column to wash the column and to elute unbound cells
The complete chromatography process should not take more than 30 min
16B(i) Very low recovery percentage  
of CD34 +  cells
Process the UCB within 2 h after collection or refer to TROUBLESHOOTING advice for  
Step 16A(vii), 16A(viii) and 16B(ix)
©
20
10
 N
at
u
re
 A
m
er
ic
a,
 In
c.
  A
ll 
ri
g
h
ts
 r
es
er
ve
d
.
protocol
nature protocols | VOL.5 NO.11 | 2010 | 1745
● tIMInG
Steps 1–7: ~17 h
Steps 8–16: 40–48 h
Step 16A(i): ~1 h
Step 16A(ii–viii): 45–60 min
Step 16B(i): ~30 min
Step 16B(ii–ix): ~60 min
Steps 17 and 18: 30 min
antIcIpateD results
affinity cryogel matrix design for cell chromatography
The cell chromatography matrix was synthesized by  
copolymerization of AAm and AGE using MBAAm as crosslink-
er at  − 12 °C for 12 h. The water-swollen poly(acrylamide-
co-allylglycidyl ether) (poly(AAm-co-AGE)) cryogel  
maintained its shape and morphology even after complete 
drying (Fig. 5a,b). Water-swollen poly(AAm-co-AGE) cryogels 
were spongy in nature and water could be squeezed out  
with compression. Analysis by scanning electron microscopy 
demonstrated that the pore diameter of dried poly(AAm-co-
AGE) cryogels is in the range of 50–100 µm (Fig. 5c).  
The thick and smooth sidewalls of pores were observed by 
scanning electron microscopy (Fig. 5c). These large inter-
connected pores in suitably designed cryogel matrix can 
function as capillaries and can quickly absorb a large amount 
of water. These swelling studies indicated that these matri-
ces have a high rate of swelling. The flow properties were checked for protein A–coupled poly(AAm-co-AGE) cryogel matrix 
and showed a high volumetric flow rate of around 8 ml min − 1 across the cryogel matrix. It was also observed that the cryogel 
matrix allowed convective movement of large particles. The amount of protein A coupled to the cryogel matrix was found to 
be ~2 mg per gel matrix, as measured by bicinconnic acid reagent.
Fractionation of lymphocytes
The interaction of protein A with cells bearing IgG antibodies on their surfaces has been successfully used for the fractionation 
of blood lymphocytes in a chromatographic format. B lymphocytes are Ig-positive cells and express IgG on the cell surface. 
The results were calculated by flow cytometry analysis, with the scatter gates set on the lymphocyte fraction. When loaded 
with 1 ml of treated cells (3.0 × 107 cells per ml), ~91% of B cells were retained in the 2-ml column. With ~11.6% of B cells in 
the total mononuclear cells, the B-cell–binding capacity was determined to be ~1.6 × 106 cells per ml of adsorbent. The cells 
in the breakthrough fraction were enriched in T cells (81%). The viability of cells investigated in the breakthrough fraction 
was  > 90%, as measured by Trypan blue staining of cells. The electron micrograph image (Fig. 6) of bound cells on the protein 
A–cryogel matrix clearly demonstrated the specific binding of the cells. The cells were attached to the pore walls rather than 
mechanically entrapped in the dead-flow zones. In all, 70% of the total bound cells were recovered by the treatment of Ig  
solution, and contain ~70% of B cells (Fig. 7). The overall recovery of B cells from lymphocyte fraction can further be  
increased if the sample is passed through the column in recycle mode. Moreover, the capacity of the column can be amplified 
by increasing the size of the affinity column to achieve  > 90–95% cell recovery. The recovery percentage could be increased by 
mechanical squeezing of gel. However, the recovered cells also contained ~20% of T cells. Probably, most of the T cells were 
retained in the column through some weak interactions of cell receptors with protein A or through some cells aggregated  
with B cells. To achieve higher purification of the recovered B cells, a pulse gradient of human Ig (10, 30 and 50 mg ml − 1) was 
applied. At the highest concentration of IgG, 60% B-cell recovery was achieved with  < 10% T cells. Furthermore, the cells that 
were directly applied to protein A–cryogel without labeling with goat anti-human IgG were completely recovered by the flow of 
buffer (Fig. 7). Affinity chromatography of human blood mononuclear cells on supermacroporous cryogel–protein A was found 
in this study to result in about a twofold enrichment of T cells by negative selection. The very low B-cell contamination (~1%) 
showed significant selectivity of the separation process. With mechanical squeezing of the cryogel matrix, ~95% of bound cells 
were recovered, which contained ~70% of B cells. The viability of the recovered cells was ~90%.
stem cell chromatography: purification and characterization
stem cell (cD34 + ) capture. Fluorescence-activated cell sorting (FACS) analysis demonstrated that all unwanted cells were 
washed out during the washing procedure. It was also found that ~8 × 106 nucleated cells were removed during washing and 
Dry
a
c
b
Cryogel 
chromatography
column
500 µm 100 µm
Swollen
Figure 5 | Physical characteristics of the monolithic cryogel chromatography 
column. (a) Cryogel chromatography column. (b) Physical shape of 
poly(AAm-co-AGE) cryogels in dry and swollen form. (c) Scanning electron 
microscope images of poly(AAm-co-AGE) cryogels at different magnifications 
(×160 and ×795).
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that washed-out nucleated cells may contain some unbound 
CD34 +  cells. The captured CD34 +  cells were recovered by 
mechanical squeezing of cryogel. The bound CD34 +  cells were 
released at 50% compression, followed by 10 ml of buffer 
wash, to elute loosely bound CD34 +  cells. The FACS analysis 
showed  > 95% cell recovery of bound cells (Fig. 7). It was 
also observed that  > 70% compression of cryogel leads to 
increase in cell recovery but decrease in viability of  
eluted CD34 +  cells. Finally, the optimized procedure for cell 
recovery through mechanical squeezing involves lengthwise 
compression of up to 50–60%, followed by 10 ml of flush-
ing by PBS. It leads to  > 95% cell recovery, as confirmed by 
Trypan blue staining and FACS analysis. The FACS analyses 
demonstrated that the released or recovered cells were 
CD34 + . The pure population of 1 × 105 CD34 +  hematopoietic 
stem cells can be recovered from 0.8 ml of labeled UCB using 
1 ml of cryogel matrix. There was an increase in the overall 
recovery of stem cells from RBC-sedimented UCB, with the recovered cell number of 7 × 105 cells per ml of cryogel column.  
A control experiment was run to demonstrate that 1 × 106 nucleated cells can pass through without any nonspecific  
interactions, and in another experiment, the unhindered movement of whole blood was observed through the cryogel  
affinity column (Fig. 7). There were very few RBCs and platelets that were retained in the column nonspecifically, which 
affects overall column efficiency as demonstrated in our result in which CD34 +  cells were separated directly from UCB. The 
overall efficiency of a 1-ml affinity cryogel column was estimated to be around 7 × 105 cells per ml of cryogel column (0.9% 
of total nucleated cells) with  > 90% purity. The efficiency of the cryogel column decreased to 1 × 105 cells per ml of cryogel 
column (0.2% of total nucleated cells) when applying UCB directly in comparison with RBC-sedimented UCB. We have  
found 20% CD34 +  cell recovery from UCB and 90% cell recovery from RBC-sedimented UCB using the 1-ml cryogel column 
(height × diameter: 1.0 × 0.9 cm2). The capacity of the cryogel column can be increased by changing the physical dimensions 
to achieve a higher percentage of cell recovery. In another experiment, it was also demonstrated that bound CD34 +  cells  
can be recovered and concentrated (50% compression followed by 1 ml buffer wash) in 1.5 ml of an elution aliquot  
containing  > 90% of bound cells. Overall, the cell chromatographic process took ~30 min.
The isolated cells were grown for 3 weeks and then labeled with FITC-conjugated anti-CD34 + . The labeled cells were  
observed under fluorescence microscope; results demonstrated that isolated stem cells maintained proliferation capacity 
and retained CD34 +  cell-surface markers. We have seen that, during the squeezing process, generally the antibody remains 
attached to protein A and mostly antibody-free cells can be recovered because the binding strength of protein A to the Fc 
portion of the IgG antibody is greater than the antibody interaction with the cell-surface markers. We confirmed this when 
regenerating the protein A–cryogel column with low-pH buffer washing, wherein we observed some concentration of antibody 
in the column wash. However, it is possible that some of the recovered cells could retain antibody on their surfaces. The anti-
body bound to recovered cells when kept in growth media can shed the surface-bound antibody during the culture process.
Although we have presented two model examples here for the separation of lymphocytes and CD34 +  cells on a protein A–
coupled cryogel column, this approach can be used for other 
cell types with similar efficiency. We have tried this with 
other cell types as well. Moreover, the regenerated protein A 
columns can be reused at least two to three times without 
showing much effect on the cell binding and recovery.
×950 20 µm
Figure 6 | Scanning electron micrograph of the inner part of the 
supermacroporous cryogel-protein A matrix loaded with lymphocytes.  
The cells are affinity bound on the pore walls. Magnification (×950)  
(adapted from Kumar et al.20 with permission).
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Figure 7 | The cell separation efficiency on an affinity-based cryogel 
chromatographic column (per milliliter adsorbent). Separation of 
lymphocytes (gray bars) showing B-cell recovery after incubation with 
immunoglobulin (B cells (Ig)) with 70% yield, and recovery by mechanical 
squeezing (B cells (M)) with 92% yield from total bound cells on the 
cryogel adsorbent. CD34 +  cell separation (white bars) showing recovery 
of CD34 +  cells (CD34 +  (UCB)) with 83% yield directly from UCB and CD34 +  
cell recovery (CD34 + (RS-UCB)) with 90% yield from RBC-sedimented UCB 
from total CD34 +  cells bound on cryogel adsorbent when direct UCB and 
RBC-sedimented UCB (RS-UCB) were applied, respectively. In both types of 
control experiments, i.e., when labeled cells were passed through a plain 
cryogel column and when unlabeled cells were passed through an affinity 
cryogel column, no cell binding was observed.
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Bacterial glycosidases for the production of universal red
blood cells
Qiyong P Liu1,9, Gerlind Sulzenbacher2,9, Huaiping Yuan1, Eric P Bennett3, Greg Pietz1,3, Kristen Saunders1,
Jean Spence1, Edward Nudelman1, Steven B Levery4, Thayer White1, John M Neveu5, William S Lane5,
Yves Bourne2, Martin L Olsson6,7, Bernard Henrissat2 & Henrik Clausen3,8
Enzymatic removal of blood group ABO antigens to develop universal red blood cells (RBCs) was a pioneering vision originally
proposed more than 25 years ago. Although the feasibility of this approach was demonstrated in clinical trials for group B RBCs,
a major obstacle in translating this technology to clinical practice has been the lack of efficient glycosidase enzymes. Here we
report two bacterial glycosidase gene families that provide enzymes capable of efficient removal of A and B antigens at neutral
pH with low consumption of recombinant enzymes. The crystal structure of a member of the a-N-acetylgalactosaminidase
family reveals an unusual catalytic mechanism involving NAD+. The enzymatic conversion processes we describe hold promise
for achieving the goal of producing universal RBCs, which would improve the blood supply while enhancing the safety of
clinical transfusions.
The ABO blood group system, discovered in 1900 (ref. 1), is the most
important blood group system to consider in transfusion medicine.
This system is based on the presence or absence of the blood group
antigens A and B. The corresponding blood group carbohydrate
structures, designated ABH, are found at the termini of oligosaccha-
ride chains on glycoproteins and glycolipids on the surface of ery-
throcytes and of endothelial and most epithelial cells2,3. The
immunodominant monosaccharide that determines blood group A
specificity is a terminal a-1,3-linked N-acetylgalactosamine (GalNAc),
whereas the corresponding monosaccharide of blood group B speci-
ficity is an a-1,3-linked galactose (Gal) (Fig. 1). Group O cells lack
both of these monosaccharides at the termini of their oligosaccharide
chains, which instead are terminated with a-1,2-linked fucose (Fuc)
residues and designated the H antigen (see review2). The genetic basis
of ABO antigens has been elucidated; genes determining A and B
blood types encode glycosyltransferases in which a few amino acid
substitutions result in differing substrate specificities: the A enzyme for
UDP-GalNAc and the B enzyme for UDP-Gal, whereas the gene for
the O blood type encodes an inactive protein4.
Plasma of blood group A individuals contains naturally occurring
antibodies to the B antigen. Conversely, that of blood group B
individuals contains antibodies to the A antigen. Blood group AB
plasma has neither antibodies, and blood group O plasma has both
antibodies. Individuals with anti-A and/or anti-B antibodies cannot
receive a transfusion of blood containing the corresponding incom-
patible antigen(s). Inappropriate transfusion of ABO-incompatible
RBCs can cause complement activation and lysis of the incompatible
RBCs, often resulting in an acute intravascular hemolytic transfusion
reaction. Inadvertent mismatching of RBCs for ABO blood groups
remains one of the most common and persistent causes of serious and
sometimes fatal adverse events following transfusion, according to
hemovigilance monitoring systems5,6. Group O RBCs contain neither
A nor B antigens and can be transfused safely into recipients of any
ABO blood group, that is, group A, B, AB or O recipients. Thus, type
O blood is considered ‘universal’ and may be used for all RBC
transfusions. Hence, blood banks strive to maintain significant inven-
tories of group O RBCs. In reality, however, there is a constant
shortage of group O units as these are always in great demand for
numerous reasons, including emergency situations in which the
patient’s blood group is unknown, shortages of blood from a parti-
cular blood group, pediatric transfusions, and lack of clarity regarding
the patient’s blood group (e.g., due to previous transfusions or
allogeneic stem cell transplantation). Enzymatic removal of the
immunodominant aGalNAc and aGal monosaccharides from group
A and B structures of non-O RBCs offers an appealing approach to
improve transfusion safety and the overall blood supply7.
Goldstein originally envisioned enzymatic conversion of the A and
B antigens on RBCs to H antigen by use of exoglycosidases for
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selective removal of aGalNAc and aGal residues of the immuno-
dominant A and B trisaccharide antigens, respectively, to expose the
underlying H antigen8 (Fig. 1). For conversion of group B RBCs, he
used an a-galactosidase derived from green coffee beans (Coffea
canephora), which has a very low pH optimum (pH 3.5) and required
as much as 1–2 g enzyme per unit of group B RBCs for adequate
conversion at acidic pH 5.5. A phase 2 crossover trial was completed
with full unit (B200–220 ml packed) transfusions of group B RBCs
enzyme-converted to group O (B-ECO), in which the converted cells
functioned and survived normally in group A and O patients9.
Although this study clearly demonstrated that enzymatic conversion
of RBCs is feasible and that B-ECO cells can function as well as
ABO-matched untreated cells in transfusions, a major obstacle to
clinical implementation of this method is the large quantities of
enzyme required. Other investigators have explored different a-galac-
tosidases and protocols for conversion of group B RBCs but without
substantial improvements in enzyme consumption10,11.
Successful conversion of group A RBCs has not yet been achieved.
The biochemistry of A antigens is more complex than that of B
antigens. Subgroup A1 RBCs have B5 more A antigens than
subgroup A2, and, in addition, subgroup A1 cells have glycolipids
with a repeated A structure, which in A2 cells mainly exist as an
A-associated H structure (see Fig. 1 and Table 1 for structures)12,13.
Conversion of only the A2 subgroup to group O was achieved with a
Figure 1 Structural basis of the ABO blood group antigens. The
immunodominant A and B trisaccharide epitopes are formed from
the common H disaccharide substrate by a1,3-N-acetylgalactos-
aminyltransferase (GTA), defined by the blood group A gene, and a-galacto-
syltransferase (GTB), defined by the blood group B gene, respectively.
Conversely, the strategy used for enzymatic conversion of blood group A
and B antigens to H involves exoglycosidases that specifically hydrolyze
the a1,3GalNAc (a-N-acetylgalactosidase, A-zyme) or the a1,3galactose
(a-galactosidase, B-zyme) to form the common H structure found on O
RBCs. Black arrows indicate the different C-2 N-acetyl group of GalNAc
and OH group of Gal in the immunodominant A and B epitopes, respec-
tively. The immunodominant epitopes are positioned at the termini of
oligosaccharide chains on glycolipids and glycoproteins as indicated by R.
Increased complexity in ABH oligosaccharide structures are provided by the
oligosaccharide carrier chain (R). On human RBCs most structures are
based on type 2 polylactosamine chains with repeating Galb1-4GlcNAc
disaccharide units (both glycolipids and N-linked glycoproteins). A minor
amount of type 1 chain ABH structures with Galb1-3GlcNAc are found
as glycolipids adsorbed from plasma3. A fraction of the blood group A
glycolipids with type 2 chain core structures are extended by a bGal residue (Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-R), which is further
preferentially modified to an A-associated H epitope in subgroup A2 RBCs (Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-R) and a repetitive A
epitope (GalNAca1-3(Fuca1-2)Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-R) in subgroup A1 RBCs (see Fig. 4 for glycolipid structures). Cleavage of
the repetitive A structure by an a-N-acetylgalactosaminidase will result in exposure of the H disaccharide epitope.
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Table 1 Substrate specificities analyzed by TLC assay
Substrate Blood group specificity
a-N-acetylgalactosaminidase a-galactosidases
E. meningosepticum
(pH 6.8)
Coffee beana
(pH 5.5)
S. griseoplanusa
(pH 6.8)
B. fragilis
(FragA) (pH 6.8)
GalNAca1-2(3,4)Gal Structures
GalNAca1-2Galb1-MCO + ND ND ND
GalNAca1-3Galb1-MCO A-di + ND ND ND
GalNAca1-3Galb1-4GlcNAcb1-MCO Linear A-tri + ND ND ND
GalNAca1-4Galb1-4Glcb1-MCO + ND ND ND
GalNAca1-3(Fuca1-2)Gal A-tri + ND ND –
GalNAca1-3(Fuca1-2)Galb1-3GalNAcb1-AMC A-tetra (type 3 chain)b + (0.25 U/mg)c – – –
GalNAca1-3(Fuca1-2)Galb1-3GalNAca1-3(Fuca1-2)
Galb1-4GlcNAcb1-AMC
A-hepta (type 3 chain,
repetitive A)
+ (0.25 U/mg) ND ND ND
Gala1-3Gal Structures
Gala1-3Gal B-di ND ND ND –
Gala1-3Galb1-4GlcNAc Linear B ND + – –
Gala1-3(Fuca1-2)Gal B-tri – + + +
Gala1-3(Fuca1-2)Galb1-4GlcNAcb1-AMC B-tetra (type 2 chain) – + (0.017 U/mg) + + (6.6 U/mg)
Gala1-4Gal Structures
Gala1-4Gal P1 – + – –
Gala1-4Galb1-4Glc Pk – + – –
aFrom published US patent application no. US 20,050,208,655. bCore structures of ABH antigens designated type 1–4, as described previously3. cSpecific activity determined using quantification
by fluorography of TLC analysis.
+, complete digestion of substrate using conditions that produce complete digestion of the AMC-labeled blood group A or B tetrasaccharide substrates. –, no detectable digestion of
substrate under the same conditions even after extended reaction time (10). ND, not determined.
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chicken liver a-N-acetylgalactosaminidase using 1 g of enzyme per
unit of RBCs at pH 5.5 (ref. 14). An a-N-acetylgalactosaminidase from
Clostridium perfringens has also been used15. Purification of an a-N-
acetylgalactosaminidase from Arenibacter latericius with neutral pH
optimum, which appeared to convert both subgroup A1 and A2 cells
after 24 h incubation, has been reported16. The efficiency of the
conversion, however, was not confirmed by licensed typing methods,
and the gene has not been identified yet. It is, therefore, not clear
whether the difficulties with conversion of the A1 subgroup relate to
the complexity of A antigens or to the poor kinetic properties and
acidic pH optima of the enzymes used to date14,15.
In the past, a-N-acetylgalactosaminidases and a-galactosidases used
for removing the immunodominant aGalNAc and aGal residues from
the A and B antigens, respectively, have mainly been identified and
characterized by enzymatic assays using simple monosaccharide
p-nitrophenyl (pNP) substrates. We hypothesized that the use of
this strategy would fail to identify enzymes with selective or exclusive
substrate specificities for the more complex branched blood group A
and B structures. We therefore screened a large panel of bacterial and
fungal isolates to search for enzymes with the preferred substrate
specificities and a neutral pH optimum. Here we describe two
previously unknown prokaryotic glycosidase families, which contain
enzymes with favorable or exclusive substrate specificities for the
branched blood group structures, neutral pH optimum, and high
efficiency and selectivity in enzymatic conversion of group A, B and
AB RBCs to group O RBCs. The a-N-acetylgalactosaminidase func-
tions with an unusual catalytic mechanism involving NAD+ and the
crystal structure of the enzyme reveals a structural fold that has not
been found previously in glycosidases. The availability of these
bacterial enzymes should allow efficient and cost-effective enzymatic
conversion of blood group A, B and AB RBCs to universal RBCs.
RESULTS
Screening for prokaryotic exoglycosidases
To identify enzymes that might have preferred or exclusive specificity
for blood group A and B structures and neutral pH optima, we
screened a large panel of 2,500 fungal and bacterial isolates for
enzymes capable of cleaving A and B oligosaccharide substrates.
Most bacteria express high levels of known a-galactosidases that
have acidic pH optima and high activity with the Gala-pNP substrate,
and some also express a-N-acetylgalactosaminidases that have simi-
larly high activity with the GalNAca-pNP substrate. We therefore used
differential screening with two assays; one with a blood group A or
B tetrasaccharide substrate labeled with 7-amino-4-methyl-coumarin
(A or B tetrasaccharide-AMC) substrate and one with the GalNAca-
pNP or Gala-pNP substrate (Table 2). Assays were performed at
neutral pH to select enzymes with the preferred pH optimum. Five of
the 2,500 isolates were found to display a-galactosidase activity
with the B tetrasaccharide-AMC substrate and not with the
monosaccharide Gala-pNP substrate, whereas two isolates showed
a-N-acetylgalactosaminidase activity with the A tetrasaccharide-AMC
substrate as well as the monosaccharide GalNAca-pNP substrate (data
not shown). Both activities exhibited neutral pH optima.
Improved enzymes for conversion of group A RBCs – family
GH109
The a-N-acetylgalactosaminidase activities identified in the screen
were similar to that of an Elizabethkingia meningosepticum (previously
termed Chryseobacterium meningosepticum, ATCC no. 13253)
a-N-acetylgalactosaminidase (GenBank accession no. AM039444),
which was originally identified and cloned using the same blood
group A tetrasaccharide-AMC substrate for screening17. The deduced
protein sequence of the E. meningosepticum enzyme was used in
GenBank searches to identify a family of enzymes found exclusively
in prokaryotes, classified as GH109 in the carbohydrate-active enzyme
database (http://www.CAZY.org/) (Supplementary Fig. 1 online). The
genes encoding five of these proteins were cloned and expressed
(Supplementary Methods online). One of two genes identified in
Bacteroides fragilis (AM039447) as well as those from Shewanella
oneidensis (AM039445) and Tannerella forsythensis (AM039448) were
found to encode functional a-N-acetylgalactosaminidases with prop-
erties similar to those of the E. meningosepticum enzyme (data not
shown). The second gene identified in B. fragilis (AM039446) and the
Streptomyces coelicolor gene (AM039449) did not appear to encode
proteins with a-N-acetylgalactosaminidase activity.
A distant relationship of these enzymes to oxidoreductases was
noted using the NCBI conserved domain search. We therefore
considered the possibility that these enzymes functioned with NAD+
and metal ions as cofactors. An N-terminal truncated construct
(amino acids 18–444) of the E. meningosepticum was expressed
efficiently in Escherichia coli with a yield of 1 g/l, purified to
homogeneity and used for the studies reported here. The purified
recombinant enzyme was not affected by EDTA/EGTA chelation of
potential metal ions, and exogenous addition of metal ions did not
enhance activity. Furthermore, addition of NAD+ or NADH had no
effect on enzyme activity (Supplementary Fig. 2 online). As a result of
these findings exogenous addition of metal ions and nucleotides were
not used in standard enzyme assays in the study. However, the enzyme
does in fact use NAD+ as a cofactor, but NAD+ is tightly bound, and
the enzyme is saturated in its purified recombinant form.
The substrate specificity and kinetic properties of the recombinant
E. meningosepticum a-N-acetylgalactosaminidase are presented in
Tables 1 and 2. The enzyme has a neutral pH optimum with
a relative high specificity for the blood group A AMC substrate
(0.25 U/mg) (Supplementary Figs. 3a and 4a online) compared
with the monosaccharide GalNAca-pNP substrate (410 U/mg).
Table 2 Kinetic properties of the a-N-acetyl-galactosaminidase and a-galactosidase
E. meningosepticum a-N-acetyl-galactosaminidase B. fragilis a-galactosidase A (FragA)
Substrate kcat (s
–1) Km (mM) kcat/Km (s
–1 mM–1) kcat (s
–1) Km (mM) kcat/Km (s
–1 mM–1)
Gala-pNP 0.026 ± 0.001 25.1 ± 1.4 0.0011 0.38 ± 0.01 0.70 ± 0.02 0.54
Galb-pNP 0.010 ± 0.000 3.6 ± 0.3 0.0031 0.00a NA NA
GalNAca-pNP 9.84 ± 0.16 0.077 ± 0.006 127.6 0.00 NA NA
GalNAcb-pNP 0.015 ± 0.000 0.23 ± 0.01 0.087 0.00 NA NA
Data represent the average of triple or more measurements.
aNo activity was found with 60-longer reaction time than was required to readily detect the activity of Gala-pNP. NA, not applicable.
456 VOLUME 25 NUMBER 4 APRIL 2007 NATURE BIOTECHNOLOGY
A R T I C L E S
©
20
07
 N
at
ur
e 
P
ub
lis
hi
ng
 G
ro
up
  
ht
tp
://
w
w
w
.n
at
ur
e.
co
m
/n
at
ur
eb
io
te
ch
no
lo
gy
Surprisingly, low but detectable activity was also observed with
GalNAcb-pNP as well as with Gala and Galb-pNP substrates
(Supplementary Fig. 5 online). Interestingly, the apparent Km value
for GalNAca-pNP is similar to that of GalNAcb-pNP, although kcat
values differ more than 1,000-fold. In contrast, the Km value for Galb-
pNP is over tenfold higher than that for the GalNAc counterpart.
Although glycoside hydrolases are usually extremely specific for the
anomeric configuration of the glycosidic bond, a member of glycosi-
dase family GH4, namely Fusobacterium mortiferum phospho-a-
glucosidase, has been reported to be able to cleave both a- and
b-anomers of the nonnatural p-NP 6-phosphoglucosides substrates18.
We did not observe any cleavage of the natural globoside (Gb4)
glycolipid structure with a terminal b1-3GalNAc residue; however,
low but detectable cleavage of the disaccharide substrate GalNAcb1-
4Galb1-O(CH2)8COOCH3 was observed (data not shown). Monitor-
ing the hydrolysis of GalNAca-pNP by NMR showed that the
a-N-acetylgalactosaminidase functions with a mechanism leading to
overall retention of the anomeric configuration (Supplementary
Results online). The combined findings of sequence relatedness to
oxidoreductases, lack of similarity to known glycosidases and the
unusual enzymatic properties motivated us to determine the structure
of the enzyme by X-ray crystallography.
Structural architecture of the a-N-acetylgalactosaminidase
The crystal structure of the E. meningosepticum a-N-acetylgalactosa-
minidase was solved by the multiple anomalous dispersion (MAD)
method, taking advantage of the anomalous dispersion of selenium,
and refined against native data to 2.3 Å resolution (Supplementary
Table 1 online). The structure of a complex with GalNAc was refined
to 2.4 Å resolution. The enzyme is present as a homodimer in the
crystal and appears to form a dimer in solution, as evidenced by
dynamic light-scattering analysis. However, analysis by size-exclusion
chromatography suggests that the enzyme exists as a monomer or a
dimer, depending on buffer conditions (data not shown). The final
structure of the enzyme comprises the entire mature protein (residues
18–444) and a molecule of NAD+. Although the distant sequence
relatedness with oxidoreductases suggested that the enzyme
could function with NAD+ as a cofactor, similarly to enzymes of the
GH4 family19–21, this was a surprise because we had observed no
stimulation of activity with exogenous addition of NAD+ or NADH in
our studies of the kinetic properties of the enzyme (Supplementary
Fig. 2 online).
Structurally, the protein consists of two independent and closely
associated domains, forming a narrow tunnel in which the NAD+
molecule is embedded (Fig. 2a). The N-terminal domain forms
a classical dinucleotide-binding Rossmann fold22, whereas the
C-terminal domain consists of an a/b domain with a large open-
faced, seven-stranded, anti-parallel b-sheet, adjacent to nine a-helices
and an a-helical bundle covering the dinucleotide-binding tunnel. The
open-faced b-sheet, with a surface area of 2,800 Å2, representing 15%
of the total surface of a monomer, makes up the dimer interface. The
NAD+ molecule, copurified with the recombinant enzyme, is
anchored within a 10 Å long, narrow tunnel, almost entirely shielded
from the solvent; the nicotinamide ring is located in a narrow pocket
situated at the bottom of a large depression at the surface of the
protein. Because exogenous addition of NAD+ did not stimulate
the enzyme, we developed a method for depletion of NAD+ by
precipitating the protein with ammonium sulfate under acidic
a
b
c
d
Figure 2 Overall structure of the E. meningosepticum a-N-acetylgalacto-
saminidase. (a) Left panel. Cartoon representation of the overall structure of
the a-N-acetylgalactosaminidase dimer. In the left subunit, the dinucleotide
binding domain (residues 19–148) is shown in pink, the a-helices of the
C-terminal domain (residues 149–444) in cyan, the b-sheet forming the
dimer interface in yellow, and the a-helical bundle covering the NAD+-
binding tunnel in green. In the right subunit, a partial surface representation
shows the entry of the NAD+ binding tunnel and the active-site pocket.
NAD+ and GalNAc are shown as orange and red sticks, respectively. Right
panel. Close-up and clipped view of the NAD+ binding tunnel created at the
interface of the dinucleotide binding domain (pink) and the a-helical bundle
(green). (b) Side-by-side representation of a-N-acetylgalactosaminidase
(left) and Zymomonas mobilis glucose-fructose oxidoreductase (PDB 1OFG)
(right,) using the same coloring convention as in a. The NAD+ molecule and
GalNAc bound to the a-N-acetylgalactosaminidase and the NADP+ cofactor
bound to 1OFG are highlighted. (c) Stereo view of the active site of a-N-
acetylgalactosaminidase oriented as in b. The GalNAc residue, part of the
NAD+ and the surrounding amino acid residues described in the text are
shown as ball-and-stick models. Maximum-likelihood/sA-weighted 2Fo-Fc
electron density (contoured at B1.5 s) is shown in blue for GalNAc and
NAD+ and in orange for protein residues. (d) Stereo view of the super-
imposition of the active sites of a-N-acetylgalactosaminidase (gray) and
B. subtilis 6-phospho-a-glucosidase (green) (PDB 1NRH).
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conditions. The release of NAD+ was confirmed by high-performance
liquid chromatography analysis using standards (data not shown). The
acid ammonium-sulfate–treated enzyme was inactive after resolubili-
zation; complete activity was restored by exogenous addition of
NAD+, but not by related compounds including NADH (Supplemen-
tary Fig. 6 online). The same dependence of NAD+ was also found for
the activity with GalNAcb-pNP, confirming that this is an intrinsic
activity of the enzyme (Supplementary Fig. 7 online).
The overall fold of the a-N-acetylgalactosaminidase is unique
among the more than 370 glycosidases with known three-dimensional
structures (carbohydrate-active enzyme database at http://www.CAZY.
org/). A Dali search23 for structural homologs within the nonredun-
dant set of protein structures from the Protein Data Bank revealed
that the closest structural relatives belong to the Gfo/Idh/MocA
oxidoreductase family (Z-score of 29.4 and r.m.s. deviation of 3.0 Å
for 329 equivalent Ca-atoms for the closest structural neighbor,
namely Zymomonas mobilis glucose-fructose oxidoreductase,
1OFG24) (Fig. 2b). More distant structural homologs are all identified
by means of the classical Rossmann fold. The structural similarity
extends to the level of the active-site architecture, where the spatial
arrangement of the cofactor and several key residues is conserved,
suggesting a common ancestor that has evolved its NAD+-based
molecular mechanism to adapt to diverse metabolic requirements.
Active site of the a-N-acetylgalactosaminidase
The complex with the reaction product, GalNAc, showed the carbo-
hydrate inside a narrow pocket situated in the middle of a large crater.
The wide opening of the crater appears suitable for the accommoda-
tion of large aglycon structures such as the blood group A antigen. The
GalNAc moiety is found close to NAD+ with the C-3 atom of the
sugar 3 Å away from the C-4 atom of the nicotinamide ring (Fig. 2c).
Four residues, Tyr307, Tyr225, His228 and Glu149, which appear to be
important for the interactions with the carbohydrate (Supplementary
Fig. 8 online), are invariant within the GH109 family (Supplementary
Fig. 9b online).
What governs the preference of the enzyme for GalNAc over Gal?
Replacement of the C-2 acetamido group by a hydroxyl substantially
impairs enzyme-substrate interaction, as suggested by a 2,000-fold
reduction in kcat for the hydrolysis of Gala-pNP compared with
GalNAca-pNP and by a more than tenfold increase in Km
(Table 2). The structure of a-N-acetylgalactosaminidase in complex
with GalNAc shows that the interaction of Tyr307 with the carbonyl
oxygen of the acetamido group of the substrate is probably responsible
for the preference for GalNAc substrates.
Our finding that the second family member from B. fragilis
(AM039446) did not exhibit a-N-acetylgalactosaminidase activity
suggests that the family includes enzymes acting on different sub-
strates. Alternative substrate specificity might originate from chemical
variability at C-4, C-5 and/or C-6, as NAD+ and the invariant residues
impose invariant interactions with the C-2 and C-3 substituents of the
carbohydrate. Indeed, in the complex structure, OH-4 establishes
hydrogen bonds with the conserved Tyr179 and residue Arg213,
whereas no hydrogen bonding partner could be observed for OH-6.
This exo-cyclic hydroxyl is surrounded by residues Leu183, Val186,
Glu209 and Arg213. Whereas Leu183 is strictly conserved in all
members of GH109, the three latter residues are conserved only in
the branch of the evolutionary tree comprising E. meningosepticum
and the enzymes from Flavobacterium sp. MED217 and Robigitalea
biformata HTCC2501 (Supplementary Figs. 1a and 9a online). These
three enzymes are also characterized by a B15-residue insertion at the
tip of the a-helical bundle.
The catalytic mechanism of the a-N-acetylgalactosaminidase
Although the a-N-acetylgalactosaminidase and the glycosidases from
family GH4 differ in their overall protein folds, their active-site
architectures show striking similarities (Fig. 2d), thereby constituting
a beautiful example of convergent evolution. The glycoside hydrolase
family GH4 groups together a- and b-glycosidases that have been
shown recently to use an NAD+-dependent mechanism that is
highly unusual for glycosidic bond cleavage19–21. The structural
superimposition of the active site of a-N-acetylgalactosaminidase
onto those of Bacillus subtilis phospho-a-glucosidase, GlvA20 and
Thermotoga maritima 6-phospho-b-glycosidase, BglT25, reveals a
perfect overlap of the dinucleotide cofactors, the sugar rings and a
tyrosine residue.
Family GH4 enzymes contain a divalent metal ion coordinated by a
conserved cysteine, a conserved histidine and the nicotinamide group
and thought to stabilize an enodiolate-reaction intermediate20. Nota-
bly, the crystal structure of the a-N-acetylgalactosaminidase is devoid
of any metal ion, in agreement with the observation that the enzyme
does not display any metal ion requirements (Supplementary Fig. 2
online). Monitoring of the reaction catalyzed by a-N-acetylgalactosa-
minidase indicated that the enzyme proceeds with a mechanism that
leads to retention of the anomeric configuration and concomitant
exchange of the GalNAc H-2 atom for a solvent proton (Supplemen-
tary Results online). These results parallel exactly those of family GH4
glycosidases and therefore indicate that GH109 enzymes most likely
operate by a similar mechanism. In this mechanism, an ‘onboard’
NAD+ molecule oxidizes the substrate at C-3, thereby acidifying
the proton at C-2. Deprotonation of C-2 by an enzymatic base
with concomitant elimination of the glycosidic oxygen generates a
1,2-unsaturated intermediate. The reaction is completed by addition
of water to the Michael-like acceptor and reduction of the resulting
ketone by the onboard NADH molecule, which returns to the initial
NAD+ state, ready for another catalytic cycle (Supplementary Fig. 10
online). This mechanism, found first in family GH4 enzymes, allows
cleavage of thioglycosides26, a feature that is extremely rare among
‘classical’ glycosidases. Thin layer chromatography (TLC) analysis
showed that a-N-acetylgalactosaminidase is indeed able to cleave
benzyl-1-thio-a-N-acetylgalactosaminide (data not shown).
During the reaction catalyzed by GH4 glycosidases, departure of the
aglycone is thought to be acid catalyzed20,25, but the role and identity
of the acid catalyst is still uncertain. Interestingly, the structure of the
a-N-acetylgalactosaminidase does not reveal any suitable residue to
protonate the interosidic atom and suggests that this step is perhaps
unnecessary in family GH109. This is perfectly compatible with the
observed activity with benzyl-1-thio-a-N-acetylgalactosaminide and
provides a structural explanation of the hydrolysis of both a- and
b-anomers of pNP substrates; indeed only a minor adjustment of the
side chain of His181 is necessary to accommodate a b-linked substrate.
After family GH4, family GH109 constitutes the second glycosidase
family that displays structural and mechanistic relatedness to oxido-
reductases. There is nothing in the a-N-acetylgalactosaminidase
sequence that suggested hydrolytic activity on glycosides. In conse-
quence it is conceivable that other distant homologs of known
oxidoreductases may also correspond to glycosidases and the reper-
toire of this category of enzymes might further develop. We note a
very distant but intriguing similarity between family GH109 members
and a recently discovered T. forsythensis sialidase27.
Improved enzymes for conversion of group B RBCs – family GH110
Of the five isolates found to express a-galactosidase activity with the
B tetrasaccharide-AMC at neutral pH, one isolate (no. 2,357) from a
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Streptomyces griseoplanus strain exhibited the highest enzyme activity
in lysates and was found to secrete the a-galactosidase enzyme into the
medium. Initial attempts to purify the enzyme from the medium
failed because of an insufficient amount of enzyme, and we therefore
screened different nutrient carbon sources using minimal medium in
an attempt to enhance secretion. A 10- to 40-fold induction of
secretion was achieved with galactose and lactose (Supplementary
Methods online), and an enzyme with a molecular weight of
B75 kDa was isolated from the medium. A number of peptide
sequences (S1-S7) were obtained by Edman degradation and
tandem mass spectrometry, and database searches identified weak
sequence similarities with a putative protein from Streptomyces
avermitilis. Further searches with the S. avermitilis sequence identified
four additional genes with substantial similarity from Bacteriodes
fragilis and Bacteriodes thetaiotaomicron (Supplementary Figs. 1b
and 9b and Supplementary Methods online). All five identified
genes were cloned by PCR from their corresponding genomic
DNA, expressed in E. coli as His6-tagged proteins, and shown to
encode a-galactosidases when analyzed with a B tetrasaccharide-AMC
substrate (data not shown). The lack of sequence similarity
between the newly identified a-galactosidases and any known glyco-
sidase in the CAZY database allows us to define the glycosidase family
GH110. One of the two a-galactosidase homologs found in B. fragilis
NCTC 9343 (designated FragA, EMBL Nucleotide Sequence
Database accession no. AM109955) was expressed in E. coli without
its N-terminal signal sequence (amino acids 23–605) with a yield of
500 mg/l, purified to homogeneity, and used for further studies.
The substrate specificity and kinetic properties of the recombinant
FragA a-galactosidase are presented in Tables 1 and 2. The enzyme has
a broad pH optimum between 5 and 7.5 with the B tetrasaccharide-
AMC substrate (Supplementary Fig. 3b online). Interestingly, the
recombinant FragA enzyme exhibited low activity with the Gala-pNP
substrate (0.3 U/mg) compared to the blood group B substrate (6.6
U/mg) (Table 2), whereas the purified endogenous enzyme from
S. griseoplanus did not exhibit detectable activity with the Gala-pNP
substrate (data not shown). The substrate specificity was remarkably
stringent for a-1,3-linked galactose in the branched blood group B
structure (Table 1 and Supplementary Fig. 4b online). The enzyme
cleaved neither a4Gal linkages found in P1 and Pk blood group
antigens nor the a3Gal linkage in the linear B structure without
fucose (the so-called Galili antigen). The FragA a-galactosidase has
more than 300-fold higher activity with the blood group B tetra-
saccharide-AMC substrate than the coffee bean enzyme, whereas the
inverse (100-fold) is the case for the Gala-pNP substrate (Tables 1 and
2). One a-galactosidase with neutral pH optimum has been isolated
previously from the marine bacterium Pseudoalteromonas sp. (KMM
701) with a specific activity of 9.8 U/mg with the Gala-pNP sub-
strate11, but given the different properties reported, this enzyme is
probably unrelated to the genes described here. We are attempting to
crystallize the a-galactosidase to further elucidate the catalytic
mechanism of this enzyme family.
Enzymatic conversion of blood group A, B and AB RBCs at
neutral pH
The two glycosidase families described here contain enzymes that have
highly suitable kinetic properties for enzymatic removal of A and B
antigens from the surface of RBCs. We first developed a buffer system
for enzymatic conversion of RBCs with the recombinant E. meningo-
septicum. The recombinant enzyme has an isoelectric point of 7.6 as
shown by isoelectrofocusing, and analysis of the electrostatic surface of
the crystal structure indicated that the protein surface near the
catalytic region is slightly positive. We therefore hypothesized that
Table 3 Blood group typing of ECO RBCs with enzyme dose titrations
ECO RBCs A-zyme dose/ml pRBCs (mg) B-zyme dose/ml pRBCs (mg)
ABO typing resultsa
Ortho anti-A ES-15 Ortho anti-B Diagast anti-B
IS 4 1C IS 4 1C IS 4 1C IS 4 1C
A1-ECO RBCs 0.73 0 0 0 0
0.60 0 0 0 0
0.50 0 0 0 0
0.37 0 0 0 0
0.23 0 0 Vw+ 0
0.13 0 0 W+ W+
0.03 0 0 1+ 1+
B-ECO RBCs 0.02 0 0 0 0
0.01 0 0 0 0
0.005 0 0 vw w
0.0025 0 w 1 2
0.0013 0 2 1 3
0.0006 w 2 2 3
A1B-ECO RBCs 0.73 0.02 0 0 0 0 0 0 0 0
0.60 0.01 0 0 0 0 0 0 0 0
0.50 0.005 0 0 0 0 0 0 0 0
0.37 0.0025 0 0 0 0 0 vw+ w+ w+
0.23 0.0013 0 0 0 0 0 w+ w+ 1+
0.13 0.0006 0 0 vw+ w+ 0 1+ 1+ 1+
0.03 0.0003 1+ 2+ 2+ 2+ vw+ 2+ 1+ 2+
aTyping with licensed ABO typing reagents and methods as indicated using agglutination score 0 to 4+.
IS, immediate spin reactions; pRBCs, packed RBCs.
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the enzyme at neutral pH could interact with the strong negative
charges of primarily sialic acids on the surface of RBCs leading to local
concentration of the enzyme at substrate sites. Enzyme conversion was
performed at low ionic strength in glycine buffer with varying
concentrations of NaCl. Complete removal of A antigens was achieved
in 200 mM glycine (pH 6.8) with 3 mM NaCl as evaluated by
agglutination typing with routine licensed reagents and methods as
well as by sensitive fluorescence-activated cell sorting (FACS) analysis
(Table 3 and Fig. 3). In this buffer system 490% of the enzyme was
associated with the RBCs after centrifugation. In contrast, increasing
the NaCl concentration to 10 mM or more resulted in release of the
enzyme from the RBCs. In agreement with our hypothesis, increased
NaCl also negatively affected the conversion efficiency, showing that
the interaction is important for efficiency (data not shown). Impor-
tantly, this feature also allowed a simple and efficient wash-removal
process of the enzyme involving three wash cycles in isotonic PBS. The
residual enzyme load associated with washed cells was consistently less
than 40 ng/ml of packed RBCs as measured with a sensitive capture
enzyme-linked immunosorbent assay using total detergent lysates of
cells (data not shown). The conversion process is linear with enzyme
dose and time, and has a low enzyme consumption of 300 mg/ml
packed RBCs for 60 min of incubation. RBCs from more than 200
group A1 and A2 donor units have been analyzed and all were
converted efficiently. Approximately 60 mg enzyme is required to
convert one unit (B200 ml packed RBCs) of blood group A1 cells.
Conversion of the weak blood group A2 subgroup, however, requires
only 15 mg enzyme. The conversion process does not affect physio-
logic and metabolic parameters of RBCs, including osmotic fragility,
levels of 2,3-DPG, ATP and methemoglobin (data not shown).
We selected the recombinant FragA a-galactosidase because it has a
slightly basic isoelectric point similar to the E. meningosepticum
enzyme; using the same glycine buffer system as for group A RBCs,
we effectively produced, by enzymatic conversion of blood group B
RBCs with the FragA enzyme, B-ECO RBCs that type as group O by
licensed reagents and methods used in clinical blood bank practice
(Table 3). Similar to our findings with the A conversion process, the
low ionic strength is required for efficient conversion, and increasing
NaCl concentration in the glycine buffer or use of other buffer systems
with higher ionic strength such as PBS and phosphate-citrate
decreases the efficiency. The conversion process is linear with enzyme
dose and time, and has a very low enzyme consumption of 10 mg/ml
packed RBCs for 60 min incubation period. RBCs from more than 50
group B donors have been analyzed in repeat studies and all were
converted efficiently with 10 mg/ml packed RBCs (data not shown).
Thus, less than 2 mg enzyme are required to convert one unit of blood
group B cells. Because the two enzymes used for conversion of A and B
RBCs were selected for similar properties and function efficiently in
the same conversion buffer system, we were able to convert blood
group AB RBCs efficiently both by sequential enzyme digest as well as
with a one-pot enzyme digest with the a-N-acetylgalactosaminidase
and a-galactosidase (Table 3).
The efficiency of the conversion processes was evaluated by sensitive
FACS analysis using anti-A and anti-B reagents (Fig. 3). FDA-licensed
anti-A blood grouping reagents showed complete removal of A
antigens on a homogenous population of RBCs. The high sensitivity
of the assay was demonstrated by clear detection of the low amount of
A antigen present on the weak Ax subgroup RBCs. We also included a
highly sensitive anti-A monoclonal antibody, ES-15, that detects the
minimal amount of A antigen, which is present naturally on group B
RBCs28. ES-15 clearly detected both the A antigen on Ax subgroup
RBCs and on group B RBCs. The ES-15 reactivity with B RBCs was
sensitive to treatment with the a-N-acetylgalactosaminidase, confirm-
ing that the antibody does detect the minor amounts of A antigens on
B RBCs. The ES-15 reagent, but not licensed anti-A reagents, did show
a tendency toward a shift in the histogram curve (Fig. 3a, middle
panel) of A-ECO RBCs, indicating that miniscule amounts of A
antigens at a level considerably lower than on group B RBC could
be detected on A1-ECO but not on A2-ECO RBCs. Similarly, FDA-
licensed anti-B reagents showed a homogeneous B-ECO cell popula-
tion almost nonreactive with anti-B. The high sensitivity of this assay
was demonstrated by including ABweak subgroup cells, on which the
weakly expressed B antigens were readily detected. Several licensed
anti-B typing reagents were tested (data not shown), and one CE-
approved anti-B blood grouping reagent, Diagast, was found to
exhibit higher sensitivity with the ABweak cells and a minor proportion
of B-ECO cells were weakly labeled by the Diagast anti-B
antibody, although at a level lower than the weak ABweak subgroup
cells. Analysis with an anti-H antibody was included to demonstrate
appearance of the appropriate H antigen product after removal of
either aGalNAc or aGal terminal residues, and both A-ECO and
B-ECO RBCs expressed H similar to group O RBCs as expected
(Fig. 3, lower panels).
Further biochemical analysis of ECO cells included TLC of glyco-
lipids as well as SDS-PAGE western blot of total membrane (glyco)-
protein extracts. TLC of glycolipid extracts revealed essentially
complete conversion of blood group A and B glycolipid species to
the corresponding H species, including the major monosialyl A and B
gangliosides designated G9A and G9B (Fig. 4). This was further
confirmed by mass spectrometric analysis of the glycolipid fractions
migrating in the region of the most abundant A-active glycolipid
species, designated Aa and Ab, which showed a complete absence of
the A glycolipid species in extracts from converted RBCs and the
presence of only the corresponding H1 and H2 products (data not
shown). The blood group A antigens are believed to be more complex
than B antigens in that a fraction of the A active glycolipids have a
repeated A structure13. This structure has been found only on
glycolipids and not on glycoproteins. Cleavage of the terminal GalNAc
residue of these glycolipids will result in exposure of an H structure
extended from an internal A structure in H-Aa and H-Ab glycolipids
(Fig. 4). Both subgroups A1 and A2 RBCs contain these glycolipids,
and after enzyme conversion the A1 subgroup RBCs will contain more
than the A2 subgroup. This H antigen resembles the mucin-type H
structure (Fuca1-2Galb1-3GalNAca1-O-Ser/Thr) expressed in epithe-
lial tissues of all ABO groups29 and is not reactive with typing anti-A
antibodies. It is therefore our hypothesis that these A-associated H-A
structures found only on glycolipids do not represent antigens
recognized by human anti-A immunity, but clinical studies are
required to address this. The analysis of glycolipids from converted
cells also showed that the E. meningosepticum a-N-acetylgalactosami-
nidase does not cleave the major glycolipid globoside (Gb4, blood
group P antigen terminating by a GalNAcb1-3 linkage) in RBC
membranes (Fig. 4), despite the finding that the enzyme has low
but detectable activity with GalNAcb-pNP (Table 2). The glycolipid
analysis clearly demonstrated the effectiveness of the process as well as
how selective the process is in digesting only the blood group A and B
terminating glycolipids. Western blot with the sensitive ES-15 anti-A
and the Diagast anti-B monoclonal antibodies revealed very faint
diffuse staining of membrane glycoproteins of A-ECO and B-ECO
RBCs, respectively (data not shown), which is in agreement with
the findings that FACS analysis with the most sensitive mono-
clonal antibody reagents reveal minute amounts of residual A and B
antigens (Fig. 3).
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DISCUSSION
The present study identified two prokaryotic glycosidase gene families,
not previously described, containing a-N-acetylgalactosaminidase
(GH109) and a-galactosidase (GH110) activities with neutral pH
optima and high activity with blood group A and B substrates,
respectively. The GH109 a-N-acetylgalactosaminidase family repre-
sents to our knowledge the only known source of enzymes suitable
for efficient enzymatic conversion of blood group A RBCs. The
GH110 a-galactosidase family has unprecedented restricted specificity
for blood group B substrates. The enzymes are expressed with high
yields in E. coli and because they have similar properties, a single
common conversion buffer system and process can be used to remove
A and B antigens and produce ECO RBCs from A, B and AB RBCs
that type as blood group O with routine licensed typing reagents and
methods. Extensive FACS and biochemical analyses confirm the
efficient removal of the immunodominant A and B antigens and
exposure of the underlying H antigens. The current process, which is
performed manually at neutral pH, is scalable to automated full-unit
conversions, and ECO cells produced by this method are predicted to
survive and function in a manner equivalent to native group O RBCs
in non-ABO matched individuals as reported previously for B-ECO
RBCs9. The process has a projected consumption of B60 mg
(A-ECO) and 2 mg (B-ECO) recombinant enzyme with 60-min
enzyme treatment per unit RBCs. This is B30- (A-ECO) and
1,000-fold less (B-ECO) enzyme than the conversion protocol devel-
oped for group B RBCs with the Coffee bean a-galactosidase9.
Accordingly, we believe that automated cost-effective processes can
be developed for practical use in transfusion medicine.
Glycosidases are grouped in over 100 sequence-based families that
have been shown to correlate with the 3-D structure and molecular
mechanisms of catalysis30,31. The glycosidase families identified in this
study exhibit no substantial sequence similarity to any other glycosi-
dase families, including families GH4, GH27, GH36 and GH57 (CAZY
database at http://afmb.cnrs-mrs.fr/CAZY/), which contain all pre-
viously reported a-N-acetylgalactosaminidases and a-galactosidases,
including the two most studied enzymes for blood group B red-cell
conversion derived from green coffee and from soy beans32,33, as well
as enzymes used previously to convert weak blood group A2 RBCs
14,34.
Figure 4 TLC analysis of native and ECO RBC
glycolipids. (a,b) Total upper neutral (UN) and
monosialyl (MS) glycolipid fractions from RBC’s
were separated on high-performance thin layer
chromatography plates. Arrows indicate mobility
of major blood group ABH glycolipids as well as
Gb4 (globoside) and SPG (sialyl-paragloboside,
NeuAca2-6Galb1-4GlcNAca1-3Galb1-4Glcb1-
Cer). The nomenclature of ABH active glycolipids
used for type 2 chain ABH active glycolipids is
H1/B1/A
a, H2/B2/A
b and H3/B3/A
c with increasing
number of Galb1-4GlcNAc disaccharide units3. Although, glycolipid bands separated by TLC may contain multiple species, the H1 (Fuca1-2Galb1-
4GlcNAcb1-3Galb1-4Glcb1-Ceramide), H2 (as H1 with one lactosamine unit Galb1-4GlcNAcb1-3 inserted) and H3 (as H1 with two lactosamine units Galb1-
4GlcNAcb1-3 inserted) bands in O UN clearly represent major distinct bands with different mobilities. The corresponding A (a) and B (b) structures Aa/B1,
Ab/B2 and A
c/B3 GalNAc/Gala1-3 added to the penultimate bGal residues in H structures in A and B UN are similarly distinct bands. Comparison with the
profile of ECO reveals disappearance of A and B variants and appearance of the corresponding H bands. This includes the branched G9A/B glycolipid
(GalNAc/Gala1-3[Fuca1-2]Galb1-4GlcNAcb1-3[NeuAca2-3Galb1-4GlcNAcb1-6]Galb1-4GlcNAcb1-3Galb1-4Glcb1-Ceramide), which is a branched structure
with one branch terminated by sialic acid and one branch with an ABH determinant. Group A active glycolipids are more complex than B in that they include
the internal A structures A-associated H (designated H-Aa and H-Ab), which migrate just below the H2 and H3 glycolipids, respectively. The A
b glycolipid
band contains a mixture of type 2 chain Ab and the repetitive A-Aa glycolipid (GalNAca1-3(Fuca1-2)Galb1-3GalNAca1-3(Fuca1-2)Galb1-4GlcNAcb1-
4Galb1-4Glcb1-Ceramide), whereas the Ac band contains type 2 chain Ac and the repetitive A-Aa glycolipid3. The loading corresponds to glycolipid fractions
derived from 4 ml of packed RBCs.
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Figure 3 FACS of native and ECO RBCs. Histograms show the degree
of staining of RBCs with different blood grouping reagents. The x-axis
represents the fluorescence intensity on a logarithmic scale whereas the
y-axis shows the number of RBCs evaluated. Solid lines represent untreated
native RBCs and dashed lines in the same color are the enzyme-treated
RBCs from the same individual (see color code below). The dotted black line
in the H-antigen staining histogram (lower panels) represents the negative
control, RBCs from a Bombay (Oh) donor lacking any A, B or H antigen on
RBCs. To facilitate interpretation of the histograms, enzyme-treated group O
and subgroup RBC were not included. However, their curves completely
overlap the result for native group O (data not shown). (a) RBCs were
stained with licensed monoclonal anti-A blood grouping reagent (upper
panel), the monoclonal ES-15 anti-A research reagent (middle panel) and
direct-conjugated monoclonal anti-H (lower panel). Red, blood group A1;
green, A2; blue, Ax; orange, B; black, O. The weak Ax subgroup control was
from a serologically and genetically characterized test RBC donor with the
Ax-1 O1 genotype. Group B RBCs were tested only with ES-15 as licensed
anti-A reagents do not detect any A antigen on their surface. (b) RBCs were
stained with the monoclonal licensed anti-B blood grouping reagents from
Ortho (US FDA-licensed) (upper panel), Diagast (CE-approved in European
Union) (middle panel), and direct-conjugated monoclonal anti-H (lower
panel). Red, blood group B; green, subgroup A2Bw; black, O.
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The human lysosomal a-galactosidase and a-N-acetylgalactosamini-
dase are close homologs to each other and are both members of family
GH27. All of these enzymes are characterized by having exclusively a
classical catalytic machinery and molecular mechanism leading to
retention of the anomeric configuration35,36, with the exception of
family GH4 enzymes that use NAD+ and Mn2+ as cofactors19–21. The
a-N-acetylgalactosaminidase family described here is unusual in that it
uses an NAD+-based mechanism, similarly to family GH4 enzymes.
Interestingly, the proposed mechanism of the a-N-acetylgalactosami-
nidase is not prone to transglycosylation, a known side reaction of
retaining glycosidases, which can fortuitously give rise to nonnatural
structures at high substrate concentration.
Preferred properties of an exoglycosidase suitable for enzymatic
conversion of RBCs include the following parameters: (i) high sub-
strate specificity for the blood group antigens to restrict the reaction to
the immunodominant blood group A and B antigens; (ii) reaction
conditions suitable for maintenance of RBC integrity and functions;
(iii) high efficiency in cleavage of antigens on the RBC surface to
minimize residual antigens and enzyme consumption; and (iv) proper-
ties to facilitate enzyme removal from the RBCs by routine cell-washing
techniques. The glycosidases presented in this study offer all of these
characteristics. In particular, the a-galactosidases represent, to our
knowledge, the only a3-linkage–specific exo-galactosidases reported
and their specificity for the branched blood group B trisaccharide
structure suggests restricted substrate specificity. This has practical
implications as human RBCs express other aGal-terminating struc-
tures, including a4Gal residues in the P1 and Pk blood group antigens,
which are cleaved by the a-galactosidases used in previous studies32,33.
The two enzyme families described here perform efficiently in conver-
sion of RBCs; ECO cells type as group O with all licensed reagents; and
sensitive FACS and glycolipid analyses confirm efficient removal of A
and B antigens (Figs. 3 and 4). Finally, enzymes from both families are
slightly basic and associate with the negatively charged RBCs through
ionic interactions, thereby enabling efficient removal with isotonic
buffer solutions, such as PBS, used for cell washing.
The availability of enzymes from these glycosidase families has
resulted in the development of a simple and efficient process for
producing universal RBCs that type as blood group O. Clinical
translation of this approach may allow improvement of the blood
supply and enhancement of patient safety in transfusion medicine.
METHODS
Enzyme assays. Structures of substrates are shown in Tables 1 and 2. The AMC
derivatives were custom synthesized by Alberta Chemical Research Council.
The 8-methoxycarbonyloctyl ((CH2)8COOCH3, MCO) oligosaccharides were
obtained from the same source, and other substrates were obtained from
Sigma-Aldrich, V-LABS and Oxford Glyco Sciences. Assays with oligosacchar-
ide structures were performed at 26 1C in reaction mixtures of 10 ml. Product
formation was analyzed by TLC using silica gel–coated TLC plates (Merck). The
AMC-labeled tetrasaccharides were used for screening and one unit of enzyme
activity was defined as the amount of enzyme required to cleave 1 mmole of A
or B tetrasaccharide-AMC substrate per minute using a 10-ml reaction volume
with 100 mM NaPO4, pH 6.8, 50 mM NaCl, 0.25 mg/ml of BSA and 0.1 mM
substrate. Importantly, calculation of the specific activities with these substrates
was based on complete cleavage of the substrate in the reaction volume. Assays
with chromogenic pNP substrates were carried out at 26 1C in reaction
mixtures of 400 ml with 100 mM NaPO4, pH 6.8, 50 mM NaCl and 2.5 mM
substrate. Reactions were terminated by addition of 600 ml 1 M
Na2CO3 and pNP formation was quantified at 405 nm (e ¼ 18,300 cm–1
M–1 at pH 4 10). In the chromogenic assays all results were based on reactions
with consumption of o10% of the substrate. Determination of kinetic
parameters was performed using substrate concentrations of 0.5 to 3–10
times the obtained Km. Reactions with the a-N-acetylgalactosiminidase and
Gala-pNP, however, were carried out using 1–12 mM substrate, which is
substantially lower that the apparent Km.
Crystallization and data collection. Before crystallization the purification
buffer was extensively exchanged with 10 mM HEPES buffer at pH 7.5.
Recombinant a-N-acetylgalactosaminidase was crystallized using the hanging
drop vapor diffusion method by mixing equal amounts of protein at 21 mg/ml
with a solution consisting of 46–50% 2-methyl-2,4-pentanediol (MPD) and
75 mM sodium citrate at pH 6.25. Rod-shaped crystals appeared within 1 d and
belong to space group P6522 with cell dimensions of 88  88  300 Å and one
molecule per asymmetric unit. A MAD data set for a selenomethionylated
protein crystal, as well as a native data set was collected at beam line ID23-EH1
(ESRF, Grenoble) and a data set for a complex with GalNAc was collected at
beam line ID14-EH2 (ESRF, Grenoble). Before data collection, crystals were
flash-frozen in a nitrogen gas stream at 100 1K. Data were indexed and
integrated with MOSFLM37 and scaled with the program SCALA38. Data
collection statistics are summarized in Supplementary Table 1 online.
Structure solution and refinement. Data were prepared for phasing with
XPREP (Bruker). The selenium substructure was solved with SHELXD39,
taking advantage of data up to the highest resolution shell, and phasing
combined with solvent flattening was carried out with SHELXE40, leading to
a pseudo-free correlation coefficient of 70.5%. Starting from experimental
phases, an initial model comprising 361 residues (out of 429), 257 of which
docked into sequence, was automatically built with the ARP/wARP package41
and completed manually using TURBO-FRODO42. The resulting model was
refined against native data extending to 2.3-Å resolution with REFMAC43.
A random set of 4% (1,231) reflections was set aside for cross validation
purposes. Automated solvent building was performed with ARP/wARP41. For
the structure solution of the enzyme-GalNAc complex, the final native model
was subjected to rigid body refinement with REFMAC43 and further refinement
was carried out as described above, with 4.1% (1,111) of reflections, taken over
from the native data set, set apart for cross validation. The final protein
structures encompass residues Lys19 to Tyr444 and have correct stereochemical
properties, with all residues contained in the allowed regions of the Ramachan-
dran plot, as verified with WHATCHECK44. Refinement and structure quality
statistics are listed in Supplementary Table 1 online. Figure 1 was drawn with
ChemDraw, CambridgeSoft Corporation, and Figure 2 was generated with
PYMOL (DeLano, W.L. The PyMOL Molecular Graphics System (2002) on
http://www.pymol.org/).
Enzymatic conversion of RBCs with glycosidases at neutral pH. Standard
enzymatic conversion reactions were performed in 1 ml reaction mixtures
containing 200 mM glycine, pH 6.8 and 3 mM NaCl with 30% packed red
blood cells and enzyme as indicated. Fresh whole blood was obtained from
Oklahoma Blood Institute and buffy coat removed. RBCs were prewashed 1:1
and 1:4 vol/vol in conversion buffer before addition of enzyme. The conversion
reaction was incubated for 60 min with gentle mixing at 26 1C, followed by four
repeat washing cycles with 1:4 vol/vol of saline by centrifugation at 1,000 r.p.m.
The washed enzyme-treated ECO RBCs were ABO-typed according to standard
blood banking techniques using licensed monoclonal antibody reagents45.
Murine monoclonal Anti-A reagent obtained from Ortho. Undiluted, concen-
trated murine monoclonal anti-A typing reagent supplied for further manu-
facturing purposes by Celliance. Murine monoclonal Anti-B reagents obtained
from Ortho and Diagast.
Flow cytometry. Flow cytometry analysis of native and ECO RBCs was
performed using a FACScan flow cytometer (Becton Dickinson) with
monoclonal antibody reagents and phycoerythrin-labeled rat-anti-mouse kap-
pa immunoglobulin (Becton Dickinson). An FITC-conjugated monoclonal
anti-H (BRIC 231 from BITS/IBGRL) was also used. Briefly, 500,000 RBCs
were suspended in PBS in 96-well plates in a 50-ml reaction volume. Cells were
fixed for 10 min in 0.1% glutaraldehyde in PBS to prevent agglutination of
antigen-positive cells. After washing 3 in 150 ml PBS, cells were again
suspended in 50 ml PBS, after which 5 ml of undiluted primary antibody was
added and incubated for 10 min. After three washes and resuspension in 50 ml
PBS, 5 ml of undiluted secondary antibody was added. Cells were then analyzed
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after another three washes (as above) and resuspension in 300 ml PBS. All
incubations were carried out in darkness at 20 1C under gentle agitation. A total
of 10,000 events were evaluated and an RBC gate corresponding to B90% of all
cells was set during analysis of the data.
Glycolipid analysis. Glycosphingolipids were prepared essentially as previously
described46. Briefly, RBC membranes were extracted by homogenization in ten
volumes of isopropanol/hexane/water (55:25:20, vol/vol/vol), filtered, evapo-
rated and partitioned by Folch extraction method. The upper phase was
collected, evaporated, dialyzed and applied to a DEAE Sephadex column.
The pass-through fraction contained the total upper neutral lipids, and the
monosialyl fraction was eluted with 0.05 M ammonium acetate, evaporated
and dialyzed against water to remove acetate. Total upper neutral (UN) and
monosialyl (MS) glycolipid fractions were analyzed by high-performance thin-
layer chromatography. TLC plates (Merck) were developed using the solvent
system chloroform/methanol/0.5 M CaCl2 in water (50:40:10, vol/vol/vol).
Glycolipids were stained by heating with 0.05% orcinol in 0.5 M H2SO4.
Accession codes. EMBL Nucleotide Sequence Database: the nucleotide
sequences of the cloned genes reported in this paper were deposited with
accession nos. AM039444, AM039445, AM039446 AM039447, AM039448 and
AM039449 for the a-N-acetylgalactosaminidases and homologs; AM109953,
AM109954, M109955, AM109956 and AM109957 for the a-galactosidases.
Protein Data Bank: coordinates of the crystal structures have been deposited
with accession reference nos. 2IXA and 2IXB.
Note: Supplementary information is available on the Nature Biotechnology website.
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 ambr® 250 modular
Performance Data
ambr® 250 modular provides a scale down model 
for bench top and pilot plant scale bioreactors.
ambr 250 modular is a high performance system 
that is easy to set up and allows users to run 
multiple parallel bioreactors.
Precise and Accurate Control
Good control is essential if the ambr 250 modular is to be used for multi 
parallel experiments, where any process deviation needs to be eliminated. 
Figure 1:
Results showing very well controlled process pH and temperature for  
a high cell density microbial fermentation. Precision and consistency  
is crucial if experiments are to be run in parallel for comparison.
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Figure 3:   
Showing carbon dioxide evaluation in 4 bioreactor in parallel
Consistent
Due to the precise control of all process parameter, the cultures run 
under the same condition have very good consistency and repeatability; 
an essential characteristic for any multi parallel bioreactor system.
Figure 2:  
Results showing DO control of 8 bioreactor system 
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and consistent behaviour  
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a 
- R&
D
 and process developm
ent for industrial biotech
- Process robustness experim
entation in support of Q
bD
 studies
- Autom
ation of D
oE approaches to process autom
ation
- Biofuels feedstock preparation R&
D
Applications
am
br® 250 autom
atically controls, feeds and sam
ples 12 or 24  
bioreactor/ferm
enter vessels in parallel
Bioreactor controller
- Three gasses per bioreactor w
ith m
ass 
flow
 sensor: 
- M
am
m
alian
 
- O
2
 
- CO
2
 
- N
2 /air
- M
icrobial
 
- O
2
 
- Air
 
- N
2
- Four positive displacem
ent liquid pum
ps 
per bioreactor for high precision at low
 
flow
 rates
- Individual bioreactor tem
perature 
control w
ith heating or cooling
- Individual im
peller speed control per 
bioreactor
- O
ptional exhaust gas analysis for O
U
R/CER
- Integrated CIP/SIP for pum
ps and  
liquid lines
Control softw
are
- Fully flexible set up and control 
interface w
ith sim
ple, dialogue based 
interaction for quick  
and easy process creation.
- Fine tuning options including 
program
m
able  
PID
 control loops and other advanced 
features
- am
br 250 softw
are is fully integrated 
w
ith U
m
etrics M
O
D
D
E D
esign of 
Experim
ent (D
oE) application, enabling 
stream
lined operation in execution of 
large D
oE studies.
Functions
am
br® 250 is configurable for m
icrobial ferm
entation or m
am
m
alian 
cell culture and able to m
odel a w
ide range of requirem
ents in a 
variety of applications across biopharm
 as w
ell as individual biotech.
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Phone +44.1763.227200
Fax +44.1763.227201
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BIOSTAT® B   
The Multi-Talented Bioreactor for  
Research and Development
BIOSTAT® B 
   at a Glance
Our BIOSTAT® B is the ideal benchtop bioreactor for your 
lab. The multi-talented control tower opens up a new 
world of flexibility for your changing requirements. Use 
it as single or twin configuration, chose your cultivation 
chamber from our proven range of options:
– Conventional stirred tank glass vessels
– Single-use stirred tank vessel Univessel® SU
– Wave-mixed Flexsafe RM bags
 Industries
–  Biopharmaceuticals
–  Vaccines
–  Cell therapies
–  Industrial biotechnology
–  Basic research
–  Education
 Process Modes
–  Batch
–  Fed-batch
–  Continuous
–  Perfusion
 Cells
– Mammalian
– Insect
– Microbial
– Yeast
– Fungi
 Applications
–  Process development  
and optimization
–  Scale-up and scaledown  
studies
–  Seed expansion
–  Cell bank production
–  Protein supply
Proven Technology
With several thousand installations in
over 50 countries, BIOSTAT® B is the most
successful benchtop bioreactor in the
world. Benefit from our experience and
collaboration with customers worldwide.
Configurable Design
Contact your Sartorius representative  
and configure your BIOSTAT® B bioreactor
solution matching your specific needs.
Benefit from our flexible and scalable
options.
Reliable Quality 
Every BIOSTAT® B is thoroughly tested
before it leaves our production facilities in
Germany. Benefit from our global service
and application specialist network for
professional installation and training.
UniVessel® SU
Our single-use 2 L stirred tank vessel  
for cell culture applications combines 
scalable design with all benefits of 
disposable solutions. No more worries 
about challenging timelines, workload  
or cross-contamination. Get started  
within minutes. 
UniVessel® Glass
Our proven autoclavable borosilicate
glass culture vessel is available in four
different volumes: 1 L, 2 L, 5 L and 10 L,
for all kinds of cell culture and microbial
applications. 
Fully interchangable glass  
and single-use stirred-tank  
culture vessels.
Benefits
 − Fully single-use vessel, DO and  
pH sensors
 − Proven, scalable stirred tank design
 − Connection kit to upgrade existing 
bioreactor controllers
Benefits
 − Classic stirred-tank design simplifies 
your scale-up and scale-down studies
 − Extensive performance and 
engineering data package available
 − Save additional investment and use 
our special design for small autoclaves
BIOSTAT® B –  
        The Universal Controller  
   for Your Lab 
 − Mammalian, insect, microbial and plant cell culture
 − Process development, optimization, characterization
 − Seed and small scale production
 − Protein supply
Main Applications
 − Mammalian, insect and plant cell culture
 − Process development, optimization, characterization
 − Seed and small scale production
 − Production of cell banks
Main Applications
 − Mammalian, insect, plant and low density  
microbial culture
 − Seed and small scale production
 − Protein supply
 − Stem cell expansion and production
Main Applications
Watch Video: 
www.sartorius.com/ video-biostat-b
 − Mammalian, insect, plant and low density  
microbial culture
 − Seed and small scale production
 − Protein supply
 − Stem cell expansion and production
RM Rocker 
Our proven wave-mixed bioreactor consists of a rocker unit with 
bag holder and pillow-shaped Flexsafe RM single-use bags for  
culture volumes from 100 mL to 25 L. Use it as basic system or in 
combination with the BIOSTAT® B control tower and single-use  
optical pH and DO sensors to enable advanced control strategies 
for batch, fed-batch and continuous perfusion.
Benefits
 − Optimized film formula, traceability of 
raw materials and control of the entire 
Flexsafe RM bag manufacturing process 
assure excellent and consistent cell 
growth of the most sensitive cell lines
 − Space-saving, individual control of two 
RM bags on the same rocker platform
 − Easy-to-use rocker with advanced alarms 
and safety features for reliable cultivation
Main Applications
12” Touch Screen
with closed frame; protected 
against water splashes and  
dust deposits. Easy-to-use and  
reliable operation of your 
 BIOSTAT® B due to intuitive  
design of human-machine-
interface and advanced touch-
screen technology – even while 
wearing laboratory gloves.
Control Tower 
The control tower contains 
both the aeration, pump and 
temperature control modules, 
saving valuable bench space in 
your lab.
New Standards for 
Interference-Free 
Measurements 
All inlets and ports for, e.g. 
cooling water, process gasses, 
electricity, ethernet and poten-
tial-free alarm contact are  
located on the rear panel of the 
control tower. An equipotential 
bonding conductor shields the 
bioreactor against electromag-
netic current and ensures inter-
ference-free measurements 
during your processes.
BIOSTAT® B 
 Configurable Flexibility
Single | Twin Control Tower 
One BIOSTAT® B control tower can control up to two vessels completely
independently to save valuable lab space. Select culture vessel types  
and volumes from our range of options, e.g. glass vessel, single-use vessel  
or wave-mixed Flexsafe® RM bags.
Fast Load Peristaltic 
Pumps 
Insert the tubing in seconds: 
Open, insert tube, close, done! 
No more pinched fingers or  
torn gloves. Up to four internal 
pumps can be selected per  
vessel. Choose between speed- 
controlled pumps and fixed-
speed pumps for feed and  
corrective agent addition.
Connections for 
Sensors and External 
Accessories
Quick-connect couplings make 
it easy to attach all cables and 
supplies to the culture vessels. 
All connections are clearly 
marked with the same names 
used on the rear control tower 
panel and in the local control 
software menu for fast, error 
proof identification.
Storage Tray 
A storage tray for accessories 
helps you organize your 
workplace.
Gas Inlet Flow Meter Gas OutletSolenoid Valve 
(4 max.)
MFC * 
(4 max.)
Sparger
Overlay
Switching CO2 from sparger to overlay
Air
O2
N2
CO2
Aeration Strategies
A series of flexible aeration options turns the BIOSTAT® B into a multi-
talented bioreactor for a wide range of different applications, including  
high-cell density microbial fermentation requiring considerable amounts  
of oxygen to high-cell density cell culture applications requiring removal  
of excessive carbon dioxide.
Five different gas lines, equipped with  
solenoid valves and|or up to four optional 
mass flow controllers and flow meters  
deliver ultimate flexibility and accuracy. 
The  BIOSTAT® B allows you to optionally 
switch between sparger and overlay supply 
of CO2 for pH control. In addition, a con-
stant air | CO2 mixture can be created in  
the overlay line to reproduce conditions  
like those prevailing in a CO2 incubator.
Various controller and hardware configura-
tions enable aeration strategies using air  
or oxygen or classical O2 enrichment of air. 
For anaerobic processes, the air inlet can  
be used for nitrogen. The standard built-in 
solenoid valves in combination with a flow 
meter ensure reliable gas supply for simple 
applications. Optional mass flow control-
lers provide exact flow rate control of  
individual gases. In combination with 
BioPAT® Xgas off-gas analysis, this allows 
mass balancing consumed and produced 
gases.
Microbial Applications  
                in Combination with UniVessel® Glass
Cell Culture and Multi-Purpose Applications  
         in Combination with UniVessel® Glass and UniVessel® SU
Air
Gas Inlet Flow  
Meter
Gas OutletSolenoid Valve 
(max. 2)
MFC* 
(max. 2)
O2
Sparger
*MFC = mass flow controller
*MFC = mass flow controller
The wave generated in the RM bags due
to the rocking motion ensures effective
gas exchange through the gas-liquid
interface. Four different gas lines for air, 
O2, N2 and CO2 are equipped with flow
meters and four high-precision mass flow 
controllers. An integrated pressure sensor 
continuously measures the pressure inside 
the bag. To ensure process safety, aeration 
is switched off when an upper threshold 
is reached.
You can configure your BIOSTAT® B 
aeration system in a similar way as your 
BIOSTAT® STR single-use stirred tank 
bioreactor. Get ready for seamless scale-up 
and -down, from laboratory scale to  
large scale single-use production.
Cell Culture Applications  
           in Combination with Our Rocking-Motion Bioreactor
Air
Gas Inlet Flow  
Meter
Gas OutletMFC*
N2
CO2
O2
Overlay
*MFC = mass flow controller
DCU – Local Control
The intuitive touch screen on the control tower is used to locally operate the BIOSTAT® B:
Since we introduced the first DCU-controlled bioreactors back in the late 
80’s, we have installed thousands of such bioreactors to date at leading 
companies in the pharmaceutical and biotech industry worldwide. We have 
continuously improved our robust, intuitive-use and industry-proven DCU 
control technology, now available in its fourth generation. It is our standard 
local control platform for our BIOSTAT® bioreactors, SARTOFLOW® crossflow
filtration units and FlexAct® configurable systems available for a large 
number of unit operations.
Aeration control Balances and gravimetric flow control
Overview  
of process 
parameters
Status displayOverview and close-up 
Culture vessels
Submenus
Pump 
module
Automatic pH Control
Control the pH of your culture by auto-
matic acid and base addition or by CO2 
aeration and base addition. If you want  
to use your BIOSTAT® B for both microbial 
and cell culture you can configure your 
bioreactor system with a combined acid 
control via CO2 aeration and acid addition.
Automatic DO Control
Besides classic DO cascade control, we  
have developed the unique advanced DO 
controller that gives you more flexibility  
to develop and optimize your DO control 
strategy.
The advanced DO controller supports paral-
lel adjustment of all DO affecting parame-
ter settings like stirrer speed and gas flow 
rates of air and pure oxygen, automatically 
and simultaneously to control the DO set 
point. Optionally, you can keep the total 
gas flow rate constant and the ratio of 
pure oxygen in the gas mixture is increased 
automatically to match the oxygen con-
sumption of the culture. This gives you ul-
timate flexibility to adapt your aeration 
strategy to your process requirements.
Base Acid
CO2
Automatic Feed Control and  
Continuous Processing
Design your process strategy or select dif-
ferent options. Configure your BIOSTAT® B 
with gravimetric feed control, gravimetric 
level control or substrate addition profiles. 
This enables you to run your BIOSTAT® B  
in batch, fed-batch, continuous or perfu-
sion mode.
BioPAT® MFCS – SCADA Process Control
BioPAT® MFCS is a multi-functional supervisory control and data acquisition software,  
specifically developed for bioprocessing applications in upstream and downstream.  
Every BIOSTAT® bioreactor comes with basic data recording functionality of our BioPAT® 
MFCS. Rely on more than 7,000 installations worldwide and over 25 years of experience.
–  Multi-user network access for up to 16 process units 
–  On-line and off-line sample data management, visualization, evaluation
–  Remote monitoring, control and alarming
BioPAT® MFCS | win
In addition to providing a genuine SCADA system for conventional and single-use  
bioprocess applications, the optional advanced version of BioPAT® MFCS includes  
a series of add-on modules:
–  Bioprocess optimization with Design  
of Experiments module (DoE)
–  Automation with recipes according to 
ANSI | ISA-88.01
–  21 CFR, Part 11 compatibility 
–  Secure integration into company  
networks
–  Flexible device connection facility  
through OPC
–  Expanded data recording and data  
archiving capabilities
–  Alarm recording and transmission  
to multimedia devices
Our Mission Is Your Productivity
We are well aware of how important smooth-running equipment is for effective process
development and efficient production. That is why we at Sartorius offer you a broad range
of preventive technical service, repair and application specialist support. Our ISO certified
quality management system ensures that you receive equipment and services that meet
the strictest quality requirements. Become one of our many customers who benefit from
our local presence worldwide, highly qualified specialists and well-versed technicians.
Services Offered for BIOSTAT® B
 − On-site installation and application  
specialist support, ensuring that your 
equipment is perfectly up and unning 
right from the start
 − Factory acceptance and site-acceptance 
testing 
 − On-site preventive maintenance and  
repair
 − Consumable and spare part kits
Technical Specifications
Control Tower Weight
Single | Twin ~ 40 | 55 kg (88 | 121 lbs.)
Control Tower Dimensions (W + H + D)
Single | Twin 410 + 810 + 520 mm (16“ + 32“ + 20“)
Utility Connections
Power supply
– 230 V (± 10%), 50 Hz, max. power consumption 10 A 
– 120 V (± 10%),  60 Hz, max. power consumption 12 A 
– Potential equalisation
International protection rating IP21
Gases
– Gas supply pressure, 1.5 barg
– Dry, oil and dust-free 
– Hose barb for tubing, external dia. = 6 mm
Water
– Water supply pressure, 2 – 8 barg 
– Flow rate up to 20 lpm 
– Temperature min. = 4°C 
– Discharge pressure-less 
– Hose barb for tubing, external dia. = 10 mm 
– Degree of hardness: 12 dH max.
Control Tower
Housing Stainless steel, AISI 304
Display Touch screen, 12”, glass, capacitive
Resolution 125 dpi
SCADA communication Industrial Ethernet
Potential-free (common) alarm contact •
Safety valve gas pressure 1 bar (14.5 psi) for UniVessel® Glass and SU | 100 mbar for RM
Water inlet pressure reduction 1.5 bar (22 psi), integrated pressure control
Motor Drive (Univessel® Glass | SU)
Maintenance-free, quiet direct drive Power: 200 W
Maintenance-free top drive with  
magnetic motor coupling Power: 200 W
Rotation speed motor, direct coupling
1L: 20 – 2,000 rpm
2L: 20 – 2,000 rpm
5L: 20 – 1,500 rpm
10L: 20 – 800 rpm
2L SU: 20 – 400 rpm
Rocker Platform
Power supply – 230 V (± 10%), 50 Hz, power consumption 10 A – 120 V (± 10%),  60 Hz, power consumption 12 A
Power consumption 600 W
International protection rating IP23
Rocking speed 8 – 42 ± 1 (r/min)
Rocking angle 4 –10 ± 0.3 (°)
BIOSTAT® B
Process Control | Sensors
Sensor | Measurement Range |  
Display Accuracy
UniVessel® 
Glass 
UniVessel® 
SU
Rocking 
Motion
Temperature Pt100 | 0–150°C (temperature control 0-80°C) | 0.1°C • • •
Dissolved oxygen, reusable Polarographic or optical | 0–100 % | 0.1 % • •
Dissolved oxygen, single-use Range: 0 –100 % Precision: 0.1% • •
pH, reusable
Combined measuring electrode 
Range: 2–12 pH 
Precision: 0.01 pH
• •
pH, single-use Range: 6.5 - 8.5 pH  Precision: 0.1 pH • •
Foam control Electrical conductive sensor,  stainless steel, ceramic insulated •
Level Electrical conductive sensor, stainless steel, ceramic insulated •
Turbidity 1-channel NIR absorption sensor |  0–6 AU | 0,01 AU •
Redox Combined measurement with  pH sensor | -1,000 – 1,000 mV | 1 mV • •
Balance substrate
7 kg max. | 1 g
60 kg max. | 2 g
300 kg max. | 100 g
• • •
Balance culture vessel 60 kg  max. |  2 g • •
RM load cells
30 kg max. | 10 g
Weight: 9 kg
Dimensions: 609 | 536 | 60-68 mm
100–240 V VAC | 24 VDC | 15 W
•
External signal input
0–10 V or 4-20 mA
UniVessel® Glass | SU: 4 max. 
Rocker: 2 max.
• • •
Aeration Module
Outlet to culture vessel | bag Hose coupling d external = 6 mm
UniVessel® Glass MO (Microbial) Two-gas mixing with sparger outlet
AIR with O2 Enrichment or Gas Flow Ratio mixing along with anaerobic fermentation; for further information,  
please see page on “aeration strategies”
Max. total flow Up to 20 l/min total volume flow
Flow rate controllers 2
Flow rate controller range Various models available: 0.1-20 liters per min. [lpm] (sparger)
Accuracy of flow rate controllers ± 5 % full scale
Mass flow controllers (optional) 2 max. 
Flow rates of mass flow controllers Various models available: 0.03-20 lpm (sparger)
Accuracy of mass flow controllers ± 1 % full scale
UniVessel® Glass CC (Cell Culture) |  
UniVessel® SU
Four-gas mxing with sparger and headspace outlet
Additive flow, 4-gas (Air, O2, N2, CO2) mixture; for further information, please see page on “Aeration Strategies”
Max. total flow Up to 13 l/min total volume flow
Number of flow rate controllers 5
Flow rate controller range
Various models available: 
3.3 ccm – 1.6 lpm (sparger)
0.16 lpm – 13 lpm (headspace)
Accuracy of flow rate controllers ± 5 % FS
Mass flow controllers (optional) 4 max. 
Flow rates of mass flow controllers
Various models available: 
1 ccm – 1.5 lpm (sparger)
0.03 lpm – 10 lpm (headspace)
Precision of mass flow controllers ± 1 % FS
UniVessel® Glass, Dual Use Four-gas mixing with sparger and headspace outlet
Additive flow, 4-gas (Air, O2, N2, CO2) mixture; for further information, please see page on “Aeration Strategies”
Max. total flow Up to 20 l/min total volume flow
Flow rate controllers 5
Flow rate controller range
Various models available: 
3.3 ccm – 20 lpm (sparger)
50 ccm – 20 lpm (headspace)
Accuracy of flow rate controllers ± 5% full scale
Mass flow controllers (optional) 4 max.
Flow rates of mass flow controllers
Various models available: 
0.6 ccm – 20 lpm (sparger)
10 ccm – 20 lpm (headspace)
Precision of mass flow controllers ± 1 % FS
Rocker Four-gas mixing with sparger and headspace outlet
Additive flow, 4-gas (Air, O2, N2, CO2) mixture; for further information, please see page on “Aeration Strategies”
Max. total flow Up to 10 l/min total volume flow
Max. CO2 flow
One bag: 1 + 1 lpm
Twin bag: 2 + 0.5 lpm
CO2 concentration controller 0.8 % – 15% | ± 5%
Flow rate controllers 4
Flow rate controller range Various models available: 16 ccm – 36 lpm (headspace)
Accuracy of flow rate controllers ± 5% full scale
Mass flow controllers (optional) 2 max.
Flow rates of mass flow controllers Various models available: 3 ccm – 3 lpm (headspace)
Precision of mass flow controllers ± 1% full scale
Pump Module
Built-in Pumps
Fixed speed (on | off controlled) Watson Marlow 114, Fast Load pump head
–  Speed 5 rpm 
Flow rate (tubing wall thickness 1.6 mm)
ID: 0.5 mm: 0–0.1 ml/min
ID: 0.8 mm: 0.05–2.4 ml/min
ID: 1.6 mm: 0.01–0.7 ml/min
ID: 2.4 mm: 0.03–1.5 ml/min
ID: 3.2 mm: 0.05–2.4 ml/min
ID: 4.8 mm: 0.09–4.3 ml/min
–  Speed 44 rpm 
Flow rate (tubing wall thickness 1.6 mm)
ID: 0.5 mm: 0.02–0.9 ml/min
ID: 0.8 mm: 0.04–1.8 ml/min
ID: 1.6 mm: 0.12–6.2 ml/min
ID: 2.4 mm: 0.26–12.8 ml/min
ID: 3.2 mm: 0.41–20.7 ml/min
ID: 4.8 mm: 0.75–37.4 ml/min
Speed-controlled Watson Marlow 114, Fast Load pump head
–  Speed 0.15–5 rpm 
Flow rate (tubing wall thickness 1.6 mm)
ID: 0.5 mm: 0–0.1 ml/min
ID: 0.8 mm: 0.01–0.2 ml/min
ID: 1.6 mm: 0.02–0.7 ml/min
ID: 2.4 mm: 0.04–1.5 ml/min
ID: 3.2 mm: 0.07–2.4 ml/min
ID: 4.8 mm: 0.13–4.3 ml/min
–  Speed 5–150 rpm 
Flow rate (tubing wall thickness 1.6 mm)
ID: 0.5 mm: 0.1–3 ml/min
ID: 0.8 mm: 0.2–6 ml/min
ID: 1.6 mm: 0.7–21 ml/min
ID: 2.4 mm: 1.45–43.5 ml/min
ID: 3.2 mm: 2.35–70.5 ml/min
ID: 4.8 mm: 4.25–127.5 ml/min
External Pumps
Speed-controlled Watson Marlow 120, Fast Load pump head, up to 200 rpm
Temperature Control Module
Heating and Cooling Heating Only
For UniVessel® Glass Single-wall Culture Vessels
Electrical heating system and automatic cooling water valve;  
connection to heating blanket and cooling finger –
Temperature control of 8°C above cooling-water inlet temperature up to 60°C –
Heating blanket capacities 1 L | 2 L | 5 L | 10 L: 100 | 170 | 400 | 780 W –
For UniVessel® Glass Double-wall (Jacketed) Culture Vessels
Open thermostat system with recirculation pump and automatic cooling  
water valve –
Temperature control of 8°C above cooling-water inlet temperature of up to 80°C –
Heating capacity: 600 W –
For UniVessel® SU Single-use Culture Vessels
Open thermostat system with recirculation pump and automatic cooling  
water valve; connection to heating | cooling jacket Electrical heating blanket
Temperature control up to 50°C Temperature control up to 50°C Heating capacity 2L : 200 W
For BIOSTAT® RM Rocking-motion Bioreactor
Open thermostat system with recirculation pump and automatic cooling  
water valve Electrical heating plates
Temperature control of 8°C above cooling-water inlet temperature of up to 40°C Temperature control from room  temperature up to 40°C
Heating capacity: 600 W Heating plates: 2 + 140 W
Culture Vessel UniVessel® Glass
Autoclavable Single-wall or Double-wall 
(Jacketed) Glass Vessel
1 L 2 L 5 L 10 L
Material Borosilicate glass, stainless steel AISI 316L, EPDM
Sizes [L] 1 2 5 10
Total volume [L] 1.6 3 6.6 13
Working volume [L] 0.4 –1 0.6 – 2 0.6 – 5 1.5 | 5 –10
Top port 19 mm | 12 mm | 6 mm 3 | 2 | 6 3 | 2 | 9 3 | 3 | 8 5 | 2 | 9
UniVessel®, Single-wall 1 L 2 L 5 L 10 L
Weight1 [kg] 6 7 12 19
Space requirements in autoclave  
[W + H + D mm] 200 + 540 + 270 230 + 600 + 300 260 + 730 + 340 330 + 860 + 420
Space requirements in autoclave, reduced2  
[W + H + D mm] 480 + 410 + 300 530 + 510 + 410 540 + 630 + 420
UniVessel®, Double-wall 1 L 2 L 5 L 10 L
Weight1 [kg] 7 8 14 23
Space requirements in autoclave  
[W + H + D mm] 330 + 540 + 270 380 + 600 + 300 410 + 730 + 340 450 + 860 + 420
Space requirements in autoclave, reduced2  
[W + H + D mm] 480 + 410 + 300 530 + 510 + 410 540 + 630 + 420
1 With tripod and head plate, without medium
2 Adapter for exhaust cooler to reduce height in the autoclave optionally available
Culture Vessel UniVessel® SU
Single-use vessel made of pre-sterilized polycarbonate for cell culture applications
Total volume [L] 2.6
Working volume [L] 0.6–2
Max. temperature 50 °C
Operating pressure < 0.5 barg
 
The BIOSTAT® B is a highly flexible and modular system that can be individually adapted to the  
requirements of your application. Below you will find an overview of the basic equipment which  
you can extend with diverse options. Please contact your Sartorius Stedim Field Representative  
or Application Specialist for additional information. 
Microbial Packages for UniVessel® Glass
Volume
Single
Twin
Digital controller, color display with touch screen
Control temperature, pH, DO, stirrer speed
Maintenance-free, quiet motor
Storage tray for accessories
Aeration module with 2 solenoid valves
2 flow rate controllers for manual flow rate control (AIR | N2, O2)
Software configured for microbial applications
4-stage DO cascade
BioPAT® MFCS software for data acquisition
2 integrated pumps for pH control (acid | base)
Temperature control module for double-wall vessels
2 external signals 0 –10 V
Standard test and documentation
Installation set for the gas and water connections
Power cable
Double-wall culture vessel 
Stirrer shaft with single-mechanical seal and direct coupling
2 addition bottles for correction agents
Exhaust cooler
Aeration filters
Rushton impellers
Ring sparger
4-way addition port
Inoculation port
Harvest pipe, height-adjustable
Manual sampler
Tool set for disassembly of vessel
Pt100 temperature sensor
pH sensor
DO sensor, amperometric
Basic Configurations
Cell Culture Packages for UniVessel® Glass
Volume
Single
Twin
Digital controller, color display with touch screen
Control temperature, pH, DO, stirrer speed
Maintenance-free, quiet motor
Storage tray for accessories
Aeration module with 4 solenoid valves
5 flow rate controllers for manual flow rate control
(AIR Overlay, AIR sparger, N2, O2, CO2)
Software configured for cell culture applications
4-stage DO cascade
BioPAT® MFCS software for data acquisition
1 integrated pump for pH control (base)
Temperature control module for single-wall vessels
2 external signals 0 –10 V
Standard test and documentation
Installation set for the gas and water connections
Power cable
Single-wall culture vessel with tripod
Heating blanket 120 | 230 V
Stirrer shaft with single mechanical seal and direct coupling
1 addition bottle for correction agent
Exhaust cooler
Aeration filters
3-blade segment impeller
Microsparger
4-way addition port
Harvest pipe, height-adjustable
Manual sampler
Tool set for vessel dismantling
Pt100 temperature sensor
pH sensor
DO sensor, amperometric
 
Control System
Advanced DO controller
Flexible switching CO2 from sparger to headspace
Software for dual use MO | CC
Mass flow controller
Antifoam control via sensor
Mechanical foam destroyer (MO applications)
Level control via sensor
Weight measurement substrates | culture vessel
Gravimetric feed | level control
Substrate addition via time profile
Redox (ORP) measurement
Turbidity measurement
BioPAT® Xgas O2 | CO2 off-gas analysis
System IQ | OQ
BioPAT® MFCS SCADA system
UniVessel® Glass
Double-wall culture vessel
Magnetic coupling for drive motor
STT connectors for safe inoculation and media transfer
Cooling finger (single-wall culture vessels)
Spin filter for perfusion mode
Aeration basket for organisms sensitive to shear stress
Rushton impellers | 3-blade segment impellers
Baffles
Bottle holder
Adapter for height reduction of exhaust cooler for the autoclave
Inoculation port
3-way addition port
Universal adapter ID 3.2 mm
Harvest pipe bent for complete draining
Port adapter 19 mm – 12 mm
Set of consumables
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BIOSTAT® D-DCU
Your “Fast Lane” to Production
BIOSTAT® D-DCU
    Your “Fast Lane” to Production
The BIOSTAT ® D-DCU is a compact bioprocess system available in microbial  
or cell culture versions with vessel choices from 10 to 200L working volume.
The optimized and proven design of the BIOSTAT® D-DCU is the result of  
thorough analysis of the most required features and functions from over 
thirty years of stainless steel fermenter | bioreactor design experience.  
This standardized solution eliminates design times, allows faster delivery,  
reduces cost, guarantees trouble free operation, allows for global service  
support as well as spare part availability.
The BIOSTAT® D-DCU incorporates many 
desirable and advanced features to  
fulfill virtually any demand for modern 
bioprocess application, such as: Automatic 
Sterilization in Place (SIP), Cleaning in 
Place (CIP), dual pH and DO measurement 
 capability, lid lifting device, Water Intru-
sion Test (WIT)-Ready filter housings, dual 
exhaust filter housing line, tube and shell 
exhaust cooler, exhaust heater, automatic 
or manual addition arrays as well as other 
accessories. Furthermore, the  BIOSTAT® 
D-DCU is designed to interface single-use 
storage bags for media addition and har-
vest as well as the TAKEONE® aseptic sam-
pling system. The modular approach allows 
multiple configurations (from baseline  
to fully featured) to meet every need and 
budget.
Three subsystems comprise every  
BIOSTAT® D-DCU:
–  Control tower with integrated gas mixing 
and pump module 
–  Culture vessel with bottom agitation  
system
–  Supply Unit, open frame skid and compact 
stainless steel piping module
The control tower features best-in class 
control capabilities utilizing proven  
industrial hardware. It is operated via a 
simple and intuitive 19” touch screen 
which keeps staff training to a minimum. 
The compact design of the stainless steel 
housing reduces the footprint and saves 
precious space.
The jacketed stainless steel culture vessel, 
with spiral baffles for efficient and  
homogenous heat transfer, are available in 
3:1 or 2:1 aspect height to diameter ratio. 
The gear free bottom drive agitation system 
provides long-term operation at minimal 
noise. The zero dead volume sanitary radial 
diaphragm harvest and radial type sampling 
valves provide fresh samples without  
residual pockets and are easy to clean and 
maintain. 
The supply unit includes all process piping 
for temperature control as well as the 
exhaust and gas inlet lines. Due to the open 
frame design direct access for operation 
and easy maintenance is ensured. Further-
more, minimal floor contact points allow 
easy cleaning even underneath the skid. 
An extended documentation and  
qualification package is available to  
support regulatory requirements. 
The BIOSTAT® D-DCU is available in both 
Single and Twin controller configuration.  
It increases flexibility and allows control  
of two separate processes at the same  
time – even with different size culture  
vessels – but independently from each 
other.
Features
 – Single or Twin Configurations
–  Available in incremental sizes from  
10 to 200 L 
–  Preconfigured systems or choose from  
an extensive list of options
–  Powerful industrial rated DCU control 
system with 19” TFT color touch screen
–  Automatic Sterilization in Place (SIP) 
included 
–  Automatic Cleaning in Place (CIP)  
optional 
–  Designed to interface single-use bags  
and sampling systems including the new 
TAKEONE® aseptic sampling system
–  Measurement and control opportunities 
of pH, DO, temperature, foam, level,  
vessel pressure, vessel weight, substrate 
addition, gas mixing, agitation, gravi-
metric feed and harvest control, constant 
total gas flow control, redox and  
turbidity, weight of storage vessels etc. 
–  Up to six integrated peristaltic pumps per 
vessel with options for fixed or variable 
speed control
–  Choice of polarographic or optical  
DO sensors 
–  Superior gas mixing with up to six  
flow meters and mass flow controllers
–  Extended documentation package  
available, including logbook and 3-Level 
password protection
–  Minimal floor contact points for ease  
of cleaning 
–  Global spare part and service availability 
Supply Unit
Culture Vessel
Agitation
Supply Unit 
The Supply Unit includes all process piping for temperature  
control as well as the exhaust and gas inlet lines. The open piping 
frame and ergonomic design of the skid allows for good and 
direct access to valves filter housings etc. All sanitary piping  
is sloped | self drained. The Supply Unit for culture vessels with  
10 – 30 L offers a choice of lockable casters or leveling | support 
feet. The Supply Unit for culture vessel with 50 – 200 L is 
equipped with leveling | support feet. Furthermore, the Supply 
Units can be separated in two pieces allowing easy movement  
to the site of installation. 
Culture vessel 
Available culture vessels from 10 L, 20 L, 30 L, 50 L, 100 L to  
200 L working volume, with a total volume aspect ratio of (H:D) 
2:1 or 3:1. 
Sterilization in Place (SIP)
For ease of operation, automatic sterilization of the culture  
vessel, gas inlet and exhaust gas flow path are included. Addition 
groups, sampling valves and drain valves are either manually or 
automatically sterilized.
NEW  Cleaning in Place (CIP) 
The BIOSTAT® D-DCU offers state of the art CIP solutions with inte-
grated SIP | CIP headers and now also with an optional mobile CIP 
cart or the ability to connect to 3rd party CIP systems providing 
an electronic handshake between the control systems. Integrated 
CIP features allow the operator to effectively, reproducibly and 
automatically clean the complete system including the culture 
vessel, gas inlets, exhaust lines, addition lines and transfer groups.
NEW  Single-use sampling 
The TAKEONE® aseptic sampling system  
is single-use and delivered ready to use. 
While traditional sampling devices require 
cleaning, preparation and sterilization  
after each use, the TAKEONE® single-use 
sampling system saves valuable time by 
being fully disposable. 
Agitation
Bottom drive agitation is available with a double mechanical seal. 
The high performance servo drive motor assembly combines low 
shear, gentle agitation for cell cultures and high speed mixing for 
microbial high cell density cultivation, ensuring high oxygen 
transfer rates. The motor is gear-free for quiet operation – even  
at high speed ranges. 
Configure a System Utilizing Options  
               (Like Gasmix, CIP) from a Baseline Unit
Control Tower 
The Control Tower is available in single or twin configurations.  
The integrated DCU control system belongs to the most proven 
and advanced bioprocess controllers ever developed. Utilizing 
proven technology and expert engineering, our existing in-house 
systems bring powerful control capabilities to the sophisticated 
biotechnology market. Proven industrial control hardware ensures 
reliable system performance. 
The DCU can be easily expanded and reconfigured to meet  
evolving research or process requirements, including scale-up 
from laboratory fermenters or scale-down to mimic production 
process conditions. 
For data logging, the Digital Control Unit (DCU) includes  
a PC interface for SCADA software connection (for example 
BioPAT® MFCS). DCU OPC communication software is available  
for interface to other OPC compliant SCADA and DCS packages. 
Using a local controller for local process control in combination 
with a high level SCADA system ensures process control safety. 
Intuitive Touchscreen
The control system presents an “intuitive-to-use”, large 19“ TFT 
color touch screen for excellent local operation and process  
control for each culture vessel. Clearly designed screens provide 
an excellent process value overview and operation. 
Gassing Systems
A variety of spargers are available for microbial and cell culture 
use. All systems provide individual flow rates and gas blending for 
each culture vessel. Gas flow rates are adjustable via precision 
flow meters with optional thermal mass flow controllers available 
for each flow path (each gas).
Dosing Pumps
Up to six integrated fast load peristaltic pumps per vessel may  
be chosen for addition of corrective agents, feeding, as well as 
culture volume control. Up to four of the six can be analog speed 
controlled pumps. Several ranges are available for both fixed and 
speed controlled pumps. Additionally, external pumps for feeding 
can be easily connected.
Control Tower 
Intuitive  
Touchscreen
Gassing Systems
Dosing Pumps
BIOSTAT® D-DCU 
  Gassing Strategies 
Airflow 
Utilizing one flow path for air, a flow meter visually indicates  
and controls the sparger flow rate. An optional mass flow  
controller may be integrated to control and measure the flow 
range via manual adjustment or automatically in conjunction 
with the DO controller.
SpargerAir
SpargerAir
O2
SpargerAir
O2
O2-Enrichment
Utilizing two flow paths for Air and O2 flows, the flow meters  
visually indicate and allow manual adjustments of the sparger 
flow rate. O2 is pulsed via solenoid valve, flowing only when 
required to maintain the dissolved oxygen (DO) setpoint.  
Air is not provided at this time. A mass flow controller can be 
integrated to measure and control the total gas flow range via 
manual adjustment or automatically in conjunction with the  
DO controller.
O2-Enrichment, design up to 50 L/min
O2-Enrichment, design up to 300 L/min
Flow meter
Optional Gas switch
Dosing shut-off valve
Optional dosing shut-off valve
3-way dosing valve
Optional Mass Flow Controller
Mass Flow Controller 
SpargerAir
O2
N2
CO2
Overlay
Advanced Additive Flow
Allows up to six gas flow paths. Solenoid valves select air, O2, N2 
and CO2 for simultaneous flow to the sparger and air to overlay. 
Up to six flow meters visually indicate and set the flow rate for 
each gas. One additional gas flow path can be added to sparger  
or overlay outlet. Furthermore, two 3-way solenoid valves can  
be installed to switch the dedicated gas from sparger to overlay 
(incl. soft switch). The design does support the installation of up 
to six mass flow controllers, which makes constant sparger gas 
flow  control as well as constant overlay gas flow control possible.
Sparger
Air
O2
Gas Flow Ratio
Utilizes two flow paths with mass flow control valves for Air  
and O2 flow. Flow meters visually indicate the flow of Air and O2. 
Both mass flow controllers can be operated manually or automat-
ically in conjunction with the DO controller. 
Flow meter
Optional Gas switch
Dosing shut-off valve
Optional dosing shut-off valve
3-way dosing valve
Optional Mass Flow Controller
Mass Flow Controller 
Discover the potential of our  
standard software…
–  Superior process value overview
– Sensor calibration
– In-process recalibration
– Alarm monitoring 
– Trend display 
–  Automatic Sterilization in Place
… and profit from advanced features
–  Overview of all vessels or single  
vessel display
– Controller status indication
– Single or group calibration
–  Advanced DO controller
–  Gravimetric flow control for very precise 
feeding
– Gravimetric harvest control
– Constant total gas flow control
– Automatic Cleaning in Place
SYNCHRONIZED
PAT
SOLUTIONS
Our DCU (digital control unit) controller belongs to the most proven,  reliable 
and advanced bioprocess controllers ever developed. Use of a modular system 
design has enabled us to offer a broad range of flexible and cost-effective 
solutions for reusable and single-use systems from R&D to production. DCU 
control systems are specially tailored for  fermentation, cell culture and down 
stream processing like cross flow  filtration applications. 
DCU control systems allow for independent and simultaneous operation of 
multiple processes.
BioPAT® DCU – Automation Solutions 
          for Advanced Process Control and Documentation
BioPAT® MFCS –  
          The Bioprocess SCADA System
BioPAT® SIMCA-Online  
          for Continuous Real-time Quality Control
BioPAT® MFCS is our SCADA software for supervisory bioprocess control and 
data acquisition. Provides GMP compliant documentation of your valuable 
process data and ensures reliable process control in combination with the  
advanced BIOSTAT® D-DCU for local process control. Supplied with every  
BIOSTAT® D-DCU package, the new BioPAT® MFCS is ideal for efficient data 
acquisition and trend monitoring.
Continuous real-time quality control and assurance is highly desired in  
biopharmaceutical manufacturing. Unique on the market and developed  
according to GAMP 5, BioPAT® SIMCA-online is your software solution  
for real-time multi variate statistical process monitoring and control.  
The software permits early detection of process deviations. It provides user 
guidance to simplify root-cause analysis by displaying easy-to-understand 
graphics.
Online Multivariate 
  Data Analysis 
MVDA
Learn more about the new BioPAT® MFCS: 
www.sartorius-stedim.com/biopatmfcs
The optional, advanced version of 
BioPAT® MFCS includes modules such as:
–  Multi-user network access for up to  
16 process units
–  Automation with recipes according  
to ANSI | ISA 88.01
– 21 CFR, Part 11 compatibility
–  Multivariate Data Analysis modules
Package overview  10 L 20 L 30 L 50 L 100 L 200 L
Cat. No. 208 VAC | Culture vessel H:D ratio RDD-M10LOBRES3 | 2:1
RDD-M20L
OBRES3 | 2:1
RDD-M30L
OBRES3 | 2:1
RDD-M50L
OBRES3 | 2:1
RDD-M1HL
OBRES3 | 2:1
RDD-M2HL
OBRES3 | 2:1
Cat. No. 400 VAC | Culture vessel H:D ratio RDD-M10LOBRET4 | 3:1
RDD-M20L
OBRET4 | 3:1
RDD-M30L
OBRET4 | 3:1
RDD-M50L
OBRET4 | 3:1
RDD-M1HL
OBRET4 | 3:1
RDD-M2HL
OBRET4 | 3:1
Control Unit Twin configuration optional 
Digital controller, color display with touch screen •
Control capabilities
Temperature, pH, DO (Multi stage cascade), Stirrer speed •
Substrate A and Substrate B •
Foam via conductive sensor •
High foam alarm •
Automatic full vessel sterilization sequence •
Gear and maintenance free agitation motor •
Gassing strategy O2-Enrichment (Airflow and Gas Flow Ratio optional)
Flow meter •
Solenoid valve for oxygen enrichment • (Mass Flow Controller optional)
Peristaltic pumps (integrated)
3 for Acid | Base | Antifoam unused pump can be configured as substrate pump 
(Up to 6 pumps per site)
Supervisory Process Control Software
BioPAT® MFCS •
Supply frame Open frame design
Temperature control system Closed loop system with recirculation pump and heat exchanger for heating and cooling
Piping with valves and steam traps for automatic in-situ sterilization •
Culture Vessel Jacketed stainless steel vessel with vertical sight glass and bottom agitation
Stirrer shaft with Double Mechanical Seal (DMS) •
Condensate pressurization of buffer system DMS steam | compressed air • | O
6-blade disk impeller 3
Stainless steel filter housing for air Inlet and exhaust filter incl.  
filter cartridges
•
Pressure gauge –1 | 3 barg •
Aeration tube with Ring sparger •
Exhaust cooler •
4-Baffles (removable) •
Resterilizable sampling valve •
1-Channel Sacova valve for needle free additions •
3-Channel Sacova valve for needle free additions •
Lamp for vessel illumination •
Storage bottles 3
Bottom harvest valve •
pH Electrode, cable •
DO Electrode, cable •
Pressure sensor, cable • 
Foam sensor, cable •
Temperature sensor Pt 100 •
High-foam sensor with installation adaptor, cable •
Options
Mobile CIP unit with DCU interface O
Culture vessel weight measurement | control O | O
Automatic vessel pressure control O
Pressure hold test O
Lid lifting device 10-20 L | 30-200 L -- | O
Dual pH measurement | Dual DO measurement O | O
Containment sampling system O
WIT ready filter housings for Inlet and Exhaust filter O
Exhaust heater | Dual Exhaust filter line (parallel) O | O
Temperature measurement of condensate trap O
Cleaning in Place (CIP)  O
Resterilizable 4-valve addition array manual | automatic O | O
Automatic harvest valve O
Transfer group O
Speed controlled pumps for feeding O
Broad range of accessories available. Please contact us for further details. • = included, — — = unavailable, O = option
BIOSTAT® D-DCU MO – Package Overview: O2-Enrichment
Package overview  10 L 20 L 30 L 50 L 100 L 200 L
Cat. No. 208 VAC | Culture vessel H:D ratio RDD-C10LABRES3 | 2:1
RDD-C20L
ABRES3 | 2:1
RDD-C30L
ABRES3 | 2:1
RDD-C50L
ABRES3 | 2:1
RDD-C1HL
ABRES3 | 2:1
RDD-C2HL
ABRES3 | 2:1
Cat. No. 400 VAC | Culture vessel H:D ratio RDD-C10LABRES4 | 2:1
RDD-C20L
ABRES4 | 2:1
RDD-C30L
ABRES4 | 2:1
RDD-C50L
ABRES4 | 2:1
RDD-C1HL
ABRES4 | 2:1
RDD-C2HL
ABRES4 | 2:1
Control Unit Twin configuration optional 
Digital controller, color display with touch screen •
Control capabilities
Temperature, pH, DO (Multi stage cascade), stirrer speed •
Substrate A – D •
Foam via conductive sensor •
High Foam alarm •
Automatic full and empty vessel sterilization sequence •
Gear and maintenance free agitation motor •
Gassing strategy Advanced Additive Flow
Flow meter sparger • for Air, O2 N2, CO2
Flow meter overlay • for Air
Automatic Gassing strategy of Air, O2, N2, CO2 for sparger • via solenoid valves (Mass Flow Controller optional)
Peristaltic pumps (integrated) 2 for Base | Afoam unused pump can be configured as substrate pump (Up to 6 pumps per system)
Data acquisition and trend monitoring software
BioPAT® MFCS •
Supply frame Open frame design
Temperature control system Closed loop system with recirculation pump and heat exchanger for heating and cooling
Solenoid valves and steam traps automatic in-situ sterilization •
Culture Vessel Jacketed stainless steel vessel with vertical sight glass and bottom agitation
Stirrer shaft with Double Mechanical Seal (DMS) •
Condensate pressurization of buffer system DMS steam | compressed air • | O
3-blade segment impeller 2
Stainless steel filter housing for Air Inlet (Sparger and Overlay)
and Exhaust filter incl. filter cartridges •
Pressure gauge –1 | 3 barg •
Aeration tube with micro sparger •
Exhaust Cooler •
4-Baffles (removable) •
Resterilizable sampling valve •
1-Channel Sacova valve for needle free additions •
3-Channel Sacova valve for needle free additions •
Lamp for vessel illumination •
Storage bottles 2
Bottom harvest valve •
pH Electrode, cable •
DO Electrode, cable •
Pressure sensor, cable • 
Foam sensor, cable •
Temperature sensor Pt 100 •
High-foam sensor with installation adaptor, cable •
Options
Mobile CIP unit with DCU interface O
Culture vessel weight measurement | control O | O
Automatic vessel pressure control O
Pressure hold test O
Lid lifting device 10-20 L | 30-200 L -- | O
Dual pH measurement | Dual DO measurement O | O
Containment sampling system O
WIT ready filter housings for Inlet and Exhaust filter O
Exhaust heater | Dual Exhaust filter line (parallel) O | O
Temperature measurement of condensate trap O
Cleaning in Place (CIP) O
Resterilizable 4-valve addition array manual | automatic O | O
Automatic harvest valve O
Transfer group O
Speed controlled pumps O
Broad range of accessories available. Please contact us for further details. • = included, — — = unavailable, O = option
BIOSTAT® D-DCU CC – Package Overview:  
Advanced Additive Flow
Technical Specification  10 L 20 L 30 L 50 L 100 L 200 L
Space requirement Single [W + H + D]  [“] 58.3 + 82.7 + 43.3 58.3 + 82.7 + 44.5 58.3 + 82.7 + 45.3 76.8 + 92.9 + 61.8 76.8 + 100.8 + 61.8 76.8 + 120.1 + 70.9
 [m] 1.48 + 2.1 + 1.1 1.48 + 2.1 + 1.13 1.48 + 2.1 + 1.15 1.95 + 2.36 + 1.57 1.95 + 2.56 + 1.57 1.95 + 3.05 + 1.8
Space requirement Twin [W + H + D]  [“] 84.6 + 82.7 + 43.3 84.6 + 82.7 + 44.5 84.6 + 82.7 + 45.3 122 + 92.9 + 61.8 122 + 100.8 + 61.8 122 + 120.1 + 70.9
 [m] 2.15 + 2.1 + 1.1 2.15 + 2.1 + 1.13 2.15 + 2.1 + 1.15 3.1 + 2.36 + 1.57 3.1 + 2.56 + 1.57 3.1 + 3.05 + 1.8
Required wall opening dimensions [W + H]  [“] 31.9 + 78.8 31.9 + 78.8 31.9 + 78.8 41.8 + 67 41.8 + 67 41.8 + 67
 [m] 0.81 + 2 0.81 + 2 0.81 + 2 1.06 + 1.7 1.06 + 1.7 1.06 + 1.7
Culture vessel weight (approx.)  [kg] 80 100 120 300 450 600
Supply Unit weight (approx.)  [kg] 170 170 170 320 320 320
Control Tower weight (approx.)  [kg] 
Single | Twin
160 | 205
Ambient temperature | relative humidity 
(non-condensating)
5 – 40°C | 85%
Utilities Requirements Conditions Max. 
Flow
Vessel Size 
10 L 20 L 30 L 50 L 100 L 200 L
Process Air MO |  
CC Sparger | Overlay 
4 barg | 58 psig, controlled,  
Class 2 (ISO 8573-1)
[L/min] 15 | 
1/10
30 | 
2/20
45 | 
3/30
75 | 
5/50
150 | 
10/100
300 | 
20/200
O2 MO Sparger |  
CC Sparger | Overlay 
4 barg | 58 psig, controlled, prefiltered [L/min] 15 | 
1/5
30 | 
2/10
45 | 
3/15
75 | 
5/25
150 | 
10/50
300 | 
20/100
CO2 MO Sparger |  
CC Sparger | Overlay 
4 barg | 58 psig, controlled, prefiltered [L/min] N | A
1 | 5
N | A
2 | 10
N | A
3 | 15
N | A
5 | 25
N | A
10 | 50
N | A
20 | 100
N2 MO Sparger |  
CC Sparger | Overlay
4 barg | 58 psig, controlled, prefiltered [L/min] N | A
1 | 5
N | A
2 | 10
N | A
3 | 15
N | A
5 | 25
N | A
10 | 50
N | A
20 | 100
Utility steam 4 barg | 58 psig, controlled, prefiltered [kg/h] 15 15 15 50 90 160
Clean steam 1.5 barg | 21.8 psig, controlled, prefiltered [kg/h] 5 5 5 8 10 26
Cooling water 4 barg | 58 psig, controlled (15°C) prefiltered [L/min] 5 5 5 25 25 50
Cooling water return Atmospheric pressure to 1.5 barg | 21.8 psig [L/min] 5 5 5 25 35 50
CIP, cleaning and rinsing fluid 1.5 barg | 21.8 psig, controlled [L/min] on request 33 43 70
Condensate Atmospheric pressure (max. Temp. 98°C)
Instrument air 6 barg | 87 psig, controlled
Power supply (TNS net):  
5 wire: 3 + phase, 1 + ground, 1 + neutral 
208 VAC/24A (FI switch intern 300mA) or 400 VAC/20A (FI switch intern 300mA)
Power supply for electrical heater (TNS net):  
5 wire: 3 + phase, 1 + ground, 1 + neutral 
208 VAC/16A or 400 VAC/10A
Control Tower Integrated DCU-Controller, Gassing System and Pumps Single or Twin configuration 
Controller Industrial PC (Siemens) 
Housing material Stainless steel AISI 304
Display | Operation Touch Panel 19“ | Touch screen
Host communication Industrial Ethernet
External connections Expandable process I/O
Balance connection 3 per vessel; expandable of up to 6 per vessel
External Inputs | Off gas analyzer input 2 per vessel; Analog in (0 – 10 V) | 2 per vessel Analog in (4 – 20 mA) 
External feed pumps up to 4 per vessel; 2 per vessel; Analog out (0 – 10 V)
Gassing System Up to 6 integrated Mass Flow Controllers and Flowmeter 
MO application Air aeration, O2-Enrichment or Gas Flow Ratio; Max. total flow rate: 1.5 vvm
CC application Advanced Additive Flow; Max. total flow rate: Overlay 1 vvm | Sparger 0.1 vvm
Flow meter Air calibrated @ 4 barg 20°C | scale lenght 120 mmm
  Flow range 0.12–1.06 L/min up to 70–330 L/min
  Accuracy +/– 4% FS
Thermal Mass Flow Controller Air | N2, O2 or CO2 calibrated
  Flow range 0.02–1.0 sLpm up to 6–300 sLpm
  Accuracy +/– 1% FS
Integrated pumps Up to 6 per vessel (2 + digital + 2 + digital | speed controlled + 2 + speed controlled) 
Pump head 
For tubings with 1.6 mm | 1/16“ wall thickness
Watson Marlow 114  
For tubings with bore 0.5-4.8 [mm] | 1/50-3/16[“]
Watson Marlow 314 
For tubings with bore 0.5-8.0 [mm] | 1/50-5/16[“] 
Rotation speed [rpm] 5 44 up to 200 6 60 up to 200
Flow range  [mL/min] Bore 0.5 mm  1/50“
  4.8 mm  3/16“
  8.0 mm  5/16“
0.1
0.09 – 4.3
N | A
0.02 – 0.9
0.75 – 37.4
N | A
0.4 – 4
17 – 170
N | A
0.0 – 0.18
2.3 – 11.4
0.48 – 24
0.04 – 1.8 
2.3 – 114 
4.8 – 240
0.6 – 6
38 – 380
80 – 800
BIOSTAT® D-DCU – Technical Specification
Supply Unit Piping Skid in open frame design
Material | Surface finish (product wetted parts) Stainless steel AISI 316L | MO: Ra < 0.8 µm (31.5 Ra or better) | CC: Ra < 0.4 µm (15.7 Ra or better)
Temperature control system – steam version Closed loop thermostat system with recirculation pump, heat exchanger for cooling and heating or | and electrical heater 
Temperature control (operation | sterilization): 8°C above cooling water to 90°C | up to 130°C
Heat exchanger (cooling | heating – steam version) Stainless steel, copper soldered, optional stainless steel | welded version available upon request
Electrical heater (optional) 6 kW (10–30 L: complete electrical heated; 50–200 L: auxiliary electrical heater only)
Culture vessel 10 L 20 L 30 L 50 L 100 L 200 L
H:D ratio 2:1 3:1 2:1 3:1 2:1 3:1 2:1 3:1 2:1 3:1 2:1 3:1
Total volume 14 L 15 L 29 L 31 L 42 L 41 L 74 L 77 L 152 L 152 L 313 L 323 L
Working volume 10 L 10 L 20 L 20 L 30 L 30 L 50 L 50 L 100 L 100 L 200 L 200 L
Minimal working volume 3.5 L 2.5 L 5.5 L 3.5 L 6.4 L 5.4 L 13 L 13L 24 L 24 L 47 L 41 L
Jacketed cylindrical part | Jacketed bottom yes | no yes | no yes | no yes | no yes | no yes | no yes | no yes | no yes | yes yes | no yes | yes yes | no 
Weight lid with blind plugs [kg] 12 11 16 14 18 16 34 22 45 35 95 68
Agitation speed ranges for MO  
(max. impeller tip speed ≥ 5 m/s)
20 –  
1500
20 – 
1500
20 –  
1200
20 –  
1200
20 –  
1100
20 –  
1100
20 –  
900
20 –  
900
20 –  
700
20 –  
700
20 –  
570
20 –  
570
Motorpower | torque [kW | Nm] 2.3 | 5 2.3 | 5 3.1 | 9.4 3.1 | 9.4 3.1 | 9.4 3.1 | 9.4 4.2 | 16.2 4.2 | 16.2 4.9 | 26.7 4.9 | 26.7 6.6 | 48.2 6.6 | 48.2
Agitation speed ranges for CC  
(max. impeller tip speed ≥ 2 m/s)
350 N | A 300 N | A 260 N | A 220 N | A 180 N | A 130 N | A
Motorpower | torque [kW | Nm] 2.3 | 5 N | A 2.3 | 5 N | A 2.3 | 5 N | A 3.1 | 9.4 N | A 4.2 | 16.2 N | A 4.2 | 16.2 N | A
Impeller to vessel diameter  
[Rushton impeller] 
0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4
Impeller to vessel diameter  
[3-blade segment impeller] 
0.5 N | A 0.5 N | A 0.5 N | A 0.5 N | A 0.5 N | A 0.5 N | A
Lid ports 1 + sight glass for illumination  
1 + port for Exhaust  
9 + 19 mm port 
1 + sight glass for illumination  
1 + spare port DN 50  
1 + port for CIP – connection  
1 + port for Exhaust  
8 + 19 mm port  
3 + lifting eye
Upper side wall 4 + 25 mm port  
1 + Sparger aeration 
1 + Overlay aeration | Bypass Sparger  
1 + port for rupture disc | safety valve  
1 + rectangular sight glass
3 + 25 mm port  
1 + Sparger aeration 
1 + Overlay aeration | Spare  
1 + port for rupture disc 
1 + spare DN50 
1 + rectangular sight glass
Lower side wall 5 + 25 mm port  
1 + sanitary TC port 
1 + port for temperature sensor 
5 + 25 mm port  
1 + sanitary TC port 
1 + port for temperature sensor 
Bottom 1 + flange for agitator 
1 + Harvest | Drain valve 
1 + flange for agitator 
1 + Harvest | Drain valve 
Jacket 1 + fluid in  
1 + fluid out
1 + fluid in  
1 + fluid out
Vessel design Jacketed stainless steel vessel with torospherical bottom and vertical sight glass Bottom agitation system
Material (product wetted parts) Stainless steel AISI 316 L | Borosilicat glass | EPDM (FDA aprroved) 
Surface finish product wetted 2:1 Vessel Ra ≤ 0.4 µm (15.7 Ra or better), electropolished | 3:1 vessel: Ra ≤ 0.8 µm (31.5 Ra or better), electropolished 
Pressure design criteria vessel | jacket –1/3 barg @ 150°C | –1/4 barg @ 150°C
Sensors | measurement ranges | resolution
Dissolved oxygen Polarographic or optical | 0–100% | 1% | 0.1%
pH Gel filled | 2–12 | 0.01 pH
Foam | Level | High Foam Conductive probe, stainless steel ceramic isolated
Temperature sensor Vessel/Jacket Pt100 | 0–150°C | 0.1 C / Pt100 | 0–150°C | 0.1 C
Redox Gel filled | –1000 – 1000 mV | 1 mV 
Pressure Piezoresistive sensor | –0.5–2 [barg] | 1 mbar
Turbidity Single Channel NIR Absorption Probe, 0–6 AU | 0.01 AU
Regulatory compliance CE | UL | CSA (EN61010, UL61010); Culture vessel: ASME or PED or China pressure vessel regulation
MO: Microbial Application; CC: Cell Culture Application
Specifications are subject to change without notice
Technical Specification
Design Mobile stainless steel skid
Dimensions (approx.) [W + H + D]  [“] 
[mm]
72.9 + 64.6 + 30.7  
1851 + 1640 + 780
Weight (approx.)  [kg] 100
Material | Surface finish (product wetted parts) Stainless steel AISI 316L | Ra < 0.8 µm (31.5 Ra or better) | EPDM | PVC | PE | PTFE | others
Utility Requirements Conditions | Flow Connection | Height
Water (WFI | PW | RO) min. 1 barg TC 64 | TC 2.5“ | 401 mm | 15.8“
Drain gravity | max. flow 3.5 m³ TC 64 | TC 2.5“ | 684 mm | 26.9“
Drain CIP pump gravity TC 25 | TC 1“ | 135 mm | 5.31“
Instrument air 6 barg | 87 psig, controlled Quick coupling 
CIP supply line TC 64 | TC 2.5“
CIP return line TC 64 | TC 2.5“
Power supply (TNS net):
5 wire: 3 + phase, 1 + ground, 1 + neutral
208 VAC | 60 Hz or 400 VAC | 50 Hz
CIP pump
Type Centrifugal pump 
Material pump head Stainless steel 316 L
Flow max. 3.5 m3/h @ 3 barg 
Valves  
Water Pneumatic operated diaphragm valve 
Recirculation Pneumatic operated diaphragm valve 
Drain Pneumatic operated diaphragm valve 
Drain valve pump housing Manual operated diaphragm valve 
NEW  Mobile CIP Unit – Technical Specification
Detergent dosing unit  
Number of dosing units 1 (2nd optional)
Pump | Flow rate Diaphragm pump | up to 25 L/h
Storage container volume | Material 40 L | PE 
Instrumentation | Measurement range 
Function  
Conductivity sensor (high) 1010 – 2000 mS
Conductivity sensor (low) 0.04 – 500 µS
Level switch Dry run protection for pump
Pressure gauge – 1/5 bar
External connections  Connection to BIOSTAT® D-DCU for automated CIP sequence control (valves and recirculation pump)
Sales and Service Contacts
For further contacts, visit www.sartorius-stedim.com
Europe
Germany
Sartorius Stedim Biotech GmbH
August-Spindler-Strasse 11
37079 Goettingen
Phone +49.551.308.0
Fax +49.551.308.3289
Sartorius Stedim Systems GmbH
Robert-Bosch-Strasse 5 – 7 
34302 Guxhagen
Phone +49.5665.407.0
Fax +49.5665.407.2200
France
Sartorius Stedim FMT S.A.S.
ZI des Paluds
Avenue de Jouques – CS 91051
13781 Aubagne Cedex
Phone +33.442.845600
Fax +33.442.845619
Sartorius Stedim France SAS
ZI des Paluds
Avenue de Jouques – CS 71058
13781 Aubagne Cedex 
Phone +33.442.845600
Fax +33.442.846545
Austria
Sartorius Stedim Austria GmbH
Franzosengraben 12
1030 Vienna
Phone +43.1.7965763.18
Fax +43.1.796576344
Belgium
Sartorius Stedim Belgium N.V.
Leuvensesteenweg, 248/B
1800 Vilvoorde
Phone +32.2.756.06.80
Fax +32.2.756.06.81
Hungary
Sartorius Stedim Hungária Kft.
Kagyló u. 5
2092 Budakeszi
Phone +36.23.457.227
Fax +36.23.457.147
Italy
Sartorius Stedim Italy S.p.A.
Via dell’Antella, 76/A
50012 Antella-Bagno a Ripoli (FI)
Phone +39.055.63.40.41
Fax +39.055.63.40.526
Netherlands
Sartorius Stedim Netherlands B.V.
Phone +31.30.60.25.080
Fax +31.30.60.25.099
filtratie.nederland@sartorius-stedim.com
Poland
Sartorius Stedim Poland Sp. z o.o.
ul. Wrzesinska 70
62-025 Kostrzyn
Phone +48.61.647.38.40
Fax +48.61.879.25.04
Russian Federation
LLC “Sartorius ICR”and LLC “Biohit”
Uralskaya str. 4, Lit. B
199155, Saint-Petersburg
Phone +7.812.327.5.327
Fax +7.812.327.5.323
Spain
Sartorius Stedim Spain, S.A.U.
Avda. de la Industria, 32
Edificio PAYMA
28108 Alcobendas (Madrid)
Phone +34.902.110.935
Fax +34.91.358.96.23
Switzerland
Sartorius Stedim Switzerland AG
Ringstrasse 24 a
8317 Tagelswangen
Phone +41.52.354.36.36
Fax +41.52.354.36.46
U.K.
Sartorius Stedim UK Ltd.
Longmead Business Centre
Blenheim Road, Epsom
Surrey KT19 9 QQ
Phone +44.1372.737159
Fax +44.1372.726171
Ukraine
LLC “Biohit”
Post Box 440 “B”
01001 Kiev, Ukraine
Phone +380.44.411.4918
Fax +380.50.623.3162
America
USA
Sartorius Stedim North America Inc.
5 Orville Drive, Suite 200
Bohemia, NY 11716
Toll-Free +1.800.368.7178
Fax +1.631.254.4253
Argentina
Sartorius Argentina S.A. 
Int. A. Ávalos 4251 
B1605ECS Munro 
Buenos Aires 
Phone +54.11.4721.0505 
Fax +54.11.4762.2333 
Brazil
Sartorius do Brasil Ltda 
Avenida Senador Vergueiro 2962 
São Bernardo do Campo 
CEP 09600-000 - SP- Brasil
Phone +55.11.4362.8900
Fax + 55.11.4362.8901
Mexico
Sartorius de México S.A. de C.V.
Circuito Circunvalación Poniente 
No. 149
Ciudad Satélite
53100, Estado de México
México
Phone +52.5555.62.1102
Fax +52.5555.62.2942
Asia|Pacific
Australia
Sartorius Stedim Australia Pty. Ltd.
Unit 5, 7-11 Rodeo Drive
Dandenong South Vic 3175
Phone +61.3.8762.1800
Fax +61.3.8762.1828
China
Sartorius Stedim Biotech (Beijing) Co. Ltd.
No. 33 Yu’an Road
Airport Industrial Park Zone B
Shunyi District, Beijing 101300
Phone +86.10.80426516
Fax +86.10.80426580
Sartorius Stedim Biotech (Beijing) Co. Ltd.
Shanghai Branch Office
3rd Floor, North Wing, Tower 1
No. 4560 Jin Ke Road
Pudong District, Shanghai 201210
Phone +86.21.68782300
Fax +86.21.68782332 | 68782882
Sartorius Stedim Biotech (Beijing) Co. Ltd.
Guangzhou Representative Office
Unit K, Building 23
Huihua Commerce & Trade Building
No. 80 Xianlie Middle Road
Guangzhou 510070
Phone +86.20.37618687 | 37618651
Fax +86.20.37619051
 
India
Sartorius Stedim India Pvt. Ltd.
#69/2-69/3, NH 48, Jakkasandra
Nelamangala Tq
562 123 Bangalore, India
Phone +91.80.4350.5250
Fax +91.80.4350.5253
Japan
Sartorius Stedim Japan K.K.
4th Fl., Daiwa Shinagawa North Bldg.
8-11, Kita-Shinagawa 1-chome
Shinagawa-ku, Tokyo, 140-0001 Japan
Phone +81.3.4331.4300
Fax +81.3.4331.4301
Malaysia
Sartorius Stedim Malaysia Sdn. Bhd.
Lot L3-E-3B, Enterprise 4
Technology Park Malaysia
Bukit Jalil
57000 Kuala Lumpur, Malaysia
Phone +60.3.8996.0622
Fax +60.3.8996.0755
Singapore
Sartorius Stedim Singapore Pte. Ltd.
1 Science Park Road, 
The Capricorn, #05-08A,
Singapore Science Park II
Singapore 117528
Phone +65.6872.3966
Fax +65.6778.2494
South Korea
Sartorius Korea Biotech Co., Ltd.
8th Floor, Solid Space B/D, 
PanGyoYeok-Ro 220, BunDang-Gu
SeongNam-Si, GyeongGi-Do, 463-400
Phone +82.31.622.5700
Fax +82.31.622.5799
www.sartorius-stedim.com Spe
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DATA SHEET HyPerforma 500 L Single-Use Mixer
HyPerforma Single-Use Mixer
HyPerforma S.U.M. options
• Powder hanger for 1 kg, 5 kg, and 25 kg Thermo 
Scientifi c™ Powdertainer™ BioProcess Containers (BPCs)
• AC and DC motor options; electrical box only available 
on AC option
• 3x load cell weighing system with summing box 
(options for displaying signal output)
• Cable management system to organize process 
tubing lines
• Available in either water-jacketed or non-jacketed 
(no heat transfer) design
• pH and conductivity probes and display
• Open-top or closed-top Thermo Scientifi c™ BPC design
• BPCs available in Thermo Scientifi c™ CX5-14 Film and 
Aegis™5-14 Film options
Options outside of the above list may be reviewed 
with a Thermo Fisher Scientifi c sales representative 
and considered for customizations to the standard 
mixer design.
The next generation of effi ciency and performance
The Thermo Scientifi c™ HyPerforma™ Single-Use Mixer 
(S.U.M.) provides you with enhanced functionality, ease 
of use, and effi ciency. The complete HyPerforma S.U.M. 
system consists of a mixer tank with a motor controller, 
available in sizes of 50, 100, 200, 500, 1,000, and 
2,000 L with a 5:1 turndown mixing ratio. The redesigned 
HyPerforma S.U.M. maintains traditional stirred-tank mixer 
design principles with a directly coupled motor impeller 
drive assembly and a cylindrical tank with a specifi c height-
to-diameter ratio, allowing for quick turnaround times for 
liquid-to-liquid mixing and powder-to-liquid mixing.
Critical upstream application steps
• Media preparation
• Final formulation steps
• Buffer preparation
• Harvest vessels
• Large-volume mixing (up to 2,000 L)
Critical downstream application steps
• Pooling and liquid transfer
• Product suspension
• Mixing and storing multiple batches
• Buffer preparation
• Viral inactivation
1. Powdertainer arm (optional)
2. Mixing assembly with shield
3. Bearing port receiver with clamp
4. Mixer motor
5. Stainless steel (grade 304) outer support container
6. Electrical control panel (optional)
7. Driveshaft (stored)
8. 3⁄8 in. dimpled jacket (side and bottom)
9. Probe access window
10. Probe hanger bracket
11. Cart assembly
12. Liquid sight windows
13. Bleed valve (water-jacketed models only)
14. Standard tool set: 3⁄8-in., 150 in.-lb. square torque 
wrench, load cell and motor cap lockout wrench
15. Bearing hub (for open-top mixing only)
16. Handles
17. Cutout for BPC loading
18. Bottom cutouts/pins for BPC attachment and alignment
19. 1½ inch tri-clamp connection ports for water inlet/outlet 
(water-jacketed models only)
20. Casters (3 swiveling and 2 fixed)
Note: Models without water jackets include the same features as the water-jacketed models shown here, but without the jacket and inlet/outlet ports.  
Optional load cells and cable management system are not shown. See the accessories section for more information about these items.
Standard S.U.M. hardware ordering information
Note: Models without water jackets may have slightly different dimensions than the water-jacketed 
model shown here. See the drawings provided with your unit for exact dimensions for non-jacketed
models. Non-jacketed models do not have the capability to heat or cool the liquid inside the tank.
Description Cat. No.
Non-jacketed, DC motor, with load cell SUM0500.9001
Jacketed, DC motor, with load cell SUM0500.9002
Non-jacketed, 120 VAC, AC motor, with load cell SUM0500.9003
Jacketed, 120 VAC, AC motor, with load cell SUM0500.9004
Non-jacketed, 240 VAC, AC motor, with load cell SUM0500.9005
Jacketed, 240 VAC, AC motor, with load cell SUM0500.9006
Design features
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Front view Back view
Front view
80 cm (31.4 in.)
Overall length
94 cm (37.0 in.)
Overall width
89 cm (34.9 in.) 
  Overall length
66 cm (26.0 in.) 
    Cart length
81 cm (32.0 in.) 
   Cart width
122 cm (48.2 in.) 
   Overall width
129 cm (50.7 in.) 
   Overall length
258 cm (101.8 in.) Powdertainer height 
164 cm (64.4 in.) Tank height
198 cm (77.8 in.) Motor height
33 cm (13.1 in.) Tank bottom 
24 cm (9.5 in.) Cart height
0 cm (0 in.) 
82 cm (32.1 in.) 
   Cart length
  40 cm (15.6 in.) 
    Electrical box
         width
Top view
Standard 500 L S.U.M. hardware
 500 L S.U.M. specifications
 AC motor DC motor
Non-jacketed Jacketed Non-jacketed Jacketed
Fl
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Jacket area: full/half volume –
2.2 m2 (23.9 ft.2)/ 
1.4 m2 (14.8 ft.2)
–
2.2 m2 (23.9 ft.2)/ 
1.4 m2 (14.8 ft.2)
Jacket volume – 11 L (2.9 gal) – 11 L (2.9 gal)
Jacket flow rate at 50 psi – 96.8 L/min (25.5 gal/min) – 96.8 L/min (25.5 gal/min)
Process connection – 1 in. sanitary tri-clamp – 1 in. sanitary tri-clamp
Temperature Control Unit (TCU) model: 
Maximum heating/cooling
– TF2500: 2,800/2,500 W – TF2500: 2,800/2,500 W
Approximate liquid heat-up time (5–37°C) – 2.6 hr – 2.6 hr
Approximate liquid chill-down time (37–5°C) – 3.7 hr – 3.7 hr
M
is
c. RTD or thermocouple, 1/8 in.  
(3.18 mm) OD
RTD: Pt-100 (standard)
S
up
p
or
t 
co
nt
ai
ne
r Overall width 122.5 cm (48.23 in.) with e-box 86.4 cm (34 in.) without e-box
Overall length 130.2 cm (51.25 in.) with e-box 130.2 cm (51.25 in.) without e-box
Overall height 251.1 cm (98.9 in.)
Dry skid weight (mass) 333 kg (734 lb) 431 kg (951 lb) 333 kg (734 lb) 431 kg (951 lb)
Wet skid weight, rated  
working volume (mass)
833 kg (1,836 lb) 931 kg (2,053 lb) 833 kg (1,836 lb) 931 kg (2,053 lb)
G
en
er
al
Ceiling height required for  
standard driveshaft loading
320 cm (126 in.)
Ceiling height required for optional,  
non-standard 2-piece drive shaft loading
275.6 cm (108.5 in.)
Electrical power supply requirement  
(voltage, phase, current)
120/240 VAC, single, 20/10 A Dependent on controller
pH and dissolved oxygen (DO) probe, 
autoclavable type (AppliSens™, Broadley 
James™, Mettler Toledo™)
12 mm diameter x 215–235 mm insertion length x 13.5 PG (pipe) thread
Noise level < 70 dB at 1.5 m
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Operating temperature range 2–40°C ±0.1°C (36–104°F ±0.2°F)
Motor speed 30–350 rpm
Volume range 100–500 L
Maximum BPC pressure 0.03 bar (0.5 psi)
Maximum BPC pressure during operation 0.007 bar (0.1 psi)
Continuous operating time 21 days mixing time at nominal volume only
Description Cat. No.
Cable management system (500 L) SV50992.03
3x load cell with summation box,  
without display
SV50988.03
Mettler Toledo IND331 display, with analog 
interface (STD), 120 VAC U.S. line cord/plug
SV50177.306
Mettler Toledo IND331 display, with  
Allen-Bradley™ RIO interface, 120 VAC U.S.  
line cord/plug
SV50177.307
Mettler Toledo IND331 display, with DeviceNet 
interface, 120 VAC U.S. line cord/plug
SV50177.308
Mettler Toledo IND331 display, with Ethernet/
IP and Modbus TCP interface, 120 VAC U.S. 
line cord/plug
SV50177.309
Mettler Toledo IND331 display, with Profibus 
interface, 120 VAC U.S. line cord/plug
SV50177.310
Powdertainer arm for 50–1,000 L mixers SV51002.01
Mettler Toledo pH monitoring device,  
single channel
SV51004.01
Mettler Toledo pH monitoring device,  
dual channel
SV51004.02
Mettler Toledo pH and conductivity monitoring 
device, dual channel
SV51004.07
 
Harvest line hook
Adjustable arm
Channels for 
additional lines
Load cells 
Load cells are typically radially mounted in sets of three. 
The mounting location varies slightly for each size in order 
to allow easy access to the bottom drain or sparging 
mechanisms and tubing.
Load cell displays
Harsh mount load cell displays are available as an option 
for all HyPerforma S.U.M. systems. They are normally 
mounted on the electrical box or a wall and are available 
with four different interfaces.
Powdertainer arm
A Powdertainer arm is available as an option for  
powder–liquid applications. It holds the container of 
powder above the mixer and attaches it to the BPC with 
a clamp. The arm adjusts vertically and swivels to enable 
convenient lifting of the Powdertainer onto the hanger.
pH and conductivity monitoring devices
Mettler Toledo pH and conductivity sensors with a display 
monitor are available in single pH, dual pH, and pH and 
conductivity configurations. The monitor is mounted on the 
post behind the electrical box, and includes a color touch 
screen and control and alarm-management features.
Mettler Toledo MTB load cell for 
50–1,000 L S.U.M. units.
Powdertainer arm
pH and conductivity monitoring device
Mettler Toledo IND331 harsh- 
mount load cell display for all 
S.U.M. systems.
Powdertainer hook
Powdertainer-to-BPC 
port clamp
Tank attachment 
mechanism 
Autoclave tray and probe assembly
The autoclave tray holds the electrochemical probes and 
bellows in place during the autoclave sterilization process. 
Design elements include the following:
• Fabricated from stainless steel
• Plastic handle provides for easy transport right  
out of the autoclave
• Positions probes on 15% incline for greater probe and 
membrane longevity
• Prevents probe bellows from collapsing  
during sterilization
• Probe holder accommodates two probes
Probe clips
Stainless steel probe clips are used to hold the probes 
in place on the S.U.M. tank. The independently movable 
probe clips hang on a thin brace above the probe port 
tank cutout and are held in place by an adjustable spring 
plunger. The probes are inserted into the clip mechanism 
and held in place by a half-spring clip.
Heavy-duty tubing clamps
Heavy-duty clamps are used for pinching off line sets 
that are not in use in order to prevent process fluids from 
escaping. Prior to sterile probe insertion, tubing clamps 
must be in place to close off probe ports.
Description Cat. No.
Autoclave tray (stainless steel with plastic 
carry handle)
SV50177.01
4 probe clips SV50177.23
Heavy-duty tubing clamp (single) SV20664.01
Heavy-duty tubing clamp (10 pack) SV20664.04
 
Autoclave tray
Handle
Probe
Threaded probe 
attachment 
Cable tie 
Molded  
bellows cover
Probe clip Heavy-duty  
tubing clamps
Standard 500 L BPC for powder–liquid applications without probe ports
Line Description Tubing set (inner diameter x outer diameter x length) End treatment
1 Addition line 12.7 mm (1/2 in.) x 15.9 mm (5/8 in.) C-Flex™ x 152 cm (60 in.) Plugged 12.7 mm (1/2 in.) MPX body
2 Recirculation/sample line
12.7 mm (1/2  in.) x 19.1 mm (3/4  in.) C-Flex x 137 cm (54 in.) splits to
12.7 mm (1/2  in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
12.7 mm (1/2  in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)
Capped 12.7 mm (1/2  in.) MPX insert
Plugged 12.7 mm (1/2  in.) MPX body
3 Bottom drain 12.7 mm (1/2  in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.) Capped 12.7 mm (1/2  in.) MPX body
4 Powder addition port 7.6 mm (3 in.) sanitary fitting, tri-clamp tube ports Capped with gasket
3. Bottom drain
4. Powder addition port
Back face
1. Addition line Impeller
2. Recirculation/sample line
Front face
Front face
Back face
Impeller
5. Addition line4. Vent filter
3. Fill line
2. Recirculation/sample line
1. Bottom drain
Standard 500 L BPC for liquid–liquid applications without probe ports
 Line Description Tubing set (inner diameter x outer diameter x length) End treatment
1 Bottom drain 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.) Capped 12.7 mm (1/2 in.) MPX body
2 Recirculation/
sample line 
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 168 cm (66 in.) splits to
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and  
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)
Capped 12.7 mm (1/2 in.) MPX insert
Plugged 12.7 mm (1/2 in.) MPX body
3 Fill line 19.1 mm (3/4 in.) x 25.4 mm (1 in.) C-Flex x 152 cm (60 in.) 38.1 mm (1 1/2 in.) tri-clamp (SterilEnz™)
4 Vent filter 6.4 mm (1/4 in.) x 12.7 mm (1/2 in.) C-Flex x 10.2 cm (4 in.) Sterile hydrophobic vent filter  
(0.2 μm PVDF, Acro™ 50)
5 Addition line 9.5 mm (3/8 in.)  x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) Plugged 9.5 mm (3/8 in.) MPX insert
Standard 500 L BPC for powder–liquid applications with probe ports
 Line Description Tubing set (inner diameter x outer diameter x length) End treatment
1 Recirculation line 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 137 cm (54 in.) splits to
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)
Capped 12.7 mm (1/2 in.) MPX insert
Plugged 12.7 mm (1/2 in.) MPX body
2 Addition line 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.) Plugged 12.7 mm (1/2 in.) MPX insert
3–4 Probe ports (2) None Kleenpak™ aseptic connector  
KPCHT series (female)
5 Unused None Plug
6 Thermowell/ 
small-volume 
sample line
Thermowell adapter for 3.2 mm (1⁄8 in.) diameter 3.2 mm (1⁄8 in.) x
6.4 mm (1/4 in.) x 30 cm (12 in.)
Luer and SmartSite™ valve port
7 Bottom drain 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.) Capped 12.7 mm (1/2 in.) MPX body
8 Powder addition 
port
7.6 mm (3 in.) sanitary fitting, tri-clamp Cap with gasket
Front face
Back face
8. Powder addition port
2. Addition line
1. Recirculation/sample line
Impeller
6. Thermowell/small-volume sample line
3-4. Probe ports (2)
5. Unused
7. Bottom drain
Standard 500 L BPC for liquid–liquid applications with probe ports
 Line Description Tubing set (inner diameter x outer diameter x length) End treatment
1—2 Probe ports (2) None Kleenpak aseptic connector KPCHT 
series (female)
3 Thermowell/ 
small-volume 
sample line
Thermowell adapter for 3.2 mm (1⁄8 in.) diameter 3.2 mm (1⁄8 in.) x
6.4 cm (1⁄4 in.) C-Flex x 30 cm (1⁄2 in.)
Luer and SmartSite valve port
4 Recirculation line 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 168 cm (66 in.) splits to
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 61 cm (24 in.) and
12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 30 cm (12 in.)
Capped 12.7 mm (1/2 in.) MPX insert
Plugged 12.7 mm (1/2 in.) MPX body
5 Fill line 12.7 mm (1/2 in.) x 25.4 mm (1 in.) C-Flex x 152 cm (60 in.) 38.1mm (1 1/2 in.) tri-clamp (SterilEnz)
6 Vent filter 6.4 mm (1⁄4 in.) x 12.7 mm (1⁄2 in.) C-Flex x 10.2 cm (4 in.) Sterile hydrophobic vent filter
(0.2 μm PVDF, Acro 50)
7 Addition line 9.5 mm (3/8 in.) x 15.9 mm (5/8 in.) C-Flex x 61 cm (24 in.) Plugged 12.7 mm (1/2 in.) MPX insert
8 Bottom drain 12.7 mm (1/2 in.) x 19.1 mm (3/4 in.) C-Flex x 122 cm (48 in.) Plugged 12.7 mm (1/2 in.) MPX body
9 Unused None Plug
Bottom drain
Quick-connect fitting
Sleeve (3/4 in. inner diameter tubing)
Impeller
Standard open-top liners 
Description Cat. No.
500 L standard open-top liner, 
0 probes, CX3-9 film
SH30762.06
 
Standard impeller sleeve
Description Cat. No.
500 L impeller sleeve for open-top mixing* SH30749.10
 * The bearing hub needed for open-top mixing is automatically supplied with the tank hardware.
8. Bottom drain
9. Unused1-2. Probe ports (2)
3. Thermowell/small-volume sample line
Impeller
Back face
7. Addition line
4. Recirculation/sample line
5. Fill line
6. Vent filter
Front face
Custom BPC products
Category Options/capability Notes
Tubing type C-Flex, platinum-cured silicone, PVC, PharMed™, PharmaPure™. More information is available in 
the tubing selection guide.
Tubing size Ranges from 3.18 mm (1/8 in.) to 25.4 mm (1 in.) inner diameter in  
various lengths.
More information is available in 
the tubing selection guide.
Connectors Luer, Colder Products Company™ (CPC) quick connects, SIP connectors, 
tri-clamp, Kleenpak, SmartSite, Clave™, Lynx™ steam-thru, CPC steam-
thru, Gore™ steam valve, Gore™ Mini TC, BioQuate™, SterilEnz, end plug.
More information is available in 
the connection system selection 
guide. Note: the only option 
for probe port connections is 
Kleenpak connectors.
Probe ports/line  
addition ports
Ports may be added if they are compatible with the hardware. The reusable probe port 
connection uses a  
Kleenpak connector.
Disposable sensors Pressure sensor: PendoTECH™ and Finesse Solutions (PendoTECH 
comes standard on 500 L and 1,000 L S.U.M.); DO and pH sensor: 
Finesse Solutions and PreSens™; pH sensor: Mettler Toledo.
Choice of qualified  
vendors available.
Port sizes Limited engineer-to-order customization only. Dependent on location in BPC 
and fit with hardware (e.g., 1 in. 
ID port on harvest line).
Rearrangement of 
lines on existing 
ports
Limited customization possible, such as moving sample/thermowell port 
to a probe tube port, or swapping exhaust outlet line with liquid lines.
Dependent on location in BPC 
and fit with hardware.
Dip tube lines Limited customization possible. Length cannot interfere with 
impeller and shaft.
Filters on media and 
supplement inlets
Limited engineer-to-order customization only. Choice of filters used to 
sterilize incoming media or supplements are available.
Note: Not all options are available for all ports. It is not possible to customize port type, port location, chamber dimensions, or mixing assembly.  
For additional information, please see the selection guides in the BPC Catalog.
BPC packaging
Description Details
Outer packaging Supplied “flat-packed” with two polyethylene outer layers 
Label Description, product code, lot number, and expiry date on outer packaging and shipping container
Sterilization Irradiation (25 to 38 kGy) inside outer packaging
Shipping container Durable cardboard carton
Documentation Certificate of analysis provided with each lot for each delivery
Find out more at thermofisher.com/sum
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.  
© 2017 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless 
otherwise specified. Allen Bradley is a trademark of Allen-Bradley Company. Applisens is a trademark of Applikon B.V. Corporation. BioQuate 
and PreSens are trademarks of General Electric Company. Broadley James is a trademark of Broadley-James Corporation. Clave is a trademark 
of ICU Medical, Inc. Colder Products Company is a trademark of Dover Corporation. Gore is a trademark of W. L. Gore & Associates. Kleenpak 
and Acro are trademarks of Pall Corporation. Lynx is a trademark of Merck KgAA. Mettler Toledo is a trademark of Mettler-Toledo AG. PharMed 
and PharmaPure are trademarks of Saint-Gobain Performance Plastics Corporation. PendoTECH is a trademark of PendoTECH. SmartSite is a 
trademark of Carefusion 303, Inc. SterilEnz is a trademark of PAW BioScience Products, Inc. COL05436 1117
Ordering information
500 L S.U.M. BPC Size Probe ports* Film type Cat. No.
Standard powder–liquid BPC
500 L 0 CX5-14 SH30751.01
500 L 0 Aegis5-14 SH30973.03
Standard liquid–liquid BPC
500 L 0 CX5-14 SH30754.01
500 L 0 Aegis5-14 SH30983.03
Standard powder–liquid BPC* 
500 L 3 CX5-14 SH30751.02
500 L 3 Aegis5-14 SH30974.03
Standard liquid–liquid BPC*
500 L 3 CX5-14 SH30754.02
500 L 3 Aegis5-14 SH30982.03
* All 500 L BPCs with probe ports are designed to allow probes to work properly at 5:1 turndown levels. These BPCs are only compatible with the HyPerforma hardware shown in this document. If you are 
using an older version of the S.U.M. hardware, do not use these items; instead refer to the legacy S.U.M. user manual or data sheets. 


USD 2719a
! High resolution flow path provides optimum efficiency, capacity, and peak symmetry.
! Central nozzle valve provides all column functions required for packing, unpacking, and running the 
column within a closed system.
! Scalable, reproducible packing methods reduce validation efforts as processes scale up.
! Common design from 280 to 1200 mm diameter (and up to 2000 mm on request).
! Designed to minimize packing events and buffer usage to optimize process economics.
! Options for manual or remote controlled nozzle valves.
Applications
Resolute columns have proven performance with a wide range of chromatography sorbents and 
chromatographic modes including ion exchange, mixed-mode, affinity and hydroxyapatite.
Resolute® Manual Chromatography Columns
Process columns for optimized, contained, 
and scalable operation
2
Principle of Slurry Transfer 
Resolute columns can be packed and unpacked with the
column fully assembled. At the center of the operation is 
a nozzle valve in both the top and bottom of the column.
Process liquids can enter and exit the column via either
nozzle valve depending on which packing method is 
employed. Top and bottom nozzle valves are identical,
making the flow profile the same in either direction. 
The ability to pack media with the top end cell in place
contributes to process hygiene by reducing exposure to
the external environment.
There are three positions for each nozzle valve (Figure 1).
Effective Column Packing 
Contained Operation
All column operations are performed in a closed system;
therefore, there is less risk of the operator coming into
contact with hazardous materials or the process being 
exposed to contamination. This results in improved safety
and hygienic operation of the column process.
Reproducibility
By eliminating labor intensive column handling operations,
the packing parameters can be set and applied within 
a standard operating procedure. This improves the 
reproducibility of the packed column performance.
Scalability
All design elements within the column mobile phase flow
path are maintained throughout the range (up to 2000 mm
diameter). Unlike conventional columns that are based on
different seal and distributor cell designs as size increases,
the Resolute column sealing arrangement and flow path
follow a single design principle that delivers proven and
consistent column performance. 
Reduced Process Validation 
Resolute columns and packing systems maintain identical
linear velocities and pressure profiles during the packing
process, whether in a 400 mm pilot-scale column or a
2000 mm process-scale column. Using the same packing
methods reduces the effort required during preparation 
of standard operating procedure (SOP) for large-scale
manufacturing packing methods. 
Figure 1
Nozzle valve in pack position
Nozzle valve in run position
Nozzle valve in unpack position
www.pall.com/biopharm3
Optimized for Efficiency and Scale Up 
Resolute columns are equipped with Pall’s proprietary 
high resolution mobile phase flow path which consists of 
a mobile phase flow path within the nozzle valve body, 
distribution end cells, and a fully flushed piston seal
arrangement. The performance of these important column
components is essential for optimal process efficiency, 
capacity, and peak symmetry. 
Resolute columns maintain identical design parameters
throughout both the standard column range (from 280 mm
to 1200 mm diameter) and the larger capacity columns (up
to 2000 mm diameter). Operation at high linear velocities
is free from non-linear column effects and assures true 
linear scalability of column performance, enabling users to
scale up simply without method redevelopment or impact
on the reproducibility of the packing process. 
Key flow path features: 
! Nozzle valve mobile phase path delivers consistent low
pressure drop across column for true linear scale up. 
! Distribution with coned end cell channels provides near
plug flow conditions. 
! Secondary cone on support ribs provides unimpeded
route via top central nozzle for simple and effective 
removal of entrapped air as well as effective recovery of
slurry via bottom central nozzle when unpacking. 
! Nozzle tip retracts flush with bed support with no 
protrusion into packed bed.  
Consistent Chromatography Performance 
Resolute columns’ high resolution mobile phase flow path
enables operation at high linear velocities up to 1000 cm/h.
The flow distribution cells and mobile phase flow path
support near plug flow conditions irrespective of column
diameter. Figure 3 shows pressure flow curves for 
Resolute columns and alternative manufacturers’ columns.
The columns were filled with water, and pressure and flow
instruments were used to measure pressure drop across
the filled column under process flow conditions. Resolute
columns exhibit identical pressure flow curves, linear up 
to 1000 cm/h, at which the pressure drop is 0.1 barg 
(1.5 psig). Alternative column designs exhibit high, 
exponential pressure flow curves. During normal operations,
actual pressure drop will be the sum of the value shown
below and the additional value from the packed bed. 
Resolute columns support true linear scale up of both the
purification performance and column packing methods: 
! Elimination of non-linear interference from column 
design enables monitoring of actual column pressure 
resulting from media bed properties. 
! Pressure versus bed height relationship for a specific
media, packed at the same compression, remains 
constant up to at least 1000 cm/h linear flow in any 
diameter of Resolute column. 
Linear Flow (cm/hr)
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Resolute Typical process velocities
Figure 2 
High resolution mobile phase flow path  
Figure 3 
Pressure vs. flow for Resolute columns and alternative
columns fitted with stainless steel mesh bed supports 
(column Ø mm)
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Designed for Durability, Reliability, Versatility
and Ease of Use 
Resolute columns are available in diameters from 280 mm
to 1200 mm, with 200 mm bed height adjustment and
choice of bed heights up to 600 mm. Alternative bed
height adjustment and diameters up to 2000 mm are
available on request. Resolute manual columns feature: 
! Manually operated nozzle valves. (See column options
for pneumatically-actuated nozzle valves.) 
! Choice of bed supports in polyethylene or 316L 
stainless steel. 
! Acrylic column tube provides visibility of the packed bed. 
! Simple, constant compression, adjuster seal, and 
precision bore eliminate need for additional mechanical
or pneumatic activation of adjuster seals. 
! Stainless steel support frame equipped with lockable
castors (available up to 1000 mm column).   
Figure 4 
Resolute manual 1000 mm internal diameter (ID) column 
Figure 5 
Manual nozzle
Sanitary Design 
Sanitary design features ensure the longevity, consistency,
and reliability of your process: 
! Fully flushed flow path and adjuster seal facilitate 
clean-in-place (CIP). 
! Minimum dead space fixed cell seal arrangement. 
! Non-metallic mobile phase flow path is ideal for high
salt, low pH conditions, and eliminates the risk of 
corrosion within the nozzle valve. 
! Phthalate-free acrylic tube and peroxide-cured EPDM
(ethylene-propylene-diene monomer) seals.
! Low-profile central nozzle retaining ring on the bottom
bed support reduces media hold-up during unpacking.  
Column Options
! Remote controlled pneumatic nozzle valve: a pneumatic 
actuator positions the nozzle to pre-set positions (Run,
Pack, Unpack) with pneumatic controller and position
feedback for increased process security. (Not available
on 280 mm column.) 
! Bed supports are available in stainless steel (10/20/50 µm)
and polyethylene (10/20/60 µm), which offers a lower-
cost alternative when frequent bed support changes 
are required. 
! Robust stainless steel column tube with increased
chemical compatibility. (Not available on 280 mm column.)
! Fixed bed capacity with no bed height adjustment 
available for media-specific or process requirements. 
! Extended adjuster range (300 mm) adds packing flexibility.
Valve actuator
Valve control
Figure 6 
Remote controlled pneumatic nozzle   
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Maximum allowable pressure 280 mm Ø column: 5.0 barg (72.5 psig);  400 –1200 mm Ø column: 4.2 barg (60.9 psig)
Operating temperature 2 – 30 ºC
Bed support type and rating Stainless steel mesh: 10, 20, 50 µm;  Polyethylene sinter: 10, 20, 60 µm
Stainless steel surface finish Product flow path: < 0.6 µm Ra, electropolished
Exterior components: < 0.9 µm Ra, electropolished
Pressure retaining plates: < 1.5 µm Ra, 240 (UK) grit sateen
Column frame: bright polished
Adjuster seal Precision bore with compression seals
Media transfer nozzle Manual or pneumatic remote controlled 
Process Wetted Components Material
Column tube Acrylic
Distribution cell Polypropylene
Nozzle body 280 –1000 mm Ø column: polyvinylidene fluoride (PVDF); 1200 mm Ø column: polypropylene
Mobile phase termination 280 –1000 mm Ø column: polyetheretherketone (PEEK);  ≥1200 mm Ø column: stainless steel 316L
Slurry nozzle tip PEEK
Slurry inlet port 280 mm Ø column: PEEK; 400 –1200 mm Ø column: stainless steel 316L
Bed support Polyethylene sinter or stainless steel mesh
Main seals EPDM (peroxide cured)
Nozzle tip seals Fluorinated ethylene propylene (FEP) encapsulated silicone
Wiper ring Polytetrafluoroethylene (PTFE)
External Components 
Stand Stainless steel 316L
Castor Stainless steel 304L
Wheel 280 –600 mm Ø column: polyurethane; 800 –1000 mm Ø column: nylon
Foot 1200 mm Ø column: stainless steel 316L 
Column Specifications
Materials of Construction
Design
The basis of design for Resolute columns is PD5500. Columns, where applicable, are CE marked in accordance with the 
European Pressure Equipment Directive 97/23/EC.
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Port Sizes and Pressure Flow Kit (PFK)
Below are the termination sizes for the column and PFK, and a schematic showing the scope of the column PFK kit. All 
connections are sanitary Tri-Clamp! connections with EPDM gaskets. PFK kits are available to complement the standard
columns and are also available within an 8 weeks lead time. 
Note that the standard PFK does not include sight glasses.
Figure 7 
Scope of column PFK kit and termination sizes for column and PFK
Pressure Burst Flexible
Gauge Disk Block Valve Termination Size* Hose Size*
Column Ø Wika!: BS&B: GEMU! 3-Way Manual Diaphragm Valve 
(mm) Nozzle Valve Termination Size* 233.50 GCR-S! 673 / 671 Bonnet Pharmaline!
NV1 NV2 NV3 NV4 NV5 NV6 G1 BD1 TC1 TC2 TC3 TC4 H1
300 0.5 in. 0.5 in. 0.5 in. 0.5 in. 0.5 in. 0.5 in. 1.0 in. 1.0 in. 0.5 in. 0.5 in. 0.5 in. 0.5 in. 0.5 in.
400–450 0.75 in. 0.75 in. 0.75 in. 0.75 in. 0.75 in. 0.75 in. 1.0 in. 1.0 in. 0.75 in. 0.75 in. 0.75 in. 0.75 in. 0.75 in.
600–630 1.0 in. 1.0 in. 1.0 in. 1.0 in. 1.0 in. 1.0 in. 1.0 in. 1.0 in. 1.0 in. 1.0 in. 1.0 in. 1.0 in. 1.0 in.
800–1000 1.5 in. 1.5 in. 1.5 in. 1.5 in. 1.5 in. 1.5 in. 1.0 in. 1.5 in. 1.5 in. 1.5 in. 1.5 in. 1.5 in. 1.5 in.
* (ASME BPE standard) 
G1
Mobile
phase
upper
Slurry inlet
upper
Slurry waste
upper
PI
TC1
TC2
BD1 NV1
NV3
NV2
NV4
TC4
TC3
H1
NV5
NV6
PI
Mobile
phase
lower
Slurry waste
lower
Slurry inlet
lower
Resolute Manual Column
Hard pipe
Flexible hose
Tri-Clamp
connections
Burst disk
Pressure gauge
2-way diaphragm
valve (manual)
Sight glass
(applicable only 
to steel tubed 
columns)
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Installation and Validation Documentation 
Resolute columns are supplied with a comprehensive 
validation and support package including an operator’s
manual. The validation support package contains 
comprehensive protocols and provides the required 
documentation and procedures to support factory 
acceptance test (FAT), installation qualification (IQ) and
operational qualification (OQ). To support validation efforts
and efficient commissioning, the documentation includes
records of the pre-shipment test results. 
Column manual documentation includes: 
! Operating guide 
! Materials and compatibility data 
! Comprehensive parts list 
! Spare parts recommendation 
! Maintenance recommendation 
Packing Station 
Resolute slurry packing systems (SPS) simplify column
packing and unpacking operations. Two system capacity
options provide flow rates suitable for packing and 
unpacking columns up to 1200 mm diameter (2000 mm
columns are also supported). Complete column packing
solutions for Resolute columns include: 
! Resolute SPS with optional control module for remote
operation of slurry and buffer tank valves 
! Media preparation system 
! Hose kits for connection of column, system, and tanks 
! Pressure and flow monitoring 
! Media and buffer tanks ready for use with Resolute
columns and SPS systems  
For more information on the Resolute slurry packing system, contact your
local Pall representative or visit www.pall.com/biopharm.  
Substance/Concentration Acrylic SS PVDF PP EPDM/FEP PE PEEK PTFE
Acetic acid < 1 M  +  +  +  +  +  +  +  +
Ethanol < 40% (v/v) +  +  +  +  + •  +  +
Benzyl alcohol < 2% (v/v) •  +  +  +  +  +  +  +
Isopropyl alcohol < 30% (v/v)  +  +  +  +  +  +  +  +
Hydrochloric acid 0.1 M + •  +  +  +  +  +  +
Nitric acid 0.1 M +  +  +  +  + •  +  +
Phosphoric acid 25% + •  +  +  + •  +  +
Sodium chloride < 2 M + •  +  +  +  +  +  +
Sodium hydroxide < 2 M +  +  +  +  +  +  +  +
Triton! X-100  +  +  +  +  +  +  +  +
Guanidine HCl < 6 M + •  +  +  +  +  +  +
Urea < 8 M +  +  +  +  +  +  +  +
+ Compatible     • Conditional compatibility; contact Pall for details
Abbreviations: EPDM = Ethylene propylene di-monomer, FEP = Fluoroethylene polymer, PE = Polyethylene, PEEK = Polyether ether ketone, PP = Polypropylene,
PTFE = Polytetrafluoroethylene, PVDF = Polyvinylidene fluoride, SS = Stainless steel
Chemical Compatibility
Additional Column and Equipment Needs 
! Column maximum allowable pressure up to 10 barg
(145 psig) 
! Pressure vessel certification to ASME 
! Alternative column diameters may be specified 
(440 and 700 mm) up to 2000 mm 
! Electric actuation of adjustable end cell (not available on
280 mm column) 
! Fully automated AutoPak systems for packing, unpacking,
repacking and CIP
! Integrated column maintenance assist system 
(not available on 280 mm column) 
! Automated column packing systems 
Figure 8 
Resolute slurry packing system
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Columns Available Within 8 Weeks Lead Time 
The following standard columns are available within 8 weeks from the point of receipt of purchase order. 
Ordering Information
All columns are acrylic tubed, with manual nozzles and a stroke length of 100–400 mm. Different diameter and bed height
ranges are available on request. 
Part Number Resolute Column Ø (mm) Mesh Material Mesh Pore Size (µm)
M-DM0301040AP10 300 PE* 10
M-DM0301040AP20 20
M-DM0301040AS10 300 SS 1.4404* 10
M-DM0301040AS20 20
M-DM0401040AP10 400 PE 10
M-DM0401040AP20 20
M-DM0401040AS10 400 SS 1.4404 10
M-DM0401040AS20 20
M-DM0451040AP10 450 PE 10
M-DM0451040AP20 20
M-DM0451040AS10 450 SS 1.4404 10
M-DM0451040AS20 20
M-DM0601040AP10 600 PE 10
M-DM0601040AP20 20
M-DM0601040AS10 600 SS 1.4404 10
M-DM0601040AS20 20
M-DM0631040AP10 630 PE 10
M-DM0631040AP20 20
M-DM0631040AS10 630 SS 1.4404 10
M-DM0631040AS20 20
M-DM0801040AP10 800 PE 10
M-DM0801040AP20 20
M-DM0801040AS10 800 SS 1.4404 10
M-DM0801040AS20 20
M-DM1001040AP10 1000 PE 10
M-DM1001040AP20 20
M-DM1001040AS10 1000 SS 1.4404 10 
M-DM1001040AS20 20
* PE = Polyethylene; SS 1.4404 = Stainless steel 1.4404
Pressure Flow Kit (PFK) 
Part Number Applicable Column Diameter (mm)
M-PFK-030 300
M-PFK-040 400
M-PFK-045 450
M-PFK-060 600
Part Number Applicable Column Diameter (mm)
M-PFK-063 630
M-PFK-080 800
M-PFK-100 1000 
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Column Accessories 
! Endcell rotation frame for safe maintenance procedures
(suitable for Resolute 400 to 1200 mm Ø columns) 
! Column transportation system 
! Bed support transportation device for safe and secure
handling 
! Column spanner set (metric) 
! Packing flow kit 
Contact Pall for details.
Services 
Pall has the resources necessary to help our customers
maintain Pall systems and columns for optimum 
performance and maximum service duty. This includes
comprehensive service maintenance programs, validation
services, and training packages such as: 
! Factory acceptance testing 
! Site acceptance testing 
! Installation and commissioning 
! IQ/OQ documentation and execution 
! Operator training (on-site or in a Pall facility) 
! Planned maintenance programs 
! Applications support and packing assistance 
! Packing studies conducted at one of Pall’s 
chromato graphy application laboratories.  
Contact Pall for details.
Visit us on the Web at www.pall.com/biopharm
E-mail us at biopharm@pall.com
International Offices
Pall Corporation has offices and plants throughout the world in locations such as:
Argentina, Australia, Austria, Belgium, Brazil, Canada, China, France, Germany,
India, Indonesia, Ireland, Italy, Japan, Korea, Malaysia, Mexico, the Netherlands,
New Zealand, Norway, Poland, Puerto Rico, Russia, Singapore, South Africa, Spain,
Sweden, Switzerland, Taiwan, Thailand, the United Kingdom, the United States, and
Venezuela. Distributors in all major industrial areas of the world. To locate the Pall
office or distributor nearest you, visit www.pall.com/contact.
The information provided in this literature was reviewed for accuracy at the time of
publication. Product data may be subject to change without notice. For current 
information consult your local Pall distributor or contact Pall directly. 
Corporate Headquarters
Port Washington, NY, USA
+1 800 717 7255  toll free (USA)
+1 516 484 5400  phone
biopharm@pall.com  e-mail
European Headquarters
Fribourg, Switzerland
+41 (0)26 350 53 00  phone
LifeSciences.EU@pall.com  e-mail
Asia-Pacific Headquarters
Singapore
+65 6389 6500  phone
sgcustomerservice@pall.com  e-mail
© 2017, Pall Corporation. Pall,         , Mustang and Resolute are trademarks of Pall
Corporation. Filtration.Separation.Solution is a service mark of Pall Corporation.  
! Triton is a trademark of The Dow Chemical Company. Tri-Clamp is a trademark of
Alfa Laval. WIKA is a trademark of WIKA Alexander Wiegand GmbH. GCR-S is a
trademark of BS&B Safety Systems LLC. GEMU is a trademark of Gebruder Muller
Apparatebau GmbH. Pharmaline is a trademark of Aflex Hose Ltd. ® indicates a
trademark registered in the USA. 
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PK and PKP Chromatography Systems
The PK and PKP chromatography
systems range incorporates
proven component technology
that delivers accurate 
precision gradients and
in-line buffer dilution. It
maintains the performance
necessary to make your
chromato graphy process
consistent from batch-to-
batch and optimal at pilot 
and manufacturing scales. 
Covering a range from 1 to greater than 4000 L/h, PK and
PKP systems ensure robust operation and flexibility for all
biochromatography applications. 
These systems can be used with Resolute chromato graphy
columns as well as Mustang® membrane adsorber products.
Chromatography Process Solutions From Pall 
Fully Automated Unit Operations with Pall Resolute
Linear Columns with AutoPak Functionality
The Resolute linear column
range offers a unique 
combination of active multi-
axis piston control, precision
linear actuation, and fully 
automated unit operations.
Building upon the proven
Resolute linear column
functionality, the AutoPak
system is a combination of 
hardware and software that 
automates three of the key unit operations necessary in
process chromatography. These key unit operations,
particularly packing, can be regarded as labor intensive,
high risk events. The risks include human error, packing
failure and the possible absence of experienced operators
which can result in plant downtime, loss of product or 
sorbent, and inefficient use of resources.
By adopting a full automation approach, AutoPak 
functionality greatly simplifies operation, effectively 
eliminating operator error during sequence execution and
reducing the burden on key operators. The automated
sequences assure that reproducible, consistent operation
is the norm.
Key features of the AutoPak system:
! Ability to pack all the slurry in the tank, eliminating 
sorbent carry over or wastage
! Simple operator orientated operation for packing, 
unpacking, and CIP
! Simplified set-up, departing from traditional pump 
pack methods for quicker turnaround of packing and
unpacking operations
! Consistent operation and reproducible results
Chromatography Sorbents
Pall offers a comprehensive,
versatile, and environ mentally
friendly range of chromato -
graphy sorbents that greatly
simplifies protein purification
challenges from lab to process
scale. Pall chromatography
sorbents can improve
downstream purification 
accuracy, speed, safety, 
and reliability, and decrease purification costs. Sorbent
chemistries include ion exchange, mixed-mode, affinity,
hydroxyapatite and solvent detergent removal.
M-7125 and M-7250 Aseptic Microfluidizer 
Processors Provide Superior Results For Pilot 
and Production Environments
Recommended for sterile processing   
 Nano-emulsions (with and without API)
 Nano-dispersions
 Microencapsulation
 Deagglomeration
 Cell disruption
Key benefits
 Guaranteed scale up from lab and pilot Microfluidizer processors
 Validatable sterility that always passes Sterile Fill Test
 Easy to operate with simple manual controls
 Easy to maintain with most maintenance points easily accessed
 Highly secure batch records, 21 CFR Part 11 compliant
 CIP process with no equipment takedown
 Thermally sensitive materials processed safely
 More efficient processing, usually requiring fewer passes than other 
processing machinery
 Batch to batch process reproducibility assured 
M-7125, M-7250 Aseptic BioPharmaceutical  
Microfluidizer® Processor
  
TB-BP7.A-1
Model shown is subject to change depending on options selected
Key features
• Up to 15 lpm (4.0 gpm) flow
rates at 690 bar (10,000 psi)
• 7.5 lpm product flow (2.0 gpm)
at 1,379 bar (20,000 psi)
• 4 lpm product flow (1.0 gpm)
at 2,068 bar (30,000 psi)
• Low product holdup volume
(<1 liter)
• Small batch capable 
(minimum 12 liters)
• Complete package unit
including motor starter panel
and process interlocks
• All product paths are sanitary
grade and BPE compliant 
• All instruments and valves are
anitary grade, BPE compliant
• On board data acquisition for
complete batch record audit trail
• Multi-point temperature
sensing for assured SIP process
• On board flow meter to measure
product and CIP flow rates
• Ultra Clean In Place (UCIP)
using supplied feed pump or 
your CIP system pump
• PID control of process chilled
water for product temperature
management 
• Factory Acceptance Testing (FAT)
• Complete document turn over
package for validation support
including IQ/OQ, materials
certifications and calibrations
• On site start-up assistance,
operator and maintenance
training, SAT and IQ/OQ 
execution by our technical staff 
Since 1984, Microfluidics has provided life 
sciences and formulation scientists with 
critical tools used in the development and 
production of pharmaceutical formulations 
and recombinant technologies. High shear 
fluid processing, Microfluidics’ proprietary 
technology, uniformly reduces droplet and 
particle size to enable the production of 
stable nano-emulsions, nano-suspensions, 
liposomes and the nano-encapsulation 
of actives. In addition it offers the most 
efficient method for disruption of yeast, 
E.coli, plant and mammalian cells. 
Discovery to 
Commercialization
As a result of recent advances in high 
throughput screening and drug discovery, many 
new chemical compounds have been identified 
as possible drug candidates.  Unfortunately, 
many of these compounds show poor water 
solubility and often are only marginally soluble 
in oil-based solvents. The ultrahigh shear 
force developed by Microfluidizer processors 
solves this problem by reducing the particle 
size of active pharmaceutical ingredients to 
therapeutically relevant sizes that enables the 
production of drug products with improved 
bioavailability and stability.    
Cell Disruption for 
Biotechnology 
From the gentle disruption of cultured cells for 
virus isolation to the challenging disruption 
of yeast and other fungi, Microfluidics 
offers technologies to meet the variable and 
demanding needs for cell membrane disruption. 
This technology provides exacting process 
control for highly reproducible and efficient 
cell breakage while keeping temperatures under 
precise control to prevent denaturing.  
Getting To Full Production
Results obtained on all laboratory units 
will scale up easily and in a linear manner 
to production volumes when the same 
operating conditions are employed. 
Asceptic Microfluidizer processors include 
Steam in Place (SIP) and Ultra Clean In 
Place (UCIP) eliminating the need for 
disassembly and Clean Out of Place (COP). 
Data recording and validation support 
documentation including IQ/OQ is included 
to ensure your ability to comply with 21CFR 
part 11 guidelines.
Specifications
M-7125 M-7250
Pressure Range   Up to 689, 1379, or 2068 bar (10,000, 20,000 or 30,000 psi)     
  
Product Flow Rate Up to 7.56 lpm (2.0 gpm)
        
Up to 15.12 lpm (4.0 gpm)        
    
Product Feed  
Temperature Range -10ºC to 75ºC (14ºF to 165ºF)
Power Requirement 18.6 kw (25 hp) 37.3 kw (50 hp)
Utility Requirements • Cooling water
 
for hydraulic
 
oil
 
heat
 
exchanger,
 
preferably
 
tower
 
or
 
city
 
water
• Cooling
 
water
 
for
 
product
 
heat
 
exchanger,
 
preferably
 
chilled
 
water
 
loop
 
• Compressed
 
air
 
for
 
feed
 
pump
 
and
 
cycling
 
control
 
switches
 
requires
  
0.65 m
3
/min @ 6.2 bar (23 scfm @ 90 psi) with -37º C to –18º C   
(-35º F to 0º F) dew point
• Sterile
 
steam
 
22.6
 
kg/hr
 
@
 
2.4
 
bar
 
(50
 
lbs/hr
 
@
 
35
 
psi) minimum
• Sterile
 
compressed
 
air
 
for
 
product
 
path
 
cool/dry
 
down,
 
0.085
 
m3/min @ 1 
bar (3 scfm @ 15 psi)
Dimensions (L x W x H)*  272 x 161 x 211 cm (107” x 63.3” x 83”)
Weight with oil* 1,592 kg (3,510 lbs)   
*all weights and dimensions are approximate
Aseptic Package Includes
• Steam In Place (SIP) with multiple RTDs to assure complete sterilization
• Ultra-Clean-In-Place (UCIP)
• Heat exchanger with product temperature control, pharma grade, double 
tubesheet style
• Flow meter for batch monitoring and validation
• Yokogawa data acquisition station for temperatures, pressures and flows
• Product wetted surfaces at 20Ra max
• IQ/OQ documentation and execution
• Factory Acceptance Testing (FAT) and Site Acceptance Test (SAT)
• Feed pump, sanitary cGMP grade
• 21 CFR part 11 compliant for electronic signature and batch record keeping
• Motor starter panel with machine and process interlocks
• CE compliant
Available Options
• Motor voltage as needed
• ATEX compliant version available
• Explosion proof (XP) version available
European OfficeGlobal Headquarters
90 Glacier Drive, Suite 1000
Westwood, MA 02090 USA
Tel: 1-800-370-5452 or: 617-969-5452 
Fax: 617-965-1213
e-mail: mixinginfo@idexcorp.com 
www.microfluidicscorp.com
Bramley Drive, Vale Park West,
Evesham, Worcestershire, WR11 1JH, UK 
Tel:  (+44) (0) 1386 769 007 
Fax: (+44) (0) 870 1911116
Email: mixinginfo@idexcorp.com
www.microfluidicscorp.com
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BIOSTAT ® RM and Flexsafe® RM  
for Seed Production and  
Small-scale Protein Supply
BIOSTAT ® RM and Flexsafe® RM Bags
The BIOSTAT ® RM, a fully GMP compliant, single-use, wave-mixed  
bioreactor and Flexsafe® bags are proven for a broad range of different  
cell lines incl. CHO, NS0, SF9, E.coli and mesenchymal stem cells.
Benefit from our excellent global application support and  
technical service and get started right away.
 Cells
–  Mammalian, insect and  
plant cells
–  Suspension cells and  
adherent cells  
on microcarriers
–  Low to medium density  
microbial cultures
–  Shear sensitive cells such  
as stem cells
 Volumes
–  100 mL to 100 L culture  
volume
–  Two rocker sizes: 20/50  
and 200
 Purpose
–  Scale-up from shake  
or T-flasks 
–  Rapid material supply  
for pre-clinical trials
–  Expansion and differen- 
tiation of stem cells
–  Production of recombinant 
proteins, mAbs and vaccines
–  Continuous cultures with  
reported cell densities  
of 150 million cells/mL
 Process Step
–  Protein and cell supply for 
preclinical purposes 
–  Seed production for large 
bioreactors
–  GMP production
 Excellent Cell Growth 
and Robustness
  Security of Supply & 
Consistent Quality
 Easy-to-use Rocker 
with Advanced  
Control Capabilities
Use our Flexsafe® RM bags in your seed train and scale-up to our BIOSTAT STR® 
 single-use stirred tank bioreactors equiped with Flexsafe STR® bags. Benefit  
from the same polyethylene film material across all your cell culture steps.  
Our Flexsafe® RM bags fit on rocking motion bioreactors from several manufacturers. 
Benefit from excellent cell growth, robustness and unprecedented assurance of supply.
Flexsafe® provides you with an unprece-
dented assurance of supply and enables  
robust business continuity plans. Our  
strategic partnership with resin and film 
suppliers ensures full traceability of raw 
materials and control over the entire  
manufacturing process from the resins  
to the final assembled bags.
Cell  Growth
Assurance  of  Supply
Robustness
Flexsafe® ensures an excellent and reproducible growth behavior with the most sensitive  
production cell lines. The complete control of our raw materials, the extrusion process and 
the bag assembling guarantees consistent lot to lot cell growth performance.
To ensure consistent cell growth performance,  
we optimized the resin and minimized the  
additive package in collaboration with our resin 
and film suppliers.
New Bag Family
The thickness, strength and flexibility of the new 
polyethylene film enhances the mechanical 
 robustness of Flexsafe®, making it ideal for all bio-
processing applications. The strength of Flexsafe® 
significantly reduces the risk of accidental damage 
to the bag due to inappropriate handling. Its 
 flexibility enables convenient installation and 
self-deployment of the bag in its container.
Flexsafe®
Bag A
Bag B
Bag C
Energy at Break
–  10-year contract with the film 
manufacturer
–  Last time buy option for minimum 
of 2 years resin demand
–  Up to 2 years safety stock of film
–  Multiple manufacturing sites
New Bag Family
Watch Video: 
www.sartorius.com/video-flexsafe
Time
Flexsafe® Bags
Reference: Borosilicate Glass
Standard Bags
Ce
ll 
De
ns
ity
The bags are proven to be free of cytotoxic 
leachables by independent labs. No bDtBPP 
identified in WFI extract of Flexsafe® bags.
Designs
The bags come in 7 different sizes supporting  working volumes from 100 mL up to 100 L.  
Standard designs are available from stock. 
Basic Bag Optical Bag Perfusion Bag
For cultivation under constant conditions without  
pH and DO control for seed train •
With single-use pH and DO sensors installed  
in bag for advanced applications • •
With integrated perfusion membrane, fixed at the 
bottom of the bag, for continuous processing with 
low membrane fouling and long cultivation times
•
With single-use viable biomass sensors  
(BioPAT® ViaMass) • • •
Available with screw caps for bulk additions • • •
Customized bag designs • • •
Can be used on competitor systems •
 
One for  All
1 L           Flexsafe® RM 200 L
BIOSTAT ® RM 20 | 50 Basic
The BIOSTAT ® RM 20 | 50 basic is a perfectly 
sized, stand-alone bioreactor for bench-
top use. It features an exchangeable bag 
holder to fit bags from 1 L to 50 L total 
volume. The BIOSTAT ® RM basic rocker with 
integrated local controller, Air | CO2 mixing 
module and load cells is the optimal choice 
for straight forward applications such as 
seed generation. 
–  Space-saving, individual control of two 
bags on the same platform
–  Advanced alarming and safety features 
for safe cultivation
–  Reduced manual handling via automated 
sampling function
One for  All
Advanced Control System
Do you want to run fully automated and controlled batch, fed-batch or high cell density 
perfusion cultures? Combine your basic rocker with our BIOSTAT ® B control tower and use 
Flexsafe® RM bags equiped with single-use pH, DO and now also viable biomass probes.
–  Advanced control of gas mixture and flow rate, filling volume and  substrate addition
–  Extra small space requirement with TWIN configuration – two culture  systems 
 controlled by one controller at the same time
Your BIOSTAT ® B controller is designed to work with a conventional glass vessel,  
the single-use UniVessel® SU and the RM rocker, making it a real multi talent.  
It allows you to use the same controller platform for research purposes, process 
 development and preclinical supply.
Watch Video: 
www.sartorius.com/video-biostat-b
NEW  BioPAT ® ViaMass* –  
                  single-use biomass sensor
for non-invasive measurement of viable biomass. BIOSTAT ® RM is the only rocking motion 
 bioreactor with inline single-use  biomass  monitoring.
 
–  Reduce your contamination risk by using inline single use cell growth  monitoring,  
e.g. in cell therapy or other critical applications
* Manufactured under license from HAMILTON.
BIOSTAT ® B with RM 200 Rocker
The system consists of the BIOSTAT ® RM 200 Rocker, BIOSTAT ® B control tower on lab-cart 
and Flexsafe® RM cultivation bag. It is your choice for larger scale seed expansion and 
production of material for preclinical and  clinical studies. It supports working volumes 
from 10 L up to 100 L. Together with our proven BIOSTAT ® B control tower, flexible  
process strategies can be enabled. 
–  Low consumable costs com-
pared to stirred single-use 
bioreactors
–  Reliable single-use probes  
for measurement of pH,  
DO and viable biomass
–  Designed for automated 
batch, fed-batch and  
perfusion processes using an 
external cell retention unit
–  Flexible arrangement of  
control tower and rocker  
unit on individual trolleys
Total Volume (L) 1 2 10 20 50 100 200
Working volume (L)* 0.1– 0.5 0.2 –1 1– 5 2 –10 5 – 25 10 – 50 20 –100
Bag Types
Basic • • • • • • •
Basic and optical with screw cap • • • •
Optical • • • • • •
Perfusion with integrated membrane • • • •
Perfusion with connection to ATF** System • • • • • •
Basic, optical, perfusion & perfusion ATF 
with ViaMass
• • •
Main Components Basic Optical Perfusion
Connectors Female | Male Luer  
Female | Male MPC
Female | Male Luer  
Female | Male MPC
Female | Male Luer  
Female | Male MPC
Filters Air Inlet | Air Outlet Air Inlet | Air Outlet Air Inlet | Air Outlet
Ports Sampling  
Fill | harvest with  
dip tube  
Acid | Base 
Sampling  
Fill | harvest with  
dip tube  
Acid | Base 
Sampling  
Fill | harvest with dip tube  
Acid | Base  
Perfusion feed | harvest
Sensors – Optical chemical pH  
Optical chemical DO
Single-use viable  
biomass
Optical chemical pH  
Optical chemical DO
Single-use viable biomass
Perfusion – – Perfusion membrane PES 1.2 µm | Opta 
aseptic connector to ATF** System
Tubing material C-Flex®*** 374, Silicone, PharMed®*** Natvar ABL-1222 TPE
Material of the bag Contact layer: LLDPE | gas barrier: EVOH | outer layer: LLDPE 
Production conditions Cleanroom environment of at least ISO 8
Biological reactivity USP for plastics Class VI
Sterility ISO 11137 – sterility assurance level (SAL) of 10-6
TSE/BSE status Compliant to EMA410/01/rev.3 guideline
Endotoxin USP<85> for sterile water for injection; < 0.25 EU/ml
Irradiated 25 – 40 kGy
* Bags with sensors might require higher minimum working volumes depending on rocking rate and angle.
( ) – optional, needs to be ordered separately
** ATF cell retention system from Repligen
*** C-Flex® and PharMed® are registered trademarks of Saint-Gobain Performance Plastics Corporation.
Technical Specifications 
Flexsafe® RM Bags
Ordering Information
Flexsafe® RM Basic 
Basic ViaMass
Basic screw cap 
Optical screw cap
Optical  
Optical ViaMass
Perfusion 
Perfusion ViaMass
Perfusion ATF  
Perfusion ATF ViaMass
1 L DFB001L 
–
– 
–
– 
–
– 
–
– 
–
2 L DFB002L 
–
DFB002L----01SC 
DFO002L----01SC
DFO002L 
–
DFP002L--SM 
–
DFP002L--AT 
–
10 L DFB010L 
DFB010L----VM
DFB010L----01SC 
DFO010L----01SC
DFO010L 
DFO010L----VM
DFP010L--SM 
DFP010L--SMVM
DFP010L--AT 
DF010L--ATVM
20 L DFB020L 
DFB020L----VM
DFB020L----01SC 
DFO020L----01SC
DFO020L 
DFO020L----VM
DFP020L--SM 
DFP020L—SMVM
DFP020L--AT 
DFP020L--ATVM
50 L DFB050L 
DFB050L----VM
DFB050L----01SC 
DFO050L----01SC
DFO050L 
DFO050L----VM
DFP050L--SM 
DFP050L—SMVM
DFP050L--AT 
DFP050L--ATVM
50 L * DFB050L----01US – – – –
100 L DFB100L 
–
– 
–
DFO100L  
–
– 
–
DFP100L--AT 
–
200 L DFB200L 
–
– 
–
DFO200L 
–
– 
–
DFP200L--AT 
–
* alternative dimension – 740 + 720 mm – suitable for competitor rockers
BIOSTAT ® RM 20 | 50  
Basic
BIOSTAT ® B  
with RM 20 | 50 Rocker 
BIOSTAT ® B  
with RM 200 Rocker
Power Supply (Country Specific) | Frequency | Electricity | Consumption | Protection Class
Rocker platform 100 (240 V) | 60 (50) Hz | 
600 W | IP23
100 (240) V | 60 (50) Hz |  
600 W | IP23
120 (230) V |  
60 (50) Hz | 10 (5.2) A |  
1200 W | IP21
Control Tower – 230 V | 50 Hz | 10 A | IP21
or 
120 V | 60 Hz | 12 A | IP21
230 V | 50 Hz | 10 A | IP21
or 
120 V | 60 Hz | 12 A | IP21
Load cells 100 – 240 V | 15 W 100 – 240 V | 15 W
Gas Supply
Inlet pressure (barg) 1.0 –1.5 1.0 –1.5 1.0 – 1.5
Quick coupling for gas tubes,  
Festo Type d 4 mm (d 6 mm) (d 6 mm)
Connection hose coupling, external – d 6 mm d 6 mm
Gas Specification According to ISO 8573-1: dry, free of oil and dust
Particle size: < 0.1 mm • • •
Max. amount 0.1 mg/m3 (class 1) • • •
Condensate: dew point < 3°C (class 4) • • •
Oil < 0.01 mg/m3 (class 1) • • •
Germs (class 0) • • •
Water
Water supply pressure (barg) – 2 – 8 2 – 8
Connection hose coupling, external – d 10 mm d 10 mm
Cooling water  
(for heating | cooling system only)
– (•) (•)
Temperature – min. 4° min. 4°
Degree of hardness – max. 12 dH max. 12 dH
Operative Environment
Ambient temperature 5-40°C
Relative humidity range 50% (40 °C) – 80% (31°C)
Facility and Utility Requirements
Technical Specifications 
System Characteristics
Dimensions W + D + H Weight Material
BIOSTAT® B Control Tower Single | Twin 410 + 520 + 810 mm
16 + 20 + 32 in
40 | 55 kg
88 | 121 lbs
Stainless steel AISI 304
BIOSTAT ® RM 20 Rocker complete 765 + 600 + 510 mm
30 + 24 + 16 in
30 kg
66 lb
Stainless steel, ABS
Bag holder 20 765 + 600 + 60 mm
30 + 24 + 2.4 in
5.5 kg
12 lb
Stainless steel, ABS
Lid 20 765 + 600 + 255 mm
30 + 24 + 10 in
2.5 kg
5.5 lb
ABS
BIOSTAT ® RM 50 Rocker complete 1085 + 600 + 510 mm
43 + 24 + 18 in
31.3 kg
69 lb
Stainless steel, ABS
Bag holder 50 1085 + 600 + 60 mm
43 + 24 + 2.4 in
7.8 kg
17 lb
Stainless steel, ABS
Lid 50 1085 + 600 + 255 mm
43 + 24 + 10 in
3.7 kg
8 lb
ABS
Load cells for BIOSTAT ® RM 20 | 50 609 + 536 + 60-68 mm
24 + 21 + 2.4 – 2.7 in
9 kg
20 lb
Stainless steel, ABS
BIOSTAT ® RM 200 Rocker  
in 45° transport position
1940 + 905 + 1285 mm
77 + 36 + 51 in
197 kg
434 lb
Stainless steel, ABS
BIOSTAT ® RM 200 Rocker 
in horizontal position
1940 + 1080 + 1155 mm 
76 + 43 + 46 in
197 kg 
434 lb
Stainless steel, ABS
Lab-cart 800 + 800  + 900 mm 
32 + 32 + 36 in
88 kg 
194 lb
Stainless steel
BIOSTAT ® RM 20 | 50  
Basic
BIOSTAT ® B  
with RM 20 | 50 Rocker 
BIOSTAT ® B  
with RM 200 Rocker
Temperature Module
Heating Only - Electrical Heating Plates
Temperature control RT-40°C RT-40°C RT-40°C
Heating capacity 2 + 140 W (48 V) 2 + 140 W (48 V) 2 + 410 W
Heating | Cooling (Option) - Open Thermostat System with Circulation Pump and Automatic Cooling Water Valve
Temperature control – 8°C above cooling water 
up to 40°C
(8°C above cooling water 
up to 40°C)
Heating capacity – 1 + 600 W 2 + 600 W
Over temperature protection • • •
Gassing Module Rocker - Optional
Max. total flow (ml/min) 
Controlled by MFC
One bag: 1 + 1 lpm 
Twin bag: 2 + 0.5 lpm
– –
Fixed CO2 gassing (%) measured  
by IR sensor
0.8 -15 ± 5 % – –
Internal air pump (•) – –
Gassing Module Control Tower 4-Gas mix (O2, N2, CO2, air) with headspace outlet
Rotameters – max. 4 max. 4
– flow rates 0.016 lpm – 8.3 lpm 0.016 lpm – 13 lpm 
– accuracy ± 5% full scale ± 5% full scale
MFC – max. 4 max. 4
– flow rates 0.003 lpm – 5 lpm 0.06 lpm – 10 lpm
– accuracy ± 1% full scale ± 1% full scale
4-stage DO cascade – • •
Advanced DO controller – (•) (•)
Sensors & Measurement
Temperature probe Pt 100 • • •
– temperature range 0 – 150°C 0 – 150°C 0 – 150°C
– display resolution 0.1°C 0.1°C 0.1°C
– amplifiers 2 1 (single) | 2 (twin) 2
pH single use – • •
– measurement range 6.5–8.5 6.5–8.5
– display resolution 0.1 pH 0.1 pH
– amplifiers 1 (single) | 2 (twin) 2
– recalibration function • •
DO single-use – • •
– measurement range 0 – 250% 0 – 250%
– display resolution 0.1% 0.1%
– amplifiers 1 (single) | 2 (twin) 2
– recalibration function • •
Single-use viable biomass  
(BioPAT® ViaMass)
– (•) (•)
Load cells (•) (•) (•)
– weight range | accuracy max. 30 kg | 10 g max. 30 kg | 10 g max. 120 kg | 100 g
Balance substrate – (up to 2) per side (up to 2) per side
External signal input – max. 2 
0 –10 V or 4 – 20 mA
2
() – optional, needs to be ordered separately
Process Control
Pump Module BIOSTAT® B with RM 20 | 50 Rocker and BIOSTAT® B with RM 200 Rocker
max. 4 internal and 2 external pumps, thereof 3 speed controlled per side
Built-in Pumps 
Fixed Speed Watson Marlow 114, Fast Load pump head
–  Speed 5 rpm 
Flow rate (tubing wall thickness  
1.6 mm)
ID: 0.5 mm: 0-0.1 ml/min
ID: 0.8 mm: 0.05-2.4 ml/min 
ID: 1.6 mm: 0.01-0.7 ml/min
ID: 2.4 mm: 0.03-1.5 ml/min
ID: 3.2 mm: 0.05-2.4 ml/min
ID: 4.8 mm: 0.09-4.3 ml/mi
–  Speed 44 rpm 
Flow rate (tubing wall thickness  
1.6 mm)
ID: 0.5 mm: 0.02-0.9 ml/min
ID: 0.8 mm: 0.04-1.8 ml/min
ID: 1.6 mm: 0.12-6.2 ml/min
ID: 2.4 mm: 0.26-12.8 ml/min
ID: 3.2 mm: 0.41-20.7 ml/min
ID: 4.8 mm: 0.75-37.4 ml/min
Speed Controlled Watson Marlow 114, Fast Load pump head
–  Speed 0.15 – 5 rpm 
Flow rate (tubing wall thickness  
1.6 mm)
ID: 0.5 mm: 0-0.1 ml/min 
ID: 0.8 mm: 0.01-0.2 ml/min
ID: 1.6 mm: 0.02-0.7 ml/min
ID: 2.4 mm: 0.04-1.5 ml/min
ID: 3.2 mm: 0.07-2.4 ml/min
ID: 4.8 mm: 0.13-4.3 ml/min
–  Speed 5 – 150 rpm 
Flow rate (tubing wall thickness  
1.6 mm)
ID: 0.5 mm: 0.1-3 ml/min
ID: 0.8 mm: 0.2-6 ml/min
ID: 1.6 mm: 0.7-21 ml/min
ID: 2.4 mm: 1.45-43.5 ml/min
ID: 3.2 mm: 2.35-70.5 ml/min
ID: 4.8 mm: 4.25-127.5 ml/min
External Pumps
Speed Controlled Watson Marlow 520, Fast Load pump head, up to 200 rpm
Watson Marlow 323
BIOSTAT ® RM 20 | 50  
Basic
BIOSTAT ® B  
with RM 20 | 50 Rocker 
BIOSTAT ® B  
with RM 200 Rocker
Industrial Ethernet 1 1 1
Profibus DP (1) – –
Communication
The BIOSTAT ® RM rocker is designed to communicate with with 
 industrial SCADA or DCS systems (e.g. DeltaV) through the 
 standard Modbus RTU or an optional Profibus DP interfaces. 
BIOSTAT ® RM 20 | 50  
Basic
BIOSTAT ® B  
with RM 20 | 50 Rocker 
BIOSTAT ® B  
with RM 200 Rocker
Max. total volume (L) 50 50 200
Working volume (L) 0.1– 25 0.1– 25 10 –100
Rocking rate (r/min) 8 – 42 ± 1 8 – 42 ± 1 2 – 20 ± 1
Rocking angle (°) 4 –10 ± 0.3 4 –10 ± 0.3 2 –10 ± 0.3
Clamping rails for bag fixation • • •
Sensor clamps for secure fixation of 
glass fiber cables
– 2 (single) | 4 (twin) 4
Filter heater 2 1 (single) | 2 (twin) 2
Integrated Rocker Controler • • –
BIOSTAT ® B Control Tower – • •
Color touch screen • • •
Potential-free alarm contact • (max. 0.5 A) • •
Safety measurement and shut-off 30 mbar (in combination 
with gassing module)
30 mbar 30 mbar
Additional safety valve gasses (mbar) – 100 mbar 100 mbar
Water inlet pressure reduction value – 1.5 bar, integrated  
pressure control
1.5 bar, integrated  
pressure control
Different user level log in • (•) (•)
Logbook function – (•) (•)
Lab-cart for BIOSTAT ® B Control Tower – – •
Technical Data
Sales and Service Contacts
For further contacts, visit www.sartorius-stedim.com
Europe
Germany
Sartorius Stedim Biotech GmbH
August-Spindler-Strasse 11
37079 Goettingen
Phone +49.551.308.0
Fax +49.551.308.3289
Sartorius Stedim Systems GmbH
Robert-Bosch-Strasse 5 – 7 
34302 Guxhagen
Phone +49.5665.407.0
Fax +49.5665.407.2200
France
Sartorius Stedim FMT S.A.S.
ZI des Paluds
Avenue de Jouques – CS 91051
13781 Aubagne Cedex
Phone +33.442.845600
Fax +33.442.845619
Sartorius Stedim France SAS
ZI des Paluds
Avenue de Jouques – CS 71058
13781 Aubagne Cedex 
Phone +33.442.845600
Fax +33.442.846545
Austria
Sartorius Stedim Austria GmbH
Modecenterstrasse 22
1030 Vienna
Phone +43.1.7965763.18
Fax +43.1.796576344
Belgium
Sartorius Stedim Belgium N.V.
Rue Colonel Bourg 105
1030 Bruxelles
Phone +32.2.756.06.80
Fax +32.2.756.06.81
Hungary
Sartorius Stedim Hungária Kft.
Kagyló u. 5
2092 Budakeszi
Phone +36.23.457.227
Fax +36.23.457.147
Italy
Sartorius Stedim Italy S.p.A.
Via dell’Antella, 76/A
50012 Antella-Bagno a Ripoli (FI)
Phone +39.055.63.40.41
Fax +39.055.63.40.526
 
Netherlands
Sartorius Stedim Netherlands B.V.
Phone +31.30.60.25.080
Fax +31.30.60.25.099
filtratie.nederland@sartorius-stedim.com
Poland
Sartorius Stedim Poland Sp. z o.o.
ul. Wrzesinska 70
62-025 Kostrzyn
Phone +48.61.647.38.40
Fax +48.61.879.25.04
Russian Federation
LLC “Sartorius Stedim RUS”
Uralskaya str. 4, Lit. B
199155 St. Petersburg
Phone +7.812.327.53.27
Fax +7.812.327.53.23
Spain
Sartorius Stedim Spain, S.A.U.
Avda. de la Industria, 32
Edificio PAYMA
28108 Alcobendas (Madrid)
Phone +34.913.586.098
Fax +34.913.589.623
Switzerland
Sartorius Stedim Switzerland AG
Ringstrasse 24 a
8317 Tagelswangen
Phone +41.52.354.36.36
Fax +41.52.354.36.46
U.K.
Sartorius Stedim UK Ltd.
Longmead Business Centre
Blenheim Road, Epsom
Surrey KT19 9 QQ
Phone +44.1372.737159
Fax +44.1372.726171
Ukraine
LLS “Sartorius RUS”
Post Box 440 “B”
01001 Kiev, Ukraine
Phone +380.44.411.4918
Fax +380.50.623.3162
Americas
USA
Sartorius Stedim North America Inc.
5 Orville Drive, Suite 200
Bohemia, NY 11716
Toll-Free +1.800.368.7178
Fax +1.631.254.4253
Argentina
Sartorius Argentina S.A. 
Int. A. Ávalos 4251 
B1605ECS Munro 
Buenos Aires 
Phone +54.11.4721.0505 
Fax +54.11.4762.2333 
Brazil
Sartorius do Brasil Ltda 
Avenida Senador Vergueiro 2962 
São Bernardo do Campo 
CEP 09600-000 - SP- Brasil
Phone +55.11.4362.8900
Fax +55.11.4362.8901
Mexico
Sartorius de México, S.A. de C.V.
Libramiento Norte de Tepotzotlan s/n,
Colonia Barrio Tlacateco,
Municipio de Tepotzotlan,
Estado de México,
C.P. 54605
Phone +52.55.5562.1102
Fax +52.55.5562.2942
leadsmex@sartorius.com
Peru
Sartorius Peru S.A.C.
Av. Emilio Cavenecia 264 San Isidro
15073 Lima, Perú
Phone +51.1.441 0158 
Fax +51.1.422 6100 
Asia|Pacific
Australia
Sartorius Stedim Australia Pty. Ltd.
Unit 5, 7-11 Rodeo Drive
Dandenong South Vic 3175
Phone +61.3.8762.1800
Fax +61.3.8762.1828
 
China
Sartorius Stedim Biotech (Beijing) Co. Ltd.
No. 33 Yu’an Road
Airport Industrial Park Zone B
Shunyi District, Beijing 101300
Phone +86.10.80426516
Fax +86.10.80426580
Sartorius Stedim (Shanghai) 
Trading Co., Ltd.
3rd Floor, North Wing, Tower 1
No. 4560 Jinke Road
Zhangjiang Hi-Tech Park 
Pudong District
Shanghai 201210, P.R. China
Phone +86.21.6878.2300
Fax +86.21.6878.2882
Sartorius Stedim Biotech (Beijing) Co. Ltd.
Guangzhou Representative Office
Unit K, Building 23
Huihua Commerce & Trade Building
No. 80 Xianlie Middle Road
Guangzhou 510070
Phone +86.20.37618687 | 37618651
Fax +86.20.37619051
India
Sartorius Stedim India Pvt. Ltd.
#69/2-69/3, NH 48, Jakkasandra
Nelamangala Tq
562 123 Bangalore, India
Phone +91.80.4350.5250
Fax +91.80.4350.5253
Japan
Sartorius Stedim Japan K.K.
4th Fl., Daiwa Shinagawa North Bldg.
8-11, Kita-Shinagawa 1-chome
Shinagawa-ku, Tokyo, 140-0001 Japan
Phone +81.3.4331.4300
Fax +81.3.4331.4301
Malaysia
Sartorius Stedim Malaysia Sdn. Bhd.
Lot L3-E-3B, Enterprise 4
Technology Park Malaysia
Bukit Jalil
57000 Kuala Lumpur, Malaysia
Phone +60.3.8996.0622
Fax +60.3.8996.0755
Singapore
Sartorius Stedim Singapore Pte. Ltd.
1 Science Park Road, 
The Capricorn, #05-08A,
Singapore Science Park II
Singapore 117528
Phone +65.6872.3966
Fax +65.6778.2494
South Korea
Sartorius Korea Biotech Co., Ltd.
8th Floor, Solid Space B/D, 
PanGyoYeok-Ro 220, BunDang-Gu
SeongNam-Si, GyeongGi-Do, 463-400
Phone +82.31.622.5700
Fax +82.31.622.5799
www.sartorius-stedim.com
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Chapter 1
Dimensional Analysis
1.1 Introduction
Before beginning the material on dimensional analysis, it is worth considering
a simple example that demonstrates what we are doing. One that qualifies
as simple is the situation of when a object is thrown upwards. The resulting
mathematical model for this is an equation for the height x(t) of the projectile
from the surface of the Earth at time t. This equation is determined using
Newton’s second law, F = ma, and the law of gravitation. The result is
d2x
dt2
=   gR
2
(R + x)2
, for 0 < t, (1.1)
where g is the gravitational acceleration constant and R is the radius of the
Earth. Finding the solution x of this equation requires two integrations. Each
will produce an integration constant, and we need more information to find
these constants. This is done by specifying the initial conditions. Assuming
the projectile starts at the surface with velocity v0 then the initial conditions
are as follows
x(0) = 0, (1.2)
dx
dt
(0) = v0. (1.3)
The resulting initial value problem for x consists in finding the solution of
(1.1) that satisfies (1.2) and (1.3). Mathematically, the problem is challenging
because it involves solving a second-order nonlinear di↵erential equation. One
option for finding the solution is simply to use a computer. However, the
limitation with this is that it does not provide much insight into how the
solution depends on the terms in the equation. One of the primary objectives
of this text is to use mathematics to derive a fundamental understanding of
how and why things work the way they do, and so, we are very interested in
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Figure 1.1 The solution (1.5) of the projectile problem in a uniform gravitational
field.
obtaining at least an approximate solution of this problem. This is the same
point-of-view taken in most physics books and it is worth looking at how
they might address this issue. Adopting for the moment the typical Physics I
approach, in looking at the equation in (1.1) it is not unreasonable to assume
R is significantly larger than even the largest value of x. If true then we should
be able to replace the x+R term with just R. In this case the problem reduces
to solving
d2x
dt2
=  g, for 0 < t. (1.4)
Integrating and then using the two initial conditions yields
x(t) =  1
2
gt2 + v0t. (1.5)
This solution is shown schematically in Figure 1.1. We have what we wanted,
a relatively simple expression that serves as an approximation to the original
nonlinear problem. To complete the derivation we should check that the as-
sumption made in the derivation is satisfied, namely x is much smaller than
R. Now, the maximum height for (1.5) occurs when
dx
dt
= 0. (1.6)
Solving this equation yields t = v0/g and from this it follows that the maxi-
mum height is
x
M
=
v20
2g
. (1.7)
Therefore, we must require that v2/(2g) is much less than R, which we write
as v20/(2g) << R.
It is now time to critique the above derivation. The first criticism is that
the approach is heuristic. The reason is that even though the argument for
replacing x + R with R seems plausible, we simply ignored a particular term
in the equation. The projectile problem is not particularly complicated so
1.2 Examples of Dimensional Reduction 3
dropping a term as we did is straightforward. However, in the real world
where problems can be quite complicated, dropping a term in one part of the
problem can lead to inconsistencies in another part. A second criticism can be
made by asking a question. Specifically, what exactly is the e↵ect of the non-
linearity on the projectile? Our reduction replaced the nonlinear gravitational
force, which is the right-hand side of (1.1), with a uniform gravitational field
given by  g. Presumably if gravity decreases with height then the projectile
will be going higher than we would expect based on our approximation in
(1.5). It is of interest to understand quantitatively what this nonlinear e↵ect
is and whether it might interfere with our reduction.
Based on the comments of the previous paragraph we need to make the
reduction process more systematic. The procedure that is used to simplify
the problem should enable us to know exactly what is large or small in the
problem, and it should also enable us to construct increasingly more accurate
approximations to the problem. Explaining what is involved in a systematic
reduction occurs in two steps. The first, which is the objective of this chapter,
involves the study of dimensions and how these can be used to simplify the
mathematical formulation of the problem. After this, in Chapter 2, we develop
techniques to construct accurate approximations of the resulting equations.
1.2 Examples of Dimensional Reduction
The first idea that we explore will, on the surface, seem to be rather simple,
but it is actually quite profound. It has to do with the dimensions of the
physical variables, or parameters, in a problem. To illustrate, suppose we
know that the speed s of a ball is determined by its radius r and the length
of time t it has been moving. Implicit in this statement is the assumption that
the speed does not depend on any other physical variable. In mathematical
terms we have that s = f(r, t). The function f is not specified and all we
know is that there is some expression that connects the speed with r and
t. The only possible way to combine these two quantities to produce the
dimension of speed is through their ratio r/t. For example, it is impossible
to have s = ↵r +  t without ↵ and   having dimensions. This would mean
↵ and   are physical parameters, and we have assumed there are no others
in the problem. This observation enables us to conclude that based on the
original assumptions that the only function we can have is s = ↵r/t, where
↵ is a number.
What we are seeing in this example is that the dimensions of the variables
in the problem end up dictating the form of the function. This is very useful
information and we will spend some time exploring how to exploit this idea.
To set the stage we need to introduce some of the terminology. The first is
the concept of a fundamental dimension. As is well known, physical variables
such as force, density, and velocity can be broken down into length L, time
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Quantity Dimensions Quantity Dimensions
Acceleration LT 2 Enthalpy ML2T 2
Angle 1 Entropy ML2T 2✓ 1
Angular Acceleration T 2 Gas Constant L2T 2✓ 1
Angular Momentum ML2T 1 Internal Energy ML2T 2
Angular Velocity T 1 Specific Heat L2T 2✓ 1
Area L2 Temperature ✓
Energy, Work ML2T 2 Thermal Conductivity MLT 3✓ 1
Force MLT 2 Thermal Di↵usivity L2T 1
Frequency T 1 Heat Transfer
Coe cient
MT 3✓ 1
Concentration L 3
Length L Capacitance M 1L 2T 4I2
Mass M Charge TI
Mass Density ML 3 Charge Density L 3TI
Momentum MLT 1 Conductivity M 1L 3T 3I2
Power ML2T 3 Electric Current
Density
L 2I
Pressure, Stress,
Elastic Modulus
ML 1T 2 Electric Current I
Surface Tension MT 2 Electric Displacement L 2TI
Time T Electric Potential ML2T 3I 1
Torque ML2T 2 Electric Field Intensity MLT 3I 1
Velocity LT 1 Inductance ML2T 2I 2
Viscosity (Dynamic) ML 1T 1 Magnetic Field
Intensity
L 1I
Viscosity (Kinematic) L2T 1 Magnetic flux L2MT 2I 1
Volume L3 Permeability MLT 2I 2
Wave Length L Permittivity M 1L 3T 4I2
Strain 1 Electric Resistance ML2T 3I 2
Table 1.1 Fundamental dimensions for commonly occurring quantities. A quantity
with a one in the dimensions column is dimensionless.
T , and mass M (see Table 1.1). Moreover, length, time, and mass are in-
dependent in the sense that one of them cannot be written in terms of the
other two. For these two reasons we will consider L, T , and M as fundamental
dimensions. For problems involving thermodynamics we will expand this list
to include temperature (✓) and for electrical problems we add current (I). In
conjunction with this, given a physical variable x we will designate the funda-
mental dimensions of x using the notation [x]. For example, [velocity] = L/T ,
[force] = ML/T 2, [g] = L/T 2, and [density] = M/L3.
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It is important to understand that nothing is being assumed about which
specific system of units is used to determine the values of the variables or
parameters. Dimensional analysis requires that the equations be independent
of the system of units. For example, both Newton’s law F = ma and the
di↵erential equation (1.1) do not depend on the specific system one selects.
For this reason these equations are said to be dimensionally homogeneous.
If one were to specialize (1.1) to SI units and set R = 6378 km and g =
9.8 m/sec2 they would end up with an equation that is not dimensionally
homogeneous.
1.2.1 Maximum Height of a Projectile
The process of dimensional reduction will be explained by applying it to
the projectile problem To set the stage, suppose we are interested in the
maximum height x
M
of the projectile. Based on Newton’s second law, and
the initial conditions in (1.2) and (1.3), it is assumed that the only physical
parameters that x
M
depends on are g, v0, and the mass m of the projectile.
Mathematically this assumption is written as x
M
= f(g,m, v0). The function
f is unknown but we are going to see if the dimensions can be used to simplify
the expression. The only way to combine g, m, v0 to produce the correct
dimensions is through a product or ratio. So, our start-o↵ hypothesis is that
there are numbers a, b, c so that
[x
M
] = [mavb0g
c]. (1.8)
Using the fundamental dimensions for these variables the above equation is
equivalent to
L = Ma(L/T )b(L/T 2)c
= MaLb+cT b 2c. (1.9)
Equating the exponents of the respective terms in this equation we conclude
L : b + c = 1,
T :  b  2c = 0,
M : a = 0.
Solving these equations we obtain a = 0, b = 2, and c =  1. This means
the only way to produce the dimensions of length using m, v0, g is through
the ratio v20/g. Given our start-o↵ assumption (1.8), we conclude that xM
is proportional to v20/g. In other words, the original assumption that xM =
f(g,m, v0) dimensionally reduces to the expression
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x
M
= ↵
v20
g
, (1.10)
where ↵ is an arbitrary number. With (1.10) we have come close to obtaining
our earlier result (1.7) and have done so without solving a di↵erential equation
or using calculus to find the maximum value. Based on this rather minimal
e↵ort we can make the following observations:
• If the initial velocity is increased by a factor of 2 then the maximum height
will increase by a factor of 4. This observation o↵ers an easy method for
experimentally checking on whether the original modeling assumptions are
correct.
• The constant ↵ can be determined by running one experiment. Namely, for
a given initial velocity v0 = v̄0 we measure the maximum height xM = x̄M .
With these known values, ↵ = gx̄
M
/v̄20 . Once this is done, the formula in
(1.10) can be used to determine x
M
for any v0.
The steps we have used are the basis for the method of dimensional reduction,
where an expression is simplified based on the fundamental dimensions of the
quantities involved. Given how easy it was to obtain (1.10) the method is very
attractive as an analysis tool. It does have limitations and one is that we do
not know the value of the number ↵. It also requires us to be able to identify
at the beginning what parameters are needed. The importance of this and
how this relies on understanding the physical laws underlying the problem
will be discussed later.
The purpose of the above example is to introduce the idea of dimensional
reduction. What it does not show is how to handle problems with several
parameters and this is the purpose of the next two examples.
1.2.2 Drag on a Sphere
In the design of automobiles, racing bicycles, and aircraft there is an overall
objective to keep the drag on the object as small as possible. It is interesting
to see what insight dimensional analysis might provide in such a situation,
but since we are beginners it will be assumed the object is very simple and
is a sphere (see Figure 1.2). The modeling assumption that is made is that
the drag force D
F
on the sphere depends on the radius R of the sphere, the
velocity v of the sphere, the density ⇢ of the air, and the dynamic viscosity µ
of the air. The latter is a measure of the resistance force of the air to motion
and we will investigate this in Chapter 8. For the moment all we need is its
fundamental dimensions and these are given in Table 1.1. In mathematical
terms the modeling assumption is
D
F
= f(R, v, ⇢, µ), (1.11)
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(a)
(b)
Figure 1.2 Air flow around an object can be visualized using smoke. The flow around
a golf ball is shown in (a) (Brown [1971]), and around a tennis ball in (b) (Bluck
[2000]). In both cases the air is moving from left to right.
and we want to use dimensional reduction to find a simplified version of this
expression. Similar to the last example, the first question is whether we can
find numbers a, b, c, d so that
[D
F
] = [Ravb⇢cµd]. (1.12)
Expressing these using fundamental dimensions yields
MLT 2 = La(L/T )b(M/L3)c(M/LT )d
= La+b 3c dT b dM c+d.
As before we equate the respective terms and conclude
L : a + b  3c  d = 1,
T :  b  d =  2,
M : c + d = 1.
(1.13)
We have four unknowns and three equations, so it is anticipated that in solv-
ing the above system of equations one of the unknowns will be undetermined.
From the T equation we have b = 2  d, and from the M equation c = 1  d.
The L equation then gives us a = 2  d. With these solutions, and based on
our assumption in (1.12), we have that
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D
F
= ↵⇢R2 dv2 d⇢1 dµd
= ↵⇢R2v2
✓
µ
Rv⇢
◆
d
,
where ↵ is an arbitrary number. This can be written as
D
F
= ↵⇢R2v2⇧d, (1.14)
where
⇧ =
µ
Rv⇢
, (1.15)
and d, ↵ are arbitrary numbers. This is the general product solution for how
D
F
depends on the given variables. The quantity ⇧ is dimensionless, and
it is an example of what is known as a dimensionless product. Physically, it
can be thought of as the ratio of the viscous force (µ) to the inertial force
(Rv⇢) in the air. Calling it a product is a bit misleading as ⇧ involves both
multiplications and divisions. Some avoid this by calling it a dimensionless
group. We will use both expressions in this book.
The formula for D
F
in (1.14) is not the final answer. What remains is to
determine the consequence of the arbitrary exponent d. The key observation
is that given any two sets of values for (↵, d), say (↵1, d1) and (↵2, d2), then
D
F
= ↵1⇢R2v2⇧d1 + ↵2⇢R2v2⇧d2
= ⇢R2v2(↵1⇢⇧d1 + ↵2⇧d2)
is also a solution. Extending this observation we conclude that another solu-
tion is
D
F
= ⇢R2v2(↵1⇧d1 + ↵2⇧d2 + ↵3⇧d3 + · · · ), (1.16)
where d1, d2, d3, . . . are arbitrary numbers as are the coe cients ↵1,↵2,↵3, . . ..
To express this in a more compact form, note that the expression within the
parentheses in (1.16) is simply a function of ⇧. From this observation we
obtain the general solution, which is
D
F
= ⇢R2v2F (⇧), (1.17)
where F is an arbitrary function of the dimensionless product ⇧. We have,
therefore, been able to use dimensional analysis to reduce (1.11), which in-
volves an unknown of four variables, down to an unknown function of one
variable. Although this is a significant improvement, the result is perhaps not
as satisfying as the one obtained for the projectile example, given in (1.10),
because we have not been able to determine F . However, there are various
ways to address this issue, and some of them will be considered below.
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Representation of Solution
Now that the derivation is complete a few comments are in order. First, it
is possible for two people to go through the above steps and come to what
looks to be very di↵erent conclusions. For example, the general solution can
also be written as
D
F
=
µ2
⇢
H(⇧), (1.18)
where H is an arbitrary function of ⇧. The proof that this is equivalent to
(1.17) comes from the requirement that the two expressions must produce
the same result. In other words, it is required that
µ2
⇢
H(⇧) = ⇢R2v2F (⇧).
Solving this for H yields
H(⇧) =
1
⇧2
F (⇧).
The fact that the right-hand side of the above equation only depends on ⇧
shows that (1.18) is equivalent to (1.17). As an example, if F (⇧) = ⇧ in
(1.17), then H(⇧) = 1/⇧ in (1.18).
Another representation for the general solution is
D
F
= ⇢R2v2G(Re), (1.19)
where
Re =
Rv⇢
µ
, (1.20)
and G is an arbitrary function of Re. This form is the one usually used in
fluid dynamics, where the dimensionless product Re is known as the Reynolds
number. The function G is related to the drag coe cient C
D
, through the
equation G = ⇡2 CD. Because of its importance in fluids, G has been measured
for a wide range of Reynolds numbers, producing the curve shown in Figure
1.3. To transform between the representation in (1.19), and the one in (1.17),
note Re = 1/⇧. From the requirement
⇢R2v2G(Re) = ⇢R2v2F (⇧),
we obtain
G(Re) = F (1/Re).
The reason for the di↵erent representations is that there are four unknowns
in (1.12) yet only three equations. This means one of the unknowns is used
in the general solution and, as expressed in (1.14), we used d. If you were to
use one of the others then a di↵erent looking, but mathematically equivalent,
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Figure 1.3 The measured values of the function G(Re) that arises in the formula
for the drag on a sphere, as given in (1.19).
expression would be obtained. The fact that there are multiple ways to express
the solution can be used to advantage. For example, if one is interested in the
value of D
F
for small values of the velocity then (1.19) would be a bit easier
to use. The reason is that to investigate the case of small v it is somewhat
easier to determine what happens to G for Re near zero than to expand
F for large values of ⇧. For the same reason, (1.17) is easier to work with
for studying large velocities. One last comment to make is that even though
there are choices on the form of the general solution, they all have exactly
the same number of dimensionless products.
Determining F
A more challenging question concerns how to determine the function F in
(1.17). The mathematical approach would be to solve the equations for fluid
flow around a sphere and from this find F . This is an intriguing idea and
one that will be used from time to time in this book. There is, however,
another more applied approach that makes direct use of (1.17). Specifically,
a sequence of experiments is run to measure F (r) for 0 < r < 1. To do
this a sphere with a given radius R0, and a fluid with known density ⇢0 and
viscosity µ0, are selected. In this case (1.17) can be written as
F (r) =
 D
F
v2
(1.21)
where   = 1/(⇢0R20) is known and fixed. The experiment consists of taking
various values of v and then measuring the resulting drag force D
F
on the
sphere. To illustrate, suppose our choice for the sphere and fluid give R = 1,
⇢0 = 2, and µ0 = 3. Also, suppose that running the experiment using v = 4
produces a measured drag of D
F
= 5. In this case r = µ0/(R0v⇢0) = 3/8
and  D
F
/v2 = 5/32. Our conclusion is therefore that F (3/8) = 5/32. In this
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way, picking a wide range of v values we will be able to determine the values
for the function F (r). This approach is used extensively in the real world and
the example we are considering has been a particular favorite for study. The
data determined from such experiments are shown in Figure 1.3.
A number of conclusions can be drawn from Figure 1.3. For example,
there is a range of Re values where G is approximately constant. Specifically,
if 103 < Re < 105 then G ⇡ 0.7. This is the reason why in the fluid dynamics
literature you will occasionally see the statement that the drag coe cient
C
D
= 2
⇡
G for a sphere has a constant value of approximately 0.44. For
other Re values, however, G is not constant. Of particular interest, is the
dependence of G for small values of Re. This corresponds to velocities v that
are very small, what is known as Stokes flow. The data in Figure 1.3 show
that G decreases linearly with Re in this region. Given that this is a log-log
plot, then this means that log(G) = a b log(Re), or equivalently, G = ↵/Reb
where ↵ = 10a. Curve fitting this function to the data in Figure 1.3 it is found
that ↵ ⇡ 17.6 and   ⇡ 1.07. These are close to the exact values of ↵ = 6⇡
and   = 1, which are obtained by solving the equations of motion for Stokes
flow. Inserting these values into (1.19), the conclusion is that the drag on the
sphere for small values of the Reynolds number is
D
F
⇡ 6⇡µRv. (1.22)
This is known as Stokes formula for the drag on a sphere, and we will have
use for it in Chapter 4 when studying di↵usion.
Scale Models
Why all the work to find F? Well, knowing this function allows for the use of
scale model testing. To explain, suppose it is required to determine the drag
on a sphere with radius R
f
for a given velocity v
f
when the fluid has density
⇢
f
and viscosity µ
f
. Based on (1.17) we have D
F
= ⇢
f
R2
f
v2
f
F (⇧
f
), where
⇧
f
=
µ
f
R
f
v
f
⇢
f
. (1.23)
Consequently, we can determine D
F
if we know the value of F at ⇧
f
. Also,
suppose that this cannot be measured directly as R
f
is large and our ex-
perimental equipment can only handle small spheres. We can still measure
F (⇧
f
) using a small value of R if we change one or more of the parameters
in such a way that the value of ⇧
f
does not change. If R
m
, µ
m
, ⇢
m
and v
m
are the values used in the experiment then we want to select them so that
µ
m
R
m
v
m
⇢
m
=
µ
f
R
f
v
f
⇢
f
, (1.24)
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Figure 1.4 Scale model testing. Dimensional analysis is used in the development of
scale models used in wind tunnels. On the left there is a flight test of an F-18 model
in NASA’s 11 ft transonic wind tunnel (NASA [2008]), and on the right a wind tunnel
test of a 1:160 scale model of the Owensboro Bridge (Hsu [2009]).
or equivalently
v
m
=
µ
m
R
f
⇢
f
µ
f
R
m
⇢
m
v
f
. (1.25)
This equation relates the values for the full-scale ball (subscript f) to those
for the model used in the experiment (subscript m). As an example, suppose
we are interested in the drag on a very large sphere, say R
f
= 100m, but our
equipment can only handle smaller values, say R
m
= 2 m. If the fluid for the
two cases is the same, so ⇢
m
= ⇢
f
and µ
m
= µ
f
, then according to (1.25),
in our experiment we should take v
m
= 50v
f
. If the experimental apparatus
is unable to generate velocities 50 times the value of v
f
then it would be
necessary to use a di↵erent fluid to reduce this multiplicative factor.
The result in the above example is the basis of scale model testing used
in wind tunnels (see Figure 1.4). Usually these tests involve more than just
keeping one dimensionless product constant as we did in (1.24). Moreover, it
is evident in Figure 1.4 that the models look like the originals, they are just
smaller. This is the basis of geometric similarity, where the lengths of the
model are all a fraction of the original. For example, the bridge in Figure 1.4
is a 120 th scale model of the Owensboro Bridge. Other scalings are sometimes
used and the most common are kinematic similarity, where velocities are
scaled, and dynamic similarity, where forces are scaled.
Endnotes
One question that has not been considered so far is, how do you know to
assume that the drag force depends on the radius, velocity, density, and
dynamic viscosity? The assumption comes from knowing the laws of fluid
dynamics, and identifying the principal terms that contribute to the drag.
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For the most part, in this chapter the assumptions will be stated explicitly, as
they were in this example. Later in the text, after the basic physical laws are
developed, it will be possible to construct the assumptions directly. However,
one important observation can be made, and that is the parameters used in
the assumption should be independent. For example, even though the drag
on a sphere likely depends on the surface area and volume of the sphere it
is not necessary to include them in the list. The reason is that it is already
assumed that D
F
depends on the radius R and both the surface area and
volume are determined using R.
The problem of determining the drag on a sphere is one of the oldest in
fluid dynamics. Given that the subject is well over 150 years old, you would
think that whatever useful information can be derived from this particular
problem was figured out long ago. Well, apparently not, as research papers
still appear regularly on this topic. A number of them come from the sports
industry, where there is interest in the drag on soccer balls (Asai et al. [2007]),
golf balls (Smits and Ogg [2004]), tennis balls (Goodwill et al. [2004]), as well
as nonspherical-shaped balls (Mehta [1985]). Others have worked on how to
improve the data in Figure 1.3, and an example is the use of a magnetic
suspension system to hold the sphere (Sawada and Kunimasu [2004]). A more
novel idea is to drop di↵erent types of spheres down a deep mine shaft, and
then use the splash time as a means to determine the drag coe cient (Maroto
et al. [2005]). The point here is that even the most studied problems in science
and engineering still have interesting questions that remain unanswered.
1.2.3 Toppling Dominoes
Domino toppling refers to the art of setting up dominoes, and then knocking
them down. The current world record for this is 4,000,000 plus dominoes for a
team, and 300,000 plus for an individual. One of the more interesting aspects
of this activity is that as the dominoes fall it appears as if a wave is propagat-
ing along the line of dominoes. The objective of this example is to examine
what dimensional analysis might be able to tell us about the velocity of this
wave. A schematic of the situation is shown in Figure 1.5. The assumption is
that the velocity v depends on the spacing d, height h, thickness t, and the
gravitational acceleration constant g. Therefore, the modeling assumption is
v = f(d, h, t, g) and we want to use dimensional reduction to find a simplified
version of this expression. As usual, the first step is to find numbers a, b, c,
e so that
[v] = [dahbtcge].
Expressing these using fundamental dimensions yields
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LT 1 = LaLbLc(L/T 2)e
= La+b+c+eT 2e.
Equating the respective terms we obtain
L : a + b + c + e = 1,
T :  2e =  1.
Solving these two equations gives us that e = 12 and b =
1
2   a  c. With this
we have that
v = ↵dah1/2 a ctcg1/2
= ↵
p
hg
✓
d
h
◆
a
✓
t
h
◆
c
= ↵
p
hg⇧a1 ⇧
c
2 , (1.26)
where ↵ is an arbitrary number, and the two dimensionless products are
⇧1 =
d
h
,
⇧2 =
t
h
.
The expression in (1.26) is the general product solution. Therefore, the gen-
eral solution for how the velocity depends on the given parameters is
v =
p
hg F (⇧1,⇧2), (1.27)
where F is an arbitrary function of the two dimensionless products. The proof
of how (1.27) follows from (1.26) is very similar to the method used to derive
(1.17) from (1.15).
Dimensional analysis has been able to reduce the original assumption in-
volving a function of four-dimensional parameters down to one involving two
dimensionless products. This example is also informative as it demonstrates
how to obtain the general solution when more than one dimensionless product
is involved. The question remains, however, if this really applies to toppling
!
"
#
$
Figure 1.5 Schematic of top-
pling dominoes, creating a wave
that propagates with velocity v.
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Figure 1.6 Data for two di↵erent types of toppling dominoes (Stronge and Shu
[1988]). In these experiments, t = 0.12h, so the thin domino approximation is appro-
priate.
dominoes. It does, but in using this formula it is usually assumed the domi-
noes are very thin, or more specifically that t << h. This means that it is
possible to assume ⇧2 = 0, and (1.27) simplifies to
v =
p
hg G(⇧1), (1.28)
where G is an arbitrary function. Some e↵ort has been made to measure G,
and the measurements for two di↵erent types of dominoes are given in Figure
1.6. Although the data show that G decreases with ⇧1, it is approximately
constant over the range of ⇧1 values used in the experiments. Therefore, as
an approximation we conclude that the speed at which dominoes topple is
v ⇡ 1.5
p
hg. A typical domino has h = 5 cm, which results in a velocity of
v ⇡ 1 m/s. To obtain a more explicit formula for G, however, requires the
solution of a challenging mathematical problem, and an expanded discussion
of this can be found in Efthimiou and Johnson [2007].
1.2.4 Endnotes
Based on the previous examples, the benefits of using dimensional reduction
are apparent. However, a word of caution is needed here as the method gives
the impression that it is possible to derive useful information without get-
ting involved with the laws of physics or potentially di cult mathematical
problems. One consequence of this is that the method is used to comment
on situations and phenomena that are simply inappropriate (e.g., to study
psychoacoustic behavior). The method relies heavily on knowing the funda-
mental laws for the problem under study, and without this whatever conclu-
sions made using dimensional reduction are limited. For example, we earlier
considered the drag on a sphere and in the formulation of the problem we
assumed that the drag depends on the dynamic viscosity. Without knowing
the equations of motion for fluids it would not have been possible to know
that this term needed to be included or what units it might have. By not in-
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cluding it we would have concluded that d = 0 in (1.14) and instead of (1.17)
we would have D
F
= ↵⇢R2v2 where ↵ is a constant. In Figure 1.3 it does
appear that D
F
is approximately independent of Re when 103 < Re < 105.
However, outside of this interval, D
F
is strongly dependent on Re, and this
means ignoring the viscosity would be a mistake. Another example illustrat-
ing the need to know the underlying physical laws arises in the projectile
problem when we included the gravitational constant. Again, this term is
essential and without some understanding of Newtonian mechanics it would
be missed completely. The point here is that dimensional reduction can be
a very e↵ective method for simplifying complex relationships, but it is based
heavily on knowing what the underlying laws are that govern the systems
being studied.
1.3 Theoretical Foundation
The theoretical foundation for dimensional reduction is contained in the
Buckingham Pi Theorem. To derive this result assume we have a physical
quantity q that depends on physical parameters or variables p1, p2, . . . , pn.
In this context, the word physical means that the quantity is measurable.
Each can be expressed in fundamental dimensions and we will assume that
the L, T,M system is su cient for this task. In this case we can write
[q] = L`0T t0Mm0 , (1.29)
and
[p
i
] = L`iT tiMmi . (1.30)
Our modeling assumption is that q = f(p1, p2, . . . , pn). To dimensionally
reduce this expression we will determine if there are numbers a1, a2, . . . , an
so that
[q] = [pa11 p
a2
2 · · · pann ]. (1.31)
Introducing (1.29) and (1.30) into the above expression, and then equating
exponents, we obtain the equations
L : `1a1 + `2a2 + · · · + `nan = `0,
T : t1a1 + t2a2 + · · · + tnan = t0,
M : m1a1 + m2a2 + · · · + mnan = m0.
This can be expressed in matrix form as
Aa = b, (1.32)
where
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A =
0
@
`1 `1 · · · `n
t1 t2 · · · tn
m1 m2 · · · mn
1
A , (1.33)
a =
0
BBB@
a1
a2
...
a
n
1
CCCA
, b =
0
@
`0
t0
m0
1
A . (1.34)
The matrix A is known as the dimension matrix. As expressed in (1.33) it
is 3 ⇥ n but if we were to have used L, T,M, ✓ as the fundamental system
then it would be 4⇥ n. In other words, the number of rows in the dimension
matrix equals the number of fundamental units needed, and the number of
columns equals the number of parameters that q is assumed to depend on.
With (1.32) we have transformed the dimensional reduction question into
a linear algebra problem. To determine the consequences of this we first
consider the situation that (1.32) has no solution. In this case the assumption
that q depends on p1, p2, . . . , pn is incomplete and additional parameters are
needed. This situation motivates the following definition.
Definition 1.1. The set p1, p2, . . . , pn is dimensionally incomplete for q if
it is not possible to combine the p
i
’s to produce a quantity with the same
dimension as q. If it is possible, the set is dimensionally complete for q.
From this point on we will assume the p
i
’s are complete and there is at
least one solution of (1.32). To write down the general solution we consider
the associated homogeneous equation, namely Aa = 0. The set of solutions
of this equation form a subspace K(A), known as the kernel of A. Letting k
be the dimension of this subspace then the general solution of Aa = 0 can
be written as a =  1a1 +  2a2 + · · · +  kak, where a1,a2, . . . ,ak is a basis
for K(A) and  1,  2, . . . ,  k are arbitrary. It is understood here that if k = 0
then a = 0. With this, the general solution of (1.32) can be written as
a = a
p
+  1a1 +  2a2 + · · · +  kak, (1.35)
where a
p
is any vector that satisfies (1.32) and  1,  2, . . . ,  k are arbitrary
numbers.
Example: Drag on a Sphere
To connect the above discussion with what we did earlier consider the drag
on a sphere example. Writing (1.13) in matrix form we obtain
0
@
1 1  3  1
0  1 0  1
0 0 1 1
1
A
0
BB@
a
b
c
d
1
CCA =
0
@
1
 2
1
1
A .
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This is the matrix equation (1.32) for this particular example. Putting this
in augmented form, and row reducing, yields the following
0
@
1 1  3  1 1
0  1 0  1  2
0 0 1 1 1
1
A!
0
@
1 0 0 1 2
0 1 0 1 2
0 0 1 1 1
1
A .
From this we conclude that a = 2   d, b = 2   d, and c = 1   d. To be
consistent with the notation in (1.35), set d =  , so the solution is
0
BB@
a
b
c
d
1
CCA =
0
BB@
2
2
1
0
1
CCA +  
0
BB@
 1
 1
 1
1
1
CCA ,
where   is arbitrary. Comparing this with (1.35) we have that k = 1,
a
p
=
0
BB@
2
2
1
0
1
CCA , and a1 =
0
BB@
 1
 1
 1
1
1
CCA . ⌅
It is now time to take our linear algebra conclusions and apply them to
the dimensional reduction problem. Just as the appearance of d in (1.14)
translated into the appearance of a dimensionless product in the general
solution given in (1.17), each of the  
i
’s in (1.35) gives rise to a dimensionless
product in the general solution for the problem we are currently studying.
To be specific, writing the ith basis vector a
i
in component form as
a
i
=
0
BBB@
↵
 
...
 
1
CCCA
, (1.36)
then the corresponding dimensionless product is
⇧
i
= p↵1 p
 
2 · · · p n. (1.37)
Moreover, because the a
i
’s are independent vectors, the dimensionless prod-
ucts ⇧1,⇧2, . . . ,⇧k are independent.
As for the particular solution a
p
in (1.35), assuming it has components
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a
p
=
0
BBB@
a
b
...
c
1
CCCA
, (1.38)
then the quantity
Q = pa1p
b
2 · · · pcn (1.39)
has the same dimensions as q.
Based on the conclusions of the previous two paragraphs, the general prod-
uct solution is q = ↵Q⇧11 ⇧
2
2 · · ·⇧

k
k
, where ↵, 1,2, . . . ,k are arbitrary
constants. From this we obtain the following theorem.
Theorem 1.1. Assuming the formula q = f(p1, p2, . . . , pn) is dimensionally
homogeneous and dimensionally complete, then it is possible to reduce it to
one of the form q = QF (⇧1,⇧2, . . . ,⇧k), where ⇧1,⇧2, . . . ,⇧k are indepen-
dent dimensionless products of p1, p2, . . . , pn. The quantity Q is a dimensional
product of p1, p2, . . . , pn with the same dimensions as q.
According to this theorem, the original formula for q can be reduced from
a function of n variables down to one with k. The value of k, which equals
the nullity of the dimension matrix, ranges from 0 to n  1 depending on the
given quantities p1, p2, . . . , pn. In the case that k = 0 the function F reduces
to a constant and the conclusion is that q = ↵Q, where ↵ is an arbitrary
number.
The importance of this theorem is that it establishes that the process used
to reduce the drag on a sphere and toppling dominoes examples can be applied
to much more complex problems. It also provides insight into how the number
of dimensionless products is determined. There are still, however, fundamen-
tal questions left unanswered. For example, those with a more mathematical
bent might still be wondering if this result can really be true no matter how
discontinuous the original function f might be. Others might be wondering
if the fundamental units used here, particularly length and time, are really
independent. This depth of inquiry, although quite interesting, is beyond the
scope of this text. Those wishing to pursue further study of these and related
topics should consult Penrose [2007] and Bluman and Anco [2002].
1.3.1 Pattern Formation
The mechanism responsible for the colorful patterns on seashells, butterfly
wings, zebras, and the like has intrigued scientists for decades. An experiment
that has been developed to study pattern formation involves pouring chem-
icals into one end of a long tube, and then watching what happens as they
interact while moving along the tube. This apparatus is called a plug-flow
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Figure 1.7 Spatial pattern created in a plug-flow reactor (Bamforth et al. [2000]).
The tube occupies the interval 0  x  100, and starting at t = 0 the chemicals are
poured into the left end. As they flow along the tube a striped pattern develops.
reactor and the outcome of one such experiment is shown in Figure 1.7. It
was found in these experiments that patterns appear only for certain pouring
velocities v. According to what is known as the Lengyel-Epstein model, this
velocity depends on the concentration U of the chemical used in the experi-
ment, the rate k2 at which the chemicals interact, the di↵usion coe cient D
of the chemicals, and a parameter k3 that has the dimensions of concentration
squared. The model is therefore assuming
v = f(U, k2, D, k3). (1.40)
From Table 1.1 we have that [v] = L/T , [U ] = 1/L3, [D] = L2/T , and [k3] =
1/L6. Also, from the Lengyel-Epstein model one finds that [k2] = L3/T .
Using dimensional reduction we require
[v] = [Uakb2D
ckd3 ]. (1.41)
Expressing these using fundamental dimensions yields
LT 1 = (L 3)a(L3T 1)b(L2T 1)c(L 6)d
= L 3a+3b+2c 6dT b c.
As before we equate the respective terms and conclude
L :  3a + 3b + 2c  6d = 1
T :  b  c =  1.
These equations will enable us to express two of the unknowns in terms of
the other two. There is no unique way to do this, and one choice yields
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b =  1 + 3a + 6d and c = 2  3a  6d. From this it follows that the general
product solution is
v = ↵Uak3a+6d 12 D
2 3a 6dkd3
= ↵k 12 D
2(Uk32D
 3)a(k62D
 6k3)d.
This can be rewritten as
v = ↵k 12 D
2⇧a1 ⇧
d
2 , (1.42)
where
⇧1 =
Uk32
D3
, (1.43)
and
⇧2 =
k62k3
D6
. (1.44)
The dimensionless products ⇧1 and ⇧2 are independent, and this follows
from the method used to derive these expressions. Independence is also evi-
dent from the observation that ⇧1 and ⇧2 do not involve exactly the same
parameters. From this result it follows that the general form of the reduced
equation is
v = k 12 D
2F (⇧1,⇧2). (1.45)
It is of interest to compare (1.45) with the exact formula obtained from
solving the di↵erential equations coming from the Lengyel-Epstein model. It
is found that
v =
p
k2DUG( ), (1.46)
where   = k3/U2 and G is a rather complicated square root function (Bam-
forth et al. [2000]). This result appears to di↵er from (1.45). To investigate
this, note that   = ⇧2/⇧21 . Equating (1.45) and (1.46) it follows that
F (⇧1,⇧2) =
k3/22 U
1/2
D3/2
G( )
=
p
⇧1G(⇧2/⇧21 ).
Because the right-hand side is a function of only ⇧1 and ⇧2 then (1.45) does
indeed reduce to the exact result (1.46). Dimensional reduction has therefore
successfully reduced the original unknown function of four variables in (1.40)
down to one with only two variables. However, the procedure is not able to
reduce the function down to one dimensionless variable, as given in (1.46).
In this problem that level of reduction requires information only available
from the di↵erential equations, something that dimensional arguments are
not able to discern.
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1.4 Similarity Variables
Dimensions can be used not just to reduce formulas, they can be also used
to simplify complex mathematical problems. The degree of simplification de-
pends on the parameters, and variables, in the problem. One of the more
well-known examples is the problem of finding the density u(x, t) of a chemi-
cal over the interval 0 < x <1. In this case the density satisfies the di↵usion
equation
D
@2u
@x2
=
@u
@t
, (1.47)
where the boundary conditions are
u|
x=0 = u0, u|x!1 = 0, (1.48)
and the initial condition is
u|
t=0 = 0. (1.49)
The constant D is called the di↵usion coe cient, and its dimensions can
be determined from the terms in the di↵erential equation. In particular, the
dimensions of the left and right sides of (1.47) must be the same, and this
means [Du
xx
] = [u
t
]. Because [u] = M/L3 then [u
xx
] = [u]/L2 = M/L5
and [u
t
] = [u]/T = M/(TL3). From this we have [D]M/L5 = M/(TL3), and
therefore [D] = L2/T . In a similar manner, in boundary condition (1.48),
[u0] = [u] = M/L3. As a final comment, the physical assumptions underlying
the derivation of (1.47) are the subject of Chapter 4. In fact, the solution we
are about to derive is needed in Section 4.5.2 to solve the di↵usion equation.
Dimensional Reduction
The conventional method for solving the di↵usion equation on a semi-infinite
spatial interval is to use an integral transform, and this will be considered
in Chapter 4. It is also possible to find u using dimensional reduction. The
approach is based on the observation that the only dimensional variables, and
parameters, appearing in the problem are u, u0, D, x, and t. In other words,
it must be true that u = f(x, t,D, u0). With this we have the framework
for dimensional reduction, and the question is whether we can find numbers
a, b, c, d so that
[u] = [xatbDc(u0)d]. (1.50)
Using fundamental dimensions yields
ML 3 = LaT b(L2/T )c(M/L3)d
= La+2c 3dT b cMd,
and then equating the respective terms gives us
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L : a + 2c  3d =  3,
T : b  c = 0,
M : d = 1.
(1.51)
The solution of the above system can be written as d = 1 and b = c =  a/2.
Given the assumption in (1.50), we conclude that the general product solution
is
u = ↵u0
✓
xp
Dt
◆
a
.
The general solution therefore has the form
u = u0F (⌘), (1.52)
where
⌘ =
xp
Dt
. (1.53)
In this case, ⌘ is called a similarity variable as it is a dimensionless product
that involves the independent variables in the problem.
When working out the drag on a sphere example, we discussed how it is
possible to derive di↵erent representations of the solution. For the current
example, when solving (1.51), instead of writing b = c =  a/2, we could
just as well state that a =  2b and c = b. In this case (1.52) is replaced
with u = u0G(⇠) where ⇠ = Dt/x2. Although the two representations are
equivalent, in the sense that one can be transformed into the other, it does
make a di↵erence which one is used when deriving a similarity solution. The
reason is that we will be di↵erentiating the solution, and (1.52) leads to much
simpler formulas than the other representation. The rule of thumb here is that
you want x in the numerator of the similarity variable. If you would like a
hands on example of why this is true, try working out the steps below using
the representation u = u0G(⇠) instead of (1.52).
Similarity Solution
Up to this point we have been using a routine dimensional reduction argu-
ment. Our result, given in (1.52), is interesting as it states that the solution
has a very specific dependence on the independent variables x and t. Namely,
u can be written as a function of a single intermediate variable ⌘. To deter-
mine F we substitute (1.52) back into the problem and find what equation
F satisfies. With this in mind note, using the chain rule,
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@u
@t
= u0F 0(⌘)
@⌘
@t
= u0F 0(⌘)
⇣
  x
2D1/2t3/2
⌘
=  u0F 0(⌘)
⌘
2t
.
In a similar manner one can show that
@2u
@x2
= u0F 00(⌘)
1
Dt
.
Substituting these into (1.47) yields
F 00 =  1
2
⌘F 0, for 0 < ⌘ <1. (1.54)
We must also transform the boundary and initial conditions. The boundary
condition at x = 0 takes the form
F (0) = 1, (1.55)
while the condition as x!1 and the one at t = 0 both translate into
F (1) = 0. (1.56)
With this we have transformed a problem involving a partial di↵erential
equation (PDE) into one with an ordinary di↵erential equation (ODE). As
required, the resulting problem for F is only in terms of ⌘. All of the original
dimensional quantities, including the independent variables x and t, do not
appear anywhere in the problem. This applies not just to the di↵erential
equation, but also to the boundary and initial conditions.
The problem for F is simpler than the original di↵usion problem and, by
itself, makes the use of dimensional analysis worthwhile. In this particular
problem it is so simple that it is possible to solve for F . This can be done
by letting G = F 0, so the equation takes the form G0 =   12⌘G. The general
solution of this is G = ↵ exp( ⌘2/4). Because F 0 = G, we conclude that the
general solution is
F (⌘) =   + ↵
Z
⌘
0
e s
2
/4ds. (1.57)
From (1.55) we have that   = 1 and from (1.56) we get
1 + ↵
Z 1
0
e s
2
/4ds = 0. (1.58)
Given that
R1
0 e
 s2/4ds =
p
⇡, then
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F (⌘) = 1  1p
⇡
Z
⌘
0
e s
2
/4ds. (1.59)
Expressions like this arise so often that they have given rise to a special
function known as the complementary error function erfc(⌘). This is defined
as
erfc(⌘) = 1  2p
⇡
Z
⌘
0
e r
2
dr. (1.60)
Therefore, we have found that the solution of the di↵usion problem is
u(x, t) = u0 erfc
✓
x
2
p
Dt
◆
. (1.61)
As the above example demonstrates, using similarity variables and dimen-
sional analysis provides a powerful tool for solving PDEs. It is, for example,
one of the very few methods known that can be used to solve nonlinear prob-
lems. Its limitation is that the problem must have a specific form to work. We
were able to solve the above di↵usion problem because dimensional analysis
reduced the form of the solution down to a function of one variable. This
does not always happen and in such cases the method provides no insight
into how the problem can be solved. As an example, if the spatial interval in
the above di↵usion problem is changed to one that is finite, so 0 < x < `,
then dimensional analysis will show that there are two independent similarity
variables. This represents no improvement as we already know it is a function
of two independent variables, so a reduction is not possible. Even with these
limitations, however, similarity variables and their use in solving di↵erential
equations is a thriving area and a good introduction of the material can be
found in Bluman and Cole [1974].
1.5 Nondimensionalization and Scaling
Another use we will have for dimensional analysis is to transform a problem
into dimensionless form. The reason for this is that the approximation meth-
ods that are used to reduce di cult problems are based on comparisons. For
example, in the projectile problem we simplified the di↵erential equation by
assuming that x was small compared to R. In contrast there are problems
where the variable of interest is large, or it is slow or that it is fast compared
to some other term in the problem. Whatever the comparison, it is important
to know how all of the terms in the problem compare and for this we need
the concept of scaling.
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1.5.1 Projectile Problem
The reduction of the projectile equation (1.1) was based on the assumption
that x is not very large, and so x + R could be replaced with just R. We
will routinely use arguments like this to find an approximate solution and it
is therefore essential we take more care in making such reductions. The way
this is done is by first scaling the variables in the problem using characteristic
values. The best way to explain what this means is to work out an example
and the projectile problem is an excellent place to start.
Change Variables
The first step in nondimensionalizing a problem is to introduce a change of
variables, which for the projectile problem will have the form
t = t
c
s,
x = x
c
u.
In the above formula, x
c
is a constant and it is a characteristic value of the
variable x. It is going to be determined using the physical parameters in
the problem, which for the projectile problem are g, R, and v0. In a similar
manner, t
c
is a constant that has the dimensions of time and it represents
a characteristic value of the variable t. In some problems it will be clear at
the beginning how to select x
c
and t
c
. However, it is assumed here that we
have no clue at the start what to choose and will not select them until the
problem is studied a bit more. All we know at the moment is that whatever
the choice, the new variables u, s are dimensionless. To make the change of
variables note that from the chain rule
d
dt
=
ds
dt
d
ds
=
1
t
c
d
ds
, (1.62)
and
d2
dt2
=
d
dt
✓
d
dt
◆
=
1
t2
c
d2
ds2
. (1.63)
With this the projectile equation (1.1) takes the form
1
t2
c
d2
ds2
(x
c
u) =   gR
2
(R + x
c
u)2
. (1.64)
The method requires us to collect the parameters into dimensionless groups.
There is no unique way to do this, and this can cause confusion when first
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learning the procedure as there is no fixed method or answer. For example,
to nondimensionalize the denominator in (1.64) one can factor it as either
R(1 + x
c
u/R) or as x
c
(R/x
c
+ u). The first has the benefit of enabling us to
cancel the R in the numerator. Making this choice yields
x
c
gt2
c
d2u
ds2
=   1
(1 + x
c
u/R)2
, (1.65)
where the initial conditions (1.2), (1.3) are
u(0) = 0, (1.66)
du
ds
(0) =
t
c
x
c
v0. (1.67)
Find the Dimensionless Groups
Our change of variables has resulted in three dimensionless groups appearing
in the transformed problem. They are
⇧1 =
x
c
gt2
c
, (1.68)
⇧2 =
x
c
R
, (1.69)
⇧3 =
t
c
v0
x
c
. (1.70)
There are a few important points that need to made here. First, the ⇧’s
do not involve the variables u, s and only depend on the parameters in the
problem. Second, they are dimensionless and to accomplish this it was neces-
sary to manipulate the projectile problem so the parameters end up grouped
together to form dimensionless ratios. The third, and last, point is that the
above three dimensionless groups are independent in the sense that it is not
possible to write any one of them in terms of the other two. For example, ⇧1
is the only one that contains the parameter g while ⇧2 is the only one contain-
ing R. It is understood that in making the statement that the three groups
are independent that x
c
and t
c
can be selected, if desired, independently of
any of the parameters in the problem.
Before deciding on how to select x
c
and t
c
, it is informative to look a lit-
tle closer at the above dimensionless groups. We begin with ⇧2. In physical
terms it is a measure of a typical, or characteristic, height of the projectile
compared to the radius of the Earth. In comparison, ⇧3 is a measure of a
typical, or characteristic, velocity x
c
/t
c
compared to the velocity the pro-
jectile starts with. Finally, the parameter group ⇧1 measures a typical, or
characteristic, acceleration x
c
/t2
c
in comparison to the acceleration due to
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gravity in a uniform field. These observations can be helpful when deciding
on how to nondimensionalize a problem as will be shown next.
Use Dimensionless Groups to Determine Scaling
It is now time to actually decide on what to take for x
c
and t
c
. There are
whole papers written on what to consider as you select these parameters,
but we will take a somewhat simpler path. For our problem we have two
parameters to determine, and we will do this by setting two of the above
dimensionless groups equal to one. What we need to do is decide on which
two to pick, and we will utilize what might be called rules of thumb.
Rule of Thumb 1 : Pick the ⇧’s that appear in the initial and/or boundary
conditions.
We only have initial conditions in our problem, and the only dimensionless
group involved with them is ⇧3. So we set ⇧3 = 1 and conclude
x
c
= v0tc. (1.71)
Rule of Thumb 2 : Pick the ⇧’s that appear in the reduced problem.
To use this rule it is first necessary to explain what the reduced problem is.
This comes from the earlier assumption that the object does not get very
high in comparison to the radius of the Earth, in other words, ⇧2 is small.
The reduced problem is the one obtained in the extreme limit of ⇧2 ! 0.
Taking this limit in (1.65)-(1.67), and using (1.71), the reduced problem is
⇧1
d2u
ds2
=  1 ,
where
u(0) = 0, and
du
ds
(0) = 1.
According to the stated rule of thumb, we set ⇧1 = 1, and so
x
c
= v20/g. (1.72)
This choice for x
c
seems reasonable based on our earlier conclusion that the
maximum height for the uniform field case is v20/(2g).
Combining (1.71) and (1.72), we have that x
c
= v20/g and tc = v0/g. With
this scaling then (1.65) - (1.67) take the form
d2u
ds2
=   1
(1 + ✏u)2
, (1.73)
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where
u(0) = 0, (1.74)
du
ds
(0) = 1. (1.75)
The dimensionless parameter appearing in the above equation is
✏ =
v20
gR
. (1.76)
This parameter will play a critical role in our constructing an accurate ap-
proximation of the solution of the projectile problem. This will be done in
the next chapter but for the moment recall that since R ⇡ 6.4 ⇥ 106 m and
g ⇡ 9.8 m/s2 then ✏ ⇡ 1.6 ⇥ 10 8v20 . Consequently for baseball bats, sling
shots, BB-guns, and other everyday projectile-producing situations, where
v0 is not particularly large, the parameter ✏ is very small. This observation
is central to the subject of the next chapter.
Changing Your Mind
Before leaving this example it is worth commenting on the nondimension-
alization procedure by asking a question. Namely, how bad is it if di↵erent
choices would have been made for x
c
and t
c
? For example, suppose for some
reason one decides to take ⇧2 = 1 and ⇧3 = 1. The resulting projectile
problem is
✏
d2u
ds2
=   1
(1 + u)2
, (1.77)
where u(0) = 0, du
ds
(0) = 1, and ✏ is given in (1.76). No approximation has
been made here and therefore this problem is mathematically equivalent to
the one given in (1.73)-(1.75). Based on this, the answer to the question would
be that using this other scaling is not so bad. However, the issue is amenability
and what properties of the solution one is interested in. To explain, earlier we
considered how the solution behaves if v0 is not very large. With the scaling
that produced (1.77), small v0 translates into looking at what happens when
✏ is near zero. Unfortunately, the limit of ✏ ! 0 results in the loss of the
highest derivative in the di↵erential equation and (1.77) reduces to 0 =  1.
How to handle such singular limits will be addressed in the next chapter
but it requires more work than is necessary for this problem. In comparison,
letting ✏ approach zero in (1.73) causes no such complications and for this
reason it is more amenable to the study of the small v0 limit. The point here
is that if there are particular limits, or conditions, on the parameters that it
is worth taking them into account when constructing the scaling.
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1.5.2 Weakly Nonlinear Di↵usion
To explore possible extensions of the nondimensionalization procedure we
consider a well-studied problem involving nonlinear di↵usion. The problem
consists of finding the concentration c(x, t) of a chemical over an interval
0 < x < `. The concentration satisfies
D
@2c
@x2
=
@c
@t
   (    c)c, (1.78)
where the boundary conditions are
c|
x=0 = c|x=` = 0, (1.79)
and the initial condition is
c|
t=0 = c0 sin(5⇡x/`). (1.80)
The nonlinear di↵usion equation (1.78) is known as Fisher’s equation, and
it arises in the study of the movement of genetic traits in a population. A
common simplifying assumption made when studying this equation is that the
nonlinearity is weak, which means that the term  c2 is small in comparison
to the others in the di↵erential equation. This assumption will be accounted
for in the nondimensionalization.
Before starting the nondimensionalization process we should look at the
fundamental dimensions of the variables and parameters in the problem.
First, c is a concentration, which corresponds to the number of molecules
per unit volume, and so [c] = L 3. The units for the di↵usion coe cient D
were determined earlier, and it was found that [D] = L2/T . As for  , the
    c term in the di↵erential equation requires these two quantities to have
the same dimensions, and so [ ] = [c]. Similarly, from the di↵erential equation
we have [ (   c)c] = [@c
@t
], and from this it follows that [ ] = L3T 1. Finally,
from the initial condition we have that [c0] = [c]. It is important to make an
observation related to dimensions, and this will be done by asking a question:
is it possible to replace the initial condition (1.80) with c|
t=0 = c0 sin(5⇡x)
or with c|
t=0 = c0 sin(x)? The answer in both cases is no, and the reason is
that the argument of the sine function must be dimensionless. For exactly
the same reason it is not possible to use c|
t=0 = c0ex. It is possible, however,
to use c|
t=0 = c0x or c|t=0 = c0x2, although the dimensions of c0 di↵er from
what we found earlier.
Now, to nondimensionalize the problem we introduce the change of vari-
ables
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x = x
c
y, (1.81)
t = t
c
s, (1.82)
c = c
c
u. (1.83)
In this context, x
c
has the dimensions of length and is a characteristic value
of the variable x. Similar statements apply to t
c
and c
c
. Using the chain rule
as in (1.62) the above di↵erential equation takes the form
Dc
c
x2
c
@2u
@y2
=
c
c
t
c
@u
@s
   c
c
(    c
c
u)u.
It is necessary to collect the parameters into dimensionless groups, and so in
the above equation we rearrange things a bit to obtain
Dt
c
x2
c
@2u
@y2
=
@u
@s
   t
c
c
c
( /c
c
  u)u. (1.84)
In conjunction with this we have the boundary conditions
u|
y=0 = u|
y=`/x
c
= 0, (1.85)
and the initial condition is
u|
s=0 = (c0/cc) sin(5⇡xcy/`). (1.86)
The resulting dimensionless groups are
⇧1 =
Dt
c
x2
c
, (1.87)
⇧2 =  tccc, (1.88)
⇧3 =  /cc, (1.89)
⇧4 = `/xc, (1.90)
⇧5 = c0/cc. (1.91)
It is important to note that the five dimensionless groups given above are
independent in the sense that it is not possible to write one of them in terms
of the other four. As before this statement is based on our ability to select,
if desired, the scaling parameters x
c
, t
c
, c
c
independently of each other and
the other parameters in the problem. Also, in counting the dimensionless
groups one might consider adding a sixth. Namely, in the initial condition
(1.86) there is ⇧6 = 5⇡xc/`. The reason it is not listed above is that it is
not independent of the others because ⇧6 = 5⇡/⇧4. The 5⇡ is a number and
does not play a role in determining dimensional independence.
We have three scaling parameters to specify, namely x
c
, t
c
, c
c
. Using Rule
of Thumb 1, the ⇧’s that appear in the boundary and initial conditions are
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set equal to one. In other words, we set ⇧4 = 1 and ⇧5 = 1, from which it
follows that x
c
= ` and c
c
= c0.
To use Rule of Thumb 2, we need to investigate what it means to say that
the nonlinearity is weak. The equation (1.84) is nonlinear due to the term
 t
c
c
c
u2, and the coe cient  t
c
c
c
is the associated strength of the nonlinearity.
For a weakly nonlinear problem one is interested in the solution for small
values of  t
c
c
c
. Taking the extreme limit we set  t
c
c
c
= 0 in (1.84) to produce
the reduced equation. The only group that remains in this limit is ⇧1, and for
this reason this is the group we select. So, setting ⇧1 = 1 then we conclude
t
c
= `2/D.
The resulting nondimensional di↵usion equation is
@2u
@y2
=
@u
@s
  ✏(b  u)u, (1.92)
with boundary conditions
u(0, s) = u(1, s) = 0, (1.93)
and the initial condition
u(y, 0) = sin(5⇡y). (1.94)
The dimensionless parameters appearing in the above equation are ✏ =
 c0`2/D and b =  /c0. With this, weak nonlinearity corresponds to assuming
that ✏ is small.
1.5.3 Endnotes
As you might have noticed, the assumption of a weak nonlinearity was used in
the projectile problem, although it was stated in more physical terms. In both
examples the reduced problem, obtained setting ✏ = 0, is linear. It is certainly
possible that a physical problem is not weakly nonlinear but involves some
other extreme behavior. As an example, in nonlinear di↵usion problems you
come across situations involving weak di↵usion. What this means for (1.84) is
that Dt
c
/x2
c
has a small value. In the extreme limit that this term is zero then
the only group that remains in the reduced problem is ⇧2. Setting ⇧2 = 1
then t
c
= c0/ . With this, (1.84) becomes
✏
@2u
@x2
=
@u
@t
+ (b  u)u, (1.95)
where ✏ = Dc0/( `2) and b =  /c0. With this, weak di↵usion corresponds to
assuming that ✏ is small.
Exercises 33
For those keeping track of the rules of thumb used to nondimensionalize
a problem we have two. The first we ran across is the rule that the dimen-
sionless groups in the initial and boundary conditions are set to one. The
second rule arose when setting the dimensionless groups in the reduced prob-
lem to one. Although these can be e↵ective rules, it is certainly possible to
find problems where another scaling should be considered, and examples are
given in Exercises 1.17 and 3.8. The overall objective in all cases is that the
nondimensionalization is based on characteristic values of the variables.
Exercises
1.1. The amount of noise permitted from the large rollers used in road con-
struction was recently limited by changes in the environmental laws. Rather
than build multiple full-sized rollers in an attempt to find one that satisfied
the new law a manufacturer decided that dimensional analysis could be used.
The assumption they made was that the frequency f of the sound coming
o↵ the roller depends on the elastic modulus E and the density ⇢ of the steel
used to construct the roller as well as on the length ` of the roller.
(a) Find a dimensionally reduced form for f .
(b) In building a scale model for testing the manufacturer selected the param-
eters so that
f
m
f
f
=
`
f
`
m
s
⇢
f
E
m
⇢
m
E
f
,
where the subscript f designates full-sized and the subscript m designates
scale model. Explain why this was done.
1.2. For a pendulum that starts from rest, the period p depends on the length
` of the rod, on gravity g, on the mass m of the ball, and on the initial angle
✓0 at which the pendulum is started.
(a) Use dimensional analysis to determine the functional dependence of p on
these four quantities.
(b) For the largest pendulum ever built, the rod is 70 ft and the ball weighs
900 lbs. Assuming that ✓0 = ⇡/6 explain how to use a pendulum that fits
on your desk to determine the period of this largest pendulum.
(c) Suppose it is found that p depends linearly on ✓0, with p = 0 if ✓0 = 0.
What does your result in part (a) reduce to in this case?
1.3. The velocity v at which flow in a pipe will switch from laminar to tur-
bulent depends on the diameter d of the pipe as well as on the density ⇢ and
dynamic viscosity µ of the fluid.
(a) Find a dimensionally reduced form for v.
(b) Suppose the pipe has diameter d = 100 and for water (where ⇢ = 1 and
µ = 10 2) it is found that v = 0.25 . What is v for olive oil (where ⇢ = 1
and µ = 1)? The units here are in cgs.
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1.4. The luminosity of certain giant and supergiant stars varies in a periodic
manner. It is hypothesized that the period p depends upon the star’s average
radius r, its mass m, and the gravitational constant G.
(a) Newton’s law of gravitation asserts that the attractive force between two
bodies is proportional to the product of their masses divided by the square
of the distance between them, that is,
F =
Gm1m2
d2
,
where G is the gravitational constant. From this determine the (funda-
mental) dimensions of G.
(b) Use dimensional analysis to determine the functional dependence of p on
m, r, and G.
(c) Arthur Eddington used the theory for thermodynamic heat engines to
show that
p =
r
3⇡
2 G⇢
,
where ⇢ is the average density of the star and   is the ratio of specific
heats for stellar material. How does this di↵er from your result?
(d) In Figure 1.8 the data for a pulsating star are given. Explain how you
could use data like this to complete the formula you derived in part (b).
1.5. When a drop of liquid hits a wetted surface a crown formation appears,
as shown in Figure 1.9(a). It has been found that the number of points N on
the crown depends on the speed U at which the drop hits the surface, the
radius r and density ⇢ of the drop, and the surface tension   of the liquid
making up the drop. How N depends on these quantities has been studied
extensively and some of the reasons why are given in Rioboo et al. [2003].
(a) Use dimensional reduction to determine the functional dependence of N
on U , r, ⇢, and  . Express your answer in terms of the Weber number
W
e
= ⇢U2r/ .
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Figure 1.8 Luminosity of a Mira type variable star, 1621+19 U Herculis (AAVSO
[2009]).
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Figure 1.9 (a) Formation of a crown when a liquid drop hits a wetted surface. (b)
The measured values of the number of points N (Hobbs and Kezweent [1967]).
(b) The value of N has been measured as a function of the initial height h of
the drop and the results are shown in Figure 1.9(b). Express your answer
in part (a) in terms of h by writing U in terms of h and g. Assume the
drop starts with zero velocity.
(c) The data in Figure 1.9(b) show a piecewise linear dependence on h, specif-
ically, N can be described as a continuous function made up of two linear
segments. Use this, and your result from part (b), to find the unknown
function in part (a). In the experiments, r = 3.6 mm, ⇢ = 1.1014 gm/cm3,
and   = 50.5 dyn/cm.
(d) According to your result from part (c), what must the initial height of the
drop be to produce at least 80 points?
(e) According to your result from part (c), how many points are generated
for a drop of mercury when h = 200 cm? Assume r = 3.6 mm, ⇢ = 13.5
gm/cm2, and   = 435 dyn/cm.
1.6. The frequency ! of waves on a deep ocean is found to depend on the
wavelength   of the wave, the surface tension   of the water, the density ⇢
of the water, and gravity.
(a) Use dimensional reduction to determine the functional dependence of !
on  ,  , ⇢, and g.
(b) In fluid dynamics it is shown that
! =
s
gk +
 k3
⇢
,
where k = 2⇡/  is the wavenumber. How does this di↵er from your result
in (a)?
1.7. A ball is dropped from a height h0 and it rebounds to a height hr.
The rebound height depends on the elastic modulus E, radius R, and the
mass density ⇢ of the ball. It also depends on the initial height h0 and the
gravitational constant g.
(a) Find a dimensionally reduced form for h
r
.
(b) Suppose it is found that h
r
depends linearly on h0, with hr = 0 if h0 = 0.
What does your formula from part (a) reduce to in this case?
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(c) Suppose the density of the ball is doubled. Use the result in (a) to explain
how to change E so the rebound height stays the same.
1.8. A ball, when released underwater, will rise towards the surface with
velocity v. This velocity depends on the density ⇢
b
and radius R of the ball,
on gravity g, and on the density ⇢
f
and kinematic viscosity ⌫ of the water.
(a) Find a dimensionally reduced form for v.
(b) In fluid mechanics, using Stokes’ Law, it is found that
v =
2gR2(⇢
b
  ⇢
f
)
9⌫⇢
f
.
How does this di↵er from your result from part (a)? It is interesting to note
that this formula is used by experimentalists to determine the viscosity of
fluids. They do this by measuring the velocity in an apparatus called a
falling ball viscometer, and then solving for ⌫ in the above formula.
1.9. In electric image tomography the objective is to determine the properties
inside an object and this is done by applying a potential U to the surface.
What is measured is the resulting electric current j on the surface. Suppose
that it is found that the electric potential u within a spherical body depends
on the object’s radius R and conductivity   as well as depends on U and j.
(a) Find a dimensionally reduced form for u.
(b) Suppose that given a particular object that doubling the applied potential
U causes the internal potential u to increase by a factor of four. How does
this help simply your result in (a)?
(c) Suppose it is necessary to know the internal potential u when using a large
applied potential, say U = 2500V . However, for legal reasons it is required
that only applied potentials less than 250V can be used. Explain, using
your result from (a), how to legally determine the large applied potential
value.
1.10. The velocity v of water through a circular pipe depends on the pressure
di↵erence p between the two ends of the pipe, the length ` and radius r of
the pipe, as well as on the dynamic viscosity µ and density ⇢ of the water.
(a) Use dimensional analysis to determine the functional dependence of v on
the above quantities.
(b) Suppose it is found that v depends linearly on p, with v = 0 if p = 0.
What does your formula from part (a) reduce to in this case?
(c) Your formula from part (b) should contain a general function of one, or
more, dimensionless products. Explain how to experimentally determine
this function. Be specific about which parameters are fixed, and which are
varied, in the experiment. Also, your experiment should vary as few of the
parameters as possible in determining this function.
1.11. In a high energy explosion there is a very rapid release of energy E
that produces an approximately spherical shock wave that expands in time
(Figure 1.10).
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Figure 1.10 Shock wave produced by a nuclear explosion, at 6 msec, 16 msec, 25
msec, and 90 msec. The width of the white bar in each figure is 100m (Brixner [2009]).
(a) Assuming the radius R of the shock wave depends on E, the length of
time t since the explosion, and the density ⇢ of the air, use dimensional
reduction to determine how the radius depends on these quantities. This
expression is known as the Taylor-Sedov formula.
(b) It was shown by G. I. Taylor that if E = 1J and ⇢ = 1 kg/m3 then
R = t2/5 m/s2/5. Use this information and the result from (a) to find the
exact formula for R.
(c) Use the photographs in Figure 1.10, and your result from (b) to estimate
the energy released. The air density is ⇢ = 1 kg/m3.
(d) The blast wave from a supernova can be modeled using the Taylor-Sedov
formula. Explain how this can be used to estimate the date the supernova
took place, using your result from part (b). As an example, use Tycho,
which currently has a radius of about 33.2 light years, an estimated energy
of 1044J , and density ⇢ = 2⇥ 10 21 kg/m3.
1.12. The vertical displacement u(x) of an elastic string of length ` satisfies
the boundary value problem
⌧
d2u
dx2
+ µu = p, for 0 < x < `,
where u(0) = 0, u(`) = U . Also, p is a constant and has the dimensions of
force per length.
(a) What are the dimensions for the constants ⌧ and µ?
(b) Show how it is possible to nondimensionalize this problem so it takes the
form
d2v
ds2
+ ↵v =  , for 0 < s < 1,
where v(0) = 0, v(1) = 1. Make sure to state what ↵,   are.
1.13. From Newton’s second law, the displacement y(t) of the mass in a mass,
spring, dashpot system satisfies
m
d2y
dt2
= F
s
+ F
d
, for 0 < t,
where m is the mass, F
s
is the restoring force in the spring, and F
d
is the
damping force. To have a compete IVP we need to state the initial conditions,
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and for this problem assume
y(0) = 0,
dy
dt
(0) = v0.
(a) Suppose there is no damping, so F
d
= 0, and the spring is linear, so
F
s
=  ky. What are the dimensions for the spring constant k? Nondi-
mensionalize the resulting IVP. Your choice for y
c
and t
c
should result in
no dimensionless products being left in the IVP.
(b) Now, in addition to a linear spring, suppose linear damping is included,
so,
F
d
=  cdy
dt
.
What are the dimensions for the damping constant c? Using the same
scaling as in part (a), nondimensionalize the IVP. Your answer should
contain a dimensionless parameter ✏ that measures the strength of the
damping. In particular, if c is small then ✏ is small. The system in this
case is said to have weak damping.
1.14. The velocity v(t) of the waves on a deep ocean satisfies the equation
dv
dt
+ kv2 = `v, for 0 < t,
where v(0) = V .
(a) What are the dimensions of the constants k, `, and V ?
(b) Assuming a weak nonlinearity, use the Rules of Thumb given in Section
1.5 to nondimensionalize this problem.
1.15. The equation for an elastic beam is
EI
@4u
@x4
+ ⇢
@2u
@t2
= 0,
where the boundary conditions are u = u0 sin(!t) and @u
@x
= 0 at x = 0, while
u = @u
@x
= 0 at x = `. Assume the initial conditions are u = 0 and @u
@t
= 0
at t = 0. Here E is the elastic modulus, I is the moment of inertia, and ⇢
is the mass per unit length of the beam. Nondimensionalize the problem in
such a way that the resulting boundary conditions contain no nondimensional
groups.
1.16. When an end of a slender strip of paper is put into a cup of water,
because of absorption, the water rises up the paper. The density ⇢ of the
water along the strip satisfies the di↵erential equation
@⇢
@t
+
@J
@x
= 0,
where J is known as the flux.
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(a) What are the dimensions of J?
(b) The flux J depends on the gravitational constant g, the strip width d,
the density gradient @⇢
@x
, and the surface tension   of the water. Find a
dimensionally reduced form for J .
(c) What does your result in (b) reduce to if it is found that J depends linearly
on the density gradient, with J = 0 if ⇢
x
= 0? What is the resulting
di↵erential equation?
(d) If the strip has length h the boundary conditions are ⇢ = ⇢0 at x = 0 and
J = 0 at x = h. The initial condition is ⇢ = 0 at t = 0. With this, and
your di↵erential equation from (c), nondimensionalize the problem for ⇢
in such a way that no nondimensional groups appear in the final answer.
1.17. A thermokinetic model for the concentration u and temperature q of a
mixture consists of the following equations (Gray and Scott [1994])
du
dt
= k1   k2uek3q,
dq
dt
= k4uek3q   k5q.
The initial conditions are u = 0 and q = 0 at t = 0.
(a) What are the dimensions of the k
i
’s?
(b) Explain why the rule of thumb for scaling used in the projectile problem
does not help here.
(c) Find the steady-state solution, that is, the solution of the di↵erential equa-
tions with u0 = 0 and q0 = 0.
(d) Nondimensionalize the problem using the steady-state solution from (c) to
scale u and q. Make sure to explain how you selected the scaling for t.
1.18. The equations that account for the relativistic motion of a planet
around the sun are
d2r
dt2
  r
✓
d✓
dt
◆2
=  Gm
r2
+
b
r3
,
d
dt
✓
r2
d✓
dt
◆
= 0,
where b is a constant. Assume the initial conditions are r = r0, r0 = 0, and
✓ = 0 at t = 0.
(a) What are the dimensions of r0, b?
(b) Nondimensionalize the problem. The scaling should be chosen so the only
nondimensional group appearing in the problem involves b.
1.19. Suppose you are given a dimensionless function f(⇧) where ⇧ is a
dimensionless group. Also, suppose ⇧ = AaBbCc where A, B, C are dimen-
sional parameters and the exponents a, b, c are nonzero numbers.
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(a) Show that if f(⇧) is found to be linear in A then it must be that f(⇧) =
↵⇧1/a +   where ↵,   are arbitrary numbers.
(b) What can you conclude if it is found that
p
ABf(⇧) is linear in A?
(c) Suppose it is found that if A is doubled that the value of F increases by a
factor of four. Can this be used to determine F?
1.20. This problem explores some consequences of dimensional quantities.
(a) If g is the gravitational acceleration constant, explain why sin(g) and eg
make no sense.
(b) Explain why density, volume, and velocity can be used in place of length,
mass, and time as fundamental units.
(c) Explain why volume, velocity, and acceleration cannot be used in place of
length, mass, and time as fundamental units.
1.21. In quantum chromodynamics three parameters that play a central role
are the speed of light c, Planck’s constant ~, and the gravitational constant
G.
(a) Explain why it is possible to use [c], [~], [G] as fundamental units.
(b) The distance `
p
at which the strong, electromagnetic and weak forces be-
come equal depends on c, ~, G. Find a dimensionally reduced form for how
`
p
depends on these three parameters. Based on this result, if the speed
of light were to double what happens to `
p
?
(c) The Bohr radius a of an electron depends on ~, the electron’s charge e,
and the mass m
e
of the electron. Find a dimensionally reduced form for a.
1.22. The speed c
m
at which magnetonsonic waves travel through a plasma
depends on the intensity B of the magnetic field, the permeability µ0 of free
space, and the density ⇢ and pressure p of the plasma.
(a) Use dimensional reduction to determine the functional dependence of c
m
on B, µ0, ⇢, and p.
(b) From the basic laws for plasmas it is shown that
c
m
=
q
V 2
A
+ c2
s
,
where V
A
= B/
p
µ0⇢ is the Alfven speed and cs =
p
 p/⇢ is the sound
speed in the gas. In the latter expression,   is a number. How does this
di↵er from your result in (a)?
1.23. In the study of the motion of particles moving along the x-axis one
comes across the problem of finding the velocity u that satisfies the nonlinear
partial di↵erential equation
u
t
+ uu
x
= 0, (1.96)
where
u(x, 0) =
⇢
0 if x < 0
u0 if 0 < x.
(1.97)
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Assume that u0 is a positive constant. The equation (1.96) is derived in
Chapter 5, and it is known as the inviscid Burgers’ equation. It, along with
the jump condition in (1.97), form what is known as a Riemann problem.
(a) What three physical quantities does u depend on?
(b) Use dimensional reduction, and a similarity variable, to reduce this prob-
lem to a nonlinear ordinary di↵erential equation with two boundary con-
ditions.
(c) Use the result from part (b) to solve the Riemann problem. The solution,
which is known as an expansion fan, must be continuous for t > 0.
(d) What is the solution if the initial condition (1.97) is replaced with u(x, 0) =
u0?
(e) Suppose that, rather than velocity, the variable u is displacement. Explain
why it is not possible for u to satisfy (1.96).
1.24. Consider the partial di↵erential equation
u
t
+ Du
xxxx
= 0,
where u = u0 at x = 0, u! 0 as x!1, and u = 0 at t = 0. Use dimensional
reduction, and a similarity variable, to reduce this problem to an ordinary
di↵erential equation.
1.25. The equation of the concentration c, on an interval of length `, is
@c
@t
= D
@2c
@x2
+ µc,
where the boundary conditions are c(x, 0) = 0, c(0, t) = c0, and c(`, t) = 0.
(a) What are the dimensions of D, c0, and µ?
(b) Nondimensionalize the problem so it has the form
@u
@s
=
@2u
@y2
+ ↵u,
where the boundary conditions are u(y, 0) = 0, u(0, s) = 1, and u(1, s) = 0.
1.26. One of the standard experimental tests used in the study of fluid motion
through porous materials consists of determining the displacement u when
the material is given a constant load. The governing di↵erential equation in
this case is
H
"
1 +
✓
@u
@x
◆3#@2u
@x2
=
@u
@t
.
The boundary conditions are
@u
@x
=  1, at x = 0,
and
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u = 0, as x!1.
The initial condition is
u = 0, at t = 0.
(a) What are the dimensions of the constant H?
(b) Find a dimensionally reduced form for the solution and then use this to
transform the above di↵usion problem into one involving a nonlinear ordi-
nary di↵erential equation. Make sure to state what happens to the bound-
ary and initial conditions. You do not need to solve this problem.
(c) In the experiment the surface displacement u(0, t) is measured. Without
solving the problem use your results from (b) to sketch u(0, t) as a function
of t.
(d) Suppose the experimental data show that u(0, t) = 16t cm/sec. Using your
result from part (c), explain why the mathematical model is incorrect.
Also, explain why changing the di↵erential equation to either Hu
xx
= u
t
or to H[1 + (u
x
)5]u
xx
= u
t
will also produce an incorrect model.
1.27. Consider the problem of solving the di↵usion equation
D
@2u
@x2
=
@u
@t
,
where the boundary conditions are
u = 0, as x! ±1.
Instead of an initial condition, assume the solution satisfies
Z 1
 1
udx =  , 8t > 0.
(a) What are the dimensions of  ?
(b) Find a dimensionally reduced form for the solution and then use this to
transform the above di↵usion equation into an ordinary di↵erential equa-
tion. How do the boundary conditions transform? The integral condition
should be considered in the dimensional reduction but its conversion using
the similarity variable will wait until part (d).
(c) Find the solution of the problem from part (b). You can assume F 0 ! 0
and ⌘F ! 0 as ⌘ ! ±1. As a hint, you might want to look for the
expression (⌘F )0 in your equation.
(d) The solution from part (c) should contain an arbitrary constant. Find its
value using the given integral condition and with this show that
u =
 p
⇡Dt
e x
2
/(4Dt).
This is known as the fundamental, or point source, solution of the di↵usion
equation.
http://www.springer.com/978-0-387-87749-5
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MULTIPLE-USE QUATERNARY DIAPHRAGM PUMPS
SINGLE-USE QUATERNARY DIAPHRAGM PUMPS
BIOPHARMA
Pumps
Where Innovation Flows
quattroflow.com
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How does a pump have to be designed to convey extremely delicate 
biologically active molecules? The solution is in nature itself!
Millions of years of evolution developed the perfect device to pump  
blood that contains albumin, gamma globulins, clotting factors and 
cells. It is the heart!
The Quattroflow displacement pump is based on this principle. 
The 4-piston (quaternary) diaphragm technology enables a 
gentle pumping through soft “heartbeats”. Each stroke of the four 
diaphragms is generated by an eccentric shaft, which is connected to 
the electric motor.
The method of operation of Quattroflow pumps allows them to gently, 
safely and securely convey aqueous solutions and biologic products 
that are sensitive to shear force with minimal impact. The four-piston 
design does not require a mechanical seal or wetted rotating parts, 
ensuring total product containment without abrasion and minimum 
particle generation. Additionally, the four-piston pumping principle 
enables risk-free dry-running, low pulsation, self-priming and a high 
turn-down ratio.
Pump Follows Evolution
The Idea:
BIOPHARMACEUTICAL: 
Quattroflow™ develops and manufactures single-use and multiple-use Quaternary (Four-Piston) Diaphragm Pumps for critical 
applications in the biopharmaceutical industry. This technology is CIP/SIP capable and offers disposable solutions that increase 
flexibility, reduce down-time, eliminate costs of cleaning validation, and risks of cross-contamination. 
Quattroflow pumps can be found in all areas of biologic manufacturing such as cross-flow filtration systems, chromatography, and 
centrifuges. Quattroflow ensures safety, efficiency and reliability for handling biologics such as plasma products, therapeutic proteins, 
monoclonal antibodies, vaccines, and other high value products. 
Typical Applications and Products Handled:
• Chromatography systems
• Cross-flow systems, TFF
• Centrifuges
• Homogenizers
• Direct flow filters
• Reaction dosing
• Virus or sterile filtration
• Depth filtration
• Buffer mixing systems
• Blood plasma fractionation
• Virus cultures
• Bacterial and viral vaccines
• Cell cultures
• Cell cultures supernatants
• Enzyme solutions
• Antibodies
• Virus inactivation
Quattroflow Pumps in the Up- and Downstream Processing of Monoclonal Antibodies
MARKETS SERVED
Separator Microfiltration Protein A 
Chromatography
Column 
Packing
Permeate 
(Waste)
Permeate 
(Waste)
Column 
Packing
Virus 
Filtration
Virus 
Inactivation  
and  
pH Adjustment
Cation Exchange 
Chromatography
TFF Buffer 
Exchange
Anion Exchange 
Chromatography
TFF 
Concen-
tration
Bulk Formulation and Filling
BioreactorBuffer & Media 
Prepatation
QuattroMix
Sterile 
Filtration
Column 
Packing
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QF4400S
Multiple-Use Quaternary
Diaphragm Pump
Pump Development for  
Special Applications
Biopharmaceutical processes require the highest level of purity, 
containment and cleanability. Quattroflow pumps meet these 
requirements as they are specially designed for such applications. 
Quattroflow provides the most versatile and efficient stainless-steel 
multiple-use pumps for worldwide applications in laboratories, 
pilot plants and production plants. 
QF-Series Multiple-Use Biopharma Pumps
The QF150S, QF1200S, QF4400S, QF5050S and QF20k Series 
quaternary diaphragm positive displacement pumps do not 
utilize mechanical shaft seals or wetted rotating parts, ensuring 
total product containment without abrasion and minimum particle 
creation. Moreover, the pumping principle of the Quattroflow 
pumps allows risk-free dry running.
Multiple-Use Pumps
4
Single-Use Pumps
5
The Single-Use Advantage
Quattroflow single-use pumps have a disposable product wetted chamber constructed of 
solid polypropylene (PP) or injection-molded polyethylene (PE) that can be replaced as a 
complete unit. The simple disposability of the pump chamber saves time and money by 
eliminating cleaning validation, sterilization and product cross-contamination. Single-use 
pumps are critical to reduce equipment turnaround times in the development biosimilar 
processes. In general, multi-product facilities is the typical field of application of the single-
use pumps (e.g. process development, production of clinical reference samples, contract 
manufacturing).
QF150SU, QF1200SU, QF4400SU and QF5050SU 
Single-Use Quaternary Diaphragm Pumps
The Quattroflow single-use pumps are self-priming and can be run dry. Inside the pump 
chamber, there are no rotating parts that are subject to friction that might cause particle 
generation and/or product modification/degradation due to heat generation. A single-use 
pump chamber can be replaced and ready for a new batch in a few minutes. Its simple 
design requires only one tool. An exchange kit is available to retrofit a multi-use pump into 
a single-use pump.
Images supplied courtesy of Pall Corporation
PALL Allegro™ Single-Use Tangential Flow 
Filtration System” using a Quattroflow 
QF1200SU as recirculation pump.
PALL Allegro™ MVP Single-Use System” also 
with a Quattroflow QF1200SU pump, for 
different applications like virus filtration, sterile 
filtration, membrane chromatography, etc.
TECHNOLOGY: 4-PISTON DIAPHRAGM
Multiple-Use and Single-Use 
Quaternary Diaphragm Pumps
Quattroflow multiple-use pumps have a vast array of options and flow rates to 
accommodate many biopharmaceutical applications. Whether your requirement 
is 1 lph (0.017 lpm) or 20,000 lph (333 lpm) Quattroflow has your application 
covered with high purity, easily cleanable, multiple use units. From OEM’s and 
small scale automated systems, to large laboratories and crossflow systems, the 
QF Series provides the purity needed for the most demanding pharmaceutical 
and bio-technology applications.
Quattroflow single-use combines convenience with the ability to save time 
and money by eliminating the cost of cleaning and decontamination. Gamma-
irradiated upon request, these pumps ensure the integrity of your process and 
production output by providing the safe, clean and reliable transfer of your high 
purity process fluids. 
QF1200SU
Single-Use Quaternary
Diaphragm Pump
QF150S
Multiple-Use Quaternary
Diaphragm Pump
Performance Data
• Flow range: 1 lph - 20,000 lph (0.017 - 333 lpm)
• Max. discharge pressure: 6 bar (87 psi)
• Max. temperature: 130°C (266°F)
Technical Data
• Stainless steel materials of construction
• Single-use pump chamber: Solid polypropylene or injection-molded 
polyethylene
• Valves: EPDM
• Diaphragm: TPE (EPDM/PP)
Certifications & Associations
   
Applications and Products
• Chromatography systems
• Cross-flow systems, TFF
• Centrifuges
• Homogenizers
• Direct flow filters
• Reaction dosing
• Virus or sterile filtration
• Depth filtration
• Buffer mixing systems
• Blood plasma fractionation
• Virus cultures
• Bacterial and viral vaccines
• Cell cultures
• Cell cultures supernatants
• Enzyme solutions
• Antibodies
• Virus inactivation
• DF/MF/UF filters
Features and Benefits
• Minimal maintenance
• Minimal downtime
• Low pulsation
• Superior containment
• Variable wide flow
• Capable of dry run
• Self-priming
• Cleanable outer surface
• Linear turndown
• Compact design
• Low heat input
• High purity
• Minimum particle shedding
• Quiet operation
• Lower life cycle cost
• Ease of use
• Quick start-up
• Scaleable
• No cell damage
• Low shear
6
PUMP SELECTION GUIDE
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Multiple-Use Pumps
Pump  
Size QF150S QF1200S QF1200S-CV QF4400S QF5050S QF20k
Flow  
Range
1 – 180 lph
0.017 - 3 lpm
10 – 1,200 lph
0.167 - 20 lpm
10 – 1,200 lph
0.167 - 20 lpm
150 – 5,000 lph
2.5 - 83 lpm
50 – 5,000 lph
0.83 - 83 lpm
1,000 – 20,000 lph
16.7 - 333 lpm
More Data 
On Page 8 9 10 11 12 13
Single-Use Pumps
Pump  
Size QF150SU QF1200SU QF1200SU-M QF1200SU-XAQ QF1200SU-CV QF4400SU QF5050SU
Flow  
Range
1 – 180 lph
0.017 - 3 lpm
10 – 1,200 lph
0.167 - 20 lpm
10 – 1,200 lph
0.167 - 20 lpm
10 – 1,200 lph
0.167 - 20 lpm
10 – 1,200 lph
0.167 - 20 lpm
150 – 5,000 lph
2.5 - 83 lpm
50 – 5,000 lph
0.83 - 83 lpm
More Data 
On Page 14 15 16 17 18 19 20
For Accessories please see page 21. 
All Quattroflow pump sizes are available with different options, such as controller, housing, ports and motor. Consider the standard versions 
of all sizes for the technical data presented on the following pages.
QF150S
Quaternary Diaphragm Pumps
Multiple-Use
• Integrated controller
• Digital key pad for manual operation
• Small and portable format
• Ideal for R&D and process development
Other connection specifications, materials and motors available on request.
Technical Data
QF150S Standard Motor
Flow Rate Maximum: Eccentric Shaft 5° 180 lph (3 lpm)
Flow Rate Minimum: Eccentric Shaft 5° 1 lph (0.017 lpm)
Pressure:
Temperature of Fluid < 40° C (104° F) 6 bar (87 psi)
Temperature of Fluid > 40° C (104° F) 4 bar (58 psi)
Maximum
Temperature:
Fluid 80° C (176° F)
CIP 90° C (194° F)
SIP 130° C (266° F)
Autoclave 130° C (266° F)
Suction Lift Dry
 at 3000 rpm:
Eccentric Shaft 5°
2 - 3 m 
(6.6 - 9.8 ft)
Volume
Specifications:
Approximated Volume per 
Revolution at Free Output
1.2 ml
Filling Volume Without Connectors 15 ml
Connection 
Specification 
(Standard):
Connectors 1/4" TC
Position of Connectors Inline
Number of Flow Directions 4
Product Wetted 
Materials (Standard):
Pump Housing SS316L
Valve Plate SS316L
Diaphragms TPE
Valves EPDM
O-rings EPDM
Certificates/Proofs 
(Optional):
Elastomere
(product wetted)
USP <88> Cl. VI;
FDA21CFR177; BSE/TSE Safe
Stainless Steel Parts 
(product wetted)
3.1; Surface Roughness;
Ferrite Content
Motor (Standard):
Rated speed 3000 min-1
Voltage 230 V (110 V as option)
Power 0.05 KW
Pump Dimension with 
Motor and Housing: 
Length 280.5 mm (11.04")
Width 115 mm (4.53")
Height 184 mm (7.24")
Pump Weight with 
Motor and Housing:
8.4 kg (19 lb.)
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Performance Charts
Eccentric Shaft: 5º
9
QF1200S
Quaternary Diaphragm Pumps
Multiple-Use
• Separate control box for manual operation available
• ATEX version available
Performance Charts
Eccentric Shaft: 3º
Depending on the selected motor/frequency drive combination, 
the motor frequency and the resulting pump speed might differ.
Eccentric Shaft: 5º
Technical Data
QF1200S Standard Motor
Flow Rate 
Maximum:
Eccentric Shaft 3° 800 lph (13.3 lpm)
Eccentric Shaft 5° 1200 lph (20 lpm)
Flow Rate 
Minimum*:
Eccentric Shaft 3° 10 lph (0.167 lpm)
Eccentric Shaft 5° 20 lph (0.333 lpm)
Pressure:
Temperature of Fluid < 40° C (104° F) 6 bar (87 psi)
Temperature of Fluid > 40° C (104° F) 4 bar (58 psi)
Maximum 
Temperature:
Fluid 80° C (176° F)
CIP 90° C (194° F)
SIP 130° C (266° F)
Autoclave 130° C (266° F)
Pump Speed 
Range:
rpm 30 - 2,400
Suction Lift Dry 
at 1800 rpm:
Eccentric Shaft 3° 2.5 - 3 m (8.2-9.8 ft)
Eccentric Shaft 5°
4 - 4.5 m 
(13.1-14.7 ft)
Volume 
Specifications:
Approximated Volume per 
Revolution at Free Output
9.6 ml (5°)
5.8 ml (3°)
Filling Volume Without Connectors 75 ml
Connection 
Specification 
(Standard):
Connectors 3/4" TC
Position of Connectors Inline
Number of Flow Directions 4
Product Wetted 
Materials 
(Standard):
Pump Housing SS316L
Valve Plate SS316L
Diaphragms TPE
Valves EPDM
O-rings EPDM
Certificates/
Proofs 
(Optional):
Elastomere 
(product wetted)
USP <88> Cl. VI;
FDA21CFR177; BSE/
TSE Safe
Stainless Steel Parts 
(product wetted)
3.1; Surface 
Roughness;
Ferrite Content
Motor 
(Standard):
Rated speed 1375 min-1 (50 Hz)
Voltage 230/400 V
Power 0.37 KW
Pump Dimension 
with Motor and 
Housing: 
Length 487 mm (19.17")
Width 159 mm (6.26")
Height 210 mm (8.27")
Pump Weight 
with Motor and 
Housing:
24 kg (53 lb.)
Other connection specifications, materials and motors available on request.
*  When using pump with control box: 20 lph (0.333 lpm) and 40 lph (0.667 lpm)
Technical Data
QF1200S-CV Standard Motor
Flow Rate Maximum: Eccentric Shaft 5° 1200 lph (20 lpm)
Flow Rate Minimum: Eccentric Shaft 5° 10 lph (0.167 lpm)
Pressure:
Temperature of Fluid < 40° C (104° F) 6 bar (87 psi)
Temperature of Fluid > 40° C (104° F) 4 bar (58 psi)
Maximum
Temperature:
Fluid 80° C (176° F)
CIP 90° C (194° F)
SIP 130° C (266° F)
Autoclave 130° C (266° F)
Pump Speed Range: rpm 10 - 2200
Suction Lift Dry
at 1800 rpm:
Eccentric Shaft 5°
4 - 4.5 m
(13.1-14.7 ft)
Volume
Specifications:
Filling Volume Without Connectors 75 ml
Connection 
Specification 
(Standard):
Connectors 3/4" TC
Position of Connectors Inline
Number of Flow Directions 4
Product Wetted 
Materials (Standard):
Pump Chamber SS316L
Valve Plate SS316L
Diaphragms TPE
Valves EPDM
O-rings EPDM
Certificates/Proofs 
(Optional):
Elastomere 
(product wetted)
USP <88> Cl. VI; 
FDA21CFR177;
BSE/TSE Safe
Stainless Steel Parts 
(product wetted)
3.1; Surface Roughness; 
Ferrite Content
Motor:
Rated speed 2200 min-1
Voltage 230 V
Power 0.75 kW
Pump Dimension with 
Motor and Housing: 
Length 487 mm (19.17")
Width 200 mm (7.87")
Height 210 mm (8.27")
Pump Weight with 
Motor and Housing:
25 kg (55 lb.)
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QF1200S-CV
Quaternary Diaphragm Pumps
Multiple-Use
• Integrated controller
• Digital key pad for manual operation
• Compact size
• 230V motor
Performance Charts
Eccentric Shaft: 5º
11
Depending on the selected motor/frequency drive combination, the motor frequency and the resulting pump speed might differ.
QF4400S
Quaternary Diaphragm Pumps
Multiple-Use 
• Separate control box for manual operation available
• ATEX version available
Technical Data
QF4400S Standard Motor
Flow Rate Maximum: Eccentric Shaft 6° 5000 lph (83 lpm)
Flow Rate Minimum: Eccentric Shaft 6° 150 lph (2.5 lpm)
Pressure:
Temperature of Fluid < 40° C (104° F) 6 bar (87 psi)
Temperature of Fluid > 40° C (104° F) 4 bar (58 psi)
Maximum 
Temperature:
Fluid 80° C (176° F)
CIP 90° C (194° F)
SIP 130°C (266° F)*
Autoclave 130°C (266° F)*
Suction Lift Dry at 
1200 rpm:
Eccentric Shaft 6° 4 - 4.5 m (13.1-14.7 ft)
Volume Specifications:
Approximated Volume per 
Revolution at Free Output
95 ml
Filling Volume Without Connectors 820 ml
Connection 
Specification 
(Standard):
Connectors 1.5" TC
Position of Connectors Front
Product Wetted 
Materials (Standard):
Pump Housing SS316L
Valve Plate SS316L or PP
Diaphragms TPE
Valves EPDM/SS316L
O-rings EPDM
Certificates/Proofs 
(Optional):
Elastomere (product wetted)
USP <88> Cl. VI; 
FDA21CFR177;  
BSE/TSE Safe
Stainless Steel Parts (product wetted)
3.1; Surface Roughness; 
Ferrite Content
Motor (Standard):
Rated speed 1410 min-1 (50 Hz)
Voltage 230/400 V
Power 2.2 KW
Pump Dimension with 
Motor and Housing: 
Length 776.4 mm (30.57")
Width 256 mm (10.08")
Height 330 mm (12.99")
Pump Weight with 
Motor and Housing:
96 kg (212 lb.)
Other connection specifications, materials and motors available on request.
*With SS316L valve plate only
Performance Charts
Eccentric Shaft: 6º
QF5050S
Quaternary Diaphragm Pumps
Multiple-Use 
• Compact footprint
• High turn-down ratio
• Multi-option installation flexibility
• Separate control box for manual operation available
Other connection specifications, materials and motors available on request.
*With SS316L valve plate only
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Technical Data
QF5050S Servo Motor
Flow Rate Maximum: Eccentric Shaft 6° 5000 lph (83 lpm)
Flow Rate Minimum: Eccentric Shaft 6° 50 lph (0.83.lpm)
Pressure:
Temperature of Fluid < 40° C (104° F) 6 bar (87 psi)
Temperature of Fluid > 40° C (104° F) 4 bar (58 psi)
Maximum 
Temperature:
Fluid 80° C (176° F)
CIP 90° C (194° F)
SIP 130°C (266° F)*
Autoclave 130°C (266° F)*
Suction Lift Dry at 
1200 rpm:
Eccentric Shaft 6° 4 - 4.5 m (13.1-14.7 ft)
Volume Specifications:
Approximated Volume per 
Revolution at Free Output
95 ml
Filling Volume Without Connectors 820 ml
Connection 
Specification 
(Standard):
Connectors 1.5" TC
Position of Connectors Front
Product Wetted 
Materials (Standard):
Pump Housing SS316L
Valve Plate SS316L or PP
Diaphragms TPE
Valves EPDM/SS316L
O-rings EPDM
Certificates/Proofs 
(Optional):
Elastomere (product wetted)
USP <88> Cl. VI; 
FDA21CFR177;  
BSE/TSE Safe
Stainless Steel Parts (product wetted)
3.1; Surface Roughness; 
Ferrite Content
Motor (Standard):
Rated speed
3000 min -1
(2.66:1 reduction)
Voltage 400 V
Power 3 KW
Pump Dimension with 
Motor and Housing: 
Length 440 mm (17.32")
Width 325 mm (12.80")
Height 320 mm (12.60")
Pump Weight with 
Motor and Housing:
66 kg (146 lb.)
Depending on the selected motor/frequency drive combination, the motor frequency and the resulting pump speed might differ.
Performance Charts
Eccentric Shaft: 6º
13
Depending on the selected motor/frequency drive combination, the motor frequency and the resulting pump speed might differ.
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QF20k
Quaternary Diaphragm Pumps
Multiple-Use
• Separate control box for manual operation available
• ATEX version available
Other connection specifications, materials and motors available on request.
Technical Data
QF20k Standard Motor
Flow Rate Maximum: Eccentric Shaft 7° 20000 lph (333 lpm)
Flow Rate Minimum: Eccentric Shaft 7° 1000 lph (16.7 lpm)
Pressure:
Temperature of Fluid < 40° C (104° F) 6 bar (87 psi)
Temperature of Fluid > 40° C (104° F) 4 bar (58 psi)
Maximum 
Temperature:
Fluid 80° C (176° F)
CIP 90° C (194° F)
SIP 130° C (266° F)
Autoclave 130° C (266° F)
Suction Lift Dry
at 330 rpm:
Eccentric Shaft 7° 4 - 4.5 m (13.1-14.7 ft)
Volume Specifications:
Approximated Volume per 
Revolution at Free Output
470 ml
Filling Volume Without Connectors 2950 ml
Connection 
Specification 
(Standard):
Connectors 2" TC
Position of Connectors Front
Product Wetted 
Materials (Standard):
Pump Housing SS316L
Valve Plate SS316L
Diaphragms TPE
Valves EPDM/SS316L
O-rings EPDM
Certificates/Proofs 
(Optional):
Elastomere (product wetted)
USP <88> Cl. VI; 
FDA21CFR177;  
BSE/TSE Safe
Stainless Steel Parts (product wetted)
3.1; Surface Roughness; 
Ferrite Content
Motor (Standard):
Rated speed 1460/474 min-1 (50 Hz)
Voltage 230/400 V
Power 4 KW
Pump Dimension with 
Motor and Housing: 
Length 1152.5 mm (45.37")
Width 400 mm (15.75")
Height 416 mm (16.38")
Pump Weight with 
Motor and Housing:
217 kg (478 lb.)
Performance Charts
Eccentric Shaft: 7º
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QF150SU
Quaternary Diaphragm Pumps
Single-Use 
• Disposable wetted product chamber
• Integrated controller
• Digital key pad for manual operation
• Small and portable format
• Ideal for R&D and process development
Other connection specifications, materials and motors available on request.
Technical Data
QF150SU Standard Motor
Flow Rate Maximum: Eccentric Shaft 5° 180 lph (3 lpm)
Flow Rate Minimum: Eccentric Shaft 5° 1 lph (0.017 lpm)
Pressure:
Temperature of Fluid < 40° C (104° F) 4 bar (58 psi)
Temperature of Fluid > 40° C (104° F) 4 bar (58 psi)
Maximum 
Temperature:
Fluid 60° C (140° F)
Autoclave* 130° C (266° F)
Suction Lift Dry at 
3000 rpm:
Eccentric Shaft 5° 2 - 3 m (6.6 - 9.8 ft)
Volume Specifications:
Approximated Volume per 
Revolution at Free Output
1.2 ml
Filling Volume Without Connectors 15 ml
Connection 
Specification 
(Standard):
Connectors 1/4" TC
Position of Connectors Inline
Number of Flow Directions 4
Product Wetted 
Materials (Standard):
Pump Chamber PP
Valve Plate PP
Diaphragms TPE
Valves EPDM
O-rings EPDM
Certificates/Proofs 
(Optional):
Elastomere (product wetted)
USP <88> Cl. VI; 
FDA21CFR177;  
BSE/TSE Safe; USP 
87/381/661
Motor (Standard):
Rated speed 3000 min-1
Voltage 230 V (110 V as option)
Power 0.05 KW
Pump Dimension with 
Motor and Housing: 
Length 285 mm (11.22")
Width 115 mm (4.53")
Height 184 mm (7.24")
Pump Weight with 
Motor and Housing:
7 kg (15.8 lb.)
Performance Charts
Eccentric Shaft: 5º
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QF1200SU
Quaternary Diaphragm Pumps
Single-Use
Other connection specifications, materials and motors available on request.
*  When using pump with control box: 20 lph (0.333 lpm) and 40 lph (0.667 lpm)
• Disposable wetted product chamber
• Pump chamber made of solid polypropylene
• Separate control box for manual operation available
• ATEX version available
Performance Charts
Depending on the selected motor/
frequency drive combination, the motor 
frequency and the resulting pump speed 
might differ.
Eccentric Shaft: 5º
Eccentric Shaft: 3º
Technical Data
QF1200SU Standard Motor
Flow Rate Maximum:
Eccentric Shaft 3° 800 lph (13.3 lpm)
Eccentric Shaft 5° 1200 lph (20 lpm)
Flow Rate Minimum*:
Eccentric Shaft 3° 10 lph (0.167 lpm)
Eccentric Shaft 5° 20 lph (0.333 lpm)
Pressure:
Temperature of Fluid < 40° C (104° F) 4 bar (58 psi)
Temperature of Fluid > 40° C (104° F) 4 bar (58 psi)
Maximum 
Temperature:
Fluid 60° C (140° F)
Autoclave 130° C (266° F)
Pump Speed Range: rpm 30 - 2,400
Suction Lift Dry at 
1800 rpm:
Eccentric Shaft 3° 2.5 - 3 m (8.2-9.8 ft)
Eccentric Shaft 5° 4 - 4.5 m (13.1-14.7 ft)
Volume Specifications:
Approximated Volume per 
Revolution at Free Output
9.6 ml (5°)
5.8 ml (3°)
Filling Volume Without Connectors 75 ml
Connection 
Specification 
(Standard):
Connectors 3/4" TC
Position of Connectors Inline
Number of Flow Directions 4
Product Wetted 
Materials (Standard):
Pump Chamber PP
Valve Plate PP
Diaphragms TPE
Valves EPDM
O-rings EPDM
Certificates/Proofs 
(Optional):
Elastomere (product wetted)
USP <88> Cl. VI; 
FDA21CFR177;  
BSE/TSE Safe; USP 
87/381/661
Motor (Standard):
Rated speed 1375 min-1 (50 Hz)
Voltage 230/400 V
Power 0.37 KW
Pump Dimension with 
Motor and Housing: 
Length 497 mm (19.56")
Width 159 mm (6.26")
Height 210 mm (8.27")
Pump Weight with 
Motor and Housing:
21 kg (46 lb.)
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Other connection specifications, materials and motors available on request.
*  When using pump with control box: 20 lph (0.333 lpm) and 40 lph (0.667 lpm)
** Connectors PP
QF1200SU-M
Quaternary Diaphragm Pumps
Single-Use
• Disposable wetted product chamber
• Pump chamber made of injection-molded polyethylene
• Separate control box for manual operation available
• ATEX version available
• Front side connections
Performance Charts
Depending on the selected motor/
frequency drive combination, the motor 
frequency and the resulting pump speed 
might differ.
Eccentric Shaft: 5º
Eccentric Shaft: 3º
Technical Data
QF1200SU-M Standard Motor
Flow Rate Maximum:
Eccentric Shaft 3° 800 lph (13.3 lpm)
Eccentric Shaft 5° 1200 lph (20 lpm)
Flow Rate Minimum*:
Eccentric Shaft 3° 10 lph (0.167 lpm)
Eccentric Shaft 5° 20 lph (0.333 lpm)
Pressure:
Temperature of Fluid < 40° C (104° F) 4 bar (58 psi)
Temperature of Fluid > 40° C (104° F) 4 bar (58 psi)
Maximum 
Temperature:
Fluid 50° C (122° F)
Pump Speed Range: rpm 30 - 2,400
Suction Lift Dry at 
1800 rpm:
Eccentric Shaft 3° 2-2.5 m (6.6-8.2 ft)
Eccentric Shaft 5° 3-3.5 m (9.8-11.5 ft)
Volume Specifications:
Approximated Volume per 
Revolution at Free Output
9.6 ml (5°)
5.8 ml (3°)
Filling Volume Without Connectors 75 ml
Connection 
Specification 
(Standard):
Connectors 3/4" TC
Position of Connectors Front
Product Wetted 
Materials (Standard):
Pump Chamber PE injection molded**
Valve Plate PE injection molded
Diaphragms TPE
Valves EPDM
O-rings EPDM
Certificates/Proofs 
(Optional):
Elastomere (product wetted)
USP <88> Cl. VI; 
FDA21CFR177;  
BSE/TSE Safe; USP 
87/381/661
Motor (Standard):
Rated speed 1375 min-1 (50 Hz)
Voltage 230/400 V
Power 0.37 KW
Pump Dimension with 
Motor and Housing: 
Length 503 mm (19.8")
Width 159 mm (6.26")
Height 210 mm (8.27")
Pump Weight with 
Motor and Housing:
20 kg (44 lb.)
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QF1200SU-XAQ
Pre-Gamma-Irradiated Single-Use Pump Chamber  
with CPC™ AseptiQuik® Connector
• Disposable wetted product chamber
• Pre-gamma-irradiated
• Fast & easy aseptic integration
• Easy replacement
Other connection specifications, materials and motors available on request.
*  When using pump with control box: 20 lph (0.333 lpm) and 40 lph (0.667 lpm)
For the performance charts, please refer to the QF1200SU pump specifications on page 15.
The use of aseptic connectors of CPC enables simple and flexible aseptic integration of gamma irradiated 
Quattroflow single-use pump chambers in biopharmaceutical processes. Depending on the process tubing 
requirements it allows users to flexibly and aseptically connect the pump chambers with bags, tubing and filters, 
which are also equipped with matching aseptic connectors.
Technical Data with Standard Drive (QF1200SU Pump)
QF1200SU-XAQ Standard Motor
Flow Rate Maximum:
Eccentric Shaft 3° 800 lph (13.3 lpm)
Eccentric Shaft 5° 1200 lph (20 lpm)
Flow Rate Minimum*:
Eccentric Shaft 3° 10 lph (0.167 lpm)
Eccentric Shaft 5° 20 lph (0.333 lpm)
Pressure: Temperature of Fluid ≤ 40° C (104° F) 4 bar (58 psi)
Maximum 
Temperature:
Fluid 40° C (104° F)
Suction Lift Dry at 
1800 rpm:
Eccentric Shaft 3° 2.5 - 3 m (8.2 - 9.8 ft)
Eccentric Shaft 5° 4 - 4.5 m (13.1 - 14.7 ft)
Volume Specifications:
Approximated Volume per 
Revolution at Free Output
5.8 ml (3°)
9.6 ml (5°)
Filling Volume Without Connectors 75 ml
Connection 
Specification 
(Standard):
Connectors AseptiQuik® G
Sanitary Clamp Sanisure® 3/4"
Number of Flow Directions 4
Product Wetted 
Materials (Standard):
Pump Chamber / Valve Plate PP
Pump Diaphragms TPE
Pump Valves EPDM
Valves / O-rings EPDM
Connector Seals / TC Gasket Platinum-Cured Silicone
Connector Main Components Polycarbonate
Certificates/Proofs 
(Optional):
Elastomere (product wetted)
USP <88> Cl. VI; FDA21CFR177;  
BSE/TSE Safe
Gamma Irradiation:
Gamma dose 25 kGy
Certificate Included
Comment Double bagged package
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QF1200SU-CV
Quaternary Diaphragm Pumps
Single-Use
• Disposable wetted product chamber
• Integrated controller
• Digital key pad for manual operation
• Compact size
Technical data for the QF1200SU-CV-M (pump chamber made of injection-molded PE) available on request.
Performance Charts
Technical Data
QF1200SU-CV
Flow Rate Maximum: Eccentric Shaft 5° 1200 lph (20 lpm)
Flow Rate Minimum: Eccentric Shaft 5° 10 lph (0.167 lpm)
Pressure:
Temperature of Fluid < 40° C (104° F) 4 bar (58 psi)
Temperature of Fluid > 40° C (104° F) 4 bar (58 psi)
Maximum 
Temperature:
Fluid 60° C (140° F)
Autoclave 130° C (266° F)
Pump Speed Range: rpm 10 - 2200
Suction Lift Dry at 
1800 rpm:
Eccentric Shaft 5° 4 - 4.5 m (13.1-14.7 ft)
Volume Specifications:
Approximated Volume per 
Revolution at Free Output
9.6 ml
Filling Volume Without Connectors 75 ml
Connection 
Specification 
(Standard):
Connectors 3/4" TC
Position of Connectors Inline
Number of Flow Directions 4
Product Wetted 
Materials (Standard):
Pump Chamber PP
Valve Plate PP
Diaphragms TPE
Valves EPDM
O-rings EPDM
Certificates/Proofs 
(Optional):
Elastomere (product wetted)
USP <88> Cl. VI; 
FDA21CFR177;  
BSE/TSE Safe; USP 
87/381/661
Motor:
Rated speed 2200 min-1
Voltage 230 V
Power 0.75 kW
Pump Dimension with 
Motor and Housing: 
Length 497 mm (19.56")
Width 200 mm (7.87")
Height 210 mm (8.27")
Pump Weight with 
Motor and Housing:
21 kg (46 lb.)
Eccentric Shaft: 5º
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QF4400SU
Quaternary Diaphragm Pumps
Single-Use
Other connection specifications, materials and motors available on request.
• Disposable wetted product chamber
• Separate control box for manual operation available
• ATEX version available
Performance Charts
Technical Data
QF4400SU Standard Motor
Flow Rate Maximum: Eccentric Shaft 6° 5000 lph (83 lpm)
Flow Rate Minimum: Eccentric Shaft 6° 150 lph (2.5 lpm) 
Pressure:
Temperature of Fluid < 40° C (104° F) 4 bar (58 psi)
Temperature of Fluid > 40° C (104° F) 4 bar (58 psi)
Maximum 
Temperature:
Fluid 60° C (140° F)
Autoclave 130° C (266° F)
Suction Lift Dry at 
1800 rpm:
Eccentric Shaft 6° 4 - 4.5 m (13.1-14.7 ft)
Volume Specifications:
Approximated Volume per 
Revolution at Free Output
95 ml
Filling Volume Without Connectors 820 ml
Connection 
Specification 
(Standard):
Connectors 1.5" TC
Position of Connectors Front
Product Wetted 
Materials (Standard):
Pump Chamber PP
Valve Plate PP
Diaphragms TPE
Valves EPDM / SS316L
O-rings EPDM
Certificates/Proofs 
(Optional):
Elastomere (product wetted)
USP <88> Cl. VI; 
FDA21CFR177;  
BSE/TSE Safe; USP 
87/381/661
Motor:
Rated speed 1410 min-1 (50 Hz)
Voltage 230/400 V
Power 2.2 KW
Pump Dimension with 
Motor and Housing: 
Length 776.4 mm (30.57")
Width 256 mm (10.08")
Height 330 mm (12.99")
Pump Weight with 
Motor and Housing:
81 kg (178 lb.)
Eccentric Shaft: 6º
Depending on the selected motor/frequency drive combination, the motor frequency and the resulting pump speed 
might differ.
Depending on the selected motor/frequency drive combination, the motor frequency and the resulting pump speed might differ.
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QF5050SU
Quaternary Diaphragm Pumps
Single-Use
Other connection specifications, materials and motors available on request.
• Disposable wetted product chamber
• Compact footprint
• High turn-down ratio
• Multi-option installation flexibility
• Separate control box for manual operation available
Technical Data
QF5050SU Servo Motor
Flow Rate Maximum: Eccentric Shaft 6° 5000 lph (83 lpm)
Flow Rate Minimum: Eccentric Shaft 6° 50 lph (0.83.lpm)
Pressure:
Temperature of Fluid < 40° C (104° F) 4 bar (58 psi)
Temperature of Fluid > 40° C (104° F) 4 bar (58 psi)
Maximum 
Temperature:
Fluid 60° C (140° F)
Autoclave 130° C (266° F)
Suction Lift Dry at 
1800 rpm:
Eccentric Shaft 6° 4 - 4.5 m (13.1-14.7 ft)
Volume Specifications:
Approximated Volume per 
Revolution at Free Output
95 ml
Filling Volume Without Connectors 820 ml
Connection 
Specification 
(Standard):
Connectors 1.5" TC
Position of Connectors Front
Product Wetted 
Materials (Standard):
Pump Chamber PP
Valve Plate PP
Diaphragms TPE
Valves EPDM / SS316L
O-rings EPDM
Certificates/Proofs 
(Optional):
Elastomere (product wetted)
USP <88> Cl. VI; 
FDA21CFR177;  
BSE/TSE Safe; USP 
87/381/661
Motor:
Rated speed
3000 min -1 
(2.66:1reduction)
Voltage 400 V
Power 3 KW
Pump Dimension with 
Motor and Housing: 
Length 440 mm (17.32")
Width 325 mm (12.80")
Height 320 mm (12.60")
Pump Weight with 
Motor and Housing:
51 kg (112 lb.)
Performance Charts
Eccentric Shaft: 6º
Accessories
Power Box
• Plug & Play installation
• Protects system and pump from overpressure
• Configurable pressure switch setpoint
• Reset button for pump reset
• To be used with pressure switch (also available)
• For multiple-use models only
PID Pressure Controller
• Ideal for processes, where the Quattroflow pump 
should be controlled to a defined pressure or 
flow rate (e.g. for  filtration)
• 4 – 20mA input for pressure or flow sensor
• 24VDC voltage supply for sensors
• Autotune function for optimization of PID 
parameters
• 0 – 5VDC output signal for use with QF150 or 
QF1200CV (requires optional analogue input)
• Configurable alarm setpoints for automatic 
shutoff of pump
21
Control Box
• Variable speed controller with integrated key 
pad for manual speed control 
• Configurable for remote speed control with 
4 –20 mA analogue input 
• 230V / 50 Hz or 115 V / 60 Hz for model 1200 
(image left)
• 400V, 3P for models 4400/5050/20k           
(image right) 
• Hygienic 1.4301 housing, IP 54 
• Easy plug & play installation 
Diaphragm Sensor
• Sensor installed in ring drive unit
• Detection of all liquids
• Signal output to a controller, 
         if diaphragm is ruptured
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Facts about peristaltic pumps used for biopharmaceutical production 
processes:
• Particle generation caused by pump design.
• Permanent mechanical stress of the hose may lead to a 
 substantial source of particles entering the fluid stream.
• Possible contamination of the pumped liquid and the 
pharmaceutical end product. 
• Drop-in flow rate over time
• Some are not capable of reaching more than 1 bar
Do you want to avoid this in your product?
The images on the right show micrographs of filter membranes, 
which were used to quantify particles created during a pumping 
process. 
• Particles from the peristaltic pump are visible as bright objects 
obstructing the pores of the membrane (lower image).
• The filter membrane of the Quattroflow test does not show 
particles just open membrane pores. The gentle working 
principle of the 4-piston Quattroflow pump minimizes 
mechanical stress and thus the generation of particles (upper 
image).
Test conditions:
Third party comparison between Quattroflow QF150SU and 
peristaltic pump using pharma-grade pumping hose. 8h 
continuous recirculation through 12µm filter filter at approximately 
100 lph (1.67 lpm)
Result: 
• 2 Mio particles with sizes between 6.1 and 12.7 µm for the 
peristaltic pump.
• No particles identifiable for the Quattroflow pump. 
Quattroflow pumps help minimize particle contamination of your 
product, reduce heat, and are suitable for securing the handling 
of expensive and/or sensitive liquids.
Particle Generation?
Concerned about 
Quattroflow™ pumps and 
peristaltic pumps:
Particle generation compared
Peristaltic Pump
Membrane Pores Blocked with Particles
200 µm
Quattroflow
200 µm
Clear Membrane Pores
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Besides the particle generation and product contamination facts mentioned on the first page, peristaltic pumps 
have some further operational limitations, which can be a disadvantage and risk for your process:
Pulsation 
Due to their operational design, peristaltic pumps 
create a pulsing flow, which can adversely affect the 
process.
Tube failure 
High mechanical stress can result in tube rupture, 
which can lead to a catastrophic failure, costly 
product loss, downtime and maintenance.
Flow rate consistency 
With increasing operating time of the tube, 
mechanical stress changes the hose geometries over 
time and can lead to an inconsistent flow.
Particle generation outside the hose 
Spallation release may also occur outside the 
hose. This may compromise the fluid path but also 
contaminate the external clean room environment.
Pump technology change
Limited flow and pressure capabilities of peristaltic 
pumps means changing pump technologies as 
processes move from process development to cGMP 
creating scale up issues.
These disadvantages inherent in peristaltic pumps 
ultimately mean potential threats to the quality 
of the process and the final product. Spallation, 
performance loss and rupture are also described in 
scientific literature (see Bahal and Romansky, “Spall-
ing and sorption of tubing for peristaltic pumps”) in 
Pharmaceutical Development and Technology, 7(3), 
317-323 (2002).
Single-use technologies have created improved 
production opportunities in bio-pharmaceutical 
production processes. The correct pump technology  
can make a significant contribution.
Quattroflow™  Pumps
make the difference
Authorized PSG Partner:
Where Innovation Flows
PSG® reserves the right to modify the information and illustrations contained in this document without prior notice.  This is a non-contractual document. 3-2016
Almatec Maschinenbau GmbH
Carl-Friedrich-Gauß-Straße 5
47475 Kamp-Lintfort, Germany
T: +49 (0) 2842/961-0
F: +49 (0) 2842/961-40
info@almatec.de
quattroflow.com Copyright ©2016    PSG®, a Dover company QTF-10100-C-01
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TERUFLEX®
250mL Blood Bag System
with 16 Gauge Needle
From pediatric, elderly or small autologous donors who  
may not tolerate larger blood collections
As directed by a patient’s physician  
The black lines of the needle protector  
and hub are conveniently aligned to:
Show evidence of a broken seal
Indicate bevel up position
®
TE
R
U
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EX
®
Flexibility and Performance
  Corporate Brand Mark
Double Bevel Design 
Ultra-thin Wall Needle
Tall narrow design enhances blood 
component separation 
Rounded corners facilitate mixing 
of blood and anticoagulant
Easy to open
Visual assurance of seal integrity
Reduces kinks which facilitates 
smooth blood flow
TERUFLEX® and  
  Corporate Brand Mark
 TERUMO are registered in U.S. Patent and Trademark Office by Terumo Corporation.
Manufactured by Terumo Corporation in Japan. © 2010 TERUMO CORPORATION.    10252010-1019
TERUMO MEDICAL CORPORATION 
2101 Cottontail Lane Somerset,  
New Jersey 08873   
Tel: 800.283.7866
Ordering Information:
Product Code:  1BB*SCD256A
Quantity:  90 blood bags/case
Shelf Life:  30 months
Contains no latex components
 Single-Use BioProcess Containers 
Standard and customized 2D and 3D 
fl uid containment systems  
2
Single-use technologies
Whether you are looking for an economical catalog product or require a specific  
custom-designed and custom-built system, we offer proven solutions at every scale.  
With a wealth of experience, knowledge, and solid quality processes behind every  
Thermo Scientific™ product, we will help you feel assured that your bioproduction  
process performs at its best.
We take pride in offering one of the largest libraries and 
catalog components in the industry, allowing us to integrate 
connectors, tubing, and sensors to design a custom 
Thermo Scientific™ BioProcess Container (BPC) or a 
customized tubing assembly to fit your specific needs. Our 
services organization is here to assist you with drawings, 
implementation, and technical support to help ensure 
optimum production performance. 
Our products and services are designed to enable proven 
performance through innovative and highly effective 
upstream or downstream applications. You can optimize 
production, improve process efficiency, add flexibility, and 
ensure fast-track product development and introduction 
to market by selecting product components and services 
from a single supplier.
Quality control and assurance
To help ensure that BPC systems conform to the 
quality standards expected in the bioprocess industry, 
BPC systems are subject to rigorous quality control in 
compliance with current good manufacturing practices 
(cGMP) (21 CFR Part 820) and ISO 9001:2000 from the 
receipt of components to the release of final product. 
Our production control processes help ensure complete 
lot traceability for each batch. The process control 
document becomes the stepwise manufacturing record 
that physically accompanies the lot through every 
step of the manufacturing process. At the end of the 
process, the production record is reviewed by the quality 
assurance team for completeness, and correctness prior 
to the release of the lot and issuance of the certificate 
of analysis (CoA).
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2D Labtainer BPC systems
This design is used for small, simple 
BPCs and is produced from two 
sheets of fi lm that are heat-sealed 
around the perimeter to form a 
pillow-shaped chamber. The ports are 
heat-sealed into the end seal or onto 
one of the faces of the chamber. 
3D Productainer BPC systems
This design is used for larger and 
more complicated BPCs. A square 
tube is formed by heat-sealing sheets 
of fi lm together. Top- and bottom- 
porting options are available, and a 
greater range of size and complexity 
of chamber designs is possible.
Tank Liner BPC systems
This design is used with commercially 
available overhead mixers. Tank liners 
remove the need for tank cleaning and 
helps reduce cycle times. Tank liners 
are optimized for use with Thermo 
Scientifi c™ drums and commonly used 
industry-standard cylindrical tanks.
What is a Single-Use BioProcess Container? 
The heart of our single-use solutions is our BioProcess 
Containers (BPCs). BPCs are single-use, fl exible container 
systems commonly used for critical liquid-handling 
applications in the biopharmaceutical industry. 
BPC systems are cost-effective alternatives to conventional 
stainless steel systems. They employ a novel design 
approach that is highly valued for its versatility and utility. 
BPC components are readily integrated into a variety of 
high-performance systems for all steps in the production 
of biologics. 
Key features
• All BPCs are produced in state-of-the-art cGMP facilities 
with common processes for manufacturing redundancy
• Production of chambers from 50 mL to 10,000 L capacity
• Automated lines for producing BPC chambers
• Strong engineering support to design and maintain 
products and processes
BPC manufacturing process
Chamber manufacture—the main components of a 
BPC chamber are the ports that enable tubing to be 
attached to the chamber. There are a number of different 
port designs depending on the type of chamber. 
All BPC chambers and related components are produced 
in an ISO 7–certifi ed cleanroom at our manufacturing 
facilities. Additional components are then attached to the 
BPC chamber to produce a complete BPC. BPC assembly 
is a manual process, which provides the required fl exibility 
in BPC confi guration. Thermo Scientifi c™ fl uid transfer 
assemblies are also produced to complement BPC 
systems. Final assembly is done under the same controlled 
environment and to the same level of quality.
Each lot of BPCs is 100% visually inspected against 
product specifi cations, and packaged and sealed in two 
independent outer layers while still in the ISO 7–certifi ed 
area. They are then placed in cardboard cartons labeled 
with product and lot identifi cation.
Main types of BPC chambers
The 3 main types of BPCs are highlighted below, which are Thermo Scientifi c™
2D Labtainer™ and 3D Productainer™ BPCs, and tank liners. Specialty BPCs are 
also available for specifi c applications and use in bioprocess equipment.
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BPC fi lms
Films engineered for the most 
demanding applications
The Thermo Scientifi c™ fi lms are engineered to meet the 
most demanding requirements of your bioproduction 
processes. Choose between: 
• Aegis™ 5-14 fi lm—for high-value applications
• CX5-14 fi lm—one of the most widely used fi lms 
in the industry, proven over 10 years
• ASI™ 26/77 fi lm—a two-layered fi lm, for 
high-value applications
• ASI™ 28 fi lm—a robust, four-layer fi lm with excellent 
oxygen- and moisture-barrier properties
• CX3-9 fi lm—a three-layered fi lm with a polyester 
elastomer coextruded outer layer with a low-density 
polyethylene product contact layer
• ASI™ 26 fi lm—a single-web fi lm with good toughness 
and puncture resistance
• ASI™ 77 fi lm—a single-web fi lm constructed from nylon 
with an ethylene vinyl alcohol EVOH barrier layer and a 
linear low-density polyethylene (LLDPE) layer
Film formulations 
• Aegis5-14 and CX5-14 fi lms are fi ve-layer fi lms produced 
in a cGMP facility—the outer layer is a polyester lastomer 
coextruded with an EVOH barrier layer and a low-density 
polyethylene product contact layer
• The ASI 26/77 polyethylene (PE) single-use bag systems 
are produced in a cGMP facility, utilizing two webs: a fl uid 
contact fi lm and a durable, coextruded outer-layer fi lm
• The ASI 28 fi lm is an ethylene vinyl acetate (EVA) 
coextruded fi lm produced in a cGMP facility—this fi lm 
provides an excellent, highly durable moisture and 
oxygen barrier
• The CX3-9 fi lm is a three-layer, 9 mil cast fi lm, which is 
used primarily for open-top tank liners
• The ASI 26 fi lm is a single-web, 5 mil cast fi lm, which is 
also used primarily for open-top tank liners
• The ASI 77 fi lm is a single-web, 7 mil cast fi lm, which 
is used primarily for the Thermo Scientifi c™ Three60™ 
Sampling System
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2D Labtainer BPC systems
Key features
• 2D Labtainer systems are 2-panel, pillow-style BPCs
• Chambers are constructed from CX5-14, Aegis5-14, 
ASI 26/77, and ASI 28 fi lms
• Labtainer BPC systems have 2–3 edge ports along 
one end with a handle on the opposing end
• 2-port Labtainer BPCs are available in sizes from 
50 mL to 2,000 mL
• 3-port Labtainer BPCs are available in sizes from 
2 to 50 L
• Line sets can be customized for easy integration with 
existing process operations and equipment
• Labtainers can be customized into multi-container 
manifold confi gurations
• Labtainers can be added as sample container adjuncts 
to 2D or 3D BPCs
Applications
• Harvest from bioreactors or fermentors
• Feed into bioreactors or fermentors
• Sample collection from bioreactors or fermentors
• Buffer preparation and storage
• Culture media preparation and storage
• Process liquid preparation and storage
• Chromatography feed and fraction collection
• Harvest, storage, and transport of bulk drug product 
and bulk drug precursors
3D Productainer BPC systems
Key features
• Use this system to eliminate post-use cleaning steps 
required with reusable containers, and to reduce 
cross-contamination risks
• All 3D BPCs are constructed in an ISO 7–certifi ed 
cleanroom under cGMP conditions
• All 3D BPCs are designed to fi t the full range of 
support containers, both square and cylindrical, 
from 50 to 3,000 L
Applications
• Hydration and fi ltration of process buffers, liquids, 
and culture media
• Chromatography feed and fraction collection
• Storage and transport of bulk drug product and bulk 
drug precursors
• Harvest from and feed into bioreactors and fermentors
• Dispensing, packaging, and storage of cell culture media, 
buffers, and process liquids
Customize catalog BPC systems for optimized 
single-use technology
Choose from the industry’s largest component library—
with over 2,000 unique components that include:
• Fittings—straight, reducing, elbow, T-style, X-style, 
and cross-style
• Connectors—quick connectors and disconnectors, 
aseptic connectors and disconnectors, steam-to and 
steam-through connectors
• Filters—used for bioburden reduction; sterilization-grade 
fi lters and vent fi lters are available
• Tubing—thermoplastic elastomers, platinum-
cured silicone
• Sample ports—septum-style and needle-free ports
• Clamps—sliders, pinch, and crimp bands
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Tank liner BPC systems
Key features
• Tank liners are designed for use with commercially 
available overhead mixers (not supplied)
• Removes the need for tank cleaning and helps reduce 
cycle times.
• Chambers are constructed from CX3-9 and ASI 26 fi lms 
(and Aegis5-14 fi lm for bottom-drain) with dimensions 
optimized for Thermo Scientifi c™ catalog drums and 
commonly used industry-standard cylindrical tanks
• Top entry for catalog products for maximum recovery 
using industry-standard cylindrical tanks in unit volumes 
of 50, 100, 200, 300, and 500 L
• Supplied gamma-irradiated to minimize bioburden
Associated applications
• Hydration of powdered media and buffers 
• Pooling of nonsterile solutions and fl uids  
Powdertainer BPC system
Handle
For support 
during emptying
Clamp
To retain powder 
prior to emptying
Tube with quick connector
For washdown to remove any 
powder residue
Three-inch tri-clamp 
connector
For secure connection to 
formulation vessel
Applications
• Storage and delivery of Thermo Scientifi c™ powder culture 
media and buffers
• Storage and dispensing of preweighed chemicals or other 
process powders
Thermo Scientifi c™ Powdertainer™ BPCs are specifi cally 
designed for powder containment and discharge 
applications, and maintain a closed system for 
maximum recovery of powder while minimizing the 
risk of cross-contamination.   
Key features
• Designed for powder containment and powder 
hydration applications 
• Employ a closed system to help minimize dust 
contaminant and cross-contamination risk
• Three-inch tri-clamp port designed for secure connection 
to, and easy integration with, hydration vessels  
• Suspensor handle for support during discharge and neck 
clamp to retain powder prior to discharge  
• Two models, including one with a washdown line to 
remove residual powder, enabling maximal recovery  
• Three sizes for process fl exibility: 1, 5, and 25 kg
• Constructed from CX3-9 fi lm
• Stainless steel fi lling stand to facilitate the powder 
discharge process
Harvestainer Microcarrier Separation BPC system
The Thermo Scientifi c™ Harvestainer™ BioProcess 
Container (BPC) system is a closed, single-use 
microcarrier separation system that helps to increase 
product yields compared to traditional methods, while 
reducing clean-in-place (CIP) and steam-in-place 
(SIP) requirements.
Unique design features
The Harvestainer system enables separation of 
microcarrier beads and harvesting of the cell culture 
supernatant in a single-step, closed system.
The Harvestainer system is designed for both small- and 
large-scale applications. When 12 L or less of microcarrier 
beads are required to be separated, the 3 L or 12 L 
Harvestainer system is ideal. These systems are designed 
around our 2D pillow-style BPC in a preassembled 
tray, designed for secondary containment and optimal 
supernatant recovery.
The large-scale Harvestainer system features a 
dual-chamber system that comprises a 200 L 3D BPC 
with either one or two interior 25 L microbarrier 2D BPCs. 
These unique design features help enable the separation 
of cell culture supernatant from the microcarrier beads.
Three60 Single-Use Sampling System
The simple design behind the Three60 Sampling System 
allows you to take a representative sample of your product 
with minimal effort. For a small-volume liquid transfer, use a 
CIP or SIP process to prepare your tank. The pre-irradiated 
BPCs and assemblies help ensure an integral fl uid path 
while the quick-turn valve and pinch-and-cut disconnectors 
maintain liquid transfer and removal from BPCs.
The Three60 system is compatible with your vessel 
through a sanitary connector; no expensive hardware is 
needed. Each Three60 package contains a valve and four 
assemblies with pinch-and-cut disconnectors.
Kit to tank
The Three60 system is pre-irradiated and assembled into a 
one-piece kit. Simply remove the device from the kit 
and apply to the vessel.
• Quick-turn Three60 valve—the face of the Three60 valve 
can be sterilized with the tank through traditional CIP/SIP 
processes. The valve has four assemblies. This helps keep 
the product and technician contamination-free.
• Pinch-and-cut disconnectors—the pinch-and-cut 
disconnectors allow the technician to quickly separate the 
sample and eliminate the need for tools or tube sealing.
• Injection ports—Luer lock injection site; extract through 
either the septum or twist-off Luer lock to pour.
• Pre-irradiated BPC assemblies—the Three60 system 
is provided with pre-irradiated BPC assemblies in sizes 
ranging from 50 mL to 2 L produced using the ASI 77 fi lm.
 Services and support
Thermo Scientifi c™ Bioproduction services involve both fi eld- 
and offi ce-based teams. The offi ce-based team is located in 
Logan, Utah, and includes technical support, BioProduction 
Xpress (BPX), quality, and services management teams. On 
a global scale, there are fi eld application specialists (FAS) 
who are trained on hardware installation, servicing, and also 
offer other post-sales support such as training, consulting, 
and process optimization assistance.
Key services
• Field support
 – Hardware installation—factory acceptance test (FAT) 
and site acceptance test (SAT)
 – Training—single-use bioreactors, mixers, fermentors, 
outer support containers, and BPCs
 – Validation service—installation qualifi cation (IQ), 
operation qualifi cation (OQ), and performance 
qualifi cation (PQ)
 – Warranty
 – Service contracts
• BioProduction Xpress
 – R&D scientists and engineers specializing in single-use 
bioreactor (S.U.B.), single-use mixer (S.U.M.), single-use 
fermentor (S.U.F.) processes
 – Scale-up studies
 – Customer-specifi c application studies
 – Quality testing
 – Non-GMP quick-response studies or tests
• Technical support
 – Phone support for sales, service, technical 
questions, and troubleshooting
 – Interfaces with quality, product management, 
and R&D teams
Find out more at thermofi sher.com/bpc
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals. 
© 2017 Thermo Fisher Scientifi c Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientifi c and its subsidiaries 
unless otherwise specifi ed. COL03900 0417
Integrated solutions for bioproduction
Integrity testing systems
A true point-of-use integrity testing system 
to confi rm the integrity of BPCs before use
Liquid- and dry-format media
We offer both custom manufacturing 
and a full range of chemically 
defi ned performance media 
and supplement products
Sera
Our sera are well 
known for consistent 
quality and reliability
Single-Use Mixers (S.U.M.s)
A variety of options up to 
5,000 L for both upstream
and downstream applications
Buffers and process liquids
Custom and standard buffers, and 
process liquids, including Gibco™ 
Water for Injection (WFI) 
BioProcess Containers (BPCs)
A variety of confi gurations up
to 2,000 L for liquid harvest,
storage, and transportation
Single-Use 
Bioreactors (S.U.B.s)
50–2,000 L bioreactors
capable of integrating with an 
existing control system
Product name Anti-Blood Group A Antigen antibody [9A]
Description Mouse monoclonal [9A] to Blood Group A Antigen
Host species Mouse
Specificity ab20131 cross reacts with EGF receptor in A431 cells only due to glycosylation defects in these
cells which reveals otherwise cryptic sugar structures.
Tested applications Suitable for: ELISA, IP
Species reactivity Reacts with: Human
Immunogen Cell preparation: A431 cells (human vulval squamous carcinoma cell line).
Form Liquid
Storage instructions Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze /
thaw cycle.
Storage buffer Preservative: None
Constituents: PBS
Clonality Monoclonal
Clone number 9A
Myeloma P3-x63-Ag8
Isotype IgG3
Light chain type unknown
Product datasheet
Anti-Blood Group A Antigen antibody [9A] ab20131
2 References
Overview
Properties
Applications
Our Abpromise guarantee covers the use of ab20131 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application Abreviews Notes
ELISA Use at an assay dependent dilution.
1
Relevance Blood-group antigens are generally defined as molecules formed by sequential addition of
saccharides to the carbohydrate side chains of lipids and proteins detected on erythrocytes and
certain epithelial cells. The A, B and H antigens are reported to undergo modulation during
malignant cellular transformation. Blood group related antigens represent a group of
carbohydrate determinants carried on both glycolipids and glycoproteins. They are usually
mucin-type, and are detected on erythrocytes, certain epithelial cells, and in secretions of certain
individuals. Sixteen genetically and biosynthetically distinct but inter-related specificities belong
to this group of antigens, including A, B, H, Lewis A, Lewis B, Lewis X, Lewis Y, and precursor
type 1 chain antigens.
Cellular localization Cell Membrane
IP Use at an assay dependent dilution.
Application Abreviews Notes
Target
Please note:  All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Our Abpromise to you: Quality guaranteed and expert technical support
Replacement or refund for products not performing as stated on the datasheet
Valid for 12 months from date of delivery
Response to your inquiry within 24 hours
We provide support in Chinese, English, French, German, Japanese and Spanish
Extensive multi-media technical resources to help you
We investigate all quality concerns to ensure our products perform to the highest standards
If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise,
please visit http://www.abcam.com/abpromise or contact our technical team.
Terms and conditions
Guarantee only valid for products bought direct from Abcam or one of our authorized distributors
2
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Safety Data Sheet
SECTION 1: Ident ificat ion of the substance/mixture and of the company/undertaking
Identification of the substance or mixture  
Product code 89964
Product name HisPur(tm) Cobalt Resin, 10 mL
Company/undertaking identification  
24 hour Emergency Response: 866-536-0631
301-431-8585
Outside of the U.S. +1-301-431-8585
Country specific Emergency Number (if available):
Use as laboratory reagent. Scientific research and development.
SECTION 2: Hazards ident ificat ion
GHS - Classification 
Signal Word
DANGER
Health hazards 
Carcinogenicity Category 1A
Reproductive Toxicity Category 1B
Life Technologies Corporation
5781 Van Allen Way
PO Box 6482
Carlsbad, CA 92008
+1 760 603 7200
Life Technologies
5250 Mainway Drive
Burlington, ONT
CANADA L7L 6A4
800/263-6236
Thermo Fisher Scientific
Pierce Biotechnology
P.O. Box 117
Rockford, IL 61105
United States
1.815.968.0747 or
1.800.874.3723
CHEMTREC Brazil (Rio De Janeiro) +(55)-2139581449 (português)
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Product code 89964 Product name  HisPur(tm) Cobalt Resin, 10 mL
www.thermofisher.com
Hazard Statements
H226 - Flammable liquid and vapor
H350 - May cause cancer
H360F - May damage fertility
H411 - Toxic to aquatic life with long lasting effects
Precautionary Statements
P370 + P378 - In case of fire, use water/water spray/water jet/carbon dioxide/sand/foam/alcohol resistant
foam/chemical powder for extinction
P303 + P361 + P353 - IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with
water/shower
P201 - Obtain special instructions before use
P273 - Avoid release to the environment
P210 - Keep away from heat/sparks/open flames/hot surfaces. - No smoking
P280 - Wear protective gloves/protective clothing/eye protection/face protection
Principle Routes of Exposure 
Potential Health Effects  
eyes May cause eye irritation with susceptible persons.
Skin May be harmful in contact with skin.
inhalation May cause irritation of respiratory tract.
Ingestion May be harmful if swallowed.
Specific effects 
Carcinogenic effects May cause cancer.
Mutagenic effects None.
Reproductive toxicity May cause harm to the unborn child.
Sensitization None.
Target Organ Effects None under normal use conditions.
HMIS 
SECTION 4: First  a id measures
Physical hazards 
GHS Physical Hazard 1 Flammable liquids
GHS Physical Hazard Category Number Category 3
Health 4 * Chronic Hazard
Flammability 3
Reactivity 0
SECTION 3: Composit ion/information on ingredients
Component CAS-No EINECS-No Weight %
Cobalt(II) chloride hexahydrate
 7791-13-1 ( 0.5-1 )
7791-13-1 - 0.5-1
We recommend handling all chemicals with caution.
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Skin contact Wash off immediately with plenty of water for at least 15 minutes. Take off all
contaminated clothing and wash it before reuse. Immediate medical attention is
required.
Eye contact Rinse immediately with plenty of water, also under the eyelids, for at least 15
minutes. Immediate medical attention is required.
Ingestion Call a physician or poison control center immediately. Never give anything by
mouth to an unconscious person. Do not induce vomiting without medical advice.
inhalation Remove to fresh air. If not breathing, give artificial respiration. Call a physician or
poison control center immediately.
Most important symptoms and effects, both acute and delayed
H226 - Flammable liquid and vapor, H350 - May cause cancer, H360F - May damage fertility, H411 - Toxic to aquatic
life with long lasting effects
Notes to Physician Treat symptomatically.
SECTION 5: Firefight ing measures
Suitable extinguishing media Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
Special protective equipment for firefighters Wear self-contained breathing apparatus and protective
suit.
Specific hazards arising from the chemical Not known
SECTION 6: Accidental re lease measures
Personal precautions Ensure adequate ventilation. Avoid contact with skin, eyes or clothing. Use
personal protection equipment.
Methods for cleaning up Soak up with inert absorbent material.
Environmental precautions 
Prevent further leakage or spillage if safe to do so. Prevent product from entering drains.
See Section 12 for more information.
SECTION 7: Handling and storage
Handling Always wear reccommended Personal Protective Equipment. No special handling
advices are necessary.
Storage Keep in a dry, cool and well-ventilated place. Keep in properly labeled containers.
SECTION 8: Exposure controls/personal protect ion
Exposure Limits  
Chemical Name OSHA PEL OSHA PEL (Ceiling) ACGIH OEL (TWA) ACGIH OEL (STEL)
Cobalt(II) chloride
hexahydrate
None None 0.02 mg/m3 None
Engineering measures Ensure adequate ventilation, especially in confined areas.
Personal Protective Equipment 
Personal Protective Equipment requirements are dependent on the user institution's risk assessment and are specific
to the risk assessment for each laboratory where this material may be used.
Respiratory protection In case of insufficient ventilation, wear suitable respiratory equipment.
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Hand protection Impervious gloves.
Eye protection Wear safety glasses with side shields (or goggles).
Skin and Body Protection Lightweight protective clothing.
Hygiene measures Handle in accordance with good industrial hygiene and safety practice.
Environmental exposure 
controls 
Prevent product from entering drains. Should not be released into the
environment.
SECTION 9: Physical and chemical propert ies
General information 
Form Liquid
Appearance No information available
Odor Mixture has not been tested
Odor Threshold Mixture has not been tested
Evaporation rate No data available
Flammability (solid, gas) No data available
Oxidizing properties Mixture has not been tested
Water solubility No data available
Upper explosion limit No data available
Lower explosion limit No data available
Partition coefficient:
n-octanol/water
No data available
Vapor Pressure No data available
vapor density No data available
Viscosity Mixture has not been tested
pH value No data available
SECTION 10: Stability and react ivity
Stability Stable under normal conditions.
Materials to avoid No information available.
Possibility of hazardous
reactions
Hazardous reaction has not been reported
Hazardous decomposition
products
No information available.
polymerization None under normal processing.
Conditions to avoid None under normal processing.
SECTION 11: Toxicological information
Acute Toxicity  
Boiling point / boiling range °C  No data available °F  No data available
Melting point / melting range °C  No data available °F  No data available
flash point °C  32.222 °F  89.996
Autoignition Temperature °C  No data available °F  No data available
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Chemical Name LD50 (oral,rat/mouse) LD50 (dermal,rat/rabbit) LC50 (inhalation,rat/mouse)
Cobalt(II) chloride hexahydrate = 766 mg/kg (Rat) = 80 mg/kg (Rat) No data available No data available
Principle Routes of Exposure 
Potential Health Effects 
eyes May cause eye irritation with susceptible persons.
Skin May be harmful in contact with skin.
inhalation May cause irritation of respiratory tract.
Ingestion May be harmful if swallowed.
Carcinogenic effects May cause cancer.
Mutagenic effects None.
Reproductive toxicity May cause harm to the unborn child.
Sensitization None.
Target Organ Effects None under normal use conditions
SECTION 12: Ecological information
Ecotoxicity Hazardous to the Aquatic Environment.
Chronic aquatic toxicity Category 2.
Mobility No information available.
Biodegradation No information available.
Bioaccumulation No information available.
SECTION 13: Disposal considerat ions
Dispose of contents/containers in accordance with local regulations.
SECTION 14: Transport  information
IATA 
Proper Shipping Name Flammable liquids, n.o.s. (ethanol, mixture)
Hazard Class 3
Subsidiary class None
Packing group III
UN-No UN1993
Environmental hazards No
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SECTION 16: Other information
Reason for revision SDS sections updated.
Use as laboratory reagent. Scientific research and development.
"The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be
used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS SDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR IMPLIED,
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PUPOSE"
End of Safety Data Sheet
SECTION 15: Regulatory information
Component US TSCA
Cobalt(II) chloride hexahydrate
 7791-13-1 ( 0.5-1 )
-
US Federal Regulations 
SARA 313
This product contains the following toxic chemical(s) subject to the notification requirements of section 313 of Title III of the
Superfund Amendments and Reauthorization Act of 1986. This law requires certain manufacturers to report on annual emissions of
specified chemicals and chemical categories. Please note that if you repackage, or otherwise redistribute, this product to industrial
customers, a notice similar to this one should be sent to those customers:.
Chemical Name CAS-No Weight % SARA 313 - Threshold Values 
Cobalt(II) chloride hexahydrate 7791-13-1 0.5-1 0.1
Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)
This product contains the following HAPs:.
Component CAS-No Weight % HAPS data 
Cobalt(II) chloride hexahydrate
 7791-13-1 ( 0.5-1 )
7791-13-1 0.5-1 Present (including any unique
chemical substance that contains
Cobalt as part of its infrastructure)
US State Regulations 
California Proposition 65
This product does not contain any Proposition 65 chemicals.
WHMIS Hazard Class
B3 - Combustible liquid
D2A - Very toxic materials
This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) and the
MSDS contains all the information required by the CPR.
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Number Description 
89964 HisPur Cobalt Resin, 10mL settled resin 
89965 HisPur Cobalt Resin, 100mL settled resin 
89966 HisPurCobalt Resin, 500mL settled resin 
 Binding Capacity: ≥ 10mg at > 90% purity of a 28kDa His-tagged protein from a bacterial source per 
milliliter of settled resin 
 Resin: Crosslinked 6% agarose in a 20% ethanol solution 
 
 Storage: Upon receipt store at 4°C. Product shipped at ambient temperature. 
 
Introduction 
The Thermo Scientific HisPur Cobalt Resin enables efficient purification of polyhistidine-tagged proteins from bacterial, 
mammalian and baculovirus-infected cells. His-tagged proteins are purified from total soluble protein extract using a cobalt-
charged tetradentate chelator immobilized onto 6% crosslinked agarose. The cobalt resin is compatible using native or 
denaturing conditions and can be used in multiple formats including conventional gravity flow chromatography, spin column 
and FPLC.  
Many immobilized metal affinity chromatography (IMAC) resins use nickel (Ni+2) as the metal source for purifying His-
tagged proteins. Although Ni+2 chelate resins achieve high protein yields, purity is often suboptimal, resulting in the need for 
additional optimization of wash and elution steps. Cobalt achieves both high protein yield and purity with minimal 
optimization. Furthermore, HisPur Cobalt Resin displays less metal leaching compared with Ni+2 resins. 
 
Important Product Information 
• Protein yield and purity are dependent upon the expression level, conformation and solubility characteristics of the 
recombinant fusion protein. Therefore, it is important to optimize these parameters before attempting a large-scale 
purification. For best results, perform a small-scale test to estimate the expression level and determine the solubility of 
each His-tagged protein. 
• Optimization of the lysis procedure is critical for maximizing protein yield. Some methods for protein extraction include 
using commercially available detergent-based reagents, such as Thermo Scientific B-PER Bacterial Protein Extraction 
Reagent (Product No. 78248), and mechanical methods, such as freeze/thaw cycles, sonication or French press.  
• Sometimes overexpressed proteins are sequestered in inclusion bodies. Inclusion bodies of His-tagged proteins can be 
solubilized in 8M urea, 6M guanidine or Inclusion Body Solubilization Reagent (Product No. 78115) and purified with 
the cobalt resin, but a denaturant must be added to buffers so the protein remains soluble throughout the procedure.  
• One advantage of using cobalt is its low nonspecific binding. Although the buffer conditions described in these 
instructions work well for many samples, optimization may be required to further reduce nonspecific binding. To 
optimize conditions, adjust the imidazole concentration in the Equilibration/Wash Buffer or decrease the buffer’s pH to 
protonate a greater proportion of histidine groups. 
• IMAC relies on cobalt chelation to both the tetradentate chelator and the target histidine tag. Avoid using protease 
inhibitors or other additives that contain chelators, such as EDTA, or strong reducing agents, such as DTT or 
β-mercaptoethanol, which will disrupt the function of the cobalt resin.  
1851.2 
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Additional Materials Required  
• MES Buffer: 20mM 2-(N-morpholine)-ethanesulfonic acid, 0.1M sodium chloride; pH 5.0 
For native conditions prepare the following buffers:  
• Equilibration/Wash Buffer: 50mM sodium phosphate, 300mM sodium chloride, 10mM imidazole; pH 7.4 
• Elution Buffer: 50mM sodium phosphate, 300mM sodium chloride, 150mM imidazole; pH 7.4 
 
For denaturing conditions prepare the following buffers:  
• Equilibration/Wash Buffer: 50mM sodium phosphate, 300mM sodium chloride, 6M guanidine•HCl, 10mM imidazole; 
pH 7.4 
• Elution Buffer: 50mM sodium phosphate, 300mM sodium chloride, 6M guanidine•HCl, 150mM imidazole; pH 7.4. 
 
Procedure for Purification of His-Tagged Proteins by Batch Method 
The HisPur Cobalt Resin allows customization of a purification strategy. Purification conditions detailed within these 
instructions can be scaled as desired. The procedure may be performed at room temperature or at 4°C.  
1. Add an appropriate amount of cobalt resin to a tube. Centrifuge tube for 2 minutes at 700 × g and carefully remove and 
discard the supernatant. 
2. Add two resin-bed volumes of Equilibration/Wash Buffer and mix until the resin is fully suspended. 
3. Centrifuge tube for 2 minutes at 700 × g and carefully remove and discard buffer. 
4. Prepare sample by mixing the protein extract with an equal volume of Equilibration/Wash Buffer. 
5. Add the prepared protein extract to the tube and mix on an end-over-end rotator for 30 minutes. 
6. Centrifuge the tube for 2 minutes at 700 × g. If desired, save supernatant for downstream analysis. 
7. Wash the resin with two resin-bed volumes of Equilibration/Wash Buffer. Centrifuge the tube for 2 minutes at 700 × g. If 
desired, save supernatant for downstream analysis. 
8. Repeat wash step and monitor supernatant by measuring its absorbance at 280nm until baseline is reached.  
9. Elute bound His-tagged proteins using one resin-bed volume of Elution Buffer. Centrifuge tube for 2 minutes at 700 × g. 
Carefully remove and save the supernatant. Repeat this step twice, saving each supernatant fraction in a separate tube. 
10. Monitor protein elution by measuring the absorbance of the fractions at 280nm or by Coomassie Plus (Bradford) Assay 
(Product No. 23236). The eluted protein can be directly analyzed by SDS-PAGE. To remove excess imidazole for 
downstream applications use gel filtration (e.g., Thermo Scientific Zeba Spin Desalting Columns) or dialysis (e.g., 
Thermo Scientific Slide-A-Lyzer Dialysis Cassettes). Samples containing 6M guanidine•HCl must be dialyzed against a 
buffer containing 8 M urea before SDS-PAGE analysis. The Thermo Scientific Pierce SDS-PAGE Sample Prep Kit 
(Product No. 89888) may also be used to remove guanidine.  
 
Procedure for Purification of His-tagged Proteins using a Gravity-flow Column 
The HisPur Cobalt Resin allows customization of a purification strategy. Purification conditions detailed within these 
instructions can be scaled as desired. Perform the procedure at room temperature or at 4°C. 
1. Pack column with an appropriate amount of cobalt resin. Allow storage buffer to drain from resin by gravity flow. 
2. Prepare sample by mixing the protein extract with an equal volume of Equilibration/Wash Buffer.  
3. Equilibrate column with two resin-bed volumes of Equilibration/Wash Buffer. Allow buffer to drain from resin, flow rate 
should be 0.5-1mL/minute.  
4. Add the prepared protein extract onto the resin. Collect the flow-through in a tube. If desired, re-apply the flow-through 
once to maximize binding. 
5. Wash resin with two resin-bed volumes of Equilibration/Wash Buffer and collect the flow-through. Repeat this step 
using a new collection tube until the absorbance of the flow-through fraction at 280nm approaches baseline. 
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6. Elute His-tagged proteins from the resin with two resin-bed volumes of Elution Buffer. Repeat this step twice, collecting 
each fraction in a separate tube. 
7. Monitor protein elution by measuring the absorbance of the fractions at 280nm or by Coomassie Plus (Bradford) Assay 
(Product No. 23236). The eluted protein can be directly analyzed by SDS-PAGE. To remove excess imidazole for 
downstream applications use gel filtration (e.g., Zeba™ Spin Desalting Columns) or dialysis (e.g., Slide-A-Lyzer® 
Dialysis Cassettes). Samples containing 6M guanidine•HCl must be dialyzed against buffer containing 8M urea before 
SDS-PAGE analysis. The Pierce® SDS-PAGE Sample Prep Kit (Product No. 89888) may also be used to remove 
guanidine.  
 
Procedure for Cobalt Resin Regeneration  
The cobalt resin may be used up to three times without affecting protein yield or purity. Between each use, perform the 
procedure as described below to remove residual imidazole and any nonspecifically adsorbed protein. To prevent cross-
contamination of samples, designate a given column to one specific fusion protein. 
1. Wash resin with 10 resin-bed volumes of 20mM MES Buffer , 0.1M sodium chloride; pH 5.0. 
2. Wash resin with 10 resin-bed volumes of ultrapure water. 
3. Store resin as a 50% slurry in 20% ethanol. 
 
Troubleshooting 
Problem Possible Cause Solution 
Low protein yield Poor expression of soluble 
protein  
Optimize bacterial expression conditions 
His-tagged protein forms 
inclusion bodies 
Alter bacterial growth conditions to minimize inclusion body 
formation and maximize soluble protein yield; alternatively, 
solubilize inclusion bodies and perform the purification with a 
compatible denaturant (e.g., Inclusion Body Solubilization 
Reagent, Product No. 78115) 
Insufficient cell lysis and 
extraction 
Optimize cell lysis protocol 
Fusion protein does not bind 
to the column 
Verify the sequence or perform an ELISA or Western blot using 
an antibody against the His tag to make sure the His-tag is 
present 
Poor protein purity Insufficient washing Wash resin additional times or modify imidazole concentration 
and pH of the Equilibration/Wash Buffer 
Slow column flow Column is overloaded Apply less protein extract onto the column and make sure the 
extract is not too viscous or highly particulate 
 
 
Additional Information 
Please visit the website for additional information including the following items: 
• Tech Tip #43: Protein stability and storage 
• Tech Tip #40: Convert between times gravity (× g) and centrifuge rotor speed (RPM) 
• Tech Tip #6: Extinction coefficients guide 
• Tech Tip #7: Remove air bubbles from columns to restore flow rate 
• Tech Tip #13: Pack beaded affinity resin into affinity columns 
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Related Thermo Scientific Products 
16100 Pierce Glutathione Agarose, 10mL 
88270 Pierce High Capacity Endotoxin Removal Resin, 10mL 
88282 Pierce LAL Chromogenic Endotoxin Quantitation Kit 
88221 HisPur Ni-NTA Resin, 10mL  
89967 HisPur Cobalt Spin Columns, 0.2mL, 25 each 
89968  HisPur Cobalt Spin Columns, 1.0mL, 5 each  
89969  HisPur Cobalt Spin Columns, 3.0mL, 5 each 
78248 B-PER® Bacterial Protein Extraction Reagent, 500mL 
78260 B-PER II Bacterial Protein Extraction Reagent, 250mL  
89802 I-PER® Insect Cell Protein Extraction Reagent, 250mL 
78410  Halt™ Protease Inhibitor Cocktail, EDTA-Free, 1mL  
78115 Inclusion Body Solubilization Reagent, 100mL 
89835  DNAse I, 5000 units 
23236 Coomassie Plus (Bradford) Assay 
89890  Zeba Spin Desalting Columns, 7K MWCO, 2mL, 25/pkg 
89892  Zeba Spin Desalting Columns, 7K MWCO, 5mL, 25/pkg 
89894  Zeba Spin Desalting Columns, 7K MWCO, 10mL, 25/pkg 
66385 Slide-A-Lyzer Dialysis Cassettes Kit, 10K MWCO, 0.1-0.5mL  
66382 Slide-A-Lyzer Dialysis Cassettes Kit, 10K MWCO, 0.5-3mL  
66807 Slide-A-Lyzer Dialysis Cassettes Kit, 10K MWCO, 3-12mL 
 
This product (“Product”) is warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, 
as set forth in the Product documentation, specifications and/or accompanying package inserts (“Documentation”) and to be free from defects in material and 
workmanship. Unless otherwise expressly authorized in writing, Products are supplied for research use only. No claim of suitability for use in applications 
regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the 
Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This 
warranty does not extend to anyone other than the original purchaser of the Product (“Buyer”). 
No other warranties, express or implied, are granted, including without limitation, implied warranties of merchantability, fitness for any particular 
purpose, or non infringement. Buyer’s exclusive remedy for non-conforming Products during the warranty period is limited to replacement of or 
refund for the non-conforming Product(s).  
There is no obligation to replace Products as the result of (i) accident, disaster or event of force majeure, (ii) misuse, fault or negligence of or by Buyer, (iii) 
use of the Products in a manner for which they were not designed, or (iv) improper storage and handling of the Products. 
 
Current product instructions are available at www.thermoscientific.com/pierce. For a faxed copy, call 800-874-3723 or contact your local distributor. 
© 2012 Thermo Fisher Scientific Inc. All rights reserved. Unless otherwise indicated, all trademarks are property of Thermo Fisher Scientific Inc. and its 
subsidiaries. Printed in the USA. 
INSTRUCTIONS 
 
 
 
 
 
 
 
 
 
 
 
 
   Pierce Biotechnology PO Box 117 (815) 968-0747 Thermofisher.com 
   3747 N. Meridian Road Rockford, lL 61105 USA (815) 968-7316 fax  
 
Number Description 
88270 Pierce High-Capacity Endotoxin Removal Resin, 10mL of settled resin supplied as 50% slurry in 
20% ethanol 
88271 Pierce High-Capacity Endotoxin Removal Resin, 100mL of settled resin supplied as 50% slurry in 
20% ethanol 
88272 Pierce High-Capacity Endotoxin Removal Resin, 250mL of settled resin supplied as 50% slurry in 
20% ethanol 
88273 Pierce High-Capacity Endotoxin Removal Spin Column, 0.25mL, 5 columns, each column contains 
25% slurry in 20% ethanol 
88274 Pierce High-Capacity Endotoxin Removal Spin Column, 0.50mL, 5 columns, each column contains 
25% slurry in 20% ethanol 
88275 Pierce High-Capacity Endotoxin Removal Spin Column, 0.50mL, 25 columns, each column 
contains 25% slurry in 20% ethanol 
88276 Pierce High-Capacity Endotoxin Removal Spin Column, 1.0mL, 5 columns, each column contains 
25% slurry in 20% ethanol 
88277 Pierce High-Capacity Endotoxin Removal Spin Column, 1.0mL, 25 columns, each column contains 
25% slurry in 20% ethanol 
 
 Storage: Upon receipt store at 4°C. Product shipped at ambient temperature.  
 
Introduction 
The Thermo Scientific™ Pierce™ High Capacity Endotoxin Removal Resin contains porous cellulose beads that have been 
surface modified with covalently attached, modified ε-poly-L-lysine. Modified polylysine has a high affinity for endotoxins 
with the affinity ligand eliminating toxicity associated with alternative technologies using polymixin B ligands and sodium 
deoxycholate buffers. The binding capacity of 2,000,000 Endotoxin Units (EU)/mL allows endotoxin levels to be reduced by 
99% in samples containing 10,000EU/mL; typical protein samples processed with the resin have a final endotoxin 
concentration below 5EU/mL. The resin is offered in a slurry format for custom packing of endotoxin removal columns for 
gravity flow or continuous flow (10-15 mL/hour) applications or a spin column format for the fast, single-use batch method. 
Removal of endotoxins from differing volumes of biological samples can be done in ≥ 1 hour (see Table 1). 
Endotoxins consist of lipopolysaccharides (LPS), which are biologically active, structural components of the outer cell 
membrane of all gram-negative bacteria. Small amounts of endotoxin in recombinant protein preparations can cause side 
effects, including endotoxin shock, tissue injury and death in host organisms; therefore, it is essential to remove endotoxins 
from drugs, injectables and other biological products. 
One milliliter of this resin can reduce the endotoxin concentration from a 1mL sample containing 10,000EU to < 5EU. 
MAN0016351 
Rev A.0 
Pub. Part No. 2162373.3  
Pierce High-Capacity Endotoxin 
Removal Resin 
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Procedure Summary 
 
 
Important Product Information 
• All materials (e.g., containers, buffers and pipette tips) must be endotoxin-free. Use endotoxin-free water to prepare 
buffers and other solutions. 
• Endotoxin binding to the resin occurs at pH 6-8; Equilibrate the resin with an endotoxin-free buffer at neutral pH that 
includes 10-50mM sodium phosphate buffer or Tris-HCl buffer containing 0.1-0.2M NaCl. Check the sample pH and 
adjust to pH 6-8 with 0.1M NaOH or 0.1M HCl.  
• The speed of sample application and wash depends on the sample endotoxin state. Free endotoxin can bind quickly to the 
resin, but protein-bound endotoxin may require longer incubation, slower flow rates and/or multiple recycling of the 
sample through the column. Tightly bound endotoxin may be incubated overnight at room temperature or 4°C in batch 
mode with gentle shaking. 
• Resins can be used a minimum of five times without loss of endotoxin-removal efficiency. 
• Sample volumes vary depending on the chosen pre-loaded column size (see Table 1). 
Table 1. Sample volumes for the Thermo 
Scientific Pierce High-Capacity Endotoxin 
Removal Columns. 
Column size (mL) Sample volume (mL) 
0.25 0.5-1.0 
0.50 1.0-4.0 
1.0 2.0-10.0 
 
Additional Materials Required  
• Endotoxin-free, ultrapure water 
• Endotoxin-free 15mL conical collection tubes (for 0.25mL and 0.5mL spin columns) 
• Endotoxin-free 50mL conical collection tubes (for 1.0mL spin columns) 
• Regeneration buffer: 0.2N NaOH for overnight incubation at room temperature OR 0.2N NaOH and 95% ethanol for       
1-2 hours of incubation at room temperature 
Note: Regenerate the column before the first use and after each subsequent use. 
• 2M NaCl solution: If possible, use ready-made endotoxin-free NaCl solution; alternatively, dissolve pure sodium 
chloride crystals in endotoxin-free water 
• Variable-speed centrifuge with rotor and carriers capable of handling 15mL and 50mL conical collection tubes  
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Endotoxin Removal Procedure using the Column Method 
• Regenerate the resin before the first use and after each subsequent use.  
• Equilibrate all solutions and the resin to room temperature before use. 
• Degas the resin slurry before applying to the column to prevent air bubbles from clogging the column and reducing flow. 
1. To degas the resin, place slurry in a suction filter flask and degas with gentle stirring. 
2. Pour the degassed resin slurry into an appropriately sized column and allow the resin to settle.  
3. Regenerate the resin by washing with five resin-bed volumes of 0.2N NaOH overnight at room temperature OR five 
resin-bed volumes of 0.2N NaOH in 95% ethanol for 1-2 hours at room temperature. 
4. Wash with five resin-bed volumes of 2M NaCl.  
5. Wash with five resin-bed volumes of endotoxin-free, ultrapure water. 
6. Equilibrate with five resin-bed volumes of endotoxin-free buffer. 
7. Apply sample to the column at a flow rate of 10-15mL/hr and collect the flow-through (see the Important Product 
Information Section). 
8. Elute the protein by adding endotoxin-free buffer and collecting fractions; one or two resin-bed volume elutions are 
sufficient.  
9. Determine the endotoxin concentration of the processed sample. Use caution to prevent sample contamination from 
dust or contaminated tubes subsequent to endotoxin removal. Store solutions frozen or assay them before use to 
ensure sterility. 
10. Regenerate the resin as described in Steps 3-5 and store the column in 20% ethanol at 2-8°C. 
 
Endotoxin Removal Procedure using the Batch Method with Spin Columns   
• Regenerate the resin before the first use and after each subsequent use. For regeneration and equilibration (steps 1-10), 
use regeneration buffer in 2mL volumes for the 0.25mL column, 3.5mL volumes for the 0.5mL column and 8mL 
volumes for the 1mL column. 
• Wear appropriate gloves while handling the spin columns. Use caution to prevent sample contamination during the 
endotoxin-removal procedure. 
1. Equilibrate the spin column to room temperature. 
2. Twist off the column’s bottom closure and loosen the top cap. Place the spin column into a collection tube. Centrifuge 
the column at 500 × g for 1 minute to remove the storage solution. Discard the storage solution. 
3. Remove the column cap and insert the bottom plug. To regenerate, add 0.2N NaOH, replace the cap, invert the column 
several times until the resin is suspended in the solution and incubate overnight at room temperature, OR add 0.2N 
NaOH in 95% ethanol, replace the cap, invert the column several times until the resin is suspended in the solution and 
incubate 1-2 hours at room temperature. 
4. Loosen the cap and remove the bottom plug. Place the column in a collection tube and centrifuge at 500 × g for 1 minute 
to remove the solution. Discard the solution. 
5. Remove the cap and insert the bottom plug. Add 2M NaCl, replace the cap and invert the column several times until the 
resin is suspended in the solution. 
6. Loosen the cap and remove the bottom plug. Place the column in a collection tube and centrifuge at 500 × g for 1 minute 
to remove the solution. Discard the solution. 
7. Remove the cap and insert the bottom plug. Add endotoxin-free, ultrapure water. Replace the cap and invert the column 
several times until the resin is suspended in the solution. 
8. Loosen the cap and remove the bottom plug. Place the column in a collection tube and centrifuge at 500 × g for 1 minute 
to remove the solution. Discard the solution. 
9. Remove the cap and insert the bottom plug. Add endotoxin-free buffer, replace the cap and invert the column several 
times until the resin is suspended in the solution. 
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10. Loosen the cap and remove the bottom plug. Place the column in a collection tube and centrifuge at 500 × g for 1 minute 
to remove the solution. Discard the solution. Repeat steps 9 and 10 two additional times. 
11. Remove the cap and insert the bottom plug. Add the sample to the resin, replace the cap and invert the column several 
times until the resin is suspended in the solution. 
12. Incubate the column with gentle end-over-end mixing at room temperature or 4°C for 1 hour. Incubation time can be 
extended depending on the sample type and requirements (see the Important Product Information Section). 
13. Loosen the cap and remove the bottom plug. Place column in a collection tube and centrifuge at 500 × g for 1 minute to 
collect the sample. 
14. Determine the endotoxin concentration of the processed sample. Use caution to prevent sample contamination after 
endotoxin removal. Store solutions at -20°C or assay before use to ensure sterility. 
15. Regenerate the resin as described in step 3 and store the column in 20% ethanol at 2-8°C. 
 
Troubleshooting 
Problem Possible Cause Solution 
Low endotoxin 
removal efficiency 
Sample pH was not within a neutral range Adjust sample to pH 6-8 
Incubation time was not sufficient Increase the incubation time for the 
batch method  
Endotoxin was bound to the target protein Recycle the sample through the column 
several times 
The removal or detection system was contaminated by 
extrinsic LPS 
Use endotoxin-free labware and buffers 
Low protein/sample 
recovery  
Target protein aggregated with endotoxin and was 
removed 
Increase NaCl concentration in the 
sample and equilibration buffer to 0.4M 
Nonspecific binding of sample to the resin 
 
Related Thermo Scientific Products 
88282 Pierce LAL Chromogenic Endotoxin Quantitation Kit 
89896, 7, 8 Pierce Centrifuge Columns, (2mL, 5mL and 10mL, respectively), 25/pkg 
23225 Pierce BCA Protein Assay Kit 
22660 Pierce 660nm Protein Assay 
 
Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in 
the Product documentation, specifications and/or accompanying package inserts (“Documentation”). No claim of suitability for use in applications regulated 
by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this 
warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to 
anyone other than Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that 
any Product will conform to such model or sample. 
NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE GRANTED, INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF 
MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER’S EXCLUSIVE REMEDY FOR NON-
CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-
CONFORMING PRODUCT(S) AT SELLER’S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS 
AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, FAULT OR NEGLIGENCE OF OR BY BUYER, 
(III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF 
THE PRODUCTS. 
Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to 
be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses, or 
any type of consumption by or application to humans or animals. 
Current product instructions are available at thermofisher.com. For a faxed copy, call 800-874-3723 or contact your local distributor. 
© 2016 Thermo Fisher Scientific Inc. All rights reserved. Unless otherwise indicated, all trademarks are property of Thermo Fisher Scientific Inc. and its 
subsidiaries. Printed in the USA. 
Endotoxin Removal Resin
Endotoxin Removal Resin, High Capacity; Endotoxin Removal Resin, Ultra Capacity;
Pierce High Capacity Endotoxin Removal Resin
Liquid.
CHEMTREC: 800.424.9300
Outside US: 703.527.3887
SAFETY DATA SHEET
GHS product identifier
Other means of identification
Product type
Emergency telephone 
number (with hours of 
operation)
Section 1. Identification
:
:
:
Supplier's details : Thermo Fisher Scientific 
Pierce Biotechnology
P.O. Box 117
Rockford, IL 61105
United States
815.968.0747 or
800.874.3723
7 AM - 5 PM Central Time (GMT -06:00)
Endotoxin Removal Resin
Relevant identified uses of the substance or mixture and uses advised against
Not applicable.
Product code
SDS #
CAS #
Chemical formula
:
:
:
:
:
0088270 0088271 0088272 0088273 0088274 0088275 0088276 0088277 1862581 
1862582 1896231 1896254
8743
Not applicable.
Not applicable.
Section 2. Hazards identification
FLAMMABLE LIQUIDS - Category 4
SKIN CORROSION/IRRITATION - Category 2
SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2A
CARCINOGENICITY - Category 2
TOXIC TO REPRODUCTION (Fertility) - Category 1A
TOXIC TO REPRODUCTION (Unborn child) - Category 1B
Classification of the 
substance or mixture
:
Signal word : Danger
Hazard statements : Combustible liquid.
Causes serious eye irritation.
Causes skin irritation.
May damage fertility or the unborn child.
Suspected of causing cancer.
Hazard pictograms :
Precautionary statements
Prevention : Obtain special instructions before use.  Do not handle until all safety precautions have 
been read and understood.  Use personal protective equipment as required.  Wear 
protective gloves.  Wear eye or face protection.  Keep away from flames and hot 
surfaces. - No smoking.  Wash hands thoroughly after handling.
GHS label elements
OSHA/HCS status : This material is considered hazardous by the OSHA Hazard Communication Standard 
(29 CFR 1910.1200).
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Section 2. Hazards identification
Response : IF exposed or concerned:  Get medical attention.  IF ON SKIN:  Wash with plenty of soap 
and water.  Take off contaminated clothing.  Wash contaminated clothing before reuse.
If skin irritation occurs:  Get medical attention.  IF IN EYES:  Rinse cautiously with water 
for several minutes.  Remove contact lenses, if present and easy to do. Continue rinsing.
If eye irritation persists:  Get medical attention.
Storage : Store locked up.  Store in a well-ventilated place.  Keep cool.
Disposal : Dispose of contents and container in accordance with all local, regional, national and 
international regulations.
Hazards not otherwise 
classified
: None known.
Section 3. Composition/information on ingredients
ethanol 10 - 20 64-17-5
Ingredient name CAS number%
There are no additional ingredients present which, within the current knowledge of the supplier and in the 
concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in 
this section.
Other means of 
identification
: Endotoxin Removal Resin, High Capacity; Endotoxin Removal Resin, Ultra Capacity;
Pierce High Capacity Endotoxin Removal Resin
CAS number : Not applicable.
Substance/mixture
CAS number/other identifiers
:
Occupational exposure limits, if available, are listed in Section 8.
Mixture
Any concentration shown as a range is to protect confidentiality or is due to batch variation.
Wash out mouth with water.  Remove dentures if any.  Remove victim to fresh air and 
keep at rest in a position comfortable for breathing.  If material has been swallowed and 
the exposed person is conscious, give small quantities of water to drink.  Stop if the 
exposed person feels sick as vomiting may be dangerous.  Do not induce vomiting 
unless directed to do so by medical personnel.  If vomiting occurs, the head should be 
kept low so that vomit does not enter the lungs.  Get medical attention.  Never give 
anything by mouth to an unconscious person.  If unconscious, place in recovery position 
and get medical attention immediately.  Maintain an open airway.  Loosen tight clothing 
such as a collar, tie, belt or waistband.
Immediately flush eyes with plenty of water, occasionally lifting the upper and lower 
eyelids.  Check for and remove any contact lenses.  Continue to rinse for at least 10 
minutes.  Get medical attention.
Flush contaminated skin with plenty of water.  Remove contaminated clothing and shoes.
Wash contaminated clothing thoroughly with water before removing it, or wear gloves.
Continue to rinse for at least 10 minutes.  Get medical attention.  Wash clothing before 
reuse.  Clean shoes thoroughly before reuse.
Remove victim to fresh air and keep at rest in a position comfortable for breathing.  If not 
breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial 
respiration or oxygen by trained personnel.  It may be dangerous to the person providing 
aid to give mouth-to-mouth resuscitation.  Get medical attention.  If unconscious, place in 
recovery position and get medical attention immediately.  Maintain an open airway.
Loosen tight clothing such as a collar, tie, belt or waistband.
Section 4. First aid measures
Eye contact
Skin contact
Inhalation
Ingestion :
:
:
:
Description of necessary first aid measures
Most important symptoms/effects, acute and delayed
Inhalation : No known significant effects or critical hazards.
Causes serious eye irritation.:Eye contact
Potential acute health effects
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Section 4. First aid measures
Protection of first-aiders : No action shall be taken involving any personal risk or without suitable training.  If it is 
suspected that fumes are still present, the rescuer should wear an appropriate mask or 
self-contained breathing apparatus.  It may be dangerous to the person providing aid to 
give mouth-to-mouth resuscitation.  Wash contaminated clothing thoroughly with water 
before removing it, or wear gloves.
Notes to physician : Treat symptomatically.  Contact poison treatment specialist immediately if large 
quantities have been ingested or inhaled.
Specific treatments : No specific treatment.
Irritating to mouth, throat and stomach.:Ingestion
Skin contact : Causes skin irritation.
Over-exposure signs/symptoms
Skin contact
Ingestion
Inhalation Adverse symptoms may include the following:
reduced fetal weight
increase in fetal deaths
skeletal malformations
Adverse symptoms may include the following:
reduced fetal weight
increase in fetal deaths
skeletal malformations
Adverse symptoms may include the following:
irritation
redness
reduced fetal weight
increase in fetal deaths
skeletal malformations
:
:
:
Eye contact : Adverse symptoms may include the following:
pain or irritation
watering
redness
See toxicological information (Section 11)
Indication of immediate medical attention and special treatment needed, if necessary
Section 5. Fire-fighting measures
Promptly isolate the scene by removing all persons from the vicinity of the incident if 
there is a fire.  No action shall be taken involving any personal risk or without suitable 
training.  Move containers from fire area if this can be done without risk.  Use water spray 
to keep fire-exposed containers cool.
Hazardous thermal 
decomposition products
Specific hazards arising 
from the chemical
Decomposition products may include the following materials:
carbon dioxide
carbon monoxide
Combustible liquid.  In a fire or if heated, a pressure increase will occur and the container 
may burst, with the risk of a subsequent explosion.  Runoff to sewer may create fire or 
explosion hazard.
Fire-fighters should wear appropriate protective equipment and self-contained breathing 
apparatus (SCBA) with a full face-piece operated in positive pressure mode.
Special protective 
equipment for fire-fighters
Use dry chemical, CO₂, water spray (fog) or foam.
Extinguishing media
:
:
:
Do not use water jet.
Suitable extinguishing 
media
:
Unsuitable extinguishing 
media
:
Special protective actions 
for fire-fighters
:
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Section 6. Accidental release measures
Environmental precautions
Personal precautions, protective equipment and emergency procedures
Stop leak if without risk.  Move containers from spill area.  Use spark-proof tools and 
explosion-proof equipment.  Approach release from upwind.  Prevent entry into sewers,
water courses, basements or confined areas.  Wash spillages into an effluent treatment 
plant or proceed as follows.  Contain and collect spillage with non-combustible,
absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in 
container for disposal according to local regulations (see Section 13).  Dispose of via a 
licensed waste disposal contractor.  Contaminated absorbent material may pose the 
same hazard as the spilled product.  Note: see Section 1 for emergency contact 
information and Section 13 for waste disposal.
:
: No action shall be taken involving any personal risk or without suitable training.
Evacuate surrounding areas.  Keep unnecessary and unprotected personnel from 
entering.  Do not touch or walk through spilled material.  Shut off all ignition sources.  No 
flares, smoking or flames in hazard area.  Avoid breathing vapor or mist.  Provide 
adequate ventilation.  Wear appropriate respirator when ventilation is inadequate.  Put on 
appropriate personal protective equipment.
Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and 
sewers.  Inform the relevant authorities if the product has caused environmental pollution 
(sewers, waterways, soil or air).
Large spill :
Stop leak if without risk.  Move containers from spill area.  Use spark-proof tools and 
explosion-proof equipment.  Dilute with water and mop up if water-soluble.  Alternatively,
or if water-insoluble, absorb with an inert dry material and place in an appropriate waste 
disposal container.  Dispose of via a licensed waste disposal contractor.
Small spill :
Methods and materials for containment and cleaning up
For non-emergency 
personnel
For emergency responders : If specialised clothing is required to deal with the spillage, take note of any information in 
Section 8 on suitable and unsuitable materials.  See also the information in "For non-
emergency personnel".
Section 7. Handling and storage
Advice on general 
occupational hygiene
Conditions for safe storage,
including any 
incompatibilities
Eating, drinking and smoking should be prohibited in areas where this material is handled,
stored and processed.  Workers should wash hands and face before eating, drinking and 
smoking.  Remove contaminated clothing and protective equipment before entering 
eating areas.  See also Section 8 for additional information on hygiene measures.
Store in accordance with local regulations.  Store in a segregated and approved area.
Store in original container protected from direct sunlight in a dry, cool and well-ventilated 
area, away from incompatible materials (see Section 10) and food and drink.  Store 
locked up.  Eliminate all ignition sources.  Separate from oxidizing materials.  Keep 
container tightly closed and sealed until ready for use.  Containers that have been 
opened must be carefully resealed and kept upright to prevent leakage.  Do not store in 
unlabeled containers.  Use appropriate containment to avoid environmental 
contamination.
:
:
Protective measures Put on appropriate personal protective equipment (see Section 8).  Avoid exposure -
obtain special instructions before use.  Avoid exposure during pregnancy.  Do not handle 
until all safety precautions have been read and understood.  Do not get in eyes or on skin 
or clothing.  Do not ingest.  Avoid breathing vapor or mist.  Use only with adequate 
ventilation.  Wear appropriate respirator when ventilation is inadequate.  Do not enter 
storage areas and confined spaces unless adequately ventilated.  Keep in the original 
container or an approved alternative made from a compatible material, kept tightly closed 
when not in use.  Store and use away from heat, sparks, open flame or any other ignition 
source.  Use explosion-proof electrical (ventilating, lighting and material handling)
equipment.  Use only non-sparking tools.  Empty containers retain product residue and 
can be hazardous.  Do not reuse container.
:
Precautions for safe handling
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ethanol ACGIH TLV (United States, 2000).
  TWA: 1880 mg/m³ 8 hours.
OSHA (United States, 0/1989).
  CEIL: 7600 ppm
  TWA: 1000 ppm
  TWA: 1900 mg/m³
MSHA (United States).
  TWA: 1900 mg/m³
NIOSH (United States, 0/1994).
  TWA: 1000 ppm
  TWA: 1900 mg/m³
ACGIH (United States, 0/1996).
  TWA: 1880 mg/m³
ACGIH (United States).
  TWA: 1000 ppm
ACGIH TLV (United States, 6/2013).
  STEL: 1000 ppm 15 minutes.
NIOSH REL (United States, 4/2013).
  TWA: 1900 mg/m³ 10 hours.
  TWA: 1000 ppm 10 hours.
OSHA PEL (United States, 2/2013).
  TWA: 1900 mg/m³ 8 hours.
  TWA: 1000 ppm 8 hours.
OSHA PEL 1989 (United States, 3/1989).
  TWA: 1900 mg/m³ 8 hours.
  TWA: 1000 ppm 8 hours.
Section 8. Exposure controls/personal protection
Ingredient name Exposure limits
Hand protection Chemical-resistant, impervious gloves complying with an approved standard should be 
worn at all times when handling chemical products if a risk assessment indicates this is 
necessary.  Considering the parameters specified by the glove manufacturer, check 
during use that the gloves are still retaining their protective properties.  It should be noted 
that the time to breakthrough for any glove material may be different for different glove 
manufacturers.  In the case of mixtures, consisting of several substances, the protection 
time of the gloves cannot be accurately estimated.
Safety eyewear complying with an approved standard should be used when a risk 
assessment indicates this is necessary to avoid exposure to liquid splashes, mists,
gases or dusts.  If contact is possible, the following protection should be worn, unless the 
assessment indicates a higher degree of protection:  chemical splash goggles.
Eye/face protection
:
:
Environmental exposure 
controls
: Emissions from ventilation or work process equipment should be checked to ensure they 
comply with the requirements of environmental protection legislation.  In some cases,
fume scrubbers, filters or engineering modifications to the process equipment will be 
necessary to reduce emissions to acceptable levels.
Appropriate engineering 
controls
: Use only with adequate ventilation.  Use process enclosures, local exhaust ventilation or 
other engineering controls to keep worker exposure to airborne contaminants below any 
recommended or statutory limits.  The engineering controls also need to keep gas, vapor 
or dust concentrations below any lower explosive limits.  Use explosion-proof ventilation 
equipment.
Wash hands, forearms and face thoroughly after handling chemical products, before 
eating, smoking and using the lavatory and at the end of the working period.  Appropriate 
techniques should be used to remove potentially contaminated clothing.  Wash 
contaminated clothing before reusing.  Ensure that eyewash stations and safety showers 
are close to the workstation location.
Hygiene measures :
Control parameters
Individual protection measures
Occupational exposure limits
Skin protection
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Section 8. Exposure controls/personal protection
Use a properly fitted, air-purifying or air-fed respirator complying with an approved 
standard if a risk assessment indicates this is necessary.  Respirator selection must be 
based on known or anticipated exposure levels, the hazards of the product and the safe 
working limits of the selected respirator.
Respiratory protection :
Body protection Personal protective equipment for the body should be selected based on the task being 
performed and the risks involved and should be approved by a specialist before handling 
this product.
:
Other skin protection : Appropriate footwear and any additional skin protection measures should be selected 
based on the task being performed and the risks involved and should be approved by a 
specialist before handling this product.
Section 9. Physical and chemical properties
Physical state
Melting point
Vapor pressure
Relative density
Vapor density
Solubility
Liquid. [Slurry]
Not available.
Not available.
Not available.
Not available.
Insoluble in the following materials: cold water.
Not available.Odor
pH
White-grayishColor
Evaporation rate Not available.
Auto-ignition temperature
Flash point
Not available.
Closed cup: 76.667°C (170°F)
Not available.
Not available.
Viscosity Not available.
Not available.Odor threshold
Partition coefficient: n-
octanol/water
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
Appearance
Boiling point : Not available.
Flammability (solid, gas) : Not available.
Lower and upper explosive 
(flammable) limits
: Not available.
Burning rate Not applicable.:
Burning time : Not applicable.
SADT Not available.:
Decomposition temperature : Not available.
Solubility in water : Not available.
Section 10. Stability and reactivity
Conditions to avoid Avoid all possible sources of ignition (spark or flame).  Do not pressurize, cut, weld,
braze, solder, drill, grind or expose containers to heat or sources of ignition.
The product is stable.Chemical stability
Reactive or incompatible with the following materials:
oxidizing materials
:
:
Incompatible materials :
Possibility of hazardous 
reactions
: Under normal conditions of storage and use, hazardous reactions will not occur.
Reactivity : No specific test data related to reactivity available for this product or its ingredients.
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Section 10. Stability and reactivity
Hazardous decomposition 
products
Under normal conditions of storage and use, hazardous decomposition products should 
not be produced.
:
Section 11. Toxicological information
Acute toxicity
ethanol LC50 Inhalation Vapor Rat 124700 mg/m³ 4 hours
LD50 Oral Rat 7 g/kg -
Product/ingredient name Result Species Dose Exposure
Conclusion/Summary : To the best of our knowledge, the toxicological properties of this product have not been 
thoroughly investigated.
Mutagenicity
ethanol DNA Damage Subject: Bacteria Positive
DNA Damage Subject: Bacteria Positive
Mutation in 
Microorganisms
Subject: Bacteria Positive
Mutation in 
Microorganisms
Subject: Bacteria Positive
Gene Conversion and 
Mitotic Recombination
Subject: Bacteria Positive
Sex chromosome loss 
and nondisjunction.
Subject: Insect Positive
Cytogenetic Analysis Subject: Mammalian-Animal Positive
Cytogenetic Analysis Subject: Mammalian-Animal Positive
Cytogenetic Analysis Subject: Mammalian-Animal Positive
Cytogenetic Analysis Subject: Mammalian-Animal Positive
DNA Adduct Subject: Mammalian-Animal Positive
DNA Adduct Subject: Mammalian-Animal Positive
DNA Damage Subject: Mammalian-Animal Positive
Micronucleus Test Subject: Mammalian-Animal Positive
- Subject: Mammalian-Animal Positive
Other Mutation Test 
Systems
Subject: Mammalian-Animal Positive
Other Mutation Test 
Systems
Subject: Mammalian-Animal Positive
Sister Chromatid 
Exchange
Subject: Mammalian-Animal Positive
Specific Locus Test Subject: Mammalian-Animal Positive
Sperm Morphology Subject: Mammalian-Animal Positive
Cytogenetic Analysis Subject: Mammalian-Human Positive
Cytogenetic Analysis Subject: Mammalian-Human
Cell: Germ
Positive
Micronucleus Test Subject: Mammalian-Human Positive
Product/ingredient name Test Experiment Result
Irritation/Corrosion
ethanol Eyes - Mild irritant Rabbit - 24 hours 500 
milligrams
-
Eyes - Moderate irritant Rabbit - 0.066666667 
minutes 100 
milligrams
-
Eyes - Moderate irritant Rabbit - 100 
microliters
-
Eyes - Severe irritant Rabbit - 500 milligrams -
Skin - Mild irritant Rabbit - 400 milligrams -
Skin - Moderate irritant Rabbit - 24 hours 20 
milligrams
-
Product/ingredient name Result Score Exposure Observation
Sensitization
Not available.
Species
Information on toxicological effects
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Section 11. Toxicological information
Carcinogenicity
ethanol Equivocal - Oral - TD Mouse 400 g/kg 57 weeks 
Intermittent
Equivocal - Unreported - TDLo Mouse 120 g/kg 18 weeks 
Intermittent
Equivocal - Oral - TDLo Mouse 320 mg/kg 50 weeks 
Intermittent
Product/ingredient name Result Species Dose Exposure
Cell: Somatic
Micronucleus Test Subject: Mammalian-Human Positive
DNA Inhibition Subject: Mammalian-Human Positive
Cytogenetic Analysis Subject: Mammalian-Human Positive
Cytogenetic Analysis Subject: Mammalian-Human Positive
Cytogenetic Analysis Subject: Mammalian-Human Positive
Sister Chromatid 
Exchange
Subject: Mammalian-Human Positive
Teratogenicity
Reproductive toxicity
Product/ingredient name Maternal 
toxicity
Fertility Development 
toxin
Species Dose Exposure
ethanol - - - Mouse Intraperitoneal:
2.9 g/kg
8 days
- - - Mouse Intraperitoneal:
2900 mg/
kg
8 days
- - - Dog - Male Unreported:
100 mg/kg
1 days
- Positive - Rat Intraperitoneal:
600 mg/kg
15 days
Positive - - Mammal - species 
unspecified
Oral: 206 
g/kg
-
- Positive - Rat - Male Unreported:
400 mg/kg
1 days
- - Positive Mouse Intraperitoneal:
15 g/kg
8 days
- Positive - Rat - Female Unreported:
2400 mg/
kg
10 days
- Positive - Woman - Female Unreported:
200 mg/kg
5 days
- Positive - Dog Oral: 221 
g/kg
-
- Positive - Mammal - species 
unspecified
Oral: 78 g/
kg
-
- - Positive Mouse Intraperitoneal:
22.8 g/kg
8 days
- - Positive Mouse Intraperitoneal:
5.8 g/kg
5 days
- - Positive Rat Intraperitoneal:
600 mg/kg
15 days
- Positive Positive Mouse Intraperitoneal:
2900 mg/
kg
8 days
- - Positive Mammal - species 
unspecified
Intravenous -
- - - Mouse - Male Oral:
1680 g/kg
70 days
Classification
ethanol + 1 -
Product/ingredient name NTPIARCOSHA
Date of issue/Date of revision : 2/17/2014. Date of previous issue : No previous validation. Version : 1 8/13
Endotoxin Removal Resin
Section 11. Toxicological information
Not available.
ethanol Positive - Oral Woman - Female 41 g/kg -
Product/ingredient name Result Species Dose Exposure
Information on the likely 
routes of exposure
Inhalation : No known significant effects or critical hazards.
Irritating to mouth, throat and stomach.:Ingestion
Skin contact : Causes skin irritation.
Causes serious eye irritation.:Eye contact
No known significant effects or critical hazards.General :
Suspected of causing cancer.  Risk of cancer depends on duration and level of exposure.Carcinogenicity :
No known significant effects or critical hazards.Mutagenicity :
May damage the unborn child.Teratogenicity :
Symptoms related to the physical, chemical and toxicological characteristics
Skin contact
Ingestion
Inhalation Adverse symptoms may include the following:
reduced fetal weight
increase in fetal deaths
skeletal malformations
Adverse symptoms may include the following:
reduced fetal weight
increase in fetal deaths
skeletal malformations
Adverse symptoms may include the following:
irritation
redness
reduced fetal weight
increase in fetal deaths
skeletal malformations
:
:
:
Eye contact : Adverse symptoms may include the following:
pain or irritation
watering
redness
Potential chronic health effects
Delayed and immediate effects and also chronic effects from short and long term exposure
Specific target organ toxicity (single exposure)
Specific target organ toxicity (repeated exposure)
Not available.
Not available.
Aspiration hazard
Not available.
: Routes of entry anticipated: Oral, Dermal, Inhalation.
Potential acute health effects
Potential immediate 
effects
: Not available.
Short term exposure
Potential delayed effects : Not available.
Potential immediate 
effects
: Not available.
Long term exposure
Potential delayed effects : Not available.
Date of issue/Date of revision : 2/17/2014. Date of previous issue : No previous validation. Version : 1 9/13
Endotoxin Removal Resin
Section 11. Toxicological information
Developmental effects : No known significant effects or critical hazards.
Fertility effects : May damage fertility.
Numerical measures of toxicity
Not available.
Acute toxicity estimates
Section 12. Ecological information
LogPow BCF Potential
Bioaccumulative potential
Other adverse effects : No known significant effects or critical hazards.
Product/ingredient name
ethanol -0.35 0.66 low
Product/ingredient name Aquatic half-life Photolysis Biodegradability
ethanol - - Readily
Toxicity
ethanol Acute EC50 17.921 mg/l Marine water Algae - Ulva pertusa 96 hours
Acute EC50 2000 µg/l Fresh water Daphnia - Daphnia magna 48 hours
Acute LC50 25500 µg/l Marine water Crustaceans - Artemia 
franciscana - Larvae
48 hours
Acute LC50 42000 µg/l Fresh water Fish - Oncorhynchus mykiss 4 days
Chronic NOEC 4.995 mg/l Marine water Algae - Ulva pertusa 96 hours
Chronic NOEC 0.375 ul/L Fresh water Fish - Gambusia holbrooki -
Larvae
12 weeks
Product/ingredient name SpeciesResult Exposure
Persistence and degradability
Soil/water partition 
coefficient (KOC)
: Not available.
Mobility in soil
Section 13. Disposal considerations
The generation of waste should be avoided or minimized wherever possible.  Disposal of 
this product, solutions and any by-products should at all times comply with the 
requirements of environmental protection and waste disposal legislation and any regional 
local authority requirements.  Dispose of surplus and non-recyclable products via a 
licensed waste disposal contractor.  Waste should not be disposed of untreated to the 
sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Waste packaging should be recycled.  Incineration or landfill should only be considered 
when recycling is not feasible.  This material and its container must be disposed of in a 
safe way.  Care should be taken when handling emptied containers that have not been 
cleaned or rinsed out.  Empty containers or liners may retain some product residues.
Vapor from product residues may create a highly flammable or explosive atmosphere 
inside the container.  Do not cut, weld or grind used containers unless they have been 
cleaned thoroughly internally.  Avoid dispersal of spilled material and runoff and contact 
with soil, waterways, drains and sewers.
:Disposal methods
Date of issue/Date of revision : 2/17/2014. Date of previous issue : No previous validation. Version : 1 10/13
Endotoxin Removal Resin
Section 14. Transport information
Combustible liquids, n.o.s. (ethanol)
Combustible liquid.
III
-
Not regulated.
-
-
NA1993
Non-bulk packages (less than or 
equal to 119 gal) of combustible 
liquids are not regulated as hazardous 
materials.
-
DOT Classification IATA
UN number
UN proper 
shipping name
Transport 
hazard class(es)
Packing group
Additional 
information
Environmental 
hazards
Special precautions for user
Transport in bulk according 
to Annex II of MARPOL 
73/78 and the IBC Code
No. No.
Transport within user’s premises: always transport in closed containers that are 
upright and secure. Ensure that persons transporting the product know what to do in the 
event of an accident or spillage.
: Not available.
:
Section 15. Regulatory information
U.S. Federal regulations :
Clean Air Act  Section 112
(b) Hazardous Air 
Pollutants (HAPs)
: Not listed
Clean Air Act Section 602 
Class I Substances
: Not listed
Clean Air Act Section 602 
Class II Substances
: Not listed
DEA List I Chemicals 
(Precursor Chemicals)
: Not listed
DEA List II Chemicals 
(Essential Chemicals)
: Not listed
TSCA 8(a) CDR Exempt/Partial exemption: Not determined
United States inventory (TSCA 8b): All components are listed or exempted.
SARA 302/304
SARA 304 RQ : Not applicable.
No products were found.
Composition/information on ingredients
SARA 311/312
Classification : Fire hazard
Immediate (acute) health hazard
Delayed (chronic) health hazard
Composition/information on ingredients
Date of issue/Date of revision : 2/17/2014. Date of previous issue : No previous validation. Version : 1 11/13
Endotoxin Removal Resin
Section 15. Regulatory information
The following components are listed: CELLULOSE; ETHYL ALCOHOL
WARNING: This product contains a chemical known to the State of California to cause birth defects or other reproductive 
harm.
Massachusetts :
ethanol No. Yes. No. No.
Ingredient name Cancer Reproductive No significant risk 
level
Maximum 
acceptable dosage 
level
California Prop. 65
New York : None of the components are listed.
New Jersey : The following components are listed: CELLULOSE; ETHYL ALCOHOL; ALCOHOL
Pennsylvania : The following components are listed: CELLULOSE; DENATURED ALCOHOL
State regulations
ethanol 10 - 20 Yes. No. No. Yes. Yes.
Name % Fire 
hazard
Sudden 
release of 
pressure
Reactive Immediate 
(acute)
health 
hazard
Delayed 
(chronic)
health 
hazard
Canada inventory : All components are listed or exempted.
Australia inventory (AICS): All components are listed or exempted.
China inventory (IECSC): All components are listed or exempted.
Japan inventory: All components are listed or exempted.
Korea inventory: All components are listed or exempted.
Malaysia Inventory (EHS Register): Not determined.
New Zealand Inventory of Chemicals (NZIoC): All components are listed or exempted.
Philippines inventory (PICCS): All components are listed or exempted.
Taiwan inventory (CSNN): Not determined.
International regulations
International lists :
Chemical Weapons 
Convention List Schedule I 
Chemicals
: Not listed
Chemical Weapons 
Convention List Schedule 
II Chemicals
: Not listed
Chemical Weapons 
Convention List Schedule 
III Chemicals
: Not listed
Section 16. Other information
Hazardous Material Information System (U.S.A.)
2
2
0
0
2
2
*
National Fire Protection Association (U.S.A.)
Health
Special
Instability/Reactivity
Flammability
Health
Flammability
The customer is responsible for determining the PPE code for this material.
Physical hazards
Chronic Health Hazard
Date of issue/Date of revision : 2/17/2014. Date of previous issue : No previous validation. Version : 1 12/13
Endotoxin Removal Resin
Section 16. Other information
2/17/2014.
History
Date of printing
Date of issue/Date of 
revision
Version
To the best of our knowledge, the information contained herein is accurate. However, neither the above-named 
supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the 
information contained herein.
Final determination of suitability of any material is the sole responsibility of the user. All materials may present 
unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot 
guarantee that these are the only hazards that exist.
Notice to reader
Date of previous issue
:
:
:
:
Indicates information that has changed from previously issued version.
References : Not available.
Key to abbreviations : ATE = Acute Toxicity Estimate
BCF = Bioconcentration Factor
GHS = Globally Harmonized System of Classification and Labelling of Chemicals
IATA = International Air Transport Association
IBC = Intermediate Bulk Container
IMDG = International Maritime Dangerous Goods
LogPow = logarithm of the octanol/water partition coefficient
MARPOL 73/78 = International Convention for the Prevention of Pollution From Ships,
1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution)
UN = United Nations
2/17/2014.
No previous validation.
1
Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 
representing significant hazards or risks Although HMIS® ratings are not required on SDSs under 29 CFR 1910.
1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS® 
program. HMIS® is a registered mark of the National Paint & Coatings Association (NPCA). HMIS® materials may 
be purchased exclusively from J. J. Keller (800) 327-6868.
Reprinted with permission from NFPA 704-2001, Identification of the Hazards of Materials for Emergency 
Response Copyright ©1997, National Fire Protection Association, Quincy, MA 02269. This reprinted material is 
not the complete and official position of the National Fire Protection Association, on the referenced subject 
which is represented only by the standard in its entirety.
Copyright ©2001, National Fire Protection Association, Quincy, MA 02269. This warning system is intended to be 
interpreted and applied only by properly trained individuals to identify fire, health and reactivity hazards of 
chemicals. The user is referred to certain limited number of chemicals with recommended classifications in NFPA 
49 and NFPA 325, which would be used as a guideline only. Whether the chemicals are classified by NFPA or not,
anyone using the 704 systems to classify chemicals does so at their own risk.
MSDS (Regulatory Specialist)Prepared by :
Date of issue/Date of revision : 2/17/2014. Date of previous issue : No previous validation. Version : 1 13/13
POROS™ HIC Resins: Ethyl, Benzyl, and Benzyl Ultra
Pub. No. 100063752   Rev. A
WARNING! Read the Safety Data Sheets (SDSs) and follow the
handling instructions. Wear appropriate protective eyewear,
clothing, and gloves. Safety Data Sheets (SDSs) are available
from thermofisher.com/support.
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Product information
Product description
POROS™ Hydrophobic Interaction Chromatography (HIC) resins are
rigid, 50-µL polymeric resins with a range of hydrophobic
functionalities for the purification of antibody fragments, antibody
drug conjugates (ADCs), recombinant proteins, viruses, and other
biomolecules. The resin backbone consists of crosslinked poly(styrene-
divinylbenzene) with a unique pore structure that provides rapid
mass transport and enables enhanced productivity. The particle
surface is coated with a novel polymer coating, which is then further
derivatized with a range of hydrophobic ligands for flexible
purification process design.
POROS™ HIC resins are suitable for bind/elute and flow‑through
applications at lower salt concentrations. These resins have superior
resolution capability, high capacity, and differentiating selectivity for a
range of biomolecules, and this performance is independent of flow
rate.
Storage
Store resins at 2– 30°C. Do not freeze.
Specifications
Table 1   Ligands, hydrophobicity, and applications
Resin Ligand Relative
hydrophobicity
[1]
Application
Ethyl Novel ethyl Low Bind/elute mode to bind
moderately to strongly
hydrophobic molecules.
Benzyl Low-density
benzyl/
aromatic
Moderate Bind/elute or flow‑through
mode depending on the
hydrophobicity of the
molecule.
Benzyl
Ultra
High-density
benzyl/
aromatic
High Flow-through mode in lower
salt concentration to bind
impurities such as
aggregates.
[1] Hydrophobicity results are based on lysozyme gradient elution. Column size: 
0.66 cmD × 20 cmL; 1.7-M ammonium sulfate, 50-mM sodium phosphate pH 7.0; 
Gradient elution: 1.7-M ammonium sulfate/50 mM sodium phosphate pH 7.0 to 
50‑mM sodium phosphate pH 7.0 over 10 column volumes; Flow rate: 100 cm/hr.
Table 2   Characteristics and stability
Characteristic Description
Support matrix Crosslinked poly(styrene-divinylbenzene)
Shipping solution 18% ethanol
Average particle size 50 µm
Mechanical
resistance
100 bar (1450 psi, 10 MPa)
pH range 1–14
Ionic strength range 0 to 5 M, all common salts
Buffer additives All common agents, including 1 M sodium
hydroxide, 8 M urea, 6 M guanidine hydrochloride,
ethylene glycol, and detergents
Salts Ammonium sulfate, sodium sulfate, sodium
chloride, sodium acetate, sodium citrate and other
common salts
IMPORTANT! POROS™ Benzyl and POROS™ Benzyl
Ultra are designed for use with lower salt
concentration than traditional HIC resins. With
some molecules, high salt concentration can cause
poor recovery due to a strong interaction between
the target and the ligand.
Solvents Water, 0–100% alcohol, acetonitrile, 1 to 2 M acids
(for example, acetic, hydrochloric, phosphoric),
other common organic solvents
Do not expose to strong oxidizers (such as
hypochlorite), oxidizing acids (such as nitric), strong
reducing agents (such as sulfite), acetone, or benzyl
alcohol.
Shrinkage/swelling <1% from 1–100% solvent
Operating
temperature
2– 30°C
Do not freeze
POROS™ HIC resins can be operated at high linear flow rates with a
pressure drop that allows use with conventional low-pressure
chromatography columns and systems. POROS™ HIC resins have
linear and predictable pressure flow responses as column diameter
increases (Figure 1 and Figure 2).
USER GUIDE
Product usage: See "Ordering information" on page 5.
Fig. 1  Pressure-flow properties of POROS™ Ethyl resin—20-cm bed
height
Fig. 2  Pressure-flow properties of POROS™ Benzyl Ultra resin—20-cm
bed height
Pack and qualify the column
Packing guidelines
• Resins are supplied in 18% ethanol. For column packing, exchange
the shipping solution with water to remove the ethanol.
• Resins are mechanically rigid and incompressible and can be
packed effectively in low-pressure glass columns and in
high-pressure stainless steel columns. The lack of wall support
with increasing column diameter has minimal impact on
chromatography performance because the beads support
themselves, allowing for flexible column packing approaches and
consistent and robust results. Columns can be packed with
traditional flow pack, axial compression, or pack-in-place/stall
pack packing methods.
• Standard 10–23 µm screens (frits) can be used.
Prepare slurry: lab-scale columns (£ 100 mL)
Buffer‑exchange using a 0.2–0.45 µm bottle‑top filter or sintered-glass
filter:
1. Transfer the required volume of resin slurry to the top of a
bottle‑top filter.
2. Apply vacuum to remove the shipping solution.
3. Resuspend the resin cake to the starting resin slurry volume with
water. Mix with a plastic or rubber spatula. Do not grind the resin
bed or tear the filter membrane.
4. Repeat the vacuum and resuspension steps for a total of three
exchanges.
5. Resuspend the exchanged resin to the original slurry
concentration, then proceed with column packing.
6. Verify that the slurry concentration is 50–70% (see “Determine the
slurry concentration“ on page 2).
7. If needed, adjust the slurry concentration to 50–70%.
Prepare slurry: lab-scale and larger scale columns
(> 100 mL)
Buffer‑exchange using repeated gravity settling:
1. Allow the resin to settle in the shipping container. Settling
requires > 8 hours because the density of the resin is
approximately that of water.
2. Carefully decant the supernatant. Do not disturb the bed.
Some particles/turbidity may be present in the decant as beads
slough off the settled bed or come loose from the carboy side
walls. This is not problematic.
3. Replace the supernatant with the same volume of the desired
packing solution.
4. Replace the supernatant with the same volume of water.
5. Resuspend the resin by gentle agitation, then allow the resin to
settle by gravity.
6. Repeat steps 1 to 4 two to three times to thoroughly exchange into
water.
7. Verify that the slurry concentration is 50–70% (see “Determine the
slurry concentration“ on page 2).
8. If needed, adjust the slurry concentration to 50–70%.
Determine the slurry concentration
1. Separate the slurry using either of the following methods.
• Gravity settling—Add 100 mL of slurry in water to a 100-mL
graduated cylinder, then allow to settle for >72 hours.
Note: The time that POROS™ HIC resins take to gravity settle
can be inconsistent due to hydrophobicity. We recommend
using the centrifugation method for faster, more consistent
results.
• Centrifugation—Add 10 mL of slurry in water to three (3)
15-mL conical tubes. Centrifuge at 3,000 rpm for 10 minutes at
20°C with the brake off. Remove the tubes from the centrifuge
and allow the tubes to sit for 5 minutes before determining the
concentration.
2. Calculate the concentration: Volume of resin/total volume in the
graduated cylinder or conical tube.
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Pack the column
When you adjust the flow rate to form the bed, you may observe some
turbidity in the eluent as packing starts. Turbidity will clear as packing
proceeds and 1–2 bed volumes of packing buffer pass through the
column.
1. Determine the required slurry volume:
Example for a POROS™ Ethyl 40 cmD × 20 cmL 25-L column using
slurry with a 50% slurry ratio:
25 L / 0.56 × 1.06 = 47.3 L slurry required
The 1.06 packing factor above accounts for the difference in bed
volume between a centrifuged bed in water and a 3-bar pressure-
packed bed. Use a 1.12 packing factor for POROS™ Benzyl and
POROS™ Benzyl Ultra.
2. Ensure that the column outlet is closed and plumbed directly to
waste. Do not connect the column outlet to the chromatography
system. Plumbing into the system creates backpressure that fights
against the inlet pressure trying to settle the bed and pack the
column.
3. Ensure that the column is level and locked in place before starting
the pack.
4. Deliver the required slurry volume to the column by hand or with
a diaphragm pump, as dictated by your equipment and the
intended packing procedure. Use a squirt bottle containing
packing solution to remove any residual resin from the column
wall.
POROS™ resin beads have a skeletal density similar to the density
of water and do not settle rapidly. Do not allow the resin to
gravity‑settle in the column before packing.
5. With the column inlet line connected to the system and the
bottom outlet closed, bring the primed top flow adapter to 1–2 cm
from the slurry level, then tighten the O-ring. Do not push up the
resin and over the O-ring. Change the top valve to force the air
and liquid out the top of the adapter and to waste using the
bypass line. Continue to lower the adapter slowly to remove the
bubbles from the top of the column. Do not allow large air
bubbles between the top adaptor and the top of the resin slurry.
6. Change the valve back to flow through the system on the top,
then open the column bottom.
7. Increase the flow rate to the maximum or desired flow rate and
pressure obtainable with the equipment used.
8. After the bed is formed, bring the adapter into contact with the
top of the bed without pushing the resin over the O-ring by
closing the column outlet and displacing liquid through the top of
the adapter to waste through the bypass line.
POROS™ resin does not shrink or swell, so an open headspace is
not recommended.
9. Flow at the packing flow rate again for 1–2 CVs, taking note of
the bed height at the desired pressure. Adjust the adapter again
to the noted bed height by displacing the liquid through the top
of the adapter and to waste.
10. After the column is packed, flow 2–3 CVs of packing solution
through the packed bed at the operating flow rate to stabilize the
bed.
The flow rate used should generate no more than 80% of the final
packing pressure.
11. If you will reverse the flow of the column during operation,
condition the column in upflow:
• Flow 2–3 CVs in upflow at the operating flow rate.
• Flow 2–3 CVs in downflow at the operating flow rate, then
adjust the adapter if needed.
• Flow 2 CVs after you adjust the adapter.
Qualify the column
To qualify the integrity of a packed column, determine HETP (height
equivalent to a theoretical plate) and asymmetry using a non-binding
analyte (a “plug”).
Recommended column qualification conditions
Condition Recommendation
Flow rate 50 cm/hour
Equilibration buffer Water
Plug solution 0.5 M sodium chloride
Plug volume 1% of column volume
Guidelines for qualification
• Ensure uniform column plumbing:
– Avoid using reducers to connect different tubing sizes.
– Minimize and keep consistent the column tubing lengths
between the plug solution to the column inlet and the column
outlet to the detector(s).
• Equilibrate with at least 4 CVs of equilibration buffer before
injection.
Setting specifications
Qualification results depend on several factors, including the:
• Solutions and method used
• Scale
• Column hardware
• Chromatography system
After you define a column qualification procedure for a specific
system (column plus chromatography system), base the qualification
acceptance criteria on historical values and ranges instead of
theoretical qualification results. Performing the column qualification
method consistently and reproducibly is critical to obtaining
meaningful results.
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Chromatography condition optimization
General guidelines
Standardized conditions or platform-type evaluations are not
recommended. Different HIC resins that are operated with the same
process conditions can yield variable results.
When optimizing conditions:
• Test different loading and elution conditions to evaluate static
binding capacity and yield based on the target molecule
characteristics and process challenges.
• Limit static binding load incubation time to 15 minutes.
• Optimize the chromatography step for peak separation: Use
conditions that remove some of the bound impurities during the
flow‑through/wash phase and that retain other bound impurities
until elution during the strip and cleaning-in-place (CIP) steps.
• Use buffer salts and reagents of the highest purity.
• Filter (0.22 or 0.45 µm) all buffers, solutions, and load before use.
Resin selection guidelines
• If the hydrophobicity of the target molecule is unknown:
– Run a small-scale bind/elute gradient separation on POROS™
Benzyl resin to determine the elution conductivity of the target
molecule, contaminants, and impurities.
– Optimize conditions on POROS™ Benzyl Ultra resin (higher
hydrophobicity) or POROS™ Ethyl resin (lower
hydrophobicity).
– If needed, continue to optimize conditions on POROS™ Benzyl
resin (mid-range hydrophobicity).
• If the target molecule is hydrophobic, optimize conditions on
POROS™ Ethyl resin or on POROS™ Benzyl with lower salt
concentration.
• For flow‑through applications where the target molecule is less
hydrophobic, optimize conditions on POROS™ Benzyl or POROS™
Benzyl Ultra with lower salt concentration.
After you select the resin, continue to optimize other process
conditions.
Binding capacity and loading condition screening guidelines
Perform high-throughput static binding capacity testing in spin
columns or in a 96-well plate to screen POROS™ HIC resin. Optimize
loading conditions as needed.
Note: A 96-well high-throughput protocol is available on request. This
protocol can be used to evaluate static binding capacity and to screen
several resins and loading conditions per resin in a single 96-well
plate.
Bind/elute chromatography optimization guidelines
Binding conditions guidelines
• Salt and salt concentration — POROS™ HIC resins are designed to
use less lyotropic salts and to bind at lower concentrations than
traditional HIC resins with similar functional groups (Table 3).
Table 3    Typical salts used in hydrophobic interaction
chromatography in order of decreasing lyotropic ("salting out")
effect and increasing chaotropic ("salting in") effect
Effect Anionic salts Cationic salts
Most lyotropic C6H5O7 3– NH4 +
PO4 3– Rb+
SO4 2– K+
CH3COO– Na+
Cl- Cs+
Br– Li+
NO3 – Mg2+
CIO4 – Ca2+
Most chaotropic I– Ba2+
Note the following:
– You can perform initial binding experiments with lower salt
concentrations than are typically used for HIC chromatography.
For example, you can start with 25%, 50% and 75% of the
salting out concentration, instead of the typical 10–15% lower
than the salting out concentration.
– The optimized ionic salt concentration for the salts listed above
can differ from ammonium sulfate, which has been traditionally
used for HIC chromatography.
– Different salts can provide different selectivity.
Optimize the salt concentration for the target molecule by using a
"salting out" experiment: increase the ionic strength of the loading
buffer until the sample precipitates. Alternatively, you can
measure increasing optical density of the loading buffer to detect
aggregation (~350 nm, but this value may differ with each salt).
Salts that are commonly used to perform salting out experiments
are ammonium sulfate, sodium chloride, sodium citrate, sodium
sulfate, and sodium acetate.
• Buffer system—Buffer systems are not as critical for HIC processes
as they are for ion-exchange chromatography steps. Citrate,
acetate, Bis-Tris propane, HEPES, MES, sodium phosphate,
succinate, and Tris are commonly used.
The buffer system is typically dictated by the upstream
purification step. When selecting the upstream buffer system,
consider molecule stability in the buffer, binding optimization, and
buffering capacity.
• pH—pH is not typically critical for HIC processes, but it can affect
the binding strength and selectivity. Because pH effects are
unpredictable on HIC, test a few pH values over the stability range
of the target molecule.
• Flow rate—The target operating flow rate is flexible. Start
optimization at 4-minute residence time (300 cm/hr in a 20-cmL
column).
• Temperature—Temperature can significantly impact HIC
performance. Perform all optimization at the final intended
process temperature.
Elution conditions guidelines
Start elution optimization with a gradient elution. Most often, after
elution performance is determined, you can implement a step elution.
• Salt gradient—To determine where the target molecule and
contaminants/ impurities elute, start with a 20-CV gradient from
high salt to buffer only. To do so, assay fractions across the peaks
(~1/10 CV). Based on this information, the process can be further
optimized.
• Dynamic binding capacity (DBC)—Assess separation as a
function of DBC. The maximum DBC depends on several factors,
including sample solubility, column selectivity, buffer pH, and
loading buffer conductivity.
• Bed height—Initial screening can be run with shorter bed heights
and a constant residence time. Use the final desired bed height for
scale up development (typically 15 cm to 30 cm).
Flow-through chromatography optimization guidelines
An optional flow‑through step can be used remove trace product and
process-related impurities such as aggregates from the target
molecule. You can add the flow‑through step as the second or third
chromatography step for polishing in a downstream process. Different
target molecules have different degrees of hydrophobicity and other
biophysical characteristics. Therefore, it is essential to optimize the
process conditions to achieve the desired aggregate clearance and
recovery of the target molecule.
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Loading conditions guidelines
• Initial study —Perform an initial study using a decreasing salt
gradient in bind/elute mode:
– Load approximately 1 mg of protein per 1 ml of resin at 0.5–
1.0 M sodium chloride (or other preferred salt), then elute using
a gradient over 10 column volumes (CVs) in a buffered solution
to determine aggregates, impurities, and target molecule
elution profiles.
– Use the elution conductivity at peak maximum to determine the
highest approximate salt concentration that is required to
remove impurities, but that allows the target molecule to flow
through (Figure 3).
Start flow-through
optimization at
~7 mS/cm
Fig. 3  Example screening chromatogram to obtain the ideal low
salt condition for flow-through conditions. Process screening
for a monoclonal antibody using POROS™ Benzyl Ultra resin in
flow-through mode. Gradient: High conductivity to low
conductivity using sodium citrate. Based on this chromatogram,
the resin was further optimized in flow-through mode at low
salt conditions starting at 7 mS/cm.
• Buffer system—Buffer systems are not as critical for HIC processes
as they are for ion-exchange chromatography steps. Citrate,
acetate, Bis-Tris propane, HEPES, MES, sodium phosphate,
succinate, and Tris are commonly used.
The buffer system is typically dictated by the upstream
purification step. When selecting the upstream buffer system,
consider molecule stability in the buffer, binding optimization, and
buffering capacity.
• pH—pH is not typically critical for HIC processes, but it can affect
the binding strength and selectivity. Because pH effects are
unpredictable on HIC, test a few pH values over the stability range
of the target molecule.
• Flow rate—The target operating flow rate is flexible. Good
impurity binding has been demonstrated at flow rates up to
600 cm/hour on a 20 cmL column (1.6-minute residence time).
• Temperature—Temperature can significantly impact HIC
performance. Perform all optimization at the final intended
process temperature.
• Dynamic binding capacity (DBC)—A conservative starting point
for DBC determination is 100–250 mg of the target molecule per
mL of resin. Determine the DBC for each impurity by using
breakthrough analysis under the desired load pH and conductivity
conditions.
• Bed height—A bed height of 15 cm to 30 cm can be used for this
step.
Resin cleaning and storage
Resin cleaning guidelines
• POROS™ resins can tolerate harsh cleaning conditions that allow
acceptable column life.
• Clean the resin with 3 to 5 CVs of water followed by 3 to 5 CVs of
1 M NaOH.
• For more stringent cleaning, use 20% ethanol/1 M acetic acid.
• Other solutions may be required for column cleaning if the resin is
used for capture chromatography.
• Degas more viscous solutions such as 1 M acetic acid or
20% ethanol before use on the column to avoid gassing out during
operation.
Note: Low-level gassing out does not impact column performance.
Store the resin
Store the resin in 20% ethanol or 0.1 M NaOH at 2–30°C.
Ordering information
Table 4   POROS™ HIC bulk resins
Resin Cat. No. Amount Product usage
Ethyl A32552 10,000 mL Pharmaceutical Grade Reagent. For
Manufacturing and Laboratory Use
Only.
A32553 5,000 mL
A32554 1,000 mL
A32555 250 mL For Research Use Only. Not for use
in diagnostic procedures.A32556 50 mL
A32557 25 mL
Benzyl A32558 10,000 mL Pharmaceutical Grade Reagent. For
Manufacturing and Laboratory Use
Only.
A32559 5,000 mL
A32560 1,000 mL
A32561 250 mL For Research Use Only. Not for use
in diagnostic procedures.A32562 50 mL
A32563 25 mL
Benzyl
Ultra
A32564 10,000 mL Pharmaceutical Grade Reagent. For
Manufacturing and Laboratory Use
Only.
A32565 5,000 mL
A32566 1,000 mL
A32567 250 mL For Research Use Only. Not for use
in diagnostic procedures.A32568 50 mL
A32569 25 mL
Support
For service and technical support, go to thermofisher.com/poros or
call toll-free in US: 1.800.831.6844.
For the latest service and support information at all locations, or to
obtain Certificates of Analysis or Safety Data Sheets (SDSs; also known
as MSDSs), go to thermofisher.com/support, or contact you local
Thermo Fisher Scientific representative.
Limited product warranty
Life Technologies Corporation and/or its affiliate(s) warrant their
products as set forth in the Life Technologies' General Terms and
Conditions of Sale found on Life Technologies' website at 
www.thermofisher.com/us/en/home/global/terms-and-
conditions.html. If you have any questions, please contact Life
Technologies at www.thermofisher.com/support.
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Manufacturer: Life Technologies Corporation | 35 Wiggins Avenue | Bedford, MA 01730
The information in this guide is subject to change without notice.
DISCLAIMER: TO THE EXTENT ALLOWED BY LAW, LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) WILL NOT BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE,
MULTIPLE, OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING YOUR USE OF IT.
Revision history: Pub. No.  100063752
Revision Date Description
A 10 July 2017 New document.
Important Licensing Information: These products may be covered by one or more Limited Use Label Licenses. By use of these products, you accept the terms and conditions of all
applicable Limited Use Label Licenses.
©2017 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.
thermofisher.com/support  | thermofisher.com/askaquestion
thermofisher.com
10 July 2017
Safety Data Sheet
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SECTION 1: Ident ificat ion of the substance/mixture and of the company/undertaking
Identification of the substance or mixture  
Product code A32561
Product name POROS Benzyl Hydrophobic Interaction Chromatography Resin
Company/undertaking identification  
24 hour Emergency Response for Hazardous Materials
[or Dangerous Goods] Incident. Spill, Leak, Fire,
Exposure, or Accident. Call CHEMTREC
Within the USA + Canada: 1-800-424-9300 and +1
703-527-3887
Outside the USA + Canada: +1 703-741-5970
Country specific Emergency Number (if available):
Pharmaceutical Grade Reagent.  For Manufacturing and Laboratory Use Only.
SECTION 2: Hazards ident ificat ion
GHS - Classification 
Signal Word
WARNING
Hazard pictograms
Health hazards
Not Hazardous
Life Technologies Corporation
5781 Van Allen Way
PO Box 6482
Carlsbad, CA 92008
+1 760 603 7200
Life Technologies
5250 Mainway Drive
Burlington, ONT
CANADA L7L 6A4
800/263-6236
CHEMTREC Brazil (Rio De Janeiro) +(55)-2139581449 (português)
Physical hazards
GHS Physical Hazard 1 
___________________________________________________________________________________________________________________
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Product code A32561 Product name  POROS Benzyl Hydrophobic Interaction
Chromatography Resin
www.thermofisher.com
Flammable liquids
Environmental hazards
Not Hazardous
Hazard Statements
H226 - Flammable liquid and vapor
Precautionary Statements
Prevention
P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition sources.  No smoking
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P233 - Keep container tightly closed
P243 - Take action to prevent static discharges
P240 - Ground/bond container and receiving equipment
Response
P370 + P378 - In case of fire: Use dry sand, dry chemical or alcohol-resistant foam for extinction
P303 + P361 + P353 - IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with
water/shower
Storage
P403 + P235 - Store in a well-ventilated place. Keep cool
Disposal
P501 - Dispose of contents/ container to an approved waste disposal plant
Other hazards
Not Applicable
HMIS 
GHS Physical Hazard Category Number Category 3
Health 0
Flammability 3
Reactivity 0
SECTION 3: Composit ion/information on ingredients
Component CAS-No EINECS-No Weight %
Ethyl alcohol
 64-17-5 ( 15-22 )
64-17-5 200-578-6 15-22
We recommend handling all chemicals with caution.
___________________________________________________________________________________________________________________
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SECTION 4: First  a id measures
Description of first aid measures
Skin contact Rinse with plenty of water . Immediate medical attention is not required.
Eye contact Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do
 .
Ingestion Not expected to present a significant ingestion hazard under anticipated conditions
of normal use. If you feel unwell, seek medical advice.
Inhalation Not expected to be an inhalation hazard under anticipated conditions of normal
use of this material. Consult a physician if necessary.
Notes to Physician Treat symptomatically.
Most important symptoms and effects, both acute and delayed
H226 - Flammable liquid and vapor
Indication of any immediate medical attention and special treatment needed
IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water/ shower.
SECTION 5: Firefight ing measures
Extinguishing media
Suitable extinguishing media Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
Unsuitable extinguishing media No information available.
Special hazards arising from the substance or mixture Not known.
Advice for fire-fighters Standard procedure for chemical fires.
SECTION 6: Accidental re lease measures
Personal precautions, protective equipment and emergency procedures
Ensure adequate ventilation. Always wear recommended Personal Protective Equipment. Use personal protection
equipment. See Section 8 for more detail.
Environmental precautions
No special environmental precautions required.
Methods and material for containment and cleaning up
Soak up with inert absorbent material.
___________________________________________________________________________________________________________________
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Reference to other sections
See section 8 for more information.
SECTION 8: Exposure controls/personal protect ion
Control parameters 
Chemical Name OSHA PEL OSHA PEL (Ceiling) ACGIH OEL (TWA) ACGIH OEL (STEL)
Ethyl alcohol 1000 ppm
1900 mg/m3
None None 1000 ppm
Engineering measures Ensure adequate ventilation, especially in confined areas
Exposure controls 
Personal Protective Equipment
Respiratory protection In case of insufficient ventilation wear respirators and components tested and
approved under appropriate government standards.
Hand protection Wear suitable gloves Glove material: Compatible chemical-resistant gloves.
Eye protection Tight sealing safety goggles
Skin and Body Protection Wear suitable protective clothing
Hygiene measures Handle in accordance with good industrial hygiene and safety practice
Environmental exposure controls
No special environmental precautions required.
SECTION 7: Handling and storage
Precautions for safe handling
Use personal protective equipment as required. No special handling advices are necessary.
Conditions for safe storage, including any incompatibilities
Keep in a dry, cool and well-ventilated place. Keep in properly labeled containers.
Specific end use(s)
Pharmaceutical Grade Reagent.  For Manufacturing and Laboratory Use Only.
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SECTION 9: Physical and chemical propert ies
Information on basic physical and chemical properties
Appearance suspension
Odor No data available
pH 6-8
Evaporation rate No data available
Flammability (solid, gas) No data available
Upper explosion limit Mixture has not been tested
Lower explosion limit Mixture has not been tested
Vapor Pressure Mixture has not been tested
Relative density Mixture has not been tested
Specific gravity No data available
Solubility No data available
Partition coefficient:
n-octanol/water
No data available
Explosive properties Mixture has not been tested
Other information No data available
SECTION 10: Stability and react ivity
Reactivity None known.
Chemical stability Stable under normal conditions.
Possibility of hazardous
reactions
Hazardous reaction has not been reported.
Conditions to avoid No information available.
Incompatible materials No dangerous reaction known under conditions of normal use.
Hazardous decomposition
products
No data available.
Melting point / melting range °C  Mixture has not been tested °F  Mixture has not been tested
Boiling point / boiling range °C  Mixture has not been tested °F  Mixture has not been tested
Flash point °C  36-49 °F  96.8-120.2
Autoignition Temperature °C  Mixture has not been tested °F  Mixture has not been tested
Decomposition temperature °C  Mixture has not been tested °F  Mixture has not been tested
___________________________________________________________________________________________________________________
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SECTION 11: Toxicological information
Information on toxicological effects
Chemical Name LD50 (oral,rat/mouse) LD50 (dermal,rat/rabbit) LC50 (inhalation,rat/mouse)
Ethyl alcohol = 7060 mg/kg (Rat) No data available =124.7mg/L(Rat)
Principal Routes of Exposure
Irritation Conclusive but not sufficient for classification
Corrosivity Conclusive but not sufficient for classification
Sensitization Conclusive but not sufficient for classification
STOT - Single Exposure Conclusive but not sufficient for classification
STOT - Repeated Exposure Conclusive but not sufficient for classification
Carcinogenicity Conclusive but not sufficient for classification
Mutagenicity Conclusive but not sufficient for classification
Reproductive toxicity May cause adverse reproductive effects - such as birth defect, miscarriages, or
infertility
Aspiration hazard Conclusive but not sufficient for classification
SECTION 12: Ecological information
Toxicity
The environmental impact of this product has not been fully investigated.
Chemical Name Freshwater Algae
Data
Water Flea Data Freshwater Fish
Species Data
Microtox Data log Pow
Ethyl alcohol No data available Daphnia magna
EC50=10800 mg/L (24
h) Daphnia magna
EC50=2 mg/L (48 h)
Daphnia magna
LC509268 - 14221
mg/L (48 h)
No data available No data available logPow-0.32
Persistence and degradability No information available.
Bioaccumulative potential No information available.
Results of PBT and vPvB assessment
No information available.
Other adverse effects No information available.
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SECTION 13: Disposal considerat ions
Waste treatment methods
The generation of waste should be avoided or minimized wherever possible. Empty containers or liners may retain
some product residues. This material and its container must be disposed of in according to approved disposal
technique. Disposal of this product, its solutions or of any by-products, shall comply with the requirements of all
applicable local, regional or national/federal regulations
SECTION 14: Transport  information
IATA / ADR / DOT-US / IMDG
This product is subjected to UN special provision A58 (144): An aqueous solution containing 24% or less alcohol by
volume is not subject to IATA Dangerous Goods Regulations.
UN number 1170
UN proper shipping name Ethanol Solution
Transport hazard class(es) 3
Packing group III
Environmental hazards Not Hazardous
Special precautions for user Not Applicable
___________________________________________________________________________________________________________________
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Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not Applicable.
SECTION 16: Other information
Reason for revision SDS sections updated.
Revision number 3
Revision date 09-Oct-2017
Pharmaceutical Grade Reagent.  For Manufacturing and Laboratory Use Only.
References
• ECHA: http://echa.europa.eu/
• TOXNET: http://toxnet.nlm.nih.gov/
• eChemPortal: http://www.echemportal.org/
• LOLI database: https://www.chemadvisor.com/loli-database
"The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be
used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS SDS DOES NOT CONSTITUTE A WARRANTY, EXPRESSED OR
IMPLIED,INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR
PURPOSE"
SECTION 15: Regulatory information
Component US TSCA
Ethyl alcohol
 64-17-5 ( 15-22 )
Listed
US Federal Regulations 
SARA 313
This product is not regulated by SARA.
Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)
This product does not contains HAPs.
US State Regulations 
California Proposition 65
This product contains the following Proposition 65 chemicals.
Chemical Name CAS-No Weight % Category 
Ethyl alcohol 64-17-5 15-22 Carcinogen
Developmental
WHMIS Hazard Class
B3 - Combustible liquid
This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) and the
MSDS contains all the information required by the CPR.
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___________________________________________________________________________________________________________________
Revision date 09-Oct-2017 Page  9 / 9
Product code A32561 Product name  POROS Benzyl Hydrophobic Interaction
Chromatography Resin
www.thermofisher.com
 
Sigma-Aldrich - PHR1383 Page 1  of  7 
SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.2 
Revision Date 01/11/2017 
Print Date 04/10/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Adenine 
 
Product Number : PHR1383 
Brand : Sigma-Aldrich 
   
CAS-No. : 73-24-5 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Acute toxicity, Oral (Category 3), H301 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Danger 
 
Hazard statement(s) 
H301 Toxic if swallowed. 
 
Precautionary statement(s) 
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse 
mouth. 
P405 Store locked up. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
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Molecular weight : 135.13 g/mol 
CAS-No. : 73-24-5 
EC-No. : 200-796-1 
  
Hazardous ingredients according to Regulation (EC) No 1272/2008 
Component Classification Concentration 
Adenine 
 CAS-No. 
EC-No. 
 
73-24-5 
200-796-1 
 
Acute Tox. 3; H301 <= 100 % 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. 
Evacuate personnel to safe areas. Avoid breathing dust. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for 
disposal. 
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6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in 
the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration 
before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Recommended storage temperature 2 - 8 °C 
 Keep in a dry place. Keep in a dry place.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
Hazardous components without workplace control parameters 
8.2 Exposure controls 
Appropriate engineering controls 
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product. 
Personal protective equipment 
Eye/face protection 
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Complete suit protecting against chemicals, The type of protective equipment must be selected according to 
the concentration and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type 
N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the 
sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and 
approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
Colour: light yellow 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
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e) Melting point/freezing 
point 
360 °C (680 °F) 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility No data available 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx) 
Other decomposition products - No data available 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx) 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 227 mg/kg 
Remarks: Behavioral:Convulsions or effect on seizure threshold. Behavioral:Muscle weakness. Lungs, Thorax, or 
Respiration:Other changes. 
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Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
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13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste 
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a 
chemical incinerator equipped with an afterburner and scrubber.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
UN number: 2811 Class: 6.1 Packing group: III 
Proper shipping name: Toxic solids, organic, n.o.s. (Adenine) 
Reportable Quantity (RQ):   
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 2811 Class: 6.1 Packing group: III EMS-No: F-A, S-A 
Proper shipping name: TOXIC SOLID, ORGANIC, N.O.S. (Adenine) 
  
 
IATA 
UN number: 2811 Class: 6.1 Packing group: III 
Proper shipping name: Toxic solid, organic, n.o.s. (Adenine) 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Acute Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Adenine 
CAS-No. 
73-24-5 
Revision Date 
 
New Jersey Right To Know Components 
 
Adenine 
CAS-No. 
73-24-5 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
H301 Toxic if swallowed. 
HMIS Rating 
Health hazard: 2 
Chronic Health Hazard:  
Flammability: 0 
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Physical Hazard 0 
NFPA Rating 
Health hazard: 2 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 5.2 Revision Date: 01/11/2017 Print Date: 04/10/2018 
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SAFETY DATA SHEET 
Version 5.2 
Revision Date 09/01/2017 
Print Date 03/24/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Ammonium sulfate, NF Grade 
 
Product Number : RES1427A-A7 
Brand : Sigma 
   
CAS-No. : 7783-20-2 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Formula : H8N2O4S 
Molecular weight : 132.14 g/mol 
CAS-No. : 7783-20-2 
EC-No. : 231-984-1 
 
No components need to be disclosed according to the applicable regulations. 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance. 
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If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid breathing dust. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for 
disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid formation of dust and aerosols.Further processing of solid materials may result in the formation of combustible 
dusts. The potential for combustible dust formation should be taken into consideration before additional processing 
occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: crystalline 
Colour: colourless 
b) Odour odourless 
c) Odour Threshold No data available 
d) pH 5.0 - 6 at 132 g/l at 25 °C (77 °F) 
e) Melting point/freezing 
point 
> 280 °C (> 536 °F) - Decomposition 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) The product is not flammable. 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 1.770 g/cm3 
n) Water solubility 754 g/l at 25 °C (77 °F) 
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o) Partition coefficient: n-
octanol/water 
log Pow: -5.1 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
 Bulk density ca.1,200 kg/m3 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents, Strong bases 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Nitrogen oxides (NOx), Sulphur oxides 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 4,250 mg/kg 
(OECD Test Guideline 401) 
 
Inhalation: No data available 
LD50 Dermal Dermal - Rat - > 2,000 mg/kg 
 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: No skin irritation 
 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: No eye irritation 
 
Respiratory or skin sensitisation 
Maximisation Test - Guinea pig 
Result: Does not cause skin sensitisation. 
 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
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probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: BS4500000 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to fish LC50 - Leuciscus idus (Golden orfe) - > 460 mg/l  - 96 h 
 
Toxicity to daphnia and 
other aquatic 
invertebrates 
LC50 - Daphnia (water flea) - 129 mg/l  - 48 h 
12.2 Persistence and degradability 
The methods for determining biodegradability are not applicable to inorganic substances. 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
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IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
 
Ammonium sulphate 
CAS-No. 
7783-20-2 
Revision Date 
1993-04-24 
Pennsylvania Right To Know Components 
 
Ammonium sulphate 
CAS-No. 
7783-20-2 
Revision Date 
1993-04-24 
 
 
Ammonium sulphate 
CAS-No. 
7783-20-2 
Revision Date 
1993-04-24 
New Jersey Right To Know Components 
 
Ammonium sulphate 
CAS-No. 
7783-20-2 
Revision Date 
1993-04-24 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 1 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 0 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 5.2 Revision Date: 09/01/2017 Print Date: 03/24/2018 
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 SAFETY DATA SHEET 
 according to the (US) Hazard Communication Standard (29 CFR 1910.1200) 
 
 Revision Date 09/16/2014  Version 3.0
 
 Page 1  of 8 
 SECTION 1. Identification 
 Product identifier 
 Product number  801962 
 Product name Brij® 35 for synthesis 
 CAS-No.  9002-92-0 
 
 Relevant identified uses of the substance or mixture and uses advised against 
 Identified uses  Chemical for synthesis 
 
 Details of the supplier of the safety data sheet 
 Company EMD Millipore Corporation | 290 Concord Road, Billerica, MA 01821, 
United States of America | General Inquiries: +1-978-715-4321 | 
Monday to Friday, 9:00 AM to 4:00 PM Eastern Time (GMT-5) 
 
 Emergency telephone 800-424-9300 CHEMTREC (USA) 
+1-703-527-3887 CHEMTREC (International) 
24 Hours/day; 7 Days/week 
 
 SECTION  2. Hazards identification 
 
 GHS-Labeling 
 Not a dangerous substance according to GHS. 
 
 Other hazards 
 None known. 
 
 SECTION  3. Composition/information on ingredients 
 Chemical nature  Alcohol 
 Formula  (C₂H₄O) nC₁₂H₂₆O              (C₂H₄O) nC₁₂H₂₆O (Hill) 
 
 Remarks  No hazardous ingredients according to the OSHA Hazard 
Communication Standard 29 CFR 1910.1200. 
 
 
 SECTION  4. First aid measures 
 Description of first-aid measures  
 Inhalation
 After inhalation: fresh air. 
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 Skin contact
 After skin contact: wash off with plenty of water. Remove contaminated clothing. 
  
 Eye contact
 After eye contact: rinse out with plenty of water. 
  
 Ingestion
 After swallowing: make victim drink water (two glasses at most). Consult doctor if feeling unwell. 
 
 Never give anything by mouth to an unconscious person. 
 
 Most important symptoms and effects, both acute and delayed 
 We have no description of any toxic symptoms. 
 
 Indication of any immediate medical attention and special treatment needed 
 No information available. 
 
 SECTION  5. Fire-fighting measures 
 Extinguishing media 
 Suitable extinguishing media
 Water, Carbon dioxide (CO2), Foam, Dry powder 
 
 Unsuitable extinguishing media
 For this substance/mixture no limitations of extinguishing agents are given. 
 
 Special hazards arising from the substance or mixture 
 Combustible. 
 Forms explosive mixtures with air on intense heating. 
 Development of hazardous combustion gases or vapors possible in the event of fire. 
 
 Advice for firefighters 
 Special protective equipment for fire-fighters
 In the event of fire, wear self-contained breathing apparatus. 
 
 Further information
 Prevent fire extinguishing water from contaminating surface water or the ground water system. 
 
 SECTION  6. Accidental release measures 
 Personal precautions, protective equipment and emergency procedures 
 Advice for non-emergency personnel: Avoid inhalation of dusts. Evacuate the danger area, 
observe emergency procedures, consult an expert. 
 
 Advice for emergency responders: Protective equipment see section 8. 
 
 Environmental precautions 
 Do not empty into drains. 
 
 Methods and materials for containment and cleaning up 
 Cover drains. Collect, bind, and pump off spills. 
 Observe possible material restrictions (see sections 7 and 10). 
 Take up dry. Dispose of properly. Clean up affected area. Avoid generation of dusts. 
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 SECTION  7. Handling and storage 
 Precautions for safe handling 
 Observe label precautions. 
 
 Conditions for safe storage, including any incompatibilities 
 Tightly closed. Dry. 
 
 Store at +15°C to +25°C (+59°F to +77°F). 
 
 SECTION  8. Exposure controls/personal protection 
 Exposure limit(s) 
 Contains no substances with occupational exposure limit values. 
 Engineering measures 
 Technical measures and appropriate working operations should be given priority over the use of personal 
protective equipment. 
 Individual protection measures 
 Protective clothing should be selected specifically for the workplace, depending on concentration and quantity of 
the hazardous substances handled. The chemical resistance of the protective equipment should be inquired at 
the respective supplier. 
 
 Hygiene measures
 Change contaminated clothing. Wash hands after working with substance. 
 
 Eye/face protection
 Safety glasses 
 
 Hand protection
 Chemical-resistant, impervious gloves complying with an approved standard should be worn at 
all times when handling chemical products if a risk assessment indicates this is necessary. 
 
 Respiratory protection 
 required when dusts are generated. 
 Use a properly fitted, air-purifying or air-fed respirator complying with an approved standard if a risk assessment 
indicates this is necessary. Respirator selection must be based on known or anticipated exposure levels, the 
hazards of the product and the safe working limits of the selected respirator. 
 
 SECTION  9. Physical and chemical properties 
 Physical state  solid 
 
 Color  white 
 
 Odor  fatty odor 
 
 Odor Threshold  No information available.  
 
 pH    5.5 - 7.0 
 at   100 g/l 
 68 °F ( 20 °C) 
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 pour point  33 °C 
 
 Boiling point/boiling range  ca.  212 °F ( 100 °C) 
 at   1,013 hPa  
 
 Flash point  > 300 °F ( > 149 °C) 
 
 Evaporation rate  No information available. 
 
 Flammability (solid, gas)  No information available. 
 
 Lower explosion limit  No information available. 
 
 Upper explosion limit  No information available. 
 
 Vapor pressure  < 1 hPa 
 at   68 °F ( 20 °C) 
 
 Relative vapor density  No information available. 
 
 Density  1.05 g/cm³ 
 at  68 °F ( 20 °C) 
 
 Relative density  No information available. 
 
 Water solubility  at  77 °F ( 25 °C) 
 soluble 
 
 Partition coefficient: n-
octanol/water 
 No information available. 
 
 Autoignition temperature  No information available. 
 
 Decomposition temperature  No information available. 
 
 Viscosity, dynamic  No information available. 
 
 Explosive properties  Not classified as explosive. 
 
 Oxidizing properties  none 
 
 
 SECTION  10. Stability and reactivity 
 Reactivity 
 The following applies in general to flammable organic substances and mixtures: in 
correspondingly fine distribution, when whirled up a dust explosion potential may generally be 
assumed. 
 Forms explosive mixtures with air on intense heating. 
 
 Chemical stability 
 Sensitivity to light 
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 Possibility of hazardous reactions 
 Violent reactions possible with: 
 
 Strong acids, Bases, Oxidizing agents 
 
 Conditions to avoid 
 Strong heating. 
 A range from approx. 15 Kelvin below the flash point is to be rated as critical. 
 
 Incompatible materials 
 no information available 
 
 Hazardous decomposition products 
 no information available 
 
 SECTION  11. Toxicological information 
 Information on toxicological effects 
   
 Likely route of exposure 
 Eye contact, Skin contact, Ingestion 
 
 Acute oral toxicity
 LD50  Rat:   > 78,000 mg/kg  (External MSDS) 
 
 
 Skin irritation
 Rabbit 
 Result:  No irritation 
 (External MSDS) 
 
 Eye irritation
 Rabbit 
 Result:  slight irritation 
 (External MSDS) 
 
 Sensitization
 Patch test:  human 
 Result:  negative 
 (External MSDS) 
 
 Specific target organ systemic toxicity - single exposure
 The substance or mixture is not classified as specific target organ toxicant, single exposure. 
 
 Specific target organ systemic toxicity - repeated exposure
 The substance or mixture is not classified as specific target organ toxicant, repeated exposure. 
 
 Aspiration hazard
 Regarding  the available data  the classification criteria are not fulfilled. 
 Carcinogenicity 
IARC  No ingredient of this product present at levels greater than or 
equal to 0.1% is identified as probable, possible or confirmed 
human carcinogen by IARC. 
OSHA  No ingredient of this product present at levels greater than or 
equal to 0.1% is identified as a carcinogen or potential 
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carcinogen by OSHA. 
NTP  No ingredient of this product present at levels greater than or 
equal to 0.1% is identified as a known or anticipated carcinogen 
by NTP. 
ACGIH  No ingredient of this product present at levels greater than or 
equal to 0.1% is identified as a carcinogen or potential 
carcinogen by ACGIH. 
 
 Further information 
 Hazardous  properties  cannot  be  excluded  but  are  unlikely when the product is handled 
appropriately. 
 Handle in accordance with good industrial hygiene and safety practice. 
 
 SECTION  12. Ecological information 
 Ecotoxicity 
 
 No information available. 
 
 Persistence and degradability 
 Biodegradability
 89 % 
 OECD Test Guideline 301B  
 Readily biodegradable. 
 
 Bioaccumulative potential 
 No information available. 
 
 Mobility in soil 
 No information available. 
 
 
 
 SECTION  13. Disposal considerations 
 The information presented only applies to the material as supplied. The identification based on characteristic(s) 
or listing may not apply if the material has been used or otherwise contaminated. It is the responsibility of the 
waste generator to determine the toxicity and physical properties of the material generated to determine the 
proper waste identification and disposal methods in compliance with applicable regulations. Disposal should be 
in accordance with applicable regional, national and local laws and regulations. 
 
 SECTION  14. Transport information 
 Land transport (DOT)
 Not classified as dangerous in the meaning of transport regulations. 
 Air transport (IATA)
 Not classified as dangerous in the meaning of transport regulations. 
 Sea transport (IMDG)
 Not classified as dangerous in the meaning of transport regulations. 
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 SECTION  15. Regulatory information 
 United States of America 
SARA 313
 This material does not contain any chemical components with known CAS numbers that exceed 
the threshold (De Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 302
 No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 
302. 
 Clean Water Act 
 This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, 
Table 116.4A. 
 This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, 
Table 117.3. 
DEA List I
 Not listed 
DEA List II
 Not listed 
US State Regulations 
Massachusetts Right To Know 
 Remarks
 No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know 
 Ingredients
 polymer of ethylene glycol and 1-dodecyl alcohol with >20 mol ethylene oxide 
New Jersey Right To Know 
 Ingredients
 polymer of ethylene glycol and 1-dodecyl alcohol with >20 mol ethylene oxide 
California Prop 65 Components 
 This product does not contain any chemicals known to the State of California to cause cancer, 
birth, or any other reproductive defects. 
 Notification status 
 TSCA: 
 
 All components of the product are listed in the TSCA-inventory. 
 DSL: 
 
 All components of this product are on the Canadian DSL. 
 
 SECTION  16. Other information 
 
 Training advice 
 Provide adequate information, instruction and training for operators. 
 
 Key or legend to abbreviations and acronyms used in the safety data sheet 
 SAFETY DATA SHEET 
 according to the (US) Hazard Communication Standard (29 CFR 1910.1200) 
 
 Product number  801962  Version 3.0
 Product name Brij® 35 for synthesis 
 
 Page 8  of 8 
 Used abbreviations and acronyms can be looked up at www.wikipedia.org. 
 
 
 Revision Date09/16/2014 
 
 
 The information contained herein is based on the present state of our knowledge. It characterizes the product with regard to 
appropriate safety precautions. It does not represent a warranty of any product properties and we assume no liability for any 
loss or injury which may result from the use of this information. Users should conduct their own investigations to determine 
the suitability of the information. 
 All rights reserved. Millipore and the “M” Mark are registered trademarks of Merck KGaA, Darmstadt, Germany. 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.0 
Revision Date 01/17/2018 
Print Date 04/10/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Chloramphenicol, United States Pharmacopeia 
(USP) Reference Standard 
 
Product Number : 1107004 
Brand : USP 
   
CAS-No. : 56-75-7 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Carcinogenicity (Category 2), H351 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Warning 
 
Hazard statement(s) 
H351 Suspected of causing cancer. 
 
Precautionary statement(s) 
P201 Obtain special instructions before use. 
P202 Do not handle until all safety precautions have been read and 
understood. 
P280 Wear protective gloves/ protective clothing/ eye protection/ face 
protection. 
P308 + P313 IF exposed or concerned: Get medical advice/ attention. 
P405 Store locked up. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
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3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Molecular weight : 323.13 g/mol 
CAS-No. : 56-75-7 
 
Hazardous components 
Component Classification Concentration 
Chloramphenicol 
   Carc. 2; H351 90 - 100 % 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate 
ventilation. Evacuate personnel to safe areas. Avoid breathing dust. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
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6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for 
disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in 
the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration 
before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Component CAS-No. Value Control 
parameters 
Basis 
Chloramphenicol 56-75-7 TWA 0.500000 
mg/m3 
USA. Workplace Environmental 
Exposure Levels (WEEL) 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
Personal protective equipment 
Eye/face protection 
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved 
under appropriate government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Impervious clothing, The type of protective equipment must be selected according to the concentration and 
amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type 
N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the 
sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and 
approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: crystalline 
Colour: light yellow 
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b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting point/freezing 
point 
149 °C (300 °F) 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility practically insoluble 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
 Solubility in other 
solvents 
Ethanol  
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
acids, Acid chlorides, Acid anhydrides, Oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Hydrogen 
chloride gas 
In the event of fire: see section 5 
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11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 2,500 mg/kg 
 
Inhalation: No data available 
Dermal: No data available 
LD50 Intraperitoneal - Rat - 1,811 mg/kg 
 
LD50 Intraperitoneal - Mouse - 1,100 mg/kg 
 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
Prolonged or repeated exposure may cause allergic reactions in certain sensitive individuals. 
Germ cell mutagenicity 
Laboratory experiments have shown mutagenic effects. 
 
Rat 
Liver  
DNA damage 
 
 
Mouse 
Cytogenetic analysis 
 
Carcinogenicity 
This product is or contains a component that has been reported to be probably carcinogenic based on its IARC, OSHA, 
ACGIH, NTP, or EPA classification. 
 
 
Suspected human carcinogens 
IARC: 2A - Group 2A: Probably carcinogenic to humans (Chloramphenicol) 
NTP: RAHC - Reasonably anticipated to be a human carcinogen (Chloramphenicol) 
 RAHC - Reasonably anticipated to be a human carcinogen (Chloramphenicol) 
OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA’s 
list of regulated carcinogens. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
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Nausea, Headache, Vomiting 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
Liver - Irregularities - Based on Human Evidence 
Liver - Irregularities - Based on Human Evidence 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to daphnia and 
other aquatic 
invertebrates 
EC50 - Daphnia magna (Water flea) - 345 mg/l  - 48 h 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a 
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. Offer surplus and 
non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Chronic Health Hazard 
Massachusetts Right To Know Components 
 
Chloramphenicol 
CAS-No. 
56-75-7 
Revision Date 
1989-12-01 
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Pennsylvania Right To Know Components 
 
Chloramphenicol 
CAS-No. 
56-75-7 
Revision Date 
1989-12-01 
 
 
Chloramphenicol 
CAS-No. 
56-75-7 
Revision Date 
1989-12-01 
New Jersey Right To Know Components 
 
Chloramphenicol 
CAS-No. 
56-75-7 
Revision Date 
1989-12-01 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
Carc. Carcinogenicity 
H351 Suspected of causing cancer.  
HMIS Rating 
Health hazard: 1 
Chronic Health Hazard: * 
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 0 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 5.0 Revision Date: 01/17/2018 Print Date: 04/10/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.2 
Revision Date 05/12/2015 
Print Date 04/08/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Citric acid, Anhydrous 
 
Product Number : PHR1071 
Brand : Sigma-Aldrich 
   
CAS-No. : 77-92-9 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Manufacture of substances 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Eye irritation (Category 2A), H319 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Warning 
 
Hazard statement(s) 
H319 Causes serious eye irritation. 
 
Precautionary statement(s) 
P264 Wash skin thoroughly after handling. 
P280 Wear eye protection/ face protection. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove 
contact lenses, if present and easy to do. Continue rinsing. 
P337 + P313 If eye irritation persists: Get medical advice/ attention. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Formula : C6H8O7  
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Molecular weight : 192.12 g/mol 
CAS-No. : 77-92-9 
EC-No. : 201-069-1 
 
Hazardous components 
Component Classification Concentration 
Citric acid 
   Eye Irrit. 2A; H319 <= 100 % 
No components need to be disclosed according to the applicable regulations. 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Move out of dangerous area.Consult a physician. Show this safety data sheet to the doctor in attendance. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate 
ventilation. Avoid breathing dust. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for 
disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
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7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible 
dust formation should be taken into consideration before additional processing occurs.Avoid contact with skin and 
eyes. Avoid formation of dust and aerosols. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Store at Room Temperature.  
Storage class (TRGS 510): Non Combustible Solids 
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
Personal protective equipment 
Eye/face protection 
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved 
under appropriate government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
impervious clothing, The type of protective equipment must be selected according to the concentration and 
amount of the dangerous substance at the specific workplace. 
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Respiratory protection 
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher level 
protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and 
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: crystalline 
Colour: white 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 1.8 at ca.50 g/l at 25 °C (77 °F) 
e) Melting point/freezing 
point 
Melting point/freezing point: 155 - 157 °C (311 - 315 °F) 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
Lower explosion limit: 8 %(V) 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility 383 g/l at 25 °C (77 °F) 
o) Partition coefficient: n-
octanol/water 
log Pow: -1.639 at 20 °C (68 °F) 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
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10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Oxidizing agents, Bases, Reducing agents, Nitrates 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 5,400 mg/kg 
(OECD Test Guideline 401) 
 
Inhalation: No data available 
LD50 Dermal - Rat - > 2,000 mg/kg 
(OECD Test Guideline 402) 
 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: Mild skin irritation 
(OECD Test Guideline 404) 
 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: Irritating to eyes. 
(OECD Test Guideline 405) 
 
Respiratory or skin sensitisation 
Prolonged or repeated exposure may cause allergic reactions in certain sensitive individuals. 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: GE7350000 
 
 
Sigma-Aldrich - PHR1071  Page 6  of  7 
 
Vomiting, Diarrhoea, Damage to tooth enamel., Dermatitis, To the best of our knowledge, the chemical, physical, and 
toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to fish mortality LC50 - Leuciscus idus melanotus - 440 mg/l  - 48 h 
(OECD Test Guideline 203) 
 
Toxicity to daphnia and 
other aquatic 
invertebrates 
static test  - Daphnia magna (Water flea) - 1,535 mg/l  - 24 h 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste 
disposal service to dispose of this material.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Acute Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 CAS-No. Revision Date 
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Citric acid 77-92-9  
New Jersey Right To Know Components 
 
Citric acid 
CAS-No. 
77-92-9 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
 
16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
Eye Irrit. Eye irritation 
H319 Causes serious eye irritation.  
HMIS Rating 
Health hazard: 2 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 2 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2015 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 5.2 Revision Date: 05/12/2015 Print Date: 04/08/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 4.5 
Revision Date 12/21/2015 
Print Date 04/08/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : D-(+)-Glucose monohydrate 
 
Product Number : 49159 
Brand : Sigma-Aldrich 
   
CAS-No. : 14431-43-7 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : Dextrosemonohydrate 
Glucose 
 
Formula : C6H12O6 · H2O 
Molecular weight : 198.17 g/mol 
CAS-No. : 14431-43-7 
EC-No. : 218-914-5 
 
No components need to be disclosed according to the applicable regulations. 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
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In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
Carbon oxides  
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Keep in a dry place. Keep in a dry place.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
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Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
Colour: white 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting point/freezing 
point 
No data available 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
No data available 
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explosive limits 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility No data available 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
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Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly 
investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
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Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
D-Glucose monohydrate 
CAS-No. 
14431-43-7 
Revision Date 
 
New Jersey Right To Know Components 
 
D-Glucose monohydrate 
CAS-No. 
14431-43-7 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
 
16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 0 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 0 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2015 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 4.5 Revision Date: 12/21/2015 Print Date: 04/08/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.5 
Revision Date 10/03/2017 
Print Date 04/07/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : N,N-Dimethylacrylamide 
 
Product Number : 274135 
Brand : Aldrich 
   
CAS-No. : 2680-03-7 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Flammable liquids (Category 4), H227 
Acute toxicity, Oral (Category 3), H301 
Acute toxicity, Dermal (Category 3), H311 
Serious eye damage (Category 1), H318 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Danger 
 
Hazard statement(s) 
H227 Combustible liquid. 
H301 + H311 Toxic if swallowed or in contact with skin 
H318 Causes serious eye damage. 
 
Precautionary statement(s) 
P210 Keep away from heat/sparks/open flames/hot surfaces. No smoking. 
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P280 Wear protective gloves/ eye protection/ face protection. 
P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse 
mouth. 
P302 + P352 + P312 IF ON SKIN: Wash with plenty of soap and water. Call a POISON 
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CENTER or doctor/ physician if you feel unwell. 
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove 
contact lenses, if present and easy to do. Continue rinsing. Immediately 
call a POISON CENTER/doctor. 
P361 Remove/Take off immediately all contaminated clothing. 
P363 Wash contaminated clothing before reuse. 
P370 + P378 In case of fire: Use dry sand, dry chemical or alcohol-resistant foam for 
extinction. 
P403 + P235 Store in a well-ventilated place. Keep cool. 
P405 Store locked up. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Formula : C5H9NO 
Molecular weight : 99.13 g/mol 
CAS-No. : 2680-03-7 
EC-No. : 220-237-5 
 
Hazardous components 
Component Classification Concentration 
N,N-Dimethylacrylamide 
   Flam. Liq. 4; Acute Tox. 3; Eye 
Dam. 1; H227, H301 + H311, 
H318 
90 - 100 % 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a 
physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
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5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
Use water spray to cool unopened containers. 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Wear respiratory protection. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Remove all sources of 
ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive concentrations. Vapours 
can accumulate in low areas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and place in 
container for disposal according to local regulations (see section 13). Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
Keep away from sources of ignition - No smoking.Take measures to prevent the build up of electrostatic charge. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed 
and kept upright to prevent leakage.  
Light sensitive.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product. 
Personal protective equipment 
Eye/face protection 
Tightly fitting safety goggles.  Faceshield (8-inch minimum). Use equipment for eye protection tested and 
approved under appropriate government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: butyl-rubber 
Minimum layer thickness: 0.3 mm 
Break through time: 480 min 
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Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M) 
 
Splash contact 
Material: Nature latex/chloroprene 
Minimum layer thickness: 0.6 mm 
Break through time: 48 min 
Material tested:Lapren® (KCL 706 / Aldrich Z677558, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Complete suit protecting against chemicals, The type of protective equipment must be selected according to 
the concentration and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-
purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. 
If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and 
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: liquid 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 7 - 10 at 200 g/l 
e) Melting point/freezing 
point 
-39.99 °C (-39.98 °F) 
f) Initial boiling point and 
boiling range 
80 - 81 °C (176 - 178 °F) at 27 hPa (20 mmHg) - lit. 
g) Flash point 70 °C (158 °F) - closed cup 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
Lower explosion limit: 0.68 %(V) 
k) Vapour pressure 0.65 hPa (0.49 mmHg) at 20 °C (68 °F) 
l) Vapour density No data available 
m) Relative density 0.962 g/cm3 at 25 °C (77 °F) 
n) Water solubility 1,000 g/l at 20 °C (68 °F) 
o) Partition coefficient: n-
octanol/water 
log Pow: -0.3 at 23 °C (73 °F) 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
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s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
Contains the following stabiliser(s): 
Mequinol (0.05 %) 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
Heat, flames and sparks. 
10.5 Incompatible materials 
Strong oxidizing agents, Strong bases, polymerisation initiators 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx) 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - > 215 - 464 mg/kg 
(OECD Test Guideline 401) 
 
LD50 Dermal - Rabbit - 519 mg/kg 
Remarks: Behavioral:Somnolence (general depressed activity). Behavioral:Tremor. Liver:Other changes. 
 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: Mild skin irritation 
 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: Risk of serious damage to eyes. 
(OECD Test Guideline 405) 
 
Eyes - Rabbit 
Result: Moderate eye irritation 
 
Respiratory or skin sensitisation 
 - Guinea pig 
Result: Did not cause sensitisation on laboratory animals. 
(OECD Test Guideline 406) 
 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
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NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
Stomach - Irregularities - Based on Human Evidence (Mequinol) 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to fish LC50 - Oncorhynchus mykiss (rainbow trout) - > 120 mg/l  - 96 h 
(OECD Test Guideline 203) 
 
Toxicity to daphnia and 
other aquatic 
invertebrates 
EC50 - Daphnia magna (Water flea) - > 120 mg/l  - 48 h 
(OECD Test Guideline 202) 
 
Toxicity to algae EC50 - Pseudokirchneriella subcapitata (green algae) - > 400 mg/l  - 72 h 
(OECD Test Guideline 201) 
 
Toxicity to bacteria EC50 - Bacteria - > 1,000 mg/l  
(OECD Test Guideline 209) 
12.2 Persistence and degradability 
Biodegradability Result:  - Not readily biodegradable.  
 (OECD Test Guideline 301C) 
12.3 Bioaccumulative potential 
No bioaccumulation is to be expected (log Pow <= 4). 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
This combustible material may be burned in a chemical incinerator equipped with an afterburner and scrubber. Offer 
surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal 
service to dispose of this material.  
Contaminated packaging 
Dispose of as unused product.  
 
Aldrich - 274135 Page 7  of  8 
 
14. TRANSPORT INFORMATION 
DOT (US) 
UN number: 2810 Class: 6.1 Packing group: III 
Proper shipping name: Toxic, liquids, organic, n.o.s. (N,N-Dimethylacrylamide) 
Reportable Quantity (RQ):   
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 2810 Class: 6.1 Packing group: III EMS-No: F-A, S-A 
Proper shipping name: TOXIC LIQUID, ORGANIC, N.O.S. (N,N-Dimethylacrylamide) 
  
 
IATA 
UN number: 2810 Class: 6.1 Packing group: III 
Proper shipping name: Toxic liquid, organic, n.o.s. (N,N-Dimethylacrylamide) 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Fire Hazard, Acute Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
N,N-Dimethylacrylamide 
CAS-No. 
2680-03-7 
Revision Date 
 
New Jersey Right To Know Components 
 
N,N-Dimethylacrylamide 
CAS-No. 
2680-03-7 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
Acute Tox. Acute toxicity 
Eye Dam. Serious eye damage 
Flam. Liq. Flammable liquids  
H227 Combustible liquid. 
H301 Toxic if swallowed. 
H301 + H311 Toxic if swallowed or in contact with skin 
H311 Toxic in contact with skin. 
H318 Causes serious eye damage. 
HMIS Rating 
Health hazard: 2 
Chronic Health Hazard:  
Flammability: 2 
Physical Hazard 0 
NFPA Rating 
Health hazard: 2 
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Fire Hazard: 2 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 5.5 Revision Date: 10/03/2017 Print Date: 04/07/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.4 
Revision Date 05/27/2016 
Print Date 04/10/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Ethylenediamine 
 
Product Number : E1649 
Brand : Sigma-Aldrich 
Index-No. : 612-006-00-6 
   
CAS-No. : 107-15-3 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Flammable liquids (Category 3), H226 
Acute toxicity, Oral (Category 4), H302 
Acute toxicity, Inhalation (Category 4), H332 
Acute toxicity, Dermal (Category 3), H311 
Skin corrosion (Category 1B), H314 
Serious eye damage (Category 1), H318 
Respiratory sensitisation (Category 1), H334 
Skin sensitisation (Category 1), H317 
Acute aquatic toxicity (Category 2), H401 
Chronic aquatic toxicity (Category 3), H412 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Danger 
 
Hazard statement(s) 
H226 Flammable liquid and vapour. 
H302 + H332 Harmful if swallowed or if inhaled 
H311 Toxic in contact with skin. 
H314 Causes severe skin burns and eye damage. 
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H317 May cause an allergic skin reaction. 
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. 
H401 Toxic to aquatic life. 
H412 Harmful to aquatic life with long lasting effects. 
 
Precautionary statement(s) 
P210 Keep away from heat/sparks/open flames/hot surfaces. No smoking. 
P233 Keep container tightly closed. 
P240 Ground/bond container and receiving equipment. 
P241 Use explosion-proof electrical/ ventilating/ lighting/ equipment. 
P242 Use only non-sparking tools. 
P243 Take precautionary measures against static discharge. 
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. 
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P271 Use only outdoors or in a well-ventilated area. 
P272 Contaminated work clothing should not be allowed out of the workplace. 
P273 Avoid release to the environment. 
P280 Wear protective gloves/ protective clothing/ eye protection/ face 
protection. 
P285 In case of inadequate ventilation wear respiratory protection. 
P301 + P312 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. 
P301 + P330 + P331 IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. 
P303 + P361 + P353 IF ON SKIN (or hair): Remove/ Take off immediately all contaminated 
clothing. Rinse skin with water/ shower. 
P304 + P340 IF INHALED: Remove victim to fresh air and keep at rest in a position 
comfortable for breathing. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove 
contact lenses, if present and easy to do. Continue rinsing. 
P310 Immediately call a POISON CENTER/doctor. 
P322 Specific measures (see supplemental first aid instructions on this label). 
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention. 
P361 Remove/Take off immediately all contaminated clothing. 
P363 Wash contaminated clothing before reuse. 
P370 + P378 In case of fire: Use dry sand, dry chemical or alcohol-resistant foam for 
extinction. 
P403 + P235 Store in a well-ventilated place. Keep cool. 
P405 Store locked up. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS 
Lachrymator. 
Rapidly absorbed through skin. 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : 1,2-Diaminoethane 
 
Formula : C2H8N2 
Molecular weight : 60.10 g/mol 
CAS-No. : 107-15-3 
EC-No. : 203-468-6 
Index-No. : 612-006-00-6 
 
Hazardous components 
Component Classification Concentration 
Ethylenediamine 
   Flam. Liq. 3; Acute Tox. 4; 
Acute Tox. 3; Skin Corr. 1B; 
Eye Dam. 1; Resp. Sens. 1; 
<= 100 % 
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Skin Sens. 1; Aquatic Acute 2; 
Aquatic Chronic 3; H226, 
H302 + H332, H311, H314, 
H317, H318, H334, H401, 
H412 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Take victim 
immediately to hospital. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.Continue rinsing eyes during 
transport to hospital. 
If swallowed 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a 
physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
Use water spray to cool unopened containers. 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Wear respiratory protection. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Remove all sources 
of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive concentrations. 
Vapours can accumulate in low areas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment 
must be avoided. 
6.3 Methods and materials for containment and cleaning up 
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and place in 
container for disposal according to local regulations (see section 13). 
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6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
Keep away from sources of ignition - No smoking.Take measures to prevent the build up of electrostatic charge. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully 
resealed and kept upright to prevent leakage.  
Air and moisture sensitive. Handle and store under inert gas.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Component CAS-No. Value Control 
parameters 
Basis 
Ethylenediamine 107-15-3 TWA 10.000000 ppm  
 
USA. ACGIH Threshold Limit Values 
(TLV) 
 Remarks Not classifiable as a human carcinogen 
Danger of cutaneous absorption 
  TWA 10 ppm  
 
USA. ACGIH Threshold Limit Values 
(TLV) 
  Not classifiable as a human carcinogen 
Danger of cutaneous absorption 
  TWA 10.000000 ppm  
25.000000 
mg/m3 
USA. Occupational Exposure Limits 
(OSHA) - Table Z-1 Limits for Air 
Contaminants 
  The value in mg/m3 is approximate. 
  TWA 10 ppm  
25 mg/m3 
USA. Occupational Exposure Limits 
(OSHA) - Table Z-1 Limits for Air 
Contaminants 
  The value in mg/m3 is approximate. 
  TWA 10.000000 ppm  
25.000000 
mg/m3 
USA. NIOSH Recommended 
Exposure Limits 
  PEL 10 ppm  
25 mg/m3 
California permissible exposure 
limits for chemical contaminants 
(Title 8, Article 107) 
8.2 Exposure controls 
Appropriate engineering controls 
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product. 
Personal protective equipment 
Eye/face protection 
Tightly fitting safety goggles.  Faceshield (8-inch minimum). Use equipment for eye protection tested and 
approved under appropriate government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
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Material: butyl-rubber 
Minimum layer thickness: 0.3 mm 
Break through time: 480 min 
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M) 
 
Splash contact 
Material: Nature latex/chloroprene 
Minimum layer thickness: 0.6 mm 
Break through time: 72 min 
Material tested:Lapren® (KCL 706 / Aldrich Z677558, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Complete suit protecting against chemicals, Flame retardant antistatic protective clothing., The type of 
protective equipment must be selected according to the concentration and amount of the dangerous substance 
at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-
purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. 
If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and 
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the 
environment must be avoided. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: liquid 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 12.2 at 110 g/l at 20 °C (68 °F) 
e) Melting point/freezing 
point 
Melting point/range: 8.5 °C (47.3 °F) - lit. 
f) Initial boiling point and 
boiling range 
118 °C (244 °F) - lit. 
g) Flash point 38 °C (100 °F) - closed cup 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
Upper explosion limit: 16 %(V) 
Lower explosion limit: 2.7 %(V) 
k) Vapour pressure 13 hPa (10 mmHg) at 20 °C (68 °F) 
l) Vapour density 2.07 - (Air = 1.0) 
m) Relative density 0.899 g/cm3 at 25 °C (77 °F) 
n) Water solubility soluble 
o) Partition coefficient: n-
octanol/water 
log Pow: -2.04 
 
Sigma-Aldrich - E1649  Page 6  of  9 
 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
 Relative vapour density 2.07 - (Air = 1.0) 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
Heat, flames and sparks. 
10.5 Incompatible materials 
Oxidizing agents, Phosphorus halides, Aldehydes, Organic halides 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx) 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 1,200 mg/kg 
Remarks: Behavioral:Ataxia. 
 
LC50 Inhalation - Rat - 4 h - 14.7 mg/l 
 
LD50 Dermal Dermal - Rabbit - 560 mg/kg 
 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: Causes burns. 
 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: Corrosive 
 
Respiratory or skin sensitisation 
Maximisation Test - Guinea pig 
Result: Causes sensitisation. 
May cause allergic respiratory and skin reactions 
 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
Carcinogenicity - This product is or contains a component that is not classifiable as to its carcinogenicity based on its 
IARC, ACGIH, NTP, or EPA classification. 
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IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: KH8575000 
 
Vomiting, Diarrhoea, Abdominal pain, To the best of our knowledge, the chemical, physical, and toxicological properties 
have not been thoroughly investigated. 
 
Liver - Irregularities - Based on Human Evidence 
Liver - Irregularities - Based on Human Evidence 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to fish LC50 - Pimephales promelas (fathead minnow) - 115.7 mg/l  - 96 h 
 
Toxicity to daphnia and 
other aquatic 
invertebrates 
EC50 - Daphnia magna (Water flea) - 3 mg/l  - 48 h 
 
 NOEC - Daphnia magna (Water flea) - 0.16 mg/l  - 21 d 
 
Toxicity to algae EC50 - Pseudokirchneriella subcapitata (green algae) - 151 mg/l  - 96 h 
12.2 Persistence and degradability 
Biodegradability Biotic/Aerobic  - Exposure time 28 d 
Result: 94 % - Readily biodegradable  
12.3 Bioaccumulative potential 
 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
An environmental hazard cannot be excluded in the event of unprofessional handling or disposal. 
Toxic to aquatic life. 
 
Avoid release to the environment. 
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13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting as this 
material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a 
licensed professional waste disposal service to dispose of this material.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
UN number: 1604 Class: 8 (3) Packing group: II 
Proper shipping name: Ethylenediamine 
Reportable Quantity (RQ): 5000 lbs 
 
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 1604 Class: 8 (3) Packing group: II EMS-No: F-E, S-C 
Proper shipping name: ETHYLENEDIAMINE 
  
IATA 
UN number: 1604 Class: 8 (3) Packing group: II 
Proper shipping name: Ethylenediamine 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
The following components are subject to reporting levels established by SARA Title III, Section 302: 
 
Ethylenediamine 
CAS-No. 
107-15-3 
Revision Date 
2007-03-01 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Fire Hazard, Acute Health Hazard, Chronic Health Hazard 
Massachusetts Right To Know Components 
 
Ethylenediamine 
CAS-No. 
107-15-3 
Revision Date 
2007-03-01 
Pennsylvania Right To Know Components 
 
Ethylenediamine 
CAS-No. 
107-15-3 
Revision Date 
2007-03-01 
New Jersey Right To Know Components 
 
Ethylenediamine 
CAS-No. 
107-15-3 
Revision Date 
2007-03-01 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
 
16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
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Acute Tox. Acute toxicity 
Aquatic Acute Acute aquatic toxicity 
Aquatic Chronic Chronic aquatic toxicity 
Eye Dam. Serious eye damage 
Flam. Liq. Flammable liquids 
H226 Flammable liquid and vapour.  
H302 Harmful if swallowed. 
H302 + H332 Harmful if swallowed or if inhaled 
H311 Toxic in contact with skin. 
H314 Causes severe skin burns and eye damage. 
H317 May cause an allergic skin reaction. 
H318 Causes serious eye damage. 
H332 Harmful if inhaled. 
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. 
H401 Toxic to aquatic life. 
H412 Harmful to aquatic life with long lasting effects. 
HMIS Rating 
Health hazard: 3 
Chronic Health Hazard: * 
Flammability: 2 
Physical Hazard 0 
NFPA Rating 
Health hazard: 3 
Fire Hazard: 2 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 5.4 Revision Date: 05/27/2016 Print Date: 04/10/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 4.13 
Revision Date 10/03/2017 
Print Date 04/08/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Ethyl alcohol, pure 
 
Product Number : E7023 
Brand : Sigma-Aldrich 
Index-No. : 603-002-00-5 
   
CAS-No. : 64-17-5 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Flammable liquids (Category 2), H225 
Eye irritation (Category 2A), H319 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Danger 
 
Hazard statement(s) 
H225 Highly flammable liquid and vapour. 
H319 Causes serious eye irritation. 
 
Precautionary statement(s) 
P210 Keep away from heat/sparks/open flames/hot surfaces. No smoking. 
P233 Keep container tightly closed. 
P240 Ground/bond container and receiving equipment. 
P241 Use explosion-proof electrical/ ventilating/ lighting/ equipment. 
P242 Use only non-sparking tools. 
P243 Take precautionary measures against static discharge. 
P264 Wash skin thoroughly after handling. 
P280 Wear protective gloves/ eye protection/ face protection. 
P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. 
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Rinse skin with water/shower. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove 
contact lenses, if present and easy to do. Continue rinsing. 
P337 + P313 If eye irritation persists: Get medical advice/ attention. 
P370 + P378 In case of fire: Use dry sand, dry chemical or alcohol-resistant foam to 
extinguish. 
P403 + P235 Store in a well-ventilated place. Keep cool. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : Absolute alcohol 
 
Formula : C2H6O 
Molecular weight : 46.07 g/mol 
CAS-No. : 64-17-5 
EC-No. : 200-578-6 
Index-No. : 603-002-00-5 
 
Hazardous components 
Component Classification Concentration 
Ethanol 
   Flam. Liq. 2; Eye Irrit. 2A; 
H225, H319 
90 - 100 % 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a 
physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
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5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
Use water spray to cool unopened containers. 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Remove all 
sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive 
concentrations. Vapours can accumulate in low areas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and place in 
container for disposal according to local regulations (see section 13). 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
Use explosion-proof equipment.Keep away from sources of ignition - No smoking.Take measures to prevent the build up 
of electrostatic charge. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed 
and kept upright to prevent leakage.  
Hygroscopic.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Component CAS-No. Value Control 
parameters 
Basis 
Ethanol 64-17-5 TWA 1,000.000000 
ppm  
 
USA. ACGIH Threshold Limit Values 
(TLV) 
 Remarks Upper Respiratory Tract irritation 
Confirmed animal carcinogen with unknown relevance to humans 
  TWA 1,000 ppm  
1,900 mg/m3 
USA. OSHA - TABLE Z-1 Limits for 
Air Contaminants - 1910.1000 
  TWA 1,000 ppm  
1,900 mg/m3 
USA. Occupational Exposure Limits 
(OSHA) - Table Z-1 Limits for Air 
Contaminants 
  The value in mg/m3 is approximate. 
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  TWA 1,000.000000 
ppm  
1,900.000000 
mg/m3 
USA. Occupational Exposure Limits 
(OSHA) - Table Z-1 Limits for Air 
Contaminants 
  The value in mg/m3 is approximate. 
  TWA 1,000.000000 
ppm  
1,900.000000 
mg/m3 
USA. NIOSH Recommended 
Exposure Limits 
  STEL 1,000.000000 
ppm  
 
USA. ACGIH Threshold Limit Values 
(TLV) 
  Upper Respiratory Tract irritation 
Confirmed animal carcinogen with unknown relevance to humans 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
Personal protective equipment 
Eye/face protection 
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: butyl-rubber 
Minimum layer thickness: 0.3 mm 
Break through time: 480 min 
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.2 mm 
Break through time: 38 min 
Material tested:Dermatril® P (KCL 743 / Aldrich Z677388, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Impervious clothing, Flame retardant antistatic protective clothing., The type of protective equipment must be 
selected according to the concentration and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-
purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. 
If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and 
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
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9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: liquid, clear 
Colour: colourless 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting point/freezing 
point 
-143.99 °C (-227.18 °F) 
f) Initial boiling point and 
boiling range 
78.0 - 80.0 °C (172.4 - 176.0 °F) 
g) Flash point 14.0 °C (57.2 °F) - closed cup 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
Upper explosion limit: 19 %(V) 
Lower explosion limit: 3.3 %(V) 
k) Vapour pressure 59.5 hPa (44.6 mmHg) at 20.0 °C (68.0 °F) 
l) Vapour density No data available 
m) Relative density 0.7974 g/cm3 
n) Water solubility completely soluble 
o) Partition coefficient: n-
octanol/water 
log Pow: -0.349 at 24 °C (75 °F) 
p) Auto-ignition 
temperature 
363.0 °C (685.4 °F) 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
Vapours may form explosive mixture with air. 
10.4 Conditions to avoid 
Heat, flames and sparks. 
10.5 Incompatible materials 
Alkali metals, Oxidizing agents, Peroxides 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
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In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 10,470 mg/kg 
 
LC50 Inhalation - Rat - 4 h - 30,000 mg/l 
 
LD50 Dermal - Rabbit - 15,800 mg/kg 
 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: No skin irritation - 24 h 
(OECD Test Guideline 404) 
 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: Moderate eye irritation 
(OECD Test Guideline 405) 
 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
Carcinogenicity - Mouse - Oral 
Tumorigenic:Equivocal tumorigenic agent by RTECS criteria. Liver:Tumors. Blood:Lymphomas including Hodgkin's 
disease. 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
Reproductive toxicity - Human - female - Oral 
Effects on Newborn: Apgar score (human only). Effects on Newborn: Other neonatal measures or effects. Effects on 
Newborn: Drug dependence. 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: KQ6300000 
 
Central nervous system depression, narcosis, Damage to the heart., To the best of our knowledge, the chemical, 
physical, and toxicological properties have not been thoroughly investigated. 
 
Stomach - Irregularities - Based on Human Evidence 
Stomach - Irregularities - Based on Human Evidence 
 
Sigma-Aldrich - E7023 Page 7  of  8 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to fish LC50 - Pimephales promelas (fathead minnow) - 14,200 mg/l  - 96 h 
 
Toxicity to daphnia and 
other aquatic 
invertebrates 
LC50 - Ceriodaphnia dubia (water flea) - 5,012 mg/l  - 48 h 
 
 NOEC - Daphnia magna (Water flea) - 9.6 mg/l  - 9 d 
 
Toxicity to algae EC50 - Chlorella vulgaris (Fresh water algae) - 275 mg/l  - 72 h 
(OECD Test Guideline 201) 
12.2 Persistence and degradability 
Biodegradability Result: 95 % - Readily biodegradable.  
12.3 Bioaccumulative potential 
Due to the distribution coefficient n-octanol/water, accumulation in organisms is not expected. 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting as this 
material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a 
licensed professional waste disposal service to dispose of this material.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
UN number: 1170 Class: 3 Packing group: II 
Proper shipping name: Ethanol 
Reportable Quantity (RQ):   
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 1170 Class: 3 Packing group: II EMS-No: F-E, S-D 
Proper shipping name: ETHANOL 
  
 
IATA 
UN number: 1170 Class: 3 Packing group: II 
Proper shipping name: Ethanol 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
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SARA 311/312 Hazards 
Fire Hazard, Acute Health Hazard, Chronic Health Hazard 
Massachusetts Right To Know Components 
 
Ethanol 
CAS-No. 
64-17-5 
Revision Date 
2007-03-01 
Pennsylvania Right To Know Components 
 
Ethanol 
CAS-No. 
64-17-5 
Revision Date 
2007-03-01 
New Jersey Right To Know Components 
 
Ethanol 
CAS-No. 
64-17-5 
Revision Date 
2007-03-01 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
Eye Irrit. Eye irritation 
Flam. Liq. Flammable liquids 
H225 Highly flammable liquid and vapour.  
H319 Causes serious eye irritation. 
HMIS Rating 
Health hazard: 2 
Chronic Health Hazard: * 
Flammability: 3 
Physical Hazard 0 
NFPA Rating 
Health hazard: 2 
Fire Hazard: 3 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 4.13 Revision Date: 10/03/2017 Print Date: 04/08/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 3.14 
Revision Date 02/24/2017 
Print Date 04/08/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Glutaraldehyde solution 
 
Product Number : G7776 
Brand : Sigma-Aldrich 
   
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Acute toxicity, Oral (Category 3), H301 
Acute toxicity, Inhalation (Category 3), H331 
Skin corrosion (Category 1B), H314 
Serious eye damage (Category 1), H318 
Respiratory sensitisation (Category 1), H334 
Skin sensitisation (Category 1), H317 
Specific target organ toxicity - single exposure (Category 3), Respiratory system, H335 
Acute aquatic toxicity (Category 1), H400 
Chronic aquatic toxicity (Category 2), H411 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Danger 
 
Hazard statement(s) 
H301 + H331 Toxic if swallowed or if inhaled 
H314 Causes severe skin burns and eye damage. 
H317 May cause an allergic skin reaction. 
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. 
H335 May cause respiratory irritation. 
H400 Very toxic to aquatic life. 
H411 Toxic to aquatic life with long lasting effects. 
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Precautionary statement(s) 
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. 
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P271 Use only outdoors or in a well-ventilated area. 
P272 Contaminated work clothing should not be allowed out of the workplace. 
P273 Avoid release to the environment. 
P280 Wear protective gloves/ protective clothing/ eye protection/ face 
protection. 
P285 In case of inadequate ventilation wear respiratory protection. 
P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse 
mouth. 
P301 + P330 + P331 IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. 
P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. 
Rinse skin with water/shower. 
P304 + P340 + P310 IF INHALED: Remove person to fresh air and keep comfortable for 
breathing. Immediately call a POISON CENTER/doctor. 
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove 
contact lenses, if present and easy to do. Continue rinsing. Immediately 
call a POISON CENTER/doctor. 
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention. 
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/doctor. 
P363 Wash contaminated clothing before reuse. 
P391 Collect spillage. 
P403 + P233 Store in a well-ventilated place. Keep container tightly closed. 
P405 Store locked up. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.2 Mixtures 
Synonyms : Pentane-1,5-dial 
Glutaric dialdehydesolution 
 
Formula : C5H8O2 
Molecular weight : 100.12 g/mol 
 
Hazardous components 
Component Classification Concentration 
Glutaral 
 CAS-No. 
EC-No. 
Index-No. 
 
111-30-8 
203-856-5 
605-022-00-X 
 
Flam. Liq. 4; Acute Tox. 3; 
Acute Tox. 2; Skin Corr. 1B; 
Eye Dam. 1; Resp. Sens. 1; 
Skin Sens. 1; STOT SE 3; 
Aquatic Acute 1; Aquatic 
Chronic 2; H227, H301, H314, 
H317, H330, H334, H335, 
H400, H411 
70 - 90 % 
Methanol 
 CAS-No. 
EC-No. 
Index-No. 
Registration number 
67-56-1 
200-659-6 
603-001-00-X 
01-2119433307-44-XXXX 
Flam. Liq. 2; Acute Tox. 3; 
STOT SE 1; H225, H301 + 
H311 + H331, H370 
0.1 - 1 % 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
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4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Move out of dangerous area.Consult a physician. Show this safety data sheet to the doctor in attendance. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Take victim immediately 
to hospital. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.Continue rinsing eyes during 
transport to hospital. 
If swallowed 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a 
physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Wear respiratory protection. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to 
safe areas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment 
must be avoided. 
6.3 Methods and materials for containment and cleaning up 
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed containers for 
disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
For precautions see section 2.2. 
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7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed 
and kept upright to prevent leakage.  
Recommended storage temperature -20 °C 
Store under inert gas. Air sensitive.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Component CAS-No. Value Control 
parameters 
Basis 
Glutaral 111-30-8 C 0.200000 ppm  
0.800000 
mg/m3 
USA. NIOSH Recommended 
Exposure Limits 
 Remarks See Appendix C 
  C 0.050000 ppm  
 
USA. ACGIH Threshold Limit Values 
(TLV) 
  Central Nervous System impairment 
Upper Respiratory Tract irritation 
Eye irritation 
Skin irritation 
Not classifiable as a human carcinogen 
Sensitizer 
  C 0.05 ppm  
 
USA. ACGIH Threshold Limit Values 
(TLV) 
  Dermal Sensitization 
Respiratory sensitization 
Central Nervous System impairment 
Upper Respiratory Tract irritation 
Eye irritation 
Skin irritation 
Not classifiable as a human carcinogen 
  C 0.05 ppm  
0.2 mg/m3 
California permissible exposure 
limits for chemical contaminants 
(Title 8, Article 107) 
Methanol 67-56-1 TWA 200.000000 
ppm  
 
USA. ACGIH Threshold Limit Values 
(TLV) 
  Headache 
Nausea 
Dizziness 
Eye damage 
Substances for which there is a Biological Exposure Index or Indices 
(see BEI® section) 
Danger of cutaneous absorption 
  STEL 250.000000 
ppm  
 
USA. ACGIH Threshold Limit Values 
(TLV) 
  Headache 
Nausea 
Dizziness 
Eye damage 
Substances for which there is a Biological Exposure Index or Indices 
(see BEI® section) 
Danger of cutaneous absorption 
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  TWA 200.000000 
ppm  
260.000000 
mg/m3 
USA. NIOSH Recommended 
Exposure Limits 
  Potential for dermal absorption 
  ST 250.000000 
ppm  
325.000000 
mg/m3 
USA. NIOSH Recommended 
Exposure Limits 
  Potential for dermal absorption 
  TWA 200.000000 
ppm  
260.000000 
mg/m3 
USA. Occupational Exposure Limits 
(OSHA) - Table Z-1 Limits for Air 
Contaminants 
  The value in mg/m3 is approximate. 
  TWA 200 ppm  
 
USA. ACGIH Threshold Limit Values 
(TLV) 
  Headache 
Nausea 
Dizziness 
Eye damage 
Substances for which there is a Biological Exposure Index or Indices 
(see BEI® section) 
Danger of cutaneous absorption 
  STEL 250 ppm  
 
USA. ACGIH Threshold Limit Values 
(TLV) 
  Headache 
Nausea 
Dizziness 
Eye damage 
Substances for which there is a Biological Exposure Index or Indices 
(see BEI® section) 
Danger of cutaneous absorption 
  TWA 200 ppm  
260 mg/m3 
USA. NIOSH Recommended 
Exposure Limits 
  Potential for dermal absorption 
  ST 250 ppm  
325 mg/m3 
USA. NIOSH Recommended 
Exposure Limits 
  Potential for dermal absorption 
  TWA 200 ppm  
260 mg/m3 
USA. Occupational Exposure Limits 
(OSHA) - Table Z-1 Limits for Air 
Contaminants 
  The value in mg/m3 is approximate. 
  STEL 250 ppm  
325 mg/m3 
USA. OSHA - TABLE Z-1 Limits for 
Air Contaminants - 1910.1000 
  Skin notation 
  TWA 200 ppm  
260 mg/m3 
USA. OSHA - TABLE Z-1 Limits for 
Air Contaminants - 1910.1000 
  Skin notation 
  C 1,000 ppm  
 
California permissible exposure 
limits for chemical contaminants 
(Title 8, Article 107) 
  Skin 
  PEL 200 ppm  
260 mg/m3 
California permissible exposure 
limits for chemical contaminants 
(Title 8, Article 107) 
  Skin 
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  STEL 250 ppm  
325 mg/m3 
California permissible exposure 
limits for chemical contaminants 
(Title 8, Article 107) 
  Skin 
Biological occupational exposure limits 
Component CAS-No. Parameters Value Biological 
specimen 
Basis 
Methanol 67-56-1 Methanol 15.0000 
mg/l 
Urine ACGIH - Biological 
Exposure Indices 
(BEI) 
 Remarks End of shift (As soon as possible after exposure ceases) 
  Methanol 15 mg/l Urine ACGIH - Biological 
Exposure Indices 
(BEI) 
  End of shift (As soon as possible after exposure ceases) 
8.2 Exposure controls 
Appropriate engineering controls 
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product. 
Personal protective equipment 
Eye/face protection 
Tightly fitting safety goggles.  Faceshield (8-inch minimum). Use equipment for eye protection tested and 
approved under appropriate government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.4 mm 
Break through time: 480 min 
Material tested:Camatril® (KCL 730 / Aldrich Z677442, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 30 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Complete suit protecting against chemicals, The type of protective equipment must be selected according to 
the concentration and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-
purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. 
If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and 
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the 
environment must be avoided. 
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9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: clear, liquid 
Colour: colourless 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting point/freezing 
point 
No data available 
f) Initial boiling point and 
boiling range 
101 °C (214 °F) at 1,013 hPa (760 mmHg) 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure 20 hPa (15 mmHg) at 20 °C (68 °F) 
l) Vapour density No data available 
m) Relative density 1.143 g/cm3 
n) Water solubility soluble 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong bases, Acids, Oxidizing agents, Alkali metals, Strong oxidizing agents, Strong acids, Acid chlorides, Acid 
anhydrides, Reducing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
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Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
Material is extremely destructive to tissue of the mucous membranes and upper respiratory tract, eyes, and skin., spasm, 
inflammation and edema of the larynx, spasm, inflammation and edema of the bronchi, pneumonitis, pulmonary edema, 
burning sensation, Cough, wheezing, laryngitis, Shortness of breath, Headache, Nausea 
 
Liver - Irregularities - Based on Human Evidence 
Liver - Irregularities - Based on Human Evidence (Glutaral) 
Stomach - Irregularities - Based on Human Evidence (Methanol) 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
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12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
An environmental hazard cannot be excluded in the event of unprofessional handling or disposal. 
Very toxic to aquatic life. 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste 
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a 
chemical incinerator equipped with an afterburner and scrubber.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
UN number: 2922 Class: 8 (6.1) Packing group: II 
Proper shipping name: Corrosive liquids, toxic, n.o.s. (Glutaral) 
Reportable Quantity (RQ):   
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 2922 Class: 8 (6.1) Packing group: II EMS-No: F-A, S-B 
Proper shipping name: CORROSIVE LIQUID, TOXIC, N.O.S. (Glutaral) 
Marine pollutant:yes   
 
IATA 
UN number: 2922 Class: 8 (6.1) Packing group: II 
Proper shipping name: Corrosive liquid, toxic, n.o.s. (Glutaral) 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Acute Health Hazard, Chronic Health Hazard 
Massachusetts Right To Know Components 
 
Glutaral 
CAS-No. 
111-30-8 
Revision Date 
1993-04-24 
Pennsylvania Right To Know Components 
 
Glutaral 
CAS-No. 
111-30-8 
Revision Date 
1993-04-24 
Water 7732-18-5  
Methanol 67-56-1 2007-07-01 
New Jersey Right To Know Components 
 
Glutaral 
CAS-No. 
111-30-8 
Revision Date 
1993-04-24 
Water 7732-18-5  
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Methanol 67-56-1 2007-07-01 
California Prop. 65 Components 
WARNING: This product contains a chemical known to the 
State of California to cause birth defects or other reproductive 
harm. 
Methanol 
CAS-No. 
67-56-1 
Revision Date 
2012-03-16 
 
 
 
16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
Acute Tox. Acute toxicity 
Aquatic Acute Acute aquatic toxicity 
Aquatic Chronic Chronic aquatic toxicity 
Eye Dam. Serious eye damage 
Flam. Liq. Flammable liquids 
H225 Highly flammable liquid and vapour.  
H227 Combustible liquid. 
H301 Toxic if swallowed. 
H301 + H311 + 
H331 
Toxic if swallowed, in contact with skin or if inhaled. 
H314 Causes severe skin burns and eye damage. 
H317 May cause an allergic skin reaction. 
H318 Causes serious eye damage. 
H330 Fatal if inhaled. 
H331 Toxic if inhaled. 
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. 
H335 May cause respiratory irritation. 
H370 Causes damage to organs. 
H400 Very toxic to aquatic life.  
H411 Toxic to aquatic life with long lasting effects. 
Resp. Sens. Respiratory sensitisation 
Skin Corr. Skin corrosion 
Skin Sens. Skin sensitisation 
STOT SE Specific target organ toxicity - single exposure 
HMIS Rating 
Health hazard: 4 
Chronic Health Hazard: * 
Flammability: 0 
Physical Hazard 1 
NFPA Rating 
Health hazard: 3 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.4 
Revision Date 08/31/2017 
Print Date 04/10/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Guanidine hydrochloride 
 
Product Number : PHG0006 
Brand : Sigma 
Index-No. : 607-148-00-0 
   
CAS-No. : 50-01-1 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Acute toxicity, Oral (Category 4), H302 
Acute toxicity, Inhalation (Category 4), H332 
Skin irritation (Category 2), H315 
Eye irritation (Category 2A), H319 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Warning 
 
Hazard statement(s) 
H302 + H332 Harmful if swallowed or if inhaled 
H315 Causes skin irritation. 
H319 Causes serious eye irritation. 
 
Precautionary statement(s) 
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. 
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P271 Use only outdoors or in a well-ventilated area. 
P280 Wear protective gloves/ eye protection/ face protection. 
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. 
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Rinse mouth. 
P302 + P352 IF ON SKIN: Wash with plenty of soap and water. 
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for 
breathing. Call a POISON CENTER/doctor if you feel unwell. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove 
contact lenses, if present and easy to do. Continue rinsing. 
P332 + P313 If skin irritation occurs: Get medical advice/ attention. 
P337 + P313 If eye irritation persists: Get medical advice/ attention. 
P362 Take off contaminated clothing and wash before reuse. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Formula : CH5N3 · HCl 
Molecular weight : 95.53 g/mol 
CAS-No. : 50-01-1 
EC-No. : 200-002-3 
Index-No. : 607-148-00-0 
 
Hazardous components 
Component Classification Concentration 
Guanidinium chloride 
   Acute Tox. 4; Skin Irrit. 2; Eye 
Irrit. 2A; H302 + H332, H315, 
H319 
90 - 100 % 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
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5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate 
ventilation. Avoid breathing dust. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for 
disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in 
the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration 
before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
Hazardous components without workplace control parameters 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
Personal protective equipment 
Eye/face protection 
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved 
under appropriate government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Complete suit protecting against chemicals, The type of protective equipment must be selected according to 
the concentration and amount of the dangerous substance at the specific workplace. 
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Respiratory protection 
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher level 
protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and 
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: crystalline 
Colour: white 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 4.5 - 6 at 573 g/l at 25 °C (77 °F) 
e) Melting point/freezing 
point 
185 - 189 °C (365 - 372 °F) 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 1.345 g/cm3 at 20 °C (68 °F) 
n) Water solubility 573 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: n-
octanol/water 
log Pow: -1.7 at ca.20 °C (68 °F) 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
> 310 °C (> 590 °F) -  
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
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10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Hydrogen 
chloride gas 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 475 mg/kg 
Remarks: Behavioral:Altered sleep time (including change in righting reflex). Behavioral:Excitement. Diarrhoea 
 
LD50 Oral - Mouse - 571 mg/kg 
Remarks: Behavioral:Altered sleep time (including change in righting reflex). Behavioral:Muscle contraction or spasticity. 
Behavioral:Irritability. 
 
LD50 Oral - Rat - 1,120 mg/kg 
 
LC50 Inhalation - Rat - female - 4 h - 3.181 mg/l 
(OECD Test Guideline 403) 
 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: Skin irritation 
 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: Irritating to eyes. 
 
Respiratory or skin sensitisation 
Buehler Test - Guinea pig 
Did not cause sensitisation on laboratory animals. 
 
Germ cell mutagenicity 
Not mutagenic in Ames Test 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
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Additional Information 
RTECS: MF4300000 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
Liver - Irregularities - Based on Human Evidence 
Liver - Irregularities - Based on Human Evidence 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to fish LC50 - Leuciscus idus (Golden orfe) - 1,759 mg/l  
12.2 Persistence and degradability 
Biodegradability Result:  - Not readily biodegradable.  
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste 
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a 
chemical incinerator equipped with an afterburner and scrubber.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Acute Health Hazard, Chronic Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
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Guanidinium chloride 
CAS-No. 
50-01-1 
Revision Date 
 
 
 
Guanidinium chloride 
CAS-No. 
50-01-1 
Revision Date 
 
New Jersey Right To Know Components 
 
Guanidinium chloride 
CAS-No. 
50-01-1 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
Acute Tox. Acute toxicity 
Eye Irrit. Eye irritation  
H302 Harmful if swallowed. 
H302 + H332 Harmful if swallowed or if inhaled 
H315 Causes skin irritation. 
H319 Causes serious eye irritation. 
HMIS Rating 
Health hazard: 2 
Chronic Health Hazard: * 
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 2 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 5.4 Revision Date: 08/31/2017 Print Date: 04/10/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.8 
Revision Date 08/31/2017 
Print Date 04/10/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : HEPES 
 
Product Number : RES6003H-B7 
Brand : Sigma 
   
CAS-No. : 7365-45-9 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Formula : C8H18N2O4S 
Molecular weight : 238.3 g/mol 
CAS-No. : 7365-45-9 
EC-No. : 230-907-9 
Registration number : 01-2120054645-54-XXXX 
 
No components need to be disclosed according to the applicable regulations. 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
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In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust 
formation should be taken into consideration before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
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8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: Crystalline powder 
Colour: colourless 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 5.0 - 6.5 at 238 g/l at 25 °C (77 °F) 
e) Melting point/freezing 
point 
Melting point/range: 212.6 °C (414.7 °F) - Decomposes before melting. 
f) Initial boiling point and 
boiling range 
Decomposes below the boiling point. 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) The product is not flammable. - Flammability (solids) 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 1.439 g/cm3 at 20 °C (68 °F) 
n) Water solubility 703.6 g/l at 20 °C (68 °F) - OECD Test Guideline 105 
o) Partition coefficient: n-
octanol/water 
log Pow: < -3.85 
p) Auto-ignition 
temperature 
does not ignite 
q) Decomposition 
temperature 
No data available 
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r) Viscosity No data available 
s) Explosive properties Not explosive 
t) Oxidizing properties The substance or mixture is not classified as oxidizing. 
9.2 Other safety information 
 Surface tension 63.98 mN/m at 20 °C (68 °F) 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Sulphur oxides 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
LD50 Oral - Rat - > 2,000 mg/kg 
 
Inhalation: No data available 
Inhalation: No data available 
Dermal: No data available 
LD50 Dermal - Rat - > 2,000 mg/kg 
(OECD Test Guideline 402) 
 
No data available 
No data available 
Skin corrosion/irritation 
No data available 
Skin - Rabbit 
Result: No skin irritation 
(OECD Test Guideline 404) 
 
Serious eye damage/eye irritation 
No data available 
Eyes - Rabbit 
Result: No eye irritation 
(OECD Test Guideline 405) 
 
Respiratory or skin sensitisation 
No data available 
Maximisation Test - Guinea pig 
Did not cause sensitisation on laboratory animals. 
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Germ cell mutagenicity 
No data available 
 
 
in vitro assay 
Result: negative 
Lymphoma Mutation Assay 
 
Chromosome aberration test in vitro 
Result: negative 
 
Result: Not mutagenic in Ames Test 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
Did not show teratogenic effects in animal experiments. 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
Repeated dose 
toxicity 
Rat - Oral - 28 d - Subacute oral toxicity - NOAEL : 1,000 mg/kg - OECD Test 
Guideline 407 
RTECS: TL6809000 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
 
Toxicity to fish LC50 - Brachydanio rerio (zebrafish) - > 100 mg/l  - 96 h 
(OECD Test Guideline 203) 
 
Toxicity to daphnia and 
other aquatic 
invertebrates 
EC50 - Daphnia magna (Water flea) - > 100 mg/l  - 48 h 
 
Toxicity to algae static test EC50 - Pseudokirchneriella subcapitata (green algae) - > 100 mg/l  - 
72 h 
(OECD Test Guideline 201) 
 
 NOEC - Pseudokirchneriella subcapitata (green algae) - 100 mg/l  - 72 h 
(OECD Test Guideline 201) 
 
Toxicity to bacteria EC50 - Sludge Treatment - > 1,000 mg/l  - 3 h 
(OECD Test Guideline 209) 
12.2 Persistence and degradability 
No data available 
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12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
No data available 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
4-(2-Hydroxyethyl)piperazin-1-ylethanesulphonic acid 
CAS-No. 
7365-45-9 
Revision Date 
 
 
 
4-(2-Hydroxyethyl)piperazin-1-ylethanesulphonic acid 
CAS-No. 
7365-45-9 
Revision Date 
 
New Jersey Right To Know Components 
 
4-(2-Hydroxyethyl)piperazin-1-ylethanesulphonic acid 
CAS-No. 
7365-45-9 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
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16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 0 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 0 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 5.8 Revision Date: 08/31/2017 Print Date: 04/10/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.0 
Revision Date 01/16/2018 
Print Date 04/10/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Imidazole (200 mg) 
 
Product Number : 1336500 
Brand : USP 
   
CAS-No. : 288-32-4 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Acute toxicity, Oral (Category 4), H302 
Skin corrosion (Category 1C), H314 
Serious eye damage (Category 1), H318 
Reproductive toxicity (Category 1B), H360D 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Danger 
 
Hazard statement(s) 
H302 Harmful if swallowed. 
H314 Causes severe skin burns and eye damage. 
H360D May damage the unborn child. 
 
Precautionary statement(s) 
P201 Obtain special instructions before use. 
P202 Do not handle until all safety precautions have been read and 
understood. 
P260 Do not breathe dust or mist. 
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P280 Wear protective gloves/ protective clothing/ eye protection/ face 
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protection. 
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. 
Rinse mouth. 
P301 + P330 + P331 IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. 
P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. 
Rinse skin with water/shower. 
P304 + P340 + P310 IF INHALED: Remove person to fresh air and keep comfortable for 
breathing. Immediately call a POISON CENTER/doctor. 
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove 
contact lenses, if present and easy to do. Continue rinsing. Immediately 
call a POISON CENTER/doctor. 
P308 + P313 IF exposed or concerned: Get medical advice/ attention. 
P363 Wash contaminated clothing before reuse. 
P405 Store locked up. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Molecular weight : 68.08 g/mol 
CAS-No. : 288-32-4 
 
Hazardous components 
Component Classification Concentration 
Imidazole 
   Acute Tox. 4; Skin Corr. 1C; 
Eye Dam. 1; Repr. 1B; H302, 
H314, H360D 
90 - 100 % 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.Continue rinsing eyes during 
transport to hospital. 
If swallowed 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a 
physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
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5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate 
ventilation. Evacuate personnel to safe areas. Avoid breathing dust. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for 
disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust 
formation should be taken into consideration before additional processing occurs.Avoid contact with skin and eyes. Avoid 
formation of dust and aerosols. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Storage class (TRGS 510): 6.1D: Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials 
causing chronic effects 
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
Hazardous components without workplace control parameters 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
Personal protective equipment 
Eye/face protection 
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
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Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Complete suit protecting against chemicals, The type of protective equipment must be selected according to 
the concentration and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type 
N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the 
sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and 
approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: crystalline 
Colour: white 
b) Odour amine-like 
c) Odour Threshold No data available 
d) pH 9 - 11 at 100 g/l at 23 °C (73 °F) 
e) Melting point/freezing 
point 
89 - 91 °C (192 - 196 °F) 
f) Initial boiling point and 
boiling range 
256 °C (493 °F) at 1,013 hPa (760 mmHg) 
g) Flash point 145 °C (293 °F) - closed cup 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure 0.003 hPa (0.002 mmHg) at 20 °C (68 °F) 
l) Vapour density No data available 
m) Relative density 1.030 g/cm3 
n) Water solubility 633 g/l at 20 °C (68 °F) 
o) Partition coefficient: n-
octanol/water 
log Pow: -0.02 at 25 °C (77 °F) 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
 Bulk density 550 kg/m3 
 Dissociation constant 7.15 at 25 °C (77 °F) 
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10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
acids, Acid anhydrides, Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Hydrogen 
cyanide (hydrocyanic acid) 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 970 mg/kg 
 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: Corrosive, category 1C - where responses occur after exposures between 1 hour and 4 hours and observations 
up to 14 days. 
 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
Did not show mutagenic effects in animal experiments. Tests on bacterial or mammalian cell cultures did not show 
mutagenic effects. 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA’s 
list of regulated carcinogens. 
Reproductive toxicity 
Presumed human reproductive toxicant May damage the unborn child. 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
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Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to fish static test LC50 - Leuciscus idus (Golden orfe) - 280 mg/l  - 48 h 
 
Toxicity to daphnia and 
other aquatic 
invertebrates 
EC50 - Daphnia (water flea) - 341.5 mg/l  - 48 h 
 
Toxicity to algae static test EC50 - Scenedesmus quadricauda (Green algae) - 133 mg/l  - 72 h 
 
Toxicity to bacteria see user defined free text - other microorganisms - 45 mg/l  - 0.5 h 
12.2 Persistence and degradability 
Biodegradability aerobic  - Exposure time 19 d 
Result: 86 % - Readily biodegradable.  
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a 
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. Offer surplus and 
non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
UN number: 3263 Class: 8 Packing group: III 
Proper shipping name: Corrosive solid, basic, organic, n.o.s. (Imidazole) 
Reportable Quantity (RQ):   
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 3263 Class: 8 Packing group: III EMS-No: F-A, S-B 
Proper shipping name: CORROSIVE SOLID, BASIC, ORGANIC, N.O.S. (Imidazole) 
  
 
IATA 
UN number: 3263 Class: 8 Packing group: III 
Proper shipping name: Corrosive solid, basic, organic, n.o.s. (Imidazole) 
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15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Acute Health Hazard, Chronic Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Imidazole 
CAS-No. 
288-32-4 
Revision Date 
 
 
 
Imidazole 
CAS-No. 
288-32-4 
Revision Date 
 
New Jersey Right To Know Components 
 
Imidazole 
CAS-No. 
288-32-4 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
Acute Tox. Acute toxicity 
Eye Dam. Serious eye damage 
H302 Harmful if swallowed. 
H314 Causes severe skin burns and eye damage.  
H318 Causes serious eye damage. 
H360D May damage the unborn child. 
Repr. Reproductive toxicity 
Skin Corr. Skin corrosion 
HMIS Rating 
Health hazard: 3 
Chronic Health Hazard: * 
Flammability: 1 
Physical Hazard 0 
NFPA Rating 
Health hazard: 3 
Fire Hazard: 1 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
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Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 5.0 Revision Date: 01/16/2018 Print Date: 04/10/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.3 
Revision Date 03/04/2018 
Print Date 04/10/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Mannitol 
 
Product Number : 1375105 
Brand : USP 
   
CAS-No. : 69-65-8 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : D-Mannitol 
Mannite 
 
Formula : C6H14O6 
Molecular weight : 182.17 g/mol 
CAS-No. : 69-65-8 
EC-No. : 200-711-8 
 
No components need to be disclosed according to the applicable regulations. 
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4. FIRST AID MEASURES 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust 
formation should be taken into consideration before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Keep in a dry place.  
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
Colour: white 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 5.0 - 6.5 at 182 g/l at 25 °C (77 °F) 
e) Melting point/freezing 
point 
165 °C (329 °F) 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility 182 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: n- No data available 
 
USP - 1375105 Page 4  of  6 
octanol/water 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 13,500 mg/kg 
 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA’s 
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list of regulated carcinogens. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
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This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
D-Mannitol 
CAS-No. 
69-65-8 
Revision Date 
 
 
 
D-Mannitol 
CAS-No. 
69-65-8 
Revision Date 
 
New Jersey Right To Know Components 
 
D-Mannitol 
CAS-No. 
69-65-8 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 0 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 0 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 5.3 Revision Date: 03/04/2018 Print Date: 04/10/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.6 
Revision Date 09/05/2017 
Print Date 04/07/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : N,N′-Methylenebis(acrylamide) 
 
Product Number : 146072 
Brand : Sigma-Aldrich 
   
CAS-No. : 110-26-9 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Acute toxicity, Oral (Category 4), H302 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Warning 
 
Hazard statement(s) 
H302 Harmful if swallowed. 
 
Precautionary statement(s) 
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. 
Rinse mouth. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : Bis-acrylamide 
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Formula : C7H10N2O2 
Molecular weight : 154.17 g/mol 
CAS-No. : 110-26-9 
EC-No. : 203-750-9 
 
Hazardous components 
Component Classification Concentration 
N,N'-Methylenediacrylamide 
   Acute Tox. 4; H302 90 - 100 % 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate 
ventilation. Avoid breathing dust. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
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6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for 
disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in 
the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration 
before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Recommended storage temperature 2 - 8 °C 
Air and light sensitive.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
Hazardous components without workplace control parameters 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
Personal protective equipment 
Eye/face protection 
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved 
under appropriate government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
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Body Protection 
Complete suit protecting against chemicals, The type of protective equipment must be selected according to 
the concentration and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher level 
protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and 
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: solid 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting point/freezing 
point 
Melting point/range: > 300 °C (> 572 °F) 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density 5.32 - (Air = 1.0) 
m) Relative density No data available 
n) Water solubility 20 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
 Relative vapour density 5.32 - (Air = 1.0) 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
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10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
Exposure to air. 
10.5 Incompatible materials 
Acids, Bases, Oxidizing agents, Reducing agents, Iron and iron salts., Copper, Aluminum, Brass, Free radical initiators 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx) 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 390 mg/kg 
Remarks: Sense Organs and Special Senses (Nose, Eye, Ear, and Taste):Eye:Other. Behavioral:Tremor. Lungs, Thorax, 
or Respiration:Other changes. 
 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
Overexposure may cause reproductive disorder(s) based on tests with laboratory animals. 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: AS3678000 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
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12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to fish LC50 - Oncorhynchus mykiss (rainbow trout) - > 100 mg/l  - 96 h 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste 
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a 
chemical incinerator equipped with an afterburner and scrubber.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Acute Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
N,N'-Methylenediacrylamide 
CAS-No. 
110-26-9 
Revision Date 
 
 
 
N,N'-Methylenediacrylamide 
CAS-No. 
110-26-9 
Revision Date 
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New Jersey Right To Know Components 
 
N,N'-Methylenediacrylamide 
CAS-No. 
110-26-9 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
Acute Tox. Acute toxicity 
H302 Harmful if swallowed.  
HMIS Rating 
Health hazard: 2 
Chronic Health Hazard: * 
Flammability: 0 
Physical Hazard 1 
NFPA Rating 
Health hazard: 2 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 4.5 
Revision Date 05/11/2016 
Print Date 04/08/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : MES 
 
Product Number : M3671 
Brand : Sigma 
   
CAS-No. : 4432-31-9 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : 4-Morpholineethanesulfonic acid 
2-(N-Morpholino)ethanesulfonic acid 
 
Formula : C6H13NO4S 
Molecular weight : 195.24 g/mol 
CAS-No. : 4432-31-9 
EC-No. : 224-632-3 
 
No components need to be disclosed according to the applicable regulations. 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
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In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Keep in a dry place.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
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8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
Colour: white 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 2.5 - 4 at 97.6 g/l at 25 °C (77 °F) 
e) Melting point/freezing 
point 
300 °C (572 °F) 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
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i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility 97.6 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Sulphur 
oxides 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
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Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: QE3479500 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly 
investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
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14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
2-Morpholinoethanesulphonic acid 
CAS-No. 
145224-94-8 
Revision Date 
 
New Jersey Right To Know Components 
 
2-Morpholinoethanesulphonic acid 
CAS-No. 
145224-94-8 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
 
16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 0 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 0 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.6 
Revision Date 08/31/2017 
Print Date 04/08/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Sodium phosphate monobasic monohydrate 
 
Product Number : RES20906-A7 
Brand : Sigma 
   
CAS-No. : 10049-21-5 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : Monosodium phosphate 
Sodium dihydrogen phosphate monohydrate 
Sodium phosphate monobasic monohydrate 
 
Formula : NaH2PO4 · H2O 
Molecular weight : 137.99 g/mol 
CAS-No. : 10049-21-5 
EC-No. : 231-834-5 
 
No components need to be disclosed according to the applicable regulations. 
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4. FIRST AID MEASURES 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust 
formation should be taken into consideration before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: crystalline 
Colour: white 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 4.1 - 4.5 at 50 g/l at 25 °C (77 °F) 
e) Melting point/freezing 
point 
No data available 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility No data available 
o) Partition coefficient: n- No data available 
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octanol/water 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents, Strong acids 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 
Hazardous decomposition products formed under fire conditions. - Oxides of phosphorus, Sodium oxides 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
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carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
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This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Sodium dihydrogenorthophosphate monohydrate 
CAS-No. 
10049-21-5 
Revision Date 
 
 
 
Sodium dihydrogenorthophosphate monohydrate 
CAS-No. 
10049-21-5 
Revision Date 
 
New Jersey Right To Know Components 
 
Sodium dihydrogenorthophosphate monohydrate 
CAS-No. 
10049-21-5 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 0 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 0 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
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1-800-521-8956 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 4.10 
Revision Date 10/03/2017 
Print Date 04/07/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Sodium phosphate 
 
Product Number : 342483 
Brand : Aldrich 
   
CAS-No. : 7601-54-9 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Skin irritation (Category 2), H315 
Eye irritation (Category 2A), H319 
Specific target organ toxicity - single exposure (Category 3), Respiratory system, H335 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Warning 
 
Hazard statement(s) 
H315 Causes skin irritation. 
H319 Causes serious eye irritation. 
H335 May cause respiratory irritation. 
 
Precautionary statement(s) 
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. 
P264 Wash skin thoroughly after handling. 
P271 Use only outdoors or in a well-ventilated area. 
P280 Wear protective gloves/ eye protection/ face protection. 
P302 + P352 IF ON SKIN: Wash with plenty of soap and water. 
P304 + P340 IF INHALED: Remove victim to fresh air and keep at rest in a position 
comfortable for breathing. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove 
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contact lenses, if present and easy to do. Continue rinsing. 
P312 Call a POISON CENTER/doctor if you feel unwell. 
P321 Specific treatment (see supplemental first aid instructions on this label). 
P332 + P313 If skin irritation occurs: Get medical advice/ attention. 
P337 + P313 If eye irritation persists: Get medical advice/ attention. 
P362 Take off contaminated clothing and wash before reuse. 
P403 + P233 Store in a well-ventilated place. Keep container tightly closed. 
P405 Store locked up. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : Trisodium phosphate 
 
Formula : Na3O4P 
Molecular weight : 163.94 g/mol 
CAS-No. : 7601-54-9 
EC-No. : 231-509-8 
 
Hazardous components 
Component Classification Concentration 
Trisodium orthophosphate 
   Skin Irrit. 2; Eye Irrit. 2A; 
STOT SE 3; H315, H319, 
H335 
90 - 100 % 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
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5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate 
ventilation. Evacuate personnel to safe areas. Avoid breathing dust. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for 
disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in 
the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration 
before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Moisture sensitive.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Component CAS-No. Value Control 
parameters 
Basis 
Trisodium 
orthophosphate 
7601-54-9 STEL 5.000000 
mg/m3 
USA. Workplace Environmental 
Exposure Levels (WEEL) 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
Personal protective equipment 
Eye/face protection 
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved 
under appropriate government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
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Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Impervious clothing, The type of protective equipment must be selected according to the concentration and 
amount of the dangerous substance at the specific workplace. 
Respiratory protection 
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher level 
protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and 
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: solid 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 11 at 20 °C (68 °F) 
e) Melting point/freezing 
point 
75 °C (167 °F) - Decomposes before melting. 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility 121 g/l at 20 °C (68 °F) 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
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q) Decomposition 
temperature 
75 °C (167 °F) - Decomposes before melting. 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong acids 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Oxides of phosphorus, Sodium oxides 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: Irritating to skin. 
 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: Moderate eye irritation 
 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
 No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
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known or anticipated carcinogen by NTP. 
 No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
 No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
Inhalation - May cause respiratory irritation. 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: TC9490000 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste 
disposal service to dispose of this material.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
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IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Acute Health Hazard 
Massachusetts Right To Know Components 
 
Trisodium orthophosphate 
CAS-No. 
7601-54-9 
Revision Date 
2007-03-01 
Pennsylvania Right To Know Components 
 
Trisodium orthophosphate 
CAS-No. 
7601-54-9 
Revision Date 
2007-03-01 
New Jersey Right To Know Components 
 
Trisodium orthophosphate 
CAS-No. 
7601-54-9 
Revision Date 
2007-03-01 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
Eye Irrit. Eye irritation 
H315 Causes skin irritation.  
H319 Causes serious eye irritation. 
H335 May cause respiratory irritation. 
Skin Irrit. Skin irritation 
STOT SE Specific target organ toxicity - single exposure 
HMIS Rating 
Health hazard: 2 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 2 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
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Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 4.10 Revision Date: 10/03/2017 Print Date: 04/07/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 6.13 
Revision Date 10/03/2017 
Print Date 04/08/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Sodium borohydride 
 
Product Number : 452882 
Brand : Aldrich 
   
CAS-No. : 16940-66-2 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Substances and mixtures, which in contact with water, emit flammable gases (Category 1), H260 
Acute toxicity, Oral (Category 3), H301 
Skin corrosion (Category 1B), H314 
Serious eye damage (Category 1), H318 
Reproductive toxicity (Category 1B), H360 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Danger 
 
Hazard statement(s) 
H260 In contact with water releases flammable gases which may ignite 
spontaneously. 
H301 Toxic if swallowed. 
H314 Causes severe skin burns and eye damage. 
H360 May damage fertility or the unborn child. 
 
Precautionary statement(s) 
P201 Obtain special instructions before use. 
P202 Do not handle until all safety precautions have been read and 
understood. 
P223 Do not allow contact with water. 
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P231 + P232 Handle under inert gas. Protect from moisture. 
P260 Do not breathe dust or mist. 
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P280 Wear protective gloves/ protective clothing/ eye protection/ face 
protection. 
P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse 
mouth. 
P301 + P330 + P331 IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. 
P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. 
Rinse skin with water/shower. 
P304 + P340 + P310 IF INHALED: Remove person to fresh air and keep comfortable for 
breathing. Immediately call a POISON CENTER/doctor. 
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove 
contact lenses, if present and easy to do. Continue rinsing. Immediately 
call a POISON CENTER/doctor. 
P308 + P313 IF exposed or concerned: Get medical advice/ attention. 
P335 + P334 Brush off loose particles from skin. Immerse in cool water/ wrap in wet 
bandages. 
P363 Wash contaminated clothing before reuse. 
P370 + P378 In case of fire: Use dry sand, dry chemical or alcohol-resistant foam to 
extinguish. 
P402 + P404 Store in a dry place. Store in a closed container. 
P405 Store locked up. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : Sodium tetrahydridoborate 
VenPure® 
 
Formula : H4BNa 
Molecular weight : 37.83 g/mol 
CAS-No. : 16940-66-2 
EC-No. : 241-004-4 
 
Hazardous components 
Component Classification Concentration 
Sodium borohydride 
   Water-react. 1; Acute Tox. 3; 
Skin Corr. 1B; Eye Dam. 1; 
Repr. 1B; H260, H301, H314, 
H360F 
90 - 100 % 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
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In case of skin contact 
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Take victim immediately 
to hospital. Consult a physician. 
In case of eye contact 
Continue rinsing eyes during transport to hospital.Rinse thoroughly with plenty of water for at least 15 minutes and 
consult a physician. 
If swallowed 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a 
physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Dry powder 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. 
Evacuate personnel to safe areas. Avoid breathing dust. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-
brushing and place in container for disposal according to local regulations (see section 13). Do not flush with water. 
Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.Further processing of solid materials may result in 
the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration 
before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed.Keep away from sources of ignition - No smoking. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Never allow product to get in contact with water during storage. 
Air and moisture sensitive. Store under inert gas. Keep in a dry place.  
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7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product. 
Personal protective equipment 
Eye/face protection 
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Complete suit protecting against chemicals, Flame retardant protective clothing, The type of protective 
equipment must be selected according to the concentration and amount of the dangerous substance at the 
specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type 
N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the 
sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and 
approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
Colour: white 
b) Odour No data available 
c) Odour Threshold No data available 
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d) pH No data available 
e) Melting point/freezing 
point 
Melting point/range: > 300 °C (> 572 °F) - dec. 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
Lower explosion limit: 3.02 %(V) 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility 55 g/l at 25 °C (77 °F) - soluble 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
 Bulk density 1,074 kg/m3 at 20 °C (68 °F) 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
Reacts violently with water. 
10.4 Conditions to avoid 
Exposure to moisture 
10.5 Incompatible materials 
Oxidizing agents, Chemically active metals, acids, Reacts violently with water. 
10.6 Hazardous decomposition products 
Other decomposition products - No data available 
Hazardous decomposition products formed under fire conditions. - Borane/boron oxides, Sodium oxides 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 162 mg/kg 
 
Inhalation: No data available 
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LD50 Dermal - Rabbit - 4,000 - 8,000 mg/kg 
 
No data available 
Skin corrosion/irritation 
Skin - Human 
Result: Corrosive 
 
Serious eye damage/eye irritation 
Eyes - Human 
Result: Corrosive to eyes 
 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
Clear evidence of adverse effects on sexual function and fertility, based on animal experiments. 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: ED3325000 
 
Material is extremely destructive to tissue of the mucous membranes and upper respiratory tract, eyes, and skin., spasm, 
inflammation and edema of the larynx, spasm, inflammation and edema of the bronchi, pneumonitis, pulmonary edema, 
burning sensation, Cough, wheezing, laryngitis, Shortness of breath, Headache, Nausea, Vomiting, To the best of our 
knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to fish mortality LC50 - Gambusia affinis (Mosquito fish) - 5,600 mg/l  - 96 h 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
Aldrich - 452882 Page 7  of  8 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting as this 
material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a 
licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a 
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
UN number: 1426 Class: 4.3 Packing group: I 
Proper shipping name: Sodium borohydride 
Reportable Quantity (RQ):   
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 1426 Class: 4.3 Packing group: I EMS-No: F-G, S-O 
Proper shipping name: SODIUM BOROHYDRIDE 
  
 
IATA 
UN number: 1426 Class: 4.3 Packing group: I 
Proper shipping name: Sodium borohydride 
IATA Passenger: Not permitted for transport  
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Reactivity Hazard, Acute Health Hazard, Chronic Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Sodium borohydride 
CAS-No. 
16940-66-2 
Revision Date 
2007-03-01 
New Jersey Right To Know Components 
 
Sodium borohydride 
CAS-No. 
16940-66-2 
Revision Date 
2007-03-01 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
Acute Tox. Acute toxicity 
Eye Dam. Serious eye damage 
H260 In contact with water releases flammable gases which may ignite spontaneously. 
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H301 Toxic if swallowed. 
H314 Causes severe skin burns and eye damage.  
H318 Causes serious eye damage. 
H360 May damage fertility or the unborn child. 
H360F May damage fertility. 
Repr. Reproductive toxicity 
Skin Corr. Skin corrosion 
HMIS Rating 
Health hazard: 3 
Chronic Health Hazard: * 
Flammability: 4 
Physical Hazard 2 
NFPA Rating 
Health hazard: 3 
Fire Hazard: 4 
Reactivity Hazard: 2 
Special hazard.I: W 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 6.13 Revision Date: 10/03/2017 Print Date: 04/08/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.10 
Revision Date 10/02/2017 
Print Date 03/24/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Sodium chloride 
 
Product Number : S7653 
Brand : Sigma-Aldrich 
   
CAS-No. : 7647-14-5 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Formula : NaCl 
Molecular weight : 58.44 g/mol 
CAS-No. : 7647-14-5 
EC-No. : 231-598-3 
 
No components need to be disclosed according to the applicable regulations. 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance. 
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If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid breathing dust. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for 
disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid formation of dust and aerosols.Further processing of solid materials may result in the formation of combustible 
dusts. The potential for combustible dust formation should be taken into consideration before additional processing 
occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: solid 
Colour: colourless 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 7 
e) Melting point/freezing Melting point/range: 801 °C (1,474 °F) 
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point 
f) Initial boiling point and 
boiling range 
1,413 °C (2,575 °F) 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure 1.33 hPa (1.00 mmHg) at 865 °C (1,589 °F) 
l) Vapour density No data available 
m) Relative density 2.1650 g/cm3 
n) Water solubility 358 g/l at 20 °C (68 °F) - soluble 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Hydrogen chloride gas, Sodium oxides 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 3,550 mg/kg 
 
LC50 Inhalation - Rat - 1 h - > 42,000 mg/m3 
 
LD50 Dermal - Rabbit - > 10,000 mg/kg 
 
No data available 
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Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: VZ4725000 
 
Vomiting, Diarrhoea, Dehydration and congestion may occur in internal organs. Hypertonic salt solutions can produce 
inflammatory reactions in the gastrointestinal tract., To the best of our knowledge, the chemical, physical, and 
toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to fish LC50 - Lepomis macrochirus (Bluegill) - 5,840 mg/l  - 96 h 
 
Toxicity to daphnia and 
other aquatic 
invertebrates 
NOEC - Daphnia (water flea) - 1,500 mg/l  - 7 d 
 
 LC50 - Daphnia magna (Water flea) - 1,661 mg/l  - 48 h 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
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13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Sodium chloride 
CAS-No. 
7647-14-5 
Revision Date 
 
New Jersey Right To Know Components 
 
Sodium chloride 
CAS-No. 
7647-14-5 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 1 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 1 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
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product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
 
Preparation Information 
Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 5.10 Revision Date: 10/02/2017 Print Date: 03/24/2018 
 
 
 
 
Aldrich - W302600 Page 1  of  7 
SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 3.8 
Revision Date 10/20/2017 
Print Date 04/08/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Sodium citrate dihydrate 
 
Product Number : W302600 
Brand : Aldrich 
   
CAS-No. : 6132-04-3 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : Sodium citrate tribasicdihydrate 
Trisodium citratedihydrate 
Citric acidtrisodium saltdihydrate 
 
Formula : C6H5Na3O7 · 2H2O 
Molecular weight : 294.1 g/mol 
CAS-No. : 6132-04-3 
EC-No. : 200-675-3 
Registration number : 01-2119457027-40-XXXX 
 
No components need to be disclosed according to the applicable regulations. 
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4. FIRST AID MEASURES 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Keep in a dry place.  
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: powder 
Colour: white 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 7.5 - 9 at 29.4 g/l at 25 °C (77 °F) 
e) Melting point/freezing 
point 
Melting point/range: > 300 °C (> 572 °F) - lit. 
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f) Initial boiling point and 
boiling range 
309.6 °C (589.3 °F) at 1,013 hPa (760 mmHg) 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density No data available 
n) Water solubility 29.4 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: n-
octanol/water 
No data available 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides 
Other decomposition products - No data available 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
No data available 
Inhalation: No data available 
Dermal: No data available 
No data available 
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Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
No data available 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
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Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
CITRIC ACID TRISODIUM SALT Dihydrate 
CAS-No. 
6132-04-3 
Revision Date 
 
New Jersey Right To Know Components 
 
CITRIC ACID TRISODIUM SALT Dihydrate 
CAS-No. 
6132-04-3 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 0 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 0 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
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Sigma-Aldrich Corporation 
Product Safety – Americas Region 
1-800-521-8956 
 
Version: 3.8 Revision Date: 10/20/2017 Print Date: 04/08/2018 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 4.6 
Revision Date 09/11/2015 
Print Date 04/08/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : N,N,N′,N′-Tetramethylethylenediamine 
 
Product Number : T7024 
Brand : Sigma 
Index-No. : 612-103-00-3 
   
CAS-No. : 110-18-9 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) 
Flammable liquids (Category 2), H225 
Acute toxicity, Oral (Category 3), H301 
Acute toxicity, Inhalation (Category 3), H331 
Skin corrosion (Category 1B), H314 
Serious eye damage (Category 1), H318 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
2.2 GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Danger 
 
Hazard statement(s) 
H225 Highly flammable liquid and vapour. 
H301 + H331 Toxic if swallowed or if inhaled 
H314 Causes severe skin burns and eye damage. 
 
Precautionary statement(s) 
P210 Keep away from heat/sparks/open flames/hot surfaces. No smoking. 
P233 Keep container tightly closed. 
P240 Ground/bond container and receiving equipment. 
P241 Use explosion-proof electrical/ ventilating/ lighting/ equipment. 
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P242 Use only non-sparking tools. 
P243 Take precautionary measures against static discharge. 
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. 
P264 Wash skin thoroughly after handling. 
P270 Do not eat, drink or smoke when using this product. 
P271 Use only outdoors or in a well-ventilated area. 
P280 Wear protective gloves/ protective clothing/ eye protection/ face 
protection. 
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/ 
physician. 
P301 + P330 + P331 IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. 
P303 + P361 + P353 IF ON SKIN (or hair): Remove/ Take off immediately all contaminated 
clothing. Rinse skin with water/ shower. 
P304 + P340 IF INHALED: Remove victim to fresh air and keep at rest in a position 
comfortable for breathing. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove 
contact lenses, if present and easy to do. Continue rinsing. 
P310 Immediately call a POISON CENTER or doctor/ physician. 
P321 Specific treatment (see supplemental first aid instructions on this label). 
P363 Wash contaminated clothing before reuse. 
P370 + P378 In case of fire: Use dry sand, dry chemical or alcohol-resistant foam for 
extinction. 
P403 + P233 Store in a well-ventilated place. Keep container tightly closed. 
P403 + P235 Store in a well-ventilated place. Keep cool. 
P405 Store locked up. 
P501 Dispose of contents/ container to an approved waste disposal plant. 
 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Synonyms : TMEDA 
1,2-Bis(dimethylamino)ethane 
TEMED 
 
Formula : C6H16N2 
Molecular weight : 116.2 g/mol 
CAS-No. : 110-18-9 
EC-No. : 203-744-6 
Index-No. : 612-103-00-3 
 
Hazardous components 
Component Classification Concentration 
N,N,N',N'-Tetramethylethylenediamine 
   Flam. Liq. 2; Acute Tox. 3; 
Skin Corr. 1B; Eye Dam. 1; 
H225, H301 + H331, H314 
<= 100 % 
For the full text of the H-Statements mentioned in this Section, see Section 16. 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Take victim 
immediately to hospital. Consult a physician. 
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In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.Continue rinsing eyes during 
transport to hospital. 
If swallowed 
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a 
physician. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
Use water spray to cool unopened containers. 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Wear respiratory protection. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Remove all sources 
of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive concentrations. 
Vapours can accumulate in low areas. 
For personal protection see section 8. 
6.2 Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
6.3 Methods and materials for containment and cleaning up 
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and place in 
container for disposal according to local regulations (see section 13). 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
Use explosion-proof equipment.Keep away from sources of ignition - No smoking.Take measures to prevent the build 
up of electrostatic charge. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully 
resealed and kept upright to prevent leakage.  
Handle and store under inert gas. Air and moisture sensitive.  
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
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8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
Contains no substances with occupational exposure limit values. 
8.2 Exposure controls 
Appropriate engineering controls 
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product. 
Personal protective equipment 
Eye/face protection 
Tightly fitting safety goggles.  Faceshield (8-inch minimum). Use equipment for eye protection tested and 
approved under appropriate government standards such as NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.4 mm 
Break through time: 125 min 
Material tested:Camatril® (KCL 730 / Aldrich Z677442, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an 
industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It 
should not be construed as offering an approval for any specific use scenario. 
 
Body Protection 
Complete suit protecting against chemicals, Flame retardant antistatic protective clothing., The type of 
protective equipment must be selected according to the concentration and amount of the dangerous substance 
at the specific workplace. 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-
purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. 
If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and 
components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: liquid, clear 
Colour: colourless 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH No data available 
e) Melting point/freezing 
point 
Melting point/range: -55 °C (-67 °F) 
f) Initial boiling point and 
boiling range 
120 - 122 °C (248 - 252 °F) 
g) Flash point 20 °C (68 °F) - closed cup 
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h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
Upper explosion limit: 9.08 %(V) 
Lower explosion limit: 0.98 %(V) 
k) Vapour pressure No data available 
l) Vapour density No data available 
m) Relative density 0.775 g/mL at 20 °C (68 °F) 
n) Water solubility soluble 
o) Partition coefficient: n-
octanol/water 
log Pow: 0.3 
p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
No data available 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
Vapours may form explosive mixture with air. 
10.4 Conditions to avoid 
Heat, flames and sparks. Extremes of temperature and direct sunlight. 
10.5 Incompatible materials 
Strong oxidizing agents, Carbon dioxide (CO2), Copper 
10.6 Hazardous decomposition products 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 268 mg/kg 
 
LC50 Inhalation - Rat - 4 h - 1318 ppm 
 
LD50 Dermal - Rabbit - 5,390 mg/kg 
 
No data available 
Skin corrosion/irritation 
No data available 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: Severe eye irritation 
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Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: KV7175000 
 
Material is extremely destructive to tissue of the mucous membranes and upper respiratory tract, eyes, and skin., 
spasm, inflammation and edema of the larynx, spasm, inflammation and edema of the bronchi, pneumonitis, pulmonary 
edema 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
No data available 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting as this 
material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a 
licensed professional waste disposal service to dispose of this material.  
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Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
UN number: 3286 Class: 3 (6.1, 8) Packing group: II 
Proper shipping name: Flammable liquid, toxic, corrosive, n.o.s. 
 
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 2372 Class: 3 Packing group: II EMS-No: F-E, S-D 
Proper shipping name: 1,2-DI-(DIMETHYLAMINO)ETHANE 
  
IATA 
UN number: 2372 Class: 3 Packing group: II 
Proper shipping name: 1,2-Di-(dimethylamino) ethane 
 
15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Fire Hazard, Acute Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
N,N,N',N'-Tetramethylethylenediamine 
CAS-No. 
110-18-9 
Revision Date 
2007-03-01 
New Jersey Right To Know Components 
 
N,N,N',N'-Tetramethylethylenediamine 
CAS-No. 
110-18-9 
Revision Date 
2007-03-01 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
 
16. OTHER INFORMATION 
Full text of H-Statements referred to under sections 2 and 3. 
Acute Tox. Acute toxicity 
Eye Dam. Serious eye damage 
Flam. Liq. Flammable liquids 
H225 Highly flammable liquid and vapour.  
H301 Toxic if swallowed. 
H301 + H331 Toxic if swallowed or if inhaled 
H314 Causes severe skin burns and eye damage. 
H318 Causes serious eye damage. 
HMIS Rating 
Health hazard: 3 
Chronic Health Hazard:  
Flammability: 3 
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Physical Hazard 0 
NFPA Rating 
Health hazard: 3 
Fire Hazard: 3 
Reactivity Hazard: 0 
Further information 
Copyright 2015 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
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SIGMA-ALDRICH sigma-aldrich.com 
SAFETY DATA SHEET 
Version 5.0 
Revision Date 01/16/2018 
Print Date 04/10/2018 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
1.1 Product identifiers 
Product name : Urea (200 mg) 
 
Product Number : 1706698 
Brand : USP 
   
CAS-No. : 57-13-6 
1.2 Relevant identified uses of the substance or mixture and uses advised against 
Identified uses : Laboratory chemicals, Synthesis of substances 
 
1.3 Details of the supplier of the safety data sheet 
Company : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
 
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
1.4 Emergency telephone number 
Emergency Phone # : +1-703-527-3887 (CHEMTREC) 
 
2. HAZARDS IDENTIFICATION 
2.1 Classification of the substance or mixture 
 
Not a hazardous substance or mixture. 
2.2 GHS Label elements, including precautionary statements 
Not a hazardous substance or mixture. 
2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none 
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
3.1 Substances 
Molecular weight : 60.06 g/mol 
CAS-No. : 57-13-6 
 
Hazardous components 
Component Classification Concentration 
Urea 
     90 - 100 % 
 
 
 
 
4. FIRST AID MEASURES 
4.1 Description of first aid measures 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
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In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
4.2 Most important symptoms and effects, both acute and delayed 
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 
 
4.3 Indication of any immediate medical attention and special treatment needed 
No data available 
 
5. FIREFIGHTING MEASURES 
5.1 Extinguishing media 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
5.2 Special hazards arising from the substance or mixture 
No data available 
5.3 Advice for firefighters 
Wear self-contained breathing apparatus for firefighting if necessary. 
5.4 Further information 
No data available 
 
6. ACCIDENTAL RELEASE MEASURES 
6.1 Personal precautions, protective equipment and emergency procedures 
Avoid dust formation. Avoid breathing vapours, mist or gas. 
For personal protection see section 8. 
6.2 Environmental precautions 
No special environmental precautions required. 
6.3 Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
6.4 Reference to other sections 
For disposal see section 13. 
 
7. HANDLING AND STORAGE 
7.1 Precautions for safe handling 
Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust 
formation should be taken into consideration before additional processing occurs. 
Provide appropriate exhaust ventilation at places where dust is formed. 
For precautions see section 2.2. 
7.2 Conditions for safe storage, including any incompatibilities 
Keep container tightly closed in a dry and well-ventilated place.  
Storage class (TRGS 510): 13: Non Combustible Solids 
7.3 Specific end use(s) 
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated 
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
8.1 Control parameters 
Components with workplace control parameters 
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Component CAS-No. Value Control 
parameters 
Basis 
Urea 57-13-6 TWA 10.000000 
mg/m3 
USA. Workplace Environmental 
Exposure Levels (WEEL) 
8.2 Exposure controls 
Appropriate engineering controls 
General industrial hygiene practice. 
Personal protective equipment 
Eye/face protection 
Use equipment for eye protection tested and approved under appropriate government standards such as 
NIOSH (US) or EN 166(EU). 
Skin protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without 
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after 
use in accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Body Protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and 
to the specific work-place., The type of protective equipment must be selected according to the concentration 
and amount of the dangerous substance at the specific workplace. 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type 
N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under 
appropriate government standards such as NIOSH (US) or CEN (EU). 
Control of environmental exposure 
No special environmental precautions required. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
9.1 Information on basic physical and chemical properties 
a) Appearance Form: solid 
Colour: white 
b) Odour No data available 
c) Odour Threshold No data available 
d) pH 7.5 - 9.5 at 480 g/l at 25 °C (77 °F) 
e) Melting point/freezing 
point 
133 - 135 °C (271 - 275 °F) 
f) Initial boiling point and 
boiling range 
No data available 
g) Flash point No data available 
h) Evaporation rate No data available 
i) Flammability (solid, gas) No data available 
j) Upper/lower 
flammability or 
explosive limits 
No data available 
k) Vapour pressure 0.009 hPa (0.007 mmHg) at 20 °C (68 °F) 
l) Vapour density No data available 
m) Relative density 1.335 g/cm3 
n) Water solubility 480 g/l at 20 °C (68 °F) - completely soluble 
o) Partition coefficient: n-
octanol/water 
log Pow: -2.59 - -1.59 
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p) Auto-ignition 
temperature 
No data available 
q) Decomposition 
temperature 
No data available 
r) Viscosity No data available 
s) Explosive properties No data available 
t) Oxidizing properties No data available 
9.2 Other safety information 
 Bulk density 700 - 800 kg/m3 at 20 °C (68 °F) 
 
10. STABILITY AND REACTIVITY 
10.1 Reactivity 
No data available 
10.2 Chemical stability 
Stable under recommended storage conditions. 
10.3 Possibility of hazardous reactions 
No data available 
10.4 Conditions to avoid 
No data available 
10.5 Incompatible materials 
Strong oxidizing agents 
10.6 Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx) 
In the event of fire: see section 5 
 
11. TOXICOLOGICAL INFORMATION 
11.1 Information on toxicological effects 
Acute toxicity 
LD50 Oral - Rat - 8,471 mg/kg 
 
Inhalation: No data available 
Dermal: No data available 
No data available 
Skin corrosion/irritation 
Skin - Rabbit 
Result: No skin irritation 
 
Serious eye damage/eye irritation 
Eyes - Rabbit 
Result: No eye irritation 
 
Respiratory or skin sensitisation 
No data available 
Germ cell mutagenicity 
No data available 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA’s 
 
USP - 1706698 Page 5  of  6 
list of regulated carcinogens. 
Reproductive toxicity 
No data available 
No data available 
Specific target organ toxicity - single exposure 
No data available 
Specific target organ toxicity - repeated exposure 
No data available 
Aspiration hazard 
No data available 
Additional Information 
RTECS: Not available 
 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
 
 
12. ECOLOGICAL INFORMATION 
12.1 Toxicity 
 
Toxicity to fish LC50 - Poecilia reticulata (guppy) - 17,500 mg/l  - 96 h 
 
Toxicity to daphnia and 
other aquatic 
invertebrates 
EC50 - Daphnia magna (Water flea) - 3,910 mg/l  - 48 h 
12.2 Persistence and degradability 
No data available 
12.3 Bioaccumulative potential 
No data available 
12.4 Mobility in soil 
No data available 
12.5 Results of PBT and vPvB assessment 
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted 
12.6 Other adverse effects 
 
No data available 
 
13. DISPOSAL CONSIDERATIONS 
13.1 Waste treatment methods 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
 
IATA 
Not dangerous goods 
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15. REGULATORY INFORMATION 
SARA 302 Components 
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De 
Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Urea 
CAS-No. 
57-13-6 
Revision Date 
 
 
 
Urea 
CAS-No. 
57-13-6 
Revision Date 
 
New Jersey Right To Know Components 
 
Urea 
CAS-No. 
57-13-6 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 
16. OTHER INFORMATION 
HMIS Rating 
Health hazard: 0 
Chronic Health Hazard:  
Flammability: 0 
Physical Hazard 0 
NFPA Rating 
Health hazard: 0 
Fire Hazard: 0 
Reactivity Hazard: 0 
Further information 
Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling 
or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing 
slip for additional terms and conditions of sale. 
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